Patent Publication Number: US-2004053245-A1

Title: Novel nucleic acids and polypeptides

Description:
1. TECHNICAL FIELD  
       [0001] The present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with uses for these polynucleotides and proteins, for example in therapeutic, diagnostic and research methods.  
       2. BACKGROUND  
       [0002] Technology aimed at the discovery of protein factors (including e.g., cytokines, such as lymphokines, interferons, CSFs, chemokines, and interleukins) has matured rapidly over the past decade. The now routine hybridization cloning and expression cloning techniques clone novel polynucleotides “directly” in the sense that they rely on information directly related to the discovered protein (ie., partial DNA/amino acid sequence of the protein in the case of hybridization cloning; activity of the protein in the case of expression cloning). More recent “indirect” cloning techniques such as signal sequence cloning, which isolates DNA sequences based on the presence of a now well-recognized secretory leader sequence motif, as well as various PCR-based or low stringency hybridization-based cloning techniques, have advanced the state of the art by making available large numbers of DNA/amino acid sequences for proteins that are known to have biological activity, for example, by virtue of their secreted nature in the case of leader sequence cloning, by virtue of their cell or tissue source in the case of PCR-based techniques, or by virtue of structural similarity to other genes of known biological activity.  
       [0003] Identified polynucleotide and polypeptide sequences have numerous applications in, for example, diagnostics, forensics, gene mapping; identification of mutations responsible for genetic disorders or other traits, to assess biodiversity, and to produce many other types of data and products dependent on DNA and amino acid sequences.  
       3. SUMMARY OF THE INVENTION  
       [0004] The compositions of the present invention include novel isolated polypeptides, novel isolated polynucleotides encoding such polypeptides, including recombinant DNA molecules, cloned genes or degenerate variants thereof, especially naturally occurring variants such as allelic variants, antisense polynucleotide molecules, and antibodies that specifically recognize one or more epitopes present on such polypeptides, as well as hybridomas producing such antibodies.  
       [0005] The compositions of the present invention additionally include vectors, including expression vectors, containing the polynucleotides of the invention, cells genetically engineered to contain such polynucleotides and cells genetically engineered to express such polynucleotides.  
       [0006] The present invention relates to a collection or library of at least one novel nucleic acid sequence assembled from expressed sequence tags (ESTs) isolated mainly by sequencing by hybridization(SBH), and in some cases, sequences obtained from one or more public databases. The invention relates also to the proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins. These nucleic acid sequences are designated as SEQ ID NO: 1-1350, The polypeptides sequences are designated SEQ ID NO: 1351-2700, The nucleic acids and polypeptides are provided in the Sequence Listing. In the nucleic acids provided in the Sequence Listing, A is adenosine; C is cytosine; G is guanine; T is thymine; and N is any of the four bases. In the amino acids provided in the Sequence Listing, * corresponds to the stop codon.  
       [0007] The nucleic acid sequences of the present invention also include, nucleic acid sequences that hybridizetothe complement of SEQ ID NO: 1-1350 under stringen thybridization conditions; nucleic acid sequences which are allelic variants or species homologues of any of the nucleic acid sequences recited above, or nucleic acid sequences that encode a peptide comprising a specific domain or truncation of thee peptides encodedby SEQ ID NO: 1-1350; A polynucleotide comprising a nucleotide sequence having at least 90% identity to an identifying sequence of SEQ ID NO: 1-1350 or a degenerate variant or fragment thereof. The identifying sequence can be 100 base pairs in length.  
       [0008] The nucleic acid sequences of thee present invention also include the sequence information from the nucleic acid sequences of SEQ ID NO: 1-1350. The sequence information can be a segment of any one of SEQ ID NO: 1-1350 that uniquely identifies or represents the sequence information of SEQ ID NO: 1-1350.  
       [0009] A collection as used in this application can be a collection of only one polynucleotide. The collection of sequence information or identifying information of each sequence can be provided on a nucleic acid array. In one embodiment, segments of sequence information is provided on a nucleic acid array to detect the polynucleotide that contains the segment. The array can be designed to detect full-match or mismatch to the polynucleotide that contains the segment The collection can also be provided in a computer-readable format.  
       [0010] This invention also includes the reverse or direct complement of any of the nucleic acid sequences recited above; cloning or expression vectors containing the nucleic acid sequences; and host cells or organisms transformed with these expression vectors. Nucleic acid sequences (or their reverse or direct complements) according to the invention have numerous applications in a variety of techniques known to those skilled in the art of molecular biology, such as use as hybridization probes, use as primers for PCR, use in an array, use in computer-readablemedia, use in sequencing full-length genes, use for chromosome and gene mapping, use in the recombinant production of protein, and use in the generation of anti-sense DNA or RNA, their chemical analogs and the like.  
       [0011] In a preferred embodiment, the nucleic acid sequences of SEQ ID NO: 1-1350 or novel segments or parts of the nucleic acids of the invention are used as primers in expression assays that are well known in the art In a particularly preferred embodiment, the nucleic acid sequences of SEQ ID NO: 1-1350 or novel segments or parts of the nucleic acids provided herein are used in diagnostics for identifying expressed genes or, as well known in the art and exemplified by Vollrath et al., Science 258:52-59 (1992), as expressed sequence tags for physical mapping of the human genome.  
       [0012] The isolated polynucleotides of the invention include, but are not limited to, a polynucleotide comprising any one of the nucleotide sequences set forth in SEQ ID NO: 1-1350; a polynucleotide comprising any of the full length protein coding sequences of SEQ ID NO: 1-1350; and a polynucleotide comprising any of the nucleotide sequences of the mature protein coding sequences of SEQ ID NO: 1-1350. The polynucleotides of thee present invention also include, but are not limited to, a polynucleotide that hybridizes under stringent hybridization conditions to (a) the complement of any one of the nucleotide sequences set forth in SEQ ID NO: 1-1350; (b) a nucleotide sequence encoding any one of the amino acid sequences set forth in the Sequence Listing (e.g, SEQ ID NO: 1351-2700); (c) a polynucleotide which is an allelic variant of any polynucleotides recited above; (d) a polynucleotide which encodes a species homolog (e.g orthologs) of any of the proteins recited above; or (e) a polynucleotide that encodes a polypeptide comprising a specific domain or truncation of any of the polypeptides comprising an amino acid sequence set forth in the Sequence Listing.  
       [0013] The isolated polypeptides of the invention include, but are not limited to, a polypeptide comprising any of the amino acid sequences set forth in the Sequence Listing; or the corresponding full length or mature protein. Polypeptides of the invention also include polypeptides with biological activity that are encoded by (a) any of the polynucleotide shaving a nucleotide sequence set forth in SEQ ID NO: 1-1350; or (b) polynucleotides that hybridize to the complement of the polynucleotides of (a) under stringent hybridization conditions. Biologically or immunologically active variants of any of the polypeptide sequences in the Sequence Listing, and “substantial equivalents” thereof (e.g., with at least about 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% amino acid sequence identity) that preferably retain biological activity are also contemplated. The polypeptides of the invention may be wholly or partially chemically synthesized but are preferably produced by recombinant means using the genetically engineered cells (e.g. host cells) of the invention.  
       [0014] The invention also provides compositions comprising a polypeptide of the invention. Polypeptide compositions of the invention may further comprise an acceptable carrier, such as a hydrophilic, e.g., pharmaceutically acceptable, carrier.  
       [0015] The invention also provides host cells transformed or transfected with a polynucleotide of the invention.  
       [0016] The invention also relates to methods for producing a polypeptide of the invention comprising growing a culture of the host cells of the invention in a suitable culture medium under conditions permitting expression of the desired polypeptide, and purifying the polypeptide from the culture or from the host cells. Preferred embodiments include those in which the protein produced by such process is a mature form of the protein.  
       [0017] Polynucleotides according to the invention have numerous applications in a variety of techniques known to those skilled in the art of molecular biology. These techniques include use as hybridization probes, use as oligomers, or primers, for PCR, use for chromosome and gene mapping, use in the recombinant production of protein, and use in generation of anti-sense DNA or RNA, their chemical analogs and the like. For example, when the expression of an mRNA is largely restricted to a particular cell or tissue type, polynucleotides of the invention can be used as hybridization probes to detect the presence of the particular cell or tissue mRNA in a sample using, e.g., in situ hybridization.  
       [0018] In other exemplary embodiments, the polynucleotides are used in diagnostics as expressed sequence tags for identifying expressed genes or, as well known in the art and exemplified by Vollrath et al., Science 258:52-59 (1992), as expressed sequence tags for physical mapping of the human genome.  
       [0019] The polypeptides according to the invention can be used in a variety of conventional procedures and methods that are currently applied to other proteins. For example, a polypeptide of the invention can be used to generate an antibody that specifically binds the polypeptide. Such antibodies, particularly monoclonal antibodies, are useful for detecting or quantitating the polypeptide in tissue. The polypeptides of the invention can also be used as molecular weight markers, and as a food supplement.  
       [0020] Methods are also provided for preventing, treating, or ameliorating a medical condition which comprises the step of administering to a mammalian subject a therapeutically effective amount of a composition comprising a polypeptide of the present invention and a pharmaceutically acceptable carrier.  
       [0021] In particular, the polypeptides and polynucleotides of the invention can be utilized, for example, in methods for the prevention and/or treatment of disorders involving aberrant protein expression or biological activity.  
       [0022] The present invention further relates to methods for detecting the presence of the polynucleotides or polypeptides of the invention in a sample. Such methods can, for example, e utilized as part of prognostic and diagnostic evaluation of disorders as recited herein and for the identification of subjects exhibiting a predisposition to such conditions. The invention provides a method for detecting the polynucleotides of the invention in a sample, comprising contacting the sample with a compound that binds to and forms a complex with the polynucleotide of interest for a period sufficient to form the complex and under conditions sufficient to form a complex and detecting the complex such that if a complex is detected, the polynucleotide of interest is detected. The invention also provides a method for detecting the polypeptides of the invention in a sample comprising contacting the sample with a compound that binds to and form a complex with the polypeptide under conditions and for a period sufficient to form the complex and detecting the formation of the complex such that if a complex is formed, the polypeptide is detected.  
       [0023] The invention also provides kits comprising polynucleotide probes and/or monoclonal antibodies, and optionally quantitative standards, for carrying out methods of the invention. Furthermore, the invention provides methods for evaluating the efficacy of drugs, and monitoring the progress of patients, involved in clinical trials for the treatment of disorders as recited above.  
       [0024] The invention also provides methods for the identification of compounds that modulate (i. e., increase or decrease) the expression or activity of the polynucleotides and/or polypeptides of the invention. Such methods can be utilized, for example, for the identification of compound: that can ameliorate symptoms of disorders as recited herein. Such methods can include, but are not limited to, assays for identifying compounds and other substances that interact with (e.g., bind to) the polypeptides of the invention. The invention provides a method for identify a compound that binds to the polypeptides of the invention comprising contacting the compound with a polypeptide of the invention in a cell for a time sufficient to form a polypeptide/compound complex, wherein the complex drives expression of a reporter gene sequence in the cell; and detecting the complex by detecting the reporter gene sequence expression such that if expression of the reporter gene is detected the compound the binds to a polypeptide of the invention is identified.  
       [0025] The methods of the invention also provides methods for treatment which involve the administration of the polynucleotides or polypeptides of the invention to individuals exhibiting symptoms or tendencies. In addition, the invention encompasses methods for treating diseases o disorders as recited herein comprising administering compounds and other substances that modulate the overall activity of the target gene products. Compounds and other substances can effect such modulation either on the level of target gene/protein expression or target protein activity.  
       [0026] The polypeptides of the present invention and the polynucleotides encoding them are also useful for the same functions known to one of skill in the art as the polypeptides and polynucleotides to which they have homology (set forth in Table 2). If no homology is set forth for a sequence, then the polypeptides and polynucleotides of the present invention are useful for a variety of applications, as described herein, including use in arrays for detection.  
       4. DETAILED DESCRIPTION OF THE INVENTION  
       4.1 Definitions  
       [0027] It must be noted that as used herein and in the appended claims, the singular forms “a”, “an” and “the” include plural references unless the context clearly dictates otherwise.  
       [0028] The term “active” refers to those forms of the polypeptide which retain the biologic and/or immunologic activities of any naturally occurring polypeptide. According to the invention, the terms “biologically active” or “biological activity” refer to a protein or peptide having structural, regulatory or biochemical functions of a naturally occurring molecule. Likewise “immunologically active” or “immunological activity” refers to the capability of the natural, recombinant or synthetic polypeptide to induce a specrifc immune response in appropriate animals or cells and to bind with specific antibodies.  
       [0029] The term “activated cells” as used in this application are those cells which are engaged in extracellular or intracellular membrane trafficking, including the export of secretory or enzymatic molecules as part of a normal or disease process.  
       [0030] The terms “complementary” or “complementarity” refer to the natural binding of polynucleotides by base pairing. For example, the sequence 5′-AGT-3′ binds to the complementary sequence 3′-TCA-5′. Complementarity between two single-stranded molecules may be “partial” such that only some of the nucleic acids bind or it may be “complete” such that total complementarity exists between the single stranded molecules. The degree of complementarity between the nucleic acid strands has significant effects on the efficiency and strength of the hybridization between the nucleic acid strands.  
       [0031] The term “embryonic stem cells (ES)” refers to a cell that can give rise to many differentiated cell types in an embryo or an adult, including the germ cells. The term “germ line stem cells (GSCs)” refers to stem cells derived from primordial stem cells that provide a steady and continuous source of germ cells for the production of gametes. The term “primordial germ cells (PGCs)” refers to a small population of cells set aside from other cell lineages particularly from the yolk sac, mesenteries, or gonadal ridges during embryogenesis that have the potential to differentiate into germ cells and other cells. PGCs are the source from which GSCs and ES cells are derived The PGCs, the GSCs and the ES cells are capable of self-renewal. Thus these cells not only populate the germ line and give rise to a plurality of terminally differentiated cells that comprise the adult specialized organs, but are able to regenerate themselves.  
       [0032] The term “expression modulating fragment,” EM, means a series of nucleotides which modulates the expression of an operably linked ORF or another EMF.  
       [0033] As used herein, a sequence is said to “modulate the expression of an operably linked sequence” when the expression of the sequence is altered by the presence of the EMF. EMFs include, but are not limited to, promoters, and promoter modulating sequences (inducible elements). One class of EMFs are nucleic acid fragments which induce the expression of an operably linked ORF in response to a specific regulatory factor or physiological event.  
       [0034] The terms “nucleotide sequence” or “nucleic acid” or “polynucleotide” or “oligonculeotide” are used interchangeably and refer to a heteropolymer of nucleotides or the sequence of these nucleotides. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA) or to any DNA-like or RNA-like material. In the sequences herein A is adenine, C is cytosine, T is thymine, G is guanine and N is A, C, G or T (U). It is contemplated that where the polynucleotide is RNA, the T (thymine) in the sequences provided herein is substituted with U (uracil). Generally, nucleic acid segments provided by this invention may be assembled from fragments of the genome and short oligonucleotide linkers, or from a series of oligonucleotides, or from individual nucleotides, to provide a synthetic nucleic acid which is capable of being expressed in a recombinant transcriptional unit comprising regulatory elements derived from a microbial or viral operon, or a eukaryotic gene.  
       [0035] The terms “oligonucleotide fragment” or a “polynucleotide fragment”, “portion,” or “segment” or “probe” or “primer” are used interchangeably and refer to a sequence of nucleotide residues which are at least about 5 nucleotides, more preferably at least about 7 nucleotides, more preferably at least about 9 nucleotides, more preferably at least about 11 nucleotides and most preferably at least about 17 nucleotides. The fragment is preferably less than about 500 nucleotides, preferably less than about 200 nucleotides, more preferably less than about 100 nucleotides, more preferably less than about 50 nucleotides and most preferably less than 30 nucleotides. Preferably the probe is from about 6 nucleotides to about 200 nucleotides, preferably from about 15 to about 50 nucleotides, more preferably from about 17 to 30 nucleotides and most preferably from about 20 to 25 nucleotides. Preferably the fragments can be used in polymerase chain reaction (PCR), various hybridization procedures or microarray procedures to identify or amplify identical or related parts of mRNA or DNA molecules. A fragment or segment may uniquely identify each polynucleotide sequence of the present invention. Preferably the fragment comprises a sequence substantially similar to any one of SEQ ID NOs: 1-1350.  
       [0036] Probes may, for example, be used to determine whether specific mRNA molecules are present in a cell or tissue or to isolate similar nucleic acid sequences from chromosomal DNA as described by Walsh et al. (Walsh, P. S. et al., 1992, PCR Methods Appl 1:241-250). They may be labeled by nick translation, Klenow fill-in reaction, PCR, or other methods well known in the art. Probes of the present invention, their preparation and/or labeling are elaborated in Sambrook, J. et al., 1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, NY; or Ausubel, F. M. et al., 1989, Current Protocols in Molecular Biology, John Wiley &amp; Sons, New York NY, both of which are incorporated herein by reference in their entirety.  
       [0037] The nucleic acid sequences of the present invention also include the sequence information from the nucleic acid sequences of SEQ ID NO: 1-1350. The sequence information can be a segment of any one of SEQ ID NO: 1-1350 that uniquely identifies or represents the sequence information of that sequence of SEQ ID NO: 1-1350. One such segment can be a twenty-mer nucleic acid sequence because the probability that a twenty-mer is fully matched in the human genome is 1 in 300, In the human genome, there are three billion base pairs in one set of chromosomes. Because 4 20  possible twenty-mers exist, there are 300 times more twenty-mers. than there are base pairs in a set of human chromosomes. Using the same analysis, the probability for a seventeen-mer to be fully matched in the human genome is approximately 1 in 5. When these segments are used in arrays for expression studies, fifteen-mer segments can be used. The probability that the fifteen-mer is fully matched in the expressed sequences is also approximately one in five because expressed sequences comprise less than approximately 5% of the entire genome sequence.  
       [0038] Similarly, when using sequence information for detecting a single mismatch, a segment can be a twenty-five mer. The probability that the twenty-five mer would appear in a human genome with a single mismatch is calculated by multiplying the probability for a full match (1÷4 25 ) times the increased probability for mismatch at each nucleotide position (3×25). The probability that an eighteen mer with a single mismatch can be detected in an array for expression studies is approximately one in five. The probability that twenty-mer with a single mismatch can be detected in a human genome is approxinmately one in five.  
       [0039] The term “open reading frame,” ORF, means a series of nucleotide triplets coding for amino acids without any termination codons and is a sequence translatable into protein.  
       [0040] The terms “operably linked” or “operably associated” refer to functionally related nucleic acid sequences. For example, a promoter is operably associated or operably linked with a coding sequence if the promoter controls the transcription of the coding sequence. While operably linked nucleic acid sequences can be contiguous and in the same reading frame, certain genetic elements e.g. repressor genes are not contiguously linked to the coding sequence but still control transcription/translation of the coding sequence.  
       [0041] The term “pluripotent” refers to the capability of a cell to differentiate into a number of differentiated cell types that are present in an adult organism. A pluripotent cell is restricted in its differentiation capability in comparison to a totipotent cell.  
       [0042] The terms “polypeptide” or “peptide” or “amino acid sequence” refer to an oligopeptide, peptide, polypeptide or protein sequence or fragment thereof and to naturally occurring or synthetic molecules. A polypeptide “fragment,” “portion,” or “segment” is a stretch of amino acid residues of at least about 5 amino acids, preferably at least about 7 amino acids, more preferably at least about 9 amino acids and most preferably at least about 17 or more amino acids. The peptide preferably is not greater than about 200 amino acids, more preferably less than 150 amino acids and most preferably less than 100 amino acids. Preferably the peptide is from about 5 to about 200 amino acids. To be active, any polypeptide must have sufficient length to display biological and/or immunological activity.  
       [0043] The term “naturally occurring polypeptide” refers to polypeptides produced by cells that have not been genetically engineered and specifically contemplates various polypeptides arising from post-translational modifications of the polypeptide including, but not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation and acylation.  
       [0044] The term “translated protein coding portion” means a sequence which encodes for the full length protein which may include any leader sequence or any processing sequence.  
       [0045] The term “mature protein coding sequence” means a sequence which encodes a peptide or protein without a signal or leader sequence. The “mature protein portion” means that portion of the protein which does not include a signal or leader sequence. The peptide may have been produced by processing in the cell which removes any leader/signal sequence. The mature protein portion may or may not include the initial methionine residue. The methionine residue may be removed from the protein during processing in the cell. The peptide may be produced synthetically or the protein may have been produced using a polynucleotide only encoding for the mature protein coding sequence.  
       [0046] The term “derivative” refers to polypeptides chemically modified by such techniques as ubiquitination, labeling (e.g., with radionuclides or various enzymes), covalent polymer attachment such as pegylation (derivatization with polyethylene glycol) and insertion or substitution by chemical synthesis of amino acids such as ornithine, which do not normally occur in human proteins.  
       [0047] The term “variant”(or “analog”) refers to any polypeptide differing from naturally occurring polypeptides by amino acid insertions, deletions, and substitutions, created using, e g., recombinant DNA techniques. Guidance in determining which amino acid residues may be replaced, added or deleted without abolishing activities of interest, may be found by comparing the sequence of the particular polypeptide with that of homologous peptides and minimizing the number of amino acid sequence changes made in regions of high homology (conserved regions) or by replacing amino acids with consensus sequence.  
       [0048] Alternatively, recombinant variants encoding these same or similar polypeptides may be synthesized or selected by making use of the “redundancy” in the genetic code. Various codon substitutions, such as the silent changes which produce various restriction sites, may be introduced to optimize cloning into a plasmid or viral vector or expression in a particular prokaryotic or eukaryotic system. Mutations in the polynucleotide sequence may be reflected in the polypeptide or domains of other peptides added to the polypeptide to modify the properties of any part of the polypeptide, to change characteristics such as ligand-binding affinities, interchain affinities, or degradation/turnover rate.  
       [0049] Preferably, amino acid “substitutions” are the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, iLe., conservative amino acid replacements. “Conservative” amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid. “Insertions” or “deletions” are preferably in the range of about 1 to 20 amino acids, more preferably 1 to 10 amino acids. The variation allowed may be experimentally determined by systematically making insertions, deletions, or substitutions of amino acids in a polypeptide molecule using recombinant DNA techniques and assaying the resulting recombinant variants for activity.  
       [0050] Alternatively, where alteration of function is desired, insertions, deletions or non-conservative alterations can be engineered to produce altered polypeptides. Such alterations can, for example, alter one or more of the biological functions or biochemical characteristics of the polypeptides of the invention. For example, such alterations may change polypeptide characteristics such as ligand-binding affinities, interchain affinities, or degradation/turnover rate. Further, such alterations can be selected so as to generate polypeptides that are better suited for expression, scale up and the like in the host cells chosen for expression. For example, cysteine residues can be deleted or substituted with another amino acid residue in order to eliminate disulfide bridges.  
       [0051] The terms “purified” or “substantially purified” as used herein denotes that the indicated nucleic acid or polypeptide is present in the substantial absence of other biological macromolecules, e.g., polynucleotides, proteins, and the like. In one embodiment, the polynucleotide or polypeptide is purified such that it constitutes at least 95% by weight, more preferably at least 99% by weight, of the indicated biological macromolecules present (but water, buffers, and other small molecules, especially molecules having a molecular weight of less than 1000 daltons, can be present).  
       [0052] The term “isolated” as used herein refers to a nucleic acid or polypeptide separated from at least one other component (e.g., nucleic acid or polypeptide) present with the nucleic acid or polypeptide in its natural source. In one embodiment, the nucleic acid or polypeptide is found in the presence of (if anything) only a solvent, buffer, ion, or other component normally present in a solution of the same. The terms “isolated” and “purified” do not encompass nucleic acids or polypeptides present in their natural source.  
       [0053] The term “recombinant,” when used herein to refer to a polypeptide or protein, means that a polypeptide or protein is derived from recombinant (e.g., microbial, insect, or mammalian) expression systems. “Microbial” refers to recombinant polypeptides or proteins made in bacterial or fungal (e.g., yeast) expression systems. As a product, “recombinant microbial“defines a polypeptide or protein essentially free of native endogenous substances and unaccompanied by associated native glycosylation. Polypeptides or proteins expressed in most bacterial cultures, e.g., E. coli, will be free of glycosylation modifications; polypeptides or proteins expressed in yeast will have a glycosylation pattern in general different from those expressed in mammalian cells.  
       [0054] The term “recombinant expression vehicle or vector” refers to a plasmid or phage or virus or vector, for expressing a polypeptide from a DNA (RNA) sequence. An expression vehicle can comprise a transcriptional unit comprising an assembly of (1) a genetic element or elements having a regulatory role in gene expression, for example, promoters or enhancers, (2) a structural or coding sequence which is transcribed into mRNA and translated into protein, and (3) appropriate transcription initiation and termination sequences. Structural units intended for use in yeast or eukaryotic expression systems preferably include a leader sequence enabling extracellular secretion of translated protein by a host cell. Alternatively, where recombinant protein is expressed without a leader or transport sequence, it may include an amino terminal methionine residue. This residue may or may not be subsequently cleaved from the expressed recombinant protein to provide a final product.  
       [0055] The term “recombinant expression system” means host cells which have stably integrated a recombinant transcriptional unit into chromosomal DNA or carry the recombinant transcriptional unit extrachromosomally. Recombinant expression systems as defined herein will express heterologous polypeptides or proteins upon induction of the regulatory elements linked to the DNA segment or synthetic gene to be expressed. This term also means host cells which have stably integrated a recombinant genetic element or elements having a regulatory role in gene expression, for example, promoters or enhancers. Recombinant expression systems as defined herein will express polypeptides or proteins endogenous to the cell upon induction of the regulatory elements linked to the endogenous DNA segment or gene to be expressed. The cells can be prokaryotic or eukaryotic.  
       [0056] The term “secreted” includes a protein that is transported across or through a membrane, including transport as a result of signal sequences in its amino acid sequence when it is expressed in a suitable host cell. “Secreted” proteins include without limitation proteins secreted wholly (e.g., soluble proteins) or partially(e.g, receptors) from the cell in which they are expressed. “Secreted” proteins also include without limitation proteins that are transported across the membrane of the endoplasmic reticulum. “Secreted” proteins are also intended to include proteins containing non-typical signal sequences (e.g Interleukin-1 Beta, see Krasney, P. A and Young, P. R. (1992) Cytokine 4(2):134-143) and factors released from damaged cells (e.g. Interleukin-1 Receptor Antagonist, see Arend, W. P. et. al. (1998) Annu. Rev. Immunol. 16:27-55)  
       [0057] Where desired, an expression vector may be designed to contain a “signal or leader sequence” which will direct the polypeptide through the membrane of a cell. Such a sequence may be naturally present on the polypeptides of the present invention or provided from heterologous protein sources by recombinant DNA techniques.  
       [0058] The term “stringent” is used to refer to conditions that are commonly understood in the art as stringent. Stringent conditions can include highly stringent conditions (i e., hybridizanon to filter-bound DNA in 0.5 M NaHPO 4 , 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65° C., and washing in 0.1×SSC/0.1% SDS at 68° C.), and moderately stringent conditions (Le., washing in 0.2×SSC/0.1% SDS at 42° C.). Other exemplary hybridization conditions are described herein in the examples.  
       [0059] In instances of hybridization of deoxyoligonucleotides, additional exemplary stringent hybridization conditions include washing in 6×SSC/0.05% sodium pyrophosphate at 37° C. (for 14-base oligonucleotides), 48° C. (for 17-base oligos), 55° C. (for 20-base oligonucleotides), and 60° C. (for 23-base oligonucleotides).  
       [0060] As used herein, “substantially equivalent” can refer both to nucleotide and amino acid sequences, for example a mutant sequence, that varies from a reference sequence by one or more substitutions, deletions, or additions, the net effect of which does not result in an adverse functional dissimilarity between the reference and subject sequences. Typically, such a substantially equivalent sequence varies from one of those listed herein by no more than about 35% (i.e., the number of individual residue substitutions, additions, and/or deletions in a substantially equivalent sequence, as compared to the corresponding reference sequence, divided by the total number of residues in the substantially equivalent sequence is about 0.35 or less). Such a sequence is said to have 65% sequence identity to the listed sequence. In one embodiment, a substantially equivalent, e.g., mutant, sequence of the invention varies from a listed sequence by no more than 30% (70% sequence identity); in a variation of this embodiment, by no more than 25% (75% sequence identity); and in a firter variation of this embodiment, by no more than 20% (80% sequence identity) and in a further variation of this embodiment, by no more than 10% (90% sequence identity) and in a further variation of this embodiment, by no more that 5% (95% sequence identity). Substantially equivalent, e.g., mutant, amino acid sequences according to the invention preferably have at least 80% sequence identity with a listed amino acid sequence, more preferably at least 85% sequence identity, more preferably at least 90% sequence identity, more preferably at least 95% identity, more preferably at least 98% identity, and most preferably at least 99% identity. Substantially equivalent nucleotide sequences of the invention can have lower percent sequence identities, taking into account, for example, the redundancy or degeneracy of the genetic code. Preferably, nucleotide sequence has at least about 65% identity, more preferably at least about 75% identity, more preferably at least about 80% sequence identity, more preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, and most preferably at least about 95% identity, more preferably at least about 98% sequence identity, and most preferably at least about 99% sequence identity. For the purposes of the present invention, sequences having substantially equivalent biological activity and substantially equivalent expression characteristics are considered substantially equivalent. For the purposes of determining equivalence, truncation of the mature sequence (e.g., via a mutation which creates a spurious stop codon) should be disregarded. Sequence identity may be determined, e.g., using the Jotun Hein method (Hein, J. (1990) Methods Enzymol. 183:626-645). Identity between sequences can also be determined by other methods known in the art, e.g. by varying hybridization conditions.  
       [0061] The term “totipotenf” refers to the capability of a cell to differentiate into all of the cell types of an adult organism.  
       [0062] The term “transformation” means introducing DNA into a suitable host cell so that the DNA is replicable, either as an extrachromosomal element, or by chromosomal integration. The term “transfection” refers to the taking up of an expression vector by a suitable host cell, whether or not any coding sequences are in fact expressed. The term “infection” refers to the introduction of nucleic acids into a suitable host cell by use of a virus or viral vector.  
       [0063] As used herein, an “uptake modulating fragment,” UMF, means a series of nucleotides which mediate the uptake of a linked DNA fragment into a cell. UMFs can be readily identified using known UMFs as a target sequence or target motif with the computer-based systems described below. The presence and activity of a UME can be confirmed by attaching the suspected UMF to a marker sequence. The resulting nucleic acid molecule is then incubated with an appropriate host under appropriate conditions and the uptake of the marker sequence is determined. As described above, a UMF will increase the frequency of uptake of a linked marker sequence.  
       [0064] Each of the above terms is meant to encompass all that is described for each, unless the context dictates otherwise.  
       4.2 Nucleic Acids of the Invention  
       [0065] Nucleotide sequences of the invention are set forth in the Sequence Listing.  
       [0066] The isolated polynucleotides of the invention include a polynucleotide comprising the nucleotide sequences of SEQ ID NO: 1-1350 ; a polynucleotide encoding any one of the peptide sequences of SEQ ID NO: 1351-2700; and a polynucleotide comprising the nucleotide sequence encoding the mature protein coding sequence of the polypeptides of any one of SEQ ID NO: 1351-2700, The polynucleotides of the present invention also include, but are not limited to, a polynucleotide that hybridizes under stringent conditions to (a) the complement of any of the nucleotides sequences of SEQ ID NO: 1-1 350 ; (b) nucleotide sequences encoding any one of the amino acid sequences set forth in the Sequence Listing; (c) a polynucleotide which is an allelic variant of any polynucleotide recited above; (d) apolynucleotide which encodes a species homolog of any of the proteins recited above; or (e) a polynucleotide that encodes a polypeptide comprising a specific domain or truncation of the polypeptides of SEQ ID NO: 1351-2700, Domains of interest may depend on the nature of the encoded polypeptide; e.g., domains in receptor-like polypeptides include ligand-binding, extracellular, transmembrane, or cytoplasmic domains, or combinations thereof; domains in immunoglobulin-like proteins include the variable immunoglobulin-like domains; domains in enzyme-like polypeptides include catalytic and substrate binding domains; and domains in ligand polypeptides include receptor-binding dornains.  
       [0067] The polynucleotides of the invention include naturally occurring or wholly or partially synthetic DNA, e.g., cDNA and genomic DNA, and RNA, e.g., mRNA. The polynucleotides may include all of the coding region of the cDNA or may represent a portion of the coding region of the cDNA.  
       [0068] The present invention also provides genes corresponding to the cDNA sequences disclosed herein. The corresponding genes can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and/or amplification of genes in appropriate genomic libraries or other sources of genomic materials. Further 5′ and 3′ sequence can be obtained using methods known in the art. For example, full length cDNA or genomic DNA that corresponds to any of the polynucleotides of SEQ ID NO: 1-1350 can be obtained by screening appropriate cDNA or genomic DNA libraries under suitable hybridization conditions using any of the polynucleotides of SEQ ID NO: 1-1350 or a portion thereof as a probe. Alternatively, the polynucleotides of SEQ ID NO: 1-1350 may be used as the basis for suitable primer(s) that allow identification and/or amplification of genes in appropriate genomic DNA or cDNA libraries.  
       [0069] The nucleic acid sequences of the invention can be assembled from ESTs and sequences (including cDNA and genomic sequences) obtained from one or more public databases, such as dbEST, gbpri, and UniGene. The EST sequences can provide identifying sequence information, representative fragment or segment information, or novel segment information for the full-length gene.  
       [0070] The polynucleotides of the invention also provide polynucleotides including nucleotide sequences that are substantially equivalent to the polynucleotides recited above. Polynucleotides according to the invention can have, e.g., at least about 65%, at least about 70%, at least about 75%, at least about 80%, 81%, 82%, 83%, 84%, more typically at least about 85%, 86%, 87%, 88%, 89%, more typically at least about 90%, 91%, 92%, 93%, 94%, and even more typically at least about 95%, 96%, 97%, 98%, 99%, sequence identity to a polynucleotide recited above.  
       [0071] Included within the scope of the nucleic acid sequences of the invention are nucleic acid sequence fragments that hybridize under stringent conditions to any of the nucleotide sequences of SEQ ID NO: 1-1350, or complements thereof, which fragment is greater than about 5 nucleotides, preferably 7 nucleotides, more preferably greater than 9 nucleotides and most preferably greater than 17 nucleotides. Fragments of, e.g. 15, 17, or 20 nucleotides or more that are selective for (i.e. specifically hybridize to any one of the polynucleotides of the invention) are contemplated. Probes capable of specifically hybridizing to a polynucleotide can differentiate polynucleotide sequences of the invention from other polynucleotide sequences in the same family of genes or can differentiate human genes from genes of other species, and are preferably based on unique nucleotide sequences.  
       [0072] The sequences falling within the scope of the present invention are not limited to these specific sequences, but also include allelic and species variations thereof. Allelic and species variations can be routinely determined by comparing the sequence provided SEQ ID NO: 1-13 50, a representative fragment thereof, or a nucleotide sequence at least 90% identical, preferably 95% identical, to SEQ ID NO: 1-1350 with a sequence from another isolate of the same species. Furthermore, to accommodate codon variability, the invention includes nucleic acid molecules coding for the same amino acid sequences as do the specific ORFs disclosed herein. In other words, in the coding region of an ORF, substitution of one codon for another codon that encodes the same amino acid is expressly contemplated  
       [0073] The nearest neighbor or homology result for the nucleic acids of the present invention, including SEQ ID NO: 1-13 50, can be obtained by searching a database using an algorithm or a program. Preferably, a BLAST which stands for Basic Local Alignment Search Tool is used to search for local sequence alignments (Altshul, S. F. J Mol. Evol. 36 290-300 (1993) and Altschul S. F. et al. J. Mol. Biol. 21:403410 (1990)). Alternativelya FASTA version 3 search against Genpept, using Fastxy algorithm.  
       [0074] Species homologs (or orthologs) of the disclosed polynucleotides and proteins are also provided by the present invention. Species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species.  
       [0075] The invention also encompasses allelic variants of the disclosed polynucleotides or proteins; that is, naturally-occurring alternative forms of the isolated polynucleotide which also encode proteins which are identical, homologous or related to that encoded by the polynucleotides.  
       [0076] The nucleic acid sequences of the invention are further directed to sequences which encode variants of the described nucleic acids. These amino acid sequence variants may be prepared by methods known in the art by introducing appropriate nucleotide changes into a native or variant polynucleotide. There are two variables in the construction of amino acid sequence variants: the location of the mutation and the nature of the mutation. Nucleic acids encoding the amino acid sequence variants are preferably constructed by mutating the polynucleotide to encode an amino acid sequence that does not occur in nature. These nucleic acid alterations can be made at sites that differ in the nucleic acids from different species (variable positions) or in highly conserved regions (constant regions). Sites at such locations will typically be modified in series, e.g., by substituting first with conservative choices (e.g., hydrophobic amino acid to a different hydrophobic amino acid) and then with more distant choices (e.g., hydrophobic amino acid to a charged amino acid), and then deletions or insertions may be made at the target site. Amino acid sequence deletions generally range from about 1 to 30 residues, preferably about 1 to 10 residues, and are typically contiguous. Amino acid insertions include amino-and/or carboxyl-terminal fusions ranging in length from one to one hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Intrasequence insertions may range generally from about 1 to 10 amino residues, preferably from 1 to 5 residues. Examples of terminal insertions include the heterologous signal sequences necessary for secretion or for intracellular targeting in different host cells and sequences such as FLAG or poly-histidine sequences useful for purifying the expressed protein.  
       [0077] In a preferred method, polynucleotides encoding the novel amino acid sequences are changed via site-directed mutagenesis. This method uses oligonucleotide sequences to alter a polynucleotide to encode the desired amino acid variant, as well as sufficient adjacent nucleotides on both sides of the changed amino acid to form a stable duplex on either side of the site of being changed. In general, the techniques of site-directed mutagenesis are well known to those of skill in the art and this technique is exemplified by publications such as, Edelman et al., DNA 2:183 (1983). A versatile and efficient method for producing site-specific changes in a polynucleotide sequence was published by Zoller and Smith,  Nucleic Acids Res . 10:6487-6500 (1982). PCR may also be used to create amino acid sequence variants of the novel nucleic acids. When small amounts of template DNA are used as starting material, primer(s) that differs slightly in sequence from the corresponding region in the template DNA can generate the desired amino acid variant. PCR amplification results in a population of product DNA fragments that differ from the polynucleotide template encoding the polypeptide at the position specified by the primer. The product DNA fragments replace the corresponding region in the plasmid and this gives a polynucleotide encoding the desired amino acid variant  
       [0078] A further technique for generating amino acid variants is the cassette mutagenesis technique described in Wells et al.,  Gene  34:315 (1985); and other mutagenesis techniques well known in the art, such as, for example, the techniques in Sambrook et al., supra, and  Current Protocols in Molecular Biology , Ausubel et al. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be used in the practice of the invention for the cloning and expression of these novel nucleic acids. Such DNA sequences include those which are capable of hybridizing to the appropriate novel nucleic acid sequence under stringent conditions.  
       [0079] Polynucleotides encoding preferred polypeptide truncations of the invention can be used to generate polynucleotides encoding chimeric or fusion proteins comprising one or more domains of the invention and heterologous protein sequences.  
       [0080] The polynucleotides of the invention additionally include the complement of any of the polynucleotides recited above. The polynucleotide can be DNA (genomic, cDNA, amplified, or synthetic) or RNA. Methods and algorithms for obtaining such polynucleotides are well known to those of skill in the art and can include, for example, methods for determining hybridization conditions that can routinely isolate polynucleotides of the desired sequence identities.  
       [0081] In accordance with the invention, polynucleotide sequences comprising the mature protein coding sequences corresponding to any one of SEQ ID NO: 1-1350, or functional equivalents thereof, may be used to generate recombinant DNA molecules that direct the expression of that nucleic acid, or a functional equivalent thereof in appropriate host cells. Also included are the cDNA inserts of any of the clones identified herein.  
       [0082] A polynucleotide according to the invention can be joined to any of a variety of other nucleotide sequences by well-established recombinant DNA techniques (see Sambrook J et al. (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, NY). Useful nucleotide sequences for joining to polynucleotides include an assortment of vectors, e.g., plasmids, cosmids, lambda phage derivatives, phagernids, and the like, that are well known in the art. Accordingly, the invention also provides a vector including a polynucleotide of the invention and a host cell containing the polynucleotide. In general, the vector contains an origin of replication functional in at least one organism, convenient restriction endonuclease sites, and a selectable marker for the host cell. Vectors according to the invention include expression vectors, replication vectors, probe generation vectors, and sequencing vectors. A host cell according to the invention can be a prokaryotic or eukaryotic cell and can be a unicellular organism or part of a multicellular organism.  
       [0083] The present invention further provides recombinant constructs comprising a nucleic acid having any of the nucleotide sequences of SEQ ID NO: 1-1350 or a fragment thereof or any other polynucleotides of the invention. In one embodiment, the recombinant constructs of the present invention comprise a vector, such as a plasmid or viral vector, into which a nucleic acid having any of the nucleotide sequences of SEQ ID NO: 1-1350 or a fragment thereof is inserted, in a forward or reverse orientation. In the case of a vector comprising one of the ORFs of the(present invention, the vector may further comprise regulatory sequences, including for example, a promoter, operably linked to the ORF. Large numbers of suitable vectors and promoters are known to those of skill in the art and are commercially available for generating the recombinant constructs of the present invention. The following vectors are provided by way of example. Bacterial: pBs, phagescript, PsiX174, pBluescript SK, pBs KS, pNH8a, pNH16a, pNH18a, pNH46a (Stratagene); pTrc99A, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia). Eukaryotic: pWLneo, pSV2cat, pOG44, PXrI, pSG (Stratagene) pSVK3, pBPV, pMSG, pSVL (Pharmacia).  
       [0084] The isolated polynucleotide of the invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufinan et al.,  NucleicAcids Res . 19, 4485-4490 (1991), in order to produce the protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman,  Methods in Enzymology  185, 537-566 (1990). As defined herein “operably linked” means that the isolated polynucleotide of the invention and an expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.  
       [0085] Promoter regions can be selected from any desired gene using CAT (chlorarnphenicol transferase) vectors or other vectors with selectable markers. Two appropriate vectors are pKK232-8 and pCM7, Particular named bacterial promoters include lacd, lacZ, T3, T7, gpt, lambda PR, and trc. Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art. Generally, recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g., the ampicillin resistance gene of  E. coli  and  S. cerevisiae  TRP1 gene, and a promoter derived from a highly-expressed gene to direct transcription of a downstream structural sequence. Such promoters can be derived from operons encoding glycolytic enzrnes such as 3-phosphoglycerate kinase (PGK), a-factor, acid phosphatase, or heat shock proteins, among others. The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium. Optionally, the heterologous sequence can encode a fusion protein including an amino terminal identification peptide imparing desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product. Useful expression vectors for bacterial use are constructed by inserting a structural DNA sequence encoding a desired protein together with suitable translation initiation and termination signals in operable reading phase with a functional promoter. The vector will comprise one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and to, if desirable, provide amplification within the host. Suitable prokaryotic hosts for transformation include  E. coli, Bacillus subtilis, Salmonella typhimurium  and various species within the genera Pseudomonas, Streptomyces, and Staphylococcus, although others may also be employed as a matter of choice.  
       [0086] As a representative but non-limiting example, useful expression vectors for bacterial use can comprise a selectable marker and bacterial origin of replication derived from commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC 37017). Such commercial vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and GEM 1 (Promega Biotech, Madison, Wis., USA). These pBR322 “backbone” sections are combined with an appropriate promoter and the structural sequence to be expressed. Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter is induced or derepressed by appropriate means (e.g., temperature shift or chemical induction) and cells are cultured for an additional period. Cells are typically harvested by centrifigation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification. .  
       [0087] Polynucleotidves of the invention can also be used to induce immune responses. For example, as described in Fan et al.,  Nat. Biotech . 17:870-872 (1999), incorporated herein by reference, nucleic acid sequences encoding a polypeptide may be used to generate antibodies against the encoded polypeptide following topical administration of naked plasmid DNA or following injection, and preferably intramuscular injection of the DNA. The nucleic acid sequences are preferably inserted in a recombinant expression vector and may be in the form of naked DNA.  
       4.3 Antisense  
       [0088] Another aspect of the invention pertains to isolated antisense nucleic acid molecules that are hybridizable to or complementary to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1-1350, or fragments, analogs or derivatives thereof. An “antisense” nucleic acid comprises a nucleotide sequence that is complementary to a “sense” nucleic acid encoding a protein, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. In specific aspects, antisense nucleic acid molecules are provided that comprise a sequence complementary to at least about 10, 25, 50, 100, 250 or 500 nucleotides or an entire coding strand, or to only aportion thereof. Nucleic acid molecules encoding fragnents, homologs, derivatives and analogs of a protein of any of SEQ ID NO: 1351-2700 or antisense nucleic acids complementary to a nucleic acid sequence of SEQ ID NO: 1-1350 are additionally provided.  
       [0089] In one embodiment, an antisense nucleic acid molecule is antisense to a “coding region” of the coding strand of a nucleotide sequence of the invention. The term “coding region” refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues. In another embodiment, the antisense nucleic acid molecule is antisense to a “noncoding region” of the coding strand of a nucleotide sequence of the invention. The term “noncoding region” refers to 5′ and 3′ sequences which flank the coding region that are not translated into amino acids (i.e., also referred to as 5′ and 3′ untranslated regions).  
       [0090] Given the coding strand sequences encoding a nucleic acid disclosed herein (e.g., SEQ ID NO: 1-1350), antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick or Hoogsteen base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of a mRNA, but more preferably is an oligonucleotide that is antisense to only a portion of the coding or noncoding region of a mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of a mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis or enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used.  
       [0091] Examples of modified nucleotides that can be used to generate the antisense nucleic acid include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, bet6-isopentenyladenine, 1-methylguanine, 1-met 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5′-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been sucloned in an antisense orientation (i. e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).  
       [0092] The antisense nucleic acid molecules of the invention are typically administered to a subject or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a protein according to the invention to thereby inhibit expression of the protein, e.g., by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule that binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, e.g., by linking the antisense nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens. The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong poll or pol m promoter are preferred.  
       [0093] In yet another embodiment, the antisense nucleic acid molecule of the invention is an a nomeric nucleic acid molecule. An -anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual -units, the strands run parallel to each other (Gaultier et al. (1987)  Nucleic Acids Res  15: 6625-6641). The antisense nucleic acid molecule can also comprise a 2′-o-methylribonucleotide (Inoue et al. (1987)  Nucleic Acids Res  15: 6131-6148) or a chimeric RNA -DNA analogue (Inoue et al. (1987)  FEBS Lett  215: 327-330).  
       4.4 Ribozymes and Pna Moities  
       [0094] In still another embodiment, an annisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity that are capable of cleaving a single-stranded nucleic acid, such as a mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes (described in Haselhoff and Gerlach (1988)  Nature  334:585-591)) can be used to catalytically cleave a mRNA transcripts to thereby inhibit translation of a mRNA. A ribozyme having specificity for a nucleic acid of the invention can be designed based upon the nucleotide sequence of a DNA disclosed herein (i.e., SEQ ID NO: 1-1350). For example, a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a SECX-encoding mRNA. See, e.g., Cech et al. U.S. Pat. No. 4,987,071; and Cech et al. U.S. Pat No. 5,116,742, Alternatively, SECX mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel et al., (1993)  Science  261:1411-1418.  
       [0095] Alternatively, gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region (e.g., promoter and/or enhancers) to form triple helical structures that prevent transcription of the gene in target cells. See generally, Helene. (1991) Anticancer Drug Des. 6: 569-84; Helene. et al. (1992)  Ann. N.Y. Acad. Sci . 660:27-36; and Maher (1992)  Bioassays  14: 807-15.  
       [0096] In various embodiments, the nucleic acids of the invention can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids (see Hyrup et al. (1996)  Bioorg Med Chem  4: 5-23). As used herein, the terms “peptide nucleic acids” or “PNAs” refer to nucleic acid mimics, e.g., DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup et al. (1996) above; Perzy-O&#39;Keefe et al. (1996)  PNAS  93: 14670-675.  
       [0097] PNAs of the invention can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, e.g., inducing transcription or translation arrest or inhibiting replication. PNAs of the invention can also be used, e.g., in the analysis of single base pair mutations in a gene by, e.g., PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, e.g., S1 nucleases (Hyrup B. (1996) above); or as probes or primers for DNA sequence and hybridization (Hyrup et al. (1996), above; Perry-O&#39;Keefe (1996), above).  
       [0098] In another embodiment, PNAs of the invention can be modified, e.g., to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras can be generated that may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes, e.g., RNase H and DNA polymerases, to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (Hyrup (1996) above). The synthesis of PNA-DNA chimeras can be performed as described in Hymp (1996) above and Finn et al. (1996)  Nucl Acids Res  24: 3357-63, For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry, and modified nucleoside analogs, e.g., 5′-(4-methoxytrityl)amino-5′-deoxy-thymidine phosphoramidite, can be used between the PNA and the 5′ end of DNA (Mag etal. (1989)  Nucl Acid Res  17: 5973-88). PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5′ PNA segment and a 3′ DNA segment (Finn et al. (1996) above). Alternatively, chimeric molecules can be synthesized with a 5′ DNA segment and a 3′ PNA segment. See, Petersen et al. (1975)  Bioorg Med Chem LettS:  1119-11124.  
       [0099] In other embodiments, the oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al., 1989 , Proc. Natl. Acad. Sci. U.S.A . 86:6553-6556; Lemaitre et al., 1987 , Proc. Natl. Acad. Sci . 84:648-652; PCT Publication No. WO88109810) or the blood-brain barrier (see, e.g., PCT Publication No. WO89/10134). In addition, oligonucleotides can be modified with hybridization triggered cleavage agents (See, e.g., Krol et al., 1988 , BioTechniques  6:958-976) or intercalating agents. (See, e.g., Zon, 1988 , Pharm. Res . 5: 539-549). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, a hybridization triggered cross-linking agent, a transport agent, a hybridization-triggered cleavage agent, etc.  
       4.5 Hosts  
       [0100] The present invention further provides host cells genetically engineered to contain the polynucleotides of the invention. For example, such host cells may contain nucleic acids of the invention introduced into the host cell using known transformation, transfection or infection methods. The present invention still further provides host cells genetically engineered to express the polynucleotides of the invention, wherein such polynucleotides are in operative association with a regulatory sequence heterologous to the host cell which drives expression of the polynucleotides in the cell.  
       [0101] Knowledge of nucleic acid sequences allows for modification of cells to permit, or increase, expression of endogenous polypeptide. Cells can be modified (e.g., by homologous recombination) to provide increased polypeptide expression by replacing, in whole or in part, the naturally occurring promoter with all or part of a heterologous promoter so that the cells express the polypeptide at higher levels. The heterologous promoter is inserted in such a manner that it is operatively linked to the encoding sequences. See, for example, PCT International Publication No. WO94/12650, PCT International Publication No. WO92/20808, and PCT International Publication No. WO91/09955, It is also contemplated that, in addition to heterologous promoter DNA, amplifiable marker DNA (e.g., ada, dhfr, and the multifimctional CAD gene which encodes carbamyl phosphate synthase, aspartate transcarbamylase, and dihydroorotase) and/or intron DNA may be inserted along with the heterologous promoter DNA. If linked to the coding sequence, amplification of the marker DNA by standard selection methods results in co-amplification of the desired protein coding sequences in the cells.  
       [0102] The host cell can be a higher eukaryotic host cell, such as a mammalian cell, a lower eukaryotic host cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. Introduction of the recombinant construct into the host cell can be effected by calcium phosphate transfection, DEAE, dextran mediated transfection, or electroporation (Davis, L. et al.,  Basic Methods in Molecular Biology  (1986)). The host cells containing one of the polynucleotides of the invention, can be used in conventional manners to produce the gene product encoded by the isolated fragment (in the case of an ORF) or can be used to produce a heterologous protein under the control of the EMF.  
       [0103] Any host/vector system can be used to express one or more of the ORFs of the present invention. These include, but are not limited to, eukaryotic hosts such as HeLa cells, Cv-1 cell, COS cells, 293 cells, and Sf9 cells, as well as prokaryotic host such as  E. coli  and  B. subtilis . The most preferred cells are those which do not normally express the particular polypeptide or protein or which expresses the polypeptide or protein at low natural level. Mature proteins can be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook, et al., in Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y. (1989), the disclosure of which is hereby incorporated by reference.  
       [0104] Various mammalian cell culture systems can also be employed to express recombinant protein. Examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts, described by Gluzman, Cell 23:175 (1981). Other cell lines capable of expressing a compatible vector are, for example, the C127, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo2O5 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from in vitro culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells. Mammalian expression vectors will comprise an origin of replication, a suitable promoter and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5′ flanking nontranscribed sequences. DNA sequences derived from the SV40 viral genome, for example, SV40 origin, early promoter, enhancer, splice, and polyadenylation sites may be used to provide the required nontranscribed genetic elements. Recombinant polypeptides and proteins produced in bacterial culture are usually isolated by initial extraction from cell pellets, followed by one or more salting-out, aqueous ion exchange or size exclusion chromatography steps. Protein refolding steps can be used, as necessary, in completing configuration of the mature protein. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps. Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents.  
       [0105] Alternatively, it may be possible to produce the protein in lower eukaryotes such as yeast or insects or in prokaryotes such as bacteria. Potentially suitable yeast strains include  Saccharomyces cerevisiae, Schizosaccharomyces pombe , Kluyveromyces strains, Candida, or any yeast strain capable of expressing heterologous proteins. Potentially suitable bacterial strains include  Escherichia coli, Bacillus subtlis, Salmonella typhimurium , or any bacterial strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional protein. Such covalent attachments may be accomplished using known chemical or enzymatic methods.  
       [0106] In another embodiment of the present invention, cells and tissues may be engineered to express an endogenous gene comprising the polynucleotides of the invention under the control of inducible regulatory elements, in which case the regulatory sequences of the endogenous gene may be replaced by homologous recombination. As described herein, gene targeting can be used to replace a gene&#39;s existing regulatory region with a regulatory sequence isolated from a different gene or a novel regulatory sequence synthesized by genetic engineering methods. Such regulatory sequences may be comprised of promoters, enhancers, scaffold-attachment regions, negative regulatory elements, transcriptional initiation sites, regulatory protein binding sites or combinations of said sequences. Alternatively, sequences which affect the structure or stability of the RNA or protein produced may be replaced, removed, added, or otherwise modified by targeting. These sequence include polyadenylation signals, mRNA stability elements, splice sites, leader sequences for enhancing or modifying transport or secretion properties of the protein, or other sequences which alter or improve the function or stability of protein or RNA molecules.  
       [0107] The targeting event may be a simple insertion of the regulatory sequence, placing the gene under the control of the new regulatory sequence, e.g., inserting a new promoter or enhancer or both upstream of a gene. Alternatively, the targeting event may be a simple deletion of a regulatory element, such as the deletion of a tissue-specific negative regulatory element. Alternatively, the targeting event may replace an existing element; for example, a tissue-specific enhancer can be replaced by an enhancer that has broader or different cell-type specificity than the naturally occurring elements. Here, the naturally occurring sequences are deleted and new sequences are added. In all cases, the identification of the targeting event may be facilitated by the use of one or more selectable marker genes that are contiguous with the targeting DNA, allowing for the selection of cells in which the exogenous DNA has integrated into the host cell genome. The identification of the targeting event may also be facilitated by the use of one or more marker genes exhibiting the property of negative selection, such that the negatively selectable marker is linked to the exogenous DNA, but configured such that the negatively selectable marker flanks the targeting sequence, and such that a correct homologous recombination event with sequences in the host cell genome does not result in the stable integration of the negatively selectable marker. Markers useful for this purpose include the Herpes Simplex Virus thymidine kinase (TK) gene or the bacterial xanthine-guanine phosphoribosyl-transferase (gpt) gene.  
       [0108] The gene targeting or gene activation techniques which can be used in accordance with this aspect of the invention are more particularly described in U.S. Pat. No. 5,272,071 to Chappel; U.S. Pat. No. 5,578,461 to Sherwin et al.; International Application No. PCT/US92/09627 (WO93/09222) by Selden et al.; and International Application No. PCT/US90/06436 (WO9106667) by Skoultchi et al., each of which is incorporated by reference herein in its entirety.  
       4.6 Polypetides of the Invention  
       [0109] The isolated polypeptides of the invention include, but are not limited to, a polypeptide comprising: the amino acid sequences set forth as any one of SEQ ID NO: 1351-2700 or an amino acid sequence encoded by any one of the nucleotide sequences SEQ ID NO: 1-1350 or the corresponding full length or mature protein. Polypeptides of the invention also include polypeptides preferably with biological or immunological activity that are encoded by: (a) a polynucleotide having any one of the nucleotide sequences set forth in SEQ ID NO: 1-1350 or (b) polynucleotides encoding any one of the amino acid sequences set forth as SEQ ID NO: 1351-2700 or (c) polynucleotides that hybridize to the complement of the polynucleotides of either (a) or (b) under stringent hybridization conditions. The invention also provides biologically active or immunologically active variants of any of the amino acid sequences set forth as SEQ ID NO: 1351-2700 or the corresponding full length or mature protein; and “substantial equivalents” thereof (e.g., with at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, 86%, 87%, 88%, 89%, at least about 90%, 91%, 92%, 93%, 94%, typically at least about 95%, 96%, 97%, more typically at least about 98%, or most typically at least about 99% amino acid identity) that retain biological activity. Polypeptides encoded by allelic variants may have a similar, increased, or decreased activity compared to polypeptides comprising SEQ ID NO: 1351-2700.  
       [0110] Fragments of the proteins of the present invention which are capable of exhibiting biological activity are also encompassed by the present invention. Fragments of the protein may be in linear form or they may be cyclized using known methods, for example, as described in H. U. Saragovi, et al., Biotechnology 10, 773-778 (1992) and in R. S. McDowell, et al., J. Amer. Chem. Soc. 114, 9245-9253 (1992), both of which are incorporated herein by reference. Such fragments may be fused to carrier molecules such as immunoglobulins for many purposes, including increasing the valency of protein binding sites.  
       [0111] The present invention also provides both full-length and mature forms (for example, without a signal sequence or precursor sequence) of the disclosed proteins. The protein coding sequence is identified in the sequence listing by translation of the disclosed nucleotide sequences. The mature form of such protein may be obtained by expression of a full-length polynucleotide in a suitable mammalian cell or other host cell. The sequence of the mature form of the protein is also determinable from the amino acid sequence of the full-length form. Where proteins of the present invention are membrane bound, soluble forms of the proteins are also provided. In such forms, part or all of the regions causing the proteins to be membrane bound are deleted so that the proteins are fully secreted from the cell in which they are expressed.  
       [0112] Protein compositions of the present invention may further comprise an acceptable carrier, such as a hydrophilic, e.g., pharmaceutically acceptable, carrier.  
       [0113] The present invention also provides isolated polypeptides encoded by the nucleic acid fragments of the present invention or by degenerate variants of the nucleic acid fragments of the present invention. By “degenerate variant” is intended nucleotide fagments which differ from a nucleic acid fragment of the present invention (e.g., an ORF) by nucleotide sequence but, due to the degeneracy of the genetic code, encode an identical polypeptide sequence. Preferred nucleic acid fragments of the present invention are the ORFs that encode proteins.  
       [0114] A variety of methodologies known in the art can be utilized to obtain any one of the isolated polypeptides or proteins of the present invention. At the simplest level, the amino acid sequence can be synthesized using commercially available peptide synthesizer. The synthetically-constructed protein sequences, by virtue of sharing primary, secondary or tertiary structural and/or conformational characteristics with proteins may possess biological properties in common therewith, including protein activity. This technique is particularly useful in producing small peptides and fragments of larger polypeptides. Fragments are useful, for example, in generating antibodies against the native polypeptide. Thus, they may be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies.  
       [0115] The polypeptides and proteins of the present invention can alternatively be purified from cells which have been altered to express the desired polypeptide or protein. As used herein, a cell is said to be altered to express a desired polypeptide or protein when the cell, through genetic manipulation, is made to produce a polypeptide or protein which it normally does not produce or, which the cell normally produces at a lower level. One skilled in the art can readily adapt procedures for introducing and expressing either recombinant or synthetic sequences into eukaryotic or prokaryotic cells in order to generate a cell which produces one of the polypeptides or proteins of the present invention.  
       [0116] The invention also relates to methods for producing a polypeptide comprising growing a culture of host cells of the invention in a suitable culture medium, and purifying the protein from the cells or the culture in which the cells are grown. For example, the methods of the invention include a process for producing a polypeptide in which a host cell containing a suitable expression vector that includes a polynucleotide of the invention is cultured under conditions that allow expression of the encoded polypeptide. The polypeptide can be recovered from the culture, conveniently from the culture medium, or from a lysate prepared from the host cells and further purified. Preferred embodiments include those in which the protein produced by such process is a full length or mature form of the protein.  
       [0117] In an alternative method, the polypeptide or protein is purified from bacterial cells which naturally produce the polypeptide or protein. One skilled in the art can readily follow known methods for isolating polypeptides and proteins in order to obtain one of the isolated polypeptides or proteins of the present invention. These include, but are not limited to, immunochromatography, HPLC, size-exclusion chromatography, ion-exchange chromatography, and immuno-afinity chromatography. See, e.g., Scopes,  Protein Purification: Principles and Practice , Springer-Verlag (1994); Sambrook, et al., in Molecular Cloning:  A Laboratory Manual ; Ausubel et al.,  Current Protocols in Molecular Biology . Polypeptide fragments that retain biological/immunological activity include fragments comprising greater than about 100 amino acids, or greater than about 200 amino acids, and fragments that encode specific protein domains.  
       [0118] The purified polypeptides can be used in invitro binding assays which are well known in the art to identify molecules which bind to the polypeptides. These molecules include but are not limited to, for e.g. small molecules, molecules from combinatorial libraries, antibodies or other proteins. The molecules identified in the binding assay are then tested for antagonist or agonist activity in in vivo tissue culture or animal models that are well known in the art. In brief, the molecules are titrated into a plurality of cell cultures or animals and then tested for either cell/animal death or prolonged survival of the animal/cells.  
       [0119] In addition, the peptides of the invention or molecules capable of binding to the peptides may be complexed with toxins, e.g., ricin or cholera, or with other compounds that are toxic to cells. The toxin-binding molecule complex is then targeted to a tumor or other cell by the specificity of the binding molecule for SEQ ID NO: 1351-2700.  
       [0120] The protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a nucleotide sequence encoding the protein.  
       [0121] The proteins provided herein also include proteins characterized by amino acid sequences similar to those of purified proteins but into which modification are naturally provided or deliberately engineered. For example, modifications, in the peptide or DNA sequence, can be made by those skilled in the art using known techniques. Modifications of interest in the protein sequences may include the alteration, substitution, replacement, insertion or deletion of a selected amino acid residue in the coding sequence. For example, one or more of the cysteine residues may be deleted or replaced with another amino acid to alter the conformation of the molecule. Techniques for such alteration, substitution, replacement, insertion or deletion are well known to those skilled in the art (see, e.g., U.S. Pat. No. 4,518,584). Preferably, such alteration, substitution, replacement, insertion or deletion retains the desired activity of the protein. Regions of the protein that are important for the protein function can be determined by various methods known in the art including the alanine-scanning method which involved systematic substitution of single or strings of amino acids with alanine, followed by testing the resulting alanine-containing variant for biological activity. This type of analysis determines the importance of the substituted amino acid(s) in biological activity. Regions of the protein that are important for protein function may be determined by the eMATRIX program.  
       [0122] Other fragments and derivatives of the sequences of proteins which would be expected to retain protein activity in whole or in part and are useful for screening or other immunological methodologies may also be easily made by those skilled in the art given the disclosures herein. Such modifications are encompassed by the present invention.  
       [0123] The protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, e.g., Invitrogen, San Diego, Calif., U.S.A. (the MaxBat™kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference. As used herein, an insect cell capable of expressing a polynucleotide of the present invention is “transformed.” 
       [0124] The protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein. The resulting expressed protein may then be purified from such culture (ie., from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the protein may also include an afinity column containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearlt™ or Cibacrom blue 3GA Sepharose™; one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity chromatography.  
       [0125] Alternatively, the protein of the invention may also be expressed in a form which will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-tnansferase (GST) or thioredoxin (TRX), or as a His tag. Kits for expression and purification of such fision proteins are commercially available from New England BioLab (Beverly, Mass.), Pharmacia (Piscataway, N.J.) and Invitrogen, respectively. The protein can also be tagged with an epit6pe and subsequently purified by using a specific antibody directed to such epitope. One such epitope (“FLAGO®”) is commercially available from Kodak (New Haven, Conn.).  
       [0126] Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the protein. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a substantially homogeneous isolated recombinant protein. The protein thus purified is substantially free of other mammalian proteins and is defined in accordance with the present invention as an “isolated protein.” 
       [0127] The polypeptides of the invention include analogs (variants). This embraces fragments, as well as peptides in which one or more amino acids has been deleted, inserted, or substituted. Also, analogs of the polypeptides of the invention embrace fusions of the polypeptides or modifications of the polypeptides of the invention, wherein the polypeptide or analog is fused to another moiety or moieties, e.g., targeting moiety or another therapeutic agent. Such analogs may exhibit improved properties such as activity and/or stability. Examples of moieties which may be fused to the polypeptide or an analog include, for example, targeting moieties which provide for the delivery of polypeptide to pancreatic cells, e.g., antibodies to pancreatic cells, antibodies to immune cells such as T-cells, monocytes, dendritic cells, granulocytes, etc., as well as receptor and ligands expressed on pancreatic or immune cells. Other moieties which may be fused to the polypeptide include therapeutic agents which are used for treatment, for example, immunosuppressive drugs such as cyclosporin, SK506, azathioprine, CD3 antibodies and steroids. Also, polypeptides may be fused to immune modulators, and other cytokines such as alpha or beta interferon.  
       [0128] 4.6.1 Determining Polypeptide and Poplynucleotide Identity and Similarity  
       [0129] Preferred identity and/or similarity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in computer programs including, but are not limited to, the GCG program package, including GAP Devereux, J., et al., Nucleic Acids Research 12(1):387 (1984); Genetics Computer Group, University of Wisconsin, Madison, Wis.), BLASTP, BLASTN, BLASTX, FASTA (Altschul, S. F. et al., J. Molec. Biol. 215:403410 (1990), PSI-BLAST (Altschul S. F. et al., Nucleic Acids Res. vol. 25, pp. 3389-3402, herein incorporated by reference), eMatrix software (Wu et al., J. Comp. Biol., Vol. 6, pp.219-235 (1999), herein incorporated by reference), eMotif software (Nevill-Manning et al, ISMB-97, Vol. 4, pp. 202-209, herein incorporated by reference), pFam software (Sonnharniner et al., Nucleic Acids Res., Vol.26(l), pp.320-322 (1998), herein incorporated by reference) and the Kyte-Doolittle hydrophobocity prediction algorithm (J. Mol Biol, 157, pp. 105-31 (1982), incorporated herein by reference). The BLAST programs are publicly available from the National Center for Biotechnology Information (NCBI) and other sources (BLAST Manual, Altschul, S., et al. NCB NLM NIH Bethesda, Md. 20894; Altschul, S., et al., J. Mol. Biol. 215:403 410 (1990).  
       4.7 Chimeric and Fusion Proteins  
       [0130] The invention also provides chimeric or fusion proteins. As used herein, a “chimeric protein” or ” fusion protein” comprises a polypeptide of the invention operatively linked to another polypeptide. Within a fusion protein the polypeptide according to the invention can correspond to all or a portion of a protein according to the invention. In one embodiment, a fusion protein comprises at least one biologically active portion of a protein according to the invention. In another embodiment, a fusion protein comprises at least two biologically active portions of a protein according to the invention. Within the fusion protein, the term “operatively linked” is intended to indicate that the polypeptide according to the invention and the other polypeptide are fused in-frame to each other. The polypeptide can be fused to the N-terminus or C-terminus.  
       [0131] For example, in one embodiment a fusion protein comprises a polypeptide according to the invention operably inked to the extracellular domain of a second protein.  
       [0132] In another embodiment, the fusion protein is a GST-fusion protein in which the polypeptide sequences of the invention are fused to the C-terminus of the GST (i.e., glutathione S-transferase) sequences.  
       [0133] In another embodiment, the fusion protein is an immunoglobulin fusion protein in which the polypeptide sequences according to the invention comprises one or more domains are fused to sequences derived from a member of the immunoglobulin protein family. The immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between a ligand and a protein of the invention on the surface of a cell, to thereby suppress signal transduction in vivo. The imnmunoglobulin fusion proteins can be used to affect the bioavailability of a cognate ligand. Inhibition of the ligand/protein interaction may be useful therapeutically for both the treatment of proliferative and differentiative disorders, e,g., cancer as well as modulating (e.g., promoting or inhibiting) cell survival. Moreover, the immunoglobulin fusion proteins of the invention can be used as immunogens to produce antibodies in a subject, to purify ligands, and in screening assays to identify molecules that inhibit the interaction of a polypeptide of the invention with a ligand.  
       [0134] A chimeric or fusion protein of the invention can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, e.g., by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive gene fragments that can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, Ausubel et al. (eds.) C URRENT  P ROTOCOLS IN  M OLECULAR  B IOLOGY , John Wiley &amp; Sons, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). A nucleic acid encoding a polypeptide of the invention can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the protein of the invention.  
       4.8 Gene Therapy  
       [0135] Mutations in the polynucleotides of the invention gene may result in loss of normal function of the encoded protein. The invention thus provides gene therapy to restore normal activity of the polypeptides of the invention; or to treat disease states involving polypeptides of the invention. Delivery of a functional gene encoding polypeptides of the invention to appropriate cells is effected ex vivo, in situ, or in vivo by use of vectors, and more particularly viral vectors (e.g., adenovirus, adeno-associated virus, or a retrovirus), or ex vivo by use of physical DNA transfer methods (e.g., liposomes or chemical treatments). See, for example, Anderson, Nature, supplement to vol. 392, no. 6679, pp.25-20 (1998). For additional reviews of gene therapy technology see Friedmann, Science, 244: 1275-1281 (1989); Venna, Scientific American: 68-84 (1990); and Miller, Nature, 357: 455460 (1992). Introduction of any one of the nucleotides of the present invention or a gene encoding the polypeptides of the present invention can also be accomplished with extrachromosomal substrates (transient expression) or artificial chromosomes (stable expression). Cells may also be cultured ex vivo in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced in vivo for therapeutic purposes. Alternatively, it is contemplated that in other human disease states, preventing the expression of or inhibiting the activity of polypeptides of the invention will be useful in treating the disease states. It is contemplated that antisense therapy or gene therapy could be applied to negatively regulate the expression of polypeptides of the invention.  
       [0136] Other methods inhibiting expression of a protein include the introduction of antisense molecules to the nucleic acids of the present invention, their complements, or their translated RNA sequences, by methods known in the art. Further, the polypeptides of the present invention can be inhibited by using targeted deletion methods, or the insertion of a negative regulatory element such as a silencer, which is tissue specific.  
       [0137] The present invention still farther provides cells genetically engineered in vivo to express the polynucleotides of the invention, wherein such polynucleotides are in operative association with a regulatory sequence heterologous to the host cell which drives expression of the polynucleotides in the cell. These methods can be used to increase or decrease the expression of the polynucleotides of the present invention.  
       [0138] Knowledge of DNA sequences provided by the invention allows for modification of cells to permit, increase, or decrease, expression of endogenous polypeptide. Cells can be modified (e.g., by homologous recombination) to provide increased polypeptide expression by replacing, in whole or in part, the naturally occurring promoter with all or part of a heterologous promoter so that the cells express the protein at higher levels. The heterologous promoter is inserted in such a manner that it is operatively linked to the desired protein encoding sequences. See, for example, PCT International PublicationNo. WO 94/12650, PCT International PublicationNo. WO 92/20808, and PCT International PublicationNo. WO 91/09955, It is also contemplated that, in addition to heterologous promoter DNA, amplifiable marker DNA (e.g., ada, dhfr, and the multifunctional CAD gene which encodes carbamyl phosphate synthase, aspartate transcarbamylase, and dihydroorotase) and/or intron DNA may be inserted along with the heterologous promoter DNA. If linked to the desired protein coding sequence, amplification of the marker DNA by standard selection methods results in co-amplification of the desired protein coding sequences in the cells.  
       [0139] In another embodiment of the present invention, cells and tissues may be engineered to express an endogenous gene comprising the polynucleotides of the invention under the control of inducible regulatory elements, in which case the regulatory sequences of the endogenous gene may be replaced by homologous recombination. As described herein, gene targeting can be used to replace a gene&#39;s existing regulatory region with a regulatory sequence isolated from a different gene or a novel regulatory sequence synthesizedby genetic engineering methods. Such regulatory sequences may be comprised of promoters, enhancers, scaffold-attachmentregions, negative regulatory elements, transcriptional initiation sites, regulatory protein binding sites or combinations of said sequences. Alternatively, sequences which affect the structure or stability of the RNA or protein produced may be replaced, removed, added, or otherwise modified by targeting. These sequences include polyadenylation signals, mRNA stability elements, splice sites, leader sequences for enhancing or modifying transport or secretion properties of the protein, or other sequences which alter or improve the function or stability of protein or RNA molecules.  
       [0140] The targeting event may be a simple insertion of thee regulatory sequence, placing the gene under the control of the new regulatory sequence, e.g., inserting a new promoter or enhancer or both upstream of a gene. Alternatively, the targeting event may be a simple deletion of a regulatory element, such as the deletion of a tissue-specific negative regulatory element. Alternatively, the targeting event may replace an existing element; for example, a tissue-specific enhancer can be replaced by an enhancer that has broader or different cell-type specificity than the naturally occurring elements. Here, the naturally occurring sequences are deleted and new sequences are added. In all cases, the identification of the targeting event may be facilitated by the use of one or more selectable marker genes that are contiguous with the targeting DNA, allowing for the selection of cells in which the exogenous DNA has integrated into the cell genome. The identification of the targeting event may also be facilitated by the use of one or more marker genes exhibiting the property of negative selection, such that the negatively selectable marker is linked to the exogenous DNA, but configured such that the negatively selectable marker flanks the targeting sequence, and such that a correct homologous recombination event with sequences in the host cell genome does not result in the stable integration of the negatively selectable marker. Markers useful for this purpose include the Herpes Simplex Virus thymidine kinase (TK) gene or the bacterial xantiine-guanine phosphoribosyl-transferase (gpt) gene.  
       [0141] The gene targeting or gene activation techniques which can be used in accordance with this aspect of the invention are more particularly described in U.S. Pat. No. 5,272,071 to Chappel; U.S. Pat. No. 5,578,461 to Sherwin et al.; International Application No. PCT/US92/09627 (WO93/09222) by Selden et al.; and International Application No. PCT/US90/06436 (WO91/106667) by Skoultchi et al., each of which is incorporated by reference herein in its entirety.  
       4.9 Transgenic Animals  
       [0142] In preferred methods to determine biological functions of the polypeptides of the invention in vivo, one or more genes provided by the invention are either over expressed or inactivated in the germ line of animals using homologous recombination [Capecchi, Science 244:1288-1292 (1989)]. Animals in which the gene is over expressed, under the regulatory control of exogenous or endogenous promoter elements, are known as transgenic animals. Animals in which an endogenous gene has been inactivated by homologous recombination are referred to as “knockout” animals. Knockout animals, preferably non-human mammals, can be prepared as described in U.S. Pat. No. 5,557,032, incorporated herein by reference. Transgenic animals are useful to determine the roles polypeptides of the invention play in biological processes, and preferably in disease states. Transgenic animals are useful as model systems to identify compounds that modulate lipid metabolism. Transgenic animals, preferably non-human mammals, are produced using methods as described in U.S. Pat. No 5,489,743 and PCT Publication No. WO94/28122, incorporated herein by reference.  
       [0143] Transgenic animals can be prepared wherein all or part of a promoter of the polynucleotides of the invention is either activated or inactivated to alter the level of expression of the polypeptides of the invention. Inactivation can be carried out using homologous recombination methods described above. Activation can be achieved by supplementing or even replacing the homologous promoter to provide for increased protein expression. The homologous promoter can be supplemented by insertion of one or more heterologous enhancer elements known to confer promoter activation in a particular tissue.  
       [0144] The polynucleotides of the present invention also make possible the development, through, e.g., homologous recombination or knock out strategies, of animals that fail to express polypeptides of the invention or that express a variant polypeptide. Such animals are useful as models for studying the in vivo activities of polypeptide as well as for studying modulators of the polypeptides of the invention.  
       [0145] In preferred methods to determine biological functions of the polypeptides of the invention in vivo, one or more genes provided by the invention are either over expressed or inactivated in the germ line of animals using homologous recombination [Capecchi, Science 244:1288-1292 (1989)]. Animals in which the gene is over expressed, under the regulatory control of exogenous or endogenous promoter elements, are known as transgenic animals. Animals in which an endogenous gene has been inactivated by homologous recombination are referred to as “knockout” animals. Knockout animals, preferably non-human mammals, can be prepared as described in U.S. Pat. No. 5,557,032, incorporated herein by reference. Transgenic animals are useful to determine the roles polypeptides of the invention play in biological processes, and preferably in disease states. Transgenic animals are useful as model systems to identify compounds that modulate lipid metabolism. Transgenic animals, preferably non-human mammals, are produced using methods as described in U.S. Pat. No 5,489,743 and PCT Publication No. WO94/28122, incorporated herein by reference.  
       [0146] Transgenic animals can be prepared wherein all or part of the polynucleotides of the invention promoter is either activated or inactivated to alter the level of expression of the polypeptides of the invention. Inactivation can be carried out using homologous recombination methods described above. Activation can be achieved by supplementing or even replacing the homologous promoter to provide for increased protein expression. The homologous promoter can be supplemented by insertion of one or more heterologous enhancer elements known to confer promoter activation in a particular tissue.  
       4.10 Uses and Biological Activity  
       [0147] The polynucleotides and proteins of the present invention are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified herein. Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA). The mechanism underlying the particular condition or pathology will dictate whether the polypeptides of the invention, the polynucleotides of the invention or modulators (activators or inhibitors) thereof would be beneficial to the subject in need of treatment. Thus, “therapeutic compositions of the invention” include compositions comprising isolated polynucleotides (including recombinant DNA molecules, cloned genes and degenerate variants thereof) or polypeptides of the invention (including full length protein, mature protein and truncations or domains thereof), or compounds and other substances that modulate the overall activity of the target gene products, either at the level of target gene/protein expression or target protein activity. Such modulators include polypeptides, analogs, (variants), including fragments and fusion proteins, antibodies and other binding proteins; chemical compounds that directly or indirectly activate or inhibit the polypeptides of the invention (identified, e.g., via drug screening assays as described herein); antisense polynucleotides and polynucleotides suitable for triple helix formation; and in particular antibodies or other binding partners that specifically recognize one or more epitopes of the polypeptides of the invention.  
       [0148] The polypeptides of the present invention may likewise be involved in cellular activation or in one of the other physiological pathways described herein.  
       [0149] 4.10.1 Research Uses and Utilities  
       [0150] The polynucleotides provided by the present invention can be used by the research community for various purposes. The polynucleotides can be used to express recombinant protein for analysis, characterization or therapeutic use; as markers for tissues in which the corresponding protein is preferentially expressed (either constructively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; as a probe to “subtract-out” known sequences in the process of discovering other novel polynucleotides; for selecting and making oligomers for attachment to a “gene chip” or other support, including for examination of expression patterns; to raise anti-protein antibodies using DNA immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the polynucleotide can also be used in interaction trap assays (such as, for example, that described in Gyuris et al., Cell 75:791-803 (1993)) to identify polynucleotides encoding the other protein with which binding occurs or to identify inhibitors of the binding interaction.  
       [0151] The polypeptides provided by the present invention can similarly be used in assays to determine biological activity, including in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its receptor) in biological fluids; as markers for tissues in which the corresponding polypeptide is preferentially expressed (either constructively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative receptors or ligands. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.  
       [0152] Any or all of these research utilities are capable of being developed into reagent grade or kit format for commercialization as research products.  
       [0153] Methods for performing the uses listed above are well known to those skilled in the art.  
       [0154] References disclosing such methods include without limitation “Molecular Cloning: A Laboratory Manual”, 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E. F. Fritsch and T. Maniatis eds., 1989, and “Methods in Enzymology: Guide to Molecular Cloning Techniques”, Academic Press, Berger, S. L. and A. R. Kimmel eds., 1987.  
       [0155] 4 . 10 . 2  Nutritional Uses  
       [0156] Polynucleotides and polypeptides of the present invention can also be used as nutritional sources or supplements. Such uses include without limitation use as a protein or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate. In such cases the polypeptide or polynucleotide of the invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules. In the case of microorganisms, the polypeptide or polynucleotide of the invention can be added to the medium in or on which the microorganism is cultured.  
       [0157] 4.10.3 Gytokine and Cell Proliferation/Diferntation Activity  
       [0158] A polypeptide of the present invention may exhibit activity relating to cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytolines in certain cell populations. A polynucleotide of the invention can encode a polypeptide exhibiting such attributes. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor-dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokie activity. The activity of therapeutic compositions of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+(preB M+), 2E8, RB5, DA1 , 123, T1165, HT2, CTLL2, TF-1, Mo7e, CMK, HUVEC, and Caco. Therapeutic compositions of the invention can be used in the following:  
       [0159] Assays for T-cell or thymocyte proliferation include without limitation those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Bertagnolli et al., J. Immunol. 145:1706-1712, 1990; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Bertagnolli, et al., I. Immunol. 149:3778-3783, 1992; Bowman et al., I. Immunol. 152:1756-1761, 1994.  
       [0160] Assays for cytokine production and/or proliferation of spleen cells, lymph node cells or thymocytes include, without limitation, those described in: Polyclonal T cell stimulation, Kruisbeek, A. M. and Shevach, E. M. In Current Protocols in immunology. J. E. e.a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human interleukin-γ, Schreiber, R D. In Current Protocols in Immunology. J. E. e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994.  
       [0161] Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described in: Measurement of Human and Murine Interleulin 2 and Interleukin 4, Bottomly, K., Davis, L. S. and Lipsky, P. E. In Current Protocols in Immunology. J. E. e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; deVries et al., J. Exp. Med. 173:1205-1211, 1991; Moreau et al., Nature 336:690-692, 1988; Greenberger et al., Proc. Natl. Acad. Sci. U.S.A. 80:2931-2938, 1983; Measurement of mouse and human interleukin 6-Nordan, R. In Current Protocols in Immunology. J. E. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto. 1991; Smith et al., Proc. Natl. Aced. Sci. U.S.A. 83:1857-1861, 1986; Measurement of human Interleukin 1-Bennett, F., Giannotti, J., Clark, S. C. and Turner, K. J. In Current Protocols in Immunology. J. E. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991; Measurement of mouse and human Interleukin 9—Ciarletta, A., Giannotti, J., Clark, S. C. and Turner, K. J. In Current Protocols in Immunology. J. E. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991,  
       [0162] Assays for T-cell clone responses to antigens (which will identify, among others, proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans); Weinberger et al., Proc. Natl. Acad. Sci. USA 77:6091-6095, 1980; Weinberger et al., Eur. J. Immun. 11:405411, 1981; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988.  
       [0163] 4 . 10 . 4  Stem Cell Growth Factor Activity  
       [0164] A polypeptide of the present invention may exhibit stem cell growth factor activity and be involved in the proliferation, differentiation and survival of pluripotent and totipotent stem cells including primordial germ cells, embryonic stem cells, hematopoietic stem cells and/or germ line stem cells. Administration of the polypeptide of the invention to stem cells in vivo or ex vivo is expected to maintain and expand cell populations in a totipotential or pluripotential state which would be useful for re-engineering damaged or diseased tissues, transplantation, manufacture of bio-pharmaceuticals and the development of bio-sensors. The ability to produce large quantities of human cells has important working applications for the production of human proteins which currently must be obtained from non-human sources or donors, implantation of cells to treat diseases such as Parkinson&#39;s, Alzheimer&#39;s and other neurodegenerative diseases; tissues for grafting such as bone marrow, skin, cartilage, tendons, bone, muscle (including cardiac muscle), blood vessels, cornea, neural cells, gastrointestinal cells and others; and organs for transplantation such as kidney, liver, pancreas (including islet cells), heart and lung.  
       [0165] It is contemplated that multiple different exogenous growth factors and/or cytokines may be administered in combination with the polypeptide of the invention to achieve the desired effect, including any of the growth factors listed herein, other stem cell maintenance factors, and specifically including stem cell factor (SCF), leukemia inhibitory factor (LIF), Flt-3 ligand (Flt-3L), any of the interleukins, recombinant soluble IL-6 receptor fused to IL-6, macrophage inflammatory protein 1-alpha (MIP-1-alpha), G-CSF, GM-CSF, thrombopoietin (TPO), platelet factor 4 (PF-4), platelet-derived growth factor (PDGF), neural growth factors and basic fibroblast growth factor (bFGF).  
       [0166] Since totipotent stem cells can give rise to virtualy any mature cell type, expansion of these cells in culture will facilitate the production of large quantities of mature cells. Techniques for culturing stem cells are known in the art and administration of polypeptides of the invention, optionally with other growth factors and/or cytokines, is expected to enhance the survival and proliferation of the stem cell populations. This can be accomplished by direct administration of the polypeptide of the invention to the culture medium. Alternatively, stroma cells transfected with a polynucleotide that encodes for the polypeptide of the invention can be used as a feeder layer for the stem cell populations in culture or in vivo. Stromal support cells for feeder layers may include embryonic bone marrow fibroblasts, bone marrow stromal cells, fetal liver cells, or cultured embryonic fibroblasts (see U.S. Pat. No. 5,690,926).  
       [0167] Stem cells themselves can be transfected with a polynucleotide of the invention to induce autocrine expression of the polypeptide of the invention. This will allow for generation of undifferentiated totipotential/pluripotential stem cell lines that are useful as is or that can then be differentiated into the desired mature cell types. These stable cell lines can also serve as a source of undifferentiated totipotential/pluripotential mRNA to create cDNA libraries and templates for polymerase chain reaction experiments. These studies would allow for the isolation and identification of differentially expressed genes in stem cell populations that regulate stem cell proliferation and/or maintenance.  
       [0168] Expansion and maintenance of totipotent stem cell populations will be useful in the treatment of many pathological conditions. For example, polypeptides of the present invention may be used to manipulate stem cells in culture to give rise to neuroepithelial cells that can be used to augment or replace cells damaged by illness, autoimmune disease, accidental damage or genetic disorders. The polypeptide of the invention may be useful for inducing the proliferation of neural cells and for the regeneration of nerve and brain tissue, ie. for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders which involve degeneration, death or trauma to neural cells or nerve tissue. In addition, the expanded stem cell populations can also be genetically altered for gene therapy purposes and to decrease host rejection of replacement tissues after grafting or implantation.  
       [0169] Expression of the polypeptide of the invention and its effect on stem cells can also be manipulated to achieve controlled differentiation of the stem cells into more differentiated cell types. A broadly applicable method of obtaining pure populations of a specific differentiated cell type from undifferentiated stem cell populations involves the use of a cell-type specific promoter driving a selectable marker. The selectable marker allows only cells of the desired type to survive. For example, stem cells can be induced to differentiate into cardiomyocytes (Wobus et al., Differentiation, 48: 173-182, (1991); Klug et al., J. Clin. Invest., 98(1): 216-224, (1998)) or skeletal muscle cells (Browder, L. W. In:  Principles of Tissue Engineering eds . Lanza et al., Academic Press (1997)). Alternatively, directed differentiation of stem cells can be accomplished by culturing the stem cells in the presence of a differentiation factor such as retinoic acid and an antagonist of the polypeptide of the invention which would inhibit the effects of endogenous stem cell factor activity and allow differentiation to proceed.  
       [0170] In vitro cultures of stem cells can be used to determine if the polypeptide of the invention exhibits stem cell growth factor activity. Stem cells are isolated from any one of various cell sources (including hematopoietic stem cells and embryonic stem cells) and cultured on a feeder layer, as described by Thompson et al. Proc. Natl. Acad. Sci, U.S.A., 92: 7844-7848 (1995), in the presence of the polypeptide of the invention alone or in combination with other growth factors or cytokines. The ability of the polypeptide of the invention to induce stem cells proliferation is determined by colony formation on semi-solid support e.g as described by Bernstein et al., Blood, 77: 23162321 (1991).  
       [0171] 4.10.5 Hematopoiesis Regulating Activity  
       [0172] A polypeptide of the present invention may be involved in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell disorders. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis, e.g in supporting the growth and proliferation of erytbroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erytiroid precursors and/or erytroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysrnal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either in-vivo or ex-vivo (i.e., in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heteroiogous)) as normal cells or genetically manipulated for gene therapy.  
       [0173] Therapeutic compositions of the invention can be used in the following:  
       [0174] Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above.  
       [0175] Assays for embryonic stem cell differentiation (which will identify, among others, proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in: Johansson et al. Cellular Biology 15:141-151, 1995; Keller et al., Molecular and Cellular Biology 13:473-486, 1993; McClanahan et al., Blood 81:2903-2915, 1993.  
       [0176] Assays for stem cell survival and differentiation (which will identify, among others, proteins that regulate lympho-hematopoiesis) include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M. G. In Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 265-268, Wiley-Liss, Inc., New York, N.Y. 1994; Hirayama et al., Proc. Natl. Acad. Sci. USA 89:5907-5911, 1992; Primitive hematopoietic colony forming cells with high proliferative potential, McNiece, I. K. and Briddell, R. A. In Culture of Hematopoietic Cells. R I. Freshney, et al. eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, N.Y. 1994; Neben et al., Experimental Hematology 22:353-359, 1994; Cobblestone area forming cell assay, Ploemacher, R. E. In Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 1-21, Wiley-Liss, Inc., New York, N.Y. 1994; Long term bone marrow cultures in the presence of stromal cells, Spooncer, E., Dexter, M. and Allen, T. In Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 163-179, Wiley-Liss, Inc., New York, N.Y. 1994; Long term culture initiating cell assay, Sutherland, H. J. In Culture of Hematopoietic Cells. R I. Freshney, et al. eds. Vol pp.139-162, Wiley-Liss, Inc., New York, N.Y. 1994,  
       [0177] 4.10.6 Tissue Growth Activity  
       [0178] A polypeptide of the present invention also may be involved in bone, cartilage, tendon, ligament and/or nerve tissue growth or regeneration, as well as in wound healing and tissue repair and replacement, and in healing of burns, incisions and ulcers.  
       [0179] A polypeptide of the present invention which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and crtilage damage or defects in humans and other animals. Compositions of a polypeptide, antibody, binding partner, or other modulator of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. De novo bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.  
       [0180] A polypeptide of this invention may also be involved in attracting bone-forming cells, stimulating growth of bone-forming cells, or inducing differentiation of progenitors of bone-forming cells. Treatment of osteoporosis, osteoarthritis, bone degenerative disorders, or periodontal disease, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes may also be possible using the composition of the invention.  
       [0181] Another category of tissue regeneration activity that may involve the polypeptide of the present invention is tendon/ligament formation. Induction of tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. De novo tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon-or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors ex vivo for return in vivo to effect tissue repair. The compositions of the invention may also be useful in the treatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art.  
       [0182] The compositions of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, i.e. for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, a composition may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer&#39;s, Parkinson&#39;s disease, Huntington&#39;s disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a composition of the invention.  
       [0183] Compositions of the invention may also be useful to promote better or faster closure of non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like.  
       [0184] Compositions of the present invention may also be involved in the generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation of fibrotic scarring may allow normal tissue to regenerate. A polypeptide of the present invention may also exhibit angiogenic activity.  
       [0185] A composition of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.  
       [0186] A composition of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above.  
       [0187] Therapeutic compositions of the invention can be used in the following:  
       [0188] Assays for tissue generation activity include, without limitation, those described in: International Patent Publication No. WO95/16035 (bone, cartilage, tendon); International Patent Publication No. WO95/05846 (nerve, neuronal); International Patent Publication No. WO91/07491 (skin, endothelium).  
       [0189] Assays for wound healing activity include, without limitation, those described in: Winter, Epidermal Wound Healing, pps. 71-112 (Maibach, H. I. and Rovee, D. T., eds.), Year Book Medical Publishers, Inc., Chicago, as modified by Eaglstein and Mertz, J. Invest. Dermatol 71:382-84 (1978).  
       [0190] 4.10.7 Immune Stimulating or Suppressing Activity  
       [0191] A polypeptide of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein. A polynucleotide of the invention can encode a polypeptide exhibiting such activities. A protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SCID)), e.g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fimgal infections, or may result from autoimmune disorders. More specifically, infectious diseases causes by viral, bacterial, fingal or other infection may be treatable using a protein of the present invention, including infections by HV, hepatitis viruses, herpes viruses, mycobacteria, Leishmania spp., malaria spp. and various fimgal infections such as candidiasis. Of course, in this regard, proteins of the present invention may also be useful where a boost to the immune system generally may be desirable, i. e., in the treatment of cancer.  
       [0192] Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid aritis, autoimmune pulmonary inflarnation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitis, myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease. Such a protein (or antagonists thereof, including antibodies) of the present invention may also to be useful in the treatment of allergic reactions and conditions (e.g. anaphylaxis, serum sickness, drug reactions, food allergies, insect venom allergies, mastocytosis, allergic rhinitis, hypersensitivity pneumonitis, urticaria, angioedema, eczema, atopic dermatitis, allergic contact dermatitis, erythema multiforme, Stevens-Johnson syndrome, allergic conjunctivitis, atopic keratoconjunctivitis, venereal keratoconjunctivitis, giant papillary conjunctivitis and contact allergies), such as asthma particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired (including, for example, organ transplantation), may also be treatable using a protein (or antagonists thereof) of the present invention. The therapeutic effects of the polypeptides or antagonists thereof on allergic reactions can be evaluated by in vivo animals models such as the cumulative contact enhancement test (Lastbom et al., Toxicology 125: 59-66, 1998), skin prick test (Hofftnann et al., Allergy 54: 446-54, 1999), guinea pig skin sensitization test (Vohr et al., Arch. Toxocol. 73: 501-9), and murine local lymph node assay (Kimber et al., J. Toxicol. Environ. Health 53: 563-79).  
       [0193] Using the proteins of the invention it may also be possible to modulate immune responses, in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an immune response. The functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.  
       [0194] Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions (such as, for example, B7)), e.g., preventing high level lymphokine synthesis by activated T cells, will be useftil in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant. The administration of a therapeutic composition of the invention may prevent cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, a lack of costitnulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte antigens.  
       [0195] The efficacy of particular therapeutic compositions in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins in vivo as described in Lenschow et al., Science 257:789-792 (1992) and Turka et al., Proc. Natl. Acad. Sci USA, 89:11102-11105 (1992). In addition, murine models of GVHD (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of therapeutic compositions of the invention on the development of that disease.  
       [0196] Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms. Administration of reagents which block stimulation of T cells can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythmatosis in MRLIlpr/lpr mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 840-856).  
       [0197] Upregulation of an antigen function (e.g., a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy. Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response may be useful in cases of viral infection, including systemic viral diseases such as influenza, the common cold, and encephalitis.  
       [0198] Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells in vitro with viral antigen-pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the in vitro activated T cells into the patient. Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells in vivo.  
       [0199] A polypeptide of the present invention may provide the necessary stimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient mounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (e.g., a cytoplasmic-domain truncated portion) of an MHC class I alpha chain protein and β 2  microglobulin protein or an NBC class II alpha chain protein and an MHC class II beta chain protein to thereby express MHC class I or MHC class If proteins on the cell surface. Expression of the appropriate class I or class II MHC in conjunction with a peptide having the activity of a B lymphocyte antigen (e.g., B7-1, B7-2, B7-3) induces a T cell mediated immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.  
       [0200] The activity of a protein of the invention may, among other means, be measured by the following methods:  
       [0201] Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., I. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Bowman et al., J. Virology 61:1992-1998; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Brown et al., J. Immunol. 153:3079-3092, 1994,  
       [0202] Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Th1/Th2 profiles) include, without limitation, those described in: Maliszewski, J. Immunol. 144:3028-3033, 1990; and Assays for B cell function: In vitro antibody production, Mond, J. J. and Brunswick, M. In Current Protocols in Immunology. J. E. e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.  
       [0203] Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Th1 and CTL responses) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., J. Immunol. 149:3778-3783, 1992.  
       [0204] Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of Experimental Medicine 173:549-559, 1991; Macatonia et al., Journal of Immunology 154:5071-5079, 1995; Porgador et al., Journal of Experimental Medicine 182:255-260, 1995; Nair et al., Journal of Virology 67:4062-4069, 1993; Huang et al., Science 264:961-965, 1994; Macatonia et al., Journal of Experimental Medicine 169:1255-1264, 1989; Bhardwaj et al., Journal of Clinical Investigation 94:797-807, 1994; and Inaba et al., Journal of Experimental Medicine 172:631-640, 1990.  
       [0205] Assays for lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzlewicz et al., Cytometry 13:795-808, 1992; Gorczyca et al., Leukemia 7:659-670, 1993; Gorczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991; Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai et al., Cytometry 14:891-897, 1993; Gorczyca et al., International Journal of Oncology 1:639-648, 1992.  
       [0206] Assays for proteins that influence early steps of Tell commitment and development include, without limitation, those described in: Antica et al., Blood 84:111-117, 1994; Fine et al., Cellular Immunology 155:111-122, 1994; Galy et al., Blood 85:2770-2778, 1995; Toki et al., Proc. Nat Acad Sci. USA 88:7548-7551, 1991.  
       [0207] 4.10.8 Activin/Inhibin Activity  
       [0208] A polypeptide of the present invention may also exhibit activin-or inhibin-related activities. A polynucleotide of the invention may encode a polypeptide exhibiting such characteristics. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins and are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, a polypeptide of the present invention, alone or in heterodimers with a member of the inhibin family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals. Alternatively, the polypeptide of the invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary. See, for example, U.S. Pat. No. 4,798,885. A polypeptide of the invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as, but not limited to, cows, sheep and pigs.  
       [0209] The activity of a polypeptide of the invention may, among other means, be measured by the following methods.  
       [0210] Assays for activin/inhibin activity include, without limitation, those described in: Vale et al., Endocrinology 91:562-572, 1972; Ling et al., Nature 321:779-782, 1986; Vale et al., Nature 321:776-779, 1986; Mason et al., Nature 318:659-663, 1985; Forage et al., Proc. Natl. Acad. Sci. USA 83:3091-3095, 1986.  
       [0211] 4 . 10 . 9  Chemotatic/Chemokinetic Activity  
       [0212] A polypeptide of the present invention may be involved in chemotactic or chemokinetic activity for mammalian cells, including, for example, monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells. A polynucleotide of the invention can encode a polypeptide exhibiting such attributes. Chemotactic and chemokinetic receptor activation can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic compositions (e.g. proteins, antibodies, binding partners, or modulators of the invention) provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent.  
       [0213] A protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxs.  
       [0214] Therapeutic compositions of the invention can be used in the following:  
       [0215] Assays for chemotactic activity (which will identify proteins that induce or prevent chemotaxis) consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Marguiles, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 6.12, Measurement of alpha and beta Chemokines 6.12.1-6.12.28; Taub et al. J. Clin. Invest. 95:1370-1376, 1995; Lind et al. APMIS 103:140-146, 1995; Muller et al Eur. J. Immunol. 25:1744-1748; Gruber et al. J. of Immunol. 152:5860-5867, 1994; Johnston et al. J. of Ilnunol. 153:1762-1768, 1994.  
       [0216] 4.10.10 Hemostatic and Thrombolytic Activity  
       [0217] A polypeptide of the invention may also be involved in hemostatis or thrombolysis or thrombosis. A polynucleotide of the invention can encode a polypeptide exhibiting such attributes. Compositions may be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A composition of the invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as, for example, infraction of cardiac and central nervous system vessels (e.g., stroke).  
       [0218] Therapeutic compositions of the invention can be used in the following:  
       [0219] Assay for hemostatic and thrombolytic activity include, without limitation, those described in: Linet et al., J. Clin. Pharmacol. 26:131-140, 1986; Burdick et al., Thrombosis Res. 45:413-419, 1987; Humphrey et al., Fibrinolysis 5:71-79 (1991); Schaub, Prostaglandins 35:467-474, 1988.  
       [0220] 4.10.11 Cancer Diagnosus and Therapy  
       [0221] Polypeptides of the invention may be involved in cancer cell generation, proliferation or metastasis. Detection of the presence or amount of polynucleotides or polypeptides of the invention may be useful for the diagnosis and/or prognosis of one or more types of cancer. For example, the presence or increased expression of a polynucleotide/polypeptide of the invention may indicate a hereditary risk of cancer, a precancerous condition, or an ongoing malignancy. Conversely, a defect in the gene or absence of the polypeptide may be associated with a cancer condition. Identification of single nucleotide polymorphisms associated with cancer or a predisposition to cancer may also be useful for diagnosis or prognosis.  
       [0222] Cancer treatments promote tumor regression by inhibiting tumor cell proliferation, inhibiting angiogenesis (growth of new blood vessels that is necessary to support tumor growth) and/or prohibiting metastasis by reducing tumor cell motility or invasiveness. Therapeutic compositions of the invention may be effective in adult and pediatric oncology including in solid phase tumors/malignancies, locally advanced tumors, human soft tissue sarcomas, metastatic cancer, including lymphatic metastases, blood cell malignancies including multiple myeloma, acute and chronic leukemias, and lymphomas, head and neck cancers including mouth cancer, larynx cancer and thyroid cancer, lung cancers including small cell carcinoma and non-small cell cancers, breast cancers including small cell carcinoma and ductal carcinoma, gastrointestinal cancers including esophageal cancer, stomach cancer, colon cancer, colorectal cancer and polyps associated with colorectal neoplasia, pancreatic cancers, liver cancer, urologic cancers including bladder cancer and prostate cancer, malignancies of the female genital tract including ovarian carcinoma, uterine (including endometrial) cancers, and solid tumor in the ovarian follicle, kidney cancers including renal cell carcinoma, brain cancers including intrinsic brain tumors, neuroblastoma, astrocytic brain tumors, gliomas, metastatic tumor cell invasion in the central nervous system, bone cancers including osteomas, skin cancers including malignant melanoma, tumor progression of human skin keratinocytes, squamous cell carcinoma, basal cell carcinoma, hemangiopericytoma and Karposi&#39;s sarcoma.  
       [0223] Polypeptides, polynucleotides, or modulators of polypeptides of the invention (including inhibitors and stimulators of the biological activity of the polypeptide of the invention) may be administered to treat cancer. Therapeutic compositions can be administered in therapeutically effective dosages alone or in combination with adjuvant cancer therapy such as surgery, chemotherapy, radiotherapy, thermotherapy, and laser therapy, and may provide a beneficial effect, e.g. reducing tumor size, slowing rate of tumor growth, inhibiting metastasis, or otherwise improving overall clinical condition, without necessarily eradicating the cancer.  
       [0224] The composition can also be administered in therapeutically effective amounts as a portion of an anti-cancer cocktail. An anti-cancer cocktail is a mixture of the polypeptide or modulator of the invention with one or more anti-cancer drugs in addition to a pharmaceutically acceptable carrier for delivery. The use of anti-cancer cocktails as a cancer treatment is routine. Anti-cancer drugs that are well known in the art and can be used as a treatment in combination with the polypeptide or modulator of the invention include: Actinomycin D, Aminoglutethimide, Asparaginase, Bleomycin, Busulfan, Carboplatin, Carnustine, Chlorambucil, Cisplatin (cis-DDP), Cyclophosphamide, Cytarabine HCI (Cytosine arabinoside), Dacarbazine, Dactinomycin, Daunorubicin HCl, Doxorubicin HCl, Estramustine phosphate sodium, Etoposide (V16-213), Floxuridine, 5-Fluorouracil (5-Fu), Flutamide, Hydroxyurea (hydroxycarbamide), Ifosfamide, Interferon Alpha-2a, Interferon Alpha-2b, Leuprolide acetate (LHRH-releasing factor analog), Lomustine, Mechlorethamine HC1 (nitrogen mustard), Melphalan, Mercaptopurine, Mesna, Methotrexate (MTX), Mitomycin, Mitoxantrone HCl, Octreotide, Plicamycin, Procarbazine HCl, Streptozocin, Tamoxifen citrate, Thioguanine, Thiotepa, Vinblastine sulfate, Vincristine sulfate, Amsacrine, Azacitidine, Hexamethylmelanine, Interleukin-2, Mitoguazone, Pentostatin, Semustine, Teniposide, and Vindesine sulfate.  
       [0225] In addition, therapeutic compositions of the invention may be used for prophylactic treatment of cancer. There are hereditary conditions and/or environmental situations (e.g. exposure to carcinogens) known in the art that predispose an individual to developing cancers. Under these circumstances, it may be beneficial to treat these individuals with therapeutically effective doses of the polypeptide of the invention to reduce the risk of developing cancers.  
       [0226] In vitro models can be used to determine the effective doses of the polypeptide of the invention as a potential cancer treatment. These in vitro models include proliferation assays of cultured tumor cells, growth of cultured tumor cells in soft agar (see Freshney, (1987) Culture of Animal Cells: A Manual of Basic Technique, Wily-Liss, New York, N.Y. Ch 18 and Ch 21), tumor systems in nude mice as described in Giovanella et al., J. Natl. Can. Inst., 52: 921-30 (1974), mobility and invasive potential of tumor cells in Boyden Chamber assays as described in Piington et al., Anticancer Res., 17: 4107-9 (1997), and angiogenesis assays such as induction of vascularization of the chick chorioallantoic membrane or induction of vascular endothelial cell migration as described in Ribatta et al., Intl. J. Dev. Biol., 40: 1189-97 (1999) and Li et al., Clin. Exp. Metastasis, 17:423-9 (1999), respectively. Suitable tumor cells lines are available, e.g. from American Type Tissue Culture Collection catalogs.  
       [0227] 4.10.12 Receptor/Ligand Activity  
       [0228] A polypeptide of the present invention may also demonstrate activity as receptor, receptor ligand or inhibitor or agonist of receptor/ligand interactions. A polynucleotide of the invention can encode a polypeptide exhibiting such characteristics. Examples of such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses. Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. A protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.  
       [0229] The activity of a polypeptide of the invention may, among other means, be measured by the following methods:  
       [0230] Suitable assays for receptor-ligand activity include without limitation those described in: Current Protocols in lmunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley- Interscience (Chapter 7.28, Measurement of Cellular Adhesion under static conditions 7.28.1-7.28.22), Takai et al., Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987; Bierer et al., J. Exp. Med. 168:1145-1156, 1988; Rosenstein et al., J. Exp. Med. 169:149-160 1989; Stoltenborg et al., J. Immunol. Methods 175:59-68, 1994; Stitt et al., Cell 80:661-670, 1995,  
       [0231] By way of example, the polypeptides of the invention may be used as a receptor for a ligand(s) thereby transmitting the biological activity of that ligand(s). Ligands may be identified through binding assays, affinity chromatography, dihybrid screening assays, BIAcore assays, gel overlay assays, or other methods known in the art.  
       [0232] Studies characterizing drugs or proteins as agonist or antagonist or partial agonists or a partial antagonist require the use of other proteins as competing ligands. The polypeptides of the present invention or ligand(s) thereof may be labeled by being coupled to radioisotopes, colorimetric molecules or a toxin molecules by conventional methods. (“Guide to Protein Purification” Murray P. Deutscher (ed) Methods in Enzymology Vol. 182 (1990) Academic Press, Inc. San Diego). Examples of radioisotopes include, but are not limited to, tritium and carbon-14 , Examples of colorimetric molecules include, but are not limited to, fluorescent molecules such as fluorescamine, or rhodaimine or other calorimetric molecules. Examples of toxins include, but are not limited, to ricin.  
       [0233] 4.10.13 Drug Screening  
       [0234] This invention is particularly useful for screening chemical compounds by using the novel polypeptides or binding fragments thereof in any of a variety of drug screening techniques. The polypeptides or fragments employed in such a test may either be free in solution, affixed to a solid support, borne on a cell surface or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or a fragment thereof. Drugs are screened against such transformed cells in competitive binding assays. Such cells, either in viable or fixed form, can be used for standard binding assays. One may measure, for example, the formation of complexes between polypeptides of the invention or fragments and the agent being tested or examine the diminution in complex formation between the novel polypeptides and an appropriate cell line, which are well known in the art.  
       [0235] Sources for test compounds that may be screened for ability to bind to or modulate (i.e., increase or decrease) the activity of polypeptides of the invention include (1) inorganic and organic chemical libraries, (2) natural product libraries, and (3) combinatorial libraries comprised of either random or mimetic peptides, oligonucleotides or organic molecules.  
       [0236] Chemical libraries may be readily synthesized or purchased from a number of commercial sources, and may include structural analogs of known compounds or compounds that are identified as “hits” or “leads” via natural product screening.  
       [0237] The sources of natural product libraries are microorganisms (including bacteria and fungi), animals, plants or other vegetation, or marine organisms, and libraries of mixtures for screening may be created by: (1) fermentation and extraction of broths from soil, plant or marine microorganisms or (2) extraction of the organisms themselves. Natural product libraries include polyketides, non-ribosomal peptides, and (non-naturally occurring) variants thereof. For a review, see  Science  282:63-68 (1998).  
       [0238] Combinatorial libraries are composed of large numbers of peptides, oligonucleotides or organic compounds and can be readily prepared by traditional automated synthesis methods, PCR, cloning or proprietary synthetic methods. Of particular interest are peptide and oligonucleotide combinatorial libraries. Still other libraries of interest include peptide, protein, peptidomimetic, multiparallel synthetic collection, recombinatorial, and polypeptide libraries. For a review of combinatorial chemistry and libraries created therefrom, see Myers,  Curr. Opin. Biotechnol , 8:701-707 (1997). For reviews and examples of peptidomimetic libraries, see Al-Obeidi et al.,  Mol. Biotechnol , 9(3):205-23 (1998); Hruby et al.,  Curr Opin Chem Biol , 1(1):114-119 (1997); Domer et al.,  Bioorg Med Chem , 4(5):709-15 (1996) (alkylated dipeptides).  
       [0239] Identification of modulators through use of the various libraries described herein permits modification of the candidate “hit” (or “lead”) to optimize the capacity of the “hit” to bind a polypeptide of the invention. The molecules identified in the binding assay are then tested for antagonist or agonist activity in in vivo tissue culture or animal models that are well known in the art. In brief, the molecules are titrated into a plurality of cell cultures or animals and then tested for either cell/animal death or prolonged survival of the animal/cells.  
       [0240] The binding molecules thus identified may be complexed with toxins, e.g., ricin or cholera, or with other compounds that are toxic to cells such as radioisotopes. The toxin-binding molecule complex is then targeted to a tumor or other cell by the specificity of the binding molecule for a polypeptide of the invention. Alternatively, the binding molecules may be complexed with imaging agents for targeting and imaging purposes.  
       [0241] 4.10.14 Assay for Recceptor Activity  
       [0242] The invention also provides methods to detect specific binding of a polypeptide e.g. a ligand or a receptor. The art provides numerous assays particularly useful for identifying previously unknown binding partners for receptor polypeptides of the invention. For example, expression cloning using mammalian or bacterial cells, or dihybrid screening assays can be used to identify polynucleotides encoding binding partners. As another example, affinity chromatography with the appropriate immobilized polypeptide of the invention can be used to isolate polypeptides that recognize and bind polypeptides of the invention. There are a number of different libraries used for the identification of compounds, and in particular small molecules, that modulate (i.e., increase or decrease) biological activity of a polypeptide of the invention. Ligands for receptor polypeptides of the invention can also be identified by adding exogenous ligands, or cocktails of ligands to two cells populations that are genetically identical except for the expression of the receptor of the invention: one cell population expresses the receptor of the invention whereas the other does not. The response of the two cell populations to the addition of ligands(s) are then compared. Alternatively, an expression library can be co-expressed with the polypeptide of the invention in cells and assayed for an autocrine response to identify potential ligand(s). As still another example, BIAcore assays, gel overlay assays, or other methods known in the art can be used to identify binding partner polypeptides, including, (1) organic and inorganic chemical libraries, (2) natural product libraries, and (3) combinatorial libraries comprised of random peptides, oligonucleotides or organic molecules.  
       [0243] The role of downstream intracellular signaling molecules in the signaling cascade of the polypeptide of the invention can be determined. For example, a chimeric protein in which the cytoplasmic domain of the polypeptide of the invention is fused to the extracellular portion of a protein, whose ligand has been identified, is produced in a host cell. The cell is then incubated with the ligand specific for the extracellular portion of the chimeric protein, thereby activating the chimeric receptor. Known downstream proteins involved in intracellular signaling can then be assayed for expected modifications i.e. phosphorylation. Other methods known to those in the art can also be used to identify signaling molecules involved in receptor activity.  
       [0244] 4 . 10 . 15  Anti-Inflammatory Activity  
       [0245] Compositions of the present invention may also exhibit anti-inflammatory activity. The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response. Compositions with such activities can be used to treat inflammatory conditions including chronic or acute conditions), including without limitation intimation associated with infection (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn&#39;s disease or resulting from over production of cytokines such as TNF or IL-1. Compositions of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material. Compositions of this invention may be utiiz to prevent or treat conditions such as, but not limited to, sepsis, acute pancreatitis, endotoxin shock, cytokine induced shock, rheumatoid arthritis, chronic inflammatory arthritis, pancreatic cell damage from diabetes mellitus type 1, graft versus host disease, inflammatory bowel disease, inflammation associated with pulmonary disease, other autoimmune disease or inflammatory disease, an antiproliferative agent such as for acute or chronic mylegenous leukemia or in the prevention of premature labor secondary to intrauterine infections.  
       [0246] 4.10.16 Leukemias  
       [0247] Leukemias and related disorders may be treated or prevented by administration of a therapeutic that promotes or inhibits function of the polynucleotides and/or polypeptides of the invention. Such leukemias and related disorders include but are not limited to acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia, chronic leukemia, chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia (for a review of such disorders, see Fisbman et al., 1985, Medicine, 2d Ed, J. B. Lippincott Co., Philadelphia).  
       [0248] 4.10.17 Nervous System Disordes  
       [0249] Nervous system disorders, involving cell types which can be tested for efficacy of intervention with compounds that modulate the activity of the polynucleotides and/or polypeptides of the invention, and which can be treated upon thus observing an indication of therapeutic utility, include but are not limited to nervous system injuries, and diseases or disorders which result in either a disconnection of axons, a diminution or degeneration of neurons, or demyelination. Nervous system lesions which may be treated in a patient (including human and non-human mammalian patients) according to the invention include but are not limited to the following lesions of either the central (including spinal cord, brain) or peripheral nervous systems:  
       [0250] (i) traumatic lesions, including lesions caused by physical injury or associated with surgery, for example, lesions which sever a portion of the nervous system, or compression injuries;  
       [0251] (ii) ischemic lesions, in which a lack of oxygen in a portion of the nervous system results in neuronal injury or death, including cerebral infarction or ischemia, or spinal cord infarction or ischemia;  
       [0252] (iii) infectious lesions, in which a portion of the nervous system is destroyed or injured as a result of infection, for example, by an abscess or associated with infection by human immunodeficiency virus, herpes zoster, or herpes simplex virus or with Lyme disease, tuberculosis, syphilis;  
       [0253] (iv) degenerative lesions, in which a portion of the nervous system is destroyed or injured as a result of a degenerative process including but not limited to degeneration associated with Parkinson&#39;s disease, Alzheimer&#39;s disease, Huntington&#39;s chorea, or amyotrophic lateral sclerosis;  
       [0254] (v) lesions associated with nutritional diseases or disorders, in which a portion of the nervous system is destroyed or injured by a nutritional disorder or disorder of metabolism including but not limited to, vitamin B12 deficiency, folic acid deficiency, Wernicke disease, tobacco-alcohol amblyopia, Marchiafava-Bignami disease (prirary degeneration of the corpus callosum), and alcoholic cerebellar degeneration;  
       [0255] (vi) neurological lesions associated with systemic diseases including but not limited to diabetes (diabetic neuropathy, Bell&#39;s palsy), systemic lupus erythematosus, carcinoma, or sarcoidosis;  
       [0256] (vii) lesions caused by toxic substances including alcohol, lead, or particular neurotoxins; and  
       [0257] (viii) demyelinated lesions in which a portion of the nervous system is destroyed or injured by a demyelinating disease including but not limited to multiple sclerosis, human immunodeficiency virus-associated myelopathy, transverse myelopathy or various etiologies, progressive multifocal leukoencephalopathy, and central pontine myelinolysis.  
       [0258] Therapeutics which are useful according to the invention for treatment of a nervous system disorder may be selected by testing for biological activity in promoting the survival or differentiation of neurons. For example, and not by way of limitation, therapeutics which elicit any of the following effects may be useful according to the invention:  
       [0259] (i) increased survival time of neurons in culture;  
       [0260] (ii) increased sprouting of neurons in culture or in vivo;  
       [0261] (iii) increased production of a neuron-associated molecule in culture or in vivo, e.g., choline acetyltransferase or acetylcholinesterase with respect to motor neurons; or  
       [0262] (iv) decreased symptoms of neuron dysfunction in vivo.  
       [0263] Such effects may be measured by any method known in the art. In preferred, non-limiting embodiments, increased survival of neurons may be measured by the method set forth in Arakawa et al. (1990, J. Neurosci. 10:3507-3515); increased sprouting of neurons may be detected by methods set forth in Pestronk et al. (1980, Exp. Neurol. 70:65-82) or Brown et al. (1981, Ann. Rev. Neurosci. 4:1742); increased production of neuron-associated molecules may be measured by bioassay, enzymatic assay, antibody binding, Northern blot assay, etc., depending on the molecule to be measured; and motor neuron dysfunction may be measured by assessing the physical manifestation of motor neuron disorder, e.g., weakness, motor neuron conduction velocity, or functional disability.  
       [0264] In specific embodiments, motor neuron disorders that may be treated according to the invention include but are not limited to disorders such as infarction, infection, exposure to toxin, trauma, surgical damage, degenerative disease or malignancy that may affect motor neurons as well as other components of the nervous system, as well as disorders that selectively affect neurons such as amyotrophic lateral sclerosis, and including but not limited to progressive spinal muscular atrophy, progressive bulbar palsy, primary lateral sclerosis, infantile and juvenile muscular atrophy, progressive bulbar paralysis of childhood (Fazio-Londe syndrome), poliomyelitis and the post polio syndrome, and Hereditary Motorsensory Neuropathy (Charcot-Marie-Tooth Disease).  
       [0265] 4.10.18 Other Activities  
       [0266] A polypeptide of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height, weight, hair coloreye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or circadian cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, co-factors or other nutritional factors or component(s); effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic lineages; hormonal or endocrine activity; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for example, the ability to bind antigens or complement); and the ability to act as an antigen in a vaccine composition to raise an immune response against such protein or another material or entity which is cross-reactive with such protein.  
       [0267] 4.10.19 Identification of Polymorphims  
       [0268] The demonstration of polymorphisms makes possible the identification of such polymorphisms in human subjects and the pharmacogenetic use of this information for diagnosis and treatment. Such polymorphisms may be associated with, e.g., differential predisposition or susceptibility to various disease states (such as disorders involving inflammation or immune response) or a differential response to drug administration, and this genetic information can be used to tailor preventive or therapeutic treatment appropriately. For example, the existence of a polymorphism associated with a predisposition to inflammation or autoimmune disease makes possible the diagnosis of this condition in humans by identifying the presence of the polymorphism.  
       [0269] Polymorphisms can be identified in a variety of ways known in the art which all generally involve obtaining a sample from a patient, analyzing DNA from the sample, optionally involving isolation or amplification of the DNA, and identifying the presence of the polymorphism in the DNA. For example, PCR may be used to amplify an appropriate fragment of genomic DNA which may then be sequenced. Alternatively, the DNA may be subjected to allele-specific oligonucleotide hybridization (in which appropriate oligonucleotides are hybridized to the DNA under conditions permitting detection of a single base mismatch) or to a single nucleotide extension assay (in which an oligonucleotide that hybridizes immediately adjacent to the position of the polymorphism is extended with one or more labeled nucleotides). In addition, traditional restriction fragment length polymorphism analysis (using restriction enzymes that provide differential digestion of the genomic DNA depending on the presence or absence of the polymorphism) may be performed. Arrays with nucleotide sequences of the present invention can be used to detect polymorphisms. The array can comprise modified nucleotide sequences of the present invention in order to detect the nucleotide sequences of the present invention. In the alternative, any one of the nucleotide sequences of the present invention can be placed on the array to detect changes from those sequences.  
       [0270] Alternatively a polymorphism resulting in a change in the amino acid sequence could also be detected by detecting a corresponding change in amino acid sequence of the protein, e.g., by an antibody specific to the variant sequence.  
       [0271] 4.10.20 Arthritritis and Inflammation  
       [0272] The immunosuppressive effects of the compositions of the invention against rheumatoid artbritis is determined in an experimental animal model system. The experimental model system is adjuvant induced arthritis in rats, and the protocol is described by J. Holoshitz, et at., 1983, Science, 219:56, or by B. Waksman et al., 1963, Int. Arch. Allergy Appl. Immunol., 23:129. Induction of the disease can be caused by a single injection, generally intradermally, of a suspension of killed Mycobacterium tuberculosis in complete Freund&#39;s adjuvant (CFA). The route of injection can vary, but rats may be injected at the base of the tail with an adjuvant mixture. The polypeptide is administered in phosphate buffered solution (PBS) at a dose of about 1-5 mg/kg. The control consists of administering PBS only.  
       [0273] The procedure for testing the effects of the test compound would consist of intradermally injecting killed Mycobacterium tuberculosis in CFA followed by immediately administering the test compound and subsequent treatment every other day until day 24. At 14, 15, 18, 20, 22, and 24 days after injection of Mycobacterium CFA, an overall arthritis score may be obtained as described by J. Holoskitz above. An analysis of the data would reveal that the test compound would have a dramatic affect on the swelling of the joints as measured by a decrease of the arthritis score.  
       4.11 Therapeutic Methods  
       [0274] The compositions (including polypeptide fragments, analogs, variants and antibodies or other binding partners or modulators including antisense polynucleotides) of the invention have numerous applications in a variety of therapeutic methods. Examples of therapeutic applications include, but are not limited to, those exemplified herein.  
       [0275] 4.11.1 Example  
       [0276] One embodiment of the invention is the administration of an effective amount of the polypeptides or other composition of the invention to individuals affected by a disease or disorder that can be modulated by regulating the peptides of the invention. While the mode of administration is not particularly important, parenteral administration is preferred. An exemplary mode of administration is to deliver an intravenous bolus. The dosage of the polypeptides or other composition of the invention will normally be determined by the prescribing physician. It is to be expected that the dosage will vary according to the age, weight, condition and response of the individual patient. Typically, the amount of polypeptide administered per dose will be in the range of about 0.01 μg/kg to 100 mg/kg of body weight, with the preferred dose being about 0.1 μg/kg to 10 mg/kg of patient body weight. For parenteral administration, polypeptides of the invention will be formulated in an injectable form combined with a pharmaceutically acceptable parenteral vehicle. Such vehicles are well known in the art and examples include water, saline, Ringer&#39;s solution, dextrose solution, and solutions consisting of small amounts of the human serum albumin. The vehicle may contain minor amounts of additives that maintain the isotonicity and stability of the polypeptide or other active ingredient. The preparation of such solutions is within the skill of the art.  
       4.12 Pharmaceutical Formulations and Routes of Administration  
       [0277] A protein or other composition of the present invention (from whatever source derived, including without limitation from recombinant and non-recombinant sources and including antibodies and other binding partners of the polypeptides of the invention) may be administered to a patient in need, by itself, or in pharmaceutical compositions where it is mixed with suitable carriers or excipient(s) at doses to treat or ameliorate a variety of disorders. Such a composition may optionally contain (in addition to protein or other active ingredient and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The term “pharmaceutically acceptable” means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier will depend on the route of administration. The pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IFN, TNF0, TNF1, TNF2, G-CSF, Meg-CSF, thrombopoietin, stem cell factor, and erythropoietin. In furler compositions, proteins of the invention may be combined with other agents beneficial to the treatment of the disease or disorder in question. These agents include various growth factors such as epidermal growth factor (EGF), platelet-derived growth factor (PDGF), transforming growth factors (TGF-αand TGF-β), insulin-like growth factor (IGF), as well as cytokines described herein.  
       [0278] The pharmaceutical composition may father contain other agents which either enhance the activity of the protein or other active ingredient or complement its activity or use in treatment. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with protein or other active ingredient of the invention, or to minimize side effects. Conversely, protein or other active ingredient of the present invention may be included in formulations of the particular clotting factor, cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflanmmatory agent to minimize side effects of the clotting factor, cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent (such as IL-1Ra, IL-1 Hy1, IL-1 Hy2, anti-TNF, corticosteroids, immunosuppressive agents). A protein of the present invention may be active in multimers (e.g., heterodimers or homodimers) or complexes with itself or other proteins. As a result, pharmaceutical compositions of the invention may comprise a protein of the invention in such multimeric or complexed form.  
       [0279] As an alternative to being included in a pharmaceutical composition of the invention including a first protein, a second protein or a therapeutic agent may be concurrently administered with the first protein (e.g., at the same time, or at differing times provided that therapeutic concentrations of the combination of agents is achieved at the treatment site). Techniques for formulation and administration of the compounds of the instant application may be found in “Remington&#39;s Pharmaceutical Sciences,” Mack Publishing Co., Easton, Pa., latest edition. A therapeutically effective dose fer refers to that amount of the compound sufficient to result in amelioration of symptoms, e.g., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions. When applied to an individual active ingredient, administered alone, a therapeutically effective dose refers to that ingredient alone. When applied to a combination, a therapeutically effective dose refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.  
       [0280] In practicing the method of treatment or use of the present invention, a therapeutically effective amount of protein or other active ingredient of the present invention is administered to a mammal having a condition to be treated. Protein or other active ingredient of the present invention may be administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors. When co-administered with one or more cytokines, lymphokines or other hematopoietic factors, protein or other active ingredient of the present invention may be administered either simultaneously with the cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administerng protein or other active ingredient of the present invention in combination with cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors.  
       [0281] 4.12.1 Routes of Administration  
       [0282] Suitable routes of administration may, for example, include oral, rectal, transmucosal, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections. Administration of protein or other active ingredient of the present invention used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, topical application or cutaneous, subcutaneous, intraperitoneal, parenteral or intravenous injection. Intravenous administration to the patient is preferred.  
       [0283] Alternately, one may administer the compound in a local rather than systemic manner, for example, via injection of the compound directly into a arthritic joints or in fibrotic tissue, often in a depot or sustained release formulation. In order to prevent the scarring process frequently occurring as complication of glaucoma surgery, the compounds may be administered topically, for example, as eye drops. Furthermore, one may administer the drug in a targeted drug delivery system, for example, in a liposome coated with a specific antibody, targeting, for example, arthritic or fibrotic tissue. The liposomes will be targeted to and taken up selectively by the afflicted tissue.  
       [0284] The polypeptides of the invention are administered by any route that delivers an effective dosage to the desired site of action. The determination of a suitable route of administration and an effective dosage for a particular indication is within the level of skill in the art. Preferably for wound treatment, one administers the therapeutic compound directly to the site. Suitable dosage ranges for the polypeptides of the invention can be extrapolated from these dosages or from similar studies in appropriate animal models. Dosages can then be adjusted as necessary by the clincian to provide maximal therapeutic benefit.  
       [0285] 4.12.2 Compositions/Formulations  
       [0286] Pharmaceutical compositions for use in accordance with the present invention thus may be formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. These pharmaceutical compositions may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes. Proper formulation is dependent upon the route of administration chosen. When a therapeutically effective amount of protein or other active ingredient of the present invention is administered orally, protein or other active ingredient of the present invention will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% protein or other active ingredient of the present invention, and preferably from about 25 to 90% protein or other active ingredient of the present invention. When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid form, the pharmaceutical composition contains from about 0.5 to 90% by weight of protein or other active ingredient of the present invention, and preferably from about 1 to 50% protein or other active ingredient of the present invention.  
       [0287] When a therapeutically effective amount of protein or other active ingredient of the present invention is administered by intravenous, cutaneous or subcutaneous injection, protein or other active ingredient of the present invention will be in the form of a pyrdgen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable protein or other active ingredient solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to protein or other active ingredient of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer&#39;s Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer&#39;s Injection, or other vehicle as known in the art. The pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art. For injection, the agents of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks&#39;s solution, Ringer&#39;s solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.  
       [0288] For oral administration, the compounds can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. Pharmaceutical preparations for oral use can be obtained from a solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.  
       [0289] Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid parain, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral adni ation should be in dosages suitable for such administration. For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.  
       [0290] For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount Capsules and cartridges of, e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch. The compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain fornulatory agents such as suspending, stabilizing and/or dispersing agents.  
       [0291] Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.  
       [0292] The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides. In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.  
       [0293] A pharmaceutical carrier for the hydrophobic compounds of the invention is a co-solvent system comprising benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase. The co-solvent system may be the VPD co-solvent system. VPD is a solution of 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant polysorbate 80, and 65% w/v polyethylene glycol 300, made up to volume in absolute ethanol. The VPD co-solvent system (VPD: 5W) consists of VPD diluted 1:1 with a 5% dextrose in water solution. This co-solvent system dissolves hydrophobic compounds well, and itself produces low toxicity upon systemic administration. Naturally, the proportions of a co-solvent system may be varied considerably without destroying its solubility and toxicity characteristics. Furthermore, the identity of the co-solvent components may be varied: for example, other low-toxicity nonpolar surfactants may be used instead of polysorbate 80; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, e.g. polyvinyl pyrrolidone; and other sugars or polysaccharides may substitute for dextrose. Alternatively, other delivery systems for hydrophobic pharmaceutical compounds may be employed. Liposomes and emulsions are well known examples of delivery vehicles or carriers for hydrophobic drugs. Certain organic solvents such as dimethylsulfoxide also may be employed, although usually at the cost of greater toxicity. Additionally, the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various types of sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein or other active ingredient stabilization may be employed.  
       [0294] The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols. Many of the active ingredients of the invention may be provided as salts with pharmaceutically compatible counter ions. Such pharmaceutically acceptable base addition salts are those salts which retain the biological effectiveness and properties of the free acids and which are obtained by reaction with inorganic or organic bases such as sodium hydroxide, magnesium hydroxide, ammonia, trialkylamine, dialkylamine, monoalkylamine, dibasic amino acids, sodium acetate, potassium benzoate, triethanol amine and the like.  
       [0295] The pharmaceutical composition of the invention may be in the form of a complex of the protein(s) or other active ingredient(s) of present invention along with protein or peptide antigens. The protein and/or peptide antigen will deliver a stimulatory signal to both B and T lymphocytes. B lymphocytes will respond to antigen through their surface immunoglobulin receptor. T lymphocytes will respond to antigen through the T cell receptor (TCR) following presentation of the antigen by MHC proteins. MHC and structurally related proteins including those encoded by class I and class II MHC genes on host cells will serve to present the peptide antigen(s) to T lymphocytes. The antigen components could also be supplied as purified MHC-peptide complexes alone or with co-stimulatory molecules that can directly signal T cells. Alternatively antibodies able to bind surface immunoglobulin and other molecules on B cells as well as antibodies able to bind the TCR and other molecules on T cells can be combined with the pharmaceutical composition of the invention.  
       [0296] The pharmaceutical composition of the invention may be in the form of a liposome in which protein of the present invention is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithins, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Pat. Nos. 4,235,871; 4,501,728; 4,837,028; and 4,737,323, all of which are incorporated herein by reference.  
       [0297] The amount of protein or other active ingredient of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of protein or other active ingredient of the present invention with which to treat each individual patient. Initially, the attending physician will administer low doses of protein or other active ingredient of the present invention and observe the patient&#39;s response. Larger doses of protein or other active ingredient of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.01 μg to about 100 mg (preferably about 0.1 μg to about 10 mg, more preferably about 0.1 μg to about 1 mg) of protein or other active ingredient of the present invention per kg body weight. For compositions of the present invention which are useful for bone, cartilage, tendon or ligament regeneration, the therapeutic method includes administering the composition topically, systematically, or locally as an implant or device. When administered, the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage or tissue damage. Topical administration may be suitable for wound healing and tissue repair. Therapeutically useful agents other than a protein or other active ingredient of the invention which may also optionally be included in the composition as described above, may alternatively or additionally, be administered simultaneously or sequentially with the composition in the methods of the invention. Preferably for bone and/or cartilage formation, the composition would include a matrix capable of delivering the protein-containing or other active ingredient-containing composition to the site of bone and/or cartilage damage, providing a structure for the developing bone and cartilage and optimally capable of being resorbed into the body. Such matrices may be formed of materials presently in use for other implanted medical applications.  
       [0298] The choice of matrix material is based on biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. The particular application of the compositions will define the appropriate formulation. Potential matrices for the compositions may be biodegradable and chemically defined calcium sulfate, tricalcium phosphate, hydroxyapatite, polylactic acid, polyglycolic acid and polyanhydrides. Other potential materials are biodegradable and biologically well-defined, such as bone or dermal collagen. Further matrices are comprised of pure proteins or extracellular matrix components. Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxyapatite, bioglass, aluminates, or other ceramics. Matrices may be comprised of combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalcium phosphate. The bioceramics may be altered in composition, such as in calcium-aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability. Presently preferred is a 50:50 (mole weight) copolymer of lactic acid and glycolic acid in the form of porous particles having diameters ranging from 150 to 800 microns. In some applications, it will be useful to utilize a sequestering agent, such as carboxymethyl cellulose or autologous blood clot, to prevent the protein compositions from disassociating from the matrix.  
       [0299] A preferred family of sequestering agents is cellulosic materials such as alkylcelluloses (including hydroxyalkylcelluloses), including methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl-methylcellulose, and carboxymethylcellulose, the most preferred being cationic salts of carboxymethylcellulose (CMC). Other preferred sequestering agents include hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer and poly(vinyl alcohol). The amount of sequestering agent useful herein is 0.5-20 wt %, preferably 1-10 wt % based on total formulation weight, which represents the amount necessary to prevent desorption of the protein from the polymer matrix and to provide appropriate handling of the composition, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells. In further compositions, proteins or other active ingredients of the invention may be combined with other agents beneficial to the treatment of the bone and/or cartilage defect, wound, or tissue in question. These agents include various growth factors such as epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factors (TGF-αand TGF-β), and insulin-like growth factor (IGF).  
       [0300] The therapeutic compositions are also presently valuable for veterinary applications. Particularly domestic animals and thoroughbred horses, in addition to humans, are desired patients for such treatment with proteins or other active ingredients of the present invention. The dosage regimen of a ptotein-containing pharmaceutical composition to be used in tissue regeneration will be determined by the attending physician considering various factors which modify the action of the proteins, e.g., amount of tissue weight desired to be formed, the site of damage, the condition of the damaged tissue, the size of a wound, type of damaged tissue (e.g., bone), the patients age, sex, and diet, the severity of any infection, time of administration and other clinical factors. The dosage may vary with the type of matrix used in the reconstitution and with inclusion of other proteins in the pharmaceutical composition. For example, the addition of other known growth factors, such as IGF I (insulin like growth factor I), to the final composition, may also effect the dosage. Progress can be monitored by periodic assessment of tissue/bone growth and/or repair, for example, X-rays, histomorphometric determinations and tetracycline labeling.  
       [0301] Polynucleotides of the present invention can also be used for gene therapy. Such polynucleotides can be introduced either in vivo or ex vivo into cells for expression in a mammalian subject. Polynucleotides of the invention may also be administered by other known methods for introduction of nucleic acid into a cell or organism (including, without limitation, in the form of viral vectors or naked DNA). Cells may also be cultured ex vivo in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced in vivo for therapeutic purposes.  
       [0302] 4.12.3 Efective Dosage  
       [0303] Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amotit to achieve its intended purpose. More specifically, a therapeutically effective amount means an amount effective to prevent development of or to alleviate the existing symptoms of the subject being treated. Determination of the effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from appropriate in vitro assays. For example, a dose can be formulated in animal models to achieve a circulating concentration range that can be used to more accurately determine useful doses in humans. For example, a dose can be formulated in animal models to achieve a circulating concentration range that includes the IC 50  as determined in cell culture (i.e., the concentration of the test compound which achieves a half-maximal inhibition of the protein&#39;s biological activity). Such information can be used to more accurately determine useful doses in humans.  
       [0304] A therapeutically effective dose refers to that amount of the compound that results in amelioration of symptoms or a prolongation of survival in a patient. Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD 50  (the dose lethal to 50% of the population) and the ED 50  (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio between LD 50  and EDso. Compounds which exhibit high therapeutic indices are preferred. The data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED 50  with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient&#39;s condition. See, e.g., Fingl et al., 1975, in “The Pharmacological Basis of Therapeutics”, Ch. 1 p. 1. Dosage amount and interval may be adjusted individually to provide plasma levels of the active moiety which are sufficient to maintain the desired effects, or minimal effective concentration (MEC). The MEC will vary for each compound but can be estimated from in vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. However, HPLC assays or bioassays can be used to determine plasma concentrations.  
       [0305] Dosage intervals can also be determined using MEC value. Compounds should be administered using a regimen which maintains plasma levels above the MEC for 10-90% of the time, preferably between 30-90% and most preferably between 50-90%. In cases of local administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration.  
       [0306] An exemplary dosage regimen for polypeptides or other compositions of the invention will be in the range of about 0.01 μg/kg to 100 mg/kg of body weight daily, with the preferred dose being about 0.1 μg/kg to 25 mg/kg of patient body weight daily, varying in adults and children. Dosing may be once daily, or equivalent doses may be delivered at longer or shorter intervals.  
       [0307] The amount of composition administered will, of course, be dependent on the subject being treated, on the subject&#39;s age and weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician.  
       [0308] 4.12.4 Packaging  
       [0309] The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may, for example, comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. Compositions comprising a compound of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.  
       4.13 Antibodies  
       [0310] Also included in the invention are antibodies to proteins, or fragments of proteins of the invention. The term “antibody” as used herein refers to immunoglobulin molecules and immunologically active portions of inmmunoglobulin (1g) molecules, i.e., molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, Fg&amp;, Fab and F(ab)2 fragments, and an Fab expression library. In general, an antibody molecule obtained from humans relates to any of the classes IgG, IgM, IgA, IgE and IgD, which differ from one another by the nature of the heavy chain present in the molecule. Certain classes have subclasses as well, such as IgG 1 , IgG 2 , and others. Furthermore, in humans, the light chain may be a kappa chain or a lambda chain. Reference herein to antibodies includes a reference to all such classes, subclasses and types of human antibody species.  
       [0311] An isolated related protein of the invention may be intended to serve as an antigen, or a portion or fragment thereof, and additionally can be used as an immunogen to generate antibodies that immunospecifically bind the antigen, using standard techniques for polyclonal and monoclonal antibody preparation. The fir length protein can be used or, alternatively, the invention provides antigenic peptide fragments of the antigen for use as immunogens. An antigenic peptide fragment comprises at least 6 amino acid residues of the amino acid sequence of the full length protein, (for example the amino acid sequence shown in SEQ ID NO: 1351), and encompasses an epitope thereof such that an antibody raised against the peptide forms a specific immune complex with the full length protein or with any fragment that contains the epitope. Preferably, the antigenic peptide comprises at least 10 amino acid residues, or at least 15 amino acid residues, or at least 20 amino acid residues, or at least 30 amino acid residues. Preferred epitopes encompassed by the antigenic peptide are regions of the protein that are located on its surface; commonly these are hydrophilic regions.  
       [0312] In certain embodiments of the invention, at least one epitope encompassed by the antigenic peptide is a region of -related protein that is located on the surface of the protein, e.g., a hydrophilic region. A hydrophobicity analysis of the human related protein sequence will indicate which regions of a related protein are particularly hydrophilic and, therefore, are likely to encode surface residues useful for targeting antibody production. As a means for targeting antibody production, hydropathy plots showing regions of hydrophilicity and hydrophobicity may be generated by any method well known in the art, including, for example, the Kyte Doolittle or the Hopp Woods methods, either with or without Fourier transformation. See, e.g., Hopp and Woods, 1981 , Proc. Nat. Acad. Sci. USA  78: 3824-3828; Kyte and Doolittle 1982 , J. Mol. Biol . 157: 105-142, each of which is incorporated herein by reference in its entirety. Antibodies that are specific for one or more domains within an antigenic protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.  
       [0313] A protein of the invention, or a derivative, fragment, analog, homolog or ortholog thereof, may be utilized as an immunogen in the generation of antibodies that immunospecifically bind these protein components.  
       [0314] Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies directed against a protein of the invention, or against derivatives, fragments, analogs homologs or orthologs thereof (see, for example, Antibodies: A Laboratory Manual, Harlow E, and Lane D, 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., incorporated herein by reference). Some of these antibodies are discussed below.  
       [0315] 5.13.1 Polyclonal Antibodies  
       [0316] For the production of polyclonal antibodies, various suitable host animals (e.g., rabbit, goat, mouse or other mammal) may be immunized by one or more injections with the native protein, a synthetic variant thereof, or a derivative of the foregoing. An appropriate immunogenic preparation can contain, for example, the naturally occurring immunogenic protein, a chemically synthesized polypeptide representing the immunogenic protein, or a recombinantly expressed immunogenic protein. Furthermore, the protein may be conjugated to a second protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. The preparation can further include an adjuvant. Various adjuvants used to increase the immunological response include, but are not limited to, Freund&#39;s (complete and incomplete), mineral gels (e.g., aluminum hydroxide), surface active substances (e.g., lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), adjuvants usable in humans such as Bacille Calmette-Guerin and Corynebacterium parvum, or similar immunostimulatory agents. Additional examples of adjuvants which can be employed include MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).  
       [0317] The polyclonal antibody molecules directed against the immunogenic protein can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific antigen which is the target of the immunoglobulin sought, or an epitope thereof, may be immobilized on a column to purify the immune specific antibody by immunoaffinity chromatography. Purification of immunoglobulins is discussed, for example, by D. Wilkinson (The Scientist, published by The Scientist, Inc., Philadelphia Pa., Vol. 14, No. 8 (Apr. 17, 2000), pp. 25-28).  
       [0318] 5.13.2 Monoclonal Antibodies  
       [0319] The term “monoclonal antibody” (MAb) or “monoclonal antibody composition”, as used herein, refers to a population of antibody molecules that contain only one molecular species of antibody molecule consisting of a unique light chain gene product and a unique heavy chain gene product In particular, the complementary determining regions (CDRs) of the monoclonal antibody are identical in all the molecules of the population. MAbs thus contain an antigen binding site capable of immunoreacting with a particular epitope of the antigen characterized by a unique binding affinity for it.  
       [0320] Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein,  Nature , 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized in vitro.  
       [0321] The immunizing agent will typically include the protein antigen, a fragment thereof or a fusion protein thereof. Generally, either peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalited cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding,  Monoclonal Antibodies: Principles and Practice  Academic Press, (1986) pp. 59-103). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (“HAT medium”), which substances prevent the growth of HGPRT-deficient cells.  
       [0322] Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, Calif. and the American Type Culture Collection, Manassas, Va. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor,  J. Immunol ., 133:3001 (1984); Brodeur et al.,  Monoclonal Antibodv Production Techniques and Applications , Marcel Dekker, Inc., New York, (1987) pp. 51-63).  
       [0323] The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmrunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard,  Anal. Biochem . 107:220 (1980). Preferably, antibodies having a high degree of specificity and a high binding affnity for the target antigen are isolated.  
       [0324] After the desired hybridoma cells are identified, the clones can be subdoned by limiting dilution procedures and grown by standard methods. Suitable culture media for this purpose include, for example, Dulbecco&#39;s Modified Eagle&#39;s Medium and RPMI-1640 medium. Alternatively, the hybridoma cells can be grown in vivo as as cites in a mammal.  
       [0325] The monoclonal antibodies secreted by the subdlones can be isolated or purified from the culture medium or as cites fluid by conventional inmmunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.  
       [0326] The monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Pat. No. 4,816,567, DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g. by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Pat. No. 4,816,567; Morrison,  Nature  368, 812-13 (1994)) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.  
       [0327] 5.13.2 Humanized Antibodies  
       [0328] The antibodies directed against the protein antigens of the invention can further comprise humanized antibodies or human antibodies. These antibodies are suitable for administration to humans without engendering an immune response by the human against the administered irrunoglobulin. Humanized forms of antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab′, F(ab′) 2  or other antigen-binding subsequences of antibodies) that are principally comprised of the sequence of a human immunoglobulin, and contain minimal sequence derived from a non-human immunoglobulin. Humanization can be performed following the method of Winter and co-workers (Jones et al.,  Nature  321:522-525 (1986); Riechmann et al.,  Nature , 332:323-327 (1988); Verhoeyen et al.,  Science , 239:15341536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. (See also U.S. Pat. No. 5,225,539.) In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies can also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., 1986; Riechmann et al., 1988; and Presta,  Curr. Op. Struct. Biol ., 2:593-596 (1992)).  
       [0329] 5.13.3 Human Antibodies  
       [0330] Fully human antibodies relate to antibody molecules in which essentially the entire sequences of both the light chain and the heavy chain, including the CDRs, arise from human genes. Such antibodies are termed “human antibodies”, or “fully human antibodies” herein. Human monoclonal antibodies can be prepared by the trioma technique; the human B-cell hybridoma technique (see Kozbor, et al., 1983 Immunol Today 4: 72) and tile EBV hybridoma technique to produce human monoclonal antibodies (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies may be utilized in the practice of the present invention and may be produced by using human hybridomas (see Cote, et al., 1983, Proc Natl Acad Sci USA 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus in vitro (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96).  
       [0331] In addition, human antibodies can also be produced using additional techniques, including phage display libraries (Hoogenboom and Winter,  J. Mol. Biol ., 227:381 (1991); Marks et al.,  J. Mol. Biol . 222:581 (1991)). Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animnals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in Marks et al. ( Bio/Technology  10 779-783 (1992)); Lonberg et al.  Nature  368 856-859 (1994)); Morrison ( Nature  368, 812-13 (1994)); Fishwild et al, ( Nature Biotechnology  14, 845-51 (1996)); Neuberger ( Nature Biotechnology  14, 826 (1996)); and Lonberg and Huszar ( Intern. Rev. Immunol . 13 65-93 (1995)).  
       [0332] Human antibodies may additionally be produced using transgenic nonhuman animals which are modified so as to produce fully human antibodies rather than the animal&#39;s endogenous antibodies in response to challenge by an antigen. (See PCT publication WO94/02602). The endogenous genes encoding the heavy and light immunoglobulin chains in the nonhuman host have been incapacitated, and active loci encoding human heavy and light chain immunoglobulins are inserted into the host&#39;s genome. The human genes are incorporated, for example, using yeast artificial chromosomes containing the requisite human DNA segments. An animal which provides all the desired modifications is then obtained as progeny by crossbreeding intermediate transgenic animals containing fewer than the full complement of the modifications. The preferred embodiment of such a nonhuman animal is a mouse, and is termed the Xenomouse™ as disclosed in PCT publications WO96/33735 and WO 96/34096, This animal produces B cells which secrete fully human immunoglobulins. The antibodies can be obtained directly from the animal after immunization with an immunogen of interest, as, for example, a preparation of a polyclonal antibody, or alternatively from immortalized B cells derived from the animal, such as hybridomas producing monoclonal antibodies. Additionally, the genes encoding the immunoglobulins with human variable regions can be recovered and expressed to obtain the antibodies directly, or can be further modified to obtain analogs of antibodies such as, for example, single chain Fv molecules.  
       [0333] An example of a method of producing a nonhuman host, exemplified as a mouse, lacking expression of an endogenous immunoglobulin heavy chain is disclosed in U.S. Pat. No. 5,939,598. It can be obtained by a method including deleting the J segment genes from at least one endogenous heavy chain locus in an embryonic stem cell to prevent rearrangement of the locus and to prevent formation of a transcript of a rearranged immunoglobulin heavy chain locus, the deletion being effected by a targeting vector containing a gene encoding a selectable marker; and producing from the embryonic stem cell a transgemic mouse whose somatic and germ cells contain the gene encoding the selectable marker.  
       [0334] A method for producing an antibody of interest, such as a human antibody, is disclosed in U.S. Pat. No. 5,916,771, It includes introducing an expression vector that contains a nucleotide sequence encoding a heavy chain into one mammalian host cell in culture, introducing an expression vector containing a nucleotide sequence encoding a light chain into another mammalian host cell, and fusing the two cells to form a hybrid cell. The hybrid cell expresses an antibody containing the heavy chain and the light chain.  
       [0335] In a further improvement on this procedure, a method for identifying a clinically relevant epitope on an immunogen, and a correlative method for selecting an antibody that binds immunospecifically to the relevant epitope with high affinity, are disclosed in PCT publication WO99/53049.  
       [0336] 5.13.4 F ab  Fragments and Single Chain Antibodies  
       [0337] According to the invention, techniques can be adapted for the production of single-chain antibodies specific to an antigenic protein of the invention (see e.g., U.S. Pat. No. 4,946,778). In addition, methods can be adapted for the construction of F ab  expression libraries (see e.g., Huse, et al., 1989 Science 246: 1275-1281) to allow rapid and effective identification of monoclonal F ab  fragments with the desired specificity for a protein or derivatives, fragments, analogs or homologs thereof. Antibody fragments that contain the idiotypes to a protein antigen may be produced by techniques known in the art including, but not limited to: (i) an.F( ab )2 fragment produced by pepsin digestion of an antibody molecule; (ii) an F ab  fragment generated by reducing the disulfide bridges of an F( ab )2 fragment; (iii) an F ab  fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) F ab  fragments.  
       [0338] 5.13.5 Bispecific Antibodies  
       [0339] Bispecific antibodies are monoclonal, preferably human or hunized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for an antigenic protein of the invention. The second binding target is any other antigen, and advantageously is a cell-surface protein or receptor or receptor subunit.  
       [0340] Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two irrunoglobulin heavy-chami/light-cham. pairs, where the two heavy chains have different specificities (Milstein and Cuello,  Nature , 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture often different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published May 13, 1993, and in Traunecker et al., 1991  EMBO J ., 10:3655-3659.  
       [0341] Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh et al.,  Methods in Enzymology . 121:210 (1986).  
       [0342] According to another approach described in WO96/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 region of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophan). Compensatory “cavities” of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodiimers.  
       [0343] Bispecific antibodies can be prepared as fill length antibodies or antibody fragments (e.g. F(ab′) bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al.,  Science  229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab′) 2  fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab′ fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab′-TNB derivatives is then reconverted to the Fab′-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab′-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.  
       [0344] Additionally, Fab′ fragments can be directly recovered from  E. coli  and chemically coupled to form bispecific antibodies. Shalab′ y et al.,  J. Exn. Med . 175:217-225 (1992) describe the production of a fully humanized bispecific antibody .F(ab′ )2 molecule. Each Fab′ fragment was separately secreted from E. coli and subjected to directed chemical coupling in vitro to form the bispecific antibody. The bispecific antibody thus formed was ab′ le to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.  
       [0345] Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al.,  J. Immunol . 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab′ portions of two different antibodies by gene fuision. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The “diabody” technology described by Hollinger et al.,  Proc. Natl. Acad. Sci. USA  90:64446448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (V H ) connected to a light-chain variab′ le domain (V L ) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the V H  and V L  domains of one fragment are forced to pair with the complementary V L  and V H  domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber et al.,  J. Immunol . 152:5368, (1994).  
       [0346] Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al.,  J. Immunol . 147:60 (1991). Exemplary bispecific antibodies can bind to two different epitopes, at least one of which originates in the protein antigen of the invention. Alternatively, an anti-antigenic arm of an immunoglobulin molecule can be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG (Fe R), such as Fe RI (CD64), Fe RII (CD32) and Fc RIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular antigen. Bispecific antibodies can also be used to direct cytotoxic agents to cells which express a particular antigen. These antibodies possess an antigen-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the protein antigen described herein and further binds tissue factor (IF).  
       [0347] 5.13.6 Heteroconjugate Antibodies  
       [0348] Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Pat. No. 4,676,980), and for treatment of HIV infection (WO 91/00360; WO 92/200373; EP 03089). It is contemplated that the antibodies can be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins can be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl4-mercaptobutyrimidate and those disclosed, for example, in U.S. Pat. No. 4,676,980.  
       [0349] 5 . 13 . 7  Effector Function Engineering  
       [0350] It can be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, e.g., the effectiveness of the antibody in treating cancer. For example, cysteine residue(s) can be introduced into the Fe region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated can have improved internalization capability and/or increased complement-mediated cell dilling and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., J. Exp Med., 176: 1191-1195 (1992) and Shopes, J. Immunol., 148: 2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity can also be prepared using heterobifunctional cross-linkers as described in Wolff et al. Cancer Research, 53: 2560-2565 (1993). Alternatively, an antibody can be engineered that has dual Fe regions and can thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al., Anti-Cancer Drug Design, 3: 219-230 (1989).  
       [0351] 5.13.8 Immunoconjugates  
       [0352] The invention also pertains to Immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (ie., a radioconjugate).  
       [0353] Chemotherapeutic agents useful in the generation of such Immunoconjugates have been described above. Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include  212  Bi,  131 In,  90 Y, and  186 Re.  
       [0354] Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutareldehyde), bis-azido compounds (such as bis (pazidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis (pdiazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al., Science, 238: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO094/1 1026.  
       [0355] In another embodiment, the antibody can be conjugated to a “receptor” (such streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a “ligand” (e.g., avidin) that is in turn conjugated to a cytotoxic agent  
       4.14 Computer Readable Sequence  
       [0356] In one application of this embodiment, a nucleotide sequence of the present invention can be recorded on computer readable media. As used herein, “computer readable media” refers to any medium which can be read and accessed directly by a computer. Such media include, but are not limited to: magnetic storage media, such as floppy discs, hard disc storage medium, and magnetic tape; optical storage media such as CD-ROM; electrical storage media such as RAM and ROM; and hybrids of these categories such as magnetic/optical storage media. A skilled artisan can readily appreciate how any of the presently known computer readable mediums can be used to create a manufacture comprising computer readable medium having recorded thereon a nucleotide sequence of the present invention. As used herein, “recorded” refers to a process for storing information on computer readable medium. A skilled artisan can readily adopt any of the presently known methods for recording information on computer readable medium to generate manufactures comprising the nucleotide sequence information of the present invention.  
       [0357] A variety of data storage structures are available to a skilled artisan for creating a computer readable medium having recorded thereon a nucleotide sequence of the present invention. The choice of the data storage structure will generally be based on the means chosen to access the stored information. In addition, a variety of data processor programs and formats can be used to store the nucleotide sequence information of the present invention on computer readable medium. The sequence information can be represented in a word processing text file, formatted in comrnercially-available software such as WordPerfect and Microsoft Word, or represented in the form of an ASCII file, stored in a datab ase application, such as DB2, Sybase, Oracle, or the like. A skilled artisan can readily adapt any number of data processor structuring formats (e.g. text file or datab ase) in order to obtain computer readable medium having recorded thereon the nucleotide sequence information of the present invention.  
       [0358] By providing any of the nucleotide sequences SEQ ID NO: 1-1350 or a representative fragment thereof, or a nucleotide sequence at least 95% identical to any of the nucleotide sequences of SEQ ID NO: 1-1350 in computer readable form, a skilled artisan can routinely access the sequence information for a variety of purposes. Computer software is publicly available which allows a skilled artisan to access sequence information provided in a computer readable medium. The examples which follow demonstrate how software which implements the BLAST (Altschul et al., J. Mol. Biol. 215:403410 (1990)) and BLAZE (Brutlag et al., Comp. Chem. 17:203-207 (1993)) search algorithms on a Sybase system is used to identify open reading frames (ORFs) within a nucleic acid sequence. Such ORs may be protein encoding fragments and may be useful in producing commercially important proteins such as enzymes used in fermentation reactions and in the production of commercially useful metabolites.  
       [0359] As used herein, “a computer-based system” refers to the hardware means, software means, and data storage means used to analyze the nucleotide sequence information of the present invention. The minimum hardware means of the computer-based systems of the present invention comprises a central processing unit (CPU), input means, output means, and data storage means. A skilled artisan can readily appreciate that any one of the currently availab′ le computer-based systems are suitable for use in the present invention. As stated ab′ ove, the computer-based systems of the present invention comprise a data storage means having stored therein a nucleotide sequence of the present invention and the necessary hardware means and software means for supporting and implementing a search means. As used herein, “data storage means” refers to memory which can store nucleotide sequence information of the present invention, or a memory access means which can access manufactures having recorded thereon the nucleotide sequence information of the present invention.  
       [0360] As used herein, “search means” refers to one or more programs which are implemented on the computer-based system to compare a target sequence or target structural motif with the sequence information stored within the data storage means. Search means are used to identify fragments or regions of a known sequence which match a particular target sequence or target motif. A variety of known algorithms are disclosed publicly and a variety of commercially available software for conducting search means are and can be used in the computer-based systems of the present invention. Examples of such software includes, but is not limited to, Smith-Waterman, MacPattern (EMBL), BLASTN and BLASTA (NPOLYPEPTIDEIA). A skilled artisan can readily recognize that any one of the available algorithms or implementing software packages for conducting homology searches can be adapted for use in the present computer-based systems. As used herein, a “target sequence” can be any nucleic acid or amino acid sequence of six or more nucleotides or two or more amino acids. A skilled artisan can readily recognize that the longer a target sequence is, the less likely a target sequence will be present as a random occurrence in the database. The most preferred sequence length of a target sequence is from about 10 to 300 amino acids, more preferably from about 30 to 100 nucleotide residues. However, it is well recognized that searches for commercially important fragments, such as sequence fragrents involved in gene expression and protein processing, may be of shorter length.  
       [0361] As used herein, “a target structural motif,” or “target motif,” refers to any rationally selected sequence or combination of sequences in which the sequence(s) are chosen based on a three-dimensional configuration which is formed upon the folding of the target motif. There are a variety of target motifs known in the art. Protein target motifs include, but are not limited to, enzyme active sites and signal sequences. Nucleic acid target motifs include, but are not limited to, promoter sequences, hairpin structures and inducible expression elements (protein binding sequences).  
       4.15 Triple Helix Formation  
       [0362] In addition, the fragments of the present invention, as broadly described, can be used to control gene expression through triple helix formation or antisense DNA or RNA, both of which methods are based on the binding of a polynucleotide sequence to DNA or RNA. Polynucleotides suitable for use in these methods are preferably 20 to 40 bases in length and are designed to be complementary to a region of the gene involved in transcription (triple helix—see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 15241:456 (1988); and Dervan et al., Science 251:1360 (1991)) or to the mRNA itself (antisense—Olmno, J. Neurochem. 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, Fla. (1988)). Triple helix-formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques have been demonstrated to be effective in model systems. Information contained in the sequences of the present invention is necessary for the design of an antisense or triple helix oligonucleotide.  
       4.16 Diagnostic Assay and Kits  
       [0363] The present invention further provides methods to identify the presence or expression of one of the ORFs of the present invention, or homolog thereof, in a test sample, using a nucleic acid probe or antibodies of the present invention, optionally conjugated or otherwise associated with a suitable label.  
       [0364] In general, methods for detecting a polynucleotide of the invention can comprise contacting a sample with a compound that binds to and forms a complex with the polynucleotide for a period sufficient to form the complex, and detecting the complex, so that if a complex is detected, a polynucleotide of the invention is detected in the sample. Such methods can also comprise contacting a sample under stringent hybridization conditions with nucleic acid primers that anneal to a polynucleotide of the invention under such conditions, and amplifying annealed polynucleotides, so that if a polynucleotide is amplified, a polynucleotide of the invention is detected in the sample.  
       [0365] In general, methods for detecting a polypeptide of the invention can comprise contacting a sample with a compound that binds to and forms a complex with the polypeptide for a period sufficient to form the complex, and detecting the complex, so that if a complex is detected, a polypeptide of the invention is detected in the sample.  
       [0366] In detail, such methods comprise incubating a test sample with one or more of the antibodies or one or more of the nucleic acid probes of the present invention and assaying for binding of the nucleic acid probes or antibodies to components within the test sample.  
       [0367] Conditions for incubating a nucleic acid probe or antibody with a test sample vary. Incubation conditions depend on the format employed in the assay, the detection methods employed, and the type and nature of the nucleic acid probe or antibody used in the assay. One skilled in the art will recognize that any one of the commonly available hybridization, amplification or immunological assay formats can readily be adapted to employ the nucleic acid probes or antibodies of the present invention. Examples of such assays can be found in Chard, T., An Introduction to Radioimmunoassay and Related Techniques, Elsevier Science Publishers, Amsterdam, The Netherlands (1986); Bullock, G. R. et al., Techniques in Immunocytochemistry, Academic Press, Orlando, Fla. Vol. 1 (1982), Vol. 2 (1983), Vol. 3 (1985); Tijssen, P., Practice and Theory of immunoassays: Laboratory Techniques in Biochemistry and Molecular Biology, Elsevier Science Publishers, Amsterdam, The Netherlands (1985). The test samples of the present invention include cells, protein or membrane extracts of cells, or biological fluids such as sputum, blood, serum, plasma, or urine. The test sample used in the above-described method will vary based on the assay format, nature of the detection method and the tissues, cells or extracts used as the sample to be assayed. Methods for preparing protein extracts or membrane extracts of cells are well known in the art and can be readily be adapted in order to obtain a sample which is compatible with the system utilized.  
       [0368] In another embodiment of the present invention, kits are provided which contain the necessary reagents to carry out the assays of the present invention. Specifically, the invention provides a compartment kit to receive, in close confinement, one or more containers which comprises: (a) a first container comprising one of the probes or antibodies of the present invention; and (b) one or more other containers comprising one or more of the following: wash reagents, reagents capable of detecting presence of a bound probe or antibody.  
       [0369] In detail, a compartment kit includes any kit in which reagents are contained in separate containers. Such containers include small glass containers, plastic containers or strips of plastic or paper. Such containers allows one to efficiently transfer reagents from one compartment to another compartment such that the samples and reagents are not cross-contaminated, and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another. Such containers will include a container which will accept the test sample, a container which contains the antibodies used in the assay, containers which contain wash reagents (such as phosphate buffered saline, Tris-buffers, etc.), and containers which contain the reagents used to detect the bound antibody or probe. Types of detection reagents include labeled nucleic acid probes, labeled secondary antibodies, or in the alternative, if the primary antibody is labeled, the enzymatic, or antibody binding reagents which are capable of reacting with the labeled antibody. One skilled in the art will readily recognize that the disclosed probes and antibodies of the present invention can be readily incorporated into one of the established kit formats which are well known in the art.  
       4.17 Medical Imaging  
       [0370] The novel polypeptides and binding partners of the invention are useful in medical imaging of sites expressing the molecules of the invention (e.g., where the polypeptide of the invention is involved in the immune response, for imaging sites of inflammation or infection). See, e.g., Kunkel et al., U.S. Pat No. 5,413,778, Such methods involve chemical attachment of a labeling or imaging agent, administration of the labeled polypeptide to a subject in a pharmaceutically acceptable carrier, and imaging the labeled polypeptide in vivo at the target site.  
       4.18 Screening Assay  
       [0371] Using the isolated proteins and polynucleotides of the invention, the present invention further provides methods of obtaining and identifying agents which bind to a polypeptide encoded by an ORF corresponding to any of the nucleotide sequences set forth in SEQ ID NO: 1-1350, or bind to a specific domain of the polypeptide encoded by the nucleic acid. In detail, said method comprises the steps of:  
       [0372] (a) contacting an agent with an isolated protein encoded by an ORF of the present invention, or nucleic acid of the invention; and  
       [0373] (b) determining whether the agent binds to said protein or said nucleic acid.  
       [0374] In general, therefore, such methods for identifying compounds that bind to a polynucleotide of the invention can comprise contacting a compound with a polynucleotide of the invention for a time sufficient to form a polynucleotide/compound complex, and detecting the complex, so that if a polynucleotide/compound complex is detected, a compound that binds to a polynucleotide of the invention is identified.  
       [0375] Likewise, in general, therefore, such methods for identify compounds that bind to a polypeptide of the invention can comprise contacting a compound with a polypeptide of the invention for a time sufficient to form a polypeptide/compound complex, and detecting the complex, so that if a polypeptide/compound complex is detected, a compound that binds to a polynucleotide of the invention is identified.  
       [0376] Methods for identifying compounds that bind to a polypeptide of the invention can also comprise contacting a compound with a polypeptide of the invention in a cell for a time sufficient to form a polypeptide/compound complex, wherein the complex drives expression of a receptor gene sequence in the cell, and detecting the complex by detecting reporter gene sequence expression, so that if a polypeptide/compound complex is detected, a compound that binds a polypeptide of the invention is identified.  
       [0377] Compounds identified via such methods can include compounds which modulate the activity of a polypeptide of the invention (that is, increase or decrease its activity, relative to activity observed in the absence of the compound). Alternatively, compounds identified via such methods can include compounds which modulate the expression of a polynucleotide of the invention (that is, increase or decrease expression relative to expression levels observed in the absence of the compound). Compounds, such as compounds identified via the methods of the invention, can be tested using standard assays well known to those of skill in the art for their ability to modulate activity/expression.  
       [0378] The agents screened in the above assay can be, but are not limited to, peptides, carbohydrates, vitatin derivatives, or other pharmaceutical agents. The agents can be selected and screened at random or rationally selected or designed using protein modeling techniques.  
       [0379] For random screening, agents such as peptides, carbohydrates, pharmaceutical agents and the like are selected at random and are assayed for their ability to bind to the protein encoded by the ORF of the present invention. Alternatively, agents may be rationally selected or designed. As used herein, an agent is said to be “rationally selected or designed” when the agent is chosen based on the configuration of the particular protein: For example, one skilled in the art can readily adapt currently available procedures to generate peptides, pharmaceutical agents and the like, capable of binding to a specific peptide sequence, in order to generate rationally designed antipeptide peptides, for example see Hurby et al., Application of Synthetic Peptides: Antisense Peptides,” In Synthetic Peptides, A User&#39;s Guide, W. H. Freeman, NY (1992), pp. 289-307, and Kaspczak et al., Biochemistry 28:9230-8 (1989), or pharmaceutical agents, or the like.  
       [0380] In addition to the foregoing, one class of agents of the present invention, as broadly described, can be used to control gene expression through binding to one of the ORFs or EMs of the present invention. As described above, such agents can be randomly screened or rationally designed/selected. Targeting the ORF or EMF allows a skilled artisan to design sequence specific or element specific agents, modulating the expression of either a single ORF or multiple ORFs which rely on the same EMF for expression control. One class of DNA binding agents are agents which contain base residues which hybridize or form a triple helix formation by binding to DNA or RNA. Such agents can be based on the classic phosphodiester, ribonucleic acid backbone, or can be a variety of sulfhydryl or polymeric derivatives which have base attachment capacity.  
       [0381] Agents suitable for use in these methods preferably contain 20 to 40 bases and are designed to be complementary to a region of the gene involved in transcription (triple helix -see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science 251:1360 (1991)) or to the mRNA itself (antisense—Okano, J. Neurochem. 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, Fla. (1988)). Triple helix-formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques have been demonstrated to be effective in model systems. Information contained in the sequences of the present invention is necessary for the design of an antisense or triple helix oligonucleotide and other DNA binding agents.  
       [0382] Agents which bind to a protein encoded by one of the ORFs of the present invention can be used as a diagnostic agent. Agents which bind to a protein encoded by one of the ORFs of the present invention can be formulated using known techniques to generate a pharmaceutical composition.  
       4.19 Use of Nnucleic Acids As Probes  
       [0383] Another aspect of the subject invention is to provide for polypeptide-specific nucleic acid hybridization probes capable of hybridizing with naturally occurring nucleotide sequences. The hybridization probes of the subject invention may be derived from any of the nucleotide sequences SEQ ID NO: 1-1350, Because the corresponding gene is only expressed in a limited number of tissues, a hybridization probe derived from of any of the nucleotide sequences SEQ ID NO: 1-1350 can be used as an indicator of the presence of RNA of cell type of such a tissue in a sample.  
       [0384] Any suitable hybridization technique can be employed, such as, for example, in situ hybridization. PCR as described in U.S. Pat. Nos. 4,683,195 and 4,965,188 provides additional uses for oligonucleotides based upon the nucleotide sequences. Such probes used in PCR may be of recombinant origin, may be chemically synthesized, or a nixt of both. The probe will comprise a discrete nucleotide sequence for the detection of identical sequences or a degenerate pool of possible sequences for identification of closely related genomic sequences.  
       [0385] Other means for producing specific hybridization probes for nucleic acids include the cloning of nucleic acid sequences into vectors for the production of mRNA probes. Such vectors are known in the art and are commercially available and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerase as 17 or SP6 RNA polymerase and the appropriate radioactively labeled nucleotides. The nucleotide sequences may be used to construct hybridization probes for mapping their respective genomic sequences. The nucleotide sequence provided herein may be mapped to a chromosome or specific regions of a chromosome using well known genetic and/or chromosomal mapping techniques. These techniques include in situ hybridization, linkage analysis against known chromosomal markers, hybridization screening with libraries or flow-sorted chromosomal preparations specific to known chromosomes, and the like. The technique of fluorescent in situ hybridization of chromosome spreads has been described, among other places, in Verma et al (1988) Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York N.Y.  
       [0386] Fluorescent in situ hybridization of chromosomal preparations and other physical chromosome mapping techniques may be correlated with additional genetic map data. Examples of genetic map data can be found in the 1994 Genome Issue of Science (265:1981f). Correlation between the location of a nucleic acid on a physical chromosomal map and a specific disease (or predisposition to a specific disease) may help delimit the region of DNA associated with that genetic disease. The nucleotide sequences of the subject invention may be used to detect differences in gene sequences between normal, carrier or affected individuals.  
       4.20 Preparation of Support Bound Oligonucleotides  
       [0387] Oligonucleotides, i.e., small nucleic acid segments, may be readily preparedby, for example, directly synthesizing the oligonucleotide by chemical means, as is commonly practiced using an automated oligonucleotide synthesizer.  
       [0388] Support bound oligonucleotides may be prepared by any of the methods known to those of skill in the art using any suitable support such as glass, polystyrene or Teflon. One strategy is to precisely spot oligonucleotides synthesized by standard synthesizers. Immobilization can be achieved using passive adsorption (Inouye &amp; Hondo, (1990) J. Clin. Microbiol. 28(6) 1469-72); using UV light (Nagata et aL, 1985; Dahlen et al., 1987; Morrissey &amp; Collins, (1989) Mol. Cell Probes 3 (2) 189-207) or by covalent binding of base modified DNA (Keller et al, 1988; 1989); all references being specifically incorporated herein.  
       [0389] Another strategy that may be employed is the use of the strong biotin-streptavidin interaction as a linker. For example, Broude et al (1994) Proc. Natl. Acad. Sci. USA 91(8) 3072-6, describe the use of biotinylated probes, although these are duplex probes, that are immobilized on streptavidin-coated magnetic beads. Streptavidin-coated beads may be purchased from Dynal, Oslo. Of course, this same linking chemistry is applicable to coating any surface with streptavidin. Biotinylated probes may be purchased from various sources, such as, e.g., Operon Technologies (Alameda, Calif. ).  
       [0390] Nunc Lab′ oratories Naperville, Ill. ) is also selling suitable material that could be used. Nunc Laboratories have developed a method by which DNA can be covalently bound to the microwell surface termed Covalink NH. CovaLinkNH is a polystyrene surface grafted with secondary amino groups (&gt;NH) that serve as bridge-heads for further covalent coupling. CovaLink Modules may be purchased from Nunc Lab′ oratories. DNA molecules may be bound to CovaLink exclusively at the 5′-end by a phosphoramidatebond, allowing immobilizationof more than 1 pmol of DNA (Rasmussenet al., (1991) Anal. Biochem. 198(1) 138-42).  
       [0391] The use of CovaLinkNH strips for covalent binding of DNA molecules at the 5′-end has been described (Rasmussen et al., (1991). In this technology, a phosphoramidatebond is employed (Chu et al., (1983) Nucleic Acids Res. 11(8)6513-29). This is beneficial as immobilzationusing only a single covalent bond is preferred. The phosphoramidate bond joins the DNA to the CovaLink NH secondary amino groups that are positioned at the end of spacer arms covalently grafted onto the polystyrene surface through a 2 mn long spacer arm. To link an oligonucleotide to CovaLink NH via an phosphoramidate bond, the oligonucleotide terminus must have a 5′-end phosphate group. It is, perhaps, even possible for biotin to be covalently bound to Cov&amp;Link and then streptavidin used to bind the probes.  
       [0392] More specifically,the linkage method includes dissolving DNA in water (7.5 ng/ul) and denaturing for 10 min. at 95 ° C. and cooling on ice for 10 min. Ice-cold 0.1 M 1-methylimidazole, pH 7.0 (1-MeIm 7 ), isthenaddedto a final concentration of 10 mM 1-MeIn 7 . Ass DNA solutionis then dispensed into CovaLinkNH strips (75 ul/well) standing on ice.  
       [0393] Carbodiimide 0.2 M 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC), dissolved in 10 mM -Melm 7 , is made fresh and 251 μl added per well. The strips are incubated for 5 hours at 50° C. After incubation the strips are washed using, e.g., Nunc-Immuno Wash; first the wells are washed 3 times, then they are soaked with washing solution for 5 min., and finally they are washed 3 times (where in the washing solution is 0.4 N NaOH, 0.25% SDS heated to 50° C.).  
       [0394] It is contemplated that a further suitable method for use with the present invention is that described in PCT Patent Application WO90/03382 (Southern &amp; Maskos), incorporated herein by reference. This method of preparing an oligonucleotide bound to a support involves attaching a nucleoside 3′-reagent through the phosphate group by a covalent phosphodiester link to aliphatic hydroxyl groups carried by the support. The oligonucleotide is then synthesized on the supported nucleoside and protecting groups removed from the synthetic oligonucleotide chain under standard conditions that do not cleave the oligonucleotide from the support. Suitable reagents include nucleoside phosphoramidite and nucleoside hydrogen phosphorate.  
       [0395] An on-chip strategy for the preparation of DNA probe for the preparation of DNA probe arrays may be employed. For example, addressable laser-activated photodeprotectionmay be employed in the chemical synthesis of oligonucleotides directly on a glass surface, as described by Fodor etal. (1991) Science 251(4995)767-73, incorporated herein by reference. Probes may also be immobilized on nylon supports as described by Van Ness et al. (1 991) Nucleic Acids Res. 19(12) 3345-50; or linked to Teflon using the method of Duncan &amp; Cavalier (1988) Anal. Biochenm 169(1) 1048; all references being specifically incorporated herein.  
       [0396] To link an oligonucleotide to a nylon support, as described by Van Ness et aL (1991), requires activation of the nylon surface via alkylation and selective activation of the 5′-amine of oligonucleotides with cyanuric chloride.  
       [0397] One particular way to prepare support bound oligonucleotides is to utilize the 5 light-generated synthesis described by Pease et aL, (1994) PNAS USA 91(11) 5022-6, incorporated herein by reference). These authors used current photolithographic techniques to generate arrays of immobilized oligonucleotide probes (DNA chips). These methods, in which light is used to direct the synthesis of oligonucleotide probes in high-density, miniaturized arrays, utilize photolabile 5′-protectedN-acyl-deoxynucleoside phosphoramidites, surface linker chemistry and versatile combinatorial synthesis strategies. A matrix of 256 spatially defined oligonucleotide probes may be generated in this manner.  
       4.21 Preparation of Nucleic Acid Fragments  
       [0398] The nucleic acids may be obtained from any appropriate source, such as cDNAs, genornic DNA, chromosomal DNA, microdissected chromosome bands, cosmid or YAC inserts, and RNA, including mRNA without any amplification steps. For example, Sambrook et al (1989) describes three protocols for the isolation of high molecular weight DNA from mammalian cells (p. 9.149.23).  
       [0399] DNA fragments may be prepared as clones in 13, plasmid or lambda vectors and/or prepared directly from genomic DNA or cDNA by PCR or other amplification methods. Samples may be prepared or dispensed in multi well plates. About 100-1000 ng of DNA samples may be prepared in 2-500 ml of final volume.  
       [0400] The nucleic acids would then be fragmented by any of the methods known to those of skill in the art including, for example, using restriction enzymes as described at 924-9.28 of Sambrook et al. (1989), shearing by ultrasound and NaOH treatment.  
       [0401] Low pressure shearing is also appropriate, as described by Schriefer et al. (1990) Nucleic Acids Res. 18(24) 7455-6, incorporatedherein by reference). Inthis method, DNA samples are passed through a small French pressure cell at a variety of low to intermediate pressures. A lever device allows controlled application of low to intermediate pressures to the cell. The results of these studies indicate that low-pressure shearing is a useful alternative to sonic and enzymatic DNA fragmentation methods.  
       [0402] One particularly suitable way for fragmenting DNA is contemplated to be that using the two base recognition endonuclease, CνiJI, described by Fitzgerald et al. (1992) Nucleic Acids Res. 20(14)3753-62, These authors described an approach for the rapid fragmentation and fractionation of DNA into particular sizes that they contemplated to be suitable for shotgun cloning and sequencing.  
       [0403] The restriction endonuclease CνiJI normally cleaves the recognition sequence PuGCPy between the G and C to leave blunt ends. Atypical reaction conditions, which alter the specificity of this enzyme (CνJI* *), yield a quasi-random distribution of DNA fragments form the small molecule pUC19 (2688 base pairs). Fitzgerald etal. (1992) quantitatively evaluated the randomness of this fragmentation strategy, using a CνiJI** digest of pUC19 that was size fractionated by a rapid gel filtration method and directly ligated, without end repair, to a lac Z minus M13 cloning vector. Sequence analysis of 76 clones showed that CνiJI* * restricts pyGCPy and PuGCPu, in addition to PuGCPy sites, and that new sequence data is accumulated at a rate consistent with random fragmentation.  
       [0404] As reported in the literature, advantages of this approach compared to sonication and agarose gel fractionation include: smaller amounts of DNA are required (0.2-0.5 ug instead of 2-5 ug); and fewer steps are involved (no preligation, end repair, chemical extraction, or agarose gel electrophoresis and elution are needed  
       [0405] Irrespective of the manner in which the nucleic acid fragments are obtained or prepared, it is important to denature the DNA to give single stranded pieces available for hybridization. This is achieved by incubating the DNA solution for 2-5 minutes at 80-90° C. The solution is then cooled quickly to 2° C. to prevent renaturation of the DNA fragments before they are contacted with the chip. Phosphate groups must also be removed from genornic DNA by methods known in the art.  
       4.22 Preparation of DNAa Arrays  
       [0406] Arrays may be prepared by spotting DNA samples on a support such as a nylon membrane. Spotting may be performed by using arrays of metal pins (the positions of which correspond to an array of wells in a microtiter plate) to repeated by transfer of about 20 nl of a DNA solution to a nylon membrane. By offset printing, a density of dots higher than the density of thee wells is achieved. One to 25 dots may be accommodated in 1 mm 2 , depending on the type of label used. By avoiding spotting in some preselected number of rows and columns, separate subsets (subarrays) may be formed. Samples in one subarray may be the same genomic segment of DNA (or the same gene) from different individuals, or may be different, overlapped genomic clones. Each of the subarrays may represent replica spotting of the same samples. In one example, a selected gene segment may be amplified from 64 patients. For each patient, the amplified gene segment may be in one 96-well plate (all 96 wells containing the same sample). A plate for each of the 64 patients is prepared. By using a 96-pin device, all samples may be spotted on one 8×12 cm membrane. Subarrays may contain 64 samples, one from each patient. Where the 96 subarrays are identical, the dot span may be 1 mm 2  and there may be a 1 mm space between subarrays.  
       [0407] Another approach is to use membranes or plates (available from NUNC, Naperville, Ill. ) which may be partitioned by physical spacers e.g a plastic grid molded over the membrane, the grid being similar to the sort of membrane applied to the bottom of multi well plates, or hydrophobic strips. A fixed physical spacer is not preferred for imaging by exposure to flat phosphor-storage screens or x-ray films.  
       [0408] The present invention is illustrated in the following examples. Upon consideration of the present disclosure, one of skill in the art will appreciate that many other embodiments and variations may be made in the scope of the present invention Accordingly, it is intended that the broader aspects of the present invention not be limited to the disclosure of the following examples. The present invention is not to be limited in scope by the exemplified embodiments which are intended as illustrations of single aspects of the invention, and compositions and methods which are functionally equivalent are within the scope of the invention. Indeed, numerous modifications and variations in the practice of the invention are expected to occur to those skilled in the art upon consideration of the present preferred embodiments. Consequently, the only limitations which should be placed upon the scope of the invention are those which appear in the appended claims.  
       [0409] All references cited within the body of the instant specification are hereby incorporated by reference in their entirety. 
     
    
    
     5.0 EXAMPLES  
     5.1 Example 1  
     [0410] Novel Nucleic Acid Sequences Obtained From Various Libraries  
     [0411] A plurality of novel nucleic acids were obtained from CDNA libraries prepared from various human tissues and in some cases isolated from a genomic library derived from human chromosome using standard PCR, SBH sequence signature analysis and Sanger sequencing techniques. The inserts of the library were amplified with PCR using primers specific for the vector sequences which flank the inserts. Clones from cDNA libraries were spotted on nylon membrane filters and screened with oligonucleotide probes (e.g., 7-mers) to obtain signature sequences. The clones were clustered into groups of similar or identical sequences. Representative clones were selected for sequencing.  
     [0412] In some cases, the 5′ sequence of the amplified inserts was then deduced using a typical Sanger sequencing protocol. PCR products were purified and subjected to fluorescent dye terminator cycle sequencing. Single pass gel sequencing was done using a 377 Applied Biosystems (ABI) sequencer to obtain the novel nucleic acid sequences. In some cases RACE (Random Amplification of cDNA Ends) was performed to further extend the sequence in the 5′ direction.  
     5.2 Example 2  
     [0413] 5 Novel Contigs  
     [0414] The novel contigs of the invention were assembled from sequences that were obtained from a cDNA library by methods described in Example 1 above, and in some cases sequences obtained from one or more public databases. The sequences for the resulting nucleic acid contigs are designated as SEQ ID NO: 1-1350 and are provided in the attached Sequence Listing. The contigs were assembled using an EST sequence as a seed. Then a recursive algorithm was used to extend the seed EST into an extended assemblage, by pulling additional sequences from different datab′ ases (i.e., Hyseq&#39;sdatabase containingEST sequences,dbEST version 114, gb pri 114, and UniGene version 101) that belong to this assemblage. The algorithm terminated when there was no additional sequences from the above databases that would extend the assemblage. Inclusion of component sequences into the assemblage was based on a BLASTN hit to the extending assemblage with BLAST score greater than 300 and percent identity greater than 95%.  
     [0415] Table 3 sets forth the novel predicted polypeptides (including proteins) encoded by the novel polynucleotides (SEQ ID NO: 189-282) of the present invention, and their corresponding nucleotide locations to each of SEQ ID NO: 189-282, Table 3 also indicates the method by which the polypeptide was predicted. Method A refers to a polypeptide obtained by using a software program called FASTY (available from huo://fasta.bioch.virginia.edu) which selects a polypeptide based on a comparison of the translated novel polynucleotideto known polynucleotides (W. R Pearson, Methods in Enzymology, 183:63-98(1990), herein incorporated by reference). MethodB refers to a polypeptide obtained by using a software program called GenScan for human/vertebrate sequences (available from Stanford University, Office of Technology Licensing) that predicts the polypeptide based on a probabilistic model of gene structure/compositionalproperties (C. Burge and S. Karlin, J. Mol. Biol., 268:78-94 (1997), incorporatedhereinby reference). Method C refers to a polypeptide obtained by using a Hyseq proprietary software program that translates the novel polynucleotide and its complementary strand into six possible amino acid sequences (forward and reverse frames) and chooses the polypeptide with the longest open reading frame.  
     [0416] The nearest neighbor results for SEQ ID NO: 1-1350 were obtained by a BLASTP version 2.0 al 19MP-WashU search against Genpept release 120 and Geneseq database Oct. 12, 2000, update 21 (Derwent), using BLAST algorithm. The nearest neighbor result showed the closest homologue for SEQ ID NO: 1-1350, The nearest neighbor results for SEQ ID NO: 1-1350 are shown in Table 2 below.  
     [0417] Tab′ les 1, 2 and 3 follow. Table 1 shows the various tissue sources of SEQ ID NO: 1-1350, Table 2 shows the nearest neighbor result for the assembled contig. The nearest neighbor result shows the closest homolog with an identifiable function for each assemblage. Table 3 contains the start and stop nucleotides for the translated amino acid sequence for which each assemblage encodes. Table 3 also provides a correlation between the amino acid sequences set forth in the Sequence Listing, the nucleotide sequences set forth in the Sequence Listing and the SEQ ID NO. in U.S. Pat. No. 09/496,914.  
                           TABLE 1                       Tissue Origin   RNA Source   Hyseq Library Name   SEQ ID NOS:                  adult brain   GIBCO   AB3001   111 151 188 215 662-665 877 910 927                   976 1233 1319       adult brain   GIBCO   ABD003   41 49 74 101 111 120 132 141-142 151                   217 225 238 271 317 404 446 469 503                   513-514 535 550 564 573 666-669 798                   898 910 927 976 1067 1083 1085 1178                   1254       adult brain   Clontech   ABR001   39 216 238 327 356 535 927 1056 1121                   1178-1180 1199 1251       adult brain   Clontech   ABR006   74 611 949 1034 1136       adult brain   Clontech   ABR008   14 32 41 61 81 86 89 120 132 138 145                   147 188 197 208 225 227-239 250 300-303                   312 316 328-331 340 357-362 374                   380 384-391 408 414 446 448 464-467                   483 488 495-496 505 512 521 535 550                   566 571 577 585 590 594 598 634 641                   658 666 683 725 742 764 767 786 801                   805 810 823 826 829 831 836 841 887-923                   927 934 943 950-951 963 976 995                   1000-1001 1006 1026 1034 1048 1057-1067                   1086 1088 1090 1118 1120 1122-1128                   1142 1162 1181-1192 1199 1204                   1218-1219 1225 1232 1253 1267 1271-1306                   1342 1347 1349-1350       adult brain   Clontech   ABR011   49 238 1219       adult brain   BioChain   ABR012   74 238       adult brain   Invitrogen   ABR013   868 1268       adult brain   Invitrogen   ABT004   49 117 138 191 217 252 291 305 535                   566 596 663 670 746 798 816-819 876                   892 898 922 943 963 1034-1036 1121       cultured   Strategene   ADP001   41 74 101 138 211 238 304 537 582       preadipocytes           740 798 883 943 976 1067       adrenal gland   Clontech   ADR002   49 74 101 111 120 127 151 215 238                   240-247 316 330 363-364 404 414 534-535                   833 924-940 950 963 976 1001                   1003 1067-1070 1118 1156 1193-1200                   1325       adult heart   GIBCO   AHR001   38 49 71-72 74-77 79 92 99 101 111                   118 129 132 138 151 158-163 182 195-203                   215 217 238 264 269 353 384 398                   408 434-439 446 504 512-513 519 537                   562-573 577 611-614 616-619 658 661                   671-672 722 734 757-773 815 828-835                   874 891 898 919 926-927 976 988                   1021 1037 1041 1062 1067 1071 1080                   1083 1093 1122 1131 1185 1201 1254                   1308 1331 1335       adult kidney   GIBCO   AKD001   41 49 51 71-74 78-85 94 100-101 103-107                   111 119-120 138 151 157 215 217-218                   238 250 264 294 304 384 404 440                   446 454 477 504-505 509 514 518-519                   535 537 564 574-583 620-627 639 653                   673-675 705 753 789 831 844 851 859                   877 909 918 927 956 963 976 1067                   1074 1083 1095 1178 1302 1331 1335       adult kidney   Invitrogen   AKT002   11-12 41 49 111-112 215-217 294 316                   446 487 564 575 844 868 910 927 976                   1116       adult lung   GIBCO   ALG001   8 101 111 151 187 402 446 490 514                   518 537 545 549 580 582 592 594 634                   640 651-652 676-678 725 851 873 918                   952 976 1042 1067 1076 1083 1152       lymph node   Clontech   ALN001   8 111 121 151 180-182 188 215 537                   545 549 651 679-682 789 804-810 868                   873 927 952 976 1042 1059 1335       young liver   GIBCO   ALV001   8 64 79 111 186 215-216 238 446 514                   519 537 564 653 683-684 698 753 798                   813 833 840 858 927 976 1038-1039                   1051 1085 1224 1245 1256       adult liver   Invitrogen   ALV002   40 71 292-293 305 384 468-469 496                   505 657 675 714 753 832 844 941-942                   976 1040 1076 1256 1293       adult liver   Clontech   ALV003   976       adult ovary   Invitrogen   AOV001   8 32 36 38 41 49 51 71 74 79-80 101                   104 111 120 122-125 138 140 143-149                   151 188-190 207-212 215-217 238 264                   316 384 409 440 445-446 496 504 512                   514 518-519 535 537 549-550 564 566                   571 580 582 600 618 638 657 667 681                   685-697 699 705 722 735-744 761 771                   815 833 842-865 868 875-876 918 926-927                   950 952 963 976 1023 1042 1048                   1051 1059 1072 1076 1083 1117 1120                   1124 1131 1144 1174 1224 1268 1331                   1335       adult placenta   Clontech   APL001   102 217 238 537 641 700       placenta   Invitrogen   APL002   663 851 1048       adult spleen   GIBCO   ASP001   8 45 74 111 132 140 151 185 217 238                   294 414 446 477 504 514 534 545 549                   592 722 873 883 952 976 1041-1042                   1083 1093-1094 1152 1224       testis   GIBCO   ATS001   72 107 111 113 126 140 151 183 215                   238 446 497 537 642 701-706 811 877                   927 962 976 1083 1117 1131       adult bladder   Invitrogen   BLD001   41 151 191 402-405 409 414 496 545                   592 607 706 873 952 1178 1329-1335       bone marrow   Clontech   BMD001   8 58-62 65-68 74 79 108 111 116 137                   147 151 164-174 213-215 238 305-307                   374 404 446 460 466 516 519 534 538-541                   544-546 549-554 566 584 586 592                   596 607 610 628-629 643-645 652 707-708                   774-789 844 866-871 873 919 927                   952 963 976 998 1034 1042 1064 1083                   1085 1120 1132 1152 1225 1229 1268                   1307 1310       bone marrow   Clontech   BMD002   6 8 37-38 52 74 77 105 111 129 132                   210 317 510-511 545 549 581 598 628                   638 724 766 789 844 860 868 873 919                   927 952 963 968 976 1042 1111 1141                   1160-1161 1229 1266 1346       bone marrow   Clontech   BMD004   111 238 282 549 1083       adult colon   Invitrogen   CLN001   52 260 264 299 494 536 545 564 592                   844 873 877 952 976 1042 1152 1268                   1336-1337       adult cervix   BioChain   CVX001   49 51 129 132 151 205 207 238 332-335                   365-367 392-401 440 466 470-471                   518 537 597 629 832 877 927 976 1006                   1085 1117 1129-1134 1192 1202-1205                   1219 1309-1328       diaphragm   BioChain   DIA002   74 976 1083       endothelial cells   Strategene   EDT001   32 40-41 49 74 79 101 111 120 132                   138 151 204-206 215-217 238 269 316                   414 433 505 510 513 550 555 580 582                   596 675 722 745 798 814 836-841 851                   918 976 1041 1043 1073 1083 1131                   1331       Genomic clones   Genomic DNA   EPM001   525-532 927       from the short arm   from Genetic       of chromosome 8   Research       Genomic clones   Genomic DNA   EPM003   47 525       from the short arm   from Genetic       of chromosome 8   Research       Genomic clones   Genomic DNA   EPM004   525 927       from the short arm   from Genetic       of chromosome 8   Research       Genomic clones   Genomic DNA   EPM005   531       from the short arm   from Genetic       of chromosome 8   Research       esophagus   BioChain   ESO002   74 138 238       fetal brain   Clontech   FBR001   441-442 927       fetal brain   Clontech   FBR004   215 893 927 1001       fetal brain   Clontech   FBR006   48 61 101 120 132 138 140 147 208                   225 271 317 319 336 359 368 405-414                   519 550 571 594 686 715 722 764 824                   829 836 859 909 927 943 947 963 1057                   1067-1068 1104 1135-1140 1162 1206-1207                   1235 1268 1288 1307-1308 1319                   1338-1350       fetal brain   Clontech   FBRs03   111 446       fetal brain   Invitrogen   FBT002   41 51 120 151 192-194 264 504 512                   535 683 761 798 820-827 844 876 909                   963 976 1026 1048 1083 1144 1302       fetal heart   Invitrogen   FHR001   446 566 761       fetal kidney   Clontech   FKD001   51 74 111 127 140 151 184 294 537                   550 630-631 1319       fetal kidney   Clontech   FKD002   111 976 1083       fetal kidney   Invitrogen   FKD007   238 974       fetal lung   Clontech   FLG001   463 566 976 1074 1083 1093       fetal lung   Invitrogen   FLG003   41 238 330 407 415-416 537 573 844                   859 1048 1083 1116 1192       fetal liver-spleen   Columbia   FLS001   8 14 34-35 37 41 43 49 51 54-56 63-64           University       69-71 74 77 79 87-90 101 107 110-111                   114 120 128-131 138 140 147 150-155                   197 210 215 217 225 238 312 367 384                   414 440 446 460 468 483 496 504-507                   511-515 518-519 523 533-535 537 541                   544-545 547-550 555-560 564 566 571                   577 582 585-586 598 636 646-647 649                   652 664 698 709-710 714 722-723 731                   735-736 746-753 761 784 798 823 829                   832 844 851 858-859 868 873 876 898                   927 943 949 952 963 976 984 1002                   1021 1023 1040 1042 1044 1050 1083                   1093 1116 1120 1129 1131 1144 1174                   1217 1251 1254 1256 1302 1308 1311                   1319       fetal liver-spleen   Columbia   FLS002   8 36-37 41-46 49 54 64 71 74 79 101           University       111 120 129 147 207 210 215-216 238                   250 330 353 359 366 383-384 414 478                   505 508-509 511 515-524 534-535 537                   544-545 564 566 571 577 591 598 638                   663 671 698 714 722 725 727 751 798                   851 859 873 876 909 927 949 952 983-984                   1002 1023 1042-1044 1085 1095                   1131 1144 1178 1199 1233 1240-1270                   1331 1340       fetal liver-spleen   Columbia   FLS003   64 535 976 1256           University       fetal liver   Invitrogen   FLV001   8 101 120 138 217 446 468 535 566                   580 722 730 749 844 918 943 976 1051                   1256 1331       fetal liver   Clontech   FLV004   537 926 1256       fetal muscle   Invitrogen   FMS001   51 111 264 312 369-370 404 417-421                   425 535 537 577 598 614 836 857 1141                   1208 1268       fetal muscle   Invitrogen   FMS002   537       fetal skin   Invitrogen   FSK001   13-26 32 41 51 89 107 111 147 151                   225 264 316 405 422-429 488-494 496                   519 534-535 537 566 675 732 859 876-877                   898 947 949-950 963 976 1001                   1062 1076 1083 1117 1144 1165 1268                   1281       fetal skin   Invitrogen   FSK002   537 812       fetal spleen   BioChain   FSP001   87 549       umbilical cord   BioChain   FUC001   27-33 41 49 151 215 238 248-249 301                   316 446 495-503 519 521 534-535 537                   582 634 691 877 883 927 944-950 963                   976 1001 1075 1142-1143 1171 1218                   1243 1308       fetal brain   GIBCO   HFB001   41 49 57 79 87 103 111 120 132-135                   138 145 151 188 197 207 215 238 264                   271 294 316 367 414 440 446 466 504                   513-514 535 542-543 550 564 571 596                   635 648-654 675 711-715 722-723 798                   832 872 876 883 927 976 1095 1144                   1168 1171 1178 1211 1335       macrophage   Invitrogen   HMP001   238       infant brain   Columbia   IB2002   49-50 77 81 89 105 111 136-138 140           University       151 161 175-179 185 216-217 264 295                   299 308-310 371-373 462 476 504 511-513                   533 537 564 566 571 655-657 662                   683 716-720 723 752 790-803 829 832                   858-859 876 898 909 949 976 1045-1047                   1076-1087 1090 1093 1116 1122                   1144 1209-1213 1225 1233 1256 1319                   1341       infant brain   Columbia   IB2003   41 50 77 104 132 215 238 508 512-513           University       519 566 655 714 794 918 943 976 1067                   1092-1093 1233       infant brain   Columbia   IBM002   311 472-473 753 1214           University       infant brain   Columbia   IBS001   51 111 376 474 790 876 949 1144 1204           University       1221       lung, fibroblast   Strategene   LFB001   151 316 462 514 534 582 675 939 1131       lung tumor   Invitrogen   LGT002   1-7 41 74 79 94 115 120 138-139 156                   215 217 269 280 296 337 374-375 384                   404 446 454 475-480 498 514 518-519                   522 537 545 564 577 597 653 658 705                   721-724 754-756 779 859 868 872-874                   876-877 919 927 949 951-952 959 976                   1002 1042 1048-1053 1076 1083 1088-1089                   1131 1144-1147 1216-1218 1229                   1293 1311       lymphocytes   ATCC   LPC001   41 74 111 132 151 253 316 446 550                   634 844 927 976 1085 1268       leukocyte   GIBCO   LUC001   8 11 41 74 86 91-98 101 109 111 120                   147 151 212 215 218 238 252 288 312-314                   316 338 359 408 427 443-447 505                   510 512 514 518 534 545 549-550 561                   564 566 571 577 580 582 587-609 615                   632-638 658-659 698 714 725-728 832                   836 841 859 866 873-874 882-883 918-919                   927 943 952 963 976 1042 1076                   1083 1090 1148 1152 1168 1195 1219-1220                   1224       leukocyte   Clontech   LUC003   74 100 215 232 238 339-341 446 545                   657 660 729 873 883 927 952 963 1008                   1042 1116 1120 1149-1150 1215 1222       Melanoma from cell   Clontech   MEL004   210 215 238 342 534 545 592 722 873       line ATCC #CRL           919 929 939 952 976 1071 1118 1218       1424           1235 1245       mammary gland   Invitrogen   MMG001   8-10 40-41 49 73 80 114 138-140 147                   217 250-256 264 297-299 305 377-378                   398 446 481-486 505 512 537 545 549                   571 592 725 730-733 816 829 836 844                   868 873 876-877 898 926 943 951-960                   963 976 995 1034 1042 1048 1054-1055                   1076 1083 1091 1093 1116-1117                   1124 1152 1302       induced neuron cells   Strategene   NTD001   39 101 111 138 238 361 1225 1251                   1319       retinoid acid induced   Strategene   NTR001   74 225 976       neuronal cells       neuronal cells   Strategene   NTU001   129 225 238 304 313 361 657 976       pituitary gland   Clontech   PIT004   976       placenta   Clontech   PLA003   38 976       prostate   Clontech   PRT001   111 188 238 257-258 564 724 961-966                   1067 1095       rectum   Invitrogen   REC001   238 430-431 841 859 868 963 1001                   1116       salivary gland   Clontech   SAL001   8 151 402 432-433 446 496 868 952                   976 1083 1120 1151 1184       small intestine   Clontech   SIN001   8 101 147 215 259-266 446 462 505                   545 592 660 789 836 866 873 927 952                   963 967-978 1042 1120 1152 1223-1224       skeletal muscle   Clontech   SKM001   238 302 927 943 992 1031       spinal cord   Clontech   SPC001   74 111 132 151 215-216 238 264 267-270                   343-344 353 379 516 537 566 740                   828 927 976 979-994 1092 1153-1159                   1225 1250       adult spleen   Clontech   SPLc01   698 859 1042       stomach   Clontech   STO001   210 238 271-272 537 580 705 918 952                   995 1171       thalamus   Clontech   THA002   61 219-220 273-276 312 315 330 596                   963 996-1007 1059 1093 1160-1162       thymus   Clonetech   THM001   8 120 151 208 221 316-317 353 639                   750 867 874 878-881 927 963 1023                   1083 1094-1096 1124       thymus   Clontech   THMc02   8 61 114 129 132 210 225 231 306                   317-319 336 340 359 380 398 446 448-463                   512 519 545 554 587 598 698 724-725                   789 812 836 868 873 927 947 952                   976 1007 1042 1083 1085 1097-1116                   1122 1147 1177 1226-1229 1234 1311                   1313       thyroid gland   Clontech   THR001   14 41 49 76 94 111 144 151 183 188                   210 217 222 253 264 271 277-286 294                   320-326 345-352 361 381-382 446 467                   483 514 534 549-550 564 578 602 649                   844 882-883 927 950 956 976 1008-1028                   1076 1083 1117-1120 1142 1163-1175                   1230-1238 1308       trachea   Clontech   TRC001   223-225 238 287 353-354 514                   545 592 611 873 883-884 927                   952 1029-1031 1042 1151-1152                   1170 1176-1177 1239       uterus   Clontech   UTR001   151 226 288-290 355 537 877                   885-886 976 1001 1032-1033                   1232                  
 
     [0418]                                   TABLE 2                       SEQ               Smith-           ID   Accession           Waterman   %       NO:   No.   Species   Description   Score   Identity                                                        1   B02829     Homo sapiens     Human G protein coupled receptor hRUP5   460   100                   protein SEQ ID NO: 10.       2   G03564     Homo sapiens     Human secreted protein, SEQ ID NO: 7645.   111   51       3   R26173     Homo sapiens     Part of Major Yo paraneoplastic antigen   293   76                   (CDR62) encoded by clone pY2.       4   L29536     Homo sapiens     calcium channel L-type alpha 1 subunit   191   65       5   Y94943     Homo sapiens     Human secreted protein clone yt14_1 protein   251   50                   sequence SEQ ID NO: 92.       6   M11507     Homo sapiens     transferrin receptor   120   95       7   AF099100     Homo sapiens     WD-repeat protein 6   1941   93       8   Y92338     Homo sapiens     Human cancer associated antigen precursor from   245   82                   clone NY-REN-45.       9   G01343     Homo sapiens     Human secreted protein, SEQ ID NO: 5424.   226   91       10   AJ133798     Homo sapiens     copine VII protein   1127   68       11   G02449     Homo sapiens     Human secreted protein, SEQ ID NO: 6530.   584   99       12   X98330     Homo sapiens     ryanodine receptor 2   282   78       13   AL024498     Homo sapiens     dJ417M14.2 (novel serine/threonine-protein   293   100                   kinase (ortholog of mouse and rat MAK (male                   germ cell-associated kinase))       14   AF045577     Pan     olfactory receptor OR93Ch   191   36                 troglodytes         15   G03131     Homo sapiens     Human secreted protein, SEQ ID NO: 7212.   93   39       16   U26595     Rattus     prostaglandin F2a receptor regulatory protein   569   89                 norvegicus     precursor       17   B08918     Homo sapiens     Human secreted protein sequence encoded by   99   44                   gene 28 SEQ ID NO: 75.       18   Y36203     Homo sapiens     Human secreted protein #75.   165   75       19   U15647     Mus     reverse transcriptase   106   40                 musculus         20   G02701     Homo sapiens     Human secreted protein, SEQ ID NO: 6782.   544   100       21   Y35923     Homo sapiens     Extended human secreted protein sequence, SEQ   1691   100                   ID NO. 172.       22   G04030     Homo sapiens     Human secreted protein, SEQ ID NO: 8111.   380   96       23   G02455     Homo sapiens     Human secreted protein, SEQ ID NO: 6536.   123   50       24   AF036329     Homo sapiens     gonadotropin-releasing hormone precursor,   284   90                   second form       25   G04067     Homo sapiens     Human secreted protein, SEQ ID NO: 8148.   96   32       26   S80119   Rattus sp.   reverse transcriptase homolog   100   34       27   U83303     Homo sapiens     line-1 reverse transcriptase   101   35       28   G03267     Homo sapiens     Human secreted protein, SEQ ID NO: 7348.   135   45       29   G04067     Homo sapiens     Human secreted protein, SEQ ID NO: 8148.   83   42       30   G02872     Homo sapiens     Human secreted protein, SEQ ID NO: 6953.   116   72       31   G03371     Homo sapiens     Human secreted protein, SEQ ID NO: 7452.   96   67       32   G03224     Homo sapiens     Human secreted protein, SEQ ID NO: 7305.   58   32       33   Y66688     Homo sapiens     Membrane-bound protein PRO1152.   2457   98       34   Y87071     Homo sapiens     Human secreted protein sequence SEQ ID   348   95                   NO: 110.       35   U15131     Homo sapiens     p126   182   48       36   Y73464     Homo sapiens     Human secreted protein clone y14_1 protein   982   90                   sequence SEQ ID NO: 150.       37   AL133215     Homo sapiens     bA108L7.6 (semaphorin 4G (sema domain,   687   99                   immunoglobulin domain (Ig), transmembrane                   domain (TM) and short cytoplasmic domain))       38   AC067969   amino acids     Homo sapiens  ryanodine receptor 1 (skeletal)   386   66               3338-4088       39   AL031588     Homo sapiens     dJ1163J1.1 (mostly supported by GENSCAN,   493   76                   FGENES and GENEWISE)       40   G03628     Homo sapiens     Human secreted protein, SEQ ID NO: 7709.   110   51       41   AF132969     Homo sapiens     CGI-35 protein   228   68       42   Y36268     Homo sapiens     Human secreted protein encoded by gene 45.   220   88       43   X61048   Hydra sp.   mini-collagen   105   35       44   M76546     Helianthus     hydroxyproline-rich protein   110   31                 annuus         45   U82288     Caenorhabditis     Rac-like GTPase   139   70                 elegans         46   G03477     Homo sapiens     Human secreted protein, SEQ ID NO: 7558.   118   58       47   AF090942     Homo sapiens     PRO0657   113   63       48   G03564     Homo sapiens     Human secreted protein, SEQ ID NO: 7645.   90   59       49   AJ005560     Mus     SPR2B protein   72   56                 musculus         50   G02450     Homo sapiens     Human secreted protein, SEQ ID NO: 6531.   385   98       51   Y91649     Homo sapiens     Human secreted protein sequence encoded by   973   94                   gene 60 SEQ ID NO: 322.       52   U93563     Homo sapiens     putative p150   105   38       53   Y55927     Homo sapiens     Human STLK2 protein.   699   85       54   G02607     Homo sapiens     Human secreted protein, SEQ ID NO: 6688.   145   56       55   AB008175     Mus     hepatic nuclear factor 1-beta short form   356   74                 musculus         56   M68941     Homo sapiens     protein-tyrosine phophatase   165   41       57   AL031600     Homo sapiens     c390E6.1 (chloride channel 7)   338   76       58   AF011417     Mus     putative pheromone receptor   143   55                 musculus         59   AF167320     Mus     zinc finger protein ZFP113   558   68                 musculus         60   U73036     Homo sapiens     interferon regultory factor 7   263   96       61   X07984     Mus     protein-tyrosine kinase   297   69                 musculus         62   Y29861     Homo sapiens     Human secreted protein clone cb98_4.   791   98       63   U35376     Homo sapiens     repressor transcriptional factor   485   65       64   AF265555     Homo sapiens     ubiquitin-conjugating BIR-domain enzyme   785   74                   APOLLON       65   G03883     Homo sapiens     Human secreted protein, SEQ ID NO: 7964.   88   95       66   AF177390     Manduca     antennal specific membrane protein AMP   274   54                 sexta         67   AB040800     Homo sapiens     SREB2   614   100       68   AF030027   Equine   24   213   26               herpesvirus 4       69   G02965     Homo sapiens     Human secreted protein, SEQ ID NO: 7046.   261   95       70   W75770     Homo sapiens     Human oxidoreductase YTFO3.   1144   98       71   AB011135     Homo sapiens     KIAA0563 protein   239   76       72   AB014885     Halocynthia     HrPOPK-1   813   78                 roretzi         73   AF045454     Cavia     phospholipase B   955   73                 porcellus         74   J02870     Mus     laminin receptor   308   61                 musculus         75   Y00826     Rattus     gp210 (AA 1-1886)   413   84                 norvegicus         76   AF117754     Homo sapiens     thyroid hormone receptor-associated protein   351   54                   complex component TRAP240       77   Y38422     Homo sapiens     Human secreted protein.   468   76       78   Y14596     Homo sapiens     Human T-type voltage-gated Ca channel alpha-   1357   99                   1-I (hCavT3).       79   Y14591   Human   APM-1 protein   767   100               papillomavirus               type 68       80   AL137802     Homo sapiens     dJ798A10.2 (KIAA0445 protein)   71   34       81   AP000383     Arabidopsis     protein arginine N-methyltransferase-like protein   359   65                 thaliana         82   L46815     Mus     DNA binding protein Rc   895   75                 musculus         83   G01600     Homo sapiens     Human secreted protein, SEQ ID NO: 5681.   315   96       84   Y53886     Homo sapiens     A suppressor of cytokine signalling protein   538   71                   designated HSCOP-6.       85   AB029002     Homo sapiens     KIAA1079 protein   134   42       86   Y28678     Homo sapiens     Human cw272_7 secreted protein.   325   62       87   Y99368     Homo sapiens     Human PRO1326 (UNQ686) amino acid   156   48                   sequence SEQ ID NO: 100.       88   AJ225124     Mus     hyperpolarization-activated cation channel,   487   95                 musculus     HAC3       89   AF177203     Homo sapiens     cerebral cell adhesion molecule   290   56       90   Y28280     Homo sapiens     Human G-protein coupled receptor GRIR-2.   326   79       91   L39891     Homo sapiens     polycystic kidney disease-associated protein   1751   95       92   AF064876     Homo sapiens     ion channel BCNG-1   953   99       93   AF170723     Homo sapiens     protein kinase STK10   401   53       94   X13292     Trypanosoma     GPI-phospholipase C (AA 1-358)   151   37                 brucei         95   Y34127     Homo sapiens     Human potassium channel K + Hnov11.   661   99       96   X03638     Rattus     sodium channel protein I (aa 1-2009)   1775   92                 norvegicus         97   AF134213     Homo sapiens     ubiquitin-specific protease   1995   99       98   G00838     Homo sapiens     Human secreted protein, SEQ ID NO: 4919.   213   38       99   AF021935     Rattus     mytonic dystrophy kinase-related Cdc42-binding   675   48                 norvegicus     kinase       100   AF279265     Homo sapiens     putative anion transporter 1   867   98       101   AC007878     Homo sapiens     match to nuclear protein, NP220; note: sequence   160   60                   difference at residue 58       102   U22829     Mus     P2Y purinoceptor   264   42                 musculus         103   Y45023     Homo sapiens     Human sensory transduction G-protein coupled   516   99                   receptor-B3.       104   Y94990     Homo sapiens     Human secreted protein vb21_1, SEQ ID NO: 20.   787   98       105   Y87342     Homo sapiens     Human signal peptide containing protein HSPP-   343   57                   119 SEQ ID NO: 119.       106   AF169312     Homo sapiens     hepatic angiopoietin-related protein   212   67       107   AF116657     Homo sapiens     PRO1310   74   52       108   AE000401     Escherichia     sialic acid transporter   587   96                 coli         109   Y38395     Homo sapiens     Human secreted protein encoded by gene No. 10.   693   100       110   Y78801     Homo sapiens     Hydrophobic domain containing protein clone   182   94                   HP00631 amino acid sequence.       111   Z25535     Homo sapiens     nuclear pore complex protein hnup153   464   85       112   Y94939     Homo sapiens     Human secreted protein clone ye90_1 protein   274   51                   sequence SEQ ID NO: 84.       113   AF016365     Homo sapiens     hexokinase 1 isoform td   301   71       114   AC007956     Homo sapiens     unknown   520   75       115   M83738     Homo sapiens     protein-tyrosine phosphatase   251   92       116   AL157952     Homo sapiens     dJ875K15.1.1 (ets homologous factor (ets-   484   91                   domain transcription factor ESE-3A, isoform 1))       117   W18084     Homo sapiens     Human Aurora-2.   546   87       118   L41816     Homo sapiens     cam kinase I   407   62       119   AJ006710     Rattus     phosphatidylinositol 3-kinase   627   93                 norvegicus         120   AF026954     Bos taurus     pyruvate dehydrogenase phosphatase regulatory   1646   94                   subunit precursor, PDPr       121   S39392     Homo sapiens     protein tyrosine phosphatase, PTPase {EC   373   68                   3.1.3.48}       122   U60805     Homo sapiens     oncostatin-M specific receptor beta subunit   262   88       123   Y44403     Homo sapiens     Human truncated tankyrase-1.   111   35       124   U88167     Caenorhabditis     contains similarity to C2 domains   219   29                 elegans         125   AF300648     Homo sapiens     guanine nucleotide binding protein beta subunit 4   693   90       126   AB021861     Mus     apoptosis signal-regulating kinase 2   153   65                 musculus         127   AF305210     Homo sapiens     concentrative Na+-nucleoside cotransporter   807   97                   hCNT3       128   M90360     Homo sapiens     protein kinase   220   73       129   D32202     Homo sapiens     alpha 1C adrenergic receptor isoform 2   574   86       130   AF208043     Homo sapiens     IFI16b   496   67       131   AF201734     Mus     testis specific serine kinase-3   800   87                 musculus         132   AF112886     Bos taurus     differentiation enhancing factor 1   159   74       133   AJ278314     Homo sapiens     phospholipase C-beta-1b   554   85       134   W74802     Homo sapiens     Human secreted protein encoded by gene 73   1157   87                   clone HSQEL25.       135   AB020335     Homo sapiens     Pancreas-specific gene   668   96       136   W80408     Homo sapiens     A secreted protein encoded by clone dt674_2.   866   98       137   AC002563     Homo sapiens     putative RHO/RAC effector protein; 95%   5041   99                   similarity to P49205 (PID: g1345860)       138   Y96736     Homo sapiens     PRO3434, a novel secreted protein.   891   100       139   AB024034     Arabidopsis     DNA-damage inducible protein DDI1-like   147   55                 thaliana         140   W97809     Homo sapiens     Human GTPase regulator GRAF.   248   56       141   Y51557     Homo sapiens     Human PLA2 protein.   125   46       142   AF090113     Rattus     AMPA receptor binding protein   623   93                 norvegicus         143   W26642     Homo sapiens     Human RECK cancer-inhibiting protein.   641   82       144   U87306     Rattus     transmembrane receptor UNC5H2   578   84                 norvegicus         145   AF264014     Homo sapiens     scavenger receptor cysteine-rich type 1 protein   727   92                   M160 precursor       146   W63683     Homo sapiens     Human secreted protein 3.   140   40       147   M96264     Homo sapiens     galactose-1-phosphate uridyl transferase   513   81       148   D64014     Escherichia     HrsA   818   90                 coli         149   M83316     Escherichia     pppGpp phosphohydrolase   915   95                 coli         150   AL163279     Homo sapiens     homolog to cAMP response element binding and   1261   99                   beta transducin family proteins       151   AF179867     Homo sapiens     STE20-like kinase   940   99       152   R95332     Homo sapiens     Tumor necrosis factor receptor 1 death domain   392   61                   ligand (clone 3TW).       153   AF151859     Homo sapiens     CGI-101 protein   370   92       154   X66957     Homo sapiens     hexokinase type 1   489   81       155   Y16355     Homo sapiens     alternatively spliced form   432   92       156   G00857     Homo sapiens     Human secreted protein, SEQ ID NO: 4938.   349   78       157   AF159455     Mus     zinc finger protein   352   74                 musculus         158   L76191     Homo sapiens     interleukin-1 receptor-associated kinase   537   76       159   AP001743     Homo sapiens     putative gene, ankirin like, possible dual   670   98                   specifity Ser/Thr/Tyr kinase domain       160   AJ250425     Rattus     Collybistin I   556   74                 norvegicus         161   G02885     Homo sapiens     Human secreted protein, SEQ ID NO: 6966.   370   100       162   Z22968     Homo sapiens     M130 antigen   610   100       163   AF181121     Homo sapiens     ATP-dependent Ca2+ pump PMR1   336   92       164   AF055636     Homo sapiens     leucine-rich glioma-inactivated protein precursor   455   94       165   AF160798     Rattus     calcium transporter CaT1   700   96                 norvegicus         166   Y76332     Homo sapiens     Fragment of human secreted protein encoded by   327   45                   gene 38.       167   Y48607     Homo sapiens     Human breast tumor-associated protein 68.   1072   99       168   AB020741     Mus     NIK-related kinase   197   43                 musculus         169   AF252293     Homo sapiens     PAR3   596   44       170   U59429   Cricetinae   diacylglycerol kinase eta   481   82               gen. sp.       171   AF035268     Homo sapiens     phosphatidylserine-specific phospholipase A1   386   42       172   AF127085     Mus     semaphorin cytoplasmic domain-associated   507   82                 musculus     protein 3B       173   Y27918     Homo sapiens     Human secreted protein encoded by gene No.   653   99                   123.       174   G02979     Homo sapiens     Human secreted protein, SEQ ID NO: 7060.   538   97       175   U36488     Mus     embryonic stem cell phosphatase   168   55                 musculus         176   W95629     Homo sapiens       Homo sapiens  secreted protein gene clone   1022   100                   gm196_4.       177   AF289023     Homo sapiens     formiminotransferase cyclodeaminase form D   255   93       178   X04936     Homo sapiens     T-cell receptor alpha-chain (413 is 2nd base in   710   99                   codon)       179   AF127481     Homo sapiens     non-ocogenic Rho GTPase-specific GTP   175   80                   exchange factor       180   G00978     Homo sapiens     Human secreted protein, SEQ ID NO: 5059.   517   94       181   Y66645     Homo sapiens     Membrane-bound protein PRO1310.   671   96       182   AF110640     Homo sapiens     orphan seven-transmembrane receptor   862   100       183   AB020854     Bos taurus     orphan transporter short splicing variant   766   84       184   AF169691     Homo sapiens     cadherin-like protein VR8   375   38       185   AF126372     Homo sapiens     thyrotropin-releasing hormone degrading   985   99                   ectoenzyme       186   L20966     Homo sapiens     phosphodiesterase   541   76       187   G02920     Homo sapiens     Human secreted protein, SEQ ID NO: 7001.   254   93       188   Y94918     Homo sapiens     Human secreted protein clone dd504_18 protein   301   98                   sequence SEQ ID NO: 42.       189   Y66713     Homo sapiens     Membrane-bound protein PRO1309.   694   100       190   G03244     Homo sapiens     Human secreted protein, SEQ ID NO: 7325.   331   73       191   U36771     Rattus     sn-glycerol 3-phosphate acyltransferase   707   92                 norvegicus         192   R05935     Homo sapiens     Secreted GPIIb subunit of multiple subunit   157   72                   polypeptide (MSP)GPIIb-IIIa.       193   M92084     Theileria     casein kinase II alpha subunit   364   50                 parva         194   Y66645     Homo sapiens     Membrane-bound protein PRO1310.   448   90       195   W95631     Homo sapiens       Homo sapiens  secreted protein gene clone   382   49                   hj968_2.       196   AF255614     Rattus     scaffolding protein SLIPR   680   99                 norvegicus         197   AC021640     Arabidopsis     putative phosphatidate phosphohydrolase   300   41                 thaliana         198   AF073967     Mus     olfactory receptor   316   43                 musculus                   domesticus         199   W01730     Homo sapiens     Human G-protein receptor HPRAJ70.   617   98       200   AF117948     Homo sapiens     pancreas-enriched phospholipase C   625   89       201   AF128625     Homo sapiens     CDC42-binding protein kinase beta   636   94       202   AF117946     Homo sapiens     Link guanine nucleotide exchange factor II   1303   100       203   Y53021     Homo sapiens     Human secreted protein clone qc646_1 protein   701   99                   sequence SEQ ID NO: 48.       204   AF227968     Homo sapiens     SH2-B beta signaling protein   182   79       205   S81752     Homo sapiens     DPH2L = candidate tumor suppressor gene   375   100                   {ovarian cancer critical region of deletion}       206   U18315     Sus scrofa     parathyroid receptor   122   60       207   AF255342     Homo sapiens     putative pheromone receptor V1RL1 long form   170   96       208   S52051   Rattus sp.   neurotransmitter transporter   715   94       209   W63683     Homo sapiens     Human secreted protein 3.   840   99       210   D79992     Homo sapiens     similar to Drosophila photoreceptor cell-specific   541   82                   protein, calphotin.       211   AF117948     Homo sapiens     pancreas-enriched phospholipase C   1348   99       212   U81035     Rattus     ankyrin binding cell adhesion molecule   471   69                 norvegicus     neurofascin       213   AF154846     Homo sapiens     zinc finger protein   798   56       214   AF102777     Mus     FYVE finger-containing phosphoinositide kinase   933   93                 musculus         215   AL163303     Homo sapiens     putative gene containing transmembrane domain   523   89       216   U26595     Rattus     prostaglandin F2a receptor regulatory protein   563   78                 norvegicus     precursor       217   G04095     Homo sapiens     Human secreted protein, SEQ ID NO: 8176.   644   98       218   X75756     Homo sapiens     protein kinase C mu   314   81       219   Y66723     Homo sapiens     Membrane-bound protein PRO1100.   770   98       220   D88577     Mus     Kupffer cell receptor   567   40                 musculus         221   AF258465     Homo sapiens     OTRPC4   853   100       222   AF021935     Rattus     mytonic dystrophy kinase-related Cdc42-binding   636   96                 norvegicus     kinase       223   AL136527     Homo sapiens     bA215B13.1 (A kinase (PRKA) anchor protein   693   100                   11)       224   AB032417     Homo sapiens     WNT receptor Frizzled-4   690   99       225   AF030430     Mus     semaphorin VIa   703   68                 musculus         226   AE000218     Escherichia     putative dihydroxyacetone kinase (EC 2.7.1.2)   297   39                 coli         227   AF302150     Homo sapiens     phosphoinositol 3-phosphate-binding protein-2   2080   100       228   AB024573     Mus     GTP-binding like protein 2   265   88                 musculus         229   AF122924     Xenopus     Wnt inhibitory factor-1   316   40                 laevis         230   G03205     Homo sapiens     Human secreted protein, SEQ ID NO: 7286.   229   100       231   X98260     Homo sapiens     M-phase phosphoprotein 11   265   92       232   R92754     Homo sapiens     Human growth differentiation factor-12.   682   95       233   R75111     Homo sapiens     Glycosyl-phosphatidylinositol-specific   290   100                   phospholipase-D.       234   W69431     Homo sapiens     Human secreted protein cw1233_3.   235   97       235   Y08686     Homo sapiens     serine palmitoyltransferase, subunit II   859   81       236   AF118275     Homo sapiens     atrophin-related protein ARP   117   37       237   X81466     Mus     Embryo Brain Kinase   460   62                 musculus         238   U64857     Caenorhabditis     similar to the BPTI/Kunitz family of inhibitors;   284   33                 elegans     most similar to tissue factor pathway inhibitor                   precursor (TFPI)       239   AJ250840     Mus     serine/threonine protein kinase   739   63                 musculus         240   AJ223472     Mus     transcription elongation factor TFIIS.h   222   38                 musculus         241   Y94906     Homo sapiens     Human secreted protein clone rb649_3 protein   353   52                   sequence SEQ ID NO: 18.       242   AF169301     Homo sapiens     Na+/sulfate cotransporter SUT-1   591   99       243   L22022     Rattus     orphan transporter v7-3   667   93                 norvegicus         244   AF016191     Rattus     potassium channel   1043   98                 norvegicus         245   AF097366     Homo sapiens     cone sodium-calcium potassium exchanger   645   98       246   Y29868     Homo sapiens     Human secreted protein clone pp325_9.   497   98       247   AF180475     Homo sapiens     Not4-Np   188   83       248   Y17227     Homo sapiens     Human secreted protein (clone yal-1).   690   99       249   AF250910     Manduca     death-associated small cytoplasmic leucine-rich   182   31                 sexta     protein SCLP       250   AF192756   Kaposi&#39;s   Orf73   134   34               sarcoma-               associated               herpesvirus       251   AB022694     Homo sapiens     MOK protein kinase   209   83       252   W55045     Homo sapiens     Neural adhesion molecule (ethb0018f2 product).   469   100       253   L46815     Mus     DNA binding protein Rc   251   67                 musculus         254   W68505     Homo sapiens     Human acid sensing ionic channel.   173   82       255   AF070066     Mus     Citron-K kinase   1201   98                 musculus         256   G02491     Homo sapiens     Human secreted protein, SEQ ID NO: 6572.   460   100       257   Z12841     Oryctolagus     Phospholipase   368   80                 cuniculus         258   Y95436     Homo sapiens     Human calcium channel SOC-3/CRAC-2.   1857   99       259   AJ222968     Mus     L-periaxin   430   72                 musculus         260   AJ250839     Homo sapiens     serine/threonine protein kinase   861   100       261   AJ249977     Homo sapiens     AMP-activated protein kinase gamma 3 subunit   758   98       262   AF141386     Rattus     SLIT-2   198   40                 norvegicus         263   AF022859     Homo sapiens     neuropilin-2(a0)   335   62       264   AF160477     Homo sapiens     Ig superfamily receptor LNIR precursor   387   91       265   Y44662     Homo sapiens     Human 14273 G-protein coupled receptor   636   99                   (GPCR).       266   U27269     Mus     sodium glucose cotransporter   204   56                 musculus         267   AF124491     Homo sapiens     ARF GTPase-activating protein GIT2   159   75       268   AF127389     Rattus     putative taste receptor TR1   209   39                 norvegicus         269   X98296     Homo sapiens     ubiquitin hydrolase   215   95       270   X78482     Streptococcus     Fc-gamma receptor   129   26                 pyogenes         271   AB009883     Nicotiana     KED   109   26                 tabacum         272   AF137367     Mus     VPS10 domain receptor protein SORCS   899   97                 musculus         273   L34938     Rattus     ionotropic glutamate receptor   460   86                 norvegicus         274   AL022724     Homo sapiens     dJ413H6.1.1 (hamster Androgen-dependent   188   74                   Expressed Protein LIKE PUTATIVE protein)                   (isoform 1)       275   AF265555     Homo sapiens     ubiquitin-conjugating BIR-domain enzyme   173   94                   APOLLON       276   G02872     Homo sapiens     Human secreted protein, SEQ ID NO: 6953.   148   56       277   L40380     Homo sapiens     thyroid receptor interactor   430   61       278   AB046851     Homo sapiens     KIAA1631 protein   283   96       279   AC008075     Arabidopsis     Contains PF|00069 Eukaryotic protein kinase   157   43                 thaliana     domain.       280   M83738     Homo sapiens     protein-tyrosine phosphatase   181   73       281   AK024397     Homo sapiens     unnamed protein product   439   91       282   AF141326     Homo sapiens     RNA helicase HDB/DICE1   497   84       283   AF156530     Mus     ETS-domain transcriptional repressor PE1   605   76                 musculus         284   Y29336     Homo sapiens     Human secreted protein clone cs756_2 alternate   647   100                   reading frame protein.       285   Y73402     Homo sapiens     Human secreted protein clone yc25_1 protein   300   90                   sequence SEQ ID NO: 26.       286   AF016411     Homo sapiens     KCNA3.1B   137   100       287   W89253     Homo sapiens     Human ALP.   688   97       288   AF112886     Bos taurus     differentiation enhancing factor 1   750   96       289   AF113131     Homo sapiens     host cell factor homolog LCP   367   44       290   U52111     Homo sapiens     plexin-related protein   698   100       291   AF026504     Rattus     SPA-1 like protein p1294   603   89                 norvegicus         292   AF102854     Rattus     membrane-associated guanylate kinase-   124   53                 norvegicus     interacting protein 2 Maguin-2       293   X99211     Drosophila     ubiquitin-specific protease   143   38                 melanogaster         294   Y94943     Homo sapiens     Human secreted protein clone yt14_1 protein   185   94                   sequence SEQ ID NO: 92.       295   Y94890     Homo sapiens     Human protein clone HP02798.   108   59       296   AF019767     Homo sapiens     zinc finger protein   154   96       297   Y28568     Homo sapiens     Secreted peptide clone bd577_1.   568   84       298   Y94943     Homo sapiens     Human secreted protein clone yt14_1 protein   182   97                   sequence SEQ ID NO: 92.       299   B08906     Homo sapiens     Human secreted protein sequence encoded by   605   69                   gene 16 SEQ ID NO: 63.       300   R58890     Homo sapiens     Human-32 cadherin-related molecule.   212   97       301   AF022859     Homo sapiens     neuropilin-2(a0)   277   100       302   Y71124     Homo sapiens     Human mitogenic regulator duox2.   716   97       303   Y44297     Homo sapiens     Human receptor tyrosine kinase.   228   97       304   D32050     Homo sapiens     alanyl-tRNA synthetase   192   80       305   U43586     Homo sapiens     protein kinase related to Raf protein kinases;   428   72                   Method: conceptual translation supplied by                   author       306   R54872     Homo sapiens     Human H13 viral receptor mutant 4.   280   95       307   D78572     Mus     membrane glycoprotein   199   41                 musculus         308   AF255614     Rattus     scaffolding protein SLIPR   639   88                 norvegicus         309   S79463   Mus sp.   semaphorin homolog = M-Sema F   162   89       310   AF178941     Homo sapiens     ATP-binding cassette sub-family A member 2   736   100       311   U03413     Dictyostelium     calcium binding protein   151   36                 discoideum         312   Y87347     Homo sapiens     Human signal peptide containing protein HSPP-   744   100                   124 SEQ ID NO: 124.       313   Z97055     Homo sapiens     dJ388M5.4 (putative GS2 like protein)   789   99       314   AC004010     Homo sapiens     similar to Leucine-rich transmembrane proteins;   197   38                   44% similarity to U42767 (PID: g1736918)       315   AL021392     Homo sapiens     dJ439F8.2 (supported by GENSCAN and   278   38                   GENEWISE)       316   U70209     Mus     polycystic kidney disease 1 protein   165   38                 musculus         317   AF109643     Rattus     coxsackie-adenovirus-receptor homolog   223   38                 norvegicus         318   AF104923     Homo sapiens     putative transcription factor   138   84       319   AF100287     Trypanosoma     activated protein kinase C receptor homolog   141   38                 vivax         320   G00588     Homo sapiens     Human secreted protein, SEQ ID NO: 4669.   125   51       321   Y21591     Homo sapiens     Human secreted protein (clone CC332-33).   459   97       322   D26070     Homo sapiens     human type 1 inositol 1,4,5-trisphosphate   232   97                   receptor       323   Y27918     Homo sapiens     Human secreted protein encoded by gene No.   306   88                   123.       324   AF010144     Homo sapiens     neuronal thread protein AD7c-NTP   209   70       325   M19650     Homo sapiens     2′,3′-cyclic-nucleotide 3′-phosphodiesterase (EC   214   97                   3.1.4.37)       326   W80396     Homo sapiens     A secreted protein encoded by clone bp646_10.   140   70       327   X75756     Homo sapiens     protein kinase C mu   540   78       328   G02292     Homo sapiens     Human secreted protein, SEQ ID NO: 6373.   721   99       329   AF168990     Homo sapiens     putative GTP-binding protein   877   99       330   S67984     Homo sapiens     anti-HIV gp120 antibody heavy chain variable   581   80                   region       331   X13916     Homo sapiens     LDL-receptor related precursor (AA-19 to 4525)   2823   98       332   Y87330     Homo sapiens     Human signal peptide containing protein HSPP-   1127   100                   107 SEQ ID NO: 107.       333   Y28503     Homo sapiens     HGFH3 Human Growth Factor Homologue 3.   320   98       334   AC002563     Homo sapiens     putative RHO/RAC effector protein; 95%   327   93                   similarity to P49205 (PID: g1345860)       335   Y87347     Homo sapiens     Human signal peptide containing protein HSPP-   1111   67                   124 SEQ ID NO: 124.       336   AF006466     Mus     lymphocyte specific formin related protein   193   75                 musculus         337   AF265555     Homo sapiens     ubiquitin-conjugating BIR-domain enzyme   632   97                   APOLLON       338   Y13443     Homo sapiens     Amino acid sequence of hSlo3-2.   516   100       339   Y07637     Homo sapiens     putative GABA-gated chloride channel   189   100       340   Y05734     Homo sapiens     Human Grb7 effector 2.2412 protein.   2156   99       341   AE000497     Escherichia     L-idonate transcriptional regulator   928   98                 coli         342   D90855     Escherichia     glycerol-3-phosphate dehydrogenase (EC   769   99                 coli     1.1.99.5) chain A, anaerobic       343   D85613     Escherichia     membrane component   399   100                 coli         344   M93239     Escherichia     transmembrane protein   232   100                 coli         345   M60177     Escherichia     enterobactin   759   99                 coli         346   D90699     Escherichia     Sensor protein copS (EC 2.7.3.—).   638   97                 coli         347   D90843     Escherichia     CapB protein.   552   100                 coli         348   M13422     Escherichia     49 kd protein   1193   96                 coli         349   L10328     Escherichia     similar to drug resistance translocases   340   90                 coli         350   X69942     Mus     enhancer-trap-locus-1   560   82                 musculus         351   AF239613     Homo sapiens     apamin-sensitive small-conductance Ca2+-   463   80                   activated potassium channel       352   D90777     Escherichia     3-hydroxybutyryl-CoA dehydrogenase (EC   577   100                 coli     1.1.1.157) (b- hydroxybutyryl-CoA                   dehydrogenase) (BhbD).       353   D90863     Escherichia     similar to   311   98                 coli         354   Y52386     Homo sapiens     Human transmembrane protein HP02000.   133   58       355   Y31645     Homo sapiens     Human transport-associated protein-7 (TRANP-   482   55                   7).       356   Y58637     Homo sapiens     Protein regulating gene expression PRGE-30.   119   51       357   AF119226     Homo sapiens     dual-specificity tyrosine phosphatase YVH1   1788   100       358   Y87219     Homo sapiens     Human secreted protein sequence SEQ ID   165   100                   NO: 258.       359   J00132     Homo sapiens     beta-fibrinogen   233   93       360   G03789     Homo sapiens     Human secreted protein, SEQ ID NO: 7870.   128   70       361   R28916     Homo sapiens     Type III procollagen (prior art).   108   40       362   U16655     Rattus     phospholipase C delta-4   649   65                 norvegicus         363   G03119     Homo sapiens     Human secreted protein, SEQ ID NO: 7200.   95   42       364   U47276     Gallus gallus     chicken brain factor-2   104   34       365   G03789     Homo sapiens     Human secreted protein, SEQ ID NO: 7870.   183   65       366   G04091     Homo sapiens     Human secreted protein, SEQ ID NO: 8172.   118   46       367   X98258     Homo sapiens     M-phase phosphoprotein 9   564   75       368   AL021366     Homo sapiens     cICK0721Q.3 (Kinesin related protein)   3387   99       369   U70932     Peromyscus     reverse transcriptase   92   59                 leucopus         370   X86400     Homo sapiens     gamma subunit of sodium potassium ATPase   242   73                   like       371   G03172     Homo sapiens     Human secreted protein, SEQ ID NO: 7253.   165   56       372   U49974     Homo sapiens     mariner transposase   257   55       373   X13916     Homo sapiens     LDL-receptor related precursor (AA-19 to 4525)   21193   99       374   AF234765     Rattus     serine-arginine-rich splicing regulatory protein   1182   78                 norvegicus     SRRP86       375   U49974     Homo sapiens     mariner transposase   172   55       376   G01984     Homo sapiens     Human secreted protein, SEQ ID NO: 6065.   221   67       377   G00669     Homo sapiens     Human secreted protein, SEQ ID NO: 4750.   600   100       378   X52574     Mus     GTP binding protein   1456   91                 musculus         379   R69095     Homo sapiens     Anti-HIV Fab tat3I light chain.   68   37       380   J04974     Homo sapiens     alpha-2 type XI collagen   125   37       381   AB002405     Homo sapiens     LAK-4p   530   43       382   U64830     Dictyostelium     protein tyrosine kinase   115   44                 discoideum         383   G02916     Homo sapiens     Human secreted protein, SEQ ID NO: 6997.   618   98       384   G01194     Homo sapiens     Human secreted protein, SEQ ID NO: 5275.   617   93       385   AJ245822     Homo sapiens     type I transmembrane receptor   4560   100       386   D86974     Homo sapiens     KIAA0220   2148   98       387   G03203     Homo sapiens     Human secreted protein, SEQ ID NO: 7284.   142   50       388   G04072     Homo sapiens     Human secreted protein, SEQ ID NO: 8153.   99   59       389   M12140     Homo sapiens     envelope protein   197   51       390   AJ293309     Homo sapiens     NHP2 protein   461   77       391   Y42751     Homo sapiens     Human calcium binding protein 2 (CaBP-2).   181   94       392   W48351     Homo sapiens     Human breast cancer related protein BCRB2.   241   66       393   Y14442     Homo sapiens     olfactory receptor protein   339   54       394   W85607     Homo sapiens     Secreted protein clone da228_6.   957   100       395   Y76332     Homo sapiens     Fragment of human secreted protein encoded by   171   34                   gene 38.       396   G03930     Homo sapiens     Human secreted protein, SEQ ID NO: 8011.   250   100       397   AB032904     Hylobates     dopamine receptor D4   105   35                 syndactylus         398   AJ007798     Homo sapiens     stromal antigen 3, (STAG3)   861   85       399   Y91405     Homo sapiens     Human secreted protein sequence encoded by   1047   92                   gene 2 SEQ ID NO: 126.       400   Y29861     Homo sapiens     Human secreted protein clone cb98_4.   162   37       401   D87002     Homo sapiens     similar to rat integral membrane glycoprotein;   527   78                   accession number Z21513.       402   AF100754     Homo sapiens     ancient ubiquitous protein AUP1 isoform   853   95       403   X74904     Gallus gallus     alpha-2-macroglobulin receptor   258   60       404   AF075462     Mus     ADP-ribosylation factor-directed GTPase   545   89                 musculus     activating protein isoform b       405   X92887   Human   pol/env   162   30               endogenous               retrovirus K       406   Y30162     Homo sapiens     Human dorsal root receptor 4 hDRR4.   325   72       407   AK022626     Homo sapiens     unnamed protein product   2833   99       408   L13802     Homo sapiens     ribosmal protein small subunit   264   92       409   Y91600     Homo sapiens     Human secreted protein sequence encoded by   1788   89                   gene 9 SEQ ID NO: 273.       410   W88745     Homo sapiens     Secreted protein encoded by gene 30 clone   2004   99                   HTSEV09.       411   AB043953     Mus     Chat-H   2628   82                 musculus         412   Y86233     Homo sapiens     Human secreted protein HNTMX29, SEQ ID   1014   92                   NO: 148.       413   U10542     Pan     MHC class I A   265   71                 troglodytes         414   AF155097     Homo sapiens     NY-REN-7 antigen   850   95       415   G03203     Homo sapiens     Human secreted protein, SEQ ID NO: 7284.   88   48       416   Y57911     Homo sapiens     Human transmembrane protein HTMPN-35.   266   89       417   W27651     Homo sapiens     Secreted protein AT205.   481   60       418   Y76884     Homo sapiens     Retinoblastoma binding protein-7sequence.   3077   87       419   AF255559     Notothenia     alpha tubulin   289   68                 coriiceps         420   G01984     Homo sapiens     Human secreted protein, SEQ ID NO: 6065.   209   74       421   AL109827     Homo sapiens     dJ309K20.2 (acrosomal protein ACR55 (similar   1446   96                   to rat sperm antigen 4 (SPAG4)))       422   AC008075     Arabidopsis     F24J5.4   112   35                 thaliana         423   AF231705     Homo sapiens     Alu co-repressor 1   1090   100       424   AF234887     Homo sapiens     FLAMINGO 1   6268   97       425   Y35942     Homo sapiens     Extended human secreted protein sequence, SEQ   1961   99                   ID NO: 191.       426   AB009288     Homo sapiens     N-copine   635   98       427   L12392     Homo sapiens     Huntington&#39;s Disease protein   16080   99       428   Y94990     Homo sapiens     Human secreted protein vb21_1, SEQ ID NO: 20.   768   98       429   AJ293573     Homo sapiens     zinc finger protein Cezanne   542   87       430   Y84441     Homo sapiens     Amino acid sequence of a human RNA-   2074   100                   associated protein.       431   G02850     Homo sapiens     Human secreted protein, SEQ ID NO: 6931.   723   95       432   G04067     Homo sapiens     Human secreted protein, SEQ ID NO: 8148.   73   42       433   AF159296     Lycopersicon     extensin-like protein   613   48                 esculentum         434   W48351     Homo sapiens     Human breast cancer related protein BCRB2.   135   44       435   X73874     Homo sapiens     phosphorylase kinase   3442   97       436   AF161426     Homo sapiens     HSPC308   268   74       437   Y30812     Homo sapiens     Human secreted protein encoded from gene 2.   1055   52       438   G03798     Homo sapiens     Human secreted protein, SEQ ID NO: 7879.   168   56       439   X14766     Homo sapiens     GABA-A receptor alpha 1 subunit   2294   96       440   X02344     Homo sapiens     beta-tubulin   311   95       441   AF168418     Homo sapiens     activating signal cointegrator 1   1882   100       442   L11672     Homo sapiens     zinc finger protein   795   54       443   G03203     Homo sapiens     Human secreted protein, SEQ ID NO: 7284.   93   26       444   A52140   unidentified   HUMAN NDR   2451   100       445   X98330     Homo sapiens     ryanodine receptor 2   9356   99       446   AF116712     Homo sapiens     PRO2738   227   49       447   AF245447     Homo sapiens     sphingosine kinase type 2 isoform   576   99       448   AF133086     Homo sapiens     membrane-type serine protease 1   2630   94       449   U87305     Rattus     transmembrane receptor UNC5H1   817   93                 norvegicus         450   AF081249     Homo sapiens     JAW1-related protein MRVI1A long isoform   4568   99       451   AC005498     Homo sapiens     R31665_1   316   62       452   M60235     Homo sapiens     granule membrane protein-140   464   73       453   AB036706     Homo sapiens     intelectin   730   88       454   G00918     Homo sapiens     Human secreted protein, SEQ ID NO: 4999.   263   81       455   Y22634     Homo sapiens     Human cytokine inducible regulatory protein-1   192   67                   (CIRP-1).       456   Y36705     Homo sapiens     Fragment of human secreted protein encoded by   106   40                   gene 62.       457   N91325     Homo sapiens     DNA encoding human growth hormone receptor.   3282   96       458   M19155     Plasmodium     S-antigen precursor   110   36                 falciparum         459   Y13377     Homo sapiens     Amino acid sequence of protein PRO257.   509   98       460   Y02693     Homo sapiens     Human secreted protein encoded by gene 44   149   43                   clone HTDAD22.       461   Y14482     Homo sapiens     Fragment of human secreted protein encoded by   184   54                   gene 17.       462   Y53005     Homo sapiens     Human secreted protein clone pm749_8 protein   135   47                   sequence SEQ ID NO: 16.       463   X84960     Triticum     low molecular weight glutenin   109   33                 aestivum         464   W19919     Homo sapiens     Human Ksr-1 (kinase suppressor of Ras).   1781   85       465   AF189764     Mus     alpha/beta hydrolase-1   502   59                 musculus         466   U93569     Homo sapiens     p40   101   30       467   Y41528     Homo sapiens     Fragment of human secreted protein encoded by   1172   99                   gene 77.       468   G02872     Homo sapiens     Human secreted protein, SEQ ID NO: 6953.   149   52       469   AJ000008     Homo sapiens     PI3-kinase   5832   97       470   X70922     Mus     neurotoxin homologue   118   47                 musculus         471   G03797     Homo sapiens     Human secreted protein, SEQ ID NO: 7878.   198   75       472   Y36705     Homo sapiens     Fragment of human secreted protein encoded by   72   57                   gene 62.       473   G02313     Homo sapiens     Human secreted protein, SEQ ID NO: 6394.   328   100       474   Y07007     Homo sapiens     Breast cancer associated antigen precursor   1013   97                   sequence.       475   W93254     Homo sapiens     Human ESRP1 protein.   943   80       476   W48351     Homo sapiens     Human breast cancer related protein BCRB2.   236   65       477   Y02693     Homo sapiens     Human secreted protein encoded by gene 44   202   60                   clone HTDAD22.       478   G01870     Homo sapiens     Human secreted protein, SEQ ID NO: 5951.   267   100       479   AF102777     Mus     FYVE finger-containing phosphoinositide kinase   3427   92                 musculus         480   G03052     Homo sapiens     Human secreted protein, SEQ ID NO: 7133.   123   53       481   W87701     Homo sapiens     A human membrane fusion protein designated   221   77                   SYTAX1.       482   G03119     Homo sapiens     Human secreted protein, SEQ ID NO: 7200.   131   39       483   AF210651     Homo sapiens     NAG18   124   59       484   AF010144     Homo sapiens     neuronal thread protein AD7c-NTP   343   50       485   G00637     Homo sapiens     Human secreted protein, SEQ ID NO: 4718.   129   70       486   U15174     Homo sapiens     BCL2/adenovirus E1B 19 kD-interacting protein 3   149   73       487   Y76167     Homo sapiens     Human secreted protein encoded by gene 44.   627   100       488   AJ275213     Homo sapiens     stabilin-1   1244   91       489   G03798     Homo sapiens     Human secreted protein, SEQ ID NO: 7879.   313   65       490   L12392     Homo sapiens     Huntington&#39;s Disease protein   16081   100       491   G03789     Homo sapiens     Human secreted protein, SEQ ID NO: 7870.   197   66       492   J03799     Homo sapiens     laminin-binding protein   228   70       493   U15174     Homo sapiens     BCL2/adenovirus E1B 19 kD-interacting protein 3   128   41       494   Y02693     Homo sapiens     Human secreted protein encoded by gene 44   197   67                   clone HTDAD22.       495   AC005175     Homo sapiens     R31449_3   889   94       496   G03786     Homo sapiens     Human secreted protein, SEQ ID NO: 7867.   229   61       497   AB030237     Canis     D4 dopamine receptor   90   48                 familiaris         498   G02872     Homo sapiens     Human secreted protein, SEQ ID NO: 6953.   228   65       499   U70935     Peromyscus     reverse transcriptase   213   52                 maniculatus         500   U48508     Homo sapiens     skeletal muscle ryanodine receptor   26406   99       501   G03371     Homo sapiens     Human secreted protein, SEQ ID NO: 7452.   105   58       502   AF119851     Homo sapiens     PRO1722   156   62       503   AF113685     Homo sapiens     PRO0974   116   50       504   U79458     Homo sapiens     WW domain binding protein-2   322   59       505   W29651     Homo sapiens     Human secreted protein CD124_3.   608   55       506   W85459     Homo sapiens     Secreted protein encoded by clone dh1135_9.   986   70       507   Y86265     Homo sapiens     Human secreted protein HUSXE77, SEQ ID   115   33                   NO: 180.       508   AL160175     Homo sapiens     bA243J16.3 (similar to MYLK (myosin, light   184   92                   polypeptide kinase))       509   U43360     Peromyscus     reverse transcriptase   97   62                 maniculatus         510   G03789     Homo sapiens     Human secreted protein, SEQ ID NO: 7870.   117   63       511   W79092     Homo sapiens     Human secreted protein dn740_3.   1058   100       512   AF010144     Homo sapiens     neuronal thread protein AD7c-NTP   205   64       513   AJ133439     Homo sapiens     GRIP1 protein   2151   100       514   AE003456     Drosophila     CG6393 gene product   259   42                 melanogaster         515   Z17206     Xenopus     p46X1Eg22   128   40                 laevis         516   AF104413     Homo sapiens     large tumor suppressor 1   1766   94       517   G03797     Homo sapiens     Human secreted protein, SEQ ID NO: 7878.   92   40       518   AF151083     Homo sapiens     HSPC249   444   98       519   S80864     Homo sapiens     cytochrome c-like polypeptide   318   50       520   X92485     Plasmodium     pva1   170   61                 vivax         521   G03790     Homo sapiens     Human secreted protein, SEQ ID NO: 7871.   159   59       522   AF121857     Homo sapiens     sorting nexin 7   259   40       523   G02654     Homo sapiens     Human secreted protein, SEQ ID NO: 6735.   82   37       524   W88627     Homo sapiens     Secreted protein encoded by gene 94 clone   253   73                   HPMBQ32.       525   AF119851     Homo sapiens     PRO1722   162   57       526   Y27761     Homo sapiens     Human secreted protein encoded by gene No. 47.   154   57       527   G02707     Homo sapiens     Human secreted protein, SEQ ID NO: 6788.   70   45       528   U47924     Homo sapiens     C8   1112   86       529   G04063     Homo sapiens     Human secreted protein, SEQ ID NO: 8144.   84   45       530   G03203     Homo sapiens     Human secreted protein, SEQ ID NO: 7284.   111   60       531   G04067     Homo sapiens     Human secreted protein, SEQ ID NO: 8148.   92   65       532   G03267     Homo sapiens     Human secreted protein, SEQ ID NO: 7348.   75   29       533   G03203     Homo sapiens     Human secreted protein, SEQ ID NO: 7284.   182   48       534   AF068286     Homo sapiens     HDCMD38P   861   100       535   U07707     Homo sapiens     epidermal growth factor receptor substrate   228   60       536   G01955     Homo sapiens     Human secreted protein, SEQ ID NO: 6036.   484   75       537   AF219232     Gallus gallus     qin-induced kinase   206   53       538   AF135022     Homo sapiens     mediator   128   100       539   G03267     Homo sapiens     Human secreted protein, SEQ ED NO: 7348.   141   59       540   AF016430     Caenorhabditis     contains similarity to a BR-C/TTK domain   853   39                 elegans         541   AC003093     Homo sapiens     OXYSTEROL-BINDING PROTEIN; 45%   408   66                   similarity to P22059. (PID: g129308)       542   M29487     Homo sapiens     integrin alpha subunit precursor   517   81       543   AF102530     Mus     olfactory receptor F3   327   73                 musculus         544   Y73431     Homo sapiens     Human secreted protein clone yb186_1 protein   386   100                   sequence SEQ ID NO: 84.       545   AE004833     Pseudomonas     probable TonB-dependent receptor   279   42                 aeruginosa         546   G03793     Homo sapiens     Human secreted protein, SEQ ID NO: 7874.   264   53       547   Y69192     Homo sapiens     A human monocyte-macrophage apolipoprotein   1772   67                   B receptor protein.       548   Y91493     Homo sapiens     Human secreted protein sequence encoded by   176   100                   gene 43 SEQ ID NO: 166.       549   G01571     Homo sapiens     Human secreted protein, SEQ ID NO: 5652.   777   99       550   AF044588     Homo sapiens     protein regulating cytokinesis 1; PRC1   1953   88       551   Y29332     Homo sapiens     Human secreted protein clone pe584_2 protein   1224   94                   sequence.       552   X98330     Homo sapiens     ryanodine receptor 2   24621   99       553   Y42782     Homo sapiens     Human UC Band #331 protein.   684   95       554   AB025258     Mus     granuphilin-a   501   41                 musculus         555   AJ010346     Homo sapiens     RING-H2   1468   100       556   W92388     Homo sapiens     Human TR-interacting protein S239a.   538   92       557   AF119851     Homo sapiens     PRO1722   175   59       558   AF117756     Homo sapiens     thyroid hormone receptor-associated protein   183   32                   complex component TRAP150       559   G02872     Homo sapiens     Human secreted protein, SEQ ID NO: 6953.   319   68       560   D86214     Mus     Ca2+ dependent activator protein for secretion   1010   93                 musculus         561   AF187325     Canis     melanoma antigen   287   55                 familiaris         562   AJ001981     Homo sapiens     OXA1L   2512   99       563   Z17238     Rattus     glutamate receptor subtype delta-1   338   66                 norvegicus         564   W30638     Homo sapiens     Partial human 7-transmembrane receptor   371   100                   HAPO167 protein.       565   AC005620     Homo sapiens     R33590_1   467   97       566   Y99358     Homo sapiens     Human PRO1772 (UNQ834) amino acid   1138   78                   sequence SEQ ID NO: 63.       567   AL031177     Homo sapiens     dJ889M15.3 (novel protein)   1002   58       568   AF151043     Homo sapiens     HSPC209   798   100       569   AF097518     Homo sapiens     liver-specific transporter   231   100       570   AB035698     Homo sapiens     Misshapen/NIK-related kinase MINK-1   1532   100       571   Y07096     Homo sapiens     Colon cancer associated antigen precursor   1064   100                   sequence.       572   AL031177     Homo sapiens     dJ889M15.3 (novel protein)   735   55       573   Y66639     Homo sapiens     Membrane-bound protein PRO290.   254   45       574   AB037108     Homo sapiens     seven transmembrane domain orphan receptor   1883   99       575   D43949     Homo sapiens     This gene is novel.   836   100       576   Y48596     Homo sapiens     Human breast tumor-associated protein 57.   108   50       577   G00352     Homo sapiens     Human secreted protein, SEQ ID NO: 4433.   141   75       578   R95913     Homo sapiens     Neural thread protein.   140   65       579   AK025116     Homo sapiens     unnamed protein product   201   70       580   Y86473     Homo sapiens     Human gene 52-encoded protein fragment, SEQ   77   70                   ID NO: 388.       581   AF196779     Homo sapiens     JM10 protein   450   100       582   AF188706     Homo sapiens     g20 protein   330   98       583   AB030234     Canis     D4 dopamine receptor   64   56                 familiaris         584   G02621     Homo sapiens     Human secreted protein, SEQ ID NO: 6702.   345   90       585   AL096828     Homo sapiens     dJ963E22.1 (Novel protein similar to NY-REN-2   268   85                   Antigen)       586   Y30819     Homo sapiens     Human secreted protein encoded from gene 9.   235   35       587   G00357     Homo sapiens     Human secreted protein, SEQ ID NO: 4438.   132   56       588   G02872     Homo sapiens     Human secreted protein, SEQ ID NO: 6953.   182   79       589   AF235017     Mus     2P1 protein   764   80                 musculus         590   W88627     Homo sapiens     Secreted protein encoded by gene 94 clone   329   81                   HPMBQ32.       591   Y30709     Homo sapiens     Amino acid sequence of a human secreted   110   43                   protein.       592   Y53875     Homo sapiens     A human seven transmembrane signal transducer   1369   92                   polypeptide.       593   Y53051     Homo sapiens     Human secreted protein clone dd119_4 protein   1112   97                   sequence SEQ ID NO: 108.       594   Y27658     Homo sapiens     Human secreted protein encoded by gene No. 92.   763   79       595   G03798     Homo sapiens     Human secreted protein, SEQ ID NO: 7879.   156   58       596   AF151110     Mus     COP1 protein   2215   95                 musculus         597   G03786     Homo sapiens     Human secreted protein, SEQ ID NO: 7867.   157   65       598   AF192499     Mus     putative secreted protein ZSIG37   143   40                 musculus         599   AF119855     Homo sapiens     PRO1847   236   76       600   G02872     Homo sapiens     Human secreted protein, SEQ ID NO: 6953.   212   73       601   Y00295     Homo sapiens     Human secreted protein encoded by gene 38.   567   88       602   AF184971     Homo sapiens     class II cytokine receptor ZCYTOR7   2015   74       603   AF061936     Homo sapiens     diacylglycerol kinase iota   773   96       604   AL096828     Homo sapiens     dJ963E22.1 (Novel protein similar to NY-REN-2   1333   93                   Antigen)       605   AB033106     Homo sapiens     KIAA1280 protein   3915   100       606   X75756     Homo sapiens     protein kinase C mu   3916   99       607   D86983     Homo sapiens     similar to D. melanogaster peroxidasin(U11052)   5758   99       608   W69341     Homo sapiens     Secreted protein of clone CG279_1.   1377   99       609   W88627     Homo sapiens     Secreted protein encoded by gene 94 clone   339   82                   HPMBQ32.       610   Y27868     Homo sapiens     Human secreted protein encoded by gene No.   116   62                   107.       611   AF202636     Homo sapiens     angiopoietin-like protein PP1158   2164   100       612   AF090944     Homo sapiens     PRO0663   218   82       613   Y02693     Homo sapiens     Human secreted protein encoded by gene 44   195   59                   clone HTDAD22.       614   M87053     Rattus     lens membrane protein   450   84                 norvegicus         615   AC004232     Homo sapiens     FPM315   163   37       616   G01984     Homo sapiens     Human secreted protein, SEQ ID NO: 6065.   205   79       617   Y91524     Homo sapiens     Human secreted protein sequence encoded by   821   99                   gene 74 SEQ ID NO: 197.       618   AJ245621     Homo sapiens     CTL2 protein   2258   99       619   Y76198     Homo sapiens     Human secreted protein encoded by gene 75.   108   64       620   AF067864     Homo sapiens     transferrin receptor 2 alpha   3922   94       621   D90721     Escherichia     Transmembrane protein dppC   573   90                 coli         622   W75858     Homo sapiens     Human secretory protein of clone CS752-3.   730   100       623   Y94982     Homo sapiens     Human secreted protein vb12_1, SEQ ID NO: 4.   733   100       624   AF034745     Mus     LNXp80   637   83                 musculus         625   U42580     Paramecium     Pro-rich, IPPPNMSLPLS (3x)   94   46                 bursaria                 Chlorella               virus 1       626   U79260     Homo sapiens     unknown   194   70       627   R95913     Homo sapiens     Neural thread protein.   99   50       628   G03450     Homo sapiens     Human secreted protein, SEQ ID NO: 7531.   427   100       629   Y36281     Homo sapiens     Human secreted protein encoded by gene 58.   590   100       630   Y02693     Homo sapiens     Human secreted protein encoded by gene 44   165   76                   clone HTDAD22.       631   G02139     Homo sapiens     Human secreted protein, SEQ ID NO: 6220.   268   96       632   U16996     Homo sapiens     protein tyrosine posphatase   351   80       633   AF121857     Homo sapiens     sorting nexin 7   2019   100       634   AF283772     Homo sapiens     similar to  Homo sapiens  ribosomal protein L10   340   77                   encoded by GenBank Accession Number                   L25899       635   Y07090     Homo sapiens     Renal cancer associated antigen precursor   277   64                   sequence.       636   AB013382     Homo sapiens     DUSP6   414   76       637   G02872     Homo sapiens     Human secreted protein, SEQ ID NO: 6953.   315   71       638   M95762     Rattus     GABA transporter   924   89                 norvegicus         639   G03789     Homo sapiens     Human secreted protein, SEQ ID NO: 7870.   219   60       640   Y01400     Homo sapiens     Secreted protein encoded by gene 18 clone   137   79                   HNHFO29.       641   AC008075     Arabidopsis     F24J5.4   121   33                 thaliana         642   W74824     Homo sapiens     Human secreted protein encoded by gene 96   615   62                   clone HAQBK61.       643   AB015982     Homo sapiens     serine/threonine kinase   485   98       644   Y25806     Homo sapiens     Human secreted protein fragment encoded from   162   46                   gene 23.       645   AF122904     Homo sapiens     membrane protein DAP10   474   100       646   AF233323     Homo sapiens     Fas-associated phosphatase-1   200   38       647   W48804     Homo sapiens       Homo sapiens  clone BK158_1 protein.   1203   99       648   AF257330     Homo sapiens     COBW-like protein   1440   98       649   Y36203     Homo sapiens     Human secreted protein #75.   233   73       650   G02872     Homo sapiens     Human secreted protein, SEQ ID NO: 6953.   173   78       651   Y32199     Homo sapiens     Human receptor molecule (REC) encoded by   1012   100                   Incyte clone 2022379.       652   AB032909     Hylobates     dopamine receptor D4   122   32                 agilis         653   AK021848     Homo sapiens     unnamed protein product   186   69       654   W73411     Homo sapiens     Human secreted protein encoded by Gene No.   57   37                   15.       655   L22455     Rattus     mu opioid receptor   116   34                 norvegicus         656   G03112     Homo sapiens     Human secreted protein, SEQ ID NO: 7193.   110   45       657   G02345     Homo sapiens     Human secreted protein, SEQ ID NO: 6426.   459   97       658   W88627     Homo sapiens     Secreted protein encoded by gene 94 clone   291   75                   HPMBQ32.       659   G02832     Homo sapiens     Human secreted protein, SEQ ID NO: 6913.   134   65       660   Y91423     Homo sapiens     Human secreted protein sequence encoded by   333   96                   gene 11 SEQ ID NO: 144.       661   G03789     Homo sapiens     Human secreted protein, SEQ ID NO: 7870.   168   68       662   Y53886     Homo sapiens     A suppressor of cytokine signalling protein   375   43                   designated HSCOP-6.       663   W75771     Homo sapiens     Human GTP binding protein APD08.   629   100       664   AL096770     Homo sapiens     bA150A6.2 (novel 7 transmembrane receptor   480   55                   (rhodopsin family) (olfactory receptor like)                   protein (hs6M1-21))       665   AB037734     Homo sapiens     KIAA1313 protein   978   96       666   W82841     Homo sapiens     Human cerebral protein-1.   192   84       667   W82841     Homo sapiens     Human cerebral protein-1.   182   87       668   AB030184     Mus     contains transmembrane (TM) region and ATP   757   68                 musculus     binding region       669   AB032919     Hylobates     dopamine receptor D4   85   37                 muelleri         670   AF107295     Rattus     outer membrane protein   746   81                 norvegicus         671   Z33642     Homo sapiens     leukocyte surface protein   394   93       672   W85608     Homo sapiens     Secreted protein clone du410_5.   261   91       673   G03203     Homo sapiens     Human secreted protein, SEQ ID NO: 7284.   106   48       674   AL035587     Homo sapiens     dJ475N16.4 (KIAA0240)   2388   99       675   Y59668     Homo sapiens     Secreted protein 108-005-5-0-C1-FL.   1134   53       676   G03797     Homo sapiens     Human secreted protein, SEQ ID NO: 7878.   174   74       677   AF026954     Bos taurus     pyruvate dehydrogenase phosphatase regulatory   1013   95                   subunit precursor; PDPr       678   L11625     Mus     receptor protein-tyrosine kinase   545   96                 musculus         679   AL031427     Homo sapiens     dJ167A19.3 (novel protein)   745   100       680   AJ133430     Mus     olfactory receptor   528   77                 musculus         681   G02532     Homo sapiens     Human secreted protein, SEQ ID NO: 6613.   179   70       682   G03789     Homo sapiens     Human secreted protein, SEQ ID NO: 7870.   336   76       683   Y94943     Homo sapiens     Human secreted protein clone yt14_1 protein   118   100                   sequence SEQ ID NO: 92.       684   U43360     Peromyscus     reverse transcriptase   100   37                 maniculatus         685   G00885     Homo sapiens     Human secreted protein, SEQ ID NO: 4966.   162   60       686   AK001518     Homo sapiens     unnamed protein product   590   100       687   G01982     Homo sapiens     Human secreted protein, SEQ ID NO: 6063.   718   100       688   Y92241     Homo sapiens     Human cancer associated antigen precursor   2405   99                   (MO-REN-46).       689   AC024792     Caenorhabditis     contains similarity to TR: P78316   423   36                 elegans         690   Y27868     Homo sapiens     Human secreted protein encoded by gene No.   183   81                   107.       691   Y56514     Homo sapiens     Human Jurkat cell clone P2-15 AIM10 longest   180   88                   ORF protein sequence.       692   Y27795     Homo sapiens     Human secreted protein encoded by gene No. 79.   1539   99       693   Y36268     Homo sapiens     Human secreted protein encoded by gene 45.   428   98       694   U12465     Homo sapiens     ribosomal protein L35   308   89       695   Y45272     Homo sapiens     Human secreted protein encoded from gene 16.   1517   99       696   AF191838     Homo sapiens     TANK binding kinase TBK1   1242   98       697   Y02693     Homo sapiens     Human secreted protein encoded by gene 44   275   75                   clone HTDAD22.       698   Y87280     Homo sapiens     Human signal peptide containing protein HSPP-   576   90                   57 SEQ ID NO: 57.       699   Y97999     Homo sapiens     Human SCAD family molecule HSFM-1, SEQ   729   99                   ID NO: 1.       700   AJ006701     Homo sapiens     putative serine/threonine protein kinase   610   79       701   AF209198     Homo sapiens     zinc finger protein 277   2357   100       702   AJ298841     Mus     torsinA protein   709   45                 musculus         703   AK021729     Homo sapiens     unnamed protein product   622   98       704   Z46787     Caenorhabditis     similar to Glutaredoxin, Zinc finger, C3HC4   920   51                 elegans     type (RING finger)       705   G02882     Homo sapiens     Human secreted protein, SEQ ID NO: 6963.   589   98       706   G02501     Homo sapiens     Human secreted protein, SEQ ID NO: 6582.   125   58       707   R95326     Homo sapiens     Tumor necrosis factor receptor 1 death domain   121   95                   ligand (clone 2DD).       708   G03002     Homo sapiens     Human secreted protein, SEQ ID NO: 7083.   125   39       709   Y96202     Homo sapiens     IkappaB kinase (IKK) binding protein, Y2H56.   516   98       710   M63577     Saccharomyces     SFP1   131   59                 cerevisiae         711   AB026291     Rattus     acetoacetyl-CoA synthetase   467   85                 norvegicus         712   D21211     Homo sapiens     protein tyrosine phosphatase (PTP-BAS, type 3)   368   44       713   AF044033     Marmota     olfactory receptor   615   83                 marmota         714   G03561     Homo sapiens     Human secreted protein, SEQ ID NO: 7642.   251   100       715   AB033062     Homo sapiens     KIAA1236 protein   1380   100       716   G00577     Homo sapiens     Human secreted protein, SEQ ID NO: 4658.   80   73       717   Y96864     Homo sapiens     SEQ. ID. 37 from WO0034474.   835   99       718   AJ243396     Homo sapiens     voltage-gated sodium channel beta-3 subunit   234   100       719   U47334     Homo sapiens     similar to chicken gamma aminobutyric acid   578   99                   receptor beta4 subunit       720   AB020598     Homo sapiens     peptide transporter 3   1096   100       721   Y53886     Homo sapiens     A suppressor of cytokine signalling protein   570   74                   designated HSCOP-6.       722   J05046     Homo sapiens     insulin receptor-related receptor   6787   100       723   AF001958     Ambystoma     electrogenic Na+ bicarbonate cotransporter;   111   41                 tigrinum     NBC       724   AF127084     Mus     semaphorin cytoplasmic domain-associated   5253   94                 musculus     protein 3A       725   X54673     Homo sapiens     GABA transporter   3114   99       726   AF016191     Rattus     potassium channel   370   100                 norvegicus         727   AB029559     Rattus     BAT1   139   35                 norvegicus         728   Y28503     Homo sapiens     HGFH3 Human Growth Factor Homologue 3.   2186   97       729   AJ011415     Homo sapiens     plexin-B1/SEP receptor   729   56       730   Z93096     Homo sapiens     bK390B3.1 (manic fringe (Drosophila)   142   68                   homolog)       731   Z10062     Homo sapiens     cDNA encoding a human vanilloid receptor   675   99                   homologue Vanilrep1.       732   AF161382     Homo sapiens     HSPC264   492   94       733   AB029033     Homo sapiens     KIAA1110 protein   3826   99       734   AE000493     Escherichia     putative transport protein   592   97                 coli         735   AL033379     Homo sapiens     dJ417O22.2 (novel 7 transmembrane receptor   2173   99                   (rhodopsin family) protein similar to high-                   affinity lysophosphatidic acid receptor homolog)       736   AF132599     Homo sapiens     RANTES factor of late activated T lymphocytes-1   245   56       737   X55019     Homo sapiens     acetylcholine receptor delta subunit   883   99       738   X91906     Homo sapiens     voltage-gated chloride ion channel   1978   100       739   AB026116     Homo sapiens     organic anion transporter 4   1444   98       740   D00570     Mus     open reading frame (196 AA)   83   24                 musculus         741   W03626     Homo sapiens     Human thyrotropin GPR N-terminal sequence.   118   40       742   U66059     Homo sapiens     V_segment translation product   614   100       743   AF119815     Homo sapiens     G-protein-coupled receptor   2751   99       744   X16663     Homo sapiens     haematopoietic lineage cell protein (AA 1-486)   148   93       745   W67838     Homo sapiens     Human secreted protein encoded by gene 32   448   95                   clone HLTCJ63.       746   W57260     Homo sapiens     Human semaphorin Y.   2414   100       747   W21578     Homo sapiens     Alzheimer&#39;s disease protein encoded by DNA   968   65                   from plasmid pGCS2232.       748   Y94935     Homo sapiens     Human secreted protein clone yd218_1 protein   622   100                   sequence SEQ ID NO: 76.       749   AL022238     Homo sapiens     dJ1042K10.5 (novel protein)   314   85       750   G03889     Homo sapiens     Human secreted protein, SEQ ID NO: 7970.   391   87       751   AB025258     Mus     granuphilin-a   773   41                 musculus         752   Y52386     Homo sapiens     Human transmembrane protein HP02000.   900   99       753   Y48586     Homo sapiens     Human breast tumor-associated protein 47.   2527   99       754   AJ272207     Homo sapiens     putative G protein-coupled receptor 92   694   100       755   M85183     Rattus     vasopressin receptor   979   68                 norvegicus         756   AF190501     Homo sapiens     leucine-rich repeat-containing G protein-coupled   388   71                   receptor 6       757   Y02692     Homo sapiens     Human secreted protein encoded by gene 43   461   87                   clone HTADX17.       758   Z22535     Homo sapiens     ALK-3   439   98       759   R04932     Homo sapiens     Interferon-gamma receptor segment from clone   564   97                   39 responsiblefor binding the target.       760   W74902     Homo sapiens     Human secreted protein encoded by gene 175   1217   99                   clone HE8BI92.       761   G03706     Homo sapiens     Human secreted protein, SEQ ID NO: 7787.   223   88       762   AB020676     Homo sapiens     KIAA0869 protein   4433   99       763   AK026992     Homo sapiens     unnamed protein product   2285   99       764   AF173358     Homo sapiens     glucocorticoid receptor AF-1 coactivator-1   573   100       765   AF268066     Mus     netrin 4   2019   89                 musculus         766   Y48585     Homo sapiens     Human breast tumor-associated protein 46.   1169   89       767   AF230378     Mus     interleukin-1 delta   309   45                 musculus         768   AF121975     Mus     odorant receptor S18   268   62                 musculus         769   AB008515     Homo sapiens     RanBPM   611   57       770   Y09945     Rattus     putative integral membrane transport protein   458   50                 norvegicus         771   AF226731     Homo sapiens     AD026   688   99       772   Y27132     Homo sapiens     Human glioblastoma-derived polypeptide (clone   1384   100                   OA004FG).       773   X87832     Homo sapiens     NOV/plexin-A1 protein   1821   98       774   AB025258     Mus     granuphilin-a   500   41                 musculus         775   AF125101     Homo sapiens     HSPC040 protein   232   93       776   G02815     Homo sapiens     Human secreted protein, SEQ ID NO: 6896.   314   95       777   G02493     Homo sapiens     Human secreted protein, SEQ ID NO: 6574.   191   68       778   R03301     Homo sapiens     Sequence of pre-human atrial natriuretic peptide.   213   45       779   AL357374     Homo sapiens     bA353C18.2 (novel protein)   232   100       780   AF100346     Homo sapiens     neuronal voltage gated calcium channel gamma-   1434   89                   3 subunit       781   Y19566     Homo sapiens     Amino acid sequence of a human secreted   103   52                   protein.       782   Y36233     Homo sapiens     Human secreted protein encoded by gene 10.   1098   93       783   AF084464     Rattus     GTP-binding protein REM2   141   30                 norvegicus         784   W49042     Homo sapiens     Human low density lipoprotein binding protein   2693   99                   LBP-3.       785   AF238381     Homo sapiens     PTOV1   1904   91       786   Y91870     Homo sapiens     Human apoptosis related protein.   547   100       787   Y71062     Homo sapiens     Human membrane transport protein, MTRP-7.   1062   94       788   AF117754     Homo sapiens     thyroid hormone receptor-associated protein   8684   98                   complex component TRAP240       789   AL049569     Homo sapiens     dJ37C10.3 (novel ATPase)   2848   96       790   AF151848     Homo sapiens     CGI-90 protein   745   96       791   Y08639     Homo sapiens     nuclear orphan receptor ROR-beta   1421   95       792   Y41706     Homo sapiens     Human PRO381 protein sequence.   644   99       793   AF121228     Homo sapiens     thyroid hormone receptor-associated protein   1037   100                   complex component TRAP95       794   G04072     Homo sapiens     Human secreted protein, SEQ ID NO: 8153.   124   62       795   Y69384     Homo sapiens     Amino acid sequence of a 14274 receptor   119   100                   protein.       796   W40215     Homo sapiens     Human macrophage antigen.   1358   99       797   AF258340     Homo sapiens     hepatocellular carcinoma-associated antigen 112   1151   99       798   AF159615     Homo sapiens     FGF receptor activating protein 1   461   98       799   Y59863     Homo sapiens     Human normal uterus tissue derived protein 26.   797   99       800   W70459     Homo sapiens     Human T1-receptor ligand III splice variant 2.   572   92       801   L00073     Homo sapiens     renin   1913   93       802   P92219     Homo sapiens     CR1 protein.   11963   97                 (human)         803   X15357     Homo sapiens     ANP-A receptor preprotein (AA −32 to 1029)   5199   98       804   W64473     Homo sapiens     Human secreted protein from clone EC172_1.   4018   95       805   AJ243874     Homo sapiens     oligophrenin-4   2067   100       806   G01731     Homo sapiens     Human secreted protein, SEQ ID NO: 5812.   284   100       807   Z24680     Homo sapiens     garp   1562   83       808   AF171669     Homo sapiens     glycoprotein-associated amino acid transporter   1364   90                   LAT2       809   W70321     Homo sapiens     Secreted protein CC198_1.   1154   96       810   W74843     Homo sapiens     Human secreted protein encoded by gene 115   855   99                   clone HOVBA03.       811   AF108831     Homo sapiens     K:Cl cotransporter 3   4561   100       812   AF092135     Homo sapiens     PTD014   862   100       813   AF283772     Homo sapiens     similar to  Homo sapiens  ribosomal protein L10   784   100                   encoded by GenBank Accession Number                   L25899       814   G01563     Homo sapiens     Human secreted protein, SEQ ID NO: 5644.   330   100       815   AF051151     Homo sapiens     Toll/interleukin-1 receptor-like protein 3   3850   99       816   W95630     Homo sapiens       Homo sapiens  secreted protein gene clone   358   100                   gn114_1.       817   G01082     Homo sapiens     Human secreted protein, SEQ ID NO: 5163.   549   100       818   AF151800     Homo sapiens     CGI-41 protein   1106   95       819   L00352     Homo sapiens     low density lipoprotein receptor   3980   100       820   X04434     Homo sapiens     IGF-I receptor   5832   99       821   G03844     Homo sapiens     Human secreted protein, SEQ ID NO: 7925.   572   100       822   AF212220     Homo sapiens     TERA   396   48       823   Y50125     Homo sapiens     Human glycophosphatidylinositol-anchored   4897   99                   protein GPI-122.       824   AF156778     Homo sapiens     ASB-3 protein   2675   98       825   AF096322     Homo sapiens     neuronal voltage-gated calcium channel gamma-   1105   100                   2 subunit       826   Y07972     Homo sapiens     Human secreted protein fragment #2 encoded   1540   100                   from gene 28.       827   AB032013     Homo sapiens     potassium channel Kv8.1   2435   95       828   Y13620     Homo sapiens     BCL9   5284   96       829   Y91474     Homo sapiens     Human secreted protein sequence encoded by   541   98                   gene 24 SEQ ID NO: 147.       830   X54232     Homo sapiens     glypican   1625   87       831   X14830     Homo sapiens     acetylcholine receptor beta-subunit preprotein   2540   100       832   Y71262     Homo sapiens     Human chondromodulin-like protein, Zchm1.   1002   100       833   G03873     Homo sapiens     Human secreted protein, SEQ ID NO: 7954.   638   96       834   AC003030     Homo sapiens     R29828_1   1389   93       835   Y38422     Homo sapiens     Human secreted protein.   964   87       836   U41557     Caenorhabditis     glycine-rich   85   36                 elegans         837   AL121889     Homo sapiens     dJ1076E17.1 (KIAA0823 protein (continues in   998   75                   AL023803))       838   AJ011415     Homo sapiens     plexin-B1/SEP receptor   1580   60       839   W80398     Homo sapiens     A secreted protein encoded by clone cw1543_3.   1105   67       840   G00862     Homo sapiens     Human secreted protein, SEQ ID NO: 4943.   255   92       841   G02650     Homo sapiens     Human secreted protein, SEQ ID NO: 6731.   644   97       842   AF036717     Homo sapiens     FGFR signalling adaptor SNT-1   2629   99       843   Y73446     Homo sapiens     Human secreted protein clone yc27_1 protein   1089   100                   sequence SEQ ID NO: 114.       844   G02872     Homo sapiens     Human secreted protein, SEQ ID NO: 6953.   357   69       845   AF151810     Homo sapiens     CGI-52 protein   1443   88       846   X83378     Homo sapiens     putative chloride channel   1620   99       847   AC004883     Homo sapiens     similar to general transcription factor 2I; similar   655   96                   to AF038969 (PID: g2827207)       848   X99886     Homo sapiens     monocyte chemotactic protein-2   160   76       849   AC005587     Homo sapiens     similar to mouse olfactory receptor 13; similar to   963   98                   P34984 (PID: g464305)       850   AB038237     Homo sapiens     G protein-coupled receptor C5L2   1767   100       851   AF124490     Homo sapiens     ARF GTPase-activating protein GIT1   3415   98       852   Y86217     Homo sapiens     Human secreted protein HWHGU54, SEQ ID   1189   99                   NO: 132.       853   AF224741     Homo sapiens     chloride channel protein 7   3748   99       854   X17094     Homo sapiens     furin (AA 1-794)   3550   99       855   W78245     Homo sapiens     Fragment of human secreted protein encoded by   1245   99                   gene 19.       856   R97569     Homo sapiens     Interleukin-2 receptor associated protein p43.   1926   100       857   Y41765     Homo sapiens     Human PRO1083 protein sequence.   3211   99       858   AF057306     Homo sapiens     transmembrane proteolipid   481   84       859   AK025116     Homo sapiens     unnamed protein product   374   69       860   Y41312     Homo sapiens     Human secreted protein encoded by gene 5 clone   824   100                   HLDRM43.       862   Y25776     Homo sapiens     Human secreted protein encoded from gene 66.   895   99       863   Y74188     Homo sapiens     Human prostate tumor EST fragment derived   96   30                   protein #375.       864   AF167473     Homo sapiens     heme-binding protein   870   99       865   G02532     Homo sapiens     Human secreted protein, SEQ ID NO: 6613.   211   67       866   X54870     Homo sapiens     Type II integral membrane protein   1201   100       867   G00700     Homo sapiens     Human secreted protein, SEQ ID NO: 4781.   640   99       868   Y07894     Homo sapiens     Human secreted protein fragment encoded from   388   88                   gene 43.       869   J00123     Homo sapiens     preproenkephalin (   1349   95       870   Y91632     Homo sapiens     Human secreted protein sequence encoded by   1048   98                   gene 25 SEQ ID NO: 305.       871   L04311     Homo sapiens     GABA-alpha receptor beta-3 subunit   237   93       872   Y29988     Homo sapiens     Human cytokine family member EF-7 protein.   960   94       873   AF161382     Homo sapiens     HSPC264   1124   99       874   G03412     Homo sapiens     Human secreted protein, SEQ ID NO: 7493.   464   100       875   Y27572     Homo sapiens     Human secreted protein encoded by gene No. 6.   573   96       876   M15530     Homo sapiens     B-cell growth factor   171   56       877   W63681     Homo sapiens     Human secreted protein 1.   1652   99       878   L27867     Rattus     neurexophilin   1448   98                 norvegicus         879   Y10835     Homo sapiens     Amino acid sequence of a human secreted   321   100                   protein.       880   W88991     Homo sapiens     Polypeptide fragment encoded by gene 144.   936   100       881   AF118670     Homo sapiens     orphan G protein-coupled receptor   1971   100       882   AF208865     Homo sapiens     EDRF   528   100       883   Y18462     Homo sapiens     cathepsin L   209   72       884   Y94950     Homo sapiens     Human secreted protein clone dh1073_12 protein   348   100                   sequence SEQ ID NO: 106.       885   AF070661     Homo sapiens     HSPC005   404   100       886   Y04315     Homo sapiens     Human secreted protein encoded by gene 23.   385   100       887   X92744     Homo sapiens     hBD-1   375   100       888   Y22496     Homo sapiens     Human secreted protein sequence clone   994   94                   cn621_8.       889   Y41293     Homo sapiens     Human soluble protein ZTMPO-1.   4595   99       890   G03714     Homo sapiens     Human secreted protein, SEQ ID NO: 7795.   147   63       891   AF208856     Homo sapiens     BM-014   1012   99       892   U29195     Homo sapiens     neuronal pentraxin II   2002   98       893   X68149     Homo sapiens     Burkitt lymphoma receptor 1   1953   100       894   Y94914     Homo sapiens     Human secreted protein clone pw337_6 protein   537   100                   sequence SEQ ID NO: 34.       895   W61630     Homo sapiens     Clone HNFGW06 of EGFR receptor family.   326   63       896   M24110     Homo sapiens     G0S19-2 peptide precursor   481   100       897   Z68747     Homo sapiens     imogen 38   2018   99       898   AF186112     Homo sapiens     neurokinin B-like protein ZNEUROK1   619   100       899   AF225420     Homo sapiens     AD025   734   100       900   P60657     Homo sapiens     Sequence of human lipocortin.   1835   100       901   M27288     Homo sapiens     oncostatin M   1297   99       902   W85737     Homo sapiens     Polypeptide with transmembrane domain.   749   100       903   G01349     Homo sapiens     Human secreted protein, SEQ ID NO: 5430.   650   99       904   Y00261     Homo sapiens     Human secreted protein encoded by gene 4.   1133   99       905   AF039688     Homo sapiens     antigen NY-CO-3   771   99       906   AB007836     Homo sapiens     Hic-5   2544   100       907   AB017507     Homo sapiens     Apg12   224   100       908   AK000056     Homo sapiens     unnamed protein product   1537   98       909   Y86299     Homo sapiens     Human secreted protein HFOXB55, SEQ ID   427   100                   NO: 214.       910   AF231023     Homo sapiens     protocadherin Flamingo 1   7393   99       911   Y14134     Homo sapiens     Vascular endothelial cell growth inhibitor beta   1319   100                   protein sequence.       912   Z90420     Homo sapiens     Human GDF-3 (hGDF-3) polypeptide encoding   1950   100                   cDNA.       913   Y19757     Homo sapiens     SEQ ID NO 475 from WO9922243.   1361   100       914   G03172     Homo sapiens     Human secreted protein, SEQ ID NO: 7253.   112   48       915   U14971     Homo sapiens     ribosomal protein S9   886   90       916   AF172854     Homo sapiens     cardiotrophin-like cytokine CLC   1204   99       917   AC005525     Homo sapiens     F22162_1   1963   100       918   AF166350     Homo sapiens     ST7 protein   4711   99       919   Y87285     Homo sapiens     Human signal peptide containing protein HSPP-   430   100                   62 SEQ ID NO: 62.       920   Y36131     Homo sapiens     Human secreted protein #3.   465   88       921   AF193766     Homo sapiens     cytokine-like protein C17   724   100       922   Y95013     Homo sapiens     Human secreted protein vc48_1, SEQ ID NO: 66.   357   100       923   X75208     Homo sapiens     protein tyrosine kinase-receptor   5256   100       924   Y96202     Homo sapiens     IkappaB kinase (IKK) binding protein, Y2H56.   813   98       925   AB039886     Homo sapiens     down-regulated in gastric cancer   785   78       926   G03368     Homo sapiens     Human secreted protein, SEQ ID NO: 7449.   55   50       927   Y48606     Homo sapiens     Human breast tumor-associated protein 67.   539   100       928   Y36151     Homo sapiens     Human secreted protein #23.   668   100       929   AF110399     Homo sapiens     elongation factor Ts   1666   100       930   AF210317     Homo sapiens     facilitative glucose transporter family member   2763   99                   GLUT9       931   Y73328     Homo sapiens     HTRM clone 082843 protein sequence.   931   100       932   G01959     Homo sapiens     Human secreted protein, SEQ ID NO: 6040.   274   100       933   U47924     Homo sapiens     B-cell receptor associated protein   1469   100       934   G03827     Homo sapiens     Human secreted protein, SEQ ID NO: 7908.   529   93       935   AB039371     Homo sapiens     mitochondrial ABC transporter 3   196   63       936   X56385     Canis     rab8   1064   100                 familiaris         937   B08906     Homo sapiens     Human secreted protein sequence encoded by   117   44                   gene 16 SEQ ID NO: 63.       938   M13692     Homo sapiens     alpha-1 acid glycoprotein precursor   1064   99       939   Y53886     Homo sapiens     A suppressor of cytokine signalling protein   515   42                   designated HSCOP-6.       940   Y16630     Homo sapiens     Human Putative Adrenomedullin Receptor   1904   99                   (PAR).       941   AC005102     Homo sapiens     small inducible cytokine subfamily A member   627   99                   24       942   M12886     Homo sapiens     T-cell receptor beta chain   1289   81       943   AF226046     Homo sapiens     GK003   1049   98       944   Y36078     Homo sapiens     Extended human secreted protein sequence, SEQ   667   100                   ID NO. 463.       945   M22877     Homo sapiens     cytochrome c   565   100       946   W67869     Homo sapiens     Human secreted protein encoded by gene 63   551   93                   clone HHGDB72.       947   W67859     Homo sapiens     Human secreted protein encoded by gene 53   283   100                   clone HBMCL41.       948   W85726     Homo sapiens     Novel protein (Clone BG33_7).   789   100       949   AJ242015     Homo sapiens     eMDC II protein   4236   100       950   G04075     Homo sapiens     Human secreted protein, SEQ ID NO: 8156.   567   99       951   AF110645     Homo sapiens     candidate tumor suppressor p33 INGl homolog   1314   100       952   Y36111     Homo sapiens     Extended human secreted protein sequence, SEQ   402   70                   ID NO. 496.       953   AB012109     Homo sapiens     APC10   990   100       954   AF246221     Homo sapiens     transmembrane protein BRI   1405   100       955   AF054986     Homo sapiens     putative transmembrane GTPase   1883   100       956   W74726     Homo sapiens     Human secreted protein fg949_3.   1879   100       957   Y27096     Homo sapiens     Human viral receptor protein (ACVRP).   1581   100       958   AJ222967     Homo sapiens     cystinosin   1920   100       959   Y53052     Homo sapiens     Human secreted protein clone df202_3 protein   587   100                   sequence SEQ ID NO: 110.       960   G02694     Homo sapiens     Human secreted protein, SEQ ID NO: 6775.   283   100       961   AF151855     Homo sapiens     CG1-97 protein   1214   96       962   U26592     Homo sapiens     diabetes mellitus type I autoantigen   250   65       963   AL050306     Homo sapiens     dJ475B7.2 (novel protein)   3796   100       964   AF078859     Homo sapiens     PTD004   2089   100       965   AB020315     Homo sapiens     homologue of mouse dkk-1 gene: Acc#   1466   100                   AF030433       966   X04571     Homo sapiens     precursor polypeptide (AA-22 to 1185)   6580   99       967   AF146019     Homo sapiens     hepatocellular carcinoma antigen gene 520   993   99       968   AF071002     Homo sapiens     minK-related peptide 1; MiRP1   632   100       969   AB021227     Homo sapiens     membrane-type-5 matrix metalloproteinase   3545   100       970   AF 180920     Homo sapiens     cyclin L ania-6a   1579   100       971   AF105365     Homo sapiens     K-Cl cotransporter KCC4   5621   99       972   AF083248     Homo sapiens     ribosomal protein L26 homolog   739   100       973   AJ132429     Homo sapiens     hyperpolarization-activated cyclic nucleotide   6295   100                   gated cation channel hHCN4       974   W61619     Homo sapiens     Clone HTPEF86 of TM4SF superfamily.   454   100       975   AF155100     Homo sapiens     zinc finger protein NY-REN-21 antigen   2261   100       976   AF275948     Homo sapiens     ABCA1   11763   99       977   AB026891     Homo sapiens     cystine/glutamate transporter   2552   100       978   AF 117657     Homo sapiens     thyroid hormone receptor-associated protein   3348   99                   complex component TRAP80       979   AF044201     Rattus     neural membrane protein 35; NMP35   1570   92                 norvegicus         980   AF119297     Homo sapiens     neuroendocrine-specific protein-like protein I   1170   99       981   AF155652     Homo sapiens     potassium channel modulator factory   1983   99       982   W88499     Homo sapiens     Human stomach carcinoma clone HP 10412-   1553   99                   encoded protein.       983   Z56281     Homo sapiens     interferon regulatory factor 3   2012   98       984   AB026125     Homo sapiens     ART-4   2160   100       985   Y14482     Homo sapiens     Fragment of human secreted protein encoded by   172   70                   gene 17.       986   AB023888     Homo sapiens     b-chemokine receptor CCR4   1895   100       987   W27291     Homo sapiens     Human H1075-1 secreted protein 5′ end.   712   100       988   AF153450     Manduca     juvenile hormone esterase binding protein   226   32                 sexta         989   G03697     Homo sapiens     Human secreted protein, SEQ ID NO: 7778.   194   88       990   AF204159     Homo sapiens     potassium large conductance calcium-activated   1486   100                   channel beta 3a subunit       991   G02061     Homo sapiens     Human secreted protein, SEQ ID NO: 6142.   558   99       992   AL031266     Caenorhabditis     VM106R.1   327   40                 elegans         993   Y66749     Homo sapiens     Membrane-bound protein PRO1124.   4730   99       994   G01246     Homo sapiens     Human secreted protein, SEQ ID NO: 5327.   141   77       995   AF133845     Homo sapiens     corin   5811   99       996   AF117756     Homo sapiens     thyroid hormone receptor-associated protein   4999   100                   complex component TRAP150       997   W62066     Homo sapiens     Human stem cell antigen 2.   284   93       998   Y87173     Homo sapiens     Human secreted protein sequence SEQ ID   725   100                   NO: 212.       999   Y13379     Homo sapiens     Amino acid sequence of protein PRO263.   1654   99       1000   Y95008     Homo sapiens     Human secreted protein vf3_1, SEQ ID NO: 56.   676   47       1001   AF190167     Homo sapiens     membrane associated protein SLP-2   1747   100       1002   G01234     Homo sapiens     Human secreted protein, SEQ ID NO: 5315.   398   96       1003   W73420     Homo sapiens     Human secreted protein encoded by Gene No.   2150   100                   24.       1004   X12791     Homo sapiens     19 kD SRP-protein (AA 1-144)   742   100       1005   M23323     Homo sapiens     membrane protein   642   100       1006   X63745     Homo sapiens     KDEL receptor   326   98       1007   Y35997     Homo sapiens     Extended human secreted protein sequence, SEQ   824   99                   ID NO. 382.       1008   AB032918     Hylobates     dopamine receptor D4   92   35                 moloch         1009   Y91680     Homo sapiens     Human secreted protein sequence encoded by   1372   99                   gene 81 SEQ ID NO: 353.       1010   AL136125     Homo sapiens     dJ304B14.1 (novel protein)   825   98       1011   G03733     Homo sapiens     Human secreted protein, SEQ ID NO: 7814.   379   98       1012   Y17531     Homo sapiens     Human secreted protein clone BL205 14 protein.   818   97       1013   G00724     Homo sapiens     Human secreted protein, SEQ ID NO: 4805.   462   100       1014   AF288092     Naegleria     haem lyase   114   37                 gruberi         1015   AB045292     Homo sapiens     M83 protein   3867   99       1016   X15940     Homo sapiens     ribosomal protein L31 (AA 1-125)   644   100       1017   Y94873     Homo sapiens     Human protein clone HP02632.   1876   100       1018   AL024498     Homo sapiens     dJ417M14.1 (novel protein)   589   100       1019   X83425     Homo sapiens     Lutheran blood group glycoprotein   3054   99       1020   W03516     Homo sapiens     Prostaglandin DP receptor.   1864   100       1021   G03960     Homo sapiens     Human secreted protein, SEQ ID NO: 8041.   398   100       1022   Y91689     Homo sapiens     Human secreted protein sequence encoded by   768   100                   gene 93 SEQ ID NO: 362.       1023   AE000660     Homo sapiens     hADV36S1   573   100       1024   AF132965     Homo sapiens     CGI-31 protein   1550   100       1025   W92380     Homo sapiens     Human TR-interacting protein S103a.   1466   97       1026   R66278     Homo sapiens     Therapeutic polypeptide from glioblastoma cell   830   100                   line.       1027   X65614     Homo sapiens     S100P calcium-binding protein   476   100       1028   Y41741     Homo sapiens     Human PRO704 protein sequence.   1323   100       1029   AJ001014     Homo sapiens     RAMP1   806   100       1030   W63682     Homo sapiens     Human secreted protein 2.   1354   99       1031   AK023007     Homo sapiens     unnamed protein product   766   100       1032   W97900     Homo sapiens     Human SR-BI class B scavenger.   2672   99       1033   Y82453     Homo sapiens     Human TGC-440 secretory protein SEQ ID   639   99                   NO: 1.       1034   Y73473     Homo sapiens     Human secreted protein clone yd178_1 protein   752   93                   sequence SEQ ID NO: 168.       1035   Y86468     Homo sapiens     Human gene 48-encoded protein fragment, SEQ   96   90                   ID NO: 383.       1036   U09813     Homo sapiens     mitochondrial ATP synthase subunit 9 precursor   698   100       1037   AJ242832     Homo sapiens     calpain   3699   99       1038   X66403     Homo sapiens     acetylcholine receptor epsilon subunit CHRNE   2574   100       1039   AJ242730     Homo sapiens     polyhomeotic 2   1310   100       1040.   AF169968     Mus     DNA binding protein DESRT   1453   80                 musculus         1041   X52563     Bos taurus     permability increasing protein   383   29       1042   G00368     Homo sapiens     Human secreted protein, SEQ ID NO: 4449.   75   50       1043   G02532     Homo sapiens     Human secreted protein, SEQ ID NO: 6613.   60   53       1044   M94582     Homo sapiens     interleukin 8 receptor B   1850   100       1045   AL080239     Homo sapiens     bG256O22.1 (similar to IGFALS (insulin-like   1704   50                   growth factor binding protein, acid labile                   subunit))       1046   AF125101     Homo sapiens     HSPC040 protein   580   100       1047   W74809     Homo sapiens     Human secreted protein encoded by gene 81   176   100                   clone HMWDN32.       1048   AL022238     Homo sapiens     dJ1042K10.4 (novel protein)   2201   100       1049   W88667     Homo sapiens     Secreted protein encoded by gene 134 clone   1559   99                   HAIBP89.       1050   AF097518     Homo sapiens     liver-specific transporter   2820   100       1051   W78324     Homo sapiens     Fragment of human secreted protein encoded by   1318   98                   gene 81.       1052   Y21851     Homo sapiens     Human signal peptide-containing protein (SIGP)   1643   95                   (clone ID 2328134).       1053   AL163815     Arabidopsis     putative protein   661   62                 thaliana         1054   Y76200     Homo sapiens     Human secreted protein encoded by gene 77.   262   100       1055   AJ276567     Homo sapiens     TC10-like Rho GTPase   1160   100       1056   Y27620     Homo sapiens     Human secreted protein encoded by gene No. 54.   154   96       1057   D14530     Homo sapiens     ribosomal protein   745   100       1058   AF132000     Homo sapiens     TADA1 protein   1132   100       1059   AL031778     Homo sapiens     dJ34B21.1 (novel BZRP (benzodiazapine   920   100                   receptor (peripheral) (MBR, PBR, PBKS, IBP,                   Isoquinoline-binding protein)) LIKE protein)       1060   AF227135     Homo sapiens     candidate taste receptor T2R9   134   33       1061   Y27575     Homo sapiens     Human secreted protein encoded by gene No. 9.   1392   100       1062   Z11697     Homo sapiens     HB15   1088   100       1063   AF123757     Homo sapiens     putative transmembrane protein   819   100       1064   AF155135     Homo sapiens     novel retinal pigment epithelial cell protein   2932   99       1065   Y41674     Homo sapiens     Human channel-related molecule HCRM-2.   936   99       1066   AJ250042     Homo sapiens     Rab5 GDP/GTP exchange factor homologue   2575   100       1067   Y36087     Homo sapiens     Extended human secreted protein sequence, SEQ   770   85                   ID NO. 472.       1068   Y94959     Homo sapiens     Human secreted protein clone mc300_1 protein   301   100                   sequence SEQ ID NO: 124.       1069   Y94959     Homo sapiens     Human secreted protein clone mc300_1 protein   301   100                   sequence SEQ ID NO: 124.       1070   W64535     Homo sapiens     Human leukocyte cell clone HP00804 protein.   2014   99       1071   X03145     Homo sapiens     pot. ORF III   148   50       1072   AL031177     Homo sapiens     dJ889M15.3 (novel protein)   821   91       1073   X82200     Homo sapiens     gpStaf50   249   62       1074   G03213     Homo sapiens     Human secreted protein, SEQ ID NO: 7294.   99   47       1075   Y36233     Homo sapiens     Human secreted protein encoded by gene 10.   506   55       1076   G03187     Homo sapiens     Human secreted protein, SEQ ID NO: 7268.   424   98       1077   L25899     Homo sapiens     ribosomal protein L10   332   76       1078   Y91447     Homo sapiens     Human secreted protein sequence encoded by   898   97                   gene 48 SEQ ID NO: 168.       1079   G01862     Homo sapiens     Human secreted protein, SEQ ID NO: 5943.   290   89       1080   AB039723     Homo sapiens     WNT receptor frizzled-3   1376   92       1081   AB020527     Homo sapiens     Na/PO4 cotransporter homolog   269   100       1082   L13802     Homo sapiens     ribosmal protein small subunit   499   80       1083   W75098     Homo sapiens     Human secreted protein encoded by gene 42   143   81                   clone HSXB125.       1084   G03564     Homo sapiens     Human secreted protein, SEQ ID NO: 7645.   83   51       1085   G04063     Homo sapiens     Human secreted protein, SEQ ID NO: 8144.   88   43       1086   AF090942     Homo sapiens     PRO0657   124   64       1087   G00517     Homo sapiens     Human secreted protein, SEQ ID NO: 4598.   129   41       1088   G04091     Homo sapiens     Human secreted protein, SEQ ID NO: 8172.   126   36       1089   AF140631     Homo sapiens     G-protein coupled receptor 14   364   82       1090   G04063     Homo sapiens     Human secreted protein, SEQ ID NO: 8144.   114   32       1091   S72304   Mus sp.   LMW G-protein   146   83       1092   W88708     Homo sapiens     Secreted protein encoded by gene 175 clone   405   100                   HEMAM41.       1093   W85612     Homo sapiens     Secreted protein clone fh123_5.   4358   97       1094   Y53012     Homo sapiens     Human secreted protein clone pm514_4 protein   1013   99                   sequence SEQ ID NO: 30.       1095   Y92345     Homo sapiens     Human cancer associated antigen precursor from   409   100                   clone NY-REN-62.       1096   AF090942     Homo sapiens     PRO0657   147   60       1097   L24521     Homo sapiens     transformation-related protein   166   58       1098   X56932     Homo sapiens     23 kD highly basic protein   490   70       1099   G04063     Homo sapiens     Human secreted protein, SEQ ID NO: 8144.   83   35       1100   Y02693     Homo sapiens     Human secreted protein encoded by gene 44   149   59                   clone HTDAD22.       1101   AF119851     Homo sapiens     PRO1722   183   72       1102   G04086     Homo sapiens     Human secreted protein, SEQ ID NO: 8167.   207   62       1103   G04063     Homo sapiens     Human secreted protein, SEQ ID NO: 8144.   91   52       1104   X74856     Mus     ribosomal protein L28   128   69                 musculus         1105   G03789     Homo sapiens     Human secreted protein, SEQ ID NO: 7870.   130   62       1106   G03133     Homo sapiens     Human secreted protein, SEQ ID NO: 7214.   122   48       1107   G03040     Homo sapiens     Human secreted protein, SEQ ID NO: 7121.   69   43       1108   AF039942     Homo sapiens     HCF-binding transcription factor Zhangfei   744   99       1109   AF201951     Homo sapiens     high affinity immunoglobulin epsilon receptor   738   94                   beta subunit       1110   AF111108     Mus     transient receptor potential 2   223   79                 musculus         1111   AF119900     Homo sapiens     PRO2822   144   59       1112   Y16589     Homo sapiens     A protein that interacts with presenilins.   265   39       1113   G02872     Homo sapiens     Human secreted protein, SEQ ID NO: 6953.   178   67       1114   Y02999     Homo sapiens     Fragment of human secreted protein encoded by   164   63                   gene 121.       1115   Y30811     Homo sapiens     Human secreted protein encoded from gene 1.   1217   99       1116   X51394     Xenopus     APEG precursor protein   130   40                 laevis         1117   M27826     Homo sapiens     neutral protease large subunit   442   65       1118   G03371     Homo sapiens     Human secreted protein, SEQ ID NO: 7452.   72   60       1119   G03602     Homo sapiens     Human secreted protein, SEQ ID NO: 7683.   491   97       1120   Y35906     Homo sapiens     Extended human secreted protein sequence, SEQ   244   97                   ID NO. 155.       1121   G03714     Homo sapiens     Human secreted protein, SEQ ID NO: 7795.   122   65       1122   Y00337     Homo sapiens     Human secreted protein encoded by gene 81.   110   90       1123   AF084830     Homo sapiens     two pore domain K+ channel; TASK-2   703   94       1124   AF212862     Homo sapiens     membrane interacting protein of RGS16   442   88       1125   W64469     Homo sapiens     Human secreted protein from clone CW795_2.   191   53       1126   G01361     Homo sapiens     Human secreted protein, SEQ ID NO: 5442.   154   100       1127   G01361     Homo sapiens     Human secreted protein, SEQ ID NO: 5442.   165   100       1128   Y84320     Homo sapiens     Human cardiovascular system associated protein   815   99                   kinase-1.       1129   G02105     Homo sapiens     Human secreted protein, SEQ ID NO: 6186.   88   73       1130   Y32923     Homo sapiens     Transmembrane domain containing protein clone   700   100                   HP01512.       1131   Y29817     Homo sapiens     Human synapse related glycoprotein 2.   260   91       1132   Y91644     Homo sapiens     Human secreted protein sequence encoded by   525   96                   gene 43 SEQ ID NO: 317.       1133   Y91449     Homo sapiens     Human secreted protein sequence encoded by   542   100                   gene 49 SEQ ID NO: 170.       1134   AB017908     Homo sapiens     4F2 light chain   2399   93       1135   X51760     Homo sapiens     zinc finger protein (583 AA)   312   55       1136   Y99426     Homo sapiens     Human PRO1604 (UNQ785) amino acid   917   72                   sequence SEQ ID NO: 308.       1137   G03790     Homo sapiens     Human secreted protein, SEQ ID NO: 7871.   102   50       1138   AF155106     Homo sapiens     NY-REN-36 antigen   768   91       1139   AL031055     Homo sapiens     dJ28H20.1 (novel protein similar to membrane   117   50                   transport proteins)       1140   AF011359     Bos taurus     regulator of G-protein signaling 7   138   96       1141   Y70018     Homo sapiens     Human Protease and associated protein-12   623   100                   (PPRG-12).       1142   G04091     Homo sapiens     Human secreted protein, SEQ ID NO: 8172.   113   38       1143   AB030235     Canis     D4 dopamine receptor   89   48                 femiliaris         1144   Y94922     Homo sapiens     Human secreted protein clone pv6_1 protein   539   88                   sequence SEQ ID NO: 50.       1145   X99962     Homo sapiens     rab-related GTP-binding protein   398   96       1146   G03807     Homo sapiens     Human secreted protein, SEQ ID NO: 7888.   168   79       1147   G03712     Homo sapiens     Human secreted protein, SEQ ID NO: 7793.   512   85       1148   Y28279     Homo sapiens     Human G-protein coupled receptor GRIR-1.   705   76       1149   U13642     Caenorhabditis     exon 5 similar to transmembrane domain of  S.     247   36                 elegans       cerevisiae  zinc resistance protein       1150   G03438     Homo sapiens     Human secreted protein, SEQ ID NO: 7519.   117   62       1151   G01003     Homo sapiens     Human secreted protein, SEQ ID NO: 5084.   181   80       1152   G03798     Homo sapiens     Human secreted protein, SEQ ID NO: 7879.   198   63       1153   X88799     Oryza sativa     DNA binding protein   95   41       1154   D85245     Homo sapiens     TR3beta   155   96       1155   R74272     Homo sapiens     Tumor suppressor protein, p53.   341   87       1156   Y86265     Homo sapiens     Human secreted protein HUSXE77, SEQ ID   99   41                   NO: 180.       1157   G02577     Homo sapiens     Human secreted protein, SEQ ID NO: 6658.   263   98       1158   AF104334     Homo sapiens     putative organic anion transporter   185   42       1159   G01393     Homo sapiens     Human secreted protein, SEQ ID NO: 5474.   173   57       1160   W75771     Homo sapiens     Human GTP binding protein APD08.   224   81       1161   AF216833     Homo sapiens     M-ABC2 protein   410   83       1162   W67816     Homo sapiens     Human secreted protein encoded by gene 10   1156   100                   clone HCEMU42.       1163   AF119851     Homo sapiens     PRO1722   230   70       1164   Y87252     Homo sapiens     Human signal peptide containing protein HSPP-   113   31                   29 SEQ ID NO: 29.       1165   W64537     Homo sapiens     Human liver cell clone HP01148 protein.   338   82       1166   AF269286     Homo sapiens     HC6   134   64       1167   Y14482     Homo sapiens     Fragment of human secreted protein encoded by   149   51                   gene 17.       1168   D90789     Escherichia     Dipeptide transport system permease protein   411   90                 coli     DppC.       1169   R63783     Homo sapiens     TG0847 protein.   344   90       1170   Y45274     Homo sapiens     Human secreted protein encoded from gene 18.   478   98       1171   D64154     Homo sapiens     Mr 110,000 antigen   347   96       1172   AB026256     Homo sapiens     organic anion transporter OATP-B   311   67       1173   G00357     Homo sapiens     Human secreted protein, SEQ ID NO: 4438.   60   52       1174   D87717     Homo sapiens     similar to human GTPase-activating   178   59                   protein(A49869)       1175   M64716     Homo sapiens     ribosomal protein   391   78       1176   R08330     Homo sapiens     Human IL-7 receptor clone H6.   285   67       1177   L06505     Homo sapiens     ribosomal protein L12   242   72       1178   AJ251885     Homo sapiens     organic cation transporter (OCT2)   276   88       1179   G03258     Homo sapiens     Human secreted protein, SEQ ID NO: 7339.   155   71       1180   G01207     Homo sapiens     Human secreted protein, SEQ ID NO: 5288.   282   90       1181   AF181856     Rattus     tRNA selenocysteine associated protein   249   62                 norvegicus         1182   AF161524     Homo sapiens     HSPC176   138   90       1183   G03789     Homo sapiens     Human secreted protein, SEQ ID NO: 7870.   282   66       1184   Y02671     Homo sapiens     Human secreted protein encoded by gene 22   107   71                   clone HMSJW18.       1185   G03797     Homo sapiens     Human secreted protein, SEQ ID NO: 7878.   88   69       1186   G03564     Homo sapiens     Human secreted protein, SEQ ID NO: 7645.   118   46       1187   AB032905     Hylobates     dopamine receptor D4   96   37                 concolor         1188   G00956     Homo sapiens     Human secreted protein, SEQ ID NO: 5037.   292   78       1189   G03258     Homo sapiens     Human secreted protein, SEQ ID NO: 7339.   178   79       1190   G03361     Homo sapiens     Human secreted protein, SEQ ID NO: 7442.   324   76       1191   AF117755     Homo sapiens     thyroid hormone receptor-associated protein   187   70                   complex component TRAP230       1192   Y70455     Homo sapiens     Human membrane channel protein-5 (MECHP-   202   67                   5).       1193   G03052     Homo sapiens     Human secreted protein, SEQ ID NO: 7133.   99   42       1194   G02607     Homo sapiens     Human secreted protein, SEQ ID NO: 6688.   192   76       1195   W29661     Homo sapiens       Homo sapiens  CI542_2 clone secreted protein.   2001   98       1196   Y14104     Homo sapiens     Human GABAB receptor 1d protein sequence.   239   69       1197   X61972     Homo sapiens     macropain subunit iota   149   90       1198   G00534     Homo sapiens     Human secreted protein, SEQ ID NO: 4615.   145   51       1199   Y86260     Homo sapiens     Human secreted protein HELHN47, SEQ ID   1089   89                   NO: 175.       1200   G02607     Homo sapiens     Human secreted protein, SEQ ID NO: 6688.   154   57       1201   G00838     Homo sapiens     Human secreted protein, SEQ ID NO: 4919.   404   50       1202   M27826     Homo sapiens     neutral protease large subunit   202   49       1203   Y73424     Homo sapiens     Human secreted protein clone yi4_1 protein   265   61                   sequence SEQ ID NO: 70.       1204   AF264014     Homo sapiens     scavenger receptor cysteine-rich type 1 protein   625   98                   M160 precursor       1205   Y36203     Homo sapiens     Human secreted protein #75.   219   59       1206   U78111     Gallus gallus     AQ   205   57       1207   AF095448     Homo sapiens     putative G protein-coupled receptor   416   76       1208   AF116715     Homo sapiens     PRO2829   127   75       1209   AF099137     Homo sapiens     MaxiK channel beta 2 subunit   475   95       1210   AF205718     Homo sapiens     hepatocellular carcinoma-related putative tumor   423   79                   suppressor       1211   Y27868     Homo sapiens     Human secreted protein encoded by gene No.   224   70                   107.       1212   G00719     Homo sapiens     Human secreted protein, SEQ ID NO: 4800.   117   44       1213   G01009     Homo sapiens     Human secreted protein, SEQ ID NO: 5090.   351   73       1214   AF090942     Homo sapiens     PRO0657   124   70       1215   Y14427     Homo sapiens     Human secreted protein encoded by gene 17   99   77                   clone HSIEA14.       1216   G03905     Homo sapiens     Human secreted protein, SEQ ID NO: 7986.   173   57       1217   Y57897     Homo sapiens     Human transmembrane protein HTMPN-21.   1173   100       1218   J00194     Homo sapiens     hla-dr antigen alpha chain   454   78       1219   Y59709     Homo sapiens     Secreted protein 76-28-3-A12-FL1.   470   92       1220   W81576     Homo sapiens     EBV-induced G-protein coupled receptor (EBI-   725   100                   2) polypeptide.       1221   W96745     Homo sapiens     High affinity immunoglobulin E receptor-like   650   98                   protein (IGERB).       1222   Y35911     Homo sapiens     Extended human secreted protein sequence, SEQ   135   31                   ID NO. 160.       1223   Y00278     Homo sapiens     Human secreted protein encoded by gene 21.   260   95       1224   AF161422     Homo sapiens     HSPC304   568   90       1225   U14970     Homo sapiens     ribosomal protein S5   202   95       1226   G01733     Homo sapiens     Human secreted protein, SEQ ID NO: 5814.   610   100       1227   AF099973     Mus     schlafen2   333   56                 musculus         1228   G01218     Homo sapiens     Human secreted protein, SEQ ID NO: 5299.   155   81       1229   AF217188     Mus     YIP1B   801   63                 musculus         1230   AF176813     Homo sapiens     soluble adenylyl cyclase   275   100       1231   X98333     Homo sapiens     organic cation transporter   1704   100       1232   W74955     Homo sapiens     Human secreted protein encoded by gene 77   212   53                   clone HOEAS24.       1233   Y94940     Homo sapiens     Human secreted protein clone yi62_1 protein   526   100                   sequence SEQ ID NO: 86.       1234   U76618     Mus     N-RAP   482   82                 musculus         1235   AF044924     Homo sapiens     hook2 protein   380   97       1236   G01459     Homo sapiens     Human secreted protein, SEQ ID NO: 5540.   417   100       1237   AF000018     Homo sapiens     adapter protein   164   84       1238   W88633     Homo sapiens     Secreted protein encoded by gene 100 clone   250   90                   HE8EU04.       1239   W29660     Homo sapiens       Homo sapiens  CH27_1 clone secreted protein.   697   98       1240   AF004161     Oryctolagus     peroxisomal Ca-dependent solute carrier   154   52                 cuniculus         1241   Y92710     Homo sapiens     Human membrane-associated protein Zsig24.   709   97       1242   Y95002     Homo sapiens     Human secreted protein vc34_1, SEQ ID NO: 44.   908   88       1243   Y44905     Homo sapiens     Human potassium channel molecule ERG-LP2   325   100                   partial protein.       1244   AF284422     Homo sapiens     cation-chloride cotransporter-interacting protein   511   97       1245   Y53629     Homo sapiens     A bone marrow secreted protein designated   1888   93                   BMS115.       1246   AB039371     Homo sapiens     mitochondrial ABC transporter 3   389   97       1247   Y35911     Homo sapiens     Extended human secreted protein sequence, SEQ   168   39                   ID NO. 160.       1248   AF072509     Rattus     glutamate receptor interacting protein 2   559   90                 norvegicus         1249   AF247042     Homo sapiens     tandem pore domain potassium channel TRAAK   661   98       1250   B08974     Homo sapiens     Human secreted protein sequence encoded by   1087   97                   gene 27 SEQ ID NO: 131.       1251   L15313     Caenorhabditis     putative   858   59                 elegans         1252   Y29338     Homo sapiens     Human secreted protein clone it217_2 alternate   278   75                   reading frame protein.       1253   W01730     Homo sapiens     Human G-protein receptor HPRAJ70.   211   92       1254   G03074     Homo sapiens     Human secreted protein, SEQ ID NO: 7155.   294   83       1255   G01818     Homo sapiens     Human secreted protein, SEQ ID NO: 5899.   253   91       1256   AF286368     Homo sapiens     eppin-1   222   54       1257   AF220264     Homo sapiens     MOST-1   87   93       1258   G02227     Homo sapiens     Human secreted protein, SEQ ID NO: 6308.   281   78       1259   Y07970     Homo sapiens     Human secreted protein fragment #2 encoded   81   94                   from gene 26.       1260   R95332     Homo sapiens     Tumor necrosis factor receptor 1 death domain   986   100                   ligand (clone 3TW).       1261   AF140674     Homo sapiens     zinc metalloprotease ADAMTS6   172   36       1262   U28369     Homo sapiens     semaphorin V   237   67       1263   Y07049     Homo sapiens     Renal cancer associated antigen precursor   288   71                   sequence.       1264   Y36153     Homo sapiens     Human secreted protein #25.   187   80       1265   Y78114     Homo sapiens     Human cytokine signal regulator CKSR-2 SEQ   723   93                   ID NO: 2.       1266   Y13397     Homo sapiens     Amino acid sequence of protein PRO334.   191   100       1267   AF030558     Rattus     phosphatidylinositol 5-phosphate 4-kinase   859   95                 norvegicus     gamma       1268   U73167     Homo sapiens     candidate tumor suppressor gene LUCA-1   159   96       1269   AF190664     Mus     LMBR2   552   76                 musculus         1270   AL050332     Homo sapiens     dJ570F3.1 (homolog of the rat synaptic ras   820   98                   GTPase-activating protein p135 SynGAP)       1271   G02126     Homo sapiens     Human secreted protein, SEQ ID NO: 6207.   131   95       1272   AF125533     Homo sapiens     NADH-cytochrome b5 reductase isoform   253   92       1273   AL035661     Homo sapiens     dJ568C11.3 (novel AMP-binding enzyme   1280   100                   similar to acetyl-coenzyme A synthethase                   (acetate-coA ligase))       1274   AF064748     Mus     S3-12   3523   61                 musculus         1275   D17554     Homo sapiens     TAXREB107   377   78       1276   Y30715     Homo sapiens     Amino acid sequence of a human secreted   643   90                   protein.       1277   AF146760     Homo sapiens     septin 2-like cell division control protein   707   100       1278   Y05069     Homo sapiens     Human PIGR-2 protein sequence.   281   46       1279   X59668     Oryctolagus     aorta CNG channel (rACNG)   267   85                 cuniculus         1280   G01051     Homo sapiens     Human secreted protein, SEQ ID NO: 5132.   489   98       1281   G03411     Homo sapiens     Human secreted protein, SEQ ID NO: 7492.   120   43       1282   AF055084     Homo sapiens     very large G-protein coupled receptor-1   1635   100       1283   AF117814     Mus     odd-skipped related 1 protein   357   98                 musculus         1284   U87318     Xenopus     NaDC-2   535   60                 laevis         1285   AF061346     Mus     Edp1 protein   452   68                 musculus         1286   AB030182     Mus     contains transmembrane (TM) region   582   68                 musculus         1287   A13595     synthetic     immunosuppresive protein PP15   185   97                 construct         1288   AF254411     Homo sapiens     ser/arg-rich pre-mRNA splicing factor SR-A1   837   100       1289   AF084205     Rattus     serine/threonine protein kinase TAO1   319   98                 norvegicus         1290   AF038563     Homo sapiens     membrane associated guanylate kinase 2   523   100       1291   AF034837     Homo sapiens     double-stranded RNA specific adenosine   468   100                   deaminase       1292   M15888     Bos taurus     endozepine-related protein precursor   937   87       1293   AB010692     Arabidopsis     ATP-dependent RNA helicase-like protein   636   45                 thaliana         1294   AF209923     Homo sapiens     orphan G-protein coupled receptor   1570   100       1295   W67828     Homo sapiens     Human secreted protein encoded by gene 22   504   98                   clone HFEAF41.       1296   AC004832     Homo sapiens     similar to 45 kDa secretory protein; similar to   648   65                   CAA10644.1 (PID: g4164418)       1297   X80035     Oryctolagus     cysteine rich hair keratin associated protein   575   70                 cuniculus         1298   G02645     Homo sapiens     Human secreted protein, SEQ ID NO: 6726.   223   97       1299   Y59440     Homo sapiens     Human delta3 fragment #4.   122   32       1300   W70504     Homo sapiens     Leukocyte seven times membrane-penetrating   459   81                   type receptor protein JEG18.       1301   Y67315     Homo sapiens     Human secreted protein BL89_13 amino acid   3916   99                   sequence.       1302   M77693     Homo sapiens     spermidine/spermine N1-acetyltransferase   174   96       1303   G01331     Homo sapiens     Human secreted protein, SEQ ID NO: 5412.   254   69       1304   G01491     Homo sapiens     Human secreted protein, SEQ ID NO: 5572.   747   99       1305   AF148509     Homo sapiens     alpha 1,2-mannosidase   602   98       1306   G01658     Homo sapiens     Human secreted protein, SEQ ID NO: 5739.   333   98       1307   Y90899     Homo sapiens     D1-like dopamine receptor activity modifying   332   98                   protein SEQ ID NO: 1.       1308   AF033120     Homo sapiens     p53 regulated PA26-T2 nuclear protein   348   52       1309   Y73388     Homo sapiens     HTRM clone 3376404 protein sequence.   147   66       1310   AF063243     Bos taurus     ribosomal protein L30   296   90       1311   AF224494     Mus     arsenite inducible RNA associated protein   688   70                 musculus         1312   Y73342     Homo sapiens     HTRM clone 2709055 protein sequence.   1154   100       1313   Y99419     Homo sapiens     Human PRO1780 (UNQ842) amino acid   1145   78                   sequence SEQ ID NO: 282.       1314   AF116667     Homo sapiens     PRO1777   433   97       1315   W75100     Homo sapiens     Human secreted protein encoded by gene 44   807   97                   clone HE8CJ26.       1316   AJ272078     Homo sapiens     APOBEC-1 stimulating protein   789   100       1317   AB041533     Homo sapiens     sperm antigen   2607   98       1318   U19617     Mus     Elf-1   806   92                 musculus         1319   U82598     Escherichia     ferric enterobactin transport protein   768   100                 coli         1320   D90892     Escherichia     SORBITOL-6-PHOSPHATE 2-   709   100                 coli     DEHYDROGENASE (EC 1.1.1.140)                   (GLUCITOL-6-PHOSPHATE                   DEHYDROGENASE) (KETOSEPHOSPHATE                   REDUCTASE).       1321   W67847     Homo sapiens     Human secreted protein encoded by gene 41   601   92                   clone HPBCJ74.       1322   AJ276101     Homo sapiens     GPRC5B protein   466   93       1323   AJ276101     Homo sapiens     GPRC5B protein   504   97       1324   Y58628     Homo sapiens     Protein regulating gene expression PRGE-21.   1584   100       1325   U91561     Rattus     pyridoxine 5′-phosphate oxidase   1277   89                 norvegicus         1326   AF125533     Homo sapiens     NADH-cytochrome b5 reductase isoform   1606   100       1327   Y32206     Homo sapiens     Human receptor molecule (REC) encoded by   1531   90                   Incyte clone 2825826.       1328   AF151048     Homo sapiens     HSPC214   657   85       1329   Y10530     Homo sapiens     olfactory receptor   1645   100       1330   AF180681     Homo sapiens     guanine nucleotide exchange factor   4314   99       1331   AF111856     Homo sapiens     sodium dependent phosphate transporter isoform   3591   99                   NaPi-3b       1332   Y13583     Homo sapiens     G-protein coupled receptor   2171   100       1333   AF078866     Homo sapiens     SURF-4   1395   100       1334   Y25755     Homo sapiens     Human secreted protein encoded from gene 45.   1380   96       1335   AF152325     Homo sapiens     protocadherin gamma A5   4742   99       1336   X74070     Homo sapiens     transcription factor BTF3   639   81       1337   AF095927     Rattus     protein phosphatase 2C   1931   95                 norvegicus         1338   G03877     Homo sapiens     Human secreted protein, SEQ ID NO: 7958.   621   100       1339   AL008582     Homo sapiens     bK223H9.2 (ortholog of A. thaliana F23F1.8)   626   100       1340   X61615     Homo sapiens     leukemia inhibitory factor receptor   5820   99       1341   Y01519     Homo sapiens     A carcinogenesis-inhibiting protein.   7528   97       1342   AF207600     Homo sapiens     ethanolamine kinase   2372   100       1343   U54807     Rattus     GTP-binding protein   1167   97                 norvegicus         1344   AC020579     Arabidopsis     putative phosphoribosylformylglycinamidine   3283   51                 thaliana     synthase; 25509-29950       1345   Y28576     Homo sapiens     Secreted peptide clone pe503_1.   944   100       1346   W74787     Homo sapiens     Human secreted protein encoded by gene 58   1171   100                   clone HHFHN61.       1347   M55542     Homo sapiens     guanylate binding protein isoform I   2636   87       1348   AF183428     Homo sapiens     28.4 kDa protein   1329   100       1349   U70669     Homo sapiens     Fas-ligand associated factor 3   167   24       1350   AF295530     Homo sapiens     cardiac voltage gated potassium channel   562   99                   modulatory subunit                    
     [0419]                                           TABLE 3                                               Amino, acid sequence (A = Alanine C =                                   Cysteine, D = Aspartic Acid,                       Predicted       E = Glutamic Acid,F = Phenylalanine,                       beginning       G = Glycine, H = Histidine, I = Iso-                       nucleotide   Predicted end   leucine, K = Lysine, L = Leucine,                       location   nucleotide   M = Methionine, N = Asparagine                       corresponding   location   P = Proline, Q = Glutamine, R =                       to first   corresponding   Arginine, S = Serine, T = Threonine,       SEQ ID   SEQ ID       SEQ ID   amino acid   to last amino   V = Valine, W = Tryptophan, Y = Tyro-       NO: of   NO: of       NO: in   residue of   acid residue   sine, X = Unknown, * = Stop codon,       nucleotide   peptide       U.S. Ser. No   peptide   of peptide   / = possible nucleotide deletion,       sequence   sequence   Method   09/496,914   sequence   sequence   \ = possible nucleotide insertion                                                                1   1351   A   2   337   1   TPSLIHQAPTPCPAGLWG/PPNGHYHGS*PGC                                   HWPQAPHRA***GLLPPRWLGHGLPGGPAAP                               WAASQWVDGVAGRLPGPAWSWHASGAAPA                               QPGPL*LLVPGSSGLPDPRDP               2   1352   A   27   100   366   IRNSSIRPMKERETKLSAKHMITCSASYDRGL                               QIET\YHHTPIRMAKIQKT/GHHQC**ECGAT                               GTLIHGWWGCKVVEPLGKTVWQIPK               3   1353   A   40   3   314   HASAHASVVLKDNSELEQQLGATGAYRARA                               LELEAEVAEMRQMLQLEHPFVNGADKLRPD                               SMYVHLNEL*QSLVENMLLTVVDTH\RTPI*R                               SCNYTLALILFL               4   1354   A   74   2   292   TASALFSCPDGGSLAGFAGRRASFHLECLKR                               QKDRGGDISQKTVLPLHLVHHQVAHTFGQAT                               VTCQQARQSPG*RTNPE/ALQWVLPVSDGWH                               VLPLP               5   1355   A   78   114   850   ENCRVASNLPGVFFSEDTAQSGSYMRISAHPP                               NAGGEVSNGPKRKLTLMLNFSLPSSGLNAGA                               FYALSTLLNRMVIWHYPGEEVNAGRIGLTIVI                               AGMLGAVISGIWLDRSKTYKETTLVVYIMDT                               GGAWWCYTFYLGTGDTCG*CFITAG\TMGFF                               MTGYLPLGFEFAVEL\SYPESEGISSGLLNISA                               QVFGIIFTISQGQIIDNYGTKPGIFLCVFLCVFLTLG                               AALTAFIKADLRRQKANKETLEN               6   1356   A   81   97   376   EWFSYMLGSNMSVYHSP*SLEPLCKVLSES*A                               YLRVPFIRILLNAR*IRKAYKRMSLEIKLLI/RE                               *CLFQEMGLSLQWLYSARGDFFRATSRL               7   1357   A   93   2   872   TLSSACLIGDAWKELTIVAGAVSNQLLVWYP                               ATALADNKPVAPDRRISGHVGIIFSMSYLESK                               GLLATASEDRSVRIWKGGDLRVPGGRVQNIG                               HCFGHSARVWQVKLLENYLISAGEDCVCLV                               WSHEGEILQAFRGHQGRGIRAIAAHERQAWV                               ITGGDDSGIRLWHLVGRGYRGLG/DLGSLLQ                               VP**ARYTQGCDSGWLLATAGSD*YRGPVSL                               *RRGQVLGAARG*TFPVLLPAGGSSWSRGL                               RIVCYGQWGRSCQGCPHQHSNCCCGPDPVS                               WEGAQLELGPAWL               8   1358   A   106   3   350   FSSLLSGRISTLRDETGAILIDGDPAACAPIIKF                               LLTEELHLRGVSIYVLRHEAQIYGITPLWCAL                               LI/CRRL*SDSCMRAALNDRGLYQVLILDGLV                               QCLGFVDSDSRKMVSTLT               9   1359   A   115   49   186   QAWAIFKGKYKEGDTGGPAVWKTRRCALN                               KSSEFNEGPERERMDV               10   1360   A   123   2   1249   KGCRTQEKVDRTEVIRTCINPVYSKLFTVDFY                               FEEVQRLRFEVHDISSNHNGLKEADFLGGME                               CTLGQIVSQRKLSKSLLKHGNTAGKSSITVIA                               EELSGNDDYVELAFNARKLDDKDFFSKSDPF                               LELFRMNDDATQQLVHRTEVVMNNLSPAWK                               SFKVSVNSLCSGDPDRRLKCIVWDWDSNGK                               HDFIGEFTSTFKEMRGAMEGKQVQWECINPK                               YKAKKKNYKNSGTVILNLCKIHKMHSFLDYI                               MGGCQIQFTVAIDFTASNGDPRNSCSLHYIHP                               YQPNEYLKALVAVGEICQDYDSDKMFPAFGF                               GARIPPEYTDSHDFAINFNEDNPECAGIQGVV                               EAYQSCF\PKAPTFTGPTNICPHSSRKVAKFRR                               SEGN*HQGRAFAIIFILVDPGQVGVYSQDMGP                               DNPGGHFV               11   1361   A   147   614   9   ACARKQLLGRTVFIWFVGQLLGGELKGYSKT                               NTTSSRPASSRG\TLSSSSSSSSSLTKDALPSSL                               KSDSTTITSGLVFPFRSLCVNPAKSSVSESVSSI                               KILLSSSVKYLE*KRTSCCFPDSSESKLSQLSS                               DERVSMGTSSRKPTNSSSSLGALKMSATS\*G                               SGSESPTPFFLTGLQSPPSTRPRPGLTTARNS                               TTLTRDC               12   1362   A   177   12   416   LIPSEPALDSLVDPRVRSRKQPFVIYPVYDTAI                               DTKIHFSLLDGNVGEPDMSAGFCPNHKAAM                               VLFLDRVYGIEVQDFLLHLLEGGFLPDLRAA                               ASLDT/AEIGAMDFLLS*LFTLCLMMFFFIYPFI                               NLLTMNVY               13   1363   A   249   535   105   WTFHRHLSPAPLIVCDQGTCVVSYYPQNIVQ                               MPDTQMEQGLN/HLFLDGNA*PHSVECYCPS                               TFEIAIKITSFVLYFHRYRAPEVLLRSSVYSSPI                               DVWAVGSIMAELYMLRPLFPGTSEVDEIFKIC                               QVLGTPKKVSTLVPKLL               14   1364   A   254   572   201   YLLTXIGNLMMLLVINADSCLRTXM*FFLGH                               FFFLDICYSSVTAQDAAEPVS*LVWGYIT                               *SFFFFIFSWGTNCLLSAITYACYAAICHPLLS                               TMVMNRPLCTATVNATNKMGFLNSQVN               15   1365   A   257   425   68   THAKFLNKKFNLPKLVILPKLVYWKAWTKM                               AIEFLLECDQNIT\KLICENT*KNIAKNI*KRRV                               TFTPIET*HPVKQMIKWQ*LTAWLRNRGYKKI                               KQTPNSETAPSVCRNLVFDKCG               16   1366   A   263   104   481   FCIFRTTEEDRGGDDCVVSVWTKQENNSCVK                               SKDVFSKPVNIFWALEESVLGVKARQPKPFFA                               AGNTFEMTCKVSSKNIKSPRYSVLNAEKPV                               GDLSSPNETKYIISLDQDSVVKLENWTDASRV               17   1367   A   298   68   208   RKRTNNPIKLDKKFEHFKNEDI*ITSKHTKMW                               VSSLAMKEMLTKTTM               18   1368   A   300   904   1   LVVGITGTRHHARVIFIFLVETGFPHVGQAGL                               ELLTSGDPPALASQSAGITGMSHCAEPKGHFG                               IHLK*MFYSQKMP*PTINLILLLIIPGNLNIF                               KPNMGWLGPKTAFV*KDEVLSGIPFAKGRCR                               WK*DY*C/LQEVVTDPIMEKGKKKKRTASFFK                               GQPHQSTLALLRRCVR*RYHLS\TVETAGLP*                               KNTGHIPGQPFLFKLVFKC*NVICI**QYKW*Q                               NIGVKNKSFCFH*SSSPSL*FIGHHSRNF/CSFK                               TEPHSVVQAGGQWRNLSSLQAPPPGLMPLSR                               ISLMSSWDYRRPPQ               19   1369   A   302   3   445   NSPSRWAKIQMFEHTFCG*GCG/ER/NVHIHCS                               WICRLRPLLWRAVREYLSKLKNAELSFDPGV                               SLLRIYAIDMPTSI*DEKEALLFAFLAFHE*HC                               KSRIWAVIQ/CIHLWDWLRKL*CFHRMKFYA                               AV*NKPRHLLSHIWKDVQNILLK               20   1370   A   304   1   1339   FFFCGKEVPLFEQNKHPGPRATTSPGA/HARA                               LLSAGEFTAGVGLSP*AIHSFVWLCTFIQHGA                               GGPCHQPGGSPGPWMHTTQAGHLWEGAYPG                               GSSTWHQVPGQLGGSWGPRERSLLGSFIKCSP                               CPHPPGPRLWMSPNQKPPTENPGVMGRVWR                               LMPGESPLIWEAEGKEDHLSPEGQGHSEIPVA                               PLHSSLGNTVKP*PKNQKPKQNRSRHGQ\GF                               MAGQGQSRPAAR*PPCPALTPASHSAGTWPP                               RICRTPGGPCPSPSGFRSCRR*GFSA*TRSWP                               DAEPPSTPDTAPRCCTQSDTSSQGPQ*S*WRR                               CRALPGRLCSAPAAGLRRARPRLSESRRGNSP                               PASPAAASARCPSWGPSCPARPPSRPAAGTEP                               AAPSRCTAWLRGEREPGPRPPGPSRPRSGRGP                               VSFAPEVLSLPAVRQTKSWRWRNEEEITRPW                               ALVRSRGG               21   1371   A   326   799   1587   GSQVLPPPPSQDSATLPQDA*GPRAAPGQPVC                               E*GLQGAGVRRLRGEVLCQPQP*GAL*EQCLP                               HLSFSPRQGAAPDTEPSAWGPAPTGATGPGLP                               LRIIVRLFSAGAPRGAATPCPPALLHGPAWPP                               ARPMFRGHPPVRPLGPWGKVAAGPRALCLA                               GVPAVQGECATKPSG*GL*PNRLRGPPGPEVL                               QWHWQLSAGRDPVPAEDPPL*EGPLGPGGPA                               AAQAEPGADPEPEDKDQAAESRPAGAMSLSA                               QGSGPVGGQGLR               22   1372   A   327   146   652   PHLENPHPEHSFPGAPLT*STLSWSILSPREPSP                               GAPCYPGHPHLENPHLEHLLTWRTVTWSTLL                               PGAPCYPEHPHLEHPLTWSTPHLEHPSPGEPL                               SCRTPTRSELHRDHPLP*CLSTEESPI*GWGSLP                               APPSTPLVLDVAPPGPQPASSCPCRDSCYSVP                               GTVVSP               23   1373   A   348   397   2   CIVSSCQGTRKPCHLEDANKINKQSPTLEKIES                               LQESL*VKQ*LIVAEKYVQILHPRKKYFQRPL                               NNEKRKMKKRKEEKKKCRERMQRRSKWRR                               EEKKE*RREE\EERKKEKEDRKERRKETSPRG                               SRRLLRD               24   1374   A   362   170   352   GRALDTAAGSPVQTAHGLPSDALAPLDDSMP                               WEGRTTAQWSLHRKRHLARTLLVSRVRGPQ               25   1375   A   384   373   128   YLITTTILETGYLWKNRHSDQ*KRTENPERDQH                               KYPKVDFCKSNSMKNRLCNKWHWTNWIFTD                               KKINLNLKPHTKLTPNIKKN               26   1376   A   397   383   165   EVKNTNPFIFSGTNLTIWIRSI*RKSDEINQRTK                               *MEKYSISLDRRLNTVKMSFLPNLIYKFNTISI                               KIPANF               27   1377   A   406   103   380   KSKATGYMVNI*KLIV\FLYANDEQLEIEMNK                               IVP\FNGSKNKIAFTNLTKYQNIQNRHAENYKI                               LVNKIEDLNKWRNVLLSWIGRENIINTMT               28   1378   A   408   14   427   TLCTNKFNNLDEIK/FLERHKLSKLTQEEVENL                               ITLKTSRETELVINK*VIPHKEKPGPDSFTGEF                               YQTFKEEL/II/ILHKLFQTIKYGRILPNSVYETSI                               TLKPKPEKDL\KENYRPLPLSNIDAK\LNKTLA                               NRI**HIR               29   1379   A   434   395   128   IYSKMCMERQRLNN*ILKKNKVRGIAVPDVK                               VYYKPTVIK/TSWIL*KDSHIVEWNRLENLEID                               PN/IKRLILDKGAEATEWRKDSFFRQWQ               30   1380   A   455   2   228   FFFETESHSVTQAGVQWCNPGFKRFSCFGLSS                               SWDYRYAPPRP\ANF\*FLVETGFYYVAQAGL                               KLLSPGDLPALAS               31   1381   A   462   393   2   QLMFDKGVKNLH\WGWTPPFTK*YWKNWISI                               CRRMNLNPYLSRYIKINSR\KDLTVRPEPIKLV                               EENTGKTIQDTGLGK*FIAKTSKAQSTKTNK*                               KRQTRYIKLK\KKSTASKENNRVKRQPLE*EK                               IFAN               32   1382   A   474   125   471   VKPYEIAVFLVKPIEYK*HLLSDPAIPLSGI*LK                               EIKAYT/RRICTPMFAAPVSVIA/RN*KQSK/CQ                               KQ*YVHRMEYYTTIKRSEILICTTTWVDFRNT                               ILRETDRIHKTTYDVISLI               33   1383   A   488   1825   2   KSACSFLCSEEQPASPSPLKPGTYASET\RPRDP                               HAAGPRRDSSEAETLRPRGAIDGSGTVVKGT                               PGSPAPPCSWGHGG\ETEGAG*CPAAPGTDLR                               APGGSAGS*\GLPSAGGSRGRKGWRAAGRQP                               STR*GRPGRIHGGRGE*AGHPEPRQSALQSAG                               LIASSPEPMGAALAEDGSGDSRGAGPRPQE*P                               PSVLSRS\GS*G*G*AASGTASSFRSHSSRLGPP                               SAGFHGLRCGQPPFAAAPPGPWPGTGRPAGG                               AGSPPAAAGTAPPATRGAQSRRQNRTAGRNA                               SPQTAAGAGSPVQWALSRATG*TGETGSWC                               AGGTHQATHLTAAWVCPPTWSVRPGGSGPA                               AGLGR*QRHPAQSPPLPVPRG*PAWPQEAPSP                               SPASSEVALSSGSCWPDQAPGPARGSPPAPLA                               PAWPAAGRGRQR*GRQSAHPPPRR*STAVSL                               SGTS*WRRSP*AGTRTQQC*SPWLVPACSSRP                               L*RGTRRPSTQQSPQTTGTPGRSAGPGHPRS*                               GGRSPAGTGHLGAQTVASPH*GHWPTALSCL                               WASASPPGPEAPPQTGACIGTNCRYRAASAR                               RSSVAPACA*GWQ*AGSPPAVLRGPP*RVRER                               GALTHRPRAPDE               34   1384   A   497   422   2   APGASVGRAQAAEG*RGGPTGRPPSALGVS/E                               AGRAGRAGEGRPVPPAYPLCKSAQTSGPPKA                               RLS\PPLASCGGRGPPGGAACATCAPPAGPAR                               KLTPCRCQFRGLCA               35   1385   A   509   156   475   PTPYPGE*QAAFLLRGPGLRPPA/DPSLR/HRN                               LTELVVAVTDEMVGLFAALLAERRVLLTAS                               KLSTLTSCDHAFCALLYPMRWEHVLIPTLPPH                               LLDYC*CPPLPRT               36   1386   A   512   3   1631   FFFSFVCHLYCVSPTPGPHGRLATWL/PGLLA                               FLGLAAGGQTLCPAGELPGHAEAQASGAPGS                               VLIAVPGRRRVHTCGPGPAAPSTRGECPPPAL                               GHTRPARPRPV\PFAPAVPQEPGGQGHGAA/P                               PATGHSAPRGCPPARAAPTGSATPAPPPAACA                               AFHSAWSVPPAGRQQG*RVPAPAFRRTTPGT                               PGQHLLDRPGAPPAQGSGPAPAPPPRLAGPA                               GPAAPPPGPPAASWHSSLSKSSSSL\GWSPPLP                               VGPGSLQ*TPPPQGPHLSGSCGGTSSWRGQR                               AAVARELRSWNACGLSRVAGRSSASYPGRE                               GRPSQSQ*PAGPPGMRGCCLRGW*PSSSGSD                               GPGPHPASTWLRAGKTGPSPPACGCA*LPPPS                               VSAAPQSPRTRCPRGCAAAAGLCVLAAAGAS                               HGA\GLPGVRVHTQRVHIH*GAG/GCQTPRPR                               LRSLPVLGLPAPRCPVSAHPWHRRSGSSCHA                               ARLVPRHPAPGCP**TG*\PLITGFPEP*A*GLP                               NHQAVGLEASGALQAGHRDELPTMVQLLDH                               SPDYPLKGRPHAP               37   1387   A   620   828   1   FRLPLAAGA/RGAAEPRVAVSMAPDPSAKIH                               WEASPEMQSKCHQKGKNNQTECFNHVRFLQ                               RLNSTHLYACGTHAFQPLCAAIDAEAFTLPTS                               FEEGKEKCPYDPARGTGLIIDGGLYTATRYE                               FRSIPDIRRSRHPHSLRTEETPMHWLNG*EDE                               AQDDGG*GTISSFLLPWPADHPTPKSPGEPVH                               SIPVCCQVRGQPQSGGKESPACLKSLSNCLTH                               \DAEFVFSVLVRESKASAVGDDDKVYYFFTE                               RATEKESGSFTQSRSSHRVARGIPPL               38   1388   A   739   1   427   FRAMVSSTLKLG1SILNGGNAEVQ/QGNRGKG                               TSEEGKEG*EVPV*LPVSPPLPRPLQKMLDYL                               KDKKEVGFFQSIQALMQTC\GEKVMADDEFT                               QDLFRFLQLLCEGHNNDFQNYLRTQTGNTTT                               INIIICTVDYLLRLQESI       39   1389   A   767   1   1030   TLDLTGPLLLGGVPNVPKDFRGRNRQFGGCM                               RNLSVDGKNVDMAGFIANNGTREGCAARRN                               FCDGRRRQNGGTCVNRWNMYLCELCECPLRFGG                               KNCEQGEWPASSIPPVTAAWEALLLDVPGTT                               VRGLHIQVRQPLVVYAAFVDSHRPLQETVL                               REAPAPASGVPSPSGVGWDR*AGPAEPSPSTP                               ATVIISVPWYGLMFRTR\KEDSVLMEATSGG                               PTSFRLQVTGAPCHQGTC*VGARGRDPMLSG                               LRVTDGEWHLLIELKNVKEDSEMKHLVTM                               TLDYGMDQVSWHLHLLWG*TLPPAQGKTGA                               SEDKVSVRRGFRGCMQVRGGCGGRGEACPS                               QAAPRL               40   1390   A   801   69   399   IHKIIIHKEDLNKWKYILCSGMERLSTVMIPVV                               PQIIYKFNA*Q\VILKFTW*E*GAKITILRKNKL                               RGLVLVPLSTC*VKYLLDKVLPHIKTYYEAR                               VNKSVVLVQVTIM               41   1391   A   835   7   195   SMLKERKVFQFPSCLFFQYITWLGPPYHVLFD                               SSVTNFSIGAK*DILQSVMNCLYAKRIPCVT       42   1392   A   841   1   415   GSTHASGYDKTPDFILQVPVAVEGHIIHWIES                               KASFGDECSHIAYQFWSYWNSLKHRTW                               QGIGTVASNLSQL*TLNAPFPELLLFRSLARTG                               FVLT*\RFGPGLVIYWYGFIQELDCNRERGILL                               KACFPTNIVTL               43   1393   A   845   358   92   PALSPAPVPQKKGSPLPLDPCLGPSSWLLSVG                               LGWPRL*PRRGPGDPGSLPATPPLLTPPHTLLP                               QRPMLPPSHAGLARPPPPEPISVP               44   1394   A   853   452   1   LPQYCFFPRLSPKSKLVKHSAL**PSALKPPTK                               SPRCPRTSLYFTICC/PPALQL/SPIEDPPAIYRS                               PPTHMLRSASQPLNQAPTLVKGHPPSRFLQG                               QVSCPPQPTLPREKPLPLHLRPPPRPAQPPLPR                               PLTFSTRRNVDPEIPERFR               45   1395   A   894   379   162   GVYPPTVFDNYSVQTSVDGQIVSLNTWDTAG                               QEEYDIRLRTLS*PQTSIFVICFSIGNLEFPIYGT                               WLSMSMGK               46   1396   A   900   1   366   TTKKTLISNNVSSRSLPILPELKAFSLAFNDPL                               EIQKYMRT/DQ*CVTHDISLYIVTKLALIFLIPR                               VPLFHQLNIT**CLHFFTMTTFIAIPFSFLFLGR                               D/KSLAMLPRLVSNSWPQVILPP               47   1397   A   944   162   2   QLQNLASRGCL*SQLLRRLRRENRLNPGGGG                               CSEIAP\CTPAWVTQRDFFRKKK                   48   1398   A   963   216   308   HFTPDRIAIVKNTRDSHCWRGC*EEGAPARC               49   1399   A   967   466   1   PRKRESWWGERLPIPRGFPPAAEDAPAPGWK                               GRKHASRTARAHVFHPIRQSIRSPVRGRPGDP                               RAAIITRSAGTRLQCKASRGG*GKGPAPTR*E                               GGPGSAPAPLPASSGCSLFPDSSPWTPPPPAPG                               AAAAQP**TPRCPAALRAGAHIGRVGRPY               50   1400   A   973   45   421   EKCIQALDVFVFCYIDHSSHCLMSCD*EIDQA                               LNFMPLEMEPKMSKLAFGCQRSSTSDDDSGC                               ALEEYAWVPPGLRPEQIQLYFACLPEEKVPY                               VNSPGEKHRIKQLLYQLPPIIDNEVRYCQSLSE                               E               51   1401   A   992   2095   194   IRIRHEAARSCLGCAAGHVPAPGLRLLPTVRG                               PPGRRGPAAPGCVCY*SGESTFVSHVPQRMA                               WPGSAPPRGFHPLQSQTSPSDTVSSPQLSKEE                               DGPGWEHPLSSSL*SLGQAGGNH*QPEELAG                               WEPRGPPSLAPSSPT/TMWTALVLIWIFSLSLS                               ESHAASNDPRNFVPNKMWKGLVKRNASVET                               VDNKTSEDVTMAAASPVTLTKGTSAAHILNS                               MEVTTEDTSRTDVSEPATSGVAADGVTSIAPT                               AVASSTTAASMTAASSMTVASSAPTTAASST                               TVASIAPTTAASSMTAASSTPMTLALPAPTST                               STGRTPSTTATGHPSLSTALAQVPKSSALPRT                               ATLATLATRAQTVATTANTSSPMSTRPSPSKH                               MPSDTAASPVPPMRPQAQGPISQVSVDQPVV                               NTTNKSTPMPSNTTPEPAPTPTVVTTTKAQAR                               EPTASPVPVPHTSPIPEMEAMSPTTQPSPMPYT                               QRAAGPGTSQAPEQVETEATPGTDSTGPTPRS                               SGGTKMPATDSCQPSTQGQYMV/DHH*APHP                               GRGRQNSPSGGAVTRGDPFHHSLGFVCPAGL                               *ELQEEGLHPGGLLNQRDVCGLRNVRGAGA                               WREAWPLPRPFLLPLRPNQVLPNSFGAIEEIC                               QMLKHI               52   1402   A   994   1   462   ESGEFLVSFTLKKPTNVFHHINGMKFFNK/LIF                               *SHTDIAFYKIQHPFMLKALTKWA*EGT*PDR                               RYLH*SLRLNGEQLKTFPLRSGMR*G/CAILPL                               VLNAMLSIVPAVVPAGKTRHEKEITCPLIGQE                               EK*FS*FVGDMNTCVENKKESKKLLE               53   1403   A   1011   1   630   PEVIQQSAYDSKADIWSLGITAIELAKGEPPNS                               DMHPMRVLFLIPKNNPPTHCWRRLLESFKEV                               *LMLA*TKDPSI\RPTAKELLKHKFIVKNSKKT                               SYLTELIDRFKRWKAEGHSDDESDSEGSDSES                               TSRENNTHPEWSFITVRKKPDPKKVQNGAEQ                               DLVQTLSCLSMIITPAFAELKQQDENNASRNQ                               AIEELEKSIAVAEAAGPG               54   1404   A   1016   1   222   ISIDA*KAFDKIQH/CFMITTLKKLGIDGKYLN                               TIKAIDDRHTVSTILNVEKLKAFL*RSGTRQRF                               PISGSGARI               55   1405   A   1033   3   366   HASVDGDEGSDDVYYYYTPAILRELQALNTA                               EAAEHRPEEDRMLSEDPWRPAIIMIKGYMPL                               HNIPHTEVIDVTGLNQSHLYQHLNKGTPMKT                               QKRAA\LYTWHVLEQLEILRQINQQSHGPG               56   1406   A   1044   5   429   SVLTLQTRSPSKPLS\RKLMDWEVVSRNSISsE                               DRLETQSPASRSPPVTPNQSQETPVDGKPLAL                               PPNQSQKNTRYHIHYLHLQYYLDRHISATLPIP                               SSSGIPTPIAVITDALTDLVELILGQPCSEESGR                               APGTLFLLAL                               GAYAFETNGFPIMLVLTTDKIEGDVGIAGLYD                               MH\ISLPMAFLLRTLVRCTSYIIFVTHVLSTPV                               TCLRRREKDGVIVDVLSDTASNHNGFPVEEH                               ADDTHPARLQGPTLRSQPMGPLKHKAFEERA                               NLGLVQRRLRLED               58   1408   A   1058   258   419   LKHRDTPVVGANNRALSCTPLTSLTLCALCPL                               PCLGCPTXATCRLYQTTVAVVF               59   1409   A   1064   3   425   KAFSFITSLIGHQRMHTGERPYKCKEGGKTF                               KGSSSLNNHQRIHTGEKPYKCNECGRAFSQG                               SSLIQHHRIHTGEKPYECTQCGKAFTSISRLSR                               HHRIHTGEKPFHCNECGKVFSYHSALHHQRIH                               TGEKPYACKDVGK               60   1410   A   1065   204   419   GGPPGPFLAHTHAGLQAPGPLLAPAGDEGDL                               LLLAVQQSCLADHLLTASWGGK/DPIPTKALG                               EGQEGLPLTV               61   1411   A   1079   3   383   RHSRAIILCQPFHLVMRDLLQLGQDIPQGCHY                               LEENHLIHRDIAARNCLLSCAAPTRAATIGDF                               GMARYIYRTRYYQLGDRAL/LPRKWMPPEAL                               LEGIFTYNTDSWTFGVLLWEIFSLGYMPYPGR                               TN               62   1412   A   1080   1   859   VVEFLWSRRPSGSSDPRPRRPASKCQMMEER                               ANLMHMMKLSIKVLLQSALSLGRSLDADHA                               PLQQFFVVMEHCLKHGLKVKKSFIGQNKSFF                               GPLELVEKLCPEASDIATSVRNLPELKTAVGR                               GRAWLYLALMQKKLADYLKVLIDNKITILLSE                               FYEPEALMMEEEGMVIVGLLVGLNVLDANL\                               CLKGEDLDSQVGVDFSLYLKDVQDLDGGKE                               HERITDVLDQKNYVEELNRHLSCTVGDLQTK                               IDGLEKTNSKLQERVSAATDRICSLQEEQQQL                               REQNELIR               63   1413   A   1083   2   615   SSFAKHKRIHTGEKPFICLECGKAFTSSTTLTK                               HRRIHTGEKPYTCEECGKAFRQSAILYVHRRI                               HTGEKPYTCGECGKTFRQSANLYAHKKIHTG                               EKPYTCGDCCIKTFRQSAIILYAHKKIHTG\EKP                               YKCKECGKAFKSYYSILKHICRTHTRGMSYEG                               DEC/QRSLN/RSSILSNHKIIHNEEK/PLKCEKCE                               KAFNHTSICCRHKKN               64   1414   A   1084   946   1   KKQDLSSSLTDDSKNAQAPLALTESHLATLA                               SSSQSPEAIKQLLDSGLPSLLNRSLASFCFSHIS                               SSESIAQSIDISQDKLRRHHVPQQCNKMPITAD                               LVAPILRFLTEVGNSHLMKDWLGGSEVNPLW                               TALLFLLCHSGSTSGS\HNLG\AQQDQCKISFS                               FFSWLTTGLTTQQRTAIE\NATVAFF\LQCI\SC                               HPNNQKLMAQVLCELFQTSPQRGNLPTSGNI                               S\GFIR\RLFLQLMLEDEKVTMFLQSPCPLYKG                               RINATSHVIQHP\MYGAGHKFRTLHLPVSTTL                               SDVLDRVSDTPSITAKLISKQKDDKKKK               65   1415   A   1087   103   324   PRAFEFVHTEMIVG/RVQNIHLFTLQVLEDRA                               LFTMSVQSSLWSTYLIHVMALPIDRELLKFNA                               SVALHKLSNALV               66   1416   A   1095   3   493   HETCSVTHIVSFSLPFLNPSHPASTPGHTENEQ                               PSLVWFDRGKFYLTFEGSSRGPSPLTMGAQD                               TLPVAAAFTETVNAYFKGADPSKGIVKITGE                               MYLSFPAGITRHFANNPSPAALTFRVINFSRLE                               HVLPNPQLLCCDNTQNDANTK\EFWVNMFNL                               MTHLK               67   1417   A   1098   57   356   LKLTSLGFIIGVSVVGNLLISILLVKDKTLHRA                               PYYFLLDLCCSDILRSAICFPFVFNSVKNGST                               WTYGTLTCKVIAFLGVLSCFHTAFMLFCISVT                               RYL       68   1418   A   1106   1   1326   MGKISATGNMGTKCSWALVWHLESYDPKH                               YEREGMQDWKTASGQSEEATQQSSQKPQPH                               YTTYQSSSFLKYSSESHLLAWRENSSEGSFQF                               PGRSRARPPRTRQQRRGAAAGPGRGAVRLG                               HPQSAAQPQLRAAARIPESPAAFPAQPRPGSA                               RNSDASGPASLSRTLGRASSPRPPQAPDVTAP                               SPAALAPRAARGGSRAAALAGAEAEEPLRTL                               APRFTRAAAPPPPPPPPPLPPGAPPPPVRCVSR                               RARAPPWRIPAATGPPP\RPVAPSRKLGSARAP                               APALQIRKGTSSGLPGRGGGSGPGNNLSSVA                               GNWRGSSFAVERPGMAKYQGEVQSLKLDDD                               SVIEGVSDQVLVAVVVSFALIATLVYALFRNV                               HQNIHPENQELVRVLREQLQTEQDAPAATRQ                               QFYTDMYCPICLHQASFPVETNCGHLFCGSLT                               PNSIW               69   1419   A   1107   2   466   FDTARLHEFGTSITQ1FAVDNREDLQKWMEA                               FWQHFFDLSQWKIICCEELMKIEIMSPRKPPLF                               LTKEATSVYHDMSIDSPMKLESLTDIIQKKIEE                               TNGQFLIGQREESLP/SS/CGPHSLMVTIKWSS                               RKRY/SYPASEPLHDEKGKKRQAPLPPSDK               70   1420   A   1111   698   23   AIRRLHYVRATKV\FLSFRRPFWREEHIEGGH                               SNTDRPSRMIFYPPPREGALLLASYTWSDAAA                               AFAGLSREEALRLALDDVAALHGPVVRQLW                               DGTGVVKRWAEDQHSQGGFVVQPPALWQT                               EKDDWTVPYGRIYFAGEHTAYFHGWVETAV                               KSALRAAIKINSRKGPASDTASPEGHASDMEG                               QGHVHGVASSPSHDLAKEEC3SHPPVQGQLSL                               QNTTHTRTSH               71   1421   A   1119   2   385   QKQTLQNGYLDSSMDILYLGSLPPELQVSSDE                               PPGPPEQAGLSQFHLEPETQNPETTEEIQSS\LQ                               QEAAAQLPQLPEVVELSSTKA\EAPALPSQSL                               EGVHSSTEQKAPAQQLPAFEEILAPLLIHHE               72   1422   A   1127   1   906   HAQYVGPYRLEKTLGKGQTGLVKLGVHCIT                               GQKVAIKIVNREKLSESVLMKVEREIALL\RLI                               EHPHVLKLHGVYENKKYFPPDELTSGPSMLA                               QVSPHGKLSAERSWDLLSGFPRYLVLEHVSG                               GELFDYLVKKGRLTPKEARKFFRQIVSALDFC                               HSYSICHRDLKPENLLLDEKNNIRIADFGMAS                               LQVGDSLLETSCGSPHYACPEVIKGEKYDGR                               RADMWSCGVILFALLVGALPFDDDNLRQLLE                               KVKRGVFHMPHFIPPDCQSLLRGMIEVEPEKR                               LSLEQIQKHPWYLGGNFIS               73   1423   A   1128   1   802   LRNALDVLHREVPRVLVNLVDFLNNPTIMRQV                               FLGNPDKCPVQQAIMLEPLGSKTETLDLRAE                               MPITCPTQNEPFLRTPRNSNYTYPIKPAIENWG                               SDFLCTEWKASNSVPTSVHQLRPADIKVVAA                               LGDSLTTAVGARPNNSSDLPTSWRGLSWSIG                               GDGNLETHTTLPNTLKKFNPYLLGFSTSTWEG                               TAGLNVAAEGARARDMFAQAWDLVERMKN                               SPDINLEKDWKLVTLFIGGNDLCHYCENPEA                               HLATEYVQHIQQALDILSE               74   1424   A   1139   60   480   FREPCLLVPGDHQPLREASWLA/LPPIGLWGT                               DSPLCCVEVAIPCNKGAHSVGLKGWLLAQG                               VLGMRDTIPQEHPWESTPDLCFCRDPEEIEVE                               EQPAADAAVAKGEF/QGEQIAPVPA\IIAAHPE                               AADPAPVHITAHPKGA               75   1425   A   1147   2   413   PFPHQHPQEP\KGSCWPQSALRGQCPGPVLGV                               TTTSDLCSLQVPVSSHRNPLLDLAAYDQEGR                               RFDNFSSLSIQWESTRPVLASIEPELPMQLVSQ                               DDESGQKKLHGLQAILVHEASGTTAITATAT                               GYQESHLSSAR               76   1426   A   1155   38   410   PIISAPAQDDPILLSFIHCLHANLLGVWRRDVK                               PDCKEIWIFWWGDEPNLV\VQYIMNCMLWK                               KDSGKMAFPMNVGRC/FFKEIHNLLERCLMD                               KNFVLIGKWFVRPYYKDEKPVNKSEHLSCAF                               T               77   1427   A   1162   526   350   RFPQGLEDVSTYPVLIEELLSRGWSEEELQGV                               LRGNLLRVFRQVEKVQEENKWQSPLED               78   1428   A   1171   1   1293   MAESASPPSSSAAAPAAEPGVITEQPGPRSPP                               SSPPGLEEPLDGADPHVPHPDLAPIAFFCLRQT                               TSPRWCIKMVCNPWFECVSMLVILLNCVTL                               GMYQPCDDMDCLSDRCKILQVFDDFIFIFFA                               MEMVLKMVALGIFGKKCYLGDTWNRLDFFI                               VMAGMVEYSLDLQNNLSAIRTVRVLRPLKA                               INRVPSMRILVNLLLDTLPMLGNVLLLCFFVF                               FIFGIIGVQLWAGLLRNRCFLEENFTIQGDVAL                               PP\YYQPEEDDEMPFICSLSGDNGIMGCHEIPP                               LKEQGRECCLSKDDVYDFGAERQDLNASGL                               CVNWNRYYNVCRTGSANPHKGAINFDNIGY                               AWIVIFQVITLEGWVEIMYYVMDAHSFYNFI                               YFILLHVSVREPGLLGGSFSTAQSPKCQGDSFP                               GVAAESLLLRGWVLWLPGGG               79   1429   A   1175   1   405   PNDFFKDMFPDLPGGPLGPIKAENDYGAYLN                               FLSATHLGGLFPPWPLVEERKLKPKASQQCPI                               CHKVIMGAGKLPRHMRTHTGEKPYMCTICE                               VRFTRQDKLKIHMRKHTGERPYLCIHCNAKF                               VHNYDLKNHMR               80   1430   A   1182   25   198   EMNELSQQLSQQGGRGASQCPSPPAPTLPNPT                               PLCQLQLQRVNTGLPTPPCHPGAGAA               81   1431   A   1186   254   583   KTVLDVGAGTGILSIFCAQAGARRVYAVEAS                               AIWQQAREVVRFNGLEDRVHVLPGPVETVEL                               PEQVDAIVSEWMGYGLLHESMLSSVLHARTK                               VVKDGGFFLPXSSELFM               82   1432   A   1187   2   716   DFVDAARNLPLESTKSPAEPSKSVPSLE\DPRA                               SSQGLPSQGPVQNQGRRGEQRPKKF/TVIQHT                               SSFEKSDSLEQPSGLEGEDKPLAQFPSPPPAPH                               GRSAHSLQPKLVRQPNIQVPEILVTEEPDRPD                               TEPEPPPKEPEKTEEFQWPQGSQTLAQFPVEK                               LPPKKKRLGLAKMAQSSGESSFESSVPLFRSP                               SQESNVSLSGSSRSALFERDDHGKAEAPSPSF                               DMGPKPLGTHMLTV               83   1433   A   1188   517   804   ESPGLSKVLRTGAFAYPFLFDNLPLFYRLGLC                               WGRGHGCGQEAILSTSHGYHLFCALLTGFLFA                               SHLPERLAPGRFDYIGHSHQLFHICAVLGTHF                               Q               84   1434   A   1192   45   476   LGDVGFWVERTPVHEAAQRGESLQLQQLIES                               GACVNQVTVDS1TPLHAASLQGQARCVQLLL                               AAGAQVDARNIDGSTPLCECLRLGQHRVCEA                               LAVLRGQGQPSPVHSVPPARGLHXREFRMC*                               GFLFDVGXNLEAHEFHFGEP               85   1435   A   1194   69   410   KRSEEASAFPFPLGGTGAAPTRASLPEQILLPR                               SCLEARKSQPDEKLLSALHNSRTWN*EPRRSQ                               HRLVSPEVHPGRRGSSPGVAECICLTSAYFRT                               GRSPCPSLPGTTRTNSLL               86   1436   A   1215   3   405   LPSHTCGNPGRLPNGIQQGSTFNLGDKVRYSC                               NLGFFLEGHAVLTCHAGSENSATWDFPLPSC                               RADDACGGTLRGIAEWHHLQPPLPLGIATKN                               NADCTWTILAELGDTIALVFIDFQLEDGYDFL                               EVTGTEGSSLW               87   1437   A   1216   226   964   GTAEFGPMVGFGANRRAGRLPSLVLGVLLV                               VIVVLAFNYWSISSRHVLLQEEVAELQGQVQ                               RTEVARGRLEKRNSDLFAVVGHAQETDRPEG                               GRLRPPQQPAAGQRGPREEM\EDDKVKLQNN                               ISYQMADIHHLKEQLAELRQEFLRQEDQLQD                               YRKNNTYLVKRLEYESFQCGQQMKELRAQH                               EENIKKLADQFLEEQKQETQKIQSNDGKELDI                               NNQVVPKNIPKVAENVADKNEEPSSNHIPHG               88   1438   A   1218   1   534   PEFGTTISCGYLMATDVSRRPSVHKAVEIEQE                               RVKSAGAWIIHPYSDFRFYWDLIMLLLMVGN                               LTVLPVG1TFFKEENSP\PWIVFNVLSDTFFLLD                               LVLNFRTGIVVEEGAEILLAPRAIRTRYLRTW                               FLVDLISSIPVDYIFLVVELEPRLDAEVYKTAR                               AIRIVRFTKILSLLRL               89   1439   A   1223   1   743   MGFDEVFMINLRRRQDRRERMLRALQAQEIE                               CRLVEAVDGKVGMLTRSNAAPGRHLAMLET                               LVVVAPRFVDADNLILNPDTLSLLIAENKTVV                               APMLDSRAAYSNFWCGMTSQGYYKRTPAYI                               PIRKRDRRGCFAVPMVHSTFLIDLRKAASRNL                               \AFYPPHPDYTWSFDDIIVFAFSCKQ\AEVQMY                               VCNKEEYGFLPVPLRAHSTLQDEAESFMHVQ                               LEVMVPSSPSSAQSMAVVSADHIGLVISYL               90   1440   A   1227   2   349   NKTSFIFYLKNIVVADLIMTLTFPFRIVHDAGF                               GPWDFKFILCRYTSVLFYANMDTSWVLGLIT/                               YDRY/WKVVRHL/WDSWMTGI/SFTRVYLLG                               LGARLVWFGKLILAKGGHGGISWL               91   1441   A   1245   3   1937   LGSSDVRAPQRSELGAESPSRMVASQAYNLT                               SALTPILTRSRVLNEEPLTLAGF\SRAPANLSD                               VVQLIFLVDSNPFPFGYISNYTVSTKVASMAF                               QTQAGAQIPIERLASERAITVKVPNNSDWAAR                               GHRSSANSV\VQPQAFVGAVVTLDSSNPAAV                               LHLQLNYTLLDGRYLSEEPEPYLAVYLHSEPR                               PNEHNCSASRRIRPESLQGADIIRPYTFFISPGT                               RDPVGSYRLNLSSHFRWSALEVSVGLYTSLC                               QYFSEEDVVWRTEGLLPLEETSPRQAVCLTR                               HLTAFGTSLFVPPSHIRFVFPEPTADVNYIVML                               TCAVCLVTYMVMAAILHKLDQLDASRGRAIP                               FCGQRGRFKYEILVKTGWGRGSGTTAHVGIM                               LYGVDSRSGHRHLDGDRAFHRNSLDIFQIATP                               HSLGSMWKIRVWHDNKGLSPAWFLQHIIVRD                               LQTARSTFFLVNDWLSVETEANGGLVEKEVL                               AASKASFRVPTPS\AALLRFRRLINAELQRGF                               FDKHIWLSIWDRPPRSCFTRIQRATCCVLLICL                               FLGANAVWYGAVGDSAYSTGRVSRLNPLSV                               DTVAVGLVSSVVVYPVYLAILFLFRMSRSKV                               GWGWGPGSTGNGAWASAPCPEPPLSSAAAR                               GKGVHQRLLGKGQHT               92   1442   A   1246   5   562   VFDEENILNELNDPLREEIVNFMCRKLVATMP                               LFANADPNFVTAMLSKLRFEVFQPGDYIIREG                               AVGKKMYFIQHGVAGVITKSSKEMKLTDGS                               YFGEICLLTKGRRTASVRADTYCRLYSLSVD                               NFNEVLEEYPMMRRAFETVAIDRLDRIGKKN                               SILLQKFQKDLNTGVFNNQENEILKQIVKH               93   1443   A   1249   180   901   TVPPPPGGPSPAPLHPKPSPTSTGEARLKEERL                               PGRKASCSTAGSGSRGLPP\SSPMVSSAHNPN                               KAEIPERRKDSTSTPNNLPPSMMTRRNTYVCT                               ERPGAERPSLLPNGKENSSGTPRVPPASPSSHS                               LAPPSGERSRLARGSTIRSTFHGGQVRDRRAG                               GGGGGGVQNGPPASPTLAHEAAPLPAGRPRP                               TTNLFTKLTSKLTRRVADEPERIGGPEVTRRP                               RQEDHLSPGGRGCSEL               94   1444   A   1261   3   385   KFSQWGLTKPKLSNASP/WISLVKKLMKKWS                               VTQNLTFREQLEAGIRYFDLRVSSKPGDADQ                               EIYFIHGLFGTKVWDGLMEIDSFLTQHPQEIIFL                               DFNHFYAMDETHHKCLVLRIQEAFGNKLCPA                               CR               95   1445   A   1282   2   550   GPRDNPG\EDPRFEIVEHFGIAWFTFELVARFA                               VAPDFLKFFKNALNLIDLMSIVPFYITLVVNL                               VVESTPTLANLGRVAQVLRLMRIFRILKLARH                               STGLRSLGATLKYSYKEVGLLLLYLSVGISIFS                               VVAYTIEKEEN\EGLATIPACWWWATVSMTT                               VGYGDVVPGTTAGKLTASACILA               96   1446   A   1294   1   1456   QLLPPSNRENAGLLVGRCLCSAALRPVGDLIT                               SSGQVAVRNAPQAGSAKAGKGKFQDNFEFIQ                               YFKKFFDANCNEKDYNPVAAGQGQETEVAP                               SIVAPVLNKPNQCPEGYICVKAGRNPNYGYT                               SFDTFSWAFLSLFRLMTQDYWENLYQLTLRA                               AETTYMIF/LV/LVILLGSLYLVTLILAV/VAMA                               YEEQNQATLEEAEQICEAEFQQMLEQLKKQQ                               EAAQQAATATASEHSREPSAAGRLSDSSSEAS                               KLSSKSAKERRNRRKKRKQKEQSGGEEKDED                               EFQKSESEDSIRRKGFRFSIEGNRLTYEKRYSS                               PHQSLLSIRGSLFSPRRNSRTSLFSFRGRAKDV                               GSENDFADDEHSTFEDNESRRDSLFVPRRHGE                               RRNSNLSQTSRSSRMLAVFPANGKMHSTVDC                               NGVVSLVGGPSVPTSPVGQLLPEVIIDKPATD                               DNGTTTETEMRKRRSSSFHVSMDFLEDPSQR                               QRAMSIASILTNTVE               97   1447   A   1295   2   2057   IQTQLPTKSSQQLRKGGNCVRCKMQMNFIAE                               EVLLKYRITFYNNNKGPNMLYIEIKAFVHFMI                               NRYLSYGSGPKRFPLVDVLQYALEFASSKPV                               CTSPVDDIDASSPPSGSIPSQTLPSITEQQGALS                               SELPSTSPSSVAAISSRSVIHKPFTQSRIPPDLP                               MIIPAPRHITEEELSVLESCLHRWRTEIENDTR                               DLQESISRIHRTIELMYSDKSMIQVPYRLHAV                               LVHEGQANAGHYWAYIFDHRESRWMKYNDI                               AVTKSSWEELVRDSFGGYRNASAYCLMYIN                               DKAQFLIQE\DLIKTGQPLVGIETLPPDLRDFV                               EEDNQRFEKELEEWDAQLAQKALQEKLLAS                               QKLRESETSVTTAQAAGDPKYLEQPSRSDFSK                               HLKEETIQIITKASHEHEDKSPETVLQSAIKLE                               YARLVKLAQEDTPPETDYRLHHVVVYFIQNQ                               APKKIIEKTLLEQFGDRNLSFDERCHNIMKVA                               QAKLEMIKPEEVNLEEYEEWHQDYRKFRETT                               MYLIIGLENFQRESYIDSLLFLICAYQNNKELL                               SKGLYRGIIDEELISHYRRECLLKLNEQAAELF                               ESGEDREVNNGLIIMNEFIVPFLPLLLVDEMEE                               KDILAVEDMRNRWCSYLGQEMEPHLQEKLT                               DFLPKLLDCSMEIKSFHEPPKLPSYSTHELCER                               FARIMLSLSRTPADGR               98   1448   A   1304   118   453   SGPSSRAIYLHRKEYSQNLTSEPTLLQHRVEH                               LMTCKQGSQRVQGPEDALQKLFEMDAHGRV                               WSQDLILQVRDGWLQLLDIETKEELDSYRLD                               SIQAMNVALNTCSYNSILS               99   1449   A   1306   3   1660   CGYFCHTTCAPQAPPCPVPPDLLRTALGVHPE                               TGTGTAYEGFLSVPRPSGVRRGWQRVFAALS                               DSRLLLFDAPDLRLSPPSGALLQVLDLRDPQF                               SATPVLASDVIHAQSRDLPRIFRVTTSQLAVPP                               TTCTVLLLAESEGERERWLQVLGELQRLLLD                               ARPRIPRPVYTLKEAYDNGLPLLPHTLCAAILD                               QDRLALGTEEGLFVIHLRSNDIFQVGECRRVQ                               QLTLSPSAGLLVVLCGRGPSVRLFALAELENI                               EV\EVPKIPESRGCQVLAAGSILQARTPVLCVA                               VKRQVLCYQLGPGPGPWQRRIRELQAPATVQ                               SLGLLGDRLCVGAAGGFALYPLLNEAAPLAL                               GAGLVPEELPPSRGGLGEALGAVELSLSEFLL                               LFTTAGIYVDGAGRKSRGHELLWPAAPMGW                               GYAAPYLTVFSENSIDVFDVRRAEWVQTVPL                               KK\VRPLNPEGSLFLYGTEKVRLTYLRNQLAE                               KDEFDIPDLTDNSRRQLFRTKSKRRFFFRVSE                               EQQKQQRREMLKDPFVRSKLISPPTNFNHLV                               HVGPANGRPGAEDKSP               100   1450   A   1318   918   190   SLCVPGPVDTGTFAVMSVMVGSVTESLAPQA                               LNDSMINETARDAARVQVASTLSVLVGLFQV                               GLGLIHPGFVVTYLSEPLVRGYTTAAAVQVF                               VSQLKYVFGLHLSSHSGPLSLIYTVLEVCWKL                               PQSKVGTVVTAAVAGVVLVVVKLLNDKLQQ                               QLPMPIPGELLTLIGATGISYGMGLKHRFEAG\                               PPVANTQLFSKLVGSAFTIAVVGPAIAISLGK                               IFALRHGYRVDSNQVWVMRDV               101   1451   A   1353   220   445   DWPDLFTYPLIGSPKCFQSARPE\RMYRRTVR                               SSHGNHALQEVLPRSGHGTEPTKQKHLEAAD                               HGHPPARMSIFSR               102   1452   A   1363   542   2   AHLLMLNLAL\TDLL\YLTSLPFLIHYYASGEN                               WLFGDFMCKFIRFSFHFNLYSSILFLTCFSIFRY                               CVIIHPMSCFSIHKTRCAVVACAVVWIISLVA                               VIPMTFLITSTNRTNRSACLDLTSSDELNTIKW                               YNLILTA\LLCLPLVIVTLCYTITIIHTLTHGHAN                               \DSCLKQKARRLTILLL               103   1453   A   1371   2   410   CHSTESSSDFILPGDYLLGGLCPLHSGCLQV\C                               SFNEHGYHLFQAMRLAVEEINNSTALLPNITL                               GYQLYDVCSDSANVYATLRVLSLPGQHIIIEL                               QGDLLLHYSPTVLAVIGPDSTNRAATTAALLSP                               FLVPMLLEQ               104   1454   A   1376   3   432   NSRVEDRSINMSLWTQNITVCPVRNVTRDGG                               FGPWSPWQPCEHLDGDNSGSCLCRARSCDSP                               RPRCGGLDCLGPAIIIIANCSRNGAWTPWSSW                               ALCSTSCGIGFQVRQRSCSNPAPRHGGRICVG                               KSREERFCNENTPCPVPIF               105   1455   A   1379   2   396   GLGLLYLIFAAVEGVMRVIGGSNHLAVVLDD                               ILLAVIDSIFVWFIFISLAQTMKTLRLRKNTVKF                               SLYRIIFKNTLIFAVLASWFMGWITKTFRIAK                               CQSDWMERWVDDAFWSFLF\SLILWIMFLW                               RPSA               106   1456   A   1383   1   432   EDGHGGWSSRCLVDHAEEGHREPWKRLCTW                               QRGGHEIRFAFYFPGHPLLSPQICLAPETPPRG                               CPPVSSLHFISLQIRLPRDCQELFQVGERQSGL                               FEIQPQGSPPPLVNCKMTSGTFWTCRTDSRVF                               QNANPSNAAHSEDQPTP               107   1457   A   1386   719   558   FFFVTRSHSVAQAEGSGVFTAHRSLDLVGSSN                               YPALSLQSSWDHRHTWLIFAFL               108   1458   A   1397   631   2   RVAISLLCAAIFISFMVQSAGKRWPTGVMLM                               VVVLFAFLYSWPIQALLPTYLKTDLAYNPHT                               VANVLSFSGFGAAVGCCV/GGFLGDWLGTRK                               AYVCSLLASQLLIIPVFAIGGANVWVLGLLLF                               FQQMLGQGIAGILPKLIGGYFDTDQRAAGLG                               FTYNVGALGGALAPIIGALIAQRLDLGTALAS                               LSFSLTFVVILRNRRPGKSLVR               109   1459   A   1402   15   387   VLVALPDT\VTSETVVTEVLGHRVTLPCLYSS                               WSHNSNSMCWGKDQCPYSGCKEALIRTDGM                               RVTSRKSAKYRLQGTIPRGDVSLTILNPSESDS                               GVYCCRTEVPGWFNDVKINVRLNLQRASTT               110   1460   A   1421   3   350   HEDLSSLLTRGSGNQERERQLKKLISLRDWM                               LAELAFPVGVLATCA*SLLSC*YCVILFPCSCF                               FFHSPDALFSLLLLSCYFPSYCFFYYLFFSSSPL                               CLLLASSPFPLFILLASL               111   1461   A   1426   2   344   FTSTMTKPFEKESEQPA*ATLAFGAQTSTTAD                               QCALKPDLSYLNNSSSSSSTPATSAGGGIFGSS                               TSSSNPPVATFVFGQSSDFVSSYGFVNTAESST                               SDSLLFSQDSKLATTS               112   1462   A   1434   46   372   TTSWTTSCTRSCT*SGASSGPGWTPRTTWWR                               SRRSSQRTCSRACSGAWSRTW*RSS*TSSSSC                               STSCSSSSSRSCGRPGGPLGARGVHITSCLNSC                               MSSSTTSSTTSTF               113   1463   A   1439   3   292   HEDIMTHYDRLVDE*ALNAGKQRYEKMISG                               MYLGEIVRNILIDFTLKGFLLRGQISEMLKTR                               GIFLTFLLSNFLIVCVLLFYVSFYLFQSCINFVL               114   1464   A   1463   1   396   KQQAVPEPHSSTTTPQEQEQNWYGQDLLNLQ                               QRTKVHLPGHKTGPAVAKDTPEPVKKEFTVP                               ATSQGP*SPFSEEPPLPPSNEEVPPTLPP*EPQS                               EDP*KNA*LKQMHAATTHWQQHQQHQVGC                               QYHGIMQ               115   1465   A   1464   291   2   AGSYPSMVWSCHWGVTQKRRAL*VYSFEEG                               GRRKCGQYWPLEKDSRIEFGFLTVSNLGVEN                               MNHYKKSTLEILNPEVNPGPFFLTLWKQGEN                               NYCN               116   1466   A   1465   667   337   LPPQRPA*TDSYSTCNVSSGFLAGQSHNLHLQ                               YWTKYQVWEWLQHFLDTNQLDANCIPFQEF                               DINGEHLCSMSLQEFTRAAGTAGQLLYSNLQ                               HLKWNGDSLFLCLSLPC               117   1467   A   1479   1   381   GTSGGPKRVLVTERFPWQNPLPVNRGQAQR                               VLGPSNSFQRVPLQAQKLVSSHKPGQNQKHK                               QLQATSVPHPVCMIPLNNTQKSKQPLPSAPEN                               NPEEELASDPNNEESL*RPWALEDFEIGRPLG                               KGK               118   1468   A   1485   3   385   TYLWL*GNPPFYEKNDGGLFELILRAKDEFNS                               PYWDDMSDSAKHFIRPLTGRDP*KPFPCDQPL                               QHPWIEGHTCLDNNIHQAASEPINNNFAESKR                               NLAFLATGVVRHMRKLFMGANLEGPGPTVS                               H               119   1469   A   1486   1   398   GTTSKHH*LARSLIRGPFDHDLKPNAATRDQL                               NIIVSYPPTKQLTYEEQDLGWKFRYYLTNQE                               KALTKFLKWVNWDLPQEAKQALELLGKWK                               PMDVKDSLELLSSHYTNPTVRRYAVARLRQA                               DDEDLLMYL               120   1470   A   1497   3   999   MGESPAV*GYFVLAGMNSAGLSFGGGAGKY                               LAEWMVHGYPSENVWELDLKRFGALQSSRT                               FLRHRVMEVMPLMYDLKVPHWDFQTGRQL                               RTSPLYDRLDAQGARWMEKHGFERPKYFVP                               PDKDLLALEQSKTFYKPDWFDIVESEVKCCK                               EAVCVIDMSSFTEFEITSTGDQALEVLQYLFS                               NDLDVPVGHIVHTGMLNEGGGYENDCSIARL                               NKRSFFMISPTDQQVHCWAWLKKHMPKDSN                               LLLEDVTWKYTALNLIGPRAVDVLSELSYAP                               MTPDHFPSLFCKEMSVGYANGIRVMSMTHT                               GEPGFMLYIPIEYRWGFTMLSTLVSNS               121   1471   A   1498   3   306   AQFLLVGWDHIL*LIVL*TNLTELGRTTCDQN                               WPNSPDVLNHGCFYMQCLSKDCTIGYVSRE                               MLVAIHTHTVEEHTGTHLQYVSWPDHSVPDD                               SSDFVEFEN               122   1472   A   1533   121   329   LGLFSFVWTEVLEEPKDFSCETEDFKTLHCT                               WDPGTDTALGWSKQPSQSYTLFES*VGSGYII                               DNFFLA               123   1473   A   1547   111   408   DARITWKPRNGSSGIWPGDGAK*PPAVEQAE                               RGHVEMIEKLTFLNLHTSEKDKGGNTALHLA                               AKHGHSPAVQVLLAQWQDINEMNEKQQTPL                               HVAADRG               124   1474   A   1555   1   745   MTFDDDDKNTYGVALVWKKFQTQSLRLSDL                               HRKSHLWRGIVSITLIEGRDLKAMDSNGLSDP                               YVKFRLGHQKYKSKIMPKTLNPQWREQFDF                               HLYEERGGVIDITAWDKDAGKRDDFIGRCQV                               DLSALSREQTHKLELQLEEGEGHLVLLVTLT                               ASATVSISDLSVNSLEDQKEREEILKRYSPLRI                               FHNLKDVGFLQVKVIRAEGLMAADVTQKSD                               PFCVVELNNDRLLTHTVYKNLNPEWNKVFTL                               *VALVWKKFQTQSLRLSDLHRKSHLWRGIVS                               ITLTEGRDLKAMDSNGLSDPYVKFRILGHQKY                               KSKIMPKTLNPQWREQFDFHLYEERGGVIDIT                               AWDKDAGKRDDFIGRCQVDLSALSREQTHK                               LELQLEEGEGHLVLLVTLTASATVSISDLSVN                               SLEDQKEREEILKRYSPLRIFHNLKDVGFLQV                               KVIRAEGLMAADVTGKSDPFCVVELNNDRLL                               THTVYKNLNPEWNKVFTL               125   1475   A   1556   57   509   GGPAPNSRYAEP*KNSLAMT*AHADCENYVA                               CGGLDNICSIYNLKTREQNVRVSRELPGHTGY                               LSCCRPLDDSQIVTSSGDTTCALWDIETAQQT                               TTFTGHSGDVMSLSLSPDMRTFVSGACDASS                               KLWDIRDGMCRQSFTGHVSDINAVS               126   1476   A   1592   3   178   KSEKSCVSSLAHFGTSCQRDYDAMVKLVETL                               EMLPTCDLADQHNKFHYAFALNR*ER               127   1477   A   1612   1   497   TESPLLVRPYLPYITKSELHAIMTAGFSTIAGS                               VLGAYISFGVPSSHLLTASVMSAPASLAAAKL                               FWPETEKPKITLKNAIVIKMESGDSGNLL*AAT                               QGASSSISLVANIAVNLIAPLALLSPMNSALA                               WVGNMFDYPQLSFELICSYIFMPFSFMMGVE                               WPDSFM               128   1478   A   1619   286   486   CGMNSKAQESVFKNVLCNPPALSEMPDVKA                               EDEYDFRASSISEEVAVGSIAATLKMKQGPM                               TQAINR               129   1479   A   1627   1   395   PTRGALRYWIFGRFLCNIWAAVDVRCCTATI                               MGLCIISIDRYVGVSYPLRYPTIVTQRRGLMA                               LLCVWALSLVIYIGPLLGWRHPAPEDETICQI                               NEEPGYVLFSTPGSFYLPLAIMLVMN*RVYRV                               AKTE               130   1480   A   1638   2   466   DPRVRTKIVNRTTIYEIQDKTGSMAVVGKG                               ECHNIPCEKGDKLRLFCFRLRKRENMSKLMS                               EMHSFIQTQKNTNQRSHDSRSMALPQEQSQHP                               KPSEASTTLPESHLKTPQMPPTTPSSSSFTKVT                               KDKDIK*LLFNLYSSVEILPEVLHLKT               131   1481   A   1651   607   3   LAEGGDVFDCVLNGGPLPESRAKALFRQMVE                               AIRYCHGCGVAHRDLKCENALLQQFNLKLTD                               FGFAKVLPKSHRELSQTFCGSTAYAAPEVLQ                               GIPHDSKKGDVWSMGVVLYVMLCASLPFDD                               TDIPKMLWQQQKGVSFPTHLSISADCQDLLK                               RLLEPDMILRPSIEEVSWHPWLAST**KQWQV                               LSNKVGGESKPKKKK               132   1482   A   1656   150   48   LVAKSLLYCGCLFFLLQLAKNVGNNSFNDIM                               EANLTSPSPKPTPSSDM*VFLIY*TYFGAWHV                               VDAQ               133   1483   A   1660   3   406   RKHIKLLIQKLSDVP*ECQNNQL*KLTEICEKE                               KKEFKKKMDDQRPEKITEA*SKDKSPMEEEK                               TEMIRSYIQEVGRYIKRLEEAQSKRLEKLREK                               HKEIRQPILDEKPKGEGSSSFLSETCHEDTSWF                               PNFTP               134   1484   A   1666   1276   466   PGSTHASARITIY*L*IILSNATEVDNNFSKPPP                               FFPAGAPPASSSSSSSSSSPPTVSTAPPLIPPPGF                               PPPPGAPPPSLIPTIESGHSSGYDSRSARAFPYG                               NVAFPHLPGSAPSWPSLVDTSKQWDYYARSS                               SSSSSSSSSSSSSPRDRDRER*RTRERERERDHS                               PTPSVFNSDEERYRYREYAERGYERHRASRE                               KEERHRERRHREKEETRHKSSRSNSRRRHESE                               EGDSHRRHKHKKSKRSKEGKEAGSEPAPEQE                               STEATPAE               135   1485   A   1673   1   417   PTRPVNSSQAFALVYYTLGALGGNLIAHMGL                               GYRYWAGIGVLQSCESALTHYRLVANHVAS                               DISLTGGSVVQRIRLPDEVENPGMNSGMLQE                               DLIQYYQFLAEKGDVQAQVGLGQLHLHGGR                               GV*QNHQRAFDYFNLAA               136   1486   A   1678   525   9   ANTSLSSAAVSAVSPPPCRTSTATTLPPPMPSF                               FCVFPSPSMSPSPSEFLSCIASVSRVHSLSSSSS                               GSSSTASSLNFSAIMGSSSATASWVLSTASTPP                               CPSALPSSPAQES*SLAASSSAWPVAGISPSGA                               CTFPAGSASGAAKAPSPSWRCPSFRALFSLLD                               SSSLSL               137   1487   A   1680   1   2999   AHRDEIQRKFDALRNSCTVITDLEEQLNQLTE                               DNAELNNQNFYLSKQLDEASGANDEIVQLRS                               EVDHLRREITEREMQLTSQKQTMEALKTTCT                               MLEEQVMDLEALNDELLEKERQWEAWRSVL                               GDEKSQFECRVRELQRMLDTEKQSRARADQ                               RITESRQVVELAVKEHKAEILALQQALKEQK                               LKAESLSDKLNDLEKKHAMLEMNARSLQQK                               LETERELKQRLLEEQAKLQQQMDLQKNHIFR                               LTQGLQEALDRADLLKTERSDLEYQLENIQV                               LYSHEKVKMEGTISQQTKLIDFLQAKMDQPA                               KKKKVPLQYNELKLALEKEKARCAELEEALQ                               KTRIELRSAREEAAHRKATDHPHPSTPATARQ                               QIAMSAIVRSPEHQPSAMSLLAPPSSRRKESST                               PEEFSRRLKERMHHNIPHRFNVGLNMRATKC                               AVCLDTVHFGRQASKCLECQVMCHPKCSTC                               LPATCGLPAEYVTHFTEAFCRDKMNSPGLQT                               KEPSSSLHLEGWMKVPRNNKRGQQGWDRK                               YIVLEGSKVLIYDNEAREAGQRPVEEFELCLP                               DGDVSIHGAVGASELANTAKADVPYILKMES                               HPHTTCWPGRTLYLLAPSFPDKQRWVTALES                               VVAGGRVSREKAEADAKLLGNSLLKLEGDD                               RLDMNCTLPFSDQVVLVGTEEGLYALNVLK                               NSLTHVPGIGAVFQIYIIKDLEKLLMIAGEERA                               LCLVDVKKVKQSLAQSHLPAQPDISPNIFEAV                               KGCHLFGAGKIENGLCICAAMPSKVVILRYN                               ENLSKYCIRKEIETSEPCSCIHFTNYSILIGTNK                               FYEIDMKQKTLEEFLDKNDIISLAPAVFAASS                               NSFPVSIVQVNSAGQREEYLLCFHEFGVFVDS                               YGRRSRTDDLKWSRLPLAFAYREPYLFVTHF                               NSLEVIEIQARSSAGTPARAYLDIPNPRYLGPA                               ISSGAIYLASSYQDKLRVICCKGNLVKESGTE                               HHRGPSTSRR*PASPLPQYQGQRAFLQGRRK               138   1488   A   1686   2   526   GRPQGPAPGAGSPPESGPGLWAALGCSLVWV                               PLCCLGGAAGRL*ARSGKSGLRRRRAHAGPP                               PGGPCNSCP*CSAPESGGRGPLPGPGTGGVCS                               CWTRGCQTTARTAAAAAAPGPAGRRPPGQA                               PQNQSCAASASQEAAAPPPMCPPGRRWAVAS                               PPETRCPAAPGTRCRRLEAA               139   1489   A   1693   3   376   LPSMSNCTSCFRLQSRTES*IRQAGHLLGRNE                               FIETKALGCAWFSLCYYLVLYFESSHKVDFVF                               IV*CFSTPPGAQMTIMSQACAERCNLMRLVDR                               RWAGIAKGVGTQKIIGRVHLGEQKALGL               140   1490   A   1704   3   376   ERTNKFIKELIMDGKNLIAATKSLSVAQRKFA                               HSLRDFKFEFIGDAVTDDERCIDASLREFSNFL                               KNLEEQREIMVS*EGCKLISQLSRGKK1WIWK                               LVLVEVVKHLSLGTVVHCNGKMRFPEP               141   1491   A   1743   1   362   LITNKVFVARELSCLDYHLDSTGSTAVVADQ                               DKLELELVLKGSYEDTQTSFLGTASAFRFHY                               MAAL*TELSGRLRSSKSNGWNGDNSTGYLTV                               PLRPLTIVKEVTMDVPAPNVRGLNWMG               142   1492   A   1769   1   406   NNPSTLPRGS*PMSPRTTMGRRRQRRREHKSS                               LSLASSTVGPGGQIVHTETTEVVLCGDPLSGF                               GLQLQGGIFATETLSSPPLVCFIEPDSPAERCG                               LLQVGDRVLSLNGIATEDGTMEEANQLLRDA                               ALAHKVV               143   1493   A   1789   1   447   QMLRNGGDQNTVPDYHFADRIRELL*PTEDQ                               KNCIP*DTYLRPSALGNIVEEVTHPCSPGPCPA                               NELCEVNRKGCTSGDPCLPYFCVQGCKLGQA                               SDFIARQGTLIQVPSSAGEVECYKICSCGQSGL                               LENCMEMHCMDLPTDTSALVR               144   1494   A   1814   1   404   PGRRFRPRLSQAGTDSGS*VFPDSFPSAPAEPL                               PYFLQEPQDAYIVKNKPVELRCRAFPATQIYF                               KCNGEWVSQNDHVTQEGLDEATGLRVREVH                               IEVSRQQVEELFGLEDYWCQCVAWSSAGTTK                               SRRAYVRI               145   1495   A   1827   26   448   XVEEKHADTWRSXCLSDFFFHAAKXLCXE*N                               CGDAISLSVGDHFGKGNGLTWAEKFQCEGSE                               TIILALCPIVQHPEDTCTHSREVGVVCSRYTDV                               RLVNGKSQCDGQVEINVLGHWGSLCDTHWD                               PEDARVLCRQLNCGTAL               146   1496   A   1828   574   333   QHEGGDLRRRQLGEIQLTVRYVCLRAASAC*                               SMAAET*HHVPASGADPYVRVYLLPERKWA                               CRKKTSVKRKTLEPLFDET               147   1497   A   1855   1   372   ERLVLTSEHCLVLTLFWPSWTYHTLLLSRQH                               VRRLPKLTHAEHDHLASIMNKLLTNYDNLFE                               TSVTYSMG*HGAPTGSEAGANWNH**LHAH                               YYPPLLRSDTVRKFMVGSQMLAQAQRDLTPE                               Q               148   1498   A   1879   568   7   LLSALDDKGGTQPSASFSNAPTIVCVTACPAG                               IAHTYMAAEYLEKAGRKLGVNVYYEKQGAN                               GIEGRLTADQLNSATACIFAAEVAIKESERFN                               GIPALSVPVAEPIRHAEALMQQALTLKRSDET                               RTVQQDTQPVKSVKTELKQALLSGISFAVPLI                               VAGGTQVA*AV*RQGISSLHDVQVRTWNS               149   1499   A   1880   611   24   GLNSENALSNEAMERGWQCLRLFAERLQDIP                               PSQIRVYATATLRLAVNAGDFIAKAQEILGCP                               VQVLSGEEEARLIYQGVAHTTGGADQRLVVD                               IGGASTELVTGTGAQTT*LFSLSMGCVTWLER                               YFADRNLGQENFDAAQKAAREVLRPVADEL                               RYHSWKEVRGASVTVQALQEIMMAQGMDE                               RITMETWPVD               150   1500   A   1894   2   750   GRVDFFHTDYRPLIRDSNNYVLDEQTQQAPH                               LMPPPFLVDVDGNPHPTKYQRLVPGRENSAD                               EHLIPQLGYVATSDGEVIEQIISLQTNDNDERS                               PESSILDGMIRQLQQQQDQRMGADQDTIPRG                               LSNGEETPRRGFRRLSLDIQSPPNIGLRRSGQV                               EGVRQMHQNAPRSQIATERDLQAWKRRVVV                               PEVPLGIFRKLEDFRLEKGEEERNLYIIGRIKRK                               TLQLSHKSDSVGLVSQSRPRTCRRKYP               151   1501   A   1900   141   785   GKTIQIQTTMQNKYKTVQKQYKTIPKNKKA                               MEMQIKKQFQDTCKVQTKQYKALKNHQLEV                               TPKNEHKTILKTLKDEQTRKLAILAEQYEQSI                               NEMMASQALRLDEAQEAECQALRLQLQQEM                               ELLNAYQSKIKMQTEAQHERELQKLEQRVSL                               RRAHLEQKIEEELAALQKERSERIKNLLERQE                               REIETFDMESLRMGFGNLVTLDFPKEDYR               152   1502   A   1915   2   377   LVRLLDTQRDGLQNYEALLGLTNLSGRSDKL                               RQKIFKERALPDIENYMFENHDQLRQAATEC                               MCNMVLHKEVQERFLADGNDRLKLVVLLCG                               EDDDKVQNAAAGALAMLTAAHKKLCLKMT                               QVTT               153   1503   A   1921   1   237   AYQSLRLEYLQIPPVSRAYTTACVLTSAAVQL                               ELITPFQLYFIPELIFKHFQIIWRLITNFLFFVPFG                               FNFLLYMIFLYT               154   1504   A   1928   2   354   EMVEGGEGKMCINTEWGGFGDNGCIDDIRTR                               YDTEVDEGSLNPGKQRYEKMTSGMYLGEIV                               RQILIDLTKQGLLFRGQISERLRTRGIFETKFLS                               QIESDRLALLQVRRILQQLGLD               155   1505   A   1929   2   369   TEIAKIKMEAKKKYEKELTMFQNDFEKACQA                               KSEALVLREKSTLERIHKHQEIETKEIYAQRQ                               LLLKDMDLLRGREAELKQRVEAFESYQLELK                               DDYIIRTYRLIEDDRINIQISGHWQESP               156   1506   A   1935   1   270   VTRKLPIFIVDAFTARAFRGSPAADCLLENEL                               DEDMHQKIAREMNLSETAFIRKLHPTDNFAQ                               RSCFGLTWFTPTTDLQILTSSILPSIL               157   1507   A   1936   584   305   ESKVNNEKFRTKSPKPAESPQSATKQLDQPTA                               AYEYYDAGNHWCKDCNTICGTMFDFFTHMH                               NKKHTQGQFQKSSDFQKEELQQTFLPPERQG               158   1508   A   1939   1   423   TTHRLNVTAEPPCTSMPIYWMPDVPHRCTTA                               NTCPVDLTDYCAQNGFYCLVYGFLPYGSLED                               RLHCQTQACPPLSWPQRLDILLGTARAIQFLH                               QDSPSLIIIGDIKSSNVLLDERLTPKLGDFGLA                               RFSRFAGSSPIQSSM               159   1509   A   1974   3   401   HTSTARLLLHRGAGKEAVTSDGYTALHLAAR                               NGHLATVKLLVEEKADVLARGPLNQTALHL                               AAAHGHSEVVEELVSADVIDLFDEQGLSALH                               LAAQGRHAQTVETLLRHGAHINLQSLKFQGG                               HGPAATLLR               160   1510   A   1982   2   417   KFLKDLEKQYNKEEPHLSEIGSCFLQNQEGFA                               IYSEYCNNHPGACLELANLMKQGKYRHFFEA                               CRLLQQMIDIAIDQFLLTPVQKICKYPLQLAEL                               LKYITQEHGDYSNTKAAYEANKNVACLINER                               KRKLESIDKIA               161   1511   A   1984   4   770   RETGSVSLSPSGLEGAESYAVSPILYSSPDVKE                               LWLETLQGQRHSHTGVKSTPGQSAAILMKLR                               SSHNASKTLNANNMETLIECQSEGDIICEHPLL                               ASCESEDSICQLIEVKKRKKVLSWPFLMRRLS                               PASDFSGALETDLKASLFDQPLSIICGDSDTLP                               RPLQDILTILCLKGPSTEGIFRRAANEKARKEL                               KEELNSGDAVDLERLPVHLLAVVFKDFLRSIP                               RKLLSSDLFEEWMGALEMQDEEDRIEALK               162   1512   A   1986   864   501   LLNSGLFSAPDGSNLEMRLTRGGNMCSGRIEI                               KFQGRWGTVCDDNFNIDHASVICRQLECGSA                               VSPSGSSNFGEGSGPIWFDDLICNGNESALWN                               CKHQGWGKHNCDHAEDAGVICSSKD               163   1513   A   2001   419   187   AVDLSIDESSLTGETTPCSKVTAPQPAATNGD                               LASRSNIAFMGTLVRCGKAKGVVIGTGENSE                               FGDIINLSTFVVHS               164   1514   A   2012   284   597   SLLCLFPGTSTVVCKPIVIETQLYVIVAQLFGG                               SHIYKRDSFANKFIKIQAIEILKIRKPNDIETFKI                               ENNWYFVVADSSKAGFTTTYKWERETGFYSH                               QSFTR               165   1515   A   2013   2   403   EDPEELGHFYDYPMALFSTFELFLTIIDGPANY                               NVDLPFMYSITYAAFAIIATLLMLNLLIAMMG                               DTHWRVAHERDELWRAQIVAITVMLERKLP                               RCLWPRSGICGREYGLGDRWILRVEDRQDLN                               RQRIQRYA               166   1516   A   2019   2   927   CCQREGLGLKAVVQILLSHGRNGLPGEPASS                               QGLSAASSTPVFHLALQIDSAPDNIDWVEMLF                               NKNMVTERLQNVMVLEQCFSDSSSLYRFLTY                               SYLLAFNVWLLLAPVTLCYDWQVGSIPLVETI                               WDMRNLATIFLAVVMALLSLHCLAAFKRLE                               HKEVLVGLLFLVFPFIPASNLPFRVGFVVAER                               VLYMPSMGYCRFVHGLSKLCTWLNRCGATT                               LIVSTVLLLLLFSWKTVKQNEIWLSRESLFRS                               GVQTLPHNAKVHYNYANFLKDQQRNKRAIY                               HYRTALNNNKAWDYLCWRFRKTLTDLP               167   1517   A   2025   696   71   AAASAASSLTVTLGRLASACSHSILRPSGPGA                               ASLWSASRRFNSQSTSYLPGYVPKTSLSSPPW                               PEVVLPDPVEETRHHAEVVKKVNEMIVTGQY                               GRLFAVVIIFASRQWKVTSEDLILIGNELDLA                               CQERIRLEKVLLVGADNFTLLGKPLLGKDLV                               RVEATVIEKTESWPRIIMRFRKRKNFKKKRIV                               TTPQTVLRINSIEIAPCLL               168   1518   A   2046   2   366   LILQVAARVFMPLQAVDSAPKPLKGQAQAPQ                               ELQGAARVFMPLQAQVKAKASKPLQMQIKA                               PPRLRRAARVLMPLQAQVRAPRLLQVQSQVS                               KKQQAQTQTSEPQDLDQVPEEFQGQDQVLR               169   1519   A   2049   1   945   QNLEDREVLNGVQTELLTSPRTKDTLSDMTR                               TVEISGEGGPLGIHVVPFFSSLSGRILGLFIRGI                               EDNSRSKREGLFHENECIVKINNVDLVDKTFA                               QAQDVPRQAMKSPSVLLHVLPPQNREQYEKS                               VIGSLNIFGNNDGVLKTKVPPPVHGKSGLKTA                               NLTGTDSPETDASASLQQNKSPRVPRLGGKPS                               SPSLSPLMGFGSNKNAKKIKIDLKKGPEGLGF                               TVVTRDSSLHGPGPIFVKNILPKGAAIKDGRLQ                               SGDRILEVNGRDVTGRTQEELVAMLRSTKQG                               ETASLVIARQEGHFLPRELVMFRSQSH               170   1520   A   2050   363   1   PVATHLTKILNSDEHAVVISSAKTLCETVKDF                               VAKVEKTYDKTLENAVVADAVASKCSVLNE                               KLEQLLQALHTDSQAAPVLPGLSPLWEEDAV                               ESSSEESLGESKEQLGDDVTKPSSQKA               171   1521   A   2055   139   675   IPSRPWLGRITGLDPAGPLFNGKPHQDRLDPS                               DAQFVDVIHSDTDALGYKEPLGNIDFYPNGG                               LDQPGCPKTILGGFQYFKCDHQRSVYLYLSSL                               RESCTTTAYPCDSYQDYRNGKCVSCGTSQKE                               SCPLLGYYADNWKDIILRGKDPPMTKAFFDT                               AEESPFCMYHYFVDIITWNKNVR               172   1522   A   2056   3   361   LIQHKSAVEYAQSHLSLVSMCKESHKCSEPK                               MEWKVKIRSDGTRYITKRPVRDRILKERALKI                               KEERSGLTTDDDTMSEMKMGRYWSKEERKQ                               HLVRGKEQRRREEFMMIRLKCLKES               173   1523   A   2060   1   387   GTRILSMQIPFVGFQPIRTSEHMAAAGVFALL                               QAYAFLQYLRDRLTKQEFQTLFFLGVSLAAG                               AVFLSVIYLTYTGYIAPWSGRFYSLWDTGYA                               KIHIPIIASVSEHQP1TWVSFFFDLHILGCTFPA                               G               174   1524   A   2071   74   443   LLMGPKAKKSGSKKKKVTKAERLKLLQEEEE                               RELKEEEEARLKYEKEEMERLEIQRIEKEKW                               HRLEAKDLERRNEELEELYLLERCFPEAEKLK                               QETKLLSQWKHYIQCDGSPDPSVAQEMNT               175   1525   A   2083   139   486   AALTWSQPQEFWPMEMQPIVTDMVTVIIWV                               AESSTVGWLCALFRVTHVGVGATGHGVVCG                               RRVLCGLPLPSPAPMPIMSLPEGESRKEREVQ                               RLQFPYLEPGHELPATILLAFLAAV               176   1526   A   2092   3   587   EGSVNFKFGVLFAKDGQLTDDEMFSNEIGSEP                               FQKFLNLLGDTTTLKGWTGYRGGLDTKNDTT                               GIHSVYTVYQGHEIMFHVSTMLPYSKENKQQ                               VERKRHIGNDIVTIVFQEGEESSPAFKPSMIRS                               HFTHIFALVRYNQQNDNYRLKIFSEESVPLPG                               PPLPTPPVFTDHQEFRDFLLVKLINGEKATLET                               PCI               177   1527   A   2103   44   427   GKGQVSLEGRPHRGPLCLGSWWPGSRVPGC                               CDGAWLAWACWVFGNDFPSPASAACSALLG                               CSVSTACLCVPLCSGSPLAPFRRTAALQEGLR                               RAVSVPLTLAETVASLWPALQELARCGNLAC                               RSDLQ               178   1528   A   2104   2   409   ALQSTLGAVWLGLLLNSLWKVAESKDQVFQ                               PSTAASSEGAVVEIFCNHSVSNAYNFFWYLHP                               PGCAPRLLVKGSKPSQQGRYNMTYERFSSSL                               LILQVREADAAVYYCAVEVPNTDKLIFCITGT                               RLQVFPNIQNPD               179   1529   A   2111   1   312   PTRSSTRPPSLFVHASAKGGEKEEGDDGHYL                               MRTESHTGLKKGGNANLVFMLKRNTEPKKG                               SYHFDLERLRAAHLLFEREQEHLAPGGISMPL                               PPPLPLPACLG               180   1530   A   2116   3   366   TSIKRAIETTDVTRSFGWDSSEAWQQHDVQE                               LCRVMFDALEQKWKQTEQADLINELYQGKL                               KDYVRSLECGYEGWRIDTYLDIPLVIRPYGSS                               QAFASVVCTFHLTACVSLHRIHNSTVV               181   1531   A   2117   2   386   YGLGAHFGRLFIQAGINENDFYDGAWCAGR                               NDLQQWIEVDARELTRFTGVITQGRNSLWLS                               DWVTSYKVMVSNDSHTWVTGKNGSGDMIFE                               GNSEKEIPVLNELPVPMVARYIR1NPQSWPDN                               GSICI               182   1532   A   2123   1   493   RTKTDVYIILNLAVADLLLLFTLPFWAVNAVH                               GWVLGKIMCKITSALYTLNFVSGMQFLACISI                               DRYVAVTKVPSQSGVGKPCWIICFCVWMAAI                               LLSIPQLVFYTVNDNARCIPIFPRYLQTSMKAL                               IQMLEICIGFVVPFLIMGVCYFITARTLMKMP                               NIKIS               183   1533   A   2140   3   561   RQAWHEAFKVRKEILTVICCLLAFCIGLIFVQ                               RSGNYFVTMFDDYSATLPLLIVVELENIAVCF                               VYGIDKFMEDLKDMLGFAPSRYYYYMWKYI                               SPLMLLSLLIASVVNMGLSPPGYNAWIEDKAS                               EEPLSYPTWGLAVCASLDVFAIIPVPVAFIGR                               RFSLIDDGAGPFCSAAYTTTGCRTPYL               184   1534   A   2145   3   538   HELTVAAADRGQPPQSSVVPVTVTVLDVND                               NPPVFTRASYRVTVPEDTPVGAELLHVEASD                               ADPGPHGLVRFTVSSGDPSGLFELDESSGTLR                               LAHALDCETQARHQLVVQAADPAGAHFALA                               PVTIEVQDVNDHGPAFPLNLLSTSVAENQPPG                               TLVTTLHAIDGDAGAFGRLRYHL               185   1535   A   2151   2   671   LDKLLDRMENYNIFNEYILKQVAATYIKLGW                               PKNNFNGSLVQASYQHEELRREVIMLACSFG                               NKHCHQQASTLISDWISSNRNRIPLNVRDIVY                               CTGVSLLDEDVWEFIWMKFHSTTAVSEKKIL                               LEALTCSDDRLLNRLLNLSLNSEVVLDQDAI                               DVIIHVARNPHGRDLAWKFFRDKWKILNTRI                               RQKTLEFDFAEPLILAFPIILYTAIDNPPLVREH                               E               186   1536   A   2153   2   400   GPMCDKHSAFAEFHAGFIDYIVHPLWETWA                               HLALPDAQDILYTLEDNRNWVDSMIPQSPSPP                               LDEQNRDWQGLLENLHVELTLDEEDSEGPEK                               EGEGQTYFTSSKTLCGIVPQNTDSLGETGIHIC                               AHDKSP               187   1537   A   2158   227   442   FNCPRVASDSFLENSSLLIMILPLRNATQEFIIR                               PGAVAYTCNPSTLGGWGGWITRSGVRDQPG                               QHGGTPS               188   1538   A   2167   3   486   AHLGGAWLTQRSLGSWAAPGPARAAKEVVA                               CIPQNQKMNIWRMKTSKHLQLLSFVLGAVSP                               AVVVPYMMVLQENGYGVEEGIPTLLMAASS                               MDDILAITGFNTCLSIVFSSGCARSSGSRNSKS                               LRTPLGTICEGCDDSSIFSHLDHSSKWSSTYG                               HSGA               189   1539   A   2168   2   412   EFLSSNQITQLPNTTFRPMPNLRSVDLSYNKL                               QALAPDLFHGLRKLTTLHMRANAIQFVPVRIF                               QDCRSLKFLDIGYNQLKSLARNSFAGLFKLTE                               LHLEHNDLVKVNFAHFPRLISLHSLCLRRNKV                               AIVVSSLDW               190   1540   A   2179   64   399   MRLNQNTLLLESFGXXRPYTSEHAIPTYHQW                               MKADELLRWTTSEPLTLEHEYAMQRTWLED                               AYECTFIVLDAEKRHAQPGATEESCMVGDVN                               LFLTDLEDLTLGEIEVLIAEP               191   1541   A   2190   1   469   CLDRAAGIRHERNVIYINETHTRHRGWLARR                               LSYVLFIQERDVHKGMFATNVTENVLNSSRV                               QEAIAEVAAELNPDGSAQQQSKAVNKVKKK                               AKRILQEMVATVSPAMIRLTGWVLLKLFNSF                               FWNIQIHKGQLEMVKAATETNLPLLFLPVIIR                               SH               192   1542   A   2197   26   157   PSKXGGLRLLLTGTQLYGRFGSAIAPLGDLDR                               DGYNGEGREEPY               193   1543   A   2236   2   383   EYFPNSIWRSLFSTMDLGDIGFYTYRILQALS                               YTHSKGIMHRDVKPLNILCNSPRNKVILADW                               GLAEFYHPMRKYSVHVATRYYKSPEILLDYE                               YYDYSLDIWAVGVILLELLTLKLHVFEGGDN                               EQ               194   1544   A   2241   105   409   RKGVGKMPTSEGRPGQERSDWVTSYKVMGS                               NDSHTWVTVKNGSGDMIFEGNSEKEIPVLNE                               LPVPMGARYIRINPQSWFDNGSICMRMEILGC                               PLPDPNNY               195   1545   A   2245   1   672   MGVASDWTKIEYQPGSGSMPLFPSIHLETCD                               GAVSSLQIVTELQTNYIGKGCDRETYSEKSLQ                               KLCGASSGIIDLLPSPSAATNWTAGLLVDSSE                               MIFKFDGRQGAKIPDGIVPKNLTDQFTITMW                               MKHGPSPGVRAEKETILCYSDKTEMNRHHY                               ALYVHNCRLVFLLRKDFDQADTFRPAEFHW                               KLDQQALAKVDGQPGKSTTRQLQEMPVTIQG                               ISLKPS               196   1546   A   2256   1   396   FRGTPVSGLTNRDTLAVIRHFREPIRLKTVKP                               GKVINKDLRHYLSLQFQKGSIDHKLQQVIRD                               NLYLRTIPCTTRAPRDGEVPGVDYNFISVEQF                               KALEESGALLESGTYDGNFYGTPKPPAEPSPF                               QPDPV               197   1547   A   2259   43   594   QLAIEIGVRALLFGVFVFTEFLDPFQRVIQPEEI                               WLYKNPLGQSDNIPTRLMFAISFLTPLAVICV                               VKITRRTDKTELKEAFLAVSLALALNGVCTNTI                               KLIVGRPRPDFFYRCFPDGVMNSEMHCTGDP                               DLVSEGRKSFPSIHSSFAFSGLGFTTFYLAGKL                               HCFTESGRGKSWRLCAAILPL               198   1548   A   2275   3   404   TCTTVVVIPRMLVDFLSESKTISLPECATQMFF                               FLGFASNNCFIMAAMSYDRYTAIHNPLQYHT                               LMTRKICLQMMMASWMVGFLFSLCIWTVFN                               LSLCDLNTIQHYFCDISPVVSLACNYTFYHEM                               AIFVLSA               199   1549   A   2315   1   375   LTQMFFIHALSAIESTILLAMAFDRYVAICHPL                               RHAAVLNNTVTAQIGIVAVVRGSLFFFPLPLLI                               KRLAFCHSNVLSHSYCVHQDVMKLAYADTL                               PNVVYGLTAILLVMGXDRMFISLSYFLII               200   1550   A   2334   2   409   PRVRPQQRKMSFFFKTELGEKLVTKFLFETDF                               SDDPMLPSPDQLKKKAPFTNKKLKAIIQTPVD                               ILKQKAIIQLASMQVQAYNGGNANPRPANNE                               EEEDEEDEYDYDYESLSDDNILEDRPENKSCH                               DQLQFEYKEEM               201   1551   A   2350   3   512   ISWEAQIAEIIQWVSDEKDARGYLQALASKM                               TEELEALRSSSLGSRTLDPLWKVRRSQKLDM                               SARLELQSALEAEIRAKQLVQEELRKVKDAN                               LTLESKLKDSEAKNRELLEEMEILKKKMIEEK                               FRADTGKLMLCDSALFEYKYFSNECFYFLFD                               LIYTLEAPTEFQIQY               202   1552   A   2351   1   1003   PSSYSSDELSPGEPLTSPPWAPLGAPERPEHLL                               NRVLERLAGGATRDSAASDILLDDIVLTHSLF                               LPTEKFLQELHQYFVRAGGMEGPEGLGRKQA                               CLAMLLHFLDTYQGLLQEEEGAGHIIKDLYL                               LIMKDESLYQQLREDTLRLHQLVETVELKIPE                               ENQPPSKQVKPLFRHFRRIDSCLQTRVAERGS                               DEIFCRVYMPDHSYVTIRSRLSASVQDILGSV                               TEKLQYSEEPAGREDSLILVAVSSSGEKVLLQ                               PTEDCVFTALGINSHLFACTRDSYEALVPLPE                               EIQVSPGDTEIHRVEPEDVAMILTAFHWELFR                               CVHELEFVDYVFHGE               203   1553   A   2361   2   403   NNLNCAEPLFEQNNSLNVNFNTQICKTVWLIH                               GYRPVGSIPLWLQNFVRILLNEEDMNVIVVD                               WSRGATTFIYNRAVKNTRKVAVSLSVHIKNL                               LKHGASLDNFHFIGGSLGAHISGFVGKIFHGQ                               LGRITGLDP               204   1554   A   2390   280   476   SPSLLPQCLMSLSDLSLSPAPPSHLSPRCPSPQ                               AGSRLGAMRRCAREMDATPMPPAPSCPSERV                               T               205   1555   A   2400   543   745   AAVALRDISWQQPYPMDFYAGSSLGPWTVN                               HGQDRRPHAPGRPARGKVQEGSARPPSAVAC                               EDCSCR               206   1556   A   2406   122   485   DLSPDSREDHPQGHRRLLPKRPVRGSLMPGH                               THHPCPVSSTTNDTPDQIWVSVGSLRMGTGG                               ESRGGLLATGVGGMCACVPRNQPLTGT               207   1557   A   2409   289   418   LWTLYRHKQQVQHNHSNRLSCRPSQEDRAT                               HTIMVLDKENTLS               208   1558   A   2413   64   492   VQGTGXXFIAFTEAMTHFPASPVWAGMFFL                               MLINLGLGSMIGTMAGITTPIIDTFKVPKEMFT                               GGCCVFAFLVGLLFVQRSGNYFVTMFDDYSA                               TLPLTLIVILENIAVAWIYGTKKFMQELTEML                               GFRPYRFYFYMWKFVSP               209   1559   A   2417   3   877   EKERLLDEWFTLDEVPKGKLHLRLEWLTLMP                               NASNLDKVLTDIKADKDQANDGLSSALLILY                               LDSARNLPIRYKTNEPVWEENFTFFIHNPKRQ                               DLEVEVRDEQHQCPLGNLKVPLSQLLTSEDM                               TVSQRFQLGNSGPNSTIKMKIALRVLHLEKRE                               RPPDHQHSAQVKRPSVSKEGRKTSIKSHMSG                               SPGPGGSNTPSTPVIGGSDKPGMEEKAQPPE                               AGPQGLHDLGRSSSSLLASPGHISVKEPTPSIA                               SDISLPIATQELRQRLRQLENGTTLGQSPLGQI                               QLTIP               210   1560   A   2422   35   456   REFAASDLEPFTPTDQPISPEAITQPSCIKRQRA                               AGNPGSLAATLDIIKPCSAPLEPKIQASRNQRW                               GAVRAAESLTDLAEPASPQVHETPIDASQTQK                               VEPASKSRFTPELQAKVSHSRERALSTMDATP                               HHAQPQRGEG               211   1561   A   2431   1   764   RRYSQKLIQHTACQLLRTYPAATRIDSSNPNP                               LMFWLHGIQLVALNYQTDDLPLHLNAAMFE                               ANGGCGYVLKPPVLWDKNCPMYQKFSPLER                               DLDSMDPAVYSLTIVSGQNVCPSNSMGSPCIE                               VDVLGMPLDSCHFRTKPIHRNTLNPMWNEQF                               LFHYHFEDLVFLRFAVVENNSSAVTAQRIIPL                               KALKRGYRHLQLRNLHNEVLEISSLFINSREM                               EENSSGNTMSASSMFNTEERKCLQTHRVTVH                               GVPG               212   1562   A   2436   1   411   GIRGTTGHLGCPINDDPSLTLTVSWVMEDKPI                               YIGNGTKKEDDSLTIFAVAKRDHVSDTCGAC                               TDLDHNLDKGYLTVLGEQATPTNRLGALPKG                               RANRTRDLELTYLAERIVRLTWIPGDANNRPI                               TDYDCQIEEHQ               213   1563   A   2445   1   1294   MSSIGCLWVSRSSQIDGLTAEKSGPEKPHGT                               WLMPELHPKEQILELLVLEQFLSILPEELQIWV                               QQHNPESGEESVTLLEDLEREFDDPGQQVPAS                               PQGPAVPWKDLTCLRASQESTDIHLQPLKTQ                               LKSWKPCLSPKSDCENSETATKEGISEEKSQG                               LPQEPSFRGISEIIESNLVWKQGSATGEKLRSP                               SQGGSFSQVIFTNKSLGKRDLYDEAERCLILT                               TDSIMCQKVPPEERPYRCDVCGHSFKQHSSLT                               QHQRIHTGEKPYKCNQCGKAPSLRSYLIIHQR                               IHSGEKAYECSECGKAFNQSSALIRHRKIHTG                               EKACKCNECGKAFSQSSYLIIHQRIHTGEKPY                               ECNECGKTFSQSSKLIRHQRIHTGERPYECNE                               CGKAFRQSSELITHQRIHSGEKPYECSECGKA                               FSLSSNLIRHQRIHSG               214   1564   A   2461   1   615   GIPGSTISSSRNIFLEDDLAWQSLIHPDSSNTPL                               STRLVSVQEDAGKSPARNRSASITNLSLDRSG                               SPMVPSYETSVSPQANRTYVRTETTEDERKIL                               LDSVQLKDLWKKICHHSSGMEFQDHRYWLR                               THPNCIVGKELVNWLIRNGHIATRAQAIAIGQ                               AMVDGRWLDCVSHHDQLFRDEYALYRPLQV                               LFSVYCQLECSKLIL               215   1565   A   2464   3   2932   GPGVRSSQDGMADVFVHLRTAWPRCSFISGQ                               HGPGRHGRRVCSSQDSMADVFVHLRTAWPT                               CSLISGQHGPGESVSYEDDDIPAPASLLIIVNA                               AAPALTNPTAPVLCTAPNNTAQKEKVPSGMR                               QRPAGVRISSRTPDLTCAVSTHSTVPGVRISSC                               TPDLTCAVSIHSTVPSVCISSCTPDLTCAVSTH                               STVPGVRISSCTPDLTCAVSTHSTVPGVRISSR                               TPDLTCAVSIHATVPGVRISSCTPDLTCAVSIH                               ATVPGVRISSCTPDLTCAVSTHSTVPGVRISSR                               TPDLTCAVSIHSTVPGVRISSCTPDLTCAVSIH                               ATVPGVRISSCTPDLTCAVSTHSTVPGVRISSR                               TPDLTCAVSIHATVPGVRISSRTPDLTCAVSIH                               ATVPGVRISSCTPDLTCAVSIHATVPGVRISSC                               TPDLTCAVSIHATVPGVRISSRTPDLTCAVSIH                               ATVPGVRISSCTPDLTCAVSTHSTVPGVRISSR                               TPDLTCAVSIHATVPGVRISSCTPDLTCAVSTH                               STVPGVRISSRTPDLTCAVSIHATVPGVHISSC                               TPDLTCAVSTHSTVPGVRISSRTPDLTCAVSIH                               STVPGVCISSRTPDLTCAVSIHSTVPSVHISSCT                               PDLTCAVSIHSTVPGVRISSRTPDLTCAVSTHS                               TVPGVHISSCITDLTCAVSIHATVPGVHISSCT                               PDLTCAVSIHSTVPGVRISSRTPDLTCAVSIHS                               TVPGVRISSRTPDLTCAVSTHSTVPGVRISSRT                               PDLTCAVSTHLTVPGVRISSRTPDLTCAVSIHA                               TVPGVHISSCTPDLTCAVSIHATVPGVRISSRT                               PDLTCAVSIHATVPGVHISSCTPDLTCAVSTHS                               TVPGVRTSSRTPDLTCAVSLHSTVPGVHISSCT                               PDLTCAVSTHSTVPGVHISSCTPDLTCAVSTH                               STVPGVHISSRTPDLTCAVSIHATVPSVHISSC                               TPDLTCAVSIHSTVPGLLTSVSQTSTG               216   1566   A   2477   1   414   FRTKSYRKGSYRCIVSEWIAEQGNWQEIQEK                               AVEVATVVIQPTVLRAAVPKNVSVAEGKELD                               LTCNITTDRADDVRPEVTWSFSRMPDSTLPGS                               RVLARLDRDFLVHSSPHVALSHVDARSYHLL                               VRDVSKENSGYYY               217   1567   A   2480   2   460   CRTLCEGPQRFEEYEYLGYKAGLYEAIADHY                               MQVLVCQHECVRELATRPGRLSPIENFLPLHY                               DYLQFAYYRVGEYVKALECAKAYLLCHPDD                               EDVLDNVDYYESLLDDSIDPASIEAREDLTMF                               VKRHKLESELIKSAAEGLGXSYTEPNYW               218   1568   A   2483   140   383   AFSSPHPSPAPQFPECGFYGLYDKILLFKHDPT                               SANLLQLVRSSGDIQEGDLVEVVLSASATFED                               LQIRPHALTVHSYRAP               219   1569   A   2489   3   428   SSRLVLLAGAAALASGSQGDREPVYRDCVLQ                               CEEQNCSGGALNHFRSRQPIYMSLAGWTCRD                               DCKYECMWVTVGLYLQEGHKVPQFHGKWP                               FSRFLFFQEPASAVASFLNGLASINMLCRYRT                               FVPASSPMYHTCVAFAWVS               220    570   A   2498   1   1297   MDGEAVRFCTDNQCVSLHPQEVDSVAMAPA                               APKIPRLVQATPAPMAVTLVFSLVTLFVVDH                               HHFGREAEMRELIQTFKGHMENSSAWVVEIQ                               MLKCRVDNVNSQLQVLGDHLGNTNADIQMV                               KGVLKDATTLSLQTQMLRSSLEGTNAEIQRL                               KEDLEKADALTFQTLNFLKSSLENTSIELHVL                               SRGLENANSEIQMLNASLETANTQAQLANSS                               LKNANAEIYVLRGHLDSVNDLRTQNQVLRNS                               LEGANAEIQGLKENLQNTNALNSQTQAFIKSS                               FDNTSAEIQFLRGHLERAGDEIHVLKRDLKM                               VTAQTQKANGRLDQTDTQIQVFKSEMENVN                               TLNAQIQVLNGHMKNASREIQTLKQGMKNA                               SALTSQTQMLDSNLQKASAETQRLRGDLENT                               KALTMEIQQEQSRLKTLHVVITSQEQLQRTQ               221   1571   A   2501   3   500   RVRLNNDGLSPLMMAAKTGKIGIFQHIIREEV                               TDEDTRHLSRKFKDWAYGPVYSSLYDLSSLD                               TCGEEASVLEILVYNSKIENRHEMLAVEPINE                               LLRDKWRKFGAVSFYINVVSYLCAMVIFTLT                               AYYQPLEGTPPYPYRTTVDYLRLAGEVITLFT                               GVLFFFTN               222   1572   A   2508   3   395   DAHCQRKLAMQEFMEINERLTELHTQKQKL                               ARHVRDKEEEVDLVMQKVESLRQELRRTER                               AKKELEVHTEALAAEASKDRKLREQSEHYSK                               QLENELEGLKQKQISYSPGVCSIEHQQEITKL                               KTDLEKKS               223   1573   A   2544   2   412   NDPAIISNFSAAVVHTIVNETLESMTSLEVTK                               MVDERTDYLTKSLKEKTPPFSHCDQAVLQCS                               EASSNKDMFADRLSKSIIKHSIDKSKSVLPNID                               KNAVYKESLPVSGEESQLTPEKSPKFPDSQNQ                               LTHCSLSAA               224   1574   A   2552   401   1   GASLCFISTAFTVLTFLIDSCRFSYPERPIIFLSM                               CYNIYSIAYIVRLTVGRERISCDFEEAAEPVLI                               QEGLKNTGCAIIFLLMYFFGMASSIWWVILTL                               TWFLAAGLKWGHEAIEMHSSYFHIAAWAIPA                               VK               225   1575   A   2563   724   1   MSARKERREKGEEEGEGEKDGDEDEKEEEKE                               GLGEEEEKEAGKKKKKQEEKEKEKGAVYSR                               VARICKNDMGGSQRVLEKIIWTSFLKARLNC                               SVPGDSFFYFDVLQSITDIIQINGIPTVVGVFIT                               QLNSIPGSAVCAFSMDDIEKVFKGRFKEQKTP                               DSVWTAVPEDKVPKPRPGCCAKHGLAEAYK                               TSIDFPDETLSFIKSHPLMDSAVPPIADEPWFT                               KTRVRYRLTAISVDHSAGPYH               226   1576   A   2571   449   3   EGVLFVYGNYVGDVMNFEMAAEMAQEVAIP                               TRTVLTTDDISSSPIEDRDGRRGVAGNFFIFKV                               AGAACDRGMSLEACEAVTRKANRRTYTMG                               VALEPCSLPQTRRHNFEIGAEEMEIGMGIHGE                               RGVIREKMMPADAIVDHIMDRIFS               227   1577   A   2575   3   1197   VLSDLCLFYYRDEKEEGILGSILLPSFQIALLTS                               EDHINRKYAFKAAHPNMRTYYFCTDTGKEM                               ELWMKAMLDAALVQTEPVKRVDKITSENAP                               TKETNNIPNHRVLIKPEIQNNQKNKEMSKIEE                               KKALEAEKYGPQKDGQDRPLTKINSVKLNSL                               PSEYESGSACPAQTVHYRPTNLSSSENKIVNVS                               LADLRGGNRPNTGPLYTEADRVIQRTNSMQQ                               LEQWIKIQKGRGHEEETRGVISYQTLPRNMPS                               HRAQIMARYPEGYRTLPRNSKTRPESICSVTP                               STHDKTLGPGAEEKRRSMRDDTMWQLYEW                               QQRQFYNKQSTLPRHSTLSSPKTMVNISDQT                               MNSIPTSPSHGSIAAYQGYSPQRTYRSEVSSPI                               QRGDVTIDRRHRAHHPKVK               228   1578   A   2583   3   330   LPFLGLGSVLPQGMVMASPEMNPTICSVFEA                               HIYLLFHATTFRRGFQVTVLVGNVRQTAVVE                               KIHAKVRGTWPFISPEVRKEGGLPQTGRELLD                               PTMGIKPHLWWVAA               229   1579   A   2589   1   448   DDKNAQGIKRHVKPTSGNAFTICKYPCGKSR                               ECVAPNICKCKPGYIGSNCQTALCDPDCKNH                               GKCIKPNICQCLPGHGGATCDEEHCNPPCQH                               GGTCLAGNLCTCPYGFVGPRCETMVCNRHC                               ENGGQCLTPDICQCKPGWYGPTCSTA               230   1580   A   2593   2   138   AVTFSVVFAYVADITQEHERSMAYGLVCMFI                               LYLLYLLRNAFFLR               231   1581   A   2595   185   2   SGPYTDFTPWPTEEQKLLEQALKTYPVNPPER                               WEKIAEAVPGRTKKACIKRYKVADLRISK               232   1582   A   2596   1   391   STVTGQPRRLLDTAGHQQPFLELKIRANEPGA                               GRARRRTPTCEPATPLCCRRDHYVNFQELGW                               RDWILLPEGYQLNYCSGQCPTHLAGSPGIAAS                               LLYL               233   1583   A   2601   184   403   LLFSDEIIMAAPLRIADVTSGLIGGEDGRVYV                               YNGKETTLGDMTGKCKSWITPCPEEKVNVLQ                               NSIPYWERIT               234   1584   A   2614   178   335   PLTLCLPENNKPPQADAVPDKELTLPVDSTFL                               DGSKSSDDQKIISYLWEKTQ               235   1585   A   2616   2   896   DVLEVYGTGVASTRHEMGTLDKHKELEDLV                               AKFLNVEAAMVFGMGFATNSMNIPALVGKG                               CLILRDEVNHTSLVLGARLLGATIGIFKHNYA                               QSLEKLLRDAVIYGQPRTRRAWKKILILVEGV                               YSMEGSIVHLPQIIALKKKYKAYLYIDEAHSI                               GAVGPTGRGVTEFFGLDPHEVDVLMGTFTKS                               FGASGGYIAGRKARILSPPACLVPNTGSHSLH                               RLTRDLQMNEAMVALVTDRLQGWNSGEGN                               WDRADKFGDLVDYLRVHSHSAVYASSMSPPI                               AEQIIRSLKLIMGLDGTTQ               236   1586   A   2621   1   392   NTSSFPAQPSSPARPSLPHLSQHIPSNPLLPLAS                               ADHPQCGRFLPLHEPEPLCPSPSLSYPTLVSS                               WSSPFSSHHGCPPGLYPFPTSPKTIQPPGLAQL                               KMLGIPPGRQQLRGAQSMPGHGALSPLLLPP                               A               237   1587   A   2628   398   1   DLVCKISGFGRGPRDRSEAVYTTMSGRSPAL                               WAAPETLQFGIIFSSASDVWSFGIIMWEVMAF                               GERPYWDMSGQDVIKAVEDGPRLPPPRNCPN                               LMHRLMLDCWQKDPGERFRFSQIHSILSKMV                               QDPEPPNV               238   1588   A   2631   1   1104   WSPCSLTCGVGLQTRDVFCSHLLSREMNETV                               ILADELCRQPKPSTVQACNRFNCPPAWYPAQ                               WQPCSRTCGGGVQKREVLCKQRMADGSFLE                               LPETFCSASKPACQQACKKDDCPSEWLLSDW                               TECSTSCGEGTQTRSAICRKMLKTGLSTVVNS                               TLCPPLPFSSSIRPCMLATCARPGRPSTKHSPHI                               AAARKVYIQTRRQRKLHFVGGGFAYLLPKTA                               VVLRCPARRVRKPLITWEKDGQHLISSTHVT                               VAPFGYLKIHRLKPSDAGVYTCSAGPAREHP                               VIKLIGGNRKLVARPLSPRSEEEVLAGRKGGP                               KEALQTHKHQNGIFSNGSKAEKRGLAANPGS                               RYDDLVSRLLEQGAPCSSSKKKN               239   1589   A   2636   1   678   MKPDNILLDEHGHVHITDFNIAAMLPRETQIT                               TMAGTKPYMAPEMFSSRKGAGYSFAVDWW                               SLGVTAYELLRGRRPYHIRSSTSSFCEIVHTFET                               TVVTYPSAWSQEMVSLLKKLLEPNPDQRFSQ                               LSDVQNFPYMNDINWDAVPQKRLIPGFIPNK                               GRLNCDPTPELEEMILESKFLHKKKKRLAKK                               EKDMRKCDSSQTCLLQEHLDSVQKEFIIINRE                               KVNRDCI               240   1590   A   2639   389   3   ELLDPTTPMRTKCIELLYAALTSSSTDQPKAD                               LWQNFAREIEEHVFTLYSKNIKKYKTCIRSKV                               ANLKNPRNSHLQQNLLSGITSPREFAEMTVM                               EMANKELKQLRASYTESCIQEHYLPQVIDGTL                               Y               241   1591   A   2640   392   3   IRLTILRCVFMRLATICVLVFTLGSKITSCDDD                               TCDLCGYNQKLYPCWETQVGQEMYKLMIFD                               FIIILAVTLFVDPPRKLLVTYCSSCKLIQCWGQ                               QEFAIPDNVLGIVYGQTICWIGAFFSPLLPAM                               Y               242   1592   A   2642   405   1   YFKNTTLLLVGVICVAAAVEKWNLHKRIALR                               MYLMAGAKPGMLLLCFMCCTTLLSMWLSNT                               STTAMVMPIVEAVLQELVSAEDEQLVAGNSN                               TEEAEPISLDVKNSQPSVELIFVNEDILDFLMK                               SPLMISQACI               243   1593   A   2646   412   2   CLAMIKGIQSSGKIIYFSSLFPYVVLICFLIRAF                               LLNGSIDGIRHMFTPKLEIMLEPKVWREAATQ                               VFFALGLGFGGVIAFSSYNKRDNNCHFDAVL                               VSFINFFTSVLATLVVFAVLGFKANVINEKCIT                               QNSETV               244   1594   A   2650   1   1271   MTTTLIGLLKTARLLRLVRVARKLDRYSEYG                               AAVLMLLMCIFALIAHWLACIWYAIGNVERY                               YLTDKIGWLDSLGQQIGKRYNDSDSSSGPSIK                               DKYVTALYFTFSSLTSVGFGNVSPNTHSEKIF                               SICVMLIGSLMYASIFGNVSAIIQRLYSGTARY                               HMQMLRVKEFIRFHQIPNPLRQRLEEYFQHA                               WTYTNGIDMNMVTNGTCSSCTSDDGHFILVS                               NHHQGGLIYSWNDAASMQRPFNHTKSSLLGS                               TSDSNLNKYSTINKIPQLTLNFSEVKTEKKNSS                               PPSSDKTHAPKVKDRTHNVTEKVTQVLSLGA                               DVLPEYKLQAPRINKFTILHYSPFKAVWDWLI                               LLLVIYTAIFTPYSAAFLLNDREEQKRRECGY                               SCSPLNVVDLIVDIMPIIDILINFRTTYVNQNEE                               VVSDPASV               245   1595   A   2656   385   2   NLTWWPLFRDVSFYIVDLIMLIIFFLDNVIMW                               WESLLLLTAYPCYVVFMICFNVQVEKWVKQ                               MINRNKVVKVTAPEAQAKPSAARDKDEPTLP                               AKPRLQRGGSSASLHNSLMRNSIFQNKIHTLD                               PHV               246   1596   A   2660   200   506   VLVLQMNYYQMLIIYYVLFFKVNEFLAFEGPI                               LLDMRIKHLIKTNQLSQATALAKLCSDHFEIG                               IKGSFKQTYLVCLCTSSPNGKLIEEVSMFSFIS                               NYFLS               247   1597   A   2678   3   267   DAWVKNDIIFNQTERKQKISENLKHLASVRV                               VQKNLVFVVGLSQRLADPEVSPLVFFVIIIFF                               VSLSYLEIIFDPAQLCDSSEHIIS               248   1598   A   2687   1   404   DFTTLAAMMRTLFSLFGDVRSDVHRFSVTLF                               GAATKSVKNPDKKSIENQVLDSLVPLLLYSQD                               ENDAVAEESRQVLTICAQFLKWKLPREVYSK                               DPWHIKPTEAGTICRFFEKKCKGKINILEQTL                               MYSKNPKL               249   1599   A   2692   1   440   FRRRRRERERDCAAQGARRHCRHLAECKLV                               SFPIGIYKVLRNVSGQIHLITLANNELKSLTSK                               FMTTFSQLRELHLEGNFLHRLPSEVSALQHLK                               AIDLSRNQFQDFPEQLTALPALETINLEENEIV                               DVPVEKLAAMPALRSINL               250   1600   A   2693   459   21   LLPGSLGVPILHSQPWDPSPQCPHRAPSTPRRL                               PPLGALSQALTFLSRAAKNHSQDPGKGTKPFP                               AAPAAPPPRSSLPAPLPMGLKDKGPQPAPPTIF                               NSPWHPATLPGALGPQLSQAAPSPIPPPCLMG                               ISSCPDLKLTKSSTP               251   1601   A   2694   2   404   FVFDLKLRVPGFAAILIHGASSVPGPETVRLR                               QKRKKKAPDHSSGRKEELVTTHTVDKLETKK                               PVGRVLCGLSGELLHSLLLPRRKTEKRAIGSH                               RKAGFPEHPVAPEPLSNSCQISKEGREQVLSEI                               GAGDCL               252   1602   A   2697   421   1   PQKSHSGAYQCFATRKAQTAQDFAILALEDG                               TPRIVSSFSEKVVNPGEQFSLMCAAKGAPPPT                               VTWALDDEPWRDGSHRTNQYTMSDGTTISH                               MNVTGPQIRDGGVYRCTARNLVGSAEYQARI                               NVRGPPSIRAMRNIT               253   1603   A   2698   65   401   ACCQWRRTLIPAKSITVSCTISTPHHPFRGSYS                               FDDHITDSEALSRSSHVFFSHPRMLKRQPAIEL                               PLGGEYSSDVPRPLSTQLSSSLLGYPSTLMTG                               AAFTNNIASSTIIL               254   1604   A   2699   438   301   GQIHSQDDPPFIDQLGFGVAPGFQTFVACQEQ                               RVRGPWEAGPGVGY               255   1605   A   2700   1   842   LQNREDSSEGLRKKLVEAEELEEKHREAQVS                               AQIILEVHLKQKEQHYEEKIKVLDNQIKKDLA                               DKETLENMMQRHEEEAIIEKGKILSEQKAMIN                               AMDSKIRSLEQRIVELSEANKLAANSSLFTQR                               NMKAQEEMISELRQQKFYLETQAGKLEAQN                               RKLEEQLEKISHQDHSDKNRLLELETRLREVS                               LEHEEQKLELKRQLTELQLSLQERESQLTALQ                               AARAALESQLRQAKTELEETTAEAEEEIQALT                               VGLGSNIFRLLKASARMSVELALSILAHP               256   1606   A   2701   2   405   FVGGPGADPPVAVMWDPRAARMDLTAYAE                               LLKESGNQVLKNGNFSLAIRKYDEAIQILLQL                               YQWGVPPRDLAVLLCNKSNAFFSLGKWNEA                               FVAAKECLQWDPTYVKGYYRAGYSLLRLHQ                               PYEAARMFFEGLR               257   1607   A   2702   2   399   FVESASSRPPGCFSGDGRFWLVSEGSRRGWD                               FNPSFSFLDPRYSVGGDENIGTVTITLANILREF                               NPSLKGFSVGTGKETSPNAFLNQAVAGGRAE                               DLPVQARRLVDLMKNDTRIHFQEDWKIITLFI                               GGNDL               258   1608   A   2709   1   1097   SVGARQGEARDRIRRFFPKGDLEVLQAQVERI                               MTRKELLTVYSSEDGSEEFETIVLKALVKACG                               SSEASAYLDELRLAVAWNRVDIAQSELFRGDI                               QWRSFHLEASLMDALLNDRPEFVRLLISHGLS                               LGHFLTPMRLAQLYSAAPSNSLIRNLLDQASH                               SAGTKAPALKGGAAELRPPDVGHVLRMLLG                               KMCAPRYPSGGAWDPHPGQGFGESMYLLSD                               KATSPLSLDAGLGQAPWSDLLLWALLLNRA                               QMAMYFWEMGSNAVSSALGACLLLRVMAR                               LEPDAEEAARRKDLAFKFEGMGVDLFGECYR                               SSEVRAARLLLRRCPLWGDATCLQLAMQAD                               ARAFFAQDGVQSLPTQKWWGDMARR               259   1609   A   2721   1   403   VYLGAGPGLFFSNEGAKEGEKANIPKLMLPR                               GGFSQREMVTGERSPSPEEEEEEEEEGFGERA                               SCRRGLFRVRLTRVGLAAPSKASRGQEGDAA                               PKSPVREKSPKFRFPRVSLSPKARSGSGDQEE                               GGLRVRLP               260   1610   A   2728   1   477   LLGGDLRYHLQQNVHFTEGTVKLYICELALA                               LEYLQRYHIIHRDIKPDNILLDEHGHYIIITDFN                               IATVVKGAERASSMAGTKPYMAPEVFQVYM                               DRGPGYSYPVDWWSLGITAYELLRGWRPYEI                               HSVTPTDEILNMFKVERVIIYSSTWCKGMVAL                               LRK               261   1611   A   2730   3   547   LTITDFILVLYRYYRSPLVQIYEIEQHKIETWR                               ETYLQGCFKPLVSISPNDSLFEAVYTLIKNRIH                               RLPVLDPVSGNVLHILTHKRLLKFLIIIFGSLLP                               RPSFLYRTIQDLGIGTFRDLAVVLETAPILTAL                               DIFVDRRVSALAVVNECGTHPQDERLGLGW                               GLGEPGSEERLFPAAITSR               262   1612   A   2733   3   431   GPEFPGSAKLVFLDLSYNNLTQLGAGAFRSA                               GRLVKLSLANNNLVGVHEDAFETLESLQVLE                               LNDNNLRSLSVAAIAALPAIRSLRLDGNPWL                               CDCDFAHLFSWIQENASKLPKGLDEIQCSLPM                               ESRRISLRACRRPASRV               263   1613   A   2736   2   343   PARISGVDPPVRKATKGGENCSFEDNKNWQF                               LWGLNGNFNFFKEPWGGRNNHAKGFRTTW                               ARSSSQNNRTFQNNENFLRLQRDSQKKGQFA                               RLISPLVNLPQSPGGLEFQYQAT               264   1614   A   2738   2   245   RAMLKCLREGQPPPSYNWTRLDGPLPSGVRV                               DGDTLGFPPLTTEHSGIYVRHDTNEFSSRIDSH                               DTVDVLDPPEDSGKQVDL               265   1615   A   2752   2   388   AAGDAPLRSLEQANRTRFPFFSDVKGDHELV                               LAAVETTVLVLIPAVSLLGNVCALVLVARRR                               RRGATACLVLNLFCADLLFISAIPLVLAVRWT                               EAWLLGPVACHLLFYVMTLSGSVTILTLAAV                               SLER               266   1616   A   2755   192   1   AFREVGGYWGLLCEHLYAIPSKTSEGNWTAK                               LQGYLPLQDAFHIFQDPLTGDLPWPELILGLP                               V               267   1617   A   2760   434   714   ASRLEKQNSTPESDYDNTPNDMEPDGMGYM                               HRTSVPGEGLPRARDLAGLGQQKQFITHTPF                               LYFQTHKGLKDSSIRSEVTCLGISQCWRKGFF               268   1618   A   2762   1   405   IACTFCGQDEWSPERSTRCFRRRSRFLAWGEP                               AVLLLLLLLSLALGLVLAALGLFVHHRDSPL                               VQASQGPLACFGINCLGLVCLSVLLFPGQPSP                               ARCLAQQPLSHLPLTGCLSTLFLQAAEIFVESE                               LPLSWAE               269   1619   A   2772   3   243   TRPAEKIQYLVLFFVMSHPSQAYDKLSLSDHL                               LIAVLNLLRREVSEHGRHLQQYFNLFVMYAN                               LSKNLSFSEFCFDVSY               270   1620   A   2789   1   486   ELQSQQACTHTKETEQLRSQLQTLKQQHQQA                               VEQIAKAEETHSSLSQELQARLQTVTRIEKEEL                               LQLSIERGKVLQNKQAEICQLEEKLEIANEDR                               KIIALERFEQEAVAVDSNLRVRELQRKVDGIQ                               KAYDELRLQSEAFKKHSLDLLSKERELNGKL                               RHLSP               271   1621   A   2795   1   568   KEKRVTVQLPTESIQKNQEDKLKMVPEKQRE                               FSGSDRGKLPGSEEKNQGPSMIGRKEERLITE                               RKHEHLKNKSAPKVVKQKVIDAHLDSQTQN                               FQQTQIQTAESKAEHKKLPQPYNSLQEEKCLE                               VKGIQEKQVFSNTKDSKQEITQNKSFFSSVKE                               SQRDDGKGALNIVEFLRKREELHQILSTVKQP               272   1622   A   2797   8   523   KCMQGKYAGAMESEPCVCTEADFDCDYGYE                               RHSNGQCLPAFWFNPSSLSKDCSLGQSYLNST                               GYRKVVSNNCTDGVREQYTAKPQKCPGKAP                               RGLRIVTADGKLTAEQGHNVTLMVQLEEGD                               VQRTLIQVDFGDGIAVSYVNLSSMEDGIXHV                               YQNXGIXRXTVQVDNSLGS               273   1623   A   2801   72   395   HPSRSNVGPRQLTVWNTSNLSHDNRRKYIFS                               DEEGQNQLGIRIHQDIPLPPRREELPALRTTNG                               KADSLNVSRNSVMQELSELEKQIQVIRQELQL                               AVSRKTELEEYH               274   1624   A   2805   168   320   ILWLYFETGTWVYPVFAKLSLLGLAALPSLRE                               IFIARNGVVGETLTHCKRV               275   1625   A   2812   208   321   GSLATCQLSEPLLWFILRVLDTSDALKAFHD                               MGKIIFQ               276   1626   A   2813   41   266   AGRSLHGAGDRAWVGISPTDWSPKVVELCK                               KYQQQTVVAIDLAGDETIPGSSLLPGHVQAY                               QVGPVRRNGEAGPG               277   1627   A   2817   3   410   VLQERLDNFQRKCIQLASSTEGKVDKLLMRN                               LFISYLHTPKHKQHEVLQAMGSILGITGEEME                               PLFQEEHGTATRWMTGWLEGGSKSVPKTPL                               GLNQQPALNGSFSELFVKFLKTESLSSTLPTX                               LPPHNSPGKIK               278   1628   A   2821   238   457   GLSGPSCSCPHSPLPTIISRAQLETALKWRNYE                               VKLRLLLHLEELQMEHDIRHYDLESVPMTWD                               PVDQNPRLV               279   1629   A   2822   342   1   PLIPANLPAHSNPLQPLPSLPHPFLPATHKFPT                               TPPTFSSPPPLPSLSSILHHSPLHSELNPIILQS                               CRLPSRPSVSRELPPQSGPASSVPLAPTPLPDS                               VPSQRHPTXPPPAS               280   1630   A   2825   307   77   PSMVWSYHWGVKQKRLALCVFSFEEGGRRK                               CGQYWPLEKDSRIRFGFLTVTNLTGAVGEPG                               VAFQCDGQRRREPTC               281   1631   A   2827   81   381   KMGTAVWVPKEKEKRDKASQEGGDVLGAR                               QDCTPSLKSLVATGNLLDLEETAKAPLSTVSA                               NTTNMDEVPRPQALSGSSVVWVSGCVASRS                               VILSLTSG               282   1632   A   2830   471   160   KLPXDKYELEPSPLTQYILERKSPHTCWQVFV                               TSSGKYNELGYPPGYLKASTTLTCVNLFVMP                               YNYPVLLPLLDDLFKVIIKLKPNLKWRQAFDS                               YLKTLPPYYL               283   1633   A   2835   462   148   VSPALSLTPTIFSYSPSPGLSPFTSSSGFSFNPEE                               MKHYLHSQACSVFNYHLSPRTFPRYPGLMVP                               PLQCQMHPEESTQFSIKLQPPPVGRKNRERVE                               SSEESAP               284   1634   A   2836   2   384   KTLPRTLLDILADGTILKVGVGCSEDASKLLQ                               DYGLVVRGCLDLRYLAMRQRNNLLCNGLSL                               KSLAETVLNFPLDKSLLLRCSNWDAETLTED                               QVIYAARDAQISVALFLHLLGYPFSRNSPGEK                               KR               285   1635   A   2843   20   271   PIRPYYSYSGLDRDCSWLPLAKAWLPDVMIL                               VCDRVSEDGINRQQAQEWCIKHGFELVELSF                               EELPEEDGKCLCVRRKYGTYI               286   1636   A   2845   197   278   TAEDVLTVAYEHGVNLFDTAEVYAAGK               287   1637   A   2851   2   427   FVAEVRREWAKYMEVHEKASFTNSELHRAM                               NLHVGNLRLLSGPLDQVRAALPTPALSPKDK                               AVLQNLKRILAKVQEMRDQRVSLEQQLRELI                               QKDDITGSLVTTDHSQMKKLFEEQLKKYDQL                               KVYLEQNLAAQDRVLCALT               288   1638   A   2859   2   469   FVNLGILTCIECSGIHREMGAHISRIQSLELDK                               LGTSELLPAKNVGNNSFNDIMEANLPSPSPKP                               TPSSDMTVRKEYITAKYVDHRPSRKTCSTSSA                               KLNELLEAIKSRDLLALIQVYAEGVELMEPLL                               EPGQELAETALHLAVRTADQTSLHLVE               289   1639   A   2861   2   454   FVASGGPATARMSDSQFFCVAEERSGHCAVV                               DGNFLYVWGGYVSIEDNEVYLPNDEIWTYDI                               DSGLWRMHLMEGELPASMSGSCGACINGKL                               YIPGGYDDKGYSNRLYFVNLRTRDETYIWEK                               ITDFEGQPPTPRDKLSCWVYKDRLIYFG               290   1640   A   2868   1   378   FRQGQLYKVFLHGSQGQVYHSQQVGPPGSAI                               SPDLLLDSSGSHLYVLTAHQVDRIPVAACPQF                               PDCASCLQAQDPLCGWCVLQGRCTRKGQCG                               RAGQLNQWLWSYEEDSHCLHIQSLLPGHHPR                               QE               291   1641   A   2870   1   385   FRYMPNNRQQLLRKRHIGNDIVTIVFQEPGAIL                               PFTPKSIRSHFQHVFVIVKVHNPCTENVCYSV                               GVSRSKDVPPFGPPIPKGVTFPKSAVFRDFLL                               AKVINAENAAHKSEKFRAMATRTRQEYLKD                               LA               292   1642   A   2877   3   188   RPTRPPPATTQSPESTMDTSLKKEKSAILDLYI                               PPPPAVPYSPRYVAVHCHGMLVSCWCHL               293   1643   A   2878   1   427   REKEEEVEEEEDKVVKETEKEAEQEKEEDSL                               GAGTHPDAAIPSGERTCGSEGSRSVLDLVNYF                               LSPEKLTAENRYYCESCASLQDAEKVVELSQ                               GPCYLILTLLRFSFDLRTMRRRKILDDVSIPLL                               LRLPLAGGRGQAYDL               294   1644   A   2879   109   245   QLCCFCFRQTTLIVYILSFIGMVIFTFTLDLRYI                               IIVFVTGGVLG               295   1645   A   2880   3   320   LASSQHGIINNLSLLFSICKTCIRTMDHHCPRA                               NNCVGEQNHRFFCALHCKSKHFCIEFTLNTNF                               FNCFLPGAEKSTIDAPFSLQPFLQDSKYNTALS                               LSESISQ               296   1646   A   2892   209   363   SQYSIISLDYHLLQVTKNPFTLGDSSNPGQTE                               RLQEFSQKMDQVRGHWPVST               297   1647   A   2893   8   424   SPXTLXLDTFILLGIQDNWVLILATPPFMAGG                               KLYSTMGRFLRDRKNPACREMAYVLLANLA                               QGDSLAARAIAVQKGSIGHLLGFLEDSLAAT                               QIQQSQASLLHMHNPPFEPTSVDMMRRACRA                               LLALAKVDDNHSEF               298   1648   A   2894   310   445   FWIYFPSFFMTGYLPLGFEFAVEITYPESEGTS                               SGLLNASAQVNL               299   1649   A   2898   1   492   KIKAKNLTNYDLCSIFLGTSTLLVWVGVIRYL                               GYFQAYNVLILTMQASLPKVLRFCACAGMIY                               LGYTFCGWIVLGPYHDKFENLNTVAECLFSL                               VNGDDMFATFAQIQQKSILVWLFSRLYLYSFI                               SLFIYMILSLFIALITDSYDTIKKFQQNGFPETD                               LQEF               300   1650   A   2901   1   445   PVWWNSLNGASEVTFSVHVKDGGSFPKTDST                               TVTVRPVNKADFPKVRAKEQTFMFPENQPVS                               SLVTITITGSSLRGEPMSYYIASGNLGNTFQIDQ                               LTGQVSISQPLDFEKIQKYVYWIEARDGGVPP                               FSSYEKLDITVLDVNDNAPIF               301   1651   A   2902   162   433   THFICLPLGYCFPLLDKDLQLPSGFNCNFDFLE                               EPCGWMYDHAKWLRTTWASSSSPNDRTFPG                               KPAVSEDMKELRPACSTYFNPRFPYKL               302   1652   A   2909   2   412   GPQMLCKKIYFIWVTRSQCQFEWLADIMQEV                               EENDHQDLVSVHIYVTQLAEKFDLRTTMLYI                               CERHFQKVLNRSLFTGLRSITHFGRPPFEPFFN                               SLQEVHPQVRKIGVFSCGPPGMTKNVEKACQ                               LVNRQDRAHFM               303   1653   A   2914   291   453   KLNRWLCFFYSWSFGILLYEMVTLGAPPYPE                               VPPTSILEHLQRRKIMKRPSSCS               304   1654   A   2926   179   354   PGVPSQALRKAESLKKCLSVMEAKVKAQTAP                               NKDVQREIADLGEVGAASLPPSSGPGA               305   1655   A   2938   135   438   GMGYLHAKGILHKDLKSKNVFYDNGKVVIT                               DFGLFSISGVLQAGRREDKLRIQNGWLCHLA                               PEIIRQLSPDTEEDKLPFSKHSDVFALGTIWYE                               LHAREWP               306   1656   A   2944   2   329   VRWNSCVNCSCAFGNGASLSTSLGESSGCLW                               EIGKWLSCSLLSFPSPLAVLIITFCIVTVLGREA                               LTKGALWAVPLLAGSALLCAEVTGVIWRQPE                               SKTKLSFKVSSSA               307   1657   A   2950   2   411   NYLGIAKNSAGSAMGKTRLVVQVPPVIENGL                               PDLSTTEGSHAFLPCKARGSPEPNITWDKDGQ                               PVSGAEGKFTIQPSGELLVKNLEGQDAGTYT                               CTAENAVGRARRRVHLTILVLPVFTTLPGDRS                               LRLGDRLWLR               308   1658   A   2951   1   407   PTRPPRVRFDNEFDAESQRKRTTSVSKMERM                               DSSLPEEEEDEDKEAINGSGNAENRERHSESS                               DWMKTVPSYNQTNSSMDFRNYMMRDETLEP                               LPKNWEMAYTDTGMIYFIDHNTKTITWLDP                               RLCKKAKAPEDC               309   1659   A   2954   2   179   QDFLTLTLTEPTGLLYVGAREALFAFSMEALE                               LQGAVRGGAVGGSRACQRARPRGAVLG               310   1660   A   2959   1   419   QDMMERAIIDTFVGHDVVEPGSYVQMFPYPC                               YTRDDFLFVIEHMMPLCMVISWVYSVAMTIQ                               HIVAEKEHRLKEVMKTMGLNNAVHWVAWFI                               TGFVQLSISVTALTAILKYGQVLMHSHVVIIW                               LFLAVYAVATIMFCF               311   1661   A   2963   3   465   MKPQMPGLGAPNGYGPGRGRAGVPGGPERR                               PWVPHLLPFSSPGYLGVMKAQKPGAGEGMK                               PQKPGLRGTLKPQKSGHGHENGPWPGPCNA                               RVAPMLLPRLPTPGVPSDKEGGWGLKSQPPS                               AVQNGKLPGHQPPNGYGPGAEPGFNGGLEPQ                               KI               312   1662   A   2967   3   405   WLAQEWSPCTVTCGQGLRYRVVLCIDHRGM                               HTGGCSPKTKPHIKEECIVPTPCYKPKEKLPV                               EAKLPWFKQAQELEEGAAVSEEPSFIIPEAWS                               ACTVTCGVGTQVRIVRCQVLLSFSQSVADLPI                               DECEGPKPA               313   1663   A   2969   2   430   VVADNCRQGYLDALRFLERRGLTKEPVLWT                               LVSKEPPAPADGNWDAGCDQRRKGGLSLNW                               KVPHVQVKDVPNFEQLSPELEAALKKACTRD                               PSRWARFWHSGPGQVLTYLLLPCTLPFEYIYF                               RSRRLVVWLPDVPADLWWMQ               314   1664   A   2971   422   33   LDXSHNALQRLRPGWLAPLFQLRALHLDHNE                               LDALGRGVFVNASGLRLLDLSSNTLRALGRH                               DLDGLGALEKLLLFNNRLVHLDEHAFHGLRA                               LSHYLGCNELASFSFDHLHGLSATHLLTLDL                               SSNRM               315   1665   A   2973   1   525   ITVSTHASGSPFGLEPQSGWLWVRAALDREA                               QELYILKVMAVSGSKAELGQQTGTATVRVSI                               LNQNEHSPRLSEDPTFLAVAENQPPGTSVGRV                               FATDRDSGPNGRLTYSLQQLSEDSKAFRIHPQ                               TGEVTTLQTLDREQQSSYQLLVQVQDGGSPP                               RSTTGTVHVAVLDLNDNT               316   1666   A   2978   2   400   ELVVELVSAGKSGPERNTYEVQVVTGNVPKA                               GTDANVYLTIYGEEYGDTGERPLKKSDKSNK                               FEQGQTDTFTIYAIDLGALTKIRIRHDNTGNR                               AGWFLDRIDITDMNNEITYYPPCQRWLAVEE                               DDGQLSRE               317   1667   A   2981   3   440   VLNCQGRPTRPVRINGDGQEVLYLAESDNVR                               LGCPYVLDPDDYGPNGLDIEWMQVNSNPAH                               HRENVFLSYQDICRNHGSLPHLQHRVPFAAS                               DPSQYDASINLMNLQVSDTATYECRVKKTM                               ATPKVIVTVQARPAVPMCWTEGQ               318   1668   A   2995   119   414   LPEKEFPIIRKSSSLKVTKCLFTEQPKPIIILRFA                               ENYDARLLRIDIANTLREQVQELFNKTYGKQ                               RRTPGEGHVAAVDREVAGFPVPAEGISGETIH               319   1669   A   2999   2   332   GFFAYTYGRLVVVEDLHSGAQQHWSGHSAEI                               STLALSHSAQVLASASGRSSTTAHCQIRVWD                               VSGGLCQHLIFPHSTTVLALAFSPDDRLLVTL                               GDHDGRTLALWGTGHL               320   1670   A   3000   693   322   IDESTGLIITVNYLDYETKTSYMMNVSATDQA                               PPFNQGFCSVYITLLNELDEAVQFSNASYEAA                               ILENLALGTEIVRVQAYSIDNLNQITYRFDAY                               TSTQAKALFKIDAITVRGWGQGAPFFPI               321   1671   A   3001   6   383   RIPRGKACXTVLGRSTGELEGFASSRLPPQPC                               GWGQSSDLLSRIDLDELMKKDEPPLDFPDTLE                               GFEYAFNEKGQLRHIKTGEPFVFNYREHLHR                               WNQKRYEALGEIITKYVYELLEKDCNSKKVS               322   1672   A   3007   192   447   ERVRNSLFPGRGDSQCACCPSSPVWVFLETGF                               LFPWLFLQVEVIKKAYMQGEVEFEDGENGK                               DGAASPRNVGHNIYILAHQLARH               323   1673   A   3019   18   245   KELLFYHLIVNNLNFFNTRYAKIHIPIIASVSEH                               QPTTWVSFFFDLHILVCTFPAGLWFCIKNIND                               ERVFGKRGF               324   1674   A   3020   523   797   LCYFSARYHQRKLFGILYIFTLSAINRKEPNLFI                               YLFIFFEMESHSVTHAGVQRHNLNSLQPLPPG                               FKRFSCLCFLSSWNYRGAPPGPANF                325   1675   A   3022   2   156   NDFLPLYFGWVLTKKSSETLRKAGQVFLEEL                               GNHKAFKKELRQCRWQVGAL               326   1676   A   3023   38   172   KMVRGSKKLISFFPGGPYGILAGRDPSKGLAT                               FCLNKEALKDEFE               327   1677   A   3027   1   385   LTLEFLLLPAASELAHGKRLACCIVDHKLPEC                               GFYGLYDKILLFKHDPTSANLLQLVRSSGDIQ                               EGDLVEVVLSASATFEDFQIRPHALTVHSYRA                               PAFCDHCGEMLFGLVRQGLKCDGCGLNYHK                               RC               328   1678   A   3030   13   569   ITRPTISCQRPGPGLAAGMLPYTVNFKVSART                               LTGALNAHNKAAVDWGWQGLIAYGCHSLV                               VVIDSITAQTLQVLEKHKADVVKVKWAREN                               YHHNIGSPYCLRLASADVNGKIIVWDVAAGV                               AQCEIQEHAKPIQDVQWLWNQDASRDLLLAI                               HPPNYIVLWNADTGTKLWKKSYADNILSFSF                               D               329   1679   A   3038   90   744   SVNLPPSLWPWEEAMDSTKSEPLKGSPEAED                               GNIEYKKLVNPSQYRFEHLVTQMKWRLQEG                               RGEAVYQIGVEDNGLLVGLAEEEMRASLKTL                               HRMAEKVGADITVLREREVDYDSDMPRKITE                               VLVRKVPDNQQFLDLRVAVLGNVDSGKSTL                               LGVLTQQELDNGRGRARLNLFRHLHEIQSGR                               TSSISFEILGFNSKGEVHGINGTQWGQTLRMG                               W               330   1680   A   3040   3   397   LCSTLLLLTIPSWVLSQITLKESGPTLMKPTET                               LTLTCTFSGFSLNTSGVGVAWIRQPPGKALE                               WLALIYWDDDKRYSPSLNDRLTIAKDTSPNQ                               VVLTMTNMGPVDTATYYCAQFARGARGSN                               WFDPWGQ               331   1681   A   3043   3   1509   AGIRHEAPPTSNRHRRQIDRGVTHLNISGLK                               MPRGIAIDWVAGNVYWTDSGRDVIEVAQMK                               GENRKTLISGMIDEPHAIVVDPLRGTMYWSD                               WGNHPKIETAAMDGTLRETLVQDNIQWPTG                               LAVDYHNERLYWADAKLSVIGSIRLNGTDPI                               VAADSKRGLSHPFSIDVFEDYTYGVTYINNRV                               PKIHKFGHSPLVNLTGGLSHASDVVLYHQHK                               QPEVTNPCDRKKCEWLCLLSPSGPVCTCPNG                               KRLDNGTCVPVPSPTPPPDAPRPGTCNLQCFN                               GGSCFLNARRQPKCRCQPRYTGDKCELDQC                               EHCRNGGTCAASPSGMPTCRCPTGFTGPKC                               TQQVCAGYCANNSTCTVNQGNQPQCRCLPG                               FLGDRCQYRQCSGYCENFGTCQMAADGSRQ                               CRCTAYFEGSRCEVNKCSRCLEGACVVNKQS                               GDVTCNCTDGRVAPSCLTCVGHCSNGGSCT                               MNSKMMPECQCPPHMTGPRCEEIIVFSQQQP                               GHIASILIP               332   1682   A   3045   3   952   TTTISNFHTQVNRTYCCGTYRAGPMRQISLVG                               AVDEEVGDYFPEFLDMILEESPFLKMTLPWGT                               LSSLRLQCRSQSDDGPIMWVRPGEQMIPTAD                               MPKSPFKRRRSMNEIKNLQYLPRTSEPREVLF                               EDRTRAHADHVGQGFDWQSTAAVGVLKAV                               QFGEWSDQPRITIKDVICFHAEDFTDVVQRLQ                               LDLHEPPVSQCVQWVDEAKLNQMEREGIRY                               ARIQLCDNDIYFIPRNVIHQFKTVSAVCSLAW                               HIRLKQYHPVVEATQNTESNSNMDCGLTGKR                               ELEVDSQCVRIKTESEEACTEIQLLTTASSSFP                               PASE               333   1683   A   3046   497   167   SACSTGPELPGRATRSLTRPANQKGCDGDRL                               YYDGCAMIAMNGSVFAQGSQFSLDDVEVLT                               ATLDLEDVRSYRAEISSRNLAVSAPVDTCVG                               CSSKTWKVAPFVRAWWRP               334   1684   A   3053   37   276   VITDLEEQLNQLTEDNAELNNQNFYLSKQLD                               EASGANDEIVQLRSEVDHLRREITEREMQLTS                               QKQVRRVNKVVRSLEDF               335   1685   A   3054   2   846   WDAWGDWSDCSRTCGGGASYSLRRCLTGR                               NGEGQNIRYKTCSNHDCPPDAEDFRAQQCSA                               YNDVQYQGHYYEWLPRYNDPAAPCALKCH                               AQGQNLVVELAPKVLDGTRCNTDSLDMCISG                               ICQAVGCDRQLGSNAKEDNGGVCAGDGSTC                               RLVRGQSKSHVSPEKREENVIAVPLGSRSVRT                               TVKGPAHLFIESKTLQGSKGEHSFNSPGVFVV                               ENTTVEFQRGSERQTFKIPGPLMADFIFKTRY                               TAAKDSVVQFFFYQPISHQWRQTDFFPCTVT                               CGGG               336   1686   A   3058   54   347   VVGKQEAGAHSDSCCLLHTPPRLTPAHSRKA                               LRNSRIYSQKDDVHVCIMCLRAIMNYQVSRG                               AWDWRLGSPACPHWGLHKLPRLWDPLSLYP                               VLCWGT               337   1687   A   3059   2   709   ILTSLVELTRFETLTPRFSATVPPCWVEVQQE                               QQQRRHPQHLHQQHHGDAAQHTRTWKLQT                               DSNSWDEHVFELVLPKACMVGHVDFKFVLN                               SNITNIPQIQVTLLKNKAPGLGKVNGLRCPF                               LEDHKEDILCGPVWLASGLDLSGIIAGMLTLT                               SPKLVKGMAGGKYRSFLIHVKAVNERGTEEI                               CNGGMRPVVRLPSLKHQSNKGYSLASLLAK                               VAAGKEKSSNVKNENTSGTRK               338   688   A   3060   85   384   KAFYNYHVLELLQMLVTGGVSSQLEQHLDK                               DKVYGVADSCTSLLSGRNRCKLGLLSLHEHL                               SDVNPRNTFGQLFCGSLDLFGILCVGLYRITDE                               EELNP               339   1689   A   3063   236   362   CFLCLSGDFMVMTIFFNVSRRFGYVAFQNYV                               PSSVTTMLSWV               340   1690   A   3065   3   1249   DLWQFTPLHEAASKNRVEVCSLLLSYGADPT                               LLNCHNKSAIDLAPTPQLKERLAYEFKGHSLL                               QAAREADVTRIKKHLSLEMVNFKHPQTHETA                               LHCAAASPYPKRKQICELLLRKGANNEKTKE                               FLTPLHVASEKAHNDVVEVVVKHEAKVNAL                               DNLGQTSLHRAAYCGHLQTCRLLLSYGCDPN                               IISLQGFTALQMGNENVQQLLQEGISLGNSEA                               DRQLLEAAKAGDVETVKKLCTVQSVNCRDIE                               GRQSTPLHFAAGYNRVSVVEYLLQHGADVH                               AKDKGGLVPLHNACSYGHYEVAELLVKHGA                               VVNVADLWKFTPLHEAAAKGKYEICKLLLQ                               HGADPTKKNRDGNTPLDLVKDGDTDIQDLLR                               GDAALLDAAKKGCLARVKKISSPDNVMCRD                               TQGRHSTPLHLAGK               341   1691   A   3070   1   547   GVLIPSFQNQLFADILAGIESVTSEHNYQTLIA                               NYNYDRDSEEESVINLLSYNIDGIILSEKYHTI                               RTVKFLRSATIPVVELMDVQGERLDMEVGFD                               NRQAAFDMVCTMLEKRVRHKILYLGSKDDT                               RDEQRYQGYCDAMMLHNLSPLRMNPRAISSI                               HLRMQLMRDALSANPDLDGVFGTN               342   1692   A   3073   463   3   RINRCRKFSDADILVPGDTISLIGTFSLRIDYNE                               IDDNRVTAEEVDILLREGEKLAPVMAKTRILR                               AYSGVRPLVASDDDPSGRNVSRGIVLLDHAE                               RDGLDGFITITGGKLMTYRLMAEWATDAVC                               RKLGNTRPCTTADLALPGSQEPAKVP               343   1693   A   3075   250   1   LLIYLAIFAPVAMSALAGVKSVQQVRIRAAQS                               LGASRAQVLWFVILPGALPEILTGLRIGLGVG                               WSTLVAAELIAATRGLGFM               344   1694   A   3076   2   138   LYFDAYLQSLQVAAISTFCCLLIGYPLAWAV                               AHSKPSTRNILLLL               345   1695   A   3078   469   3   LKIRGQRIELGEIDRVMQALPDVEQAVTHAC                               VINQAAATGGDARQLVGYLVSQSGLPLDTSA                               LQAQLRETLPPHMVPVVLLQLPQLPLIANGKL                               DRKALPLPELKAQAPGRAPKAGSETIIAAAFS                               SLLGCDVQDADADFFALGCIHSLLAMKLAT               346   1696   A   3082   404   2   QNITSKDLDVRLDPQTVPLELEQLVLSFNHMI                               ERIEDVFTRQSNFSADIAHEIRTPITNLITQTEI                               ALSQSRSQKELEDVLYSNLEELTRMAKMVSD                               MLFLAQADNNQLIPEKKMLNLAHEVGKVFD                               QFEALPE               347   1697   A   3084   3   340   NELTFKEAEISKLYTKVHPAYRTLLEKRQALE                               DEKAKLNGRVTAMPKTQQEIYRLTRDVESGQ                               QVYMQLLNKEQELKITEASTVGDVRIYDPAIT                               QPGVLKPKKGLIILGAI               348   1698   A   3086   723   10   TQAMVWQQKACAEDDPQLSGRHWLHAATL                               YNIAAYPHLKGDDLAEQAQALSNRAYEEAA                               QRLPGTMRQMEFTVPGGAPITGFLHMPKGDG                               PFPTVLMCGGLDAMQTDYYSLYERYFAPRGI                               AMLTIDMFSVGFSSKWKLTQDSSLLHQHVLK                               ALPNVPWVDHTRVAAFGFRFGANVAVRLAY                               LESPRLKAVACLGPVVHTLLSGLKCQQQVPE                               MYLDVLASRLGMHDASTKSSTRENH               349   1699   A   3087   2   249   RIRSSDPEITLAGTPLHAAYLIGMTLICAGFSV                               GPGVAMSQALGPFSLRAGVASSTLGIAQVCG                               SSLWIWLAAVVGIGAWNM               350   1700   A   3099   3   424   EAPEATPQPSQPGPSSPISLSAEEENAEGEVSR                               ANTPDSDITEKTEDSSVPETPDNERKASISYFK                               NQRGIQYIDLSSDSEDVVSPNCSNTVQEKTFN                               KDTVHVSEPSEDEESQGLPTMARRNDDISELE                               DLSGMEDLK               351   1701   A   3108   2   404   IKKNIHGYQLLHRRALFEKRTRLSDYALIFG                               MFGIVVMVIETELSWGAYYKAPLYSLALKCL                               ISLFTIILLGLTIVYHAREIQLFMANYGADDWR                               SALTYEPIFLILLEAIRGVIHATPCRVSLSLWD                               GLDLP               352   1702   A   3110   341   2   AQLAEVCPPQTLLTTNTSSISITAIAAEIKNPER                               VAGLIIFFNPAPVMKLVEVVSGLATAAEVVE                               QLCELTLSWGKQPVRCHSTPGFIYNRVARPY                               YSEAWRALEEQVAAPEVI               353   1703   A   3111   3   188   HFSLFRIAFAVFLTYMTVGLPLPVIPLFVHHEL                               GYGNTMVGIAVGIQFLATVLTRGYAGRLA               354   1704   A   3116   367   225   WQLFHLNGTFLNIGETDTESCVNGWVYDRSS                               FPFSNMTEVRGLVFLS               355   1705   A   3117   101   53   VINLVYLISSPRPELKPVDKESEVVMKFPDQF                               EKFSPPILQLDEVDFYYDPKHVIFSRLSVSADL                               ESRICVVGENGAGKSTMLKLLLGDL\APVRGI                               RHAHENLKIGYFSQHHVGAAGT*TFSACGNL                               LGTQVFLGRPEEEY\RHQLGFGMGISGELGHA                               SSLPACLGGQKEAEVAFGSDGLLPCPNFL\IL\                               DEPTN\HLGHGRAIEALGPCLQTISGVGVILVS                               HR*SALSRLVCRE\LWVC*GRSTSPF               356   1706   A   3121   137   466   RGGRDWGEHNQRLEEHQARAWQGAMDAG                               AASREHARWQGTGLAPGTRVAVAPTCVQGL                               PQERSVCRPFFSSRWREGPVWALGAGAHGKP                               RWSGGVRCVVRGGRWFTPAPH               357   1707   A   3124   1249   229   MLEAPGPSDGCELSNPSASRVSCAGQMLEVQ                               PGLYFGGAAAVAEPDHLREAGITAVLTVDSE                               EPSFKAGPGVEDLWRLFVPALDKPETDLLSH                               LDRCVAFIGQARAEGRAVLVHCHAGVSRSV                               AIITAFLMKTDQLPFEKAYEKLQILKPEAKMN                               EGFEWQLKLYQAMGYEVDTSSAIYKQYRLQ                               KVTEKYPELQNLPQELFAVDPITVSQGLKDE                               VLYKCRKCRRSLFRSSSILDHREGSGPIAFAH                               KRMTPSSMLTTGRQAQCTSYFIEPVQWMESA                               LLGVMDGQLLCPKCSAKLGSFNWYGEQCSC                               GRWITPAFQIHKNRVDEMKILPVLGSQTGKI               358   1708   A   3127   816   139   EVETLGPRTPGPIEAQSPTPGSCPGWQEPSPGP                               TPPP*LSGPGPQGAPVLGKLLPDPEETPAGKTP                               LGKHPWWGL\PVTSANFSPGAAA*FGGALSPP                               GGDL/GHLLQGPPSPFRLQQQ*QTPPGSHSP                               PTANREINPGPAAAADTRSCWGHKRSWRGW                               RGLAPWRLGFGSPGIP*PAPAGIPIGRFTWEGG                               KGAGGKPSETLTRSPPVWRGKRGSANGFLSW                               VQILQ               359   1709   A   3132   3   191   HEHLLLLLLCVFLVKSQGVNDNEEGFFSARG                               HRPLDKKREDAPNLRPALAD\ITVCDYRAQIA                               *AASTPKRAASIAHNAYSCR*AQIA               360   1710   A   3134   1   286   REPPRFALLFF*DRVSLCGPGWNAVVQSQLT                               AAPTSQVQ/SDSPTFPSSWDYRHVPEYPANFL                               *RQGFPMLPRLVSNSWAQTVHPPRPPKVLDL                               QA               361   1711   A   3135   56   1449   PVPAPRVSPSARGAPGRPRLPGVRGPRHSIWA                               AD*RGSRM/PPRAPAPSPTGP/APGGKKVRGR                               VPEDPDAYEPRCSAL*V*PTHVTSPQFCDP*N                               GQIRSYFTVLLRGLNETMLVK/PLCRREP/PEA                               GPGRQSTPAVTRDHRQHEDPRGAGRQWDAD                               PRPSAPIPAEVATGSRPGRHMWMRLCLAAQQ                               APGLPHRTSIRPGWRRLTEPEAWARRHRRPW                               GQRGAVRPPPQGAAPPPSHQGRRTNTDPSAT                               PRLTVMSRCLAPDLKAPASGPRGWRRGMPQ                               SS/GALLWTPPPTPRGSHSPRPREAPLRAIHPA                               GPSKISRAGASGRLPEVIYGWVTLFTPPEAGT                               FILIPSPT*MSPALVIQPPVPPTQMGLRISGLPR                               QG*PSGAPW*LPGLAQLAFQCHLPHDEVGPP               362   1712   A   3136   1270   274   RVGMVLGTREVGDSTPPPSPPLYPFTGNEFVQ                               GQMN*GGSRDWEEGVEEQQVGNKFSSDGR                               VGECSRKLLG*EMLSVDITSRYRAPSTYLLNS                               LKEGLEGLHGESCSSFLLGPSVAMNMQTAGL                               EMDICDGHFRQNGGCGYVLKPDFLRDIQSSF                               HPEKPISPFKAQTLLNQVISVQQLPKVDKTKE                               GSIVDPLVKVQIFGVRLDTARQETNYVENNG                               FNPYWGQTLCFRVLGPDFPMLRFGKMDYDW                               KSRNDLLGKTPCPGTCMQQGYRHIIHLLSKDCI                               ISLRPASIFVYICIQEGLEGDES               363   1713   C   3139   60   248   MFAGSYGKSMFSFSKKVLNCLPKWRYHFVIA                               PAMNESPLAPHLHQHLVFSVFQVLTILIGV**               364   1714   A   3140   57   418   SAFKTLQLPAFSLYFDLGSLKLLILRIHTSIVK                               NHKVESPRTMSPG*DPQSFLQIPQPRPPQLRV                               GLTSGLIQHFHSPSSCQFPLLRGPPFPRQPPLGI                               SGASLCPVLSPPR*PLQPSSL               365   1715   A   3145   122   413   LLPYPSLFVFLRQCHFVT\RLECNGVVSAHCN                               LHLPGSSDSPASAS*VAGTTGVCHHTRUF\VF                               LV*TGFHYVAQAGLELLTA*S\PPQLPKVVGL                               QA               366   1716   A   3150   247   2   VGEKLHDIRFGNDFDMTPKAQATKEKIDKLN                               FIKLKKLCIEGYYINREPQNGRKIFANYVS\DK                               GLMATIYEELLKLSNKLIQ               367   1717   A   3152   3   2367   QKLKQNQPKRAHVEDGGSRSKQGNEQSKKT                               PIEKSDFAAATHPRAFYLSKPDETPNAWMSD                               SGTGLTYWKLEEKDMHHSLPETLEKTFISLSS                               TDVSPNQVLTLDPTLHMKPKQQISGIQPHGLP                               NALDDRISFSPDSVLEPSMSSPSDIDSFSQASN                               VTSQLPGFPKYPSHTKASPVDSWKNQTFQNE                               SRTSSTFPSVYTTTSNDISVNTVDEENTVMYAS                               ASVSQSQLPGTANSVPECISLTSLEDPVILSKIR                               QNLKEKHARHIADLRAYYESEITNSLKQKLEA                               KEISGVEDWKITNQILVDRCGQLDSALHEATS                               RVRTLENKNNLLEIEVNDLRERFSAASSASKI                               LQERIEEMRTSSKEKDNTIIRLKSRLQDLEEAF                               ENAYKLSDDKEAQLKQENKMFQDLLGEYES                               LGKEHRRVKDALNTTENKLLDAYTQISDLKR                               MISKLEAQVKQVEHENMLSLRHNSRIHYRPS                               RANTLATSDVSRRIKWLIPQAEYSIFTGQPLDT                               QDSNVDNQLEETCSLGHRSPLEKDSSP/GSSST                               SLLIICKQRETSDTPIMRALKELDEGKIFKNWG                               TQTEKEDTSNSLL*IINPRQTETSVNASRSPEK                               CAQQRQKRLNSASQRSSSLPPSNRKSSTPTKR                               EIMLTPVTVAYSPKRSPKENLSPGFSHLLSKN                               ESSPIREKTYSEKATDNHVNHSSCPEPVFNGV                               KKVSVRTAWEKNICSVSYEQCKPVSVTPQGN                               DFEYTAKLIRTLAETERFFDELTKEKDQIEAAL                               SRMPSPGGRITLQTRLNQVKCLSLNLL               368   1718   A   3163   2   2350   EFKSGGCGAGLVAAGAVLVLYPASRAGERT                               RVPGSPAPSSLPLHSPGACGTEVDMDPQRSPL                               LEVKGNIELKRPLIKALPSQLPLSGSRLKRRPDQ                               MEDGLEPEKKRTRGLGATTKITTSHPRVPSLT                               TVPQTQGQTTAQKVSKKTGPRCSTAIATGLK                               NQKPVPAVPVQKSGTSGVPPMAGGKKPSKRP                               AWDLKGQLCDLNAELKRCRERTQTLDQENQ                               QLQDQLRDAQQQVKALGTERTTLEGHLAKV                               QAQAEQGQQELKNLRACVLELEERLSTQEGL                               VQELQKKQVELQEERRGLMSQLEEKERRLQT                               SEAALSSSQAEVASLRQETVAQAALLTEREER                               LHGLEMERRRLHNQLQELKGNIRVFCRVRPV                               LPGEPTPPPGLLLFPSGPGGPSDPPTRLSLSRSD                               ERRGTLSGAPAPPTRHDFSFDRVFPPGSGQDE                               VFEEIAMLVQSALDGYPVCIFAYGQTGSGKTF                               TMEGGPGGDPQLEGLIPRALRHLFSVAQELSG                               QGWTYSFVASYVEIYNETVRDLLATGTRKGQ                               GGECEIRRAGPGSEELTVTNARYVPVSCEKEV                               DALLHLARQNRAVARTAQNERSSRSHSVFQL                               QISGEHSSRGLQCGAPLSLVDLAGSERLDPGL                               ALGPGERERLRETQAINSSLSTLGLVIMALSN                               KESHVPYRNSKLTYLLQNSLGQSAKMLMFV                               NISPLEENVSESLNSLRFASKVEPSVLFGTAQS                               NRKWKTDPDLCVCVCVCVCVCVCVCVCVP                               MSMYRVRGGRVAGGCFIGWRAPCPRAIK               369   1719   A   3165   365   12   GYTSQGRWIDIERGPLTANTESLHENNFNALP                               GYIRKIE*I*IYKKN*INFGGVGLLNIVKISILSIK                               IYRFDAIPVKILTRFFINLDKLILKFVLKTKIAK                               NRIKTFYIMRRKKLGDSS               370   1720   A   3170   393   42   GASISPSAVIDGVEGLKPMQEQEAQEAGPCLD                               *HMAPEQWVAP\RLLFRLIFSVLHALIIAAAA                               QSSAEEDEDPRN*GQSSEDQAPNQNGLIVIVH                               RVHVPLGAAATVPVHRSHFPR               371   1721   A   3173   770   510   GNGGCGLSQLPPSHLGAFSRGSLLSRG\DPRGP                               PPHPVIFFVFVVE\QGFTVLARMVSIS*PCDPP                               ALASQSAGITGVSHLARPQNLYF               372   1722   A   3180   381   76   RVLHHDNVPAHSSPQKREISQEFQLEIRHLP*S                               PDLAPSGCFLFLNLKNTFK\GTHFSLVDNVKK                               TVSTWLHISQNAQFYKDRLNGWYHCLQKCL                               QHY*AYVEK               373   1723   A   3181   410   14101   RREVAGPEGKGLLLASAHTMLTPPLLLLLPLL                               SALVAAAIDAPKTCSPKQFACRDQITCISKGW                               RCDGERDCPDGSDEAPEICPQSKAQRCQPNE                               HNCLGTELCVPMSRLCNGVQDCMDGSDEGP                               HCRELQGNCSRLGCQHHCVPTLDGPTCYCNS                               SFQLQADGKTCKDFDECSVYGTCSQLCTNTD                               GSFICGCVEGYLLQPDNRSCKAKNEPVDRPP                               VLLIANSQNILATYLSGAQVSTITPTSTRQTTA                               MDFSYANETVCWVHVGDSAAQTQLKCARM                               PGLKGFVDEHTINISLSLHHVEQMMDWLTGN                               FYFVDDIDDRIFVCNRNGDTCVTLLDLELYNP                               KGIALDPAMGKVFFTDYGQIPKVERCDMDG                               QNRTKLVDSKWFPHGITLDLVSRLVYWADA                               YLDYIEVVDYEGKGRQTIIQGILIEHLYGLTVF                               ENYLYATNSDNANAQQKTSVIRVNRFNSTEY                               QVVTRVDKGGALHIYHQRRQPRVRSHACEN                               DQYGKPGQCSDICLLANSHKARTCRCRSGFS                               LGSDGKSCKPEHELFLVYGKGRPGIIRGMD                               MGAKVPDEHMIPIENLMNPRALDFHAIETGFI                               YFADTTSYLIGRQKIDGTERETILKDGIHNVE                               GVAVDWMGDNLYWTDDGPKKTISVARLEK                               AAQTRKTLIEGKMTHPRAIVVDPLNGWMYW                               TDWEEDPKDSRRGRLERAWMDGSHRDIFVT                               SKTVLWPNGLSLDIPAGRLYWVDAFYDRIETI                               LLNGTDRKIVYEGPELNHAFGLCHHGNYLFW                               TEYRSGSVYRLERGVGGAPPTVTLLRSE\RPPI                               PEIR\MYDAQHQQVGSNKCRVNNAGCSSLCL                               ATPGSRQCACAEDQVLDADGVTCLANPSYVP                               PPQCQPGEFACANSRCIQERWKCDGDNDCLD                               NSDEAPALCHQHTCPSDRFKCENNRCIPNRW                               LCDGDNDCGNSEDESNATCSARTCPPNQFSC                               ASGRCIPISWTCDLDDDCGDRSDESASCAYPT                               CFPLTQFTCNNGRC1NINWRCDNDNDCGDNS                               DEAGCSHSCSSTQFKCNSGRCIPEHWTCDGD                               NDCGDYSDETHANCTNQATRPPGGCHTDEF                               QCRLDGLCIPLRWRCDGDTDCMDSSDEKSCE                               GVTHVCDPSVKFGCKDSARCISKAWVCDGD                               NDCEDNSDEENCESLACRPPSHPCANNTSVC                               LPPDKLCDGNDDCGDGSDEGELCDQCSLNN                               GGCSHNCSVAPGEGIVCSCPLGMELGPDNHT                               CQIQSYCAKHLKCSQKCDQNKFSVKCSCYEG                               WVLEPDGESCRSLDPFKPFITFSNRHEIRRIDLH                               KGDYSVLVPGLRNTIALDFHLSQSALYWTDV                               VEDKIYRGKLLDNGALTSFEVVIQYGLATPEG                               LAVDWIAGNIYWVESNLDQIEVAKLDGTLRT                               TLLAGDIEHPRAIALDPRDGILFWTDWDASLP                               RIEAASMSGAGRRTVHRETGSGGWPNGLTV                               DYLEKRILWIDARSDAIYSARYDQSGHMEVL                               RGHEFLSHPFAVTLYGGEVYWTDWRTNTLA                               KANKWTGHNVTVVQRTNTQPFDLQVYHPSR                               QPMAFNPCEANGGQGPCSHLCLTNYNRTVSC                               ACPHLMKLHKDNTTCYEFKKFLLYARQMEIR                               GVDLDAPYYNYIISFTVPDIDNVTVLDYDARE                               QRVYWSDVRTQAIKRAFINGTGVETVVSADL                               PNAHGLAVDWVSRNLFWTSYDTNKKQINVA                               RLDGSFKNAVVQGLEQPHGLVVHPLRGKLY                               WTDGDNISMANMDGSNRTLLFSGQKGPVGL                               AIDFPESKLYWISSGNIITINRCNLDGSGLEVID                               AMRSQLGKATALATMGDKLWWADQVSEKM                               GTCSKADGSGSVVLRNSTTLVMHMKVYDESI                               QLDHKGTNFCSVNNGDCSQLCLPTSETTRSC                               MCTAGYSLRSCIQQACEGVGSFLLYSVHEGIR                               GIPLDPNDKSDALVPVSGTSLAVGIDFHAEND                               TTYWVDMGLSTISRAKRDQTWREDVVTNGIG                               RVEGIAVDWIAGNIYWTDQGFDVIEVARLNG                               SFRYVVISQGLDKPRAITVHPEKGYLFWTEW                               GQYPRIERSRLDGTERVVLVNVSISWTPNGISV                               DYQDGKLYWCDARTDKIERIDLETGENREVV                               LSSNNMDMFSVSVFEDFIYWSDRTHANGSIK                               RGSKDNATDSVPLRTGIGVQLKDIKVFNEDR                               QKGTNVCAVANGGCQQLCLYRGRGQRACA                               CAHGMLAEDGASCREYAGYLLYSERTILKSI                               HLSDERNLNAPVQPFEDPEHMKNVIALAFDY                               RAGTSPGTPNRIFFSDIHFGNIQQLNDDGSRRIT                               IVENVGSVEGLAYHRGWDTLYWTSYTTSTTT                               RHTVDQTRPGAFERETVITMSGDDHPRAFVL                               DECQNLMFWTNWNEQHPSIMRAALSGANVL                               TLIEKDIRTPNGLAIDHRAEKLYFSDATLDKIE                               RCEYDGSHRYVILKSEPVHPFGLAVYGEHIF                               WTDWVRRAVQRANKHVGSNMKLLRVDIPQ                               QPMGIIAVANDTNSCELSPCRINNGGCQDLCL                               LTHQGHVNCSCRGGRILQDDLTCRAVNSSCR                               AQDEFECANGECINFSLTCDGVPHCKDKSDE                               KPSYCNSRRCKICTPRQCSNGRCVSNMLWCN                               GADDCGDGSDEIPCNKTACGVGEFRCRDGTC                               IGNSSRCNQFVDCEDASDEMNCSATDCSSYF                               RLGVKGVLFQPCERTSLCYAPSWVCDGAND                               CGDYSDERDCPGVKRPRCPLNYFACPSGRCIP                               MSWTCDKEDDCEHGEDETHCNKFCSEAQFE                               CQNHRCISKQWLCDGSDDCGDGSDEAAHCE                               GKTCGPSSFSCPGTHVCVPERWLCDGDKDCA                               DGADESLAAGCLYNSTCDDREFMCQNRQCIP                               KHFVCDHDRDCADGSDESPECEYPTCGPSEF                               RCANGRCLSSRQWECDGENDCHDQSDEAPK                               NPHCTSPEHKCNASSQFLCSSGRCVAEALLCN                               GQDDCGDSSDERGCHINECLSRKLSGCSQDC                               EDLKIGFKCRCRPGFRLKDDGRTCADVDECS                               TTFPCSQRCINTHGSYKCLCVEGYAPRGGDP                               HSCKAVTDEEPPLIFANRYYLRKLNLDGSNY                               TLLKQGLNNAVALDFDYREQMIYWTDVITQ                               GSMIRRMHLNGSNVQVLHRTGLSNPDGLAV                               DWVGGNLYWCDKGRDTIEVSKLNGAYRTVL                               VSSGLREPRALVVDVQNGYLYWTDWGDHSL                               IGRIGMDGSSRSVIVDTKITWPNGLTLDYVTE                               RIYWADAREDYIEPASLDGSNRHVVLSQDIPH                               IFALTLFEDYVYWTDWETKSINRAHKTTGTN                               KTLLISTLHRPMDLHVFHALRQPDVPNHPCK                               VNNGGCSNLCLLSPGGGHKCACPTNFYLGSD                               GRTCVSNCTASQFVCKNDKCIPFWWKCDTE                               DDCGDHSDEPPDCPEFKCRPGQFQCSTGICTN                               PAFICDGDNDCQDNSDEANCDLHVCLPSQFK                               CTNTNRCIPGIFRCNGQDNCGDGEDERDCPE                               VTCAPNQFQCSITKRCIPRVWVCDRDNDCVD                               GSDEPANCTQMTCGVDEFRCKDSGRCTPARW                               KCDGEDDCGDGSDEPKEECDERTCEPYQFRC                               KNNRCVPGRWQCDYDNDCGDNSDEESCTPR                               PCSESEFSCANGRCIAGRWKCDGDHDCADGS                               DEKDCTPRCDMDQFQCKSGHCIPLRWRGDA                               DADCMDGSDEEACGTGVRTCPLDEFQCNNT                               LCKPLAWKCDGEDDCGDNSDENPEECARFV                               CPPNRPFRCKNDRVCLWIGRQCDGTDNCGD                               GTDEEDCEPPTAHTTHCKDKKEFLCRNQRCL                               SSSLRCNMFDDCGDGSDEEDCSIDPKLTSCAT                               NASICGDEARCVRTEKAAYCACRSGFHTVPG                               QPGCQDINECLRFGTCSQLCNNTKGGHLCSC                               ARNFMKTHNTCKAEGSEYQVLYLADDNEIRS                               LFPGHPHSAYEQAFQGDESVRIDAMDVHVKA                               GRVYWTNWHTGTISYRSLPPAAPPITSNRHR                               RQIDRGVTHLNISGLKMPRGIADWVAGNYY                               WTDSGRDVIEVAQMKGENRKTLISGMIDEPH                               AIVVDPLRGTMYWSDWGNIIPKIETAAMDGT                               LRETLVQDNIQWPTGLAVDYHNERLYWADA                               KLSVIGSIRLNGTDPIVAADSKRGLSHPFSIDV                               FEDYIYGVTYINNRVFKIHKFGHSPLVNLTGG                               LSHASDVVLYHQHKQPEVTNPCDRKKCEWL                               CLLSPSGPVCTCPNGKRLDNGTCVPVPSPTPP                               PDAPRPGTCNLQCFNGGSCFLNARRQPKCRC                               QPRYTGDKCELDQCWEHCRNGGTCAASPSG                               MPTCRCPTGFTGPKCTQQVCAGYCANNSTCT                               VNQGNQPQCRCLPGFLGDRCQYRQCSGYCE                               NFGTCQMAADGSRQCRCTAYFEGSRCEVNK                               CSRCLEGACVVNKQSGDVTCNCTDGRVAPS                               CLTCVGHCSNGGSCTMNSKMMPECQCPPHM                               TGPRCEEHVFSQQQPGHIASILIPLLLLLLLVL                               VAGVVFWYKRRVQGAKGFQHQRMTNGAM                               NVEIGNPTYKMYEGGEPDDVGGLLDADFAL                               DPDKPTNFTNPVYATLYMGGHGSRHSLASTD                               EKRELLGRGPEDEIGDPLA               374   1724   A   3187   191   1815   CLELASAGKIPEESKALSLLAPAPTMTSLMPG                               AGLLPIPTPNPLTTLGVSLSSLGAIPAAALDPNI                               ATLGEIPQPPLMGNVDPSKIDEIRRTVYVGNL                               NSQTTTADQLLEFFKQVGEVKFVRMAGDET                               QPTRFAFVEFADQNSVPRALAFNGVMFGDRP                               LKINHSNNAIVKPPEMTPQAAAKELEEVMKR                               VREAQSFISAAIEPGWLHSTSLCNDFLGCF*RR                               RMYRE*APCTICGTFHLCIINWDL*LF*AYTA                               K*FFPPRVWKEQ*KKRR\RSRSHTRSKSRSSSK                               SHSRRKRSQSKHRSRSHNRSRSRQKDRRRSK                               SPHKKRSKSRERRKSRSRSHSRDKRKDTREKI                               KEKERVKEKDREKEREREKEREKEKERGKN                               KDRDKEREKDREKDKEKDREREREKEGEKD                               RDKEKEKEQDKEKEREKDRSKEIDEKRKKDK                               KSRTPPRSYNASRRSRSSSRERRRRRSRSSSRS                               PRTSKTIKRKSSRSPSPRSRNKKDKKREKERD                               HISERRERERSTSMRKSSNDRDGKEKLEKNST               375   1725   A   3192   415   101   AHSSHQTRAILQEFQWDIIRHPPL\SPNLALSG                               FWPNLKKSLRGTHFSSVKK\TTLTWLNSQDP                               WFIFFYP*SPDLQIPSSFRNGLNDWYHHSQKC                               PDLDGAYVKK               376   1726   A   3199   931   418   GV*WCDLGSPQPPPPGFKQFCLGRSSSWDYR                               HVPPHPANFVFLLETGFLHAGQAGL\GDPPAS                               ASQSAQITGVSHTWPKNHLIFYACLVIRSKRI                               K               377   1727   A   3201   274   1285   KTCIYTSRGSPLSPQSSIDSELSTSELEDDSISM                               GYKLQDLTDVQIMARLQEESLRQDYASTSAS                               VSRHSSSVSLSSGKKGTCSDQEYDQYSLEDEE                               EFDHLPPPQPRLPRCSPFQRGIPHSQTFSSIREC                               RRSPSSQYFPSNNYQQQQYYSPQAQTPDQQP                               NRTNGDKIPPKKYA*PSPDAKYNCH**QH\SSP                               VTVRNSQSFDSSLHGAGNGISRIQSCIPSPGQL                               QHRVHSVGIIFPVSIRQPLKATAYVSPTVQGSS                               NMPLSNGLQLYSNTGIPTPNKAAASGIMGRS                               ALPRPSLAINGSNLPRSKIAQPVRSFLQPPKPL                               SSLSTLRDGNWRDGCY               378   1728   A   3202   112   1789   VPGVTESEPSVLRGDHLFALLSSETHQEDPIT                               YKGFVHKV\ELDRVKLSFSMSLLSRFVGWG*                               PFKVNFY/TFNRQPLRV\QHRALELTGRWLLW                               PMLFP\VAPRDVPLLPSDVKLKLYDRSLESNF                               EQLQAMRHIVTGTTRPAPYIIFGPPGTGKTVT                               LVEAIKQVVKHLPKAHILACAPSNSGADLLC                               QRLRVHLPSSIYRLLAPSRDIRMVPEDIKPCCN                               WDAKKGEYVFPAKKKLQEYRVLITTLITAGR                               LVSAQFPIDIIFTHIPIDEAGHCMEPESLVAIAG                               LMEVKETGDPGGQLVLAGDPRQLGPVLRSPL                               TQKHGLGYSLLERLLTYNSLYKKGPDGYDPQ                               FITKLLRNYRSHPTILDIPNQLYYEGELQACA                               DVVDRERFCRWAG\LPRQGFPIIFHGVMGKD                               EREGNSPSFFNPEEAATVTSYLKLLLAPSSKK                               GKAELSPRSVGVISPYRKQVEKIRYCITKLDR                               ELRGLDDIKDLKVTCCSTVTPCLPCAPTCPLP                               ETSSSFHSSPRPRPTPAALNRARALPEPLTPGD                               SNLRVWDGIRKPAGLTNTSCHS               379   1729   A   3206   432   130   PKAAPSVXLWFPPFL*GSFKPTKGHTXCVXIK                               *LSTREAXDSXPGRQIAXXRQGGKVETTTAL                               XKQSNNKGTRASSYXEPDAXEQWKFPHKKL                               QLPGXTHE               380   1730   A   3207   187   507   GGTGHPHPARPPLSGVGGCQCSHSKPWTAGS                               PEQRDHPAPHKQIEAGQGLPGPQAWGG*KGP                               AXLLPGPGGGPGPVASLEARAQASSGVTPNG                               GGRTYPYPTFSSGE               381   1731   A   3225   1   840   GTRPGHLPAPSDGFCV/HL*SIPSWGSF*GESL/                               EMQLITSLGLQEFDIARNVLELIYAQTLVWIGI                               FFCPLLPFIQMIMLFIMFYSKNISLMMNFQPPS                               KAWRASQMMTFFIFLLFFPSFTGVLCTLAITI                               WRLKPSADCGPFRGLPLFIHSIYSWIDTLSTRP                               GYLWVVWIYRNLIGSVHFFFILTLIVLIITYLY                               WQITEGRKIMIRLLHEQIINEGKDKMFLIEKLI                               KLQDMEKKANPSSLVLERREVEQQGFLHLGE                               HDGSLDLRSRRSVQEGNPRA               382   1732   A   3238   256   38   LLMIKVSSTCFSCHLHHHHHHIHHRHHQGHNS                               LFFSLKSSSNSSTLPVYLSYNTILVFSKCLVFDF                               LFSNACL               383   1733   A   3241   1542   343   KGAPSFVRLYQYPNFAGPHAALANKSFFKAD                               KVTMLWNKKATAVLVIASTDVDKTGASYYG                               EQTLHYIATNGESAVVQLPKNGPIYDVVWNS                               SSTPCAVYGPMPAKATIIFNLKCDPVFDPGTG                               PRNAAYYSPHGHILVLAGFGNLILQI*AD/IMK                               VWNVKNYKLISKPVASDSTYFAWCPDGEHIL                               TATCAPRLRVNNGYKIWHYTGSTLHKYDVPS                               NAELWQVSWQPFLDGIFPAKTITYQAVPSEVP                               NEEPKVATAYRPPALRI\IKFITNSKLHEEEPPQ                               NMKPQSGNDKPLSKTALKNQRKHEAKKAAK                               QEARSDKSPDLAPTPAPQSTPRNTVSQSISGDP                               EIDKKIKNLKKKLKALEQLKEQAATGKQLEK                               NQLEKIQKETALLQELEDLELGI               384   1734   A   3242   3   678   IRSPAARSPGLETPTCLLFVIAAIAAVFVDSAIP                               RLTQHRPQDGSFPYTILDPPLYLPGQCAPPQP                               LSQCARRVHGEKLRRPTFGPRHRGAGTAKMS                               ASLVRATVRAVSKRKLQPTRAALTLTPSAVN                               KIKQLLKDKPEHVGVKVGVRTRGCNGLSYTL                               EYTKTKGDSDEEVIQDGVRVFIEKKAQLTLL                               GTEMDYVEDKLSSEFVFNNPNIKGTCGCGES                               FNI               385   1735   A   3243   3190   664   VAMGTPRAQIIPPPPQLLFLILLSCPWIQGLPL                               KEEEILPEPGSETPTVASEALAELLHGALLRR                               GPEMGYLPGPPLGPEGGEEETTTTIITTTTVTT                               TVTSPVLCNNNISEGEGYVESPDLGSPVSRTL                               GLLDCTYSIHVYPGYGIEIQVQTLNLSQEEELL                               VLAGGGSPGLAPRLLANSSMLGEGQVLRSPT                               NRLLLHFQSPRVPRGGGFRIHYQAYLLSCGFP                               PRPAHGDVSVTDLHPGGTATFHCDSGYQLQG                               EETLICLNGTRPSWNGETPSCMASCGGTIHNA                               TLGRIVSPEPGGAVGPNLTCRWVIEAAEGRRL                               HLHFERVSLDEDNDRLMVRSGGSPLSPVWDS                               DMDDVPERGLISDAQSLYVELLSETPANPLLL                               SLRFEAFEEDRCFAPFLAHGNVTTTDPEYRPG                               ALATFSCLPGYALEPPGPPNAIECVDPTEPHW                               NDTEPACKAMCGGELSEPAGVVLSPDWPQS                               YSPGQDCVWGVHVQEEKRILLQVEILNVREG                               DMLTLFDGDGPSARVLAQLRGPQPRRRLLSS                               GPDLTLQFQAPPGPPNPGLGQGFVLHFKEVPR                               NDTCPELPPPEWGWRTASHGDLIRGTVLTYQ                               CEPGYELLGSDILTCQWDLSWSAAFPACQKI                               MTCADPGEIANGHRTASDAGFPVGSHVQYRC                               LPGYSLEGAAMLTCYSRDTGTPKWSDRVPKC                               ALKYEPCLNPGVPENGYQTLYKHHYQAQESL                               RFFCYEGFELIGEVTITCVPGHPSQWTSQPPLC                               KVTQTTDPSRQLEGGNLALAILLPLGLVIVLG                               SGVYIYYTKLQGKSLFGFSGSHSYSPITVESDF                               SNPLYEAGDTREYEVSI               386   1736   A   3250   5725   3984   GTSTVTMATKKHFSIILNLLGMLLKKDNQDT                               RKLLMTWALEVAVVMKKSETYAPLFCLPSF                               HKFCKGLLADTLVEDVNICLQACSSLHALSSS                               LPDDLLQRCVDVCRVQLVHRGTCIRQAFGKL                               LKSIPLGVFLSNNNHTEIQEISLALRSHMSKAP                               SNTFHPQDFSD/VISFILYGNSHRTGKDNWLE                               RLFYSCQRLDKRDQSTIPRNLLKTDAVLWQW                               AIWEAAQFTVLSKLRTPLGRAQDTFQTIEGIIR                               SLAGHTLNPDQDVSQWTITADNDEGHGNNQL                               RLVLLLQYLENLEKLMYNAYEGCANALTSPP                               KVIRTFLYTNRQTCQDWLTRIRLSIMRVGLLA                               GQPAVTVRHGFDLLTEMKTTSLSQGNELEVSI                               MMVVEALCELHCPEAIQGIAVWSSSIVGKHL                               LWINSVAQQAEGRFEKASVEYQEHLCAMTG                               VDCCISSFDKSVLTLASAGCKSASLKHCLNGE                               SRKSVLSKPTDSSPEVENYLGNKACECYISTA                               DWAAVQEWQNAIHDLKKSTSSTSLNLKADF                               NYIKSLSSFESGKFVECTEQLELLPGENTNLLA                               GGSKEKIDMKKLLRNM               387   1737   A   3255   380   76   MD1FLYNCKYQVQTE1*NSIQHIMA\SKKLSRF                               LKYVHNL*AENYKTLMK*INEDLNKQRDVPY                               S*TARLNKMSIPTKTIFRFKAIYIKIPATYFIET                               NMQ               388   1738   A   3260   685   428   PQWLGLQVYALPPANFVFFVEMRSTILAQTG                               FELLDSSDLPASASKSAGITCMSHHARTLSLK                               *WPFCLSATQEKFC*PASEGVAW               389   1739   A   3269   1   332   LDGYHTPIYMLNRIIRLPAAL*IISDQTGHALTI                               LTRLETQMINADYQNKLTLDYLLTTDREVYE                               PFNLTNYCLHIHNQRLGAYDLG*V*Q/KLAHV                               PVQV*HGFDPEAIVIFR               390   1740   A   3270   2   372   GRCHDQNKGKS\DGPDAQAEACGGESTYQEL                               LVNQNPIGQPLACRRLTRKIYEGIKKAVKPNII                               SPRGVKKVHKFVNKGEKGIMVLAGDTLGIGV                               YCLLPCMC*DPKLTYAHIPSTTDLGAGAGY               391   1741   A   3273   1   187   FFQEMLDIMKAISDMMGKCTYPVLKEDAPRQ                               HVETFFQ\EELTRSQEGMKLGENFLMFAMPP                               DDSKESKGK*FFQEMLDIMKAISDMMGKCTY                               PVLKEDAPRQHVETFPQVGTNQKSRGHEVRR                               KFPDVCHAPR               392   1742   A   3281   901   521   FFFGDGVSPCRQAGV*WHDLDSLQNLPPGFK                               RFSYLSLPSSW\DYRHVLPRQANFGIF/M*RRG                               FTMLARMVSIS*PRDLPALASQSAGITGVSHH                               APPQMDFTFALLCFALKGCLPRQKEGGTLNLI               393   1743   A   3283   385   3   RNRSVVPEFVLLGLSAGPQTQTLLFVLFVVIC                               LLTVMGNLLLLVVINADSCLHTPMYFFLGQL                               SFLDLCHSSVTAPKLLENLLSEKKTISVEGCM                               A*VFFVFATGGTESSLLAVMAYDRYVAIRTR                               G               394   1744   A   3284   575   1054   CTKCKADCDTCFNKNFCTKCKSGFYLHLGKC                               LDNCPEQLEANNHTMECVSIVHCEVSEWNP                               WSPCTKKGKTCGFKRGTETRVREIIQHPSAKG                               NLCPPTNETRKCTVQRKKCQKGERGKKGRE                               RKRKKPNKGESKEAIPDSKSLESSKEIPEQREN                               KQQQ               395   1745   A   3286   1   340   RVLYVPSMGPCILVAHGWQKISTKSVFKKLS                               WICLSMVTILTHSLKTFHRNWDWESEYTLFMS                               ALKVNKNNAKLWNNVGHALENEKNFERAL                               KYFLQATHVQPDDIGAHMNVGR               396   1746   A   3293   1   172   GFRAVVMTVKTEAAKGTLTYSRMRGMVAIL                               IAFMKQRRMGLNDFIQKIANNSYACKQ               397   1747   A   3295   12   401   AEPACGASSCTPPSLRSSSSQSVGPLRPGRPL                               WSEACAFL*AAAPQGPASPCCGLPSGFPRVW                               AQCCPPGGALRFPEGLGSVLSPRRCPQVSRGS                               GLSAVPQEVPSGFLGPGLRACPQEAPSRFLRA                               GLT               398   1748   A   3300   1912   2768   KQRRWQNIQRKGPKRYIVIAGNSQSHQPMIFS                               MLRKLPKVTCRDVLPEIRAICIEEIGCWMQSY                               STSFLTDSYLKYIGWTLLIDKHREVRVKCVKA                               LKGLYGNRDLTARLELFTGRFKDWMVSMIV                               DREYSVAVEAVRLLILILKNMEGVLMDVDCE                               SVYPIV*ASN*GLASAVGEFLYWKLFYPECEI                               RTMGGREQRQSPGAQRTFFQLLLSFFVESKSH                               SVTQAGVQWQFSAHRDLCLPGSSNSHVSASR                           VSNS               399   1749   A   3301   536   2391   LRSYGCKAPSRISHLHK\FLFLLLPSLLMGYSE                               SPPPITDSWAPFISLTHHVLSQSQSPLSSNCWI                               CLSTHTQ*FTALPADLLTWTQSNVSLHISYLAI                               PFLADSFLKPVIL*PGNSAKHLSFKLSSLSMVS                               GRAVALLHLIASGLTSIQTNTASSKPPIWGY\L                               STQTSFISPPPLCLSRTYPNPAHATMVGQVPQ                               SLCGLIFLIRTPCRPSILHPNYKIISTSAWQKV                               LCFSGSPTIHTSLHTTGSSFLSFHPLPGFPAAN                               SALYVSSLKGPPGKNVTIPSPVTGT*QPPHRGS                               NIRLTVDKDNFFLSPKPNSLHQLPSQ\TPYQAL                               TGAALAGSYPIWENENTLSWLPTFYNFCLST                               PSLFFLCDTN*YLCLPANWSGTCTLVFQAFTI                               NLLPPNQTILISVEASISSSPIRNKWALHLITLLT                               GLGITAALGTGIAGITTSITSYQTLFTTLSNTVE                               DMHTSITSLQRQLDFLVGVILQNWRVLDLLT                               TEKGGTCIYLQEECCFCVNESGIVHIAVRRLH                               DRAAEL*HQVADSWWQGSSLLRWIPWVAPF                               LGPLIFLPLLLMTGPCIFNLVSRFISQRLNCFIQ                               ASMQKHIDNIFHLCHV*YQSLRGNHSEAPEPR                               P               400   1750   A   3303   2   453   THWRHSSGVPGSTTARRRRRELEIATSDNQE                               YYNRLCQEVTNRERNDQKMLADLDDLNRTK                               KYLEERLIELLRDKDALWQKSDALEFQQKLS                               AEERWLGDTEANHCLDCKREFSWMVRRHHC                               RICGRIFCYYCCNNYVLSKHGGKKERCC               401   1751   A   3304   1   626   MAPQHSSLDDKVPQQASTVCFEFQDILQHSQ                               CTEHKDSLWGPGARSQPFGAHNTRLSPDSCP                               EKIVLRALKDSRAGMPEQDKDPGVQENPDD                               QRRVPQGTGDAPSAFRPLWDNGGLSFFVSRF                               GPLERDLHAQRSEVTYNQRSQSSWMSSFPKR                               NAFVSPYSSMGQAQP/GLPKTNPIGESCCWEG                               LSLSTQILG*QKPSKYIPSLCKR               402   1752   A   3305   1678   172   MELPSGPGPERLFDSHIRLPGDCPLLLVLLLYA                               PVGFCLLVLRLFLGIHYFLVSCALPDSVLRRF                               VVRTMCAVLGLVARQEDSGLRDHSVRVLISN                               HVTPFDHNIVNLLTTCSTVSESEAESATGRFP                               GAQLKAPLSPLAFRMEDTEALPLTPILYPTCQ                               FFFF\IFLNIFLLAFSSPGSQPLLNSPPSFVCWSR                               GFMEMNGRGELVESLKRFCASTRLPPTPLLLF                               PEEEATNGREGLLRFSSWPFSIQDVVQPLTLQ                               VQRTLVSVTVSDASWVSELL\WSLFVPFTVY                               QVRWLRPVHRQLGEANEEFALRVQQ\LVAKE                               LG\QTGTRLTPA\DKAEHMKRQRHPR\LRPQS                               AQSSFPPSPWVLSS/SDVQTGQTLGFREFKESF                               CPHVAIGVFIPERPWPKTGCCKTLTIHLILL*G                               GPVSFSCPE\DIHPRGT*VPTQQASGLPSFPSYG                               PARGGVL*HPSAQQPLTFA\KSS\WARAGRAL                               QERKQ\ALYEYAEREFTERRAPGGLD               403   1753   A   3307   44   447   DPSPSLLAVALGLRAGERTRSGPGSSSPSGGIS                               GGASAGLASSPECACGRSHFTCAVSAIGECT                               CIPAQWQCDGDNDCGDHSDEDGCILPTCSPL                               DFHCDNGKCIRRSWVCDSDNDCEDDSDEQD                               CPPRECEED               1404   1754   A   3311   409   1   PRHGWGRRVLGRDRPRLQKVKKSVKAIYIPG                               QDHVQNEEIYARVLDKFGSNFLSRDNAIDLGT                               STLTK*LSALLKNLLQGLSRNVIFTLDS                               IEKEKREREWR               405   1755   A   3322   12   458   AAVPVENPWDDPRVRPRVRIFTWEDCIAGQA                               KVLCNDSYGVTIIDWSPKGAFIRLTSQSVGNG                               HPASKENDQMVDTIKNTTKVPIIWTYGDMVE                               PRPQMIRPAVGAKHKELWKILMALKKIK\IWE                               GKYTKPSQYNPNYMLELAHNDSVW               406   1756   A   3324   1   426   LSMLSTISTEHRLSVLWPLWYCCHCPTIILSAV                               MCVLLWALSLLQSILEWMFCSFLFSDVDSDN                               WCQILDFLTAVWLIFLI\LVLCGFTLVLLVRIIC                               GSQKMPLTRLYVTILLTGLVFLFCSLPLSIQ*F                               LLYWIEKDLDDL               407   1757   A   3328   213   1841   SGDLSPAELMMLTIGDVIKQLIEAHEQGKDID                               LNKVKTKTAAKYGLSAQPRLVDHAAVPPQY                               RKVLMPKLKAKPIRTASGIAVVAVMCKPHRC                               PHISFTGNICVYCPGGPDSDFEYSTQSYTGYEP                               TSMRAIRARYDPFLQTRHRIEQLKQLGHSVD                               KVEFIVMGGTFMALPEEYRDYFIRNLHDALS                               GHTSNNIYEAVKYSERSLTKCIGITLETRPDYC                               MKRHLSDMLTYGCTRLEIGVQSVYEDVARD                               TNRGHTVKAVCESFIILAKDSGFKVVAHMMP                               DLPNVGLERDIEQFTEFFENFAFRPDGLKLYP                               TLVIRGTGLYELWKSGRYKSYSPSDLVELVA                               RLVPPWTRVYRVQRDIPMPLVSSGVEHG                               NLRELALARMKDLGIQCRDVRTREVGIQEIH                               HKVRPYQVELVRRDYVANGGWETFLSYEDP                               DQDILIGLLRLRKCSEETFRFELGGGVSIVREL                               HVYGSVVPVSSRDPTKFQHQGFGMLLMEEA                               ERIAREEHGSGKIAVISGVGTRNYYRKIGYRL                               QGPYMVKMLK               408   1758   A   3335   3   467   AIASPRAAGIRHELTSTMAAGKNKRLTKGGK                               KGAKKKAV/DNIINIGKTLVTRTQRTKIASDG                               LKGRVFEESLADLQND\TDGYLLRVI*VAFTT                               ERTNQI/REVFNKLIPDSIGKDIEKACQSIYPLH                               DDFARKVKMLKKPKFELRKLMELHGEGSS               409   1759   A   3338   7   1252   PRWRNSARDEILLSFPQNYYIQWLNGSLIHGL                               WNLASLFSNLCLFVLMPFAFFFLESEGFAGLK                               KGIRARILETLGMLLLLALLILGIVWVASALID                               NDAASMESLYDLWEFYLPYLYSCISLMGCLL                               LLLCTPVGL\SRMFTVMGQLLVKPTILEDLDE                               QIYIITLEEEALQRPTKWAVFIRW/KYNIMELE                               QELENVKTLKTKLERRKKASAWERNLVYPA                               VMVLLLIETSTSVLLVACNILCLLVDETAMPK                               GTRGPGIGNASLSTFGFVGAALEIILIFYLMVS                               SVVGFYSLRFFGNFTPKKDDTTMTKIIGNCVS                               ILVLSSALPVMSRTLGITRFDLLGDFGRFNWL                               GNFYIVLSYNLLFAIVTTLCLVRKFTSAVREE                               AL               410   1760   A   3339   127   1433   GSHRFSLASPLDPEVGPYCDTPTMRTLFNLL                               WLALACSPVH1TLSKSDAKKAASKTLLEKSQ                               FSDKPVQDRGLVVTDLKAESVVLEHRSYCSA                               KARDRHFAGDVLGYVTPWNSHGYDVTKVFG                               SKFTQISPVLQLKRRGREMFEVTGLHDVDQ                               GWMRAVRKHAKGL\P*CLGSCLRTGLTMISG/                               YVLDSEDEIEELSKTVVQVAKNQHFDGFVVE                               VWNQLLSQKRVGLIHMLTHLAEALHQAELL                               ALLVIPPAITPGTDQLGMFTHKEFEQLAPVLD                               GFSLMTYDYSTAIIQPGPNAPLSWVRACVQV                               LDPKSKWRSKILLGLNFYGMDYATSKDAREP                               VVGARYIQTLKDHRPRMVWDSQVSEHFFEY                               KKSRSGRHVVFYPTLKSLQVRLELARELGVG                               PWSE               411   1761   A   3342   74   2701   VATRKLAKGFTQFAKMTEGTKKTSKKFKFFK                               FKGFGSFSNLPRSETLRRSSASISRQSHLEPDTP                               EATQDDMVTVPKSPPAYARSSDMYSHMGTM                               PRPSLKKAQNSQAARQAQEAGPKFNLVPGGV                               PDPPGLEAAKEVMVKATGPLEDTPAMEPNPS                               AVEVDPIRKPEVPTGDVEEERLPPRDVHSERAA                               GEPEAGSDYVKFSKEKYILDSSPEKLHKELEE                               ELKLSSTDLRSHAWYHGRIPREVSETLVQRN                               GDFLIRDSLTSLGDYVLTCRWRNQALHFKIN                               KVVVKAGESYTHIQYLFEQESFDHVPALVRY                               HVGSRKAVSEQSGAIIYCFVNRTFPLRYLEAS                               YGLGQGSSKPASPVSPSGPKGSHMKRRSVTM                               TDGLTADKVTRSDGCPTSTSLPRPRDSTRSCA                               LSMDQIPDLHSPMSPISESPSSPAYSTVTRVHA                               APAAPSATALPASPVARRSSEPQLCPGSAPKT                               HGESDKGPHTSPSHTLGKASPSPSLSSYSDPDS                               GHYCQLQPPVRGSREWAATETSSQQARSYGE                               RLKELSENGAFEGDWGKTFTVPIVEVTSSFNP                               ATPQSLLIPRDNRPLEVGLLRKVKELLAEVDA                               RTLARHVTKVDCLVARILGVTKEMQTLMGV                               RWGMELLTLPHG\RKLRLDLLERFHTMSIML                               AVDILGCTGSAEERAALLHKTIQLAAELRGT                               MGNMPSFAAVMGALDMAQISRLEQTWVTLR                               QRHTEGAILYEKKLKPFLKSLNEGKEGPPLSN                               TTFPIIVLPLITLLECDSAPPEGPEPWGSTEHGV                               EVVLAHLEAARTVAHHGGLYHTNAEVKLQG                               FQARPELLEVFSTEEQMRLLWGSQGASSSQA                               RRYEKFDKVLTALSHKLEPAVRSSEL               412   1762   A   3347   1   898   IDRAAECRTKPLPMAVSIRGNADSIVACLVLM                               VLYLIKKRLVACAAVFYGFAVHMKIYPETYI                               LPITLHLLPDRDNDKSLRQFRYTFQACL*ELL                               KRLCNRTALMFVAVAGLTFFALSFGFYYEYG                               WEFLEHTYFYHLTRRDIRHNFSPYFYMLYLT                               AESKWSFSLGIAAFLPQLILLSAVSFAYYRDL                               VFCWFLHTSIFVTFNKVCTSQYFLWYLCLLPL                                       VMPLVRMPWKRAVVLLMLWFIGQAMWLAP                               AYVLEFQGKNTFLFIWLAGLFFLLINCSILIQII                               SHYKEEPLTERIKYD               413   1763   A   3361   3   474   PIPVRWNSLEGRLLRGYEQHANDGKDYISRN                               *DLRSWTAADMAAQITKRKWEAEEFAEQIKA                               YLEGTCVERILRTHLENGKETLQLTEQSSQPTI                               PIVGIVAGLVLLGAVVTGAVVSAVMCRKKNS                               GHFLPTDRVSYSEAASSDHAQGSDVSLTACK                               V               414   1764   A   3363   1488   453   HQILELKKKILKTYNPDYDEDLVQEASSEDVL                               GVHMVDKDTERDIEMKRQLRRLRELHLYST                               WKKYQEAMKTSLGVPQEERDEGSLGKPLCP                               PEILSETLPGSVKKRVCFPSEDHLEEFIAEHLP                               EASNQSLLTVAHADAGTQTNGDLEDLEEHGP                               GQTVSEEATEVHMMEGDPDTLAELLIRDVLQ                               ELSSYNGEEE\DPEEVKTSLGVPQRGDLEDLE                               EHVPGQTVSEEATGVHMMQVDPATLAKSDL                               EDLEEHVPEQTVSEEATGVHMMQVDPATLA                               KQLEDSTITGSHQQMSASPSSAPAEEATEKTK                               VEEEVKTRKPKKKTRKPSKKSRWNVLKCWD                               TFNIF               415   1765   A   3369   431   315   IPWSWVGRLSVRKMSTLF*LTYNYNAILNKTP                               PSPSPSL               416   1766   A   3373   42   651   RQEKMGLGEIGASGVLRSMLKERKKQNMKG                               NGNVTLTPLLPAVQCGCELQPAGRSPLPSSHS                               APGLCSPLHPLQPQQEASTCPSGTLQGREKAA                               PGQGRPLCSLWAQGAGA\PGERGAEGRGPSD                               QAPDPKSGPWLFPPGLGAPAEVRLHNVPHNL                               RRPPLP*ARGK*PPNSCICPWSEGRAKQPLSCG                               PKPQCSLPSQVPGDTH               417   1767   A   3382   2   2061   EAQDPRACGPDAGGRFAARDAPGNSLRPPPS                               SPP/GWPGQLRLLPRVPGSELRCGKPERGRLP                               ASPPGKIRGWPPGISKRPGLGGRSFPPGFAPRT                               WRPEARGPSVQSLPPIFSPQSAQITAR*RPGAP                               KNAGRCGGA\RGPRLSLGPPPGPPPAPALPAR                               ASAGAGAAAAALAVGGVRGAGGARGTGGY                               GHCSGRIPTGRTGPGPQGPGPPMPARPR*AS\S                               TRGSRRGPGSRPARAAAAPRAGDHGRRPVRV                               HLRQHTAV*EPRLGDATAPPGGAAGPGAPAP                               R\GPGWDCALLPSPGPRSPRAVGCAEPEIWDP                               SPRRGTSPVPSVRSLRSEPANPRLGLPALLNSY                               PLKGPGLPPPWGPRTQTGHVIITVQPSGSCIEH                               SKSLDIRGPWGAPPWGPSSSGLCSPKLATAGP                               PQSWGLCQIGRRRGLGGPGLKRGET/GLL*GC                               SMDHANRTKGPGVPTSNRCFSHIPG\GDGCSD                               HSSCEGHPDLHAGREMPAAPGLSELERVRFT                               VGCGGLASGISSASVSGLSPNRAGGPGQGDW                               EMYPVSWQTQESGGQG/SPKTGR*VGMLQA                               GAGSLQGGTGDGVWGLWEDGP/RG*DSPLPS                               GTGTEP*TPTTSIPFFPQPSGVYPSRATLLPMPS                               Y*ALGPSANKSEKPLLSFLYRGLCCRISLQLA                               KGIGQLSEIPLLNVETAFWSMWVTYFRK               418   1768   A   3398   304   2121   EEEEEEEDEDDDDNNEEEEFECYPPGMKVQV                               RYGRGKNQKMYEASIKDSDVEGGEVLYLVH                               YCGWNVRYDEWIKADKIVRPADKNVPKIKH                               RKKIKNKLDKEKDKDEKYSPKNCKPPALGPN                               PPFQTNPISWKWYPKLDLTDAKNSDTAHIKSI                               EITSILNGLQASESSAEDSEQEDERGAQDMDN                               NGKEESKIDHLNNRNDLISKEEQNSSSLLEE                               NKVHADLVISKPVSKSPERLPKDIEVLSEDTD                               YEEDEVTKKRKDVKKDTTDKSSKPQIKRGKR                               RYCNTEECLKTGSPGKKEEKAKNKESLCMEN                               SSNSSSDEDEEETKAKMTPTKKYNGLEEKRK                               SLRTTGFYSGFSEVAEKRIKLLNNSDERLQNS                               RAKDRKDVWSSIQGQWPKKTLKELFSDSDTE                               AAASPPHPAPEEGVAEESLQTVAEEESCSPSV                               ELEKIPPPVNVDSKPIEEKTVEVNDRKAEFPSS                               GSNFSA*IPLPYLHLNRLHQSL*QKGSRQQSS                               VTVSEPLAPNQEEVRSIKSETDSTIEVDSVAGE                               LQDLQSERE*LASRF*CQCELKQ**SARTRTS*                               KSLYRSEKSERCSGRRKFIKKAEKKP*SNSGK                               QQKEGK               419   1769   A   3399   206   463   QRECLSIHIGQAGIQIGDACWELYCLEHGIQP                               NGVVLDTQQDQLENAKMEHTNASFDTFFCE                               TRAGKHVPRALFVDLEPTVIDGIR               420   1770   A   3408   1010   685   RRLSFFF*IWSSVLVTQARVQWRDLGSPQPLP                               PGFKRFSGLSLPSSWDYRIIPSPRPVNF/HVFLV                               VMGFHHVGQAGLELLTSGDLPALASQSARIT                               GVNHCAQPRGHFH               421   1771   A   3409   355   1326   ADSNLLESCWQELGLGPWGQDWRVEQVGAS                               ASLRFPREVCSIRFLFTAVSLLSLFLSAFWLGL                               LYLVSPLENEPKEMLTLSEYHERVRSQGQQL                               QQLQAELDKLHKEVSTVRAANSERVAKLVF                               QRLNEDFVRKPDYALSSVGASIDLQKTSHDY                               ADRNTAYFWNRFSFWNYARPPTVILEPHVFP                               GNCWAFEGDQGQVVIQLPCIRVQLSDTTLQHP                               PPSVEHTGGANSAPRDFAVFFLLSFFTHQGLQ                               VYDETEVSLGKFTFDVEKSEIQTFHLQNDPPA                               AFPKVKIQILSNWGHPRFTCLYRVRAHGVRT                               SEGAEGSAQGPH               422   1772   A   3412   2   421   EFDAQPSIGALVVFKRP*AITGSDPGPKRGMN                               YLVSCSMRSPESGKGEPGTARDYTPMGRPPP                               PVPSVSPGPLPGSLAIALPHSPEPHPWEQQPPRG                               QARSPPGGWLGSAT/RVRRPHNHPIRGHIHSP                               VDTAGAPASPGPDVCE               423   1773   A   3420   91   706   DAQRAIYSSVGPAVSLRQRQQDGAVKESGRI                               RGGVRSFSRAAAAMAPIKVGDAIPAVEVFEG                               EPGNKVNLAELFKGKKGVLFGVPGAFTPGCS                               KTHLPGFVEQAEALKAKGVQVVACLSVNDA                               FVTGEWGRAHKAEGKVRLLADPTGAFGKET                               DLLLDDSLVSIFGNERLKEFSMVVQDGIVKA                               LNVEPDGTGLTCSLAFNIISQL               424   1774   A   3421   4   7688   RQVTRVGTRVLGSTTAAVFLSVEDDNDNAPQ                               FSEKRYVVQVREDVTPGAPVLRVTASDRDKG                               SNAVVHYSIMSGNARGQPYLDAQTGALDVV                               SPLDYETTKEYTLRVRAQDGGRPPLSNVSGL                               VTVQVLDTNDNAPIFVSTPFQATVLESVPLGY                               LVLHVQAIDADAGDNARLEYRLAGVGHDFP                               FTINNGTGWISVAAELDREEVDFYSFGVEAR                               DHGTPALTASASVSVTALDVNDNNPTFTQPE                               YTVRLNEDAAVGTSVVTSAVDRDAHSVITY                               QITSGNTRNRFSITSQSGGGLVSLALPLDYKLE                               RQYVLAVTASDGTRQDTAQIVVNVTDANTH                               RPVFQSSHYTVNVNEDRPAGTTVVLISATDE                               DTGENARITYFMEDSIPQFRIDADTGAVTTQA                               ELDYEDQVSYTLAITARDNGIPQKSDTTYLEI                               LVNDVNDNAPQFLPDSYQGSVYEDVPPFTSV                               LQISATDRDSGLNGRVFYTFQGGDDGDGDFI                               VESTSGIVRTLRRLDRENVAQYVLRAYAVDK                               GMPPARTPMEVTVTVLDVNDNPPVFEQDEFD                               VFVEENSPIGLAVARVTATDPDEGTNAQIMY                               QIVEGNIPEVFQLDIFSGELTALVDLDYEDRPE                               YVLVIQATSAPLVSRATVHVRLLDRNDNPPV                               LGNFEILFNNYVTLRSSSFPGGAIGRVPAIIDP                               DISDSLTYSFERGNELSLVLLNASTGELKLSR                               ALDNNRPLEAIMSVLVSDGVHSVTAQCALRV                               TIITDEMLTHSITLRLEDMSPERFLSPLLGLFIQ                               AVAATLATPPDHVVVFNVQRDTDAPGGHILN                               VSLSVGQPPGPGGGPPFLPSEDLQERLYLNRS                               LLTAISAQRVLPFDDNICLREPCENYMRCVSV                               LRFDSSAPFIASSSVLFRPIHPVGGLRCRCPPGF                               TGDYCETEVDLCYSRPCGPHGRCRSREGQYT                               CLCRDGYTGEHCEVSARSGRCTPGVCKNGGT                               CVNLLVGGFKCDCPSGDFEKPYCQVTTRSFP                               AHSFITFRGLRQRFHFTLALSFATKERDGLLL                               YNGRFNEKHDFVALEVIQEQVQLTFSAGEST                               ITVSPFVPGGVSDGQWHTVQLKYYNKPLLG                               QTGLPQGPSEQKVAVVTVDGCDTGVALRFGS                               VLGNYSCAA\QGTQGGSKKSLDLTGPLLLGG                               VPDLPESFPVRMRQFVGCMRNLQVDSRHIDM                               ADFIANNGTVPGCPAKKNVCDSKTCHNGGTC                               VNQWDAFSCECPLGFGGKSCAQEMANPQHF                               LGSSLVAWIIGLSLPISQPWYLSLMPRTRQAD                               GVLLQAITRGRSTITLQLREGHVMLSVEGTGL                               QASSLRLEPGRANDGDWHHAQLALGAIGGP                               GHAILSFDYGQQRAEGNLGPRLHGLHLSNITV                               GGIPGPAGGVARGFRGCLQGVRVSDTPEGVN                               SLDPSHGESINVEQGCSLPDPCDSNPCPANSY                               CSNDWDSYSCSCDPGYYGDNCTNVCDLNPC                               EHQSVCTRKPSAPHGYTCECPPNYLGPYCET                               RIDQPCPRGWWGHPTCGPCNCDVSKGFDPDC                               NKTSGECHCKENHYRPPGSPTCLLCDCYPTG                               SLSRVCDPEDGQCPCKPGVIGRQCDRCDNPF                               AEVTITNGCEVNYDSCPRAIEAGIWWPRTRFG                               LPAAAPCPKGSFGTAVRHCDEHRGWLPPNLF                               NCTSITFSELKGFAERLQRNESGLDSGRSQQL                               ALLLRNATQHTAGYPGSDVKVAYQLATRLL                               AHESTQRGFGLSATQDVHFTENLLRVGSALL                               DTANKRHWELIQQTEGGTAWLLQHYEAYAS                               ALAQNMRHTYLSPFTIVTPNIVISVVRLDKGN                               FAGAKLPRYEALRGEQPPDLETTVILPESVFR                               ETPPVVRPAGPGEAQEPEELARRQRRHPELSQ                               GEAVASVIIYRTLAGLLPHNYDPDKRSLRVPK                               RPIINTPVVSISVHDDEELLPRALDKPVTVQFR                               LLETEERTKPICVFWNWSILVSGTGGWSARGC                               EVVFRNESHVSCQCNHMTSFAVLMDVSRRE                               NGEILPLKTLTYVALGVTLAALLLTFFFLTLL                               RILRSNQHGIRRNLTAALGLAQLVFLLGINQA                               DLPFACTVIAILLHFLYLCTFSWALLEALHLY                               RALTEVRDVNTGPMRFYYMLGWGVPAPITG                               LAVGLDPEGYGNPDFCWLSIYDTLIWSFAGP                               VAFAVSMSVFLYILAARASCAAQRQGFEKKG                               PVSGLQPSFAVLLLLSATWLLALLSVNSDTLL                               FHYLFATCNCIQGPFIFLSYVVLSKEVRKALK                               LACSRICPSPDPALTTKSTLTSSYNCPSPYADG                               LYQP\YGDSAGSLHSTSRSGKSQPSYIPFLLR                               EESALNPG\QGPPGLGGIPGRILCFLGRFKDQQ                               H\DS*TRDFDSDLSLEDDQSGSYASTHSSDSEE                               EEEEEEEEAAFPGEQGWDSLLGPGAERLPLHS                               TPKDGGPGPGKAPWPGDFGTTAKESSGNGAP                               EERLRENGDALSREGSLGPLPGSSAQPHKGIL                               KKKCLPTISEKSSLLRLPLEQCTGSSRGSSASE                               GSRGGPPSRPPPRQSLQEQLNGVMPIAMSIKA                               GTVDEDSSGSEFLFFNFLH               425   1775   A   3429   155   1417   GEPAVQSCDCGGTQRSCPWLLVAPGLLSSSSS                               RAASVREAEDAPLQPASIHPVSQGSRGPEGSL                               GSAECLPGDPLGARRATRAHSPVPGPPPSLPA                               AGTAVKRGLQPG*GAIGATSTPGTGAATGGL                               CGPAWAAPSAVGPCCCCPSISTWSQMRSARP                               SLGCLPSWAS\PGTEHPPGPQGPGPS*DLCSV*                               KREFQRGPWAGMVILHRISAADPARAPGPDS                               NLQSALQQPATGCSEPAAVYSPPIGLWGA**P                               EYG*PQHSLPG*TAPADR*P\AGIKDRVYSNSI                               YELLENGQRAGTCVLEYATPLQTLFAMSQYS                               QAGFSREDRLEQAKLFCRTLEDILADAPESQN                               NCRLIAYQEPADDSSFSLSQEVLRHLRQEEKE                               EVTVGSLKTSAVPSTSTMSQEPELLISGMEKP                               LPLRTDFS               426   1776   A   3431   1662   369   AIWWLSWLQHDLLPTPTQVAIDFTASNGDPR                               SSQSLHCLSPRQPNHYLQALRAVGGICQDYD/                               SVGESGAGGNRQGGLAQRIPQLFLLPSDKRFP                               AFGFGARLPPNFEVG*MRGKEGDGGRVSQAE                               KAGPHCSRLALTG\SHDFAINFDPENPECEGK                               RGDFIILPRLPADTLHTGAQTPLPRAQLPVPST                               HPRPVF1\EISGVIASYRRCLPQIQLYGPTNVAP                               IINRVAEPAQREQSTGQATKYSVLLVLTDGV                               VSDMAETRTAIVRASRLPMSIIIVGVGNADFS                               DMRLLDGDDGPLRCPRGVPAARDIVQFVPFR                               DFKDVSPPGPFRLKDSSASHPPKSDLRLPPFD                               VLLRTREPSWPP*SPTSPSDDPASPTLPLTPNHI                               TVPTL\AAPSALAKCVLAEVPRQVVEYYASQ                               GISPGAPRPCTLATTPSPSP               427   1777   A   3446   79   9748   GCQSCWPAWPRLRRRGPASAGARLGRKAPW                               GLPGRVQDGRPLRFCFYLRPRAPFIAPVLSGA                               ASRPEASGDCRAGRETAMATLEKLMKAFESL                               KSFQQQQQQQQQQQQQQQQQQQQQQQPPPP                               PPPPPPPQLPQPPPQAQPLLPQPQPPPPPPPPPP                               GPAVAEEPLHRPKKELSATKKDRVNHGLTIC                               ENIVAQSVRNSPEFQKLLGIAMELFLLCSDDA                               ESDVRMVADECLNKVIKALMDSNLPRLQLEL                               YKEIKKNGAPRSLRAALWRFAELAHLVRPQK                               CRPYLVNLLPCLTRTSKRPEESVQETLAAAVP                               KIMASFGNFANDNEIKVLLKAFIANLKSSSPTI                               RRTAAGSAVSICQHSRRTQYFYSWLLNVLLG                               LLVPVEDEHSTLLILGVLLTLRYLVPLLQQQV                               KDTSLKGSFGVTRKEMEVSPSAEQLVQVYEL                               TLHHTQHQDHNVVTGALELLQQLFRTPPPEL                               LQTLTAVGGIGQLTAAKEESGGRSRSGSIVELI                               AGGGSSCSPVLSRKQKGKVLLGEEEALEDDS                               ESRSDVSSSALTASVKDEISGELAASSGVSTPG                               SAGHDILTEQPRSQHTLQADSVDLASCDLTSS                               ATDGDEEDILSHSSSQVSAVPSDPAMDLNDG                               TQASSPISDSSQTTTEGPDSAVTPSDSSEIVLD                               GTDNQYLGLQIGQPQDEDEEATGILPDEASEA                               FRNSSMALQQAHLLKNMSHCRQPSDSSVDKF                               VLRDEATEPGDQENKPCRIKGDIGQSTDDDS                               APLVHCVRLLSASFLLTGGKNVLVPDRDVRV                               SVKALALSCVGAAVALHPESFFSKLYKVPLD                               TTEYPEEQYVSDILNYIDHGDPQVRGATAILC                               GTLICSILSRSRFHVGDWMGTIRTLTGNTFSL                               DCIPLLRKTLKDESSVTCKLACTAVRNCVM                               SLCSSSYSELGLQLIIDVLTLRNSSYWLVRTEL                               LETLAEIDFRLVSFLEAKAENLHRGAHHYTGL                               LKLQERVLNNVVIHLLGDEDPRVRHVAAASL                               IRLVPKLFYKCDQGQADPVVAVARDQSSVYL                               KLLMHETQPPSHFSVSTITRIYRGYNLLPSITD                               VTMENNLSRVIAAVSHELITSTTRALTFGCCE                               ALCLLSTAFPVCIWSLGWHCGVPPLSASDESR                               KSCTVGMATMILTLLSSAWFPLDLSAHQDAI                               ILAGNLLAASAPKSLRSSWASEEEANPAATK                               QEEVWPALGDRALVPMVEQLFSHLLKVINIC                               AHVLDDVAPGPAIKAALPSLTNPPSLSPIRRK                               GKEKEPGEQASVPLSPKKGSEASAASRQSDTS                               GPVTTSKSSSLGSFYHLPSYLKLHDVLKATHA                               NYKVTLDLQNSTEKFGGFLRSALDVLSQILEL                               ATLQDIGKCVEEILGYLKSCFSREPMMATVC                               VQQLLKTLFGTNLASQFDGLSSNPSKSQGRA                               QRLGSSSVRPGLYHYCFMAPYTHFTQALADA                               SLRNMVQAEQENDTSGWFDVLQKVSTQLKT                               NLTSVTKNRADKNAIHNHIRLFEPLVIKALKQ                               YTTTTCVQLQKQVLDLLAQLVQLRVNYCLL                               DSDQVFIGFVLKQFEYIEVGQFRESEAIIPNIFF                               FLVLLSYERYHSKQIIGIPKIIQLCDGIMASGR                               KAVTHAIPALQPWHDLFVLRGTNKADAGKE                               LETQKEVVVSMLLRLIQYHQVLEMFILVLQQ                               CHKENEDKWKRLSRQIADIILPMLAKQQMHI                               DSHEALGVLNTLFEILAPSSLRPVDMLLRSMF                               VTPNTMASVSTVQLWISGILAILRVLISQSTED                               WLSRIQELSFSPYLISCTVINRLRDGDSTSTLE                               EHSEGKQIKNLPEETFSRFLLQLVGILLEDIVT                               KQLKVEMSEQQHTFYCQELGTLLMCLIHIFKS                               GMPRRITAAATRLFRSDGCGGSFYTLDSLNLR                               ARSMIITHPALVLLWCQILLLVNHTDYRWW                               AEVQQTPKRHSLSSTKLLSPQMSGEEEDSDLA                               AKLGMCNREIVRRGALILFCDYVCQNLHDSE                               HLTWLIVNIIIQDLISLSHEPPVQDFISAVHIRNS                               AASGLFIQAIQSRGENLSTPTMLKKTLQCLEGI                               HLSQSGAVLTLYVDRLLCTPFRVLARMVDIL                               ACRRVEMLLAANLQSSMAQLPMEELNRIQEY                               LQSSGLAQRHQRLYSLLDRFRLSTMQDSLSPS                               PPVSSHPLDGDGHVSLETVSPDKDWYVHIVK                               SQCWTRSDSALLEGAELVNRIPAEDMNAFM                               MNSEFNLSLLAPCLSLGMSEISGGQKSALFEA                               AREVTLARVSGTVQQLPAVHHYPQPELPAEP                               AAYWSKLNDLFGDAALYQSLPTLARALAQY                               LVVVSKLPSHLHLPPETCEKDIVKFVVATLEAL                               SWHLIHEQTPLSLDLQAGLDCCCLALQLPGL                               WSVVSSTEFVTHACSLIYCVHFILEAVAVQPG                               EQLLSPERRTNTPKAISEEEEEVDPNTQNPKYI                               TAACEMVAEMVESLQSVLALGHKRINSGVPA                               FLTPLLRNIIISLARLPLVNSYTRVPPLVWKIG                               WSPKPGGDFGTAFPEIPVEFLQEKEVFKEFIYR                               INTLGWTSRTQFEETWATLLGVLVTQPLVME                               QEESPPEEDTERTQINVLAVQAITSLVLSAMT                               VPVAGNPAVSCLEQQPRNKPLKALDTRFGRK                               LSIIRGIVEQEIQAMVSKRENIATHHLYQAWD                               PVPSLSPATTGALISHEKLLLQINPERELGSMS                               YKLGQVSTHSVWLGNSITPLRIEEEWDEEEEEE                               ADAPAPSSPPTSPVNSRKHRAGVDIHSCSQFL                               LELYSRWILPSSSARRTPATILISEVVRSLLVVS                               DLFTERNQFELMYVTLTELRRVHPSEDEILAQ                               YLVPATCKAAAVLGMDKAVAEPVSRLLESTL                               RSSHLPSRVGALHGILYVLECDLLDDTAKQLI                               PVISDYLLSNLKGIAHCVNIHSQQIIVLVMCAT                               AFYLIENYPLDVGPEFSASIIQMCGVMLSGSE                               ESTPSIIYHCALRGLERLLLSEQLSRLDAESLV                               KLSVDRVNVHSPHRAMAALGLMLTCMYTG                               KEKVSPGRTSDPNPAAPDSESVIVAMERVSVL                               FDRLRKGFPCEARVVARILPQFLDDFFPPQDIM                               NKVIGEFLSNQQPYPQFMATVVYKVFQTLHS                               TGQSSMVRDWVMLSLSNFTQRAPVAMATWS                               LSCFFVSASTSPWVAAILPHVISRMGKLEQVD                               VNLFCLVATDFYRHQIEEELDRRAFQSVLEV                               VAAPGSPYHRLLTCLRNVHKVTTC               428   1778   A   3449   3   430   NSRPSPSAALVEVLLRSGSTFPHTVSGGWAA                               WGPWSSCSRDCELGFRVRKRTCTNPEPRNGG                               LPCVGDAAEYQDCNPQACPVRGAWSCWTS                               WSPCSASCGGGHYQRTRSCTSPAPSPGEDICL                               GLHTEEALCATQAGPEGWS               429   1779   A   3464   583   3   DALDRRYLERCHPAAGGWVGEGE*ALCQKT/                               RFSGVLEPPLPSLKDGGRFPAWT*RSCSKSLR                               AAFTSQFFPSRRSRASPGSAP\GNGQNLTEQHP                               CPGSCDPQVLSASWM*VEHRSKFRPPP*NSTI                               PPESIRS*QGGTVQTGQHSSGREAGSWRARGR                               NAGRR*KGQGKIGTKQGAVRARKECRGEMA                               SGETDSE               430   1780   A   3473   2802   270   FRMRIFLHCPWNQQMWKIWNLLETSLESCKA                               HLSIQKLLKER\Q\QLPVFKHRDSWETLKRHR                               VVVVAGET\GSGKSTQVPfffLLEDLLLNEWE                               ASKCNIVGTQPRRISAVSLANRVCDELGGENG                               PGGRNSLCGYQIRMESRACESTRLLYCTTGV                               LLRKLQEDGLLSNVS/HMFIVDEV\IIER\SVQS                               DFLLIILKEILQKRSDLHLILMSATVDSEKFST                               YFTHCPILRISGRSYPVEVFHLEDITEETGFVLE                               KDSEYCQKFLEEEEEVTINVTSKAGGIKKYQE                               YIPVQTGAHADLNPFYQKYSSRTQHAILYMN                               PHKINLDLILELLAYLDKSPQFRMEGAVLIFL                               PGLAHIQQLYDLLSNDREFYSERYKVIALIISI                               LSTQDQAAAFTLPPPGVRKIVLATNIAETGITI                               PDVVFVIDTGRTKENKYHESSQMSSLVETFVS                               KASALQRQGRAGRVRDGFCFRMYTRERFEG                               FMDYSVPEILRVPLEELCLHIMKCNLGSPEDF                               LSKALDPPQLQVISNAMNLLRKIGACELNEPK                               LTPLGQHLAALPVNVKGIGKMLIFGAIFGCLDP                               VATLAAVMTEKSPFTTPIGRKDEADLAKSAL                               AMADSDHLTWNAYLGWKKARQEGGYRSEI                               TYCRRNFLNRTSLLTLEDVKQELIKLVKAAGF                               SSSTTSTSWEGNRASQTLSFQEIALLKAVLVA                               GLYDNVGKIIYTKSVDVTEKLACIVETAQGK                               AQVHPSSVNRDLQTHGWLLYQEKIRYARVY                               LRETTLITPFPVLLFGGDIEVQHRERLLSIDGW                               IYFQAPVKIAVIFKQLRVLIDSVLRKKLENPK                               MSLENDKILQIITELIKTENN               431   1781   A   3474   1   441   FRPAPGHVQP*GGSSAAAGGGLLSHPRPCQQ                               PCPPAPAPSRPRSLGSLGQRVPAALATAAQEL                               PATLGGDGGKPALTAGEAALPGLHRSGVPAA                               AARC*PCT/SRPT*STLSPTQAAWWCRPSRRQ                               QRGEASTGGASGRRCGSCFQV               432   1782   A   3478   416   23   QLRRLTLPNFKTY/YSS*IIEIAWH**KNMQID                               QWFRRESPEIDLCKYS*LSFDKEAKAIKIWKE                               CSLFNKWC/YKNWM/LHVQKKRI*VQTLHPS                               QKLK\SKWIKDLNVECRITKLLDQEYPGDLGY                               SRALNSGSR               433   1783   A   3504   1876   552   CLAPCSPQPEKNGMQPLLLLLPPLLYQQLLHS                               SLGAPGESTLLVRTSKLLVGLGLQLLVWLLL                               QTRSLLALQLHLTSSAPLLAAPTAVCSCSRCS                               APRSRCVARPAARTGLPTPAPASSPAPAASPA                               PAASPESTA\PQPLILLPKPIPPAPGAPPPRP                               GAPPPRPAASPSPAASPAPPAASPVLTASPPLP                               AASPSPAASPAPPAASPVLTASPPLPAASPSPA                               ASPAPPAASPVLTASPPLPAASPALAASPVHT                               ASPPVHVASPPVHTASPPVHVASPPVHTASPP                               VHVASPPVHTASPHVHVASPPVHVASPPVHV                               ASPPVHTASPPVHVASPPVHTASPHVIIVASPP                               VHTASPPVHVASPPVHVASPPVHVAYPPVHV                               ASPPVHVASPPVHVASPPVSCSGDSTSDCFPP                               QPGAVFPHSLAPSLGGWSHLVAALP               434   1784   A   3516   142   590   GGVNRPRSETEQVKTPVIISSWDYRHPPPRPA                               SFFVFLV*TCIF\TALARMVLISWPCDLPTSASQ                               SAGITGVRHHA\RLLYFEQESHSVTQAGW\VQ                               WHNLGSLQPLSLEDRLSPGVLGCSALCRSGV                               RTKFGINMVTSRERGTPRLPKEG               435   1785   A   3529   1   3161   MSLVRAALEALDELDLFGVKGGPQSVLHVLA                               DEVQHCQSILNSLLPRASTSKEVDASLLSVVS                               FPAFAVEDSQLVELTKQEIITKLQGRYGCCRF                               LRDGYKTPKEDPNRLYY/ENPAELKLFENIEC                               EWPLFWTYFILDGVFSGNAEQVQEYKEALEA                               VLIKGKNGVPLLPELYSVPPDRVDEEYQNPHT                               VDRVPMGKLPHMWGQSLYILGSLMAEGFLA                               PGEIDPLNRRFSTVPKPDVVYQVYPSLPHGCS                               SKSPSHQCTIISIRTTRKITAPVSILAETEEIICTIL                               KDKGIYVETIAEVYPIRVQPARILSIIIYSSLEIF                               LPFLNSVSGCNNRMKISGRPYRITLIGVLGTSK                               LYDIRKTIFTFTPQFIDQQQFYLALDNKMIVE                               MLRTDLSYLCSRWRMTHGQPTITFPISHSMLDE                               DGTSLNSSILAALRKMQDGYFGGARVQTGKL                               SEFLTTSCCTHLSFMDPGPEGKLYSEDYDDN                               YDYLESGNWMNDYDSTHARCGDEVARYL                               DHLLAIITAPHPKLAPTSQKGGLDRFQAAVQT                               TCDLMSLVTKAKELHVQNVHMYLPTKLFQA                               SRPSFNLLDSPHPRQENQVPSVRVEIHLPRDQ                               SGEVDFKALVLQLKETSSLQEQADILYMLYT                               MKGPDWNTELYNERSATVRELLTELYGKVG                               EIRHWGLIRYISGILRIKKVEAIDEACTDLLSH                               QKHLTVGLPPEPREKTISAPLPYEALTQLIDEA                               SEGDMSISILTQEIMVYLAMYMRTQPGLFAE                               MFRLRIGLIIQVMATELAHSLRCSAEEATEGL                               MNLSPSAMKNLLHHILSGKEFGVERSVRPTD                               SNVSPAISIHIEIGAVGATKTERTGIMQLKSEIK                               QSPGTSMTPSSGSFPSAYDQQSSKDSRQGQW                               QRRRRLDGALNRVPVGFYQKVWKVLQKCH                               GLSVEGFVLPSSTTREMTPGEIKFSVHVESVL                               NRVPQPEYRQLLVEAIL\VLTMLADIEI\HSIGS                               IIAVEKIVHIANDLFLQEQKTLGADDTMLAKD                               PASGICTLLYDSAPSGRFGTMTYLSKAAATY                               VQEFLPHSICAMQ               436   1786   A   3546   73   393   CP*LTWELLEVKKAEVLQDSLDGRYSTPSSCL                               EQPDSCRPYGRSFYALEEKHVIFSLDVGETDN                               KGKGKTIRGI*TFKGRKGGTYQREHDANPLA                               PXSARSCWMRKG               437   1787   A   3554   5157   2939   AVRAEPGLEELSSGLRAHSPSKITVCEPEAQG                               SASGCRYAAHPHWGLGGAAAAGGSWEPQPP                               RPVCEPAGRGKPPPAAPRSPLLPGSRRRPHA                               AQPGARARTSPPPASARNMAARPAATLAWSL                               LLLSSALLREGCRARFVAERDSEDDGEEPVVF                               PESPLQSPTVLVAVLARNAAHTLPHFLGCLER                               LDYPKSRMAIWAATDHNVDNTTEIFREWLK                               NVQRLYHYVEWRPMDEPESYPDEIGPKHWP                               TSRFAHVMKLRQAALRTAREKWSDYILFIDV                               DNFLTNPQTLNLLIAENKTIVAPMIESRGLYS                               NFWCGITPKGFYKRTPDY\VQIREWKRTGCFP                               VPMVHSTFLIDLRKEASDKLTFYPPHQDYTW                               TFDDIIVFAFSSRQAGIQMYLCNREHYGYLPIP                               LKPHQTLQEDIENLIHVQIEAMIDRPPMEPSQ                               YVSVVPKYPDKMGFDEIFMINLKIRRKGQGGD                               RWLRTLYEQEIEVKIVEAVDGKALNTSQLKA                               LNIEMLPGYRDPYSSRPLTRGEIGCFLSHyYV                               WKEVIDRELEKTLVIEDDVRFEHQFKKKLMK                               LMDNIDQAQLDWELIYIGRKRMQVKEPEKA                               VPNVANLVEADYSYWTLGYVISLEGAQKLV                               GANPFGKMLPVDEFLPVMYNKHPVAEYKEY                               YESIWLKAFSAEPLLIYPTHYTGQPGYLSDTE                               TSTIWDNETVATDWDRTHAWKSRKQSRIYSN                               AKNTEALPPPTSLDTVPSRDEL               438   1788   A   3563   130   527   IFFNSSSLFCRVFCLFLRWSFTLVAQARVQ*C                               NLSSLQPLPPGFK*FSCLSPPRS*DYRRPPPRPA                               NFLYF**RQGPGQAGLELLT/S/GDPPTSA                               SQSAGITGVSHRAWPVHAISTHISLVKTRPSLT                               TLG               439   1789   A   3565   446   1834   LLQPAMRKSPGLSDCLWAWILLLSTLTGRSY                               GQPSLQDELKDNTTVFTRILDRLLDGYDNRL                               RPGLGERVTEVKTDIFVTSFGPVSDHDMEYTI                               DVFFRQSWKDERLKPKGPMTVLRLNNLMAS                               KIWTPDTFFHNGKKSVARNMTMPNKLLRITE                               DGTLLYTMELTVR\AECPMAFGRDFPM\D\AH                               ACPLKGSYAYTRAEVVYEWTREPARSVVV                               AEDGSRLNQYDLLGQTVDSGIVQSSTGEYVV                               MTTHFHLKRKIGYFVIQTYLPCIMTVILSQVSF                               WLNRESVPARTVFGVTTVLTMTTLSISARNSL                               PKVAYATAMDWFIAVCYAFVFSALIEFATVN                               YFTKRGYAWDGKSVVPEKPKKVKDPLIKKN                               NTYAPTATSYTPNLARGDPGLATIAKSATIEP                               KEVKPETKPPEPKKTFNSVSKIDRLSRIAFPLL                               FGIFNLVYWATYLNREPQLICAPTPHQ               440   1790   A   3568   1   350   STSSCFPAAAAAIMREIVHILQAGQCGNQIGAK                               FWEVISDEHGIDPTGTYHGDSDLQLERINVYY                               NEATGEAFVPSPTAIRGPRGPCLG*RPPVPAG                               GKYTLVDMEPGTMIDSV               441   1791   A   3569   2   1751   FVAVAGAVSGEPLVHWCTQQLRKTFGLDVS                               EEIIQYVLSIESAEEIREYVTDLLQGNEGKKGQ                               FIEELITKWQKNDQELISDPLQQCFKKDEILDG                               QKSGDHLKRGRKKGRNRQEVPAFTEPDTTAE                               VKTPFDLAKAQENSNSVKKKTKFVNLYTREG                               QDRLAVLLPGRRPCDCLGQKHKLINNCLICG                               R1YCEQEGSGPCLFCGTLVCTHEEQDILRGDS                               N\KSQKLLKKLMSGVENSGKVDISTKDLLPH                               QELRIKSGLEKAIKHKDKLLEFDRTSIRRTQVI                               DDESDYFASDSNQWLSKLERETLQKREEELR                               ELRHASRLSKKVTIDFAGRKILEEENSLAEYH                               SRLDETIQAIANGTLNQPLTKLDRSSEEPLGVL                               VNPNMYQSPPQWVDHTGAASQKKAFRSSGF                               GLEFNSFQHQLRIQDQEFQEGFDGGWCLSVH                               QPWASLLVRGIKRVEGRSWYTPHRGRLWIAA                               TAKKPSPQEVSELQATYRLLRGKDVEFPNDY                               PSGCLLGCVDLIDCLSQKQFKEQFPDISQESDS                               PFVFICKNPQEMVVKFPIKGNPKIWKLDSKIH                               QGAKKGLMKQNKAV               442   1792   A   3576   1   2019   MPRSHTGERLCEGKEGSQCAENFSPNLSVTK                               KTAGVKPYECTICGKAFMRLSSLTRHMRSIIT                               AIRAI\EKPYKCKEC\GRAFSLSQILSK\IIERSH                               TGEKPYKCKQCGKTFIYHQPFQRIIERTHIGEK                               PYECKQCGKALSCSSSLRVHERIHTGEKPYEC                               KQCGKAFSCSSSIRVHERTHTGEKPYACK\EC                               GKAFIS\TTSVLTHMITHNGDRPYKCKECGKA                               PIPPSFLRVHERIHTGEKPYKCKQCGKAFRWS                               TSIQIHERIHTGEKPYKCKECGKSFSARPAFRV                               HVRVHTGEKPYKCKECGKAFSRISYFRIHERT                               HTGEKPYECKKCGKTFNYPLDLKIHKRNHTG                               EKPYECKECAKTFISLENFRRHMITHTGDGPY                               KCRDCGKVFIFPSALRTHERTHTGEKPYECKQ                               CGKAFSGSSYIRIHKRTHTGEK\PYECKECGK                               AFIYPTSFQGHMRMIITGEKPYKCKECGKAFS                               LHSSFR\RHTRIHNYEKPLEC*Q\CGKAFSVSTS                               LKKPMRNAQSDRKLYIKCEK*EKVFNSNRCF                               QSCENSH*REKSCQCK*YRKRDTR*FMYSQV                               PHNVSVSNGPYRICGSPIRLYNT*NISINRNL                               VAVVTP*CSTLFKCLWCWCKRAALSVV*IIVQ                               DSGRGRWLWVIPALWEAKAGGSRGQEIKTIL                               ANTVKPHLY               443   1793   A   3578   287   114   DFYERKFEQFIEGHKQIVNKWRDLLCSWKRK                               LSIIKKSVLQNNL*FSAASMRFQKVFF               444   1794   A   3582   3335   1909   HLFFSLFLAAMAMTGSTPCSSMSNHTKERVT                               MTKVTLENFYSNLIAQIIEEREMRQKKLEKV                               MEEEGLKDEEKRLRRSAHARKETEFLRLKRT                               RLGLEDFESLKVIGRGAPGEVRLVQKKDTGH                               VYAMKILRKADMLEKEQVGHIRAERDILVEA                               DSLWVVKMFYSFQDKLNLYLIMEFLPGGDM                               MTLLMKKDTLTEEETQFYLAETVLAIDSIHQL                               GFIHRDIKPDNLLLDSKGHVKLSDFGLCTGLK                               KAHRTEFYRNLNHSLPSDFTFQNMNSKRKAE                               TWKENRRQLAFSTVGTPDYIAPEVFMQTGYN                               KLCDWWSLGVIMYEMLIGYPPFCSETPQETY                               KKVMNWKETLTFPPEVPLSEKAKDLILRFCCE                               WEHRIGAPGVEEIKSNSFFEGVDWEHIRERPA                               AISIEIKSIDDTSNFDEFPESDILICPTVATSNHPE                               TDYKNKDWVPINYTYKRFEGLTARGAIPSYM                               KAAK               445   1795   A   3584   1   6169   RTRQIEKRFAYSFLQQLIRYVDEAHQYILEFD                               GGSRGKGEIIFPYEQEIKFFAKVVLPLIDQYFK                               NHRLYFLSAASRPLCSGGHASNKEKEMVTSL                               FCKLGVLVRHRISLFGNDATSIVNCLHILGQT                               LDARTVMKTGLESVKSALRAFLDNAAEDLE                               KTMENLKQGQFTHTRNQPKGVTQIINYITVA                               LLPMLSSLFEHIGQHQFGEDLILEDVQVSCYRI                               LTSLYALGTSKSIYVERQRSALGECLAAFAGA                               FPVAFLETHLDKIINIYSIYNTKSSRERAALSLP                               TNVEDVCPNTPSLEKLMEEIVELAESGIRYTQ                               MPHVMEVILPMLGSYMSRWWEHGPENNPER                               AEMCCTALNSEHMNTLLGNILKIIYNNLGIDE                               GAWMKRLAVFSQPIINKVKPQLLKTHFLPLM                               EKLKKKAATVVSEEDHLKAEARGDMSEAEL                               LILDETLARDLYAFYPLLIRFGDYNRAKWL                               KEPNPEAEELFRMVAEVFIYWSKSHNFKREE                               QNFVVQNE1NNMSFLITDTKSKMSKAAVSDQ                               ERKKMKRKGDRYSMQTSLWAALKRLLPIGL                               NICAPGDQELIALAKNRFSLKDTEDEVRDIIRS                               NIHLQGKLEDPAIRWQMALYKDLPNRTDDTS                               DPEKTVERVLDIANVLFHLEQKSKRVGRRHY                               CLVEHPQRSKKAVWHKLLSKQRKRAVVACF                               RMAPLYNLPRHRAVNLFLQGYEKSWIETEEH                               YFEDKLIEDLAKPGAEPPEEDEGTKRVDPLHQ                               LILLFSRTALTEKCKLEEDFLYMAYADIMAKS                               CHDEEDDDGEEEVKSFEEKEMEKQKLLYQQ                               ARLHDRGAAEMVLQTISASKGETGPMVAAT                               LKLGIAILNGGNSTVQQKMLDYLKEKKDVGF                               FQSLAGLMQSCSVLDLNAFERQNKAEGLGM                               VTEEGSGEKVLQDDEFTCDLFRFLQLLCEGH                               NSDFQNYLRTQTGNNTTVNIIISTVDYLLRVQ                               ESISDFYWYYSGKDVIDEQGQRNFSKAIQVA                               KQVFNTLTEYIQGPCTGNQQSLAHSRLWDAV                               VGFLHVFAHMQMKLSQDSSQIELLKELMDLQ                               KDMVVMLLSMLEGNVVNGTIGKQMVDMLV                               ESSNNVEMILKFFDMFLKLKDLTSSDTFKEYD                               PDGKGVIFKRDFHICAMESHKHYTQSETEFLL                               SCAETDENETLDYEEFVKRFHEPAKDIGFNVA                               VLLTNLSEHMPNDTRLQTFLELAESVLNYFQP                               FLGRIEIMGSAKRIERVYFEISESSRTQWEKPQ                               VKESKRQFIFDVVNECIGEKEKMELFVNFCED                               TIFEMQLAAQISESDLNERSANKEESEKERPEE                               QGPRMAFFSILTVRSALPALRYNTLTLMRMLS                               LKSLKKQMKKVKKMTVKDMVTAFFSSYWSI                               FMTLLHFVASVFRGPFRIICSLLLGGSLVEGA                               KKIKVAELLANMPDPTQDEVRGDGEEGERKP                               LEAALPSEDLTDLKELTEESDLLSDIFGLDLKR                               EGGQYKLIPHNPNAGLSDLMSNPVPMPEVQE                               KFQEQKAKEEEICEEKEETKSEPEKALEGEDGE                               KEEKAKEDKGKQKLRQLHTHRYGEPEVPESA                               FWKKIIAYQQKLLNYFARNFYNMRMLALFV                               AFAINFILLFYKVSTSSVVEGKELPTRSSSENA                               KVTSLDSSSHRIIAVHYVLEESSGYMEPTVRIL                               PILHTVISFFCIIGYYCLKVPLVIFKREKEVARIK                               LEFDGLYITEQPSEDDIKGQWDRLVINTQSPP                               NNYWDKFVKRKVMDKYGEFYGRDRISELLG                               MDKAALDFSDAREKKKPKKDSSLSAVLNSID                               VKYQMWKLGVVFTDNSFLYLAWYMTMSVL                               GHY\NNFPFAAHLLDIAMGFKTLRTLLSSVTH                               NGKQLVLTVGLLAVVVYLYTVVAFNFFRKF                               YNKSEDGDTPDMKCDDMITCYMFHMYVGV                               RAGGGIGDEIEDPAGDEYEIYRIIFDITFFFFVI                               VILLAIIQGLDAFGELRDQQEQVKEDMETKC                               FICGIGNDYFDTVPHGPETHTLQEHNLANYLF                               FLMYLINKDETEHTGQESYVWKMYQERCWE                               FFPAGDCFRKQYEDQLN               446   1796   A   3592   1   355   AGLELLNSDDPPALASQSAGITGVTRTPSLFF*                               DTVLLCCSGWSAVAPSRLTAALPS*AQAVCL                               SLPRSWDYRRW/PPHPANFCIFCRDE/SLA/ML                               PRLVSNSWTQAILLPRPPKMLQLQV               447   1797   A   3598   1202   1070   LFVGGGPICPEGASGFAPGPAPAPRVGVDAEV                               GR*V*GAAASQGAIGSLRPRPTGPGHPGAWL                               QVWGAAAVCAGPAM*/AVRAKRGPRAG*EP                               NSPWRSGVLAA\RAVGAGPWP*P*PGCS*ARG                               PSSRSAPGLASGPAAPLLQGVHSSAGPLLCYI                               NGTLALGLKP**AWGWGEWRPKG               448   1798   A   3604   3115   557   FRRKGGGGPKDFGAGLKYNSRHEKVNGLEE                               GVEFLPVNNVKKVEKHGPGRWVVLAAVLIG                               LLLVLLGIGFLVWHLQYRDVRVQKVFNGYM                               RLTNENFVDAYENSNSTEFVSLASKVKDALKL                               LYSGVPFLGPYHKESAVTAFSEGSVIAYYWSE                               PSIPQHLVEEAERVMAEERVVMLPPRARSLKS                               FVVTSVVAFPTDSKTVQRTQDNSCSFGLHAR                               GVELMRFTTPGFPDSPYPAHARCQWALRGD                               ADSVLSLTFRSFDLASCDERGRHLV\TVYNT\L                               SPMEPHA\LVQLCGTYPPSYNLTFHS\S\QNVL                               LITLITNTERRIIPG\FEATFFQLPRMSSCGGRL                               RKAQGTFNSPYYPGHYPPNIDCTWNLEVPNN                               QHYKVRFKFFYLLEPGVPAGTCPKDYVEING                               EKYCGERSQFVVTSNSNKITVRFHSDQSYTDT                               GFLAEYLSYDSSDPCPGQFTCRTGRCIRKELR                               CDGWADCTDHSDELNCSCDAGHQFTCKNKF                               CKPLFWVCDSLNDCGDNSDEQGCSCP\AQTF                               RCSNGKCLSKSQQCNGKDDCGDGSDEASCP                               KVNVVTCTKHTYRCLNGLCLSKGNPECDGK                               EDCSDQSDEKDCDCGLRSFTRQARVVGGTD                               ADEGEWPWQVSLHALQQGHICQASLISPNWL                               VSAAHCYIDDRGFRYSDPTQWTAFLGLHDQS                               QRSAPGVQERRLKRIIISHPFFNDFTFDYDIALL                               ELEKPAEYSSMVTRPICLPDASHVFPAGKAIWV                               TGWGHTQYGGTGALILQKGEIRVINQTTCEN                               LLPQQITPRMMCVGFLSGGVDSCQGDSGGPL                               SSVEADGRIFQAGVVSWGDGCAQENKPG\TY                               TRLPLFRDWIICENTGV               449   1799   A   3618   2   613   FVSGSPWRMDGSTERLEARRPAGRLPWSSRQ                               EMTRRPSLMAGRQHGWSAQQSATVANPVPG                               ANPDLLPHFLQEPEDVYIVKNKPVLLVCKAV                               PATQIFFKCNGEWVRQVDHVIERSTDGSSGLP                               TMEVVRINVSRQQVEKVFGLEEYWCQCVAWS                               SSGTTKSQKAYIRIAYLRKNFEQEPLAKEVSL                               EQGIVLPCRPPEGIPPAE               450   1800   A   3620   1   2676   MEPSLGQGMDLTCPFGVSPACGAQASWSIFG                               ADAAEVPGTRGHSQQEAAMPHIPEDEEPPGE                               PQAAQSPAGQQGPPTAGVSCSPTPTIVLTGDA                               TSPEGETDKNLANRVHSPHKRLSHRHLKVST                               ASLTSVDPAGHIIDLVNDQLPDISISEEDKKKN                               LALLEEAKLVSERFLTRRGRKSRSSPGDSPSA                               VSPNLSPSASPTSSRSNSLTVPTPPEGDEADVS                               SPHPGEPNVPKGLADRKQNDQRKVSQGRLAP                               RPPPVEKSKEIAIEQKENFDPLQYPETEPKGLA                               PVTNSSGKMALNSPQPGPVESELGKQLLKTG                               WEGSPLPRSPTQDAAGVGPPASQGRGPAGEP                               MGPEAGSKAELPPTVSRPPLLRGLSWDSGPEE                               PGPRLQKVLAKLPLAEEEKRPAGKAGGKLAK                               APGLKDFQIQVQPVRMQKLTKLREEHILMRN                               QNLVGLKLPDLSEAALEQEKGLPSELSPAIEEE                               ESKSGLDVMPNISDVLLRKLRVHRSLPGSAPP                               LTEKEVENVFVQLSSAFRNDSYTLESEINQAE                               RERNLTEENTEKELENFKASITSSASLWHIICE                               HRETYQKLLEDIAVLHRLAARLSSRAEVVGA                               VRQEKRMSKATEVMMQYVENLKRTYEKDH                               AELMEFKKLANQNSSRSCGPSEDGVLRTARS                               MSLTLGKNMPRERVSVAVVPKFNALNLPGQ                               TPSSSSIPSPALSESPNGKGSLPVTSALPALLE                               NGKTNGDPDCEASAPALTLSCLEELSQETKA                               RMEEEAYSKGFQEGLKKTKELQDLKEEEEEQ                               KSESPEEPEEVEETEEEEKDPRSSKLEELVHFL                               QVMYPKLCQHWQVIWMMAAVMLVLTVVL                               GLYNSYNSCAEQADGPLGRSTCSAAQKDSW                               WSSGLQHEQPTEQ               451   1801   A   3623   504   198   QLIQHQTVHTGRKLYECKECGKAFNQGSTLI                               RHQRIHTGEKPYECKVCGKAFRVSSQLKQHQ                               RIHTGERPYQCKELKGRGAEMLAVLAVKEQ                               NRTPVNYGK               452   1802   A   3628   2   195   MTCLHSAKAFHY*SSCSFSCEEGFALIGPEVV                               QCTALGVWTAPAPVCIAVQCQIILEALNEGT                               MG*DYPFTAFAYGSSCKYECHTVYRVRGLD                               MLHSRGCYLWNGHFTT*EAISCEPLERPCH*S                               V*CSFSCEEGFALIGPEVVQCTALGVWTAPAP                               VCIAVQCQHLEALNEGTMG               453   1803   A   3637   662   142   IQAKGLGIWHVPNKSPMQHWR\KGSLLRYRT                               DTGFLQTLGHNLLGIYQKYPVKYGEGKCWT                               DNGPVIPVVYDFGDAQKTASYYSPYGQREFT                               AGFVQPRVFNNERAANALCAGMRVTGCNTE                               HHCIGGGYFPEASPQQCGDFSGFDWSGYGT                               \HVGYSSSREITE\AAVLLFYR               454   1804   A   3641   1   362   TQVHPAMLGLDELGRSGCGHCTQADLRFGD                               AAGRDPGQDNDRNTAEPAFPPPPRVMAMA                               ALRAPAQSSVTFEDVAVNFSLEEWSLLNEAQ                               GCLYHDVMLETLTLISSLGKVLLLNCDLS               455   1805   A   3646   2   414   AAAGRGASGALTGEGGGEQGRRVGLGSRAH                               SLLLGPTFNSCQVSSQPPRVAGLGLPLKHEPS                               RPQPPSPRGPRTVRAGVPGAHPQDTPCPEFVR                               PRKVPLVGEAPGLPPEERSRGWRRDTPGLQE                               SRVRAPSYDDIT               456   1806   A   3656   396   8   QIVSFNSYLTLYTKNNLKSMKDLNVNTEMIK                               LLELKNTHNLG*AKFFLN*IQKALIKRKILIHW                               P/LIKIK/SFCSLSDTIKKMKRQTIVWEQTFTIIII                               SVKELVSRIYEAFLQFNKTVNRFVFDIKKEQK                               F               457   1807   A   3660   14   1961   SEAKLGGPTGMDLWQLLLTLALAGSSDAFSG                               SEATAAILSRAPWSLQSVNPGLKTNSSKEPKF                               TKCRSPERETFSCHWTDEVHIIGTKNLGPIQLF                               YTRRNTQEWTQEWKECPDYVSAGENSCYFN                               SSFTSIWIPYCIKLTSNGGTVDEKCFSVDEIVQ                               PDPPIALNWTLLNVSLTGIHADIQVRWEAPRN                               ADIQKGWMVLEYELQYKEVNETKWKMMDP                               ILTTSVPVYSLKVDKEYEVRVRSKQRNSGNY                               GEFSEVLYVTLPQMSQFTCEEDFYFPWLLITIP                               GIFGLTVMLFVFLFSKQQRIKMLILPPVPVPKI                               KGIDPDLLKEGKLEEVNTILAIHDSYKPEFHS                               DDSWVEFIELDIDEPDEKTEESDTDRLLSSDH                               EKLHINLGVKDGDSGRTSCCEPDILETDFNAII                               DIHEGTSEVAQPQRLKGEADLLCLDQKNQNN                               SPYHDACPATQQPSVIQAEKNKPQPLPTEGAE                               STHQAAHIQLSNPSSLSNIDFYAQVSDITPAGS                               VVLSPGQKNKAGMSQCDMHPEMVSLCQENF                               LMDNAYFCEADAKKCIPVAPHTKVESHIQP\S                               LNQEDIYTTESLT\TAAGSP\GTGEHVPGSEM                               PVPDYTSIHIVQSPQGL1LNATALPLPDKEFLS                               SCGYVSTDQLNKIMP               458   1808   A   3663   154   462   TRAPASGRSGAGLALSANAPDSGGHPGATEG                               PAGSLAHASGSARGTWRVRGRGSHGWERTV                               GAGGCANPALHSCASAPRGTGRVSALGPK                               TGSSPLSSPKG               459   1809   A   3664   902   135   LGKYNTSMALFDFVLHNSTGERYITEDDVIQ                               SQNALGKYNTSMALPESNSFEKTILESPYYVD                               LNQTLPVQVSLHTSDPNLVVFLDTCRASPTSD                               FASPTYDLLKSGCSRDETCK\VYPLFGHYGRF                               QFNAFKFLRSMSSVYLQCKVLICDSSDHQSRC                               \NQGCVSRSKRDISSYKWKTDSIIGPIRLKRDR                               SA\NGNSGFQHETHAEETPNQPFNSVHLFSFM                               VLALNVVTVATITVRHFVNQRADYQ\YQKLQ                               NY               460   1810   A   3670   850   557   LGILMSPQVEAGEI*ALLTPPPGCMQFSPLTL/P                               K*WVSPGLTP/PPPEVPSVFLVEPGLPHAGQA                               GLDLL\TSGDPPASTSQSARTTDVSHRAQPLAI               461   1811   A   3671   2472   2099   IGVLAFETGSCSVTRLYCIGIIMPHCSLDLAGS\                               TSAFRIAGTTSVHHHPQLTFFFFWIETGSHGV                               VQTGL*LLALSNPPALASQIAGISGMSHRAWP                               GLVLYSLEFSLLCASQSLIMLFTCYNE               462   1812   A   3672   394   110   VKPVNGESKRD*GADTQTCEGEADEQLQT\N                               CYYD/STKSFFYISCG*K\RKPTWAENRRLNA                               KMFGIPLHSNSDPWGYEEREVIGFHRSRVSRG                               HGS               463   1813   A   3673   348   1   QRNPFSAGHPQRPPTSGSQSELLAQPRLRPGR                               KSSFSRDQDVW* SQAVPKRQ*QRNPFSAGHP                               QRPPTSGSQSELLAQPRLRPGRKSSFSRDQDV                               WPGQKPRPSQQQHQMCASPTLGQRSPFALEP                               VPAYHGGRDPFASARPSPVGIPKPRAAPAGG                               GWRRIRPKSSTK               464   1814   A   3676   2253   320   PVIQRCSQPYGFSLLISFFLKCVSETSQQPPSR                               KVFQLLPSFPTLTRSKSHESQLGNRIDDVSSM                               RFDLSHGSPQMVRRDIGLSVTHEFSTKSWLS                               QVCHVCQKSMIFGVKCKHCRLKCHNKCTKE                               APACRISFLPLTRLRRTESVPSDINNPVDRAAE                               PHFGTLPKALTKKEHPPAMNHLDSSSNPSSTT                               FSTPSSPAFFPTSSNPSSATIW\NPSP\GQR\DSR                               FNFPSC/AYFIHFIR\Q\QFIFPDISAFAHAAPLPE                               AADGTRLDDQPKADVLEAHEAEAEEPEAGK                               SEAEDDEDEVDDLPSSRRPWRGPISRKASQTS                               VYLQEWDIPFEQVELGEPIGQGRWGRVHRGR                               WHGEVAIRLLEMDGHNQDIILKLPKKEVMN                               YRQTRHENVVLFMGACIVINPPHLAIITSFCKG                               RTLHSFVRDPKTSLDINKTRQIAQEIIKGMGY                               LHAKGIVHKDLKSRNVFYDNG\KVVITDFGLF                               \GISGVVP\EGRRENQLKLSHDWLCYLAPEIVR                               EMTPGKDEDQLPFSKAADVYAFGTVWYELQ                               ARDWPLKNQAAEASIWQIGSGEGMKRVLTS                               VSLGKEVSENLSACWAPDLQERPS\FSLLMD                               MLEKLPKLNRRLSHPGHF*KSADINSSKVVPR                               FERFGLGVLESSNPKM               465   1815   A   3679   8   803   TPSPAWWNSTWADTFSLLLALAVALYLGYY                               WACVLQTLIRAFCASNTEDLETVVNHIKHRYP                               QAPLLAVGISFGGILVLNHLAQARQAAGLVA                               ALTLSACWDSFETTRSLETPLNSLLFNQPLTA                               GLCQLVERLSYIE*DLQARTIRQFDERYTSVA               466   1816   A   3684   3   307   SSQYIVQSKTKIFL*AAREKQ/RHTGRRFSRLS                               ANISSQTGEARGQWPSVFKVLKEKKLSTKKS                               FGQK*GR\RKTFPDKQK/IREFDTTRPTIQEML                               TGVLQG               467   1817   A   3687   2465   837   ELPTPLIAAHQLYNYVADHASSYHMKPLRMA                               RPGGPEHNEYALVSAWHSSGSYLDSEGLRHQ                               DDFDVSLLVCHCAAPFEEQGEAERHVLRLQF                               FVVLTSQRELFPRLTADMRRFRKPPRLPPEPE                               APGSSAGSPGEASGLILAPGPAPLFPPLAAEVG                               MARARLAQLVRLAGGHCRRDTLWKRLPLLE                               PPGPDRLRLGGRLALAELEELLEAVHAKSIGD                               IDPQLDCFLSMTVSWYQSLIKVLLSRFPQSCR                               HFQSPDLGTQYLVVLNQKFTDCFVLVFLDSH                               LGKTSLTVVFREPFPVQPQDSESPPAQLVSTY                               HHLESVINTACFTLWTRLL*GSGLDH*MSLFL                               ESWAYQIACQRQD*PALLGPRASQTLSDTKG                               FVTMS*GSAAPAWQQEPPSPNTHSH*PIQDSR                               ESGQPRGPLGPFWGTPFGPPGRVSGVHTGWQ                               TPPRAPLPESCPL\PLTTVSHLCPLSLRVFTSHL                               DITAGHSHRDDTWVPTPALPLKHLRPPSSPFA                               LGPWVSHPLMRWVQKLSHLHSNPGTGFSMG                               GKQQRN               468   1818   A   3691   960   499   QTCRKDKRAIYPHFQNE*MNEIKAI*SGTGGI                               QCFHSQNDSAFFFFLFLLETEFCSAA/TVQWH                               DPLSMQPPPPGFKQFTCLSLLSSWNYREAPPPF                               PGNP\*FLVKTGFPHVGQTGFELLTSSDLAPLA                               SQNGGITGMSPCAWPFFFFFFFGLC               469   1819   A   3714   4747   495   MAYSWQTDPNPNESHEKQYEHQEFLFVNQP                               HSSSQVSLGFDQIVDEISGKIPHYESEEDENTFF                               VFTAPKWDSTGHSLNEAHQISLNEFTSKSREL                               SWHQVSKAPAIGFSPSVLPKPQNTNKECSWG                               SPIGKHHGADDSRFSILAPSFTSLDKINLEKEL                               ENENHNYHIGFESSIPPTNSSFSSDFMPKEENK                               RSGHVNIVEPSLMLLKGSLQPGMWESTWQK                               NIESIGCSIQLVEVPQSSNTSLASFCNKVKKIR                               ERYHAADVNFNSGKIWSTTTAFPYQLFSKTL                               FNIHIFIDNSTQPLHPMPCANYLVKDLIAEILH                               FCTNDQLLPKDHILSVWGSEEFLQNDHCLGS                               HKMFQKDKSVIQLHLQKSREAPGKLSRKHEE                               DHSQFYLNQLLEFMHIWKVSRQCLLTLIRKY                               DFHLKYLLKTQENVYNIIEEVKKICSVLGCVE                               TKQITDAVNELSLILQRKGENFYQSSETSAKG                               LIEKVTTELSTSIYQLINVYCNSFYADFQPVNV                               PRCTSYLNPGLPSIILSFTVYAAHNIPETWVHR                               INFPLEIKSLPRESMLTVKLFGIACATNNANLL                               AWTCLPLFPKEKSILGSMLFSMTLQSEPPVEM                               ITPGVWDVSQPSPVTLQIDFPATGWEYMKPD                               SEENRSNLEEPLKECIKHIARLSQKQTPLLLSE                               EKKRYLWFYRFYCNNENCSLPLVLGSAPGW                               DERTVSEMHTILRRWTFSQPLEALGLLTSSFP                               DQEIRKVAVQQLDNLLNDELLEYLPQLVQAV                               KFEWNLESPLVQLLLHRSLQSIQVAHRLYWL                               LKNAENEAYFKSWYQKLLAALQFCAGKALN                               DEFSKEQKLIKILGDIGERVKSASDHQRQEVL                               KKEIGRLEEFFQDVNTCHLPLNPALCIKGIDH                               DACSYFTSNALPLKITFINANLMGKNISIIFKA                               GDDLRQDMLVLQLIQVMDNIWLQEGLDMQ                               MIIYRCLSTGKDQRLVQMVPDAVTLAKIHRH                               SGLIGPLKENTTKKWFSQHNHLKADYEKALR                               NFFYSCAGWCVVTFILGVCDRHINDNIMLTKS                               GHMPIDDFGKFLGHAQTFGGIKRDRAPFIFTS                               EM\EYFITEGG\KNPQHFQDFV\ELCCRAYNIIR                               KHSQLLL\NLL\EMMLYAG\LPELSGI\QDLKY                               VYNNLRPQDTDLEATSHFTKKIKESLECFPVK                               LNNLIHTLAQMSAIISPAKSTSQTFPQESCLLST                               TRSIERATILGFSKKSSNLYLIQVTHSNNETSL                               TEKSFEQFSKLHSQLQKQFASLTLPEFPHWW                               HLPFTNSDIIRRFRDLNHYMEQILNVSHEVTN                               SDCVLSFFLSEAGQQTVEESSPVYLGEKFPDK                               KPKVQLVISYEDVKLTILVKHMKNIHLPDGSA                               PSAHVEPYLLPYPSEVRRRKTKSVPKCTDPTY                               NEIVVYDEVTELQGHVLMLIVKSKTVFVGAI                               NIRLCSVPLDKEKWYPLGNSII*PLLLFSSFGM                               KSLEKDEFVGGMLLSNPIW               470   1820   A   3718   430   75   SHGSISLLNLHQGCVFLPSLPAQGLRCYRCLA                               VLEGASCSVVSCPFLDGVCVSQKVSS/CWQ*/                               CPWGARAEGRLSAVVDSQISCCKGDLCNAV                               VLAAGSPWALCVQLLLSLGSVFLWALL               471   1821   A   3723   891   494   LRQSLINSVPQAGVQWRDSSLQAPPPRPTPLS                               CLSLPSSWDYRRLPPCLANFLYF**RRGPTML                               ARMVLIS*PRDPPASASQ\STEITGGSHRAQHP                               TDSRDHSERSVKKSHIEVISELRMKVIKCKVAF                               SKNPI               472   1822   A   3734   443   251   GFIET*NFCVSKDTSKKLS/RLPTKWKNVFAN                               *ISDKGLVSRICQELLRHLDAEQVSSTAGLSL               473   1823   A   3746   3   500   THASGGARSGAGWAGRGVRAGTEAGRQGIF                               LTLSILRTRDLPSGAMSEGVDLIDIYADEEFNQ                               DPEFNNTDQIDLYDDVLTATSQPSDDRSSSTE                               PPPPVRQEPSPKPNNKTPAILYTYSGLRNRRA                               AVYVGSFSWWTTDQQLIQVIRSIGVYDVGEV                               KFAENRAK               474   1824   A   3753   2   5262   RPLFAEEGGIYAVLVCMQEYKTSV\LVQQAG                               LAALKMLAVASSSEIPTFVTGRDSIHSLFDAQ                               MTREIFASIDSATRPGSESLLLTVPAAVILMLN                               TEGCSSAARNGLLLLNLLLCNHHTLGDQIITQ                               ELRDTLFRHSGIAPRTEPMPTTRTILMMLLNR                               YSEPPGSP\ERAALETPIIQGQDGSPELLIRSLV                               GGPSAELLLDLERVLCREGSPGGAVRPLLKRL                               QQETQPFLLLLRTLDAPGPNKTLLLSVLRVIT                               RLLDFPEAMVLPWHEVLEPCLNCLSGPSSDSE                               IVQELTCFLHRLASMHKDYAVVLCCLGAKE1                               LSKVLDKHSAQLLLGCELRDLVTECEKYAQL                               YSNLTSSILAGCIQMVLGQIEDHRRTHQPINIP                               FFDVFLRHLCQGSSVEVKEDKCWEKVEVSSN                               PHRASKLTDHNPKTYWESNGSTGSHYITLHM                               HRGVLVRQLTLLVASEDSSYMPARVVVFGG                               DSTSCIGTELNTVNVMPSASRVILLENLNRFW                               PIIQIRIKRCQQGGIDTRVRGVEVLGPKFTFWP                               LFREQLCRRTCLFTIRAQAWSRDIAEDHRRL                               LQLCPRLNRVLRHEQNFADRFLPDDEAAQAL                               GKTCWEALVSPLVQNITSPDAEGVSALGWLL                               DQYLEQRETSRNPLSRAASFASRVRRLCHLL                               VHVEPPPGPSPEPSTRPFSKNSKGRDRSPAPSP                               VLPSSSLRNITQCWLSVVQEQVSRFLAAAWR                               APDFVPRYCKLYEHLQRAGSELFGPRAAFML                               ALRSGFSGALLQQSFLTAAHMSEQFARYIDQ                               QIQGGLIGGAPGVEMLGQLQRHLEPIMVLSG                               LELATTFEHFYQHYMADRLLSFGSSWLEGAV                               LEQIGLCFPNRLPQLMLQSLSTSEELQRQFHLF                               QLQRLDKLFLEQEDEEEKRL*EEEEEEEEEEA                               EKELFIEDPSPAISILVLSPRCWPVSPLCYLYHP                               RKCLPTEFCDALDRPSSFYSQSQNHPVLDMG                               PHRRLQWTWLGRAELQFGKQILHVSTVQMW                               LLLKFNQTEEVSVETLLKDSDLSPELLLQALV                               PLTSGNGPLTLHEGQDFPHGGVLRLHEPGPQ                               RSGEALWLIPPQAYLNVEKDEGRTLEQKRNL                               LSCLLVRILKAHGEKGLHIDQLVCLVLEAWQ                               KGPNPPGTLGHTVAGGVACTSTDVLSCILHLL                               GQGYVKRRDDRPQILMYAAPEPMGPCRGQA                               DVPFCGSQSETSKPSPEAVATLASLQLPAGRT                               MSPQEVEGLMKQTVRQVQETLNLEPDVAQH                               LLAHSHWGAEQLLQSYSEDPEPLLLAAGLCV                               HQAQAVPVRPDHCPVCVSPLGCDDDLPSLCC                               MHYCCKSCWNEYLTTRIEQNLVLNCTCPIAD                               CPAQPTGAFIRAIVSSPEVISKYEKALLRGYVE                               SCSNLTWCTNPQGCDRILCRQGLGCGTTCSK                               CGWASCFNCSFPEAHYPASCGHMSQWVDDG                               GYYDGMSVEAQSKHLAKLISKRCPSCQAPIE                               KNEGCLHMTCAKCNHGFCWRCLKSWKPNH                               KDYYNCSAMVSKAARQEKRFQDYNERCTFH                               HQAREFAVNLRNRVSAIHEVPPPRSFTFLNDA                               CQGLEQARKVLAYAGVYSFYSQDAEYMDVV                               EQQTENLELHTNALQILLEETLLRGRDLASSL                               LLRADCLSTGMELLRRIQERLLAILQHSAQD                               FRVGLQSPSVEAWEAKGPNMPGSQPQASSGP                               EAEEEEEDDEDDVPEWQQDEFDEELDNDSFS                               YDESENLDQETFFFGDEEEDEDEAYD               475   1825   A   3754   1093   96   GTSRNQHSPKTHA*RSS/WPQPPPLFLPPLQPQ                               ATGRRRERTRTQQRTAALLTDGTTKTGAAW                               SRRPSLCWPSRTTGAPGAK*AVLVRSATFITN                               PPNPQSPTGAAGKLRAPGNRAGISEPSSQEPPP                               DGPASITGVAQSPATRATPSLPCLHVPAP                               SRGQTLGVRTTGRASRLTVDRSRISWPGRSA                               RSGGGRWRPNAPRGRWPRM*SWEPGSWTE                               PWRWPFPAAESPPHRCIYCTNHVSPAGPARPS                               HVYIIRATINSISHPLCRAQSSPWEAAGVWRR                               PAQPAPTSDVNTNLLRKPRVKRHDLIYQFLGN                               TLWEEGRQRPPETLQPAR               476   1826   A   3758   901   521   FFFGNGVSPCPQAGV*WHDLDSLQNLPPGFK                               RFSYLSLPSSW\DYRHVPPRQANFCIF/M*RRG                               FTMLARMVSIS*PRDLPALASQSAGITGVSHH                               APPQMDFTFALLCFAPKGCLPRQKEGGTLNLI               477   1827   A   3761   843   575   GVISAHCNLRL/CHLPGSSNSPASASQVAGTIG                               ARTTPS*IFVFLVETGFHHVSQDGLDLL/NFVI                               RPRRPLKVLGLQACTRARLPSPLKEL               478   1828   A   3763   267   1240   HLLSFHLWSASLDCLEQLSQERHVKGMLLGP                               PPVNESTKPSPSPWKLTPPMCSIPPVFPPKSGS                               PTTSWS/PSGHSKLEVERAQTGPFCLHIYCP*P                               GVTDNTTSLLHY1PFPRL\SGLVCFPAH*FPSY                               WTGHSFASQAWLRQVPEVSKHLQCPSAESLL                               TMEYHQPEDPAPGKAGTAEAVIPENHEVLAG                               PDEHPQDTDARDADGEAREREPIRRPSFAA*P                               VWGQP\ESPLPEASSAPPGPTWTLPEVETIRA                               CSMPQELP*SPRTRQPEPDFYCVKWIPWKGE                               QTPIITQSTNGPLPSPCHHEHPLSSVEGEAPPA                               EGSDHIG               479   1829   A   3766   2   2152   YSPIRLLEVCVPLPKLFIKRQAPLKVSLLQDLK                               DFFQKVSQVYVAIDERLASLKTDTFSKTREEK                               MEDIFAQKEMEEGEFKNWIEKMQARLMSSS                               VDTPQQLQSVFESLIAKKQSLCEVLQAWNNR                               LQDLFQQEKGRKRPSVPPSPGRLRQGEESKIS                               AMDASPRNISPGLQNGEKEDRFLTTLSSQSST                               SSTHLQLPTPPEVMSEQSVGGPPELDTASSSE                               DVFDGHLLGSTDSQVKEKSTMKAIFANLLPG                               NSYNPIPFPFDPDKHYLMYEHERVPIAVCEKE                               PSSIIAFALSCKEYRNALEELSKATQWNSAEE                               GLPTNSTSDSRPKSSSPIRLPEMSGGQTNRTTE                               TEPQPTKKASGMLSFFRGTAGKSPDLSSQKRE                               TLRGADSAYYQVGQTGKEGTENQGVEPQDE                               VDGGDTQKKQLINPHVELQFSDANAKFYCRL                               YYAGEFHKMREVLLDSSEEDFIRSLSHSSPWQ                               ARGGKSGAAFYATEDDRFLLKQMPRLEVQSF                               LDFAPHYFNYITNAVQQKRPTALAKILGVYRI                               GYKNSQNNTEKKLDLLVMENLFYGRKMAQ                               VFDLKGSLRNRNVKTDTGKESCDVVLLDENL                               LKMVRDNPLYIRSHSKAVLRTSIHSDSHFLSS                               HLHDYSLLVGRDDTSNELVVGIIDYIRTFTWD                               KKLEMVVKSTGILGGQG*MPTVVSPELYRTR                               FCEAMDNYFLMVPDHCTGLGLNC               480   1830   A   3777   251   3   QGCGSAGTLIHY**ECKMVQLLWKTV*QFLI                               KLNI\KDPAITLDVYPNEVKNYVRTKTYTQMF                               I/ANFIMAKSWKQPTHPSVRT               481   1831   A   3779   333   3   EAAIRQPEPNILDVNQIFKDLAMIIHDQGDLID                               SIEANAESSEVLVERAFGQLQRPA\YYQKKSR                               KKMCLVVLVQTAIILICERIM*VVYTTKWSPPI                               VLPVSCFQGQKLFN               482   1832   A   3780   2   371   TGGRQGKNDHTSITEKPSRDFNRHLITQNI*M                               PNQDMKSSSNSLIIRKVQIKPTILYHHIFTRKA                               KMKTTDKTKYR*GFKAITILIHCSQDCILQ*S                               /L*ENHFMIFPKAEQHITYDTTIPFLR               483   1833   A   3787   43   448   LMKDLSPYVMETHYILNRLNER/RSMWRHHG                               KLPNTKDQEKILKAIRGRREVIQGS/RQQYRR                               PAAFSAAEKARRLWCS/VFNIERRNL/CEYPTK                               LSFNIKGEMTFSDKTEF1TNRPSLKMLLKDRI                               QEEGKMF*KEKCFKRKE               484   1834   A   3798   1   727   FFFFETESRSVAQAGVQWCNLGSLQALPPGF\                               SHSPASASRVAGTTGTRH*ARLIFYIFSRDGVS                               PC*PGWS*SPDLVIRPP\RLPKCWDYRREPPRP                               A*FFVFLVE\QGFTMLARMVSIS*PQICDLPAS                               VSQNAGITGVSHCAWLHFCFFGFFFEMESC                               SVAQAEVQWHDLRSLQAPPPGFTPFSCLSLPG                               SWDYRRPPPRPIQTF\CIFSPDGVSPC*PGWSRS                               PDLVIRPPRPPKVLGLQA               485   1835   A   3802   1   239   FFFFEMECLTVSQAGVQWYNLHSLQPLPPGF                               KQFSCLSLPSSWD*RVPTSRPAKF/CVIF*DGV                               SHCQPGWSAVVQPPLH               486   1836   A   3811   378   98   RYD*SSQSENIP\QKEFLLKYP*CTATLGMRN                               MSIMKKKS1FSAEFYKVSLPSLLL\HLLAIEWG                               FHIEIQLTIHQHFLNYELESDFVHIVEYM               487   1837   A   3814   771   320   FDPDWTRAAGIRHEKKPKALAYRRENSPGDL                               PPPPLPPPEEEASWAL/GAEGSRQHVLPGAGA                               QWGEESGPGRAPGSPAGAPPR*RGLAP\NSRP                               SFLSRGQGTSTCSTAGSNSSRGSSSSRGSRGPG                               RSRSRSQSRSQSQRPGQKRREEPR               488   1838   A   3818   1   781   FRACLLELIPYAPTLSWTACPPAMAGPRGLLP                               LCLLAFCLAGFSFVRGQVLKGCDVKTTFVT                               HVPCTSCAAIKKQTCPSGWLRELPDQITQDCR                               YEVQLGGSMVSMSGCRRKCRKQVVQKACCP                               GYWGSRCHECPGGAETPCNGHGTCLDGMDR                               NGTCVCQENFRGSACQECQDPNRFGPDCQSV                               CSCVHGVCNHGPRGDGSCLCFAGYTGPHCD                               QELPVWQELGFPQNNPRLRKAPNCKCLPG*H                               RNGLIATPNPCRIP               489   1839   A   3822   934   669   FFFSEMESRSVTRLECSGAISAHLRTLLGSSNSP                               ASAS*VAGTIGACHHAQLIPVFLVETGPHHVG                               QDGLDLL/NLMIHPPRPPKVLGPQA               490   1840   A   3825   79   9748   QDGLDLL/NLMIHPPRPPKVLGFQA                               GCQSCWPAWPRLRRRGPASAGARLGRKAPW                               GLPGRVQDGRPLRFCFYLRPRAPFIAPVLSGA                               ASRPEASGDCRAGRETAMATLEKLMIKAFESL                               KSFQQQQQQQQQQQQQQQQQQQQQQQPPPP                               PPPPPPPQLPQPPPQAQPLLPQPQPPPPPPPPPP                               GPAVAEEPLHRPKKELSATKKDRVNHCLTIC                               ENIVAQSVRINSPEFQKLLGIAMELFLLCSDDA                               ESDVRVADECLNKVIKALMDSNLPRLQLEL                               YKEIKKNGAPRSLRAALWRFAELAHLVRPQK                               CRPYLVNLLPCLTRTSKPEESVQETLAAAVP                               KIMASFGNFANDNEIKVLLKAFIANLKSSSPTI                               RRTAAGSAVSICQHSRRTQYFYSWLLNVLLG                               LLVPVEDEHSTLLILGVLLTLRYLVPLLQQQV                               KDTSLKGSFGVTRKEMEVSPSAEQLVQVYEL                               TLHHTQHQDHNVYTGAIELLQQLFRTPPPEL                               LQTLTAVGGIGQLTAAKEESGGRSRSGSIVELI                               AGGSSCSPVLSRKQKGKVLLGEEEAIEDDS                               ESRSDVSSSALTASVKDEISGELAASSGVSTPG                               SAGIDIITEQPRSQHTLQADSVDLASCDLTSS                               ATDGDEEDILSHSSSQVSAVPSDPAMDLNDG                               TQASSPISDSSQLTEGPDSAVTPSDSSEIVLD                               GTDNQYLGLQIGQPQDEDEEATGILPDEASEA                               FRNSSMALQQAHLLKNMSHCRQPSDSSVDKF                               VLRDEATEPGDQENKPCRIKGDIGQSTDDDS                               APLVHCVRLLSASFLLTGGKNVLVPDRDVRV                               SVKALALSCVGAAVALHPESFFSKLYKVPLD                               TTEYPEEQYVSDILNYIDHGDPQVRGATAILC                               GTLICSILSRSRFHVGDWMGTRTGNTFSL                               ADCIPLLRKTLKDESSVTCKLACTAVRNCVM                               SLCSSSYSELCILQLIIDVLTLRNSSYWLVRTEL                               LETLAEIDFRLVSFLEAKAENLHRGAHHYTGL                               LKLQERVLNNVVIHLLGDEDPRVRHAAASL                               LVPKLFYKCDQGQADPVVAVARDQSSVYL                               KLLMHETQPPSHFSVSTITRIYRGYNLLPSITD                               VTMENNLSRVIAAVSHELITSTTRALTFGCCE                               ALCLLSTAFPVCIWSLGWHCGVPPLSASDESR                               KSCTVGMATMILTLLSSAWPPLDLSAHQDAL                               ILAGNLLAASAPKSLRSSWASEEEANPAATK                               QEEVWPALGDRAIVPMVEQLFSHLLKVINIC                               AHVLDDVAPGPAIKAAIPSLTNPPSLSPIRRK                               GKEKEPGEQASVPLSPKKGSEASAASRQSDTS                               GPVTTSKSSSLGSFHLPSYLKLHDVLKATHA                               NYKVTLDLQNSTEKFGGFLRSAIDVLSQREL                               ATLQDIGKCVEEILGYLKSCFSREPMMATVC                               VQQLLKTLFGTNLASQFDGLSSNPSKSQGRA                               QRLGSSSVRPGLYHYCFIVLAPYTHFTQALADA                               SLRNMVQAEQENDTSGWFDVLQKVSTQLKT                               NLTSVTKNRADKNAIHNHIRLFEPLVIKALKQ                               YTTTTCVQLQKQVLDLLAQLVQLRVNYCLL                               DSDQVFIGFVLKQFEYIEVGQFRESEAIIPNIFF                               FLVLLSYERYHSKQIIGIPKIIQLCDGIMASGR                               KAVTHAIPALQPTVHDLFVLRGTNKADAGKE                               LETQKEVVVSMLLRLIQYHQVLEMFILVLQQ                               CHKENEDKWKRLSRQIADIIILPMLAKQQMHI                               DSHEALGVLNTLFEILAPSSLRPVDMLLRSMF                               VTPNTMASVSTVQLWISGILAILRVLISQSTED                               IVLSRIQELSFSPYLISCTVINRLRDGDSTSTLE                               EHSEGKQIKNLPEETFSRFLLQLVGILLEDIVT                               KQLKVEMSEQQHTFYCQELGTLLMCLIHIFKS                               GMFRRITAAATRLFRSDGCGGSFYTLDSLNLR                               ARSMITTHPALVLLWCQILLLVNHTDYRWW                               AEVQQTPKRHSLSSTKLLSPQMSGEEEDSDLA                               AKLGMCNPEIVRRGAULFCDYVCQNLHDSE                               HLTWLIVNHIQDLISLSHEPPVQDFISAVHRNS                               AASGLFIQAIQSRCENLSTPTMLKKTLQCLEGI                               HLSQSGAVLTLYVDRLLCTPFRVLARMVDIL                               ACRRVEMLLAANLQSSMAQLPMEELNRIQEY                               LQSSGLAQRHQRLYSLLDRFRLSTMQDSLSPS                               PPVSSHPLDGDGHVSLETVSPDKDWYVHLVK                               SQCWTRSDSALLEGAELVNRIPAEDMNAFM                               MNSEFNLSLLAPCLSLGMSEISGGQKSALFEA                               AREVTLARVSGTVQQLPAVHHVFQPELPAEP                               AAYWSKLNDLPGDAALYQSLPTLARALAQY                               LVVVSKLPSHLHLPPEKEKDIVKFVVATLEAI                               SWIILIHEQIPLSLDLQAGLDCCCLALQLPGL                               WSVVSSTEFVTHACSLIYCVHFILEAVAVQPG                               EQLLSPERRTNTPKAISEEEEEVDPNTQNPKYI                               TAACEMVAEMVESLQSVLALGHKRNSGVPA                               FLTPLLRNTIISLARLPLVNSYTRVPPLVWKLG                               WSPKPGGDFGTAFPEIPVEFLQEKEVFKEFIYR                               INTLGWTSRTQFEETWATLLGVLVTQPLVME                               QEESPPEEDTERTQINVLAVQAITSLVLSAMT                               VPVAGNPAVSCLEQQPRNKPLKALDTRFGRK                               LSIIIRGTVEQEIQAMVSKRENIATHHLYQAWD                               PVPSLSPAITGALISHEKLLLQINPERELGSMS                               YKLGQVSIHSVWLGNSITPLREEEWDEEEEEE                               ADAPAPSSPPTSPVNSRKHRAGVDIIASCSQFL                               LELYSRWILPSSSARRTPAILISEVVRSLLVVS                               DLFTERNQFELMYVTLTELRRVHPSEDEILAQ                               YLVPATCKAAAVLGMDKAVAEPVSRLLESTL                               RSSHLPSRVGALHGVLYVLECDLLDDTAKQL                               IPVISDYLLSNLKGIAHCVNIHSQQHVLVMCA                               TAFYLIENYPLDVGPEFSASIIQMCGVMLSGS                               EESTPSIIYHCALRGLERLLLSEQLSRLDAESL                               VKLSVDRVNVHSPHRAMAALGLMLTCMYT                               GKEKVSFGRTSDPNPAAPDSESVIVAMERVS                               VLFDRIRKGFPCEARVVARILPQFLDDPFPPQ                               DIMNKVIGEFLSNQQPYPQFMATVVYKVFQT                               LHSTGQSSMVRDWVMLSLSNFTQRAPVAMA                               TWSLSCFFVSASTSPWVAAILPHYISRMGKLE                               QVDVNLFCLVATDFYRHQIEEELDRRAFQSV                               LEVVAAPGSPYHRLLTCLRNVHKVITC               491   1841   A   3826   469   302   SNPPASASRVAGITGVHQHAWLIFVFLVEMEF                               HHVGQAVLKLLISGDLPVSASQSA               492   1842   A   3836   392   88   VAPSPMIMPDLYFYRDPEEIEKEE*AAAEK\EE                               FQSEWTAVV/PIEFTATQSEVADWFKDMQVP                               SVPIQQFPTEDWST*PTMNDWSATSTAQ1TE                               WVRITTEWP               493   1843   A   3838   19   380   TPSDMNRAFETDTQSIGEKNRSPSEPDYFERK                               KFKRS*EKAIHIRYKIDQPEDLPLK\EFLCKLSK                               CTATLSMRNMSLMKKKCSFSEEF\LAFFPSLL                               VCHLLAIKLGFYIEIHLTTFNNTF               494   1844   A   3845   2   352   FFFLRRSLIDSVAQAEAQWL\ELGLLQAPPPGF                               KPISLP\GLPSSWDYGRPPPCPANFCIF/M*RRG                               FTVLARMVLIS*PCDPPTLASQGTAITGMSYH                               ARPQDIDFLYAHQGRCWFRLL               495   1845   A   3847   1774   40   DIFFRRAKEGMGQDEAQFSVEMPLTGKAYL                               WADKYRPRKPRFFNRVHTGFEWNKYNQTHY                               DFDNPPPKIVQGYKFNIFYPDLIDKRSTPEYFL                               EACADNKDFAILRFHAGPFYEDLAFKIVNREW                               EYSHRHGFRCQFANGIFQLWFHFKRYRYRR*                               RPWGTAGRCPRGHSKGASVKLVVTPGPLSGL                               QGRGFTSHLRPHLSFARPQFPPI*KGGHH*AC                               HGELRRHWDRLA*GPDATEGALGASFEHEG                               GQQPPADLTVQADTLHRPSARLGGAHRACPK                               RRPHRVLWRWARGAWAWRCQAREKQETQG                               QPCHITGHPLGREAEPAAAGAAPALAHRPPF                               ARTGSTE\PGPCWRPIRIICRRDPLWTPTLC\RD                               WPPTHPVLAGGVHFPAAGIIGGCVEVPVSVN                               VMGTKSH*AVLPPPPSTGPGGQGLPEGWGLE                               KGEGLPPGIPPPGLLTGPW\SMRPVTPSFAHIR                               TVAPSHSPFSGQEGRGPHGCHSPGR\SGP\AGR                               LVLQHPTGTSPTEAKRKVPPGPPEGHPTSPVT                               SPRPPTAPPRHPASSGNSSVCFSKKTCRWEKK                               SFVLMELAYWQDRMFF               496   1846   A   3849   830   442   AKSPLPLG*IQWR/NLGSLKLRLPGFK*FTCLG                               LLSSWDYRSLPPRPVNFCIINELGFHHYDQAG                               LKLLTSSALPALASQSAEITGMSHRIWPLPLLR                               RPPVIRIRAPPQRLPFNLITSLKALSPNMATF               497   1847   A   3859   2   393   ALRICTRRDGIARTGAQPAASWKGTNNYPWR                               LEMAGRPGSQEQSKDRGTGSLPPPSQRPLGPS                               PEGAGPSPPPPGIPRGGGSSSSEGPIPQLLFVPR                               VPIL               498   1848   A   3860   253   634   KNASTVYSSQGDPKSFFFLLRWSLALVAQAG                               EQ*RDLSSLQPPPPGFK*FSCLSLPSSWD\YRCP                               LPCLANF\*FLVETGFHHVGQADLKLLTSGDP                               PTSASESAGITGVSHRAWPRIHFLYWKTFFL               499   1849   A   3863   423   263   APSQISVAFLYAAIDKLFEKEI*KKIPFIIASIDKI                               KIGINLTKEVKYLYTENYITLMKEIKIDTDKW                               ICDILY*WIGKINI*KMSTPPKAIYRFNAIPTKIP                               MTFFTEIEKSIIKFIWNHKKPPNTQSNTEQKE*S                               FCSILLWVFGQFLWFHMNFMIDFSISVKNVIGI                               LVGIALNL               500   1850   A   3865   2   15246   LPRGCLWCLQRSPTPARPQPSRPARSPLPLFP                               DLRPWASDLDIMGDAEGEDEVQFLRTDDEV                               VLQCSATVLKEQLKLCLAAEGFGNELCPLEP                               TSNAQNVPPDLAICCFVLEQSLSVRALQEML                               ANTVEAGVESSQGGGHRTLLYGHAILLRHAH                               SRMYLSCLITSRSMTDICLAFDVGLQEDATGE                               ACWWTMHPASKQRSEGEKVRVGDDIILVSVS                               SERYLHLSTASGELQVDASFMQTLWNMNPIC                               SRCEEGFVTGGHVLRLFHGHMDECLTISPADS                               DDQRRLVYYEGGAVCTHARSLWRLEPLRIS                               WSGSHLRWGQPLRVRHVTTGQYLALTEDQG                               LVVVDASKAHTKATSPCFRISKEKLDVAPKR                               DVEGMGPPEIKYGESLCFVQHVASGLWLTYA                               APDPKALRLGVLKKKAMLHQEGHMDDAISL                               TRCQQEESQAARMIHSTNGLYNQFIKSLDSFS                               GKPRGSGPPAGTALPIEQVILSLQDLIIYFEPPS                               EDLQHEEKQSKLRSLRNRQSLPQEEGMLSMV                               LNCIDRLNVYITAAHFAEFAGEEAAESWKEI                               VNLLYELLASLIRGNRSNCALFSTNLDWLVS                               KLDRLEASSGILEVLYCVLIESPEVLNIIQENHI                               KSIISLLDKHGRNHKVLDVLCSLCVCNGVAV                               RSNQDLITENLLPGRELLLQTNLINYVTSIRPN                               IFVGRAEGITQYSKWYPEVMVDEVTPFLTAQ                               ATILLRVGWALTEGYTPYPGAGEGWGGNGV                               GDDLYSYGFDGLHLWTGHVARPVTSPGQHL                               LAPEDVISCCLDLSVPSISFRINGGPVQGVFESF                               NLDGLFFPVVSFSAGVKVRFLLGGRHGEFKF                               LPPPGYAPCHEAVLPRIERIHIEPIKEYRREGP                               RGPHLVGPSRCLSHTDFVPCPVDTVQIVLPPH                               LERIREKLAENIHELWALTRIEQGWTYGPVRD                               DNKRLHPGLVDFHSLPEPERNYNLQMSGIETL                               KTLLALGCHVGMADEKAEDNLKKTKLPKTY                               MMSNGYKPAPLDLSHVRLTPAQTTLVDRLAE                               NGHNVWARDRVGQGWSYSAVQDIPARRNPR                               LVPYRLLDEATKRSNRDSLCQAVRTLLGYGY                               NIEPPDQEPSQVENQSRCDRVRTFRAEKSYTV                               QSGRWYFEPEAVTTGEMRVGWARPELRPDV                               ELGADELAYVFNGHRGQRWHLGSEPFGRPWW                                QPGDVVGCMIDLTENTIIFTLNGEVLMSDSGS                               ETAFREIEIGDGFLPVCSLGPGQVGHILNLGQD                               VSSLRFFAICGLQEGFEPPAINMQRPVTTWPS                               KGLPQFEPVPLEHPHYEVSRVDGTVDTPPCLR                               LTRTWGSQNSLVEMLFLRLSLPVQFHQHFR                               CTAGATPLAPPGLQPPAEDEARAAEPDPDYE                               NLRRSAGGWSEAENGKEGTAKEGAPGGTPQ                               AGGEAQPARAENEKDATTEKNKKRGFLFKA                               KKVAMMTQPPATPTLPRLPIIDVVPADNRDD                               PEIILNTITYYYSVRVFAGQEPSCVWAGWVT                               PDYHQHDMSFDLSKVRVVTVTMGDEQGNV                               HSSLKCSNCYMVWGGDFVSPGQQGRISHTDL                               VIGCLVDLATGLMTFTANGKESNTFFQVEPN                               TKLFPAVFVLPTHQNVIQFELGKQKNIMPLSA                               AMFQSERKNPAPQCPPRLEMQMLMPVSWSR                               MPNHFLQVETRRAGERLGWAVQCQEPLTMM                               ALHIPEENRCMDILELSERLDLQRFHSHTLRL                               YRAVCALGNNRVAHALCSHVDQAQLLHALE                               DAHLPGPLRAGYYDLLTSIHIESACRSRRSML                               SEYIVPLTPETRAITLFPPGRSTENGHYRHGLP                               GVGVTTSLRPPHIIFSPPCFVAALPAAGAAEAP                               ARLSPAIPLEALRDKALRMLGEAVRDGGQHA                               RDPVGASVEFQFVPVLKLVSTLLVMCIIFGDE                               DVKQILKMIEPEVFTEEEEEEDEEEEGEEEDEE                               EKEEDEEETAQEKEDEEKEEEEAAEGEKEEG                               LEEGLLQMKLPESVKLQMCHLLEYFCDQELQ                               HRVESLAAPAERYVDKLQANQRSRYGLLIKA                               FSMTAAETARRTREFRSPPQEQINMLLQFKDG                               TDEEDCPLPEEIRQDLLDFHQDLLAHCGIQLD                               GEEEEPEEETTLGSRLMSLLEKVRLVKKKKEEK                               PEEERSAEESKPRSLQELVSHMVVRWAQEDF                               VQSPELVRAMFSLLHRQYDGLGELLRALPRA                               YTISPSSVEDTMSLLECLGQIRSLLIVQMGPQE                               ENLMIQSIGNIMNNKVFYQHPNLMIRALGMHE                               TVMEVMVNVLGGQESKEIRFPKMVTSCCRFL                               CYFCRISRQNQRSMFDHLSYLLENSGIGLGM                               QGSTPLDVAAASVIDNNELALALQEQDLEKV                               VSYLAGCGLQSCPMLVAKGYPDIGWKPCGG                               ERYLDFLRFAVPVNGESVEENANVVVRLLIR                               KPECFGPALRGEGGSGLLAAIEEAIRISEDPAR                               DGPGIRRDRRREHFGEEPPEENRVHLGHAIMS                               FYAALIDLLGRCAPEMHLIQAGKGEALRIRAI                               LRSLVPLEDLVGIISLPLQIPTLGKDGALVQPK                               MSASFPDHKASMVLFLDRVYGIENQDFLLH                               VLDVGFLPDMRAAASLDTATFSTTEMALAV                               NRYLCLAVLPLITKCAPLFAGTEHRAIMVDS                               MLHTVYRLSRGRSLTKAQRDVIEDCLMSLCR                               YIRPSMLQHLLRRLVFDVPILNEFAKMPLKLL                               TNIIYERCWKYYCLPTGWANFGVTSEEELHL                               TRKLFWGIFDSLAHKKYDPELYRMAMPCLC                               AIAGALPPDYVDASYSSKAEKKATVDAEGNF                               DPRPVETLNVIIPEKLDSFINKFAEYTHEKWAF                               DKIQNNWSYGENIDEELKTHIPMLRPYKTFSE                               KDKEIYRWPLKESLKAMIAWEWTIEKAREGE                               EEKTEKKKTAKISQSAQTYDPREGYNPQPPDL                               SAVTLSRELQAMAEQLAENYHNTWGRKKKQ                               ELEAKGGGTHPLLVPYDTLTAKEKARDREKA                               QELLKFLQMNGYAVTRGLKDMELDSSSIEKR                               FAFGFLQQLLRWMDISQEFIAHLEAVVSSGRV                               EKSPHEQEIKFFAKILLPLINQYFTNHCLYFLS                               TPAKVLGSGGHASNKEKEMITSLFCKLAALV                               RHRVSLFGTDAPAVVNCLHILARSLDARTVM                               KSGPEIVKAGLRSFFESASEDIEKMVENLRLG                               KVSQARTQVKGVGQNLTYITVALLPVLTTLF                               QHIAQHQFGDDVILDDVQVSCYRTLCSIYSLG                               TTKNTYVEKLRPALGECLARLAAAMPVAFLE                               PQLNEYNACSVYITKSPREPAILGLPNSVEEM                               CPDIPVLERLMADIGGLAESGARYTEMPHVIE                               ITLPMLCSYLPRWWERGPEAPPSALPAGAPPP                               CTAVTSDHLNSLLQNILRIIVNNLGIDEASWM                               KRLAVFAQPWSRARPELLQSHFIPTIGRLRKR                               AGKVVSEEEQLALEAKAEAQEGELLVRDEFS                               VLCRDLYALYPLLIRYVDNNRAQWLTEPNPS                               AEELFRMVGEIPIYWSKSHNPKREEQNFVVQ                               NEINNMSFLTADNKSKMAKAGDIQSGGSDQE                               RTKKKRRGDRYSVQTSLIVATLKKMLPIGLN                               MCAPTDQDLITLAKTRYALKDTDEEVREFLH                               NNLHLQGKVEGSPSLRWQMALYRGVPGREE                               DADDPEKIVRRVQEVSAVLYYLDQTEHPYKS                               KKAVWHKLLSKQRRRAVVACFRMTPLYNLP                               THRACNMFLESYKAAWILTEDHSFEDRMIDD                               LSKAGEQEEEEEEVEEKKPDPLHQLVLHPSRT                               ALTEKSKLDEDYLYMAYADIMAKSCHLEEG                               GENGEAEEEVEVSFEEKQMEKQRLLYQQARL                               HTRGAAEMVLQMISACKGETGAMVSSTLKL                               GISILNGGNAEVQQKMLDYLKDKKEVGFFQS                               IQALMQTCSVLDLNAFERQNKAEGLGMVNE                               DGTVTNRQNGEKVMADDEFTQDLFRFLQLLC                               EGHNNDFQNYLRTQTGNTTTINIIICTVDYLL                               RLQESISDFYWYYSGKDVIEEQGKRNFSKAM                               SVAKQVFNSLTEYIQGPCTGNQQSLAHSRLW                               DAVVGPLHVFAHMMMKLAQDSSQIELLKEL                               LDLQKDMVVMLLSLLEGNVVNGMIARQMV                               DSSSNVEMTLKFFDMFLKLKDIVGSEAF                               QDYVTDPRGLISKKDFQKAMDSQKQFSGPEI                               QFLLSCSEADENEMINCEEFANRFQEPARDIG                               FNVAVLLTNLSEHVPIIDPRLHNFLELAESILE                               YFRPYLGRIEIMGASRRIERIYFEISETNRAQW                               EMPQVKESKRQFIFDVVNEGGEAEKMELFVS                               FCEDTIFEMQIAAQISEPEGEPETDEDEGAGA                               AEAGAEGAEEGAAGLEGTAATAAAGATARV                               VAAAGRALRGLSYRSLRRRVRRLRRLTAREA                               ATAVAALLWAAVTRAGAAGAGAAAGALGL                               LWGSLFGGGLVEGAKKVTVTELLAGMPDPT                               SDEVHGEQPAGPGGDADGEGASEGAGDAAE                               GAGDEEEAVHEAGPGGADGAVAVTDGGPFR                               PEGAGGLGDMGDITPAEPPTPEGSPILKRKLG                               VDGVEEELPPEPEPEPEPELEPEKADAENGEK                               EEVPEPTPEPPKKQAPPSPPPKKEEAGGEFWG                               ELEVQRVKFLNYLSRNPYTLRFLALFLAFAIN                               FILLFYKVSDSPPGEDDMEGSAAGDVSGAGS                               GGSSGWGLGAGEEAEGDEDENMVYYFLEES                               TGYMEPALRCLSLLHTLVAFLCIIGYNCLKVP                               LVIFKREKELARKLEFDGLYITEQPEDDDVKG                               QWDRLVLNTPSFPSNYWDKFVKRKVLDKHG                               DIYGRERIAELLGMDLATLEITAHNERKPNPP                               PGLLTWLMSIDVKYQIWKFGVIFTDNSFLYLG                               WYMVMSLLGHYNNFFFAAHLLDIAMGVKTL                               RTILSSVTHNGKQLVMTVGLLAVVVYLYRVV                               AFNFFRKFYNKSEDEDEPDMKCDDMMTCYL                               FHMYVGVRAGGGIGDEIEDPAGDEYELYRVV                               FDITFFFFVIVILLAHQGLIIDAFGELRDQQEQV                               KEDMETKCFICGIGSDYFDTTPHGFETHTLEE                               HNLANYMFFLMYLINKDETEHTGQESYVWK                               MYQERCWDFFPAGDCFRKQYEDQLS               501   1851   A   3869   467   665   VIVAIYCQLIFDKGAKTIQ*PFQQIAL/CKRMK                               LGPCFTPCGKNSEWIRELSVRVKTIKIILEIGV                               N               502   1852   A   3888   1042   724   SGMQWEDLTPLQPLPPRFKQFSCLSLPGSWD                               YRHAP\PLLTNF\*FLVEMGFCYVGQAGRKLL                               ASSDQSALASQSAGLTGISTAPGPPFFFLNFEA                               GSCSVAQAGVQ               503   1853   A   3891   1773   1193   EVDSQSGVQ*QAPGSLQLQTPGLKNSCLLSR                               QDYRSSLPHLASCCYYYYYY/VFL*RRGLTTL                               VQGGLKLLPSSNPFASAP*TACIITQMSHCAGP                               HFNF*MFRKISCIRE*F*HTRIYDIPFLILFFKET                               LLCYPGWPQIPGLKPSSCLRLLSSWDIIRC                               APPCPASFPIFHVDRVSPPCPGLVSITFKMLLL                               L               504   1854   A   3896   279   70   MVSKSKSILMSYNHYELTFSDMKKMPEAFRR                               TQKHTIYLIPYQVIFWSTGKDAMRSFMMPFY                               QKEYYENQ*               505   1855   A   3899   2   13   EPGVPTKKTWFDKPDFNRTNSPGFQKKVQFG                               NENTKLELRKVPPELNNISKINEHFSRFGTLV                               NLQVAYNGDPEGALIQFATYEEAKKAISSTEA                               VLNNRFIKVYWHREGSTQQLQTTSPKVMQPL                               VQQPILPVVICQSVKERLGPVPSSTIEPAEAQS                               ASSDLPQVLST\LLA*QKQCIIQLL/WKAAQKT                               LLVSTSAVDNNEAQKKKQEALKLQQDVRKR                               KQEILEKHIETQKMLISKLEKNKTMKSEDKAE                               IMKTLEVLTKNITKLKDEVKAASPGRCLPKSI                               KTKTQMQKELLDTELDLYKKMQAGEEVTEL                               RRKYTELQLEAAKRGILSSGRGRGIHSRGRGA                               VHGRGRGRGRGRGVPGHAVVDHRPRALEIS                               AFTESDREDLLPHFAQYGEIEDCQTDDSSLHA                               VITFKTRAEAEAAAVHGARFKGQDLKLAWN                               KPVTNISAVETEEVEPDEEEQRELIIA               506   1856   A   3911   1952   919   DAELSGTLSLVLTQCCKRIKDTVQKLASDHK                               DIHSSVSRVGKAIDKNFDSDISSVGIDGCWQA                               DSQRLLNEVMVEHFFRQGMLDVAEELCQES                               GLSVDPSQKEPFYELNRILEALKVRVLRPALE                               WAVSNREMLIAQNSSLEFKLHRLYFISLLMG                               GTTITNQREALQYAKNFQPFALNHQKDIQVLM                               GSLVYLRQGIENSPYVHLLDAI\IQWADICDIFT                               RDACALLGLSVESPLSVSFSAGCVALPALINIK                               AVIEQRQGTGVWNQKDELPIEV\DLG*KSAGY                               HSIFACPILRQQITDNNPPMKLVCGHIISRDAL                               NKMFNGSKLKCPYCPMEQSPGDAKQIFF               507   1857   A   3936   439   18   SHPFSPAPGICPDAPPPLPRPSKGLGHPGTAGA                               PGSGARCHPPSTCSPSWASPG*GAKASPALPR                               SHGVTLLCKAQAHLCRGEDSKDASGSTSQA                               WEPG*GAWGMPRCQGPALGSCFCPPGTTVQ                               RPAKQRDKRNRHLGR               508   1858   A   3944   120   412   WCPAGTLDFPGPQEMVLLEIEVMNQLNHRNL                               IQLYAAIETPHEIVLFIVIE\YECPK*W*GLGGGT                               TRHGASRGGVCAHSIEGGELFERIVDEDYHLT                               EV               509   1859   A   3949   31   392   LTKTPSPREKGRGVLSVLLMNII*KCRVIFVKIP                               MVFFLQNFCIRIILNVA\WTGD*PNTL*KEQRG                               ITFSDSKS*YKATKIKTMWYCHKNRYID/ERN                               RIEIPEINPCICDKIIFRKLSMTTQ               510   1860   A   3954   1013   885   FSETRACCPRLEHSGRIEAIICSLNTIPGSSDPPT                               SASSVAATTG               511   1861   A   3956   1   1054   PPAWAPRSPLIWAPTSGRHPGRAALPWSTSSV                               RWQPSEKQPPPPAHRGPADSLSTAAGAAELS                               AEGAGKSRGSGEQDWVNRPKTVRDTLLALH                               QHGHSGPFESKFKKEPALTAVARTARKRKPS                               PEPEGEVGPPK\TTERPSRGCPHPQRGSRSP*L                               LHPLLCLRPLPHLIPTGPHRLKRPRM\P\SP                               MAALILVADNAGGSHASKDANQVHSITRRN                               SNSPPSPSSMNQRRLGPREVQGQGAGNTGGL                               EPVHPASLPDSSLATSAPLCCTLCHERLEDTH                               FVQCPSVPSHKFCFPCSRQSIKQQGASGEVYC                               PSGEKCPLVGSNVPWAFMQGEIATILAGDVK                               VKKERDS               512   1862   A   3957   1086   3   QDRARLDGSSATSAHCNLRLPGS*DSPASASR                               VAGTTDTHHHTWLILGSSVQTGFDHVGQAG                               LELLTSGDPPISASESAGIMGMSHCVWP*SWG                               LSHHMAPPQGDGGRARGTPGPEQSFWNLSC                               H*PRCQVPS*LMTQLIFWGRHQYNPTMKRGK                               LRHREACSLPLPGEGEPGLQPSS\*SQNPCSSPL                               FHHGL*AWLWCPELLLQGQAERII*RSPPS/FK                               CPATLSLTAWSQTKRLRSQFLLLPWL*RAL*H                               PP\CHWPSRRSLGDPLLPRSQG*RDGT*ASTFC                               SYF*DTESHLVAQAGVQWRDLGSLQPPCPRL                               K\RFSRLSPPSSYTHRYVPSHLAESCISSRDRIP                               PSRPDRSRNSNSLSR               513   1863   A   3961   3038   476   VATTSMCCNKQVIVIDKIKSASIADRCGALH                               VGDHILSIDGTSMEYCTLAEATQFLANITDQ                               VKLEILPHHQTRLALKGPDHVKIQRSDRQLT                               WDSWASNHSSELHHTNHHYNTYHPDHCRVPAL                               TFPKAPPPNSPPALVSSSFSPTSMSAYSLSSLN                               MGTLPRSLYSTSPRGTMMRRRLKKKDFKSSL                               SLASSTVGLAGQVVHTETIEVVLTADPVTGF                               GIQLQGSVFATETLSSPPLISYIEADSPAERCG                               VLQIGDRVMAINGIPTEDSTFEEASQLLRDSSL                               TSKVTLEIEFDVAESVIPSSGTFHVKLPKKHN                               VELGITISSPSSRKPGDPLVISDIKKGSVAHRT                               GTLELGDKLLAIDNIRLDNCSMEDAVQILQQC                               EDLVKLKIRKDEDNSDEQESSGAIIYTVELKR                               YGGPLG\ITISGTEEP\FDL*IISSLTKGGLAERT                               GAIHIGDRIL\AINSSSLKGKPLSEAIHLLQMAG                               ETVTLKIKKQTDAQSASSPKKFPISSHLSDLGD                               VEEDSSPAQKPGKLSDMYPSHGCPSVDSAVD                               SWDGSA\IDTS\YGTEGT\SFQASGYYNFNTYD                               WRSPKQRGS\LSPVT\KPRSQTYPDVQLSYED                               WDRSTASGFAGAA\DSAETEQEENFWSQALE                               DLETCGQSGILRELEATIMSGSTMSLNHEAPT                               PRSPAGSDRPSFQERSSSRPHYSQTTRSNTLPS                               DVGRKSVTLRKMKQEIKEIMSPTPVELHKVT                               LYKDSDMEDFGFSVADGLLEKGVYVKNIRPA                               GPGDLGGLKPYDRLLQVNHVRTRDFDCCLV                               VPLIAESGNKLDLVISRNPLASQKSIDQQSLPG                               D*SEQNSAFPQQPSHGGNLETRDLVVYV               514   1864   A   3967   833   800   LEKQGVSGMATKRLARQLGLIRRKSLAPANG                               NLGRSKSKQLFDYLIVIDFESTCWNDGKHHH                               SQEIIEFPAVLLNTSTGQIDSEFQAYVQPQEHPI                               LSEFCMELTGIKQAQVDEGVPLKICLSQFCK                               WIHKIQQQKNUFATGISEPS/DF*SKIMCICYL                               VR*RISYTY*SKHKSKGC               515   1865   A   3969   492   182   CRFWGISTHCDTCDPLSPQITEG**EGDLWSL                               DLLGPEFLARKPLFKTKTYQSTF*SISKNE/FTC                               PNFIIEEGTDLIF\*QVKHNPCHRLTPEEGTVQL                               NRADS               516   1866   A   3977   2   1357   KMLC/QKESNYIRLKRAKMDKSMFVKIKTLGI                               GAFGEVCLARKVDTKALYATKTLRKKDVLL                               RNQVAIIVKAEEDILAEADNEWVVRLYYSFQ                               DKDNLYFVMDYIPGGDMMSLLIRMGLFPESL                               ARFYIAELTCAVESVHKMGFIHRDIKPDNLLID                               RDGHIKLTDFGLCTGFRWTHDSKYYQSGDHP                               RQDSMDFSNEWGDPSSCRCGDRLKPLERRAA                               RQHQRCLAHSLVGTPNYIAPEVLLRTGYTQL                               CDWWSVGVILFEMLVGQPPFLAQTPLETQM                               KVINWQTSLHIPPQAKLSPEASDLIIKLCRGPE                               DELGKNGADEIKAHPIF*NQFDFSQ*PEDSRS                               AFKQFP*NHTTPTDTSNFDP\VDPDKLWSDDN                               EEENVNDTLNGWYKNGKHPEHAFYEFIFRRF                               FDDNGYPYNYPKPIEYEYINSQGSEQQSDEDD                               QNTGSEIKNRDLVYV               517   1867   A   3980   1358   1022   FFFKKFTQSLGFLLFSFSFLFSCFFFFHFVLFGY                               VFLDRVPLCHPGWSAVVQSQVTIVNLPPSWD                               *RCRPPH/LANLCNFCRD\SFITLPRLVLNTWA                               QAIFQPQPPKVLGLQV               518   1868   A   3986   974   666   SPEMESHPITQAGVQWHHLSSLQPLPPGFK*F                               SCFSLPE*LQYRHVPPCLANSVFSVEMG\FLH                               VGQAGLELLTSGDLPALASQSAGITG\SHRAR                               PENGFENIF               519   1869   A   3994   751   126   NQGLRIIVGLCRTCLVNQMFASSILGKSHHHS                               LISINQGHNALWKAAG\PLPLKAGYC\QSPSPC                               DSLKYG\SWDEKDLTVPQEDTHKRSVLRWIS                               QRGK\LAVEMEEGHCLL/LPLGTECLGIK\PIV                               HLFSSEMGE\NRPMVG\ARIHVYSNAALLSFTP                               LRCLGGEKHKSGLHARPVIVPSLELHYDMDSI                               AHV\FADLLLIITLPSYYIPFC               520   1870   A   3999   882   698   QSFRLSLLSSWDYRHM*PRLANF*TWFCRDRI                               SLALLPRLVSNSWPQAILPPRPPKVLGLQT               521   1871   A   4011   1346   1178   FFF*ETVSCSAS*AGVRSHDNSSLQPPSPG\SSN                               PPTSASHVAGATGTHHHAWLLSV               522   1872   A   4015   2   377   QGIALLTRMGESVKHVTGGYKLRTRPLEFAA                               IGDYLDTFALKLGTIDRIAQRIIKEEIEYLVELR                               YGPVYSTWSALEGELAEPLEGVSACIGNCST               523   1873   A   4018   341   19   ERVIHNQ1QQAQRSPHIFNARRSS/PRPNIYELP                               KVKEVCKTSKS/GQVIYKGVSIRLRANFLAEP                               L*NRREWDEAIKVLKEKQ\FLSKMVYPANLSF                               GNEGDITSFPAK               524   1874   A   4020   1067   743   FFLRWSLIDSVAQAGVKWCNLGSLQAPPPGF                               TPFSCLSLPSSWDYRIHPPPRLAN*LTNFLCF**                               RQGFTVLARMVLIS*PHDLPASASQSAGITGL                               SHCSWPTSSILS               525   1875   A   4021   781   351   QFRVIFFFLRRSHSVAQAGMQWHDHSLLQPL                               PPRLKQIF/SHLSPPSIWDYRRVPPCLVNFSIFF                               VETGSCQPCLQLLGSSNPPASASQSAGIAGISH                               QGQPE*SFDIRFACVIAALRETFQCLCSASRVN                               NKIINRPTHPVESSF               526   1876   A   4024   80   341   TPSSTSRGTEEQQSSKMAWQRREEKEHLNVR                               RSSAEDGWKADKPIVDG*TPGEDHLPTPSPFQ                               LHIHSSESQLHIISVKSPPSLSFRLM               527   1877   A   4026   593   230   DFYLYPERKKRGQMMTAVSLTTRPQESVAPE                               DVAVYFTTKEWAIMG\PAERALYRDVMLEN                               YGGGGPL*CHPTSKPALVFS\LEQGKESCFSPA                               TGSSLSRNDWPAGWIGYLELRRYTYLS               528   1878   A   4028   1160   242   GTSELLCIQRWNWGPAFPPRPGLALAPTLQLL                               VEMGSAKSVPVTPARPPPHNKHLARVADPRS                               PSAGILRTPIQVESSPQPGLPAGEQLEGLKHAQ                               DSDPRSPTLGIARTPMKTSSGDPPSPLVKQLSE                               VFETEDSKSNLPPEPVLPPEAPLSSELDLPLGT                               QLSVEEQMPPWNQTEFPSKQVFSKEEARQPT                               ETPVASQSSDKPSRDPETPRSS\GSMRNRWKF\                               NSSKVL\GKSPLHPSCQDDNSPGTLTLRQGKA                               AFKPLSENVSELK\EGA\ILGTGR\LLKTEGRA                               WEQGQD\HDKENQHFPLVES               529   1879   A   4039   2   366   KDMVLIMEMQSMITMKCPQYL*E*RKIPDITK                               CW*GCGSTG1L1FC/WS*PL*KTI*QPR*FKQI*T                               ILTIIYSIM*EHTFHNAGV*LSDIYPRFMKGYV                               HTEICT*MFIAVLFVVVKTWKQF               530   1880   A   4057   358   3   LLEVNGNTIVTVFTKAQNKKNKGSRSILFKQL                               RKYGSENLLKSKHDKNICTENYKT*IVIKEIEA                               /DTDKWKDILCSWIRRIHMKDILCSWIGRTHV                               VKISILPKVNYRFYLISIKIIMAI               531   1881   A   4061   50   278   TQGTEEIYKISSCEWVQASFSTPLITLHDFKIY                               HKATVIKMVWYWHRQ*KFSKN/RIESSEIEPH                               IYDQFIFDKGEKIIQEKGNSFFNN/MCWKNWIF                               T*KR               532   1882   A   4069   19   368   NDLLENFKFWE*FKE*LENINGTVTEKETGGV                               YKELSSPKYSGTRQFYGQTISNFPGKIISMVY                               KLFQNTE/TEGRHPISLYEFRITLITIPNKDNIYL                               QIWMPVSLMNIVTLKCPT               533   1883   A   4076   1   355   PIRKFTKVAG*KSNTPK*LAFLHINNEQFENKII                               ITNL/PFIIASKRIKYSGISLTKEMKDLYTETLLR                               KIKEDTNKWKDI/SCFWVGRILNIVKMPKNIC                               IFNAIPIKMPMMCMAKIEKNSS               534   1884   A   4088   3   1931   IIDSSTRRMESERSPLYRQLIDLGYLSSSIIWNC                               GAPGQDTKAQSMILVEQSEKLRHLSTFSHQVL                               QTRLVDAAKALNLVHCHCLDIFNQAFDMQR                               DLQITPKRLEYTRKKENELYESLMNIANRKQE                               EMKDMIVETLNTMKEELLDDATNMEFKDVI                               VPENGEPVGTREIKGCIRQIQELIISRLNQAVA                               NKLISSVDYLRESFVGTLERCLQSLEKSQDVS                               VHITSNYLKQILNAAYHVEVTFHSGSSVTRM                               LWEQIKQIIQRITWVSPPAITLEWKRKVAQEAI                               ESLSASKLAKSICSQFRTRLNSSHEAFAASLRQ                               LEAGHSGRLEKTEDLWLRVRKDHAPRILARLS                               LESRSLQDVLLHRKPKLGQELGRGQYGVVYL                               CDNWGGHFPCALKSVVPPDEKHWNDLALEF                               HYMRSLPKHERLVDLHGSVIDYNYGGGSSIA                               VLLIMERLHRDLYTGLKAGLTLETRLQIALDV                               VEGIRFLHSQGLVHRDIKLKNVLLDKQNRAKI                               TDLGFCKPEAMMSGSIVGTPIHMAPELFTGK                               YDNSVDVYAFGILFWYICSGSVKLPEAFERCA                               SKDHLWNNVRRGARPERLPVFDEECWQLME                               ACWDGDPLKRPLLGIVQPMLQGIMNRLCKS\                               NSEQPNRGLDDST               535   1885   A   4090   2   417   ALMPHEANYEEIFLKTDKDMDGFESGLEVRE                               IFLKTRIGLPSTLLAHIWALCDSKDCGKLSKD                               IIFALAFHLIT\QKLTKGIDPPLVLTPEKISPSNR                               ASLQKVTELTRKPVCIIFKGTILWRITDSIWMK                               HNRKRIWLRA               536   1886   A   4102   569   829   DHQK*KNIPCSWIGRINIVKMSILPKAIYRFSAI                               PIKIPMTFFTEI*S*NVYRITKTQE*AKAILSKK                               EQNLEESHYLDFK*YYRAV               537   1887   A   4104   54   281   SIDCEHLIRRMLVLDPSKLRLTIAQIKEHKWML                               IEVPVQRPVLYPQEQENEPSIGEFNEQVLRLM                               HSLGIDQQKTIE               538   1888   A   4109   141   314   IREIPLKIRSVVSLILKCPYKFILTFFFAGCSQPL                               VPRENITAWMNAIGLIITALPVS               539   1889   A   4111   268   1   ASRPWGHSYP*FNQQEVDTLKRPIASSEI*MM                               I*KFAT\KKSPGPYRFTAEFSHTFKEDLVPILW                               PLFPKTYREGTLPHSFYEASITL               540   1890   A   4142   198   2064   PEPGAGRAATPWGPLFWRGRGSGRCEKAAE                               AALGDFLGLHERTQQPAVDRLLSDASAQWR                               VRGHGGVRESGRAPQQPGRRRGRRPRKRPR                               GRWRREGCGAGGRGVCVAAWSQRSIAGNN                               DYRLFHKMSNSHPLRPFTAVGEIDHVHILSEH                               IGALLIGEEYGDVTFVVEKKRFPAHRVILAAR                               CQYFRALLYGGMRESQPEAEIPLQDTTAEAFT                               MLLKYIYTGRATLTDEKEEVLLDFLSLAHKY                               GFPELEDSTSEYLCTILNIQNVCMTFDVASLY                               SLPKLTCMCCMFMDRNAQEVLSSEGFLSLSK                               TALLNIVLRDSFAAPEKDIFLALLNWCKHNSK                               ENHAEIMQAVRLPLMSLTELLNVVRPSGLLSP                               DAILDAIKVRSESRDMDLNYRGMLIPEENIAT                               MKYGAQVVKGELKSALLDGDTQNYDLDHG                               FSRHPIDDDCRSGIEIKLGQPSIINHVRILLWDR                               DSRSYSYFIEVSMDELDWVRVIDHSQYLCRS                               WQKLYFPARVCRYIRIVGTHNTVNKIFHIVAF                               ECMFTNKTFTLEKGLIVPMENVATIADCASVI                               EGVSRSRNALLNGDTKNYDWDSGYTCHQLG                               SGAIVVQLAQPYMIGSIRVLLWDCDDRSY               541   1891   A   4146   282   778   GTLGYFNGARGQPQDNFFAHQ\VSHHPPISAC                               HAESENFAFWQDMKWKNKFWGKSLEIVPVG                               TVNVSLPRFGDHFEWNKVTSCIHNVLSGQRW                               IEHYGEVLIRNTQDSSCHCKITFCKAKYWSSN                               VHEVQGAVLSRSGRVLHRLFGKWHEGLYRCI                               PTPGGQCIWKP               542   1892   A   4147   44   433   SVDAYVCNDIVFSYRTTITLLEGA*LTHRYVA                               QDPKQGQLRSLHLTCDSAPAGSQGTWSTSCR                               INIILIFRGGAQ1TFLATFDDSPKAVLGDRLLLT                               SSH               543   1893   A   4153   678   11   TISYPQCLTQMYFLISFANVDTFLLPIMALDH                               YVAICSALQ*CSIITP/ELCQGLPVLA*AGSSLIS                               PVHTVIMSRLAFCSSAQISHFYRDAYLLMKIA                               CSHT4\NQHVFLGAVVLFILAPCALILVSYIRIA                               AAILRIPSPTRRRKACSICSSHISLVTLFYGTV                               LGICI*PPDSFSAQDAIATIMYTVVTSMLNPFIY                               SLMNKEVQEAVRRLFSRGSHSSWCW               544   1894   A   4158   3   538   LLYAQAGVQ*LNLSSLQPQPAGLKQSSHPSLP                               SSWDYRYSTPHPANFFVEMEFHHVAQAGLEL                               LGSGDLPTSTSHSAGITGV\SHHAPPRLISSEGS                               LLGHLLCLPMVFPLLCVFVLISSSLAGEEAAG                               LRVQKLWPAVVLSHLPVCWFHCSGIWSEVIE                               LKVGREGHVLPWQAHVVEF               545   1895   A   4160   1   412   HPLGLGLVPSEIFSPQDKKAADGSILAPARGE                               DLEAGLKGSFMDGRLQASVSVFRIQRVGSAM                               QDTASAMPGLPYYPTSHCFMAGGKSRSQGW                               ELELSGEPAPGWQVLAGYTYTQARYLRDASE                               ANVGQPLRPVDPR               546   1896   A   4174   1252   1190   FFQVFIFLFLIFFKTEFHSCGPGAVQWHNLDSL                               QPPPPRFKGFSCLSLPSSWDYRHAPAHPANFV                               FLVETGFV\GQ\ASLELPTSGDTPAS\ASQSA                               GITGVSHHA*PRASGRRCW               547   1897   A   4176   3029   1   AGPDGLAAPASCQGARGQTRVPGAFSWLAP                               GSHIIASEGLAPGVPPAGGVSAQELTAPPQEG                               WGLGAPPAAPRPESDEKRAGSDAVRSFSRGA                               RDSLGQRRLGGTRGAGPAGKGAQRTMGPAS                               GFHSFPPRPHQEPSPRSSCWQHLLWHCPWPQ                               PSRLPRLTPAQLLQGPGVLAAPPGP*HVPGFL                               AQSPWPLPSGPRSP*DPLHQGALVPLPQGGSP                               HTAPHCLPSVLSPAIQQPLLPTAST/SSRSPPAS                               TMAPIPSALAVWEPAGSSPQLSSAPADSS\PLP                               ALPKVLPPWTQKPLLQCLCQSPLPLLSFPDQI/                               RCPPACSPAAASSFSFESQPCPSAPSKASPAPA                               AL\IVGPHHPP*SQQPQSQSVHPHGPGGPQPPL                               AASSLFWMFCQPPPPHPQFLWHRPLPVTGKA                               LAS\PLCFRPAPGSLRQTPLPPQFHIPRPGLSAP/                               PPPASGTSDSSDSRSPSASAARVWPPA\SPPPP                               AARHRPHPPEYFLSPCPFSCGFPRLLGRPRRPQ                               ALQTPRAWDLPPGSSPAPLCSQPELP*APPPLP                               PFPRVA*LGSGHPPSAQVPGLW*RCV*GHPIP                               RPVGHS*SGPPHSPPL*APPQAWPLELPPSRQC                               LQPLHLRAAQPLDPCCSLSPPGPPLPVPALPS                               WPGRP*SPSPASSQPPYHAGLPGPQSSPLPPGL                               PQLPSLRSGSQQPLLFFQCPGPGAVWGKGSPQ                               PLSPHPPPP/ARTQTFPVASRSLSPGTAPYSVCL                               TPSRSASSLPEVVLASSLPKIPQSSGS\PLGPTSP                               MP*CFHRPSPPLP/LSSPFPA\LRPQAPQFPLHLP                               P*PPAPSPGCPLPPLAQQHQPSPPSPPSPHARSTLT                               PPLWPSLALLP*PLPPPPPVPSFSASLLCSLPAH                               GTFASPGLGRSCLGKPQTLPWISFWPPSGPRLA                               PGTWQPWIPVSPAPLSCLSAWDPWELPSPQPQ                               VCSTAELPTSCLLSSPGP\PAYQPPRPGCL*GPP                               GPPGLPPLQSSLSFPPPPPPVPQPPAPPALQWG                               LHLPGGRTK               548   1898   A   4180   2369   844   RIHREEDFQFILKGLARLLSNPLLQTYLPNSTK                               KIQFHQELLVLFWKICDFNKVGQPRGALQGD                               GEQLPQ*PGGRDSVRLRGVGQSCPSLELSPLG                               PSPHP*KFLFFVLKSSDVLDILVPILFFLNDAR                               ADQSRVGLMHIGVFILLLLSGECNFGVRLNKP                               YSIRVPMDIPVFTGTHIMDLLW\VFHKIITSGHQ                               RLQPLFDCLLTIVVNVSPYLKSLSMVTANKLL                               HLLEAFSTTWPLFSAAQNHHLVFFLLEVFNNI                               IQYQFDGNSNLVYAIIRKRSIFHQLANLPTDPP                               TIHKALQRRRRTPEPLSRTGSQGGAYPWRAPA                               PLPLQSQAPSRPVWWLLQALTS*PRSPRCQR                               MAPCGPWNLSPSRAWRMAARLRGSPARRHGG                               SSGDRPIHSSASGQWSPTPEWVLSWKSKLPLQ                               TIMRLLQVLVPQVEKICIDKGLTDESELLRFLQ                               HGTLVGLLPVPHILIRKYQANSGTAMWFRT                               YMWGVIYLRNVDPPVWYDTDVKLPEIQRV               549   1899   A   4191   858   321   LPWQRLGVLLSRGKIVIAVTGWLESLRTAQKT                               ALLQDGRRKVHYLFPDGKEMAEEYDEKTSE                               LLVRKWRVKSALGAMGQWQLEVGDPAPLG                               AGNLGPELIKESNANPIFMRKDTKMSFQWRIR                               NLPYPKDVYSVSVDQKERCIIVRTTNKKYYK                               KFSIPDLDRHQLPLDDALLSFA\TPTAP               550   1900   A   4192   1   1980   IRHTGSDIAGVCGWLLLSGPCGVGLDLDSPIL                               GASAMRRSEVLAEESIVCLQKALNHLREIWE                               LIGIPEDQRLQRTEVVKKHIKELLDMMIAEEE                               SLKERLIKSISVCQKELNTLCSELHVEPFQEEG                               ETTILQLEKDLRTQVELMRKQKKERKQE\LKL                               LQEQDQELC\EILCMPHYDIDSASVPSLEELNQ                               FRQHVTTLRETKASRREEF/VSSIKRQIILCME                               ELDHTPDTSFERDVVCEDEDAYCLSLENIAT+433 L                               QKLLRQ\LEMQKSQNEAVCEG\LRTQI\RELW                               DRLQIPEEEREAVATIMSGSKAKVRK\ALQ\LE                               VDRLEELEKCKTMKKVIEAIRVELVQYWDQC                               FYSQEQRQAFAPFCAEDYTESLLQLHDAEIVR                               LKNYYEVHKELFEGVQKWEETWRLFLEFER                               KASDPNRFRGGNLLKEEKQRAKLQKMLP                               KLEEELKARIELWEQEHSKAFMVNGQKFME                               YVAEQWEMHRLEKERAKQERQLKNKKQTET                               EMLYGSAPRTPSKRRGLAPNTPGKARKLNTT                               TMSNATANSSIRPIFGGTVYHSPVSRLPPSGSK                               PVAASTCSGKIIPRTGRHGANKENLELNGSI                               LSGGYPGSAPLQRNFSINSVASTYSEFADPSLS                               DSSTVGLQRELSKASKSDATSGILNSTNIQS               551   1901   A   4194   3   1008   AWIIEGLVSSPAIGAYLSASYGDSLVVLVAW                               VALLDICFILVAVPESLPEKMRPVSWGAQISW                               KQADPFASLKKVGKDSTVLL\ICITVCLSYVPE                               AG\QYSSFF\LYLR\QVIQFG\TVKIAAYIAMVIGI                               LSIVAQTAFLSILMRSLGNKNTVLLGLGFQML                               QLAWYGFGSQAWMMWAAGTVAAMSSTTFP                               AISALVSRNAESDQQGVAQGIITGIRGLCNGL                               GPALYGFIFYMFHVELTELGPKINSNNVPLQ                               GAVIPGPPFLFGACWLMSFLVAIFIPEYSKSA                               GVQKHSNSSSGSLTNTPERGSDEDIEPLLQDS                               SIWELSSFEEPGNQCTEL               552   1902   A   4197   2   14302   APYPPAPGSRQQKQKAALPGAAAAAELRGAR                               EPAPARRRGTMADGGEGEDEIQFLRTDDEVV                               LQCTATLIIKEQQKLCLAAEGFGNRLCFLESTS                               NSKNVPPDLSICTFVLEQSLSVRALQEMLANT                               VEKSEGQVDVEKWKFMMKTAQGGGHRTLL                               YGHAILLRHSYSGMYLCCLSTSRSSTDKLAFD                               VGLQEDITGEACWWTIHPASKQRSEGEKVR                               VGDDLILVSVSSERYLHLSYGNGSLHVDAAF                               QQTLWSVAPISSGSEAAQGYLIGGDVLRLLH                               GHMDECLTVPSGEHGEEQRRTVHYEGGAVS                               VHARSLWRLETLRVAWSGSHIRWGQPFRLR                               HVTTGKYLSLMEDKNLLLMDKEKADVKSTA                               FTFRSSKEKLDVGVRKEVDGMGTSEIKYGDS                               VCYIQHVDTGLWLTYQSVDVKSVRMGSIQR                               KAIMIIHEGHMDDGISLSRSQHEESRTARVIRS                               TVFLFNRFIRGLDALSKKAKASTVDLPIESVSL                               SLQDLIGYFHPPDEHLEHEDKQNRLRALKNR                               QNLFQEEGMINLVLECIDRLHVYSSAAHFAD                               VAGREAGESWKSILNSLYELLAALIRGNRKN                               CAQFSGSLDWLISRLERLEASSGILEVLHCVL                               VESPEALNIIKEGHIKSIISLLDKIIGRNHKVLD                               VLCSLCVCHGVAVRSNQHLICDNLLPGRDLL                               LQTRLVNHVSSMRPNWLGVSEGSAQYKKWY                               YELMVDHTEPPVTAEATHLRVGWASTEGYSP                               YPGGQEEWGGNGVGDDLFSYGFDGLIILWSG                               CIARTVSSPNQHLLRTDDVISCCLDLSAPSISF                               RINGQPVQGMFENFNIDGLFFPVVSFSAGIKV                               RFLLGGRHGEFKFLPPPGYAPCYEAVLPKEKL                               KVEHSREYKQERTYTRDLLGPTVSLTQAAFT                               PIPVDTSQIVLPPHLERLREKLAENIHELWVMN                               KIELQWQYGPVRDDNKRQEPCLVEFSKLPEQ                               ERNYNLQMSLETLKTLLALGCHVGISDEHAE                               DKVKKMKLPKNYQLTSGYKPAPMDLSFIKLT                               PSQEAMVDKLAENAHNVWALRDRIRQGWTY                               GIQQDVKNRRNPRLVPYTPLDDRTKKSNKDS                               LREAVRTLLGYGYNLEAPDQDHAARAEVCS                               GTGERFRIFRAEKTYAVKAGRWYFEFETVTA                               GDMRVGWSRPGCQPDQELGSDERAFAFDGF                               KAQRWHQGNEHYGRSWQAGDVVGCMVDM                               NEHTMMFTLNGEILLDDSGSELAFKDFDVGD                               GFIPVCSLGVAQVGRMNFGKDVSTLKYFTIC                               GLQEGYEPFAVNTNRDITMWLSKRLPQFLQV                               PSNHEHLEVTRIDGTLDSSPCLKVTQKSFGSQN                               SNTDIMFYRLSMPIECAEVFSKTVAGGLPGAG                               LFGPKNDLEDYDADSDFEVLMKTAIIGHLVP                               DRVDKDKEATKPEFNNHKDYAQEKPSRLKQ                               RIFLLRRTKPDYSTSHSARLTEDVLADDRDDY                               DFLMQTSTYYYSVRIFPGQEPANVWVGWITS                               DFHQYDTGFDLDRVRTVTVTLGDEKGKVHE                               SIKRSNCYMVCAGESMSPGQGRNNNGLEIGC                               VVDAASGLLTFIANGKELSTYYQVEPSTKLFP                               AVFAQATSPNVFQFELGRIKNVMPLSAGLFKS                               EHKNPVPQCPPRLHVQFLSHVLWSRMPNQFL                               KVDVSRISERQGWLVQCLDPLQFMSLHIPEEN                               RSVDILELTEQEELLKFHYHTLRLYSAVCALG                               NHRVAHALCSHVDEPQLLYAIENKYMPGLLR                               AGYYDLLIDIHLSSYATARLMMNNEYIYPMT                               EETKSITLFPDENKKHGLPGIGLSTSLRPRMQF                               SSPSFVSISNECYQYSPEPPLDILKSKTIQMLTE                               AVKEGSLHARDPVGG1TEFLFVPLIKLFYTLLI                               MGIFHNEDLKHILQLIEPSVFKEAATPEEESDT                               LEKELSVDDAKLQGAGEEEAKGGKRPKEGLL                               QMKLPEPVKLQMCLLLQYLCDGQVRHRIEAI                               VAFSDDFVAKLQDNQRFRYNEVMQALNMSA                               ALTARKTKEFRSPPQEQINMLLNFKDDKSECP                               CPEEIRDQLLDFHEDLMTHCGIELDEDGSLDG                               NSDLTIRGRLLSLVEKVTYLKKKQAEKPVES                               DSKKSSTLQQLISETMVRWAQESVIEDPELVR                               AMFVLLHRQYDGIGGLVRALPKTYTINGVSV                               EDTINLLASLGQIRSLLSVRMGKEEEKLMIRG                               LGDIMNNKVFYQHPNLMRALGMHETVMEV                               MVNVLGGGESKEITFPKMVANCCRFLCYFCR                               ISRQNQKAMFDHLSYLLENSSVGLASPAMRG                               STPLDVAAASVMDNNELALALREPDLEKVVR                               YLAGGGLQSCQMLVSKGYPDIGWNPVEGER                               YLDFLRFAVFCNGESVEENANVVVRLLIRRPE                               CFGPALRGEGGNGLLAAMEEAIKIAEDPSRD                               GPSPNSGSSKTLDTEEEEDDTLHMGNAIMTFY                               SALIDLLGRCAPEMHLIHAGKGEAIRIRSILRS                               LIPLGDLVGVISIAFQMPTIAKDGNVVEPDMS                               AGFCPDHKAAMVLFLDRVYGIEVQDFLLHLL                               EVGFLPDLRAAASLDTAALSATDMALALNRY                               LGTAVLPLLTRGAPLFAGTEHHASLIDSLLHT                               VYRLSKGCSLTKAQRDSIEVCLLSICGQLRPS                               MMQIILLRRLVFDVPLLNEHAKMPLKLLTNH                               YERCWKYYCLPGGWGNFGAASEEELHLSRK                               LFWGIFDALSQKKYEQELPKLALPCLSAVAG                               ALPPDYMESNYVSMMEKQSSMDSEGNFNPQ                               PVDTSNITIPEKLEYFINKYAEHSHDKWSMDK                               LANGWIYGEIYSDSSKVQPLMKPYKLLSEKE                               KEIYRWPIKESLKTMLARTMRTERTREGDSM                               ALYNRTRRISQTSQVSVDAAHGYSPRAIDMS                               NVTLSRDLHAMAEMMAENYHNIWAKKKKM                               ELESKGGGNHPLLVPYDTLTAKEKAKDREKA                               QDILKFLQINGYAVSRGFKDLELDTPSIEKRFA                               YSFLQQLIRYVDEAHQYLLEFDGGSRGKGEHF                               PYEQEIICFFAKVVLPLIDQYFKNHRLYFLSAA                               SRPLCSGGHASNKEKEMVTSLFCKLGVLVRII                               RISLFGNDATSIVNCLHILGQTLDARTVMKTG                               LESVKSALRAFLDNAAEDLEKTMENLKQGQF                               THTRNQPKGVTQIINYTTVALLPMLSSLFEHI                               GQHQFGEDLILEDVQVSCYRILTSLYALGTSK                               SYVERQRSALGECLAAFAGAFPVAFLETIILD                               KHNIYSIYNTKSSRERAALSLPTNVEDVCPNIP                               SLEKLMEEIVELAESGIRYTQMPHVMEVTLPM                               LCSYSRWWEHGPENNPERAEMCCTALNSE                               HMNTLLGNILKIIYNNLGIDEGAWMKRLAVF                               SQPIINKVKFQLLKTHFLPLMEICLKICKAATVV                               SEEDHLKAEARGDMSEAELLILDEFHLARDL                               YAFYPLLIRFVDYNRAKWLKEPNPEAEELFR                               MVAEVFWWSKSHNFKREEQNFVVQNEINN                               MSFLITDTKSKMSKAAVSDQERKKMKRKGD                               RYSMQTSLIVAALKRLLPIGLNICAPGDQELIA                               LAKNEFSLKDTEDEVRDIIRSNIHLQGKLEDP                               AIRWQMALYKDLPNRTDDTSDPEKTVERVL                               DIAIWLFHLEQKSKRVGRRHYCLVEHPQRSK                               KAVWHKLLSKQRKRAVVACFRMAPLYNLPR                               KRAVNLFLQGYEKSWTETEEHYFEDKLIEDLA                               KPGAEPPEEDEGTKRVDPLHQLILLFSRTALT                               EKCKLEEDFLYMAYADIMAKSCHDEEDDDG                               EEEVKSFEEKEMEKQKLLYQQARLHDRGAA                               EMVLQTISASKGETGPMVAATLKLGIAILNGG                               NSTVQQKMLDYLKEKKDVGFFQSLAGLMQS                               CSVLDLNAFERQNKAEGLGMVTEEGSGEKV                               LQDDEFTCDLFRFLQLLCEGHNSDFQNYLRT                               QTGNNTTVNIIISTVDYLLRVQESISDFYWYY                               SGKDVIDEQGQRNFSKAIQVAKQVFNTLTEYI                               QGPCTGNQQSLAHSRLWDAVVGFLHVFAHM                               QMKLSQDSSQIELLKELMDLQKDMVVMLLS                               MLEGNVVNGTIGKQMYDMLVESSNNVEMIL                               KFFDMFLKLKDLTSSDTFKEYDPDGKGVISK                               RDFHKAMESHKHYTQSETEFLLSCAETDENE                               TLDYEEFVKRFHEPAKDIGFNVAVLLTNLSEH                               MPNDTRLQTFLELAESVLNYFQPFLGRIEIMG                               SAKRIERVYFEISESSRTQWEKPQVKESKRQFI                               FDVVNEGGEKEKMELFVNFCEDTIFEMQLAA                               QISESDLNERSANKEESEKERPEEQGPRMAFF                               SILTVRSALFALRYNILTLMRMLSLKSLKKQM                               KKVKKIVITVKDMVTAFFSSYWSIFMTLLHFV                               ASVFRGFFRIICSLLLGGSLVEGAICKIKVAELL                               ANMPDPTQDEVRGDGEEGERKPLEAALPSED                               LTDLKELTEESDLLSDIFGLDLKREGGQYKLIP                               HNPNAGLSDLMSNPVPMIPEVQEKFQEQKAK                               EEEKEEKEETKSEPEKAEGEDGEKEEKAKED                               KGKQKLRQLHTHRYGEPEVPESAFWKKIIAY                               QQKLLNYFAEI\IFYNMEMLALFVAFAINFILL                               FYKVSTSSVVEGKELPTRSSSENAKVTSLDSS                               SHRIIAVHYVLEESSGYMEPTVRILPILHTVISF                               FCIIGYYCLKVPLVIFKREKEVARKLEFDGLYI                               TEQPSEDDTKGQWDRLVINTQSFPNNYWDKF                               VKRKVMDKYGEFYQRDRISELLGMDKAALD                               FSDAREKKKPKKDSSLSAVLNSIDVKYQMW                               KLGVVFTDNSFLYLAWYMT               553   1903   A   4199   31   767   LPELNGRGAGLRRAEPSERGGGAERTQQVAA                               LPLSHGIISHGGGGCRCAAERNGAARGSAAC                               AYGLYLRIDKGRLQCLNESREGSGRGVFKPW                               ERAD\DRSKPVESDADEELLFNIPFTG\HVKLK                               GIIIMGEDDDSHPSEMRLYKNIPQMSFDDTER                               EPDQTFSLNRDLTGELEYATKISRFSNVYHLSI                               HTSKNFGADTTKVFYIGLRGEWTELRRHEVTI                               CNYEASANPADIIRVHQVTPQTIIFIS               554   1904   A   4200   1   961   GIPCTEMGNFDNANVTGELEFAIHYCFKTHSL                               EICIKACKNLAYGEEKKKKCNPYVKTYLLPD                               RSSQGKRKTGVQRNTVDPTFQETLKYQVAPA                               QLVTRQLQVSVWHLGTLAERVFLGEVIIPLAT                               WDFEDSTTQSFRWHPLRAKADKYEDSVPQS                               NGELTVRAKLVLPSRTRKLQEAQEGTDQPSL                               HGQLCLVVLGAKNLPVRPDGTLNSFVKGCLT                               LPDQQKLRLKSPVLRKQACPQWKHSFVFSGV                               TPAQLRQSSLELTVWDQALFGMNDRLLGGT\                               RLGSKGDTAVGGDACSQSKLQWQKVLSSPN                               LWTDMTLVLH               555   1905   A   4211   331   2419   KENKKARNLEMNQSRSRSDGGSEETLPQDH                               NHHENERRWQQERLHREEAYYQFINELNDE                               DYRLMRDHNLLGTPGEITSEELQQRLDGVKE                               QLASQPDLRDGTNYRDSEVPRESSHEDSLLE                               WLNTFRRTGNATRSGQNGNQTWRAVSRTNP                               NNGEFEFSLEIHVNHENRGFELHGEDYTDIPLS                               DSNRDHTANRQQRS1\SPVARRTRSQTSVNFN                               GSSSNIPRTRLASRGQNPAEGSFSTLGRLRNGI                               GGAAGIPRANASRTNFSSHTNQSGGSELRQRE                               GQRFGAAHVWENGARSNVTVRNTNQRLEPI                               RLRSTSNSRSRSPIQRQSGTVYHNSQRESRPV                               QQTTRRSVRRRGRTRVFLEQDRERERRGTAY                               TPFSNSRLVSRITVEEGEESSRSSTAVRRIWHT                               LDLQVR\RIRPGENRDRDSIANRTRSRVGLAE                               NTVTIESNSGGFRRTISRLERSGIRTYVSTITVP                               LRRISENELVEPSSVALRSILRQLMTGFGELSSL                               MEADSESELQRNGQHLPDMHSELSNLGTDN                               NRSQHREGSSQDRQAQGDSTEMHGENETTQP                               HTRNSDSRGGRQLRNPNNLVETGTLPILRLAII                               FFLLNESDDDDIURGLTKEQIDNLSTRIIYEHN                               SIDSELGKICSVCISDYVTGNKLRQLPCMHEF                               HIHCIDRWLSENCTCPICRQPVLGSNIANNG               556   1906   A   4212   3   462   LQRQRQHPAAAPAVPVRCFTFCFTDIVIMPKR                               KSPENTEGKDGSKVTKQEPTRRSAELSAKPA                               PPKPEPKPRKTSAKKEPGAKISRGAKGKKEEK                               QEAGKEGTAPSENGETKAEEIHISRSTVNVST                               SRGTPPSTLSVKGQIETVRVKGTEN               557   1907   A   4213   774   507   ARRFSCLTLQTSWGHRH\GPPRP\ANFVFLVET                               GFLHIGQAGHKLPTSGDPPASASQSARITGMS                               HRTWFLASFLIDSCKNFIVYKIMYTL               558   1908   A   4225   3   1253   TYRHAEREHPETSSATKVSYDYRHKRPKLLD                               GDQDFSDGRTQKYCKEEDRKYSFQKGPLNRE                               LDCFNTGRGRETQDGQVKEPPKPSKKDSIAC                               TYSNKNDVDLRSSNDKWKEKKKKEGDCRKE                               SNSSSNQLDKSQKLPDVKFSPINLRKKSLTVK                               VDVKKTVDTFRVASSYSTERQMSHDLVAVG                               RKSENFHPVFEHLDSTQNTENKPTGEFAQEIIT                               IIHQVKANYFPSPGITLHERFS\KMADIHKADV                               NETPLNSDPEIHRRIDMSLAELQSKQAVIYESE                               QTLIKIIDPNDLRHDIERREKERLQNEDEHIFHI                               ASAAERDDQNSSFSKNYITQRKDIITHKPFEV                               EGNHRNTRVRPFKSNFRGGRCQPNYKSGLVQ                               KSLYIQAKYQRLRFTGPRGFITHKFRERLMRK               559   1909   A   4235   1   323   KFSIPFFLRWSFTLV\PRLEGNDMISVHCNLGL                               LGLSHSPASASQVGGITGTQHHTGLIFGFLIET                               EFHHVGQAGLELLTSGDPPALAFQSAGITGVS                               HHAWLQVLNS               560   1910   77   4246   2   1569   TLSLLERVLMKDIVTPVPQEEVKTVLRKCLEQ                               AALVNYSRLSEYAKIEGKKREMYELPVFCLA                               SQVMDLTIQNQKDAENVGRLITPAKKLEDTIR                               LAELVIEVLQQNEEHHAEAIFAWWSDLMVEH                               AETFLSLFAVDMDAALEVQPPDTWDSFPLFQ                               LL\NDFLRTGLLICGNGK\FIIKHLQDLFAPLVV                               R/YMWDLDGSSPIAQSIHRGLLSRESWEPVNN                               GSGTSEDLFWKLDALQTFIRDLHWPEEEFGK                               HLEQRLKLMASDMIESCVKRTR\IAFEVKLQK                               TSSIQQIFRVPQFNMAPCFNVMGLMAKGSIQP                               KL\CSMEMGQEFAKMWIIQYHSKIDELIEETV                               KEMITLLVAKFVTILEGVLAKLSRYDEGTLFS                               SFLSFTVKAASKYVDVPKPGMDVADAYVTF                               VRHSQDVLRDKVNEEMYIERLFDQWYNSSM                               NVICTWLTDRMDLQLHIYQLKTLIRMVKKTY                               RDFRLQGVLDSTLNSKTYETIRNRLTVEEATA                               SVSEGGGLQGISMKDSDEEDH               561   1911   A   4257   1300   654   SELVQFLLIKDQKKIPIKRADILKHVIGDYKDI                               FPDLFKRAAERLQYVFGYKLVELEPKSNTYIL                               INTLEPVEEDAEMRGDQGTPTTGLLMIVLGLI                               FMKGNTLKETEAWDFLLAL\GVYPTKKHLLFG                               DPKKLITEDFVRQRYLEYRRIPHTDPVDYEFQ                               WGPRTNLETSKMKVLKFVAKVLINQDPKDW                               PAQYCEALADEENRAEPQPSGPAPSS               562   1912   A   4260   1   1498   MVTWLYRFLPTSNMAAKLRSLLPPDLRLQF                               WLHARLQKCFLSRGCGSYCAGAKASPLPGK                               MAMGLMCGRRELLRLLQSGRRVHSVAGPSQ                               WLGKPLTTRLLFPAAPCCCRPHYLFLAASGPR                               SLSTSAISFAEVQVQAPPVVAATPSPTAVPEV                               ASGETADVVQTAAEQSFAELGLGSYTPVGLI                               QNLLEFMHVDLGLPWWGAIAACTVFARCLIF                               PLIVTGQREAARIHNHLPEIQKFSSRIREAKLA                               QDHIEYYKASSEMALYQKKHGIKLYKPLILPV                               TQAPIFISFFIALREMANLPVPSLQTGGLWWF                               QDLTVSDPIYILPLAVTATMWAVLELGAETG                               VQSSDLQWMRNVIRMMPLITLPITMHFPTAV                               FMYWLSSNLFSLVQVSCLRIPAVRTVLKIPQR                               VVHDLDKLPPREGFLESFKKGWKNAEMTRQ                               LREREQRMRNQLELAARGPLRQTFTHNPLLQ                               PGKDNPPNIPSS\SSSSSKPKSKYPWHDTLG               563   1913   A   4265   623   116   MGGLAPTQTLEPT\REYQNTQLSVSYLLPEQN                               THGTRETLSSGPSNNLPLPLSSSATMPSMQCK                               HRSPNGGLFRQSPVKITPPIPMSFQPVPGGV\L                               PRGSGNPPHGTSILTAPPALLPHPPTHPTQQSF                               LIQENNNTNHTHSHTHTYTETLSFFLYICVNN                               DRMEWGICSVF               564   1914   A   4270   3   368   ILKRKLSSLNSEVSTIQNTRMLAFKATAQLFIL                               GCTWCLGLLQVGPAAQVMAYLFTIINSLQGF                               FIFLVYCLLS\QQVQKQYQKWFREIVKSKSES                               ETYTLSSKMGPDSKFSEGDVFPRTSE               565   1915   A   4288   83   406   RNSRPLWCSPPASQPRQAPVSQSCCCPLPSSSS                               PPSALLAPTKPRALGTLRLYECSPELCTTMLP                               PAWLLMLCQAPRPQDPDPRLTQPEKSLQEAP                               GQTGASRTPRT               566   1916   A   4298   1041   229   LNSSQKLACLIGVEGGHSLDSSLSVLRSFYVL                               GVRYLTLTFTCSTPWAESSTKFRHHMYTNVS                               GLTSFGEKVVEELNRLGMMIDLSYASDTLIRR                               VLEVSQAPVIFSHSAARAVCDNLLNVPDDILQ                               LLKKNGGIVMVTLSMGVLQCNLLANVSTVA                               DHFDHIRAVIGSEFIGIGGNYDGTGRFPQGL\E                               DVSTYPVLIEELLSRSWSEEELQGVLRGNLLR                               VFRQVEKVREESRAQSPVEAEFPYGQLSTSCH                               FHLGASEWTPRLLIWR               567   1917   A   4299   1   1106   GATPLGSVGGRTCKMDAATLTYDTLRFAEFE                               DFPETSEPVWILGRKYSIFTEKDEILSDVASRL                               WFTYRKNFPAIGGTGPTSDTGWGCMLRCGQ                               MIFAQALVCRHLGRDWRWTQRKRQPDSYFS                               VLNAFIDRKDSYYSIHQIAQMGVGEGKSIGQ                               WYGPNTVAQVLKKLAVFDTWSSLAVHIAMD                               NTVVMEEIRRLCRTSVPCAGATAFPADSDRR                               CNGFPAGAEVTNRPSPWRILVLLIPLPLGLTD                               INEAYVETLKHCFMMPQSLGVIGGKPNSAIIY                               FIGYVGEELIYLDPHTTQPAVEPTDGCFIPDES                               FHCQHIPPCRMSIAELDPSIAVVRGGHLSTQAF                               GAECCLGMTRKTFGFLRFFFSMLG               568   1918   A   4300   2012   1843   SRKFLTTTPTVLYFLTSFYTKYDQIHFVLNTVS                               LMSVLIPKLPQLHGVRIFGINKY               569   1919   A   4302   186   531   WTFCLFIIWWVPESARWLLTQGHVKEAHRY                               LLHCARLNGRPVCEDSFSQEVRVNVCVSMHI                               CVWWGVGCVKCLPPRAHHIWQEKPLGPHRT                               VTESKLEAEGKTKEKAREKERKKKS               570   1920   A   4308   3   869   RSGQGKVYGLIGREEFQQMDVLEGLNLLLTIS                               GKRNKLRVYYLSWLRNKILHNDPEVEKKQG                               WTTVGDMEGCGHYRVVKYERIKFLVIALKSS                               VEVYAWAPKPYHKFMAFKSFADLPHRPLLV                               DLTVEEGQRLKVIYGSSAGFHAVDVDSGNSY                               DIYIPVHIQSQITPHAIIIFLPNTDGMEMLLCYE                               DEGVYVNTYGRIIKDVVLQWGEMPTSVAYIC                               SNQIMGWGEKAIEIRSVETGHLDGVFMIHKRA                               QRLKFLCERNDKVFFASVRSGGSSQVYFMTL                               NRNCIMNW               571   1921   A   4309   9   524   ASREMDVTKVCGEMRYQLNKTNMEKDEAE                               KEHREFRAKTNRDLEIKDQEIEKLRIELDESK                               QHLEQEQQKAALAREECLRLTELLGESEHQL                               HLTRQEICDSIQQSFSKEAKAQALQAQQREQE                               LTQKIQQMEAQHDKTENEQYLLLTSQNTFLT                               KLKEECCTLAKKLEQISQ               572   1922   A   4318   1   1119   GATPLGSVGGRTGKMDAATLTYDTLRFAEFE                               DFPETSEPVWLLGRKYSIFTEKDEILSDVASRL                               WFTYRKNFPAIGGTGPTSDTGWGCMLRCGQ                               MIPAQALLVCRELGRDWRWTQRKRQPDSYFS                               VLNAFIDRKDSYYSIHQIAQMGVGEGKSIGQ                               WYGPNTVAQVLKKLAVFDTWSSLAVHIAMD                               NTVVMEEIRRLCRTSVPCAGATAFPADSDRH                               CNGFPAGAEVTNRFSPWEPLVLLIPLRLGL\T                               DINEAYV\ETL\KHCFHGWPQFPGIVVHREGK                               PNSAHYFIGYVGEELIYLDPHTTQPAVEPTDG                               CFLPDESFHCQHPPGRMSIAELDPSLAVVRGGH                               LSTQAFGARCCLGMTRKTFGFLRFFFSMLG               573   1923   A   4333   363   1066   GGVPVGLASKPFQILYGHTNEVLSVGISTELD                               MAVSGSRDGTVIIHTIQKGQYMRTLRPPCESS                               LFLTIPNLAISWEGHIVVYSSTEEKTTLK\ERM                               HYICFSINGKYLGSQILKEQVSDLCIIGEHIVTG                               SIQGFLSIRDLHSLNLSINPLAIVIELPIIICVCVT                               KEYSHILVGLEDGKLIVVGVGKPAEVKPSISN                               FISHAVGDYFGSPSFQLIEKSPLGNKLKAKFD                               FSKGSK               574   1924   A   4346   359   1234   MDTLEEVTWANGSTALPPPLAPNISVPHRCLL                               LLYEDIGTSRVRYWDLLLLIPNVLFLIFLLWK                               LPSARAKIRITSSPIFITFYILVFVVALVGIARA                               VVSMTVSTSNAATVADKILWEITRFFLLAIEL                               SVIILGLAFGHLESKSSIKRVLAITTVLSLAYSV                               TQGTLFILYPDAHLSAEDFNIYGHGGRQFWL                               VSSCFFFLVYSLVVILPKTPLKERISLPSRRSFY                               VYAGILALLNLLQGLGSVLLCFDIIEGLCCVD                               ATI2FLYFSFFAPLTYVAFLRGFFGSEPKILF               575   1925   A   4360   2038   1512   GCWWRHPWLASQRDCLDCRIQLAEKFVKAV                               SKPSRPDMMPIRVKEVYRLEEMEKIFVRILEM                               KIIKGSSGTPKLSYTGRDDRIIFVPMGLYIVRT                               VNEPWTMGFSKSFKKKFFYNKKTKDSTFDLP                               ADSIAFFHICYYGRLFWEWGDGIRVHDSQKP                               QDQDKLSKEDVLSFIQMHRA               576   1926   A   4365   69   500   QVEGRQGREVKRTAWRISPVWRPARCRRRST                               PQP/PEIPGAQQQERHRQGEAPMQALDPRAEP                               GPQAQSHAACQPEPEPPRVLLDPTAARGGVQ                               GRP/GLSRHPGLAPHPQTHTPWPQSGRLPCAS                               EPLPLGGIRPTPGLEPKGRDLM               577   1927   A   4366   785   502   SAPPKKKNGVLFLSPRLKSSGAIWVHSTPTLW                               ASSNSRASTPKVAGITGARPHARIIFVFLIEMG                               FHNVGQAGLIDTLTLVIGPPQPPKLLGLQM               578   1928   A   4367   1   221   FFFFLKKSRCVTQAGVQG\PISLHPPPPGFKRF                               SRLSLLSSWDYRHP/HAANFCIFSRDG\VSPYW                               SGWSRTPDLR               579   1929   A   4383   1   224   FETESHSVTQAGMQWHNLGSLQPMP/PGLKR                               FSCLRLQSSWDHRHAPPHLAHFCIFSRDGVSP                               CWPGWSSTPDLK               580   1930   A   4397   410   94   SRLPYSNVTAKKLPATNIPNLDCFTAKLYQ                               \VFKKGI\IHILHELFQNKEEGAFPNS/FYEASFT                               LRPKSDRDIAKEESYSTLSLLSTDTKILMSKYK                               QLKSSDL               581   1931   A   4414   670   3   VLVHRQCGG1LRLRKEAVSVLDSADIEVTDS                               RLPHATIVDHRPQHRWLETCNAPPQLIQGKA                               RSAPKPSQASGHFSVELVRGYAGFGLTLGGG                               RDVAGDTPLAVRGLLKDGP\AQRCGRLEVGD                               LVLHINGESTQGLT\AQAVERIRAGGPQLHL                               VIRRPLETHPGKPRGVGEPRKGVVPSWPDRSP                               DPGGPEVTGSRSSSTSLVQHPPSRTTLKKTRG                               SPE               582   1932   A   4424   194   449   VLYIRKKKRLEKLRLIQLMPMYNFDPTEEQDE                               LEQELLEIIGRDAASVQAATSVQAMQGKTTL                               PS\QGPLQRPSRLVFT\DVANAIHV               583   1933   A   4435   1   166   APGPPVPPPGSPPEQMPGPCPASMPPIDPPPGS                               PPEQMPGPCPVSAPP/GPPPGSPPEQMPGPCPV                               SAIPPALLQDTSV               584   1934   A   4439   1   628   SATPQQPSAPQHQGTLNQPPVPGMDESMSYQ                               APPQQLPSAQPPQPSNPPHGAHTLNSGPQPGT                               APATQHSQAGPATGQAYGPHTYTEPAKPKK                               GQQLWNRMKPAPGT\EVSSSTSRSDPLLLPPR                               ALAIPTQRASTVVLAPSPT/SEKVQNHSGSSAR                               GNLSGKPDDWPILGHERVCGALLHRL*VGGG                               QGPHGKAAQGGAAGAAAGRLGLYH               585   1935   A   4463   10   144   HKPVTNSRDTQEVPLEKAKQVLKIIATFKHTT                               SIFDDFAHYEKRQ               586   1936   A   4464   1309   103   LNAESYVSFTTKLDIPTAAKYEYGVPLQTSDS                               FLRPSSLTSSLCTDNNPAAFLVNQAVKCTRK                               NLEQCEEIEALSMAFYSSPEILRVPDSRKKVPI                               TVQSIVIQSLNKTLTRREDTDVLQPTLVNAGH                               FSLCVNVYLEVKYSLTYTDAGEVTKADLSFV                               LGTVSSVVVPLQQKFEIHFLQENTQPVPLSGN                               PGYVVGLPLAAGFQPHKGSGIIQTTNRYGQLT                               ILHSTTEQDCLALEGVRTPVLFGYTMQSGCK                               LRLTGALPCQLVAQKVKSLLWGQGFPDYVA                               PFGNSQGP/ADMLDWVPIHFITQSFNRKDSCQ                               LPGALVIEVKWTKYGSLLNPQAKIVNVTANLI                               SSSFPEANSGNERTILISTAVTFVDVSAPAEAG                               FRAPPAINARLPFNFFFPFV               587   1937   A   4471   614   387   LLGRASAC/LQLQSSW/D/HRPMLPYLANFVF                               CKDRISFTWLPRLVLNSWLQVILLPWPPTGCD                               NKHEPPCPATKRRHSGSI               588   1938   A   4480   1720   1458   HDLGSLQPPPPGFKRFSCLSLPSSWDYRLMPP                               CPANFCIIII/DFLVETGFHHVGQASHELLTSGD                               PPTSASQSAGLTGMSYHTWFGES               589   1939   A   4487   922   332   APVTTSPRVGQPWIRTALALRSLYEARPSLRC                               PPVELPWAPRRGHRLSPADDELYQRTRISLLQ                               REAAQAMYIDSYNSRGFMINGNRVLGPCALL                               PHSVVQWNVGSHQDITEDSFSLFWLLEPRIEI                               VVVGTGDRTERLQSQVLQAMRQRGIAVEVQ                               DTPNACATFNFLCHEGRVTGAALIPPPGGTSL                               TSLGQAAQ               590   1940   A   4492   1   472   FFFFETESRSVAQAGVQWRDLGSLQAPPPGFT                               PFSCLSLPSSWDYRRPPLRPANFFVFLVETGFP                               RFSRDGLDLLT/SIGDPPTSASQSAGITGVSHR                               ARPKRIGEPRRKCGNAVVWPSTSLGDHRVTS                               VPHQGGLPGPIRVAPSSAGQREASQGPPGR               591   1941   A   4495   1444   1116   IAARFTLAKTWNQLKRP\TMIDSIKKTR\YIYT                               MIEYYADTERNEIMSF\AGTWVELEAIILSKLM                               LKDNWVEDTIPQGAVPCTATAEGMKRLLFAL                               EPWDSSCFPHPSSGV               592   1942   A   4496   2   919   RTRPLFSGRPTRPVCTMSDERRLPGSAVGWL                               VCGGLSLLANAWGILSVGAKQKKWKPLEFL                               LCTLAATHMLNVAVPIATYSVVQLRRQRPDF                               EWNEGLCKVFVSTFYTLTLATCFSVTSLSYHR                               MWMVCWPVNYRLSNAKKQAGHTVMGIWM                               GSFILSALPAVGWHDTSERPYTIIGCRFIYAEI                               GLGFGVCFLLLVGGSVAMGVICTAIALFQTL                               AVQVGRQADHRAFTVPTIVVEDAQGKRRSSI                               DGSEPAKTSLQTTGLVTITIVFIYDCLMGFPVL                               GPFSLADTHLSDLPYTWGDRDSGGACVM               593   1943   A   4506   2   193   FFFEAESCSVPQAGVQRPDLGWLHAPPP\GSC                               HFPASASQVAGTTHARHHTQLIF\AFLVENGL                               C               594   1944   A   4507   1327   647   KMAGGVRPLRQLRALCRVLLFLSQFCILSGG                               ESTEIPPYVMKCPSNGLCSRLPADCIDCTTNFS                               CTYGKPVTFDCAVKPSVTCVDQDFKSQKNFII                               NMTCRFCWQLPETDYECTNSTSCMTVSCPRQ                               RYPANCTVR\DLIVIICLGNRTFPKMLYCNWT                               GGYKWVYGLWLLRHHPRWGLGADRF\YLGF                               VAGTASGKLFSFGGLGIWTLIDVLLIGVGYVG                               PADGSLYI               595   1945   A   4512   533   264   FFFKMESYSVARLECSGAISAPCNLHLLGSNN                               SPASASRV/AGNIGARHHTQQIFVLLVQMRVH                               YVGQDGLDLL/NLMIHPPRSPKVLGLQA               596   1946   A   4513   3   1674   HASDHLYPNFLVNELILKQKQRFEEKRFKLD                               HSVSSTNGHRWQIFQDWLGTDQDNLDLANV                               NLMLELLVQKKKQLEAESHAAQLQILMEFLK                               VARRNKREQLEQIQKELSVLEEDIKRVEEMS                               GLYSPVSEDSTVPQFEAPSPSHSSIIDSTEYSQP                               PGFSGSSQTKKQPWYNSTLASRRKRLTAHFE                               DLEQCYFSTRMSRISDDSRTASQLDEFQEG\LS                               KF\TRYNSVRPL\ATLSYASDLYNGSQYKSLV                               FEFDRDCDYFAIAGVTKKIKVYEYDTVIQDA                               VDIHYPENEMTCNSKISCISWSSYHKNLLASS                               DYEGTVILWDGFTGQRSKVYQEHEKRCWSV                               DFNLMDPKLLASGSDDAKVKLWSTNLDNSV                               ASIEAKANVCCVKFSPSSRYHLAFGCADHCV                               HYYDLRNTKQPIMVFKGHRKAVSYAKFVSG                               EEIVSASTDSQLKLWNVGKP\YCLRSFKGHIN                               EKNFV\GLASNGDYIACGSENNSLYLYYKGLS                               KTLLTFKFDTVKSVLDKDRKEDDTNEFVSAV                               CWRALPDGESNVLIAANS\QGTI\KVLELV               597   1947   A   4518   536   824   RSLALSPGLECSGMISAHCNLHLLGSSDPPTS                               ASQVAEITSVRHHTWLIFCI\LGQMGFHHVGE                               QAGLELLTSWDPAILPSQSAGHGMSPHAWPP               598   1948   A   4524   1   384   FDTEFVNIGGDFDAAAGVPR\CRLPGAYFFSF                               TLGKLPRKTLSVKIMKNEDEVQAMIYDDGSS                               RRREMQSQSVMLALRRGDAVWLLSHDHDG                               YGAYSNIIGKYITFSGFLVYPDLAPAAPPGLG                               ASELL               599   1949   A   4526   366   776   MGQPAFYAEGPIQGGDAGELCKCDFLVFTSF                               NPEAVCEAGTPAMFQTAWRQMESCSI/AQAG                               VQWRDPGSLFPPLGFKEFSCLSLPSSWDYK                               HAPPHPANFCIFSRDQVSPCWPGWSRSLDLVI                               PPPWLPKVLGLQA               600   1950   A   4529   776   334   FFFETESCYVAQAGVQWCDLCSLQAPPPG\SS                               DPPASASRVAGTTGARHHTQLIFVFLVETGFH                               \MLARDGLKLLTSSDPPASASQSSWDYRREPP                               RLANFFVFLVETGSRYVAQAGVQWLFTGAIP                               LLISTGVLTCSVSDLGRFTPP               601   1951   A   4533   1460   403   HEVQESIHFLESESRGISDNYTLALITYALSS                               VGSPKAKEALNMLTWRAEQEGGMQFWVSSE                               SKLSDSWQPRSLDIEVAAYALLSHFLQFQTSE                               GIPIMRWLSRQRNSLGGFASTQDTTVALKALS                               EFAALMNTERTNIQVTVTGPSSPSPVKFLDT                               HNRLLLQTAELADGTANGSV/SISANGFGFAI                               CQLNVVYNVKASGSSRRRRSIQNQEAFDLDV                               AVKENKDDLNHVDLNVCTSFSGPGRSGMAL                               MEVNLLSGFMVPSEAISLSETVKK\TEYDHGK                               LNLYLDSVNETQFCVNIPAVRNFKVSNTQDA                               SVSIVDYYEPRRQAVRSYNSEVKLSSCDLCSD               602   1952   A   4540   1963   295   MRAFGRPALRPLPLPPLLLLLLSSPWGRAVPC                               VSGGLPKPAN1TFLSNMKNVLQWTPPEGLQG                               VKVTYTVQYFIYGQKKWLNKSECRNINRTYC                               DLSAETSDYEHQYYAKVIWGTKCSKWAE                               SGRFYPFLETQLGPPEVALITDEKSISVVLTAP                               EKWKRPEDLPVSMQQIYSNLKYNVSVLNT                               KSNRTWSQCYTNHTLVLTW\LEPNTLYCVEY                               ESFPGPPRAQPSEKQCARTLKDQSSEFKAK                               IIFWYVLPISITVFLFSVMGYSIYRYIHVG\KEK                               HP\ANLILIYG\NEFDKRFFVPA\EKIV\INFI\TL                               NIS\DDSKISHQDMSLLGKSSDVSSLNDPQPSG                               PPQEEEEVKTLGYASHLMEIFCDSEEN\                               EGTSFFQQESLSRTIPPDKTVWYEYDVRTTDI                               CAGPEEQELSLQEEVSTQGTLLESQAALAVL                               GPQTLQYSYTPQLQDLDPLAQEHTDSEEGPEE                               EPSTTLVDWDPQTGRLCIPSLSSFDQDSEGCE                               PSEGDGLGEEGLLSRLYEEPAPDRPPGENETY                               LMQFMEEWGLYVQMEN               603   1953   A   4543   3   600   YSAVEFVEQASGISDWWNPALRKRMLSDSGL                               GMAPYYEDSDLKDLSHSRVLQSPVSSEDHAI                               LQAVIAGDLMKLIESYKNGGSLLIQGPDHCSL                               LHYAATGNGEWKYILDHQPSELLDMADSE                               TGETALHKAACQRNRAVCQLLVDAGASLRK\                               TDSKGKTPQERAQQA\GDPDLAA/YTIESRQN                               YKVIGHEDLETAV               604   1954   A   4548   3   938   QDNKVQNGSLHQKDTVHDNDFEPYLTGQAN                               QSNSYPSMSDPYLSSYYPPSIGFPYSLNEAFW                               STAGDPPIPYLTTYGQLSNGDHHPMHDAVFG                               QPGGLGNNIYQHEFNFFPENPAFSAWGTSGS                               QGQQTQSSAYGSSYTYPPSSLGGTVVDGQPG                               FHSDTLSKAPGMNSLEQGMVGLKIGDVSSSA                               VKTVGSVVSSVALTGVLSGNGGTNVNMPVS                               KPTSWAAIASKPAKPQPKMKTKSGPVMGGG                               LPPPPIKHNMDIGTWDNKGPVPKAPVPQQAP                               SPQAAPQPQQVAQPLPAQPPALAQPQYQSPQ                               QPPQ               605   1955   A   4553   2   2304   TLLQEKRNCLLMQLEEATRLTSYLQSQLKSLC                               ASTLTVSSGSSRGSLASSRGSLASSRGSLSSVS                               FTDIYGLPQYEKPDAECISQLLRFDLIPFDSLGR                               DAPFSEPPGPSGFHKQRRSLDTPQSLASLSSRS                               SLSSLSPPSSPLDTPFLPASRDSPLAQLADSCE                               GPGLGALDRLRAHASAMGDEDLPGMAALQP                               HGVPGDGEGPHERGPPPASAPVGGTVTLRED                               SAKRLERRARRISACLSDYSLASDSGVFEPLT                               KENEDAEEPAYGDTASNGDPQIHVGLLRDSG                               SEGLLVHVLQLKNPAGLAVKEDCKVHIRVYL                               PPLDSGTPNTYCSKALEFQVPLVFNEVFRIPV                               HSSALTLKSLQLYVCSVTPQLQEELLGIAQIN                               LADYDSLSEMQLRWHSVQVFTS\LNHQGRGR                               LGVQERAPPGTLHTPSPSPA/STDAVTVLLAR                               TTAQLQAVERELAEERAKLEYTEEEVLEMER                               KEEQAEAISERSWQADSVDSGCSNCTQTSPPY                               PEPCCMGIDSTLGHPFAAQAGPYSPEKFQPSPL                               KVDKETNTEDLFLEEAASLVKERPSRRARGSP                               PVRSGTIVRSQTFSPGARSQYVCRLYRSDSDS                               STLPRKSPFVRNTLERRTLRYKQSCRSSLAEL                               MARTSLDLELDLQASRTRQRQLNEELCALRE                               LRQRLEDAQLRGQTDLPPWVLRDERLRGLLR                               EAERQTRQTKLDYRHEQAAEKMLKKASKEI                               YQLRGQSHKEPIQVQTFREKIAFFTRPRINTPPL                               PADDV               606   1956   A   4555   3429   776   PGSGPGPAPFLAPVAAPVGGISFHLQIGLSREP                               VLLLQDSSGDYSLAHVREMACSIVDQKFPEC                               GFYGMYDKILLFRHDPTSENILQLVKAASDIQ                               EGDLIEVVLSASATPEDFQIRPHALFVHSYRA                               PAFCDHCGEMLWGLV\RQGLKCEGCGLNYH                               KRCAFKIPNNCSGVRPRRLSNVSLTGVSTIRT                               SSAELSTSAPDEPLLQKSPSESFIGREKRSNSQ                               SYIGRPTHLDKILMSKVKVPHTFVIHSYTRPTV                               CQYCKKLLKGLFRQGLQCKDCRFNCHKRCA                               PKVPNNCLGEVTTNGDLLSPGAESDVVMEEG                               SDDNDSERNSGLMDDMEEAMVQDAEMAMA                               ECQNDSGEMQDPDPDHEDANRTISPSTSNNIP                               LMRVVQSVKHTKRKSSTVMKEGWMVHYTS                               KDTLRKRHYWRLDSKCITLPQNDTGSRYYKE                               IPLSEILSLEPVKTSALIPNGANPHCFEITTANV                               VYYVGENVVNPSSPSPNNSVLTSGVGADVAR                               MWEIAIQIIALMPVIPKGSSVGTGTNLHRDISV                               SISVSNCQIQENVDISTVYQIFPDEVLGSGQFGI                               VYGGKHRKTGRDVAIKIIDKLRFPTKQESQLR                               NEVAILQNLHHPGVVNLECMFETPERVFVVM                               EKLHGDMLEMILSSEKGRLPEHITKFLITQILV                               ALRHLHFKNIVHCDLKPENVLLASADPFPQV                               KLCDFGFARHGEKSFRRSVVGTPAYLAPEVL                               RNKGYNRSLDMWSVGVIIYVSLSGTFPFNED                               EDIHDQIQNAAFMYPPNPWKEISHEAIDLINN                               LLQVKMRKRYSVDKTLSHPWLQDYQTWLDL                               RELECKIGERYITHESDDLRWEKYAGEQGLQ                               YPTHLINPSASHSDTPETEETEMKALGERVSIL               607   1957   A   4563   1   4499   SRPWWLRASERPSAPSAMAKRSRGPGRRCLL                               ALVLFCAWGTLAVVAQKPGAGCPSRCLCFRT                               TVRCMHLLLEAVPAVAPQTSILDLRFNRIREI                               QPGAFRRLRNLNTLLLNNNQIKRIPSGAFEDL                               ENLKYLYLYKNEIQSIDRQAFKGLASLEQLYL                               HFNQIETLDPDSFQHLPKLERLFLHNNRITHL                               VPGTFNHLESMKRLRLDSNTLHCDCEILWLA                               DLLKTYAESGNAQAAAICEYPRRIQGRSVATI                               TPEELNCERPRITSEPQDADVTSGNTVYFTCR                               AEGNPKPEIIWLRNNNELSMKTDSRLNLLDD                               GTLMIQNTQETDQGIYQCMAKNVAGEVKTQ                               EVTLRYFGSPARPTFVIQPQNTEVLVGESVTL                               ECSATGHPPPRISWTRGDRTPLPVDPRVNITPS                               GGLYIQNVVQGDSGEYACSATNNIDSVHATA                               FIIVQALPQFTVTPQDRVVIEGQTVDFQCEAK                               GNPPPVIAWTKGGSQLSVDRRHLVLSSGTLRI                               SGVALHDQGQYECQAVNIIGSQKVVAHLTVQ                               PRVTPVFASIPSDTTVEVGANVQLPCSSQGEF                               EPAITWNKDGVQVTESGKFHISPEGFLTINDV                               GPADAGRYECVAIRNTIGSASVSMVLSVNVPD                               VSRNGDPFVATSIVEAIATVDRAINSTRTHLF                               DSRPRSPNDLLALFRYPRDPYTVEQARAGEIF                               ERTLQLIQEHVQHGLMVDLNGTSYIIYNDLVS                               PQYLNLIANLSGCTAHRRVNNCSDMCFHQKY                               RTHDGTCNNLQHPMWGASLTAPERLLKSVY                               ENGFNTPRGINPHRLYNGHALPMPRLVSTTLI                               GTETVTPDEQFTHMLMQWGQFLDHDLDSTV                               VALSQARFSDGQHCSNVCSNDPPCFSVMIPPN                               DSRARSGARGMFFVRSSPVCGSGMTSLLMNS                               VYPREQINQLTSYIDASNVYGSTEHEARSIRD                               LASHRGLLRQGIVQRSGKPLLPFATGPPTECM                               RDENESPIPCFLAGDHRANEQLGLTSMHTLW                               FREHNRIATELLKLNPHWDGDTIYYETRKIVG                               AEIQHITYQHWLPKILGEVGMRTLGEYHGYD                               PGINAGIFNAFAT\AAFRFGHTLVNPLLLPGLD                               ENPQPIAQDHLPLHKAFPSPFRIVNEGGIDPLL                               RGLFGVAGKMRVPSQLLNTELTERLFSMAIIT                               VALDLAAINIQRGRDHGIPPYHDYRVYCNLS                               AAHTFEDLKNEIKNPEIREKLKRLYGSTLNID                               LFPALVVEDLVPGSRLGPTLMCLLSTQFKRLR                               DGDRLWYENPGVFSPAQLTQIKQTSLARILCD                               NADNITRVQSDVFRVAEFPHGYGSCDEIPRVD                               LRVWQDCCEDCRTRGQFNAFSYHFRGRRSLE                               FSYQEDKPTKKTRPRKIPSVGRQGEHLSNSTS                               A\FSTRSDASG\TNDFQRVCSWEMQKTTTDLR                               TQIKKLESR\LSITECVDAGGESHANNTKWK                               KDACTICECKDGQVTCFVEACPPATCAVPVNI                               PGACCPVCLQKRAEEKP               608   1958   A   4566   354   1135   FSFLCIGVSGRLGLDSEEDYYTPQKVDVPKAL                               IIVAVQCGCDGTFLLTQSGKVLACGLNEFNKL                               GLNQCMSGIINHEAYHEVPYTITSFTLAKQLSF                               YKIRTLAPGKTHTAAIDERGRLLTFGCNKCGQ                               LGVGNYKKRLGINLLGGPLGGKQVIRVSCGD                               EFTIAATDDNHIFAWGNGGNGRLAMTPTERP                               HGSDICTSWPRPIFGSLHHVPDLSGRGWHTIILI                               VEKVLNSKTIRSNSSGLSIGTVFQSSSPGGGGE                               GGPDAW               609   1959   A   4567   1   412   FFFFETESRSVAQAGVQWRDLGSLQAPPPGFT                               PFSCLSLPSSWDYRRPPLRPANFFVFLVETGF                               HIRFSRDGLDLLTIS/GDPPASASQSAGITGVSH                               RARPRINLRNVIYSFAVTYCLNYISLAMSSTL                               KLSFIIVLSGS               610   1960   A   4570   697   467   ECRGVISAH\CCTLCLPSSSDSASAF\RVARTIT                               GTCDYAQLIFAFLVEMGFHHVGQDGLHLLIM                               LVIRPPRPPKVLGLQA               611   1961   A   4571   25   1396   ADPHTTVIRFFPAASATKRVLPPVLRVSSPRT                               WNPNVPESPRIPAPRLPKRMSGAPTAGAALM                               LCAATAVLLSAQGGPVQSKSPRFASWDEMN                               VLAIIGLLQLGQG\CANT\GAHPQSAERAGA\R                               LSACGSACQGTEGSTDLPLAPESRVDPEVLHS                               LQTQLKAQNSRIQQLFHKVAQQQRHLEKQHL                               RIQHLQSQFGLLDHKHLDHEVAKPARRKRLP                               EMAQPVDPAHNVSRLHRLPRDCQELFQVGER                               QSGLFEIQPQGSPPFLVNCKMTSDGGWTVIQR                               RHDGSVDFNRPWEAYKAGFGDPHGEFWLGL                               EKVHSITGDRNSRLAVQLRDWDGNAELLQFS                               VHLGGEDTAYSLQLTAPVAGQLGAITVPPSG                               LSVPFSTWDQDHDLRRDKNCAKSLSGGWWF                               GTCSHSNLNGQYFRSIPQQRQKLKKGIFWKT                               WRGRYYPLQATTMLIQPMAAEAAS               612   1962   A   4575   162   3   FFFETESRSVAQAGVQWRDLSSLQPPPPG\SR                               GSPASASPVAGITGTRHHRTRG               613   1963   A   4584   687   321   PLAQRRPFLWVTVKTNGHIWGSSTYPIIFWGS                               SNS/PASASQVAGIPNARHQARIIFVFLVEPRF                               HHVGRAGLGFLINLAICLPQHPKVLGLQACN                               LNIKPHPAHKYISMIQFNVHFMCMSVHIYI               614   1964   A   4589   727   299   PGSAQSAQRGRGRRRARAGSATQITMYSFMG                               GGLFCAWVGTILLVVAMATDHWMQYRLSGS                               FALIQGLWRYCLGNKCYLQTDSIAYWNATRA                               FMILSALCAISGIIMGIMAF/GWVAVLMTFFA                               GIFYMCAYRVHECRRLSTPR               615   1965   A   4590   2   414   TILPEKIQAWAQKQCPQSGEEAVALVVHLEK                               ETGRLRQQVSSPVHREKHSPLGAAWEVADFQ                               PEQVETQPRAVSREEPGSLHSGHQEQLNRKR                               ERRPLPKNARPSPWVPALADEWNTLHQEVTT                               TRLPAGSQEPVKD               616   1966   A   4592   773   488   DFALVAQAGVQWHNLGSPQPLPPGFKRIFSCL                               SLPSSWEYRCVFPIRLAMVFLVEMGFLHVGQ                               AGLELPTSGDPPALASQSAGITGVTTVPSGPG               617   1967   A   4595   84   478   XRHGLREPLLERRCAAASSFQHSSSLGRELPY                               DPVDTEGFGEGGDMQERPLFPEYILDPEPQPT                               REKQLQELQQQQEEEERQRQQRREEERQQNL                               RARSREHPVVGHPDPALPPSGVNCSGCGAEL                               HCQDAR*               618   1968   A   4596   2945   1188   ARSRNSARGVYGMCVDTLFLCFLEDLERNDG                               SAERPYFMCSTLKKPLARRCFPAIHAYKGVL                               MVGNETTYEDGHGSRKNITDLVEGAKKANG                               VLEARQLAMRIFEDYTVSWYWIIIGLVIAMA                               MSLLSIILLHLLAGIMGWVMIIIVIEI\SELGYRIF                               HCYMEYSRLRGEAGSDVSLVDLGFQTDFRV                               YLIILRQTWLAFMIILSILEVIIILLLIFLRKRILI                               AIALIKEASRAVGYVMCSLLYPLVTFFLLCLCI                               AYWASTAVFLSTSNEAVYKIFDDSPCPFTAKT                               CNPETFPSSNESRQCPNARCQFAFYGGESGYH                               RALLGLQIFNAFMFFWLANFVLALGQVTLAG                               AFASYYWALRKPDDLPAFPLFSAFGRALRYH                               TGSLAFGALILAIVQHRVILEYLDQRLKAAEN                               KFAKCLMTCLKCCFWCLEKFIKFLNRNAYIM                               IAIYGTNFCTSARNAFFLLMRNIIRVAVLDKV                               TDFLFLLGKLLIVGSVGILAFFFFTHRIRIVQDT                               APPLNYYWVPILTVIVGSYLIAHGFFSVYGMC                               VDTLFLCFLEDLERNDGSAERPYFMSSTLKKL                               LNKTNKKAAES               619   1969   A   4601   2   357   RTSVEPYILGEF/RKLSNNTKVVKTEYKATEY                               GLAYGHFSYEFSNHRDVVVDLQGWVIGNGK                               GLIYLTDPQLHSVDQKVFTTNFGKRGIFYFFN                               NQHVECNEICHELSLTRPSMEKPCKS               620   1970   A   4606   1   2415   MERLWGLFQRAQQLSPRSSQTVYQRVEGPR                               KGHIEEEEEDGEEGAETLAHFCPMELRGPEP                               LGSRPRQPNLIPWAAAGRRAAPYLVLTALLIF                               TGAFLLGYVAFRGSCQACGDSVLVVSEDVN                               YEPDLDFHQGRLYWSDLQAMFLQFLGEGRL                               EDTIRQTSLRERVAGSAGMAALTQDIRAALS                               RQKLDHVWTDTHYVGLQFPDPAHPNTLHWV                               DEAGKVGEQLPLEDPDVYCPYSAIGNVTGEL                               VYAHYGRPEDLQDLPARGVDPVGRLLLVRV                               GVISFAQKVTNAQDFGAQGVLIYPEPADFSQ                               DPPKPSLSSQQAVYGHVHLGTGDPYTPGFPSF                               NQTQFPPVASSGLPSIPAQPISADIASRLLRKL                               KGPVAPQEWQGSLLGSPYHLGPGPRLRLVVN                               NHRTSTPTINNIFGCIEGRSEPDHYVVIGAQRDA                               WGPGAAKSAVGTAILLELVRTFSSMVSNGFR                               PRRSLLFISWDGGDFGSVGSTEWLEGYLSVL                               HLKAVVYVSLDNAVLGDDKFHAKTSPLLTSL                               IESVLKQVDSPNHSGQTLYEQVVFTN\PSWD\                               AEVIRPLPM\DSSAY\SFIAFVGVPAVEFSFME\                               DDQ\AYPFLHTKEDTYENLHKVLQGRLPAVA                               QAVAQLAGQLLIRLSHDRLLPLDFGRYGDVY                               LRHIGNLNEFSGDLKARGLTLQWVYSARGDY                               LRAAEKLRQEIYSSEERDERLTRMYNVRIMRV                               EPYFLSQYVSPADSPFRHIFMGRGDHTLGALL                               DHLRLLRSNSSGTPQATSSTGFQ\ESRFRRQL\                               ALL\TWDACKGAANALSGDVWNIDNNF               621   1971   A   4610   793   334   ISRVDDFVGSGIANVIIAVAIFSIFAFARLVRG\                               NTLVLKQQTFLESARSIGASDMTVLLRHILPGT                               GSSIVVFFTMRIGTSIISAASLSFLGLGAQPPTP                               EWGAMLNEARADMVIAPHVAVFPALAIFLTV                               LAENLLGDGLRDALDPKIKG               622   1972   A   4614   2   820   LVYVMLAIFCIASAMSLYNCLAALIHKIPYGQ                               CTIACRGKNMEVRLIFLSGLCIAVAVVWAVP                               RNEDRWAWILQDILGIAFCLNLIKTLKLPNFK                               SGVILLGLLLLYDVFPVFITPFITKNGESIMVEL                               AAGPFGNNEKNDGNLVEATGQPSAPHEKLPV                               VIRVPKLIYFSVMSVCLMPVSILGFGDIIPGL                               LIAYCRRFDVQTGSSYIYYVSV\TVAYAIGMIL                               TFVVLG\LMICKGQPALLYLVPCTLITA/CQFV                               AWETVRRMKKFWERVTS               623   1973   A   4619   17   691   TLVSVVEFVRRADLTREDLAFSSVDSGQAGP                               GGCCESGLPNTMPSAFSVSSFPVSIPAVLTQT                               DWTEPWLMGLATFRALCVLLTCLSSRSYRLQ                               IGHPLCLVILVYCAEYINEAAAMNWRLFSKY                               QYFDSRGMFISIVFSAPLLVNAMIIVVMWVW                               KTLNVMTDLKNAQERRKEKKRRRKED*GAA                               AAWSLRPSRPPSAAPSAAVCVAWASFQLTHG                               LKNRCFI               624   1974   A   4622   164   668   VSCYTALQSIMNQPESANDPEPLCAVCGQAH                               SLEENHFYSYPEEVDDDLICHICLQALLDPLD                               TPCGHTYCTLCLTNFLVEKDFCPMDRKPLVL                               QHCKKSSILVNKLLNKLLVTCPFREHCTQVL                               QRCDLEHHFQTSQAWGTHL*SQLLGRLRQED                               CLSPGVHHCSEV               625   1975   A   4625   474   473   CFLSPSPLLPPLLLSSSSSPSFPLPPPPTLLPSTLP                               PPLLIPSS*LSP               626   1976   A   4629   249   3   KLKGNECFCYHCNVCWLMIKK*GLFLC*IYFI                               LFFET*SHSFTRLECSGTISAHCSLQLQGSSNSP                               ASASQVAGIAGTHH               627   1977   A   4635   1   301   FFFFETKPFFAPQAGGQGPSRGSLNPLPTGLK                               QFSGLTLSRSGNNGPRPPPRVNFGILRGNGVP                               PGGAG*PRPPDLRGPPGLAPPQGGNGDPP                               ARAYL               628   1978   A   4648   1357   782   LFSSQRLFGPHIQAPSFLLLSFFPS*LLAMR                               TVGNNAFILVFLVYRIVLLLF*HV*PAYFQPSK                               NKTAKNCN*RPFLFLVCYLL*AELHIGTFIANF                               YDGIPNKLNEHLWPKLLQSLIFHVDFCGFLHK                               VFYICFTEFLLFLYFL*LFIIKVSCSII*CSTICVF                               SYKSFAVIIFFVDNTRFFSFGF               629   1979   A   4660   18   999   HHELHTLELLQNPKEVLTRSEIQDVNYSLEAV                               KVKTVCQIPLMKEMLKRFQVAVNLAEDTAH                               PKLVFSQEGRYVNTASASSWPVFSSAWNYF                               AGWRNPQKTAFVERFQHLSCVLGKNVFTSG                               KHYWEVESRDSLEVAVGVCREDVMGITDRS                               KMSPDVGIWAIYWSAAGYWPLIGPPGTPTQQ                               EPALHRVGVYLDRGTQNVSFYSAVDGVHLH                               FSCSSVSRLRPFFWLSPLASLVIPPVTDRK*G                               FSSPDQNSFPVVQLRDTHPWALFCPSCLYPG                               WSIFWVSLTVPFGICPLCASQEAVPWEVGLA                               NGDGTGNFPRRFWEIFL               630   1980   A   4669   2   358   FFFFFETESHSVAQAGMQWRNLGSLPAPPPGF                               TPFFCLSLLNGWDYREPPPHLANFFVLLVETG                               FHDVGQDGLDLLTS*STPSASQSAEITGVSHC                               TRLKKIRFAKGHVEFFFESHVE               631   1981   A   4674   953   614   TPIRGTDDEHEECTVQEYSAGKNTCLRPGAV                               AHTCNPCTLGGRGRWIT*GSGVQDQPGPTWQ                               NLEEPRALHSSPGLITQRILWAQGLWV                               GAGSTGCSRGPRGEGVFREG               632   1982   A   4678   34   314   RSTHASGMISPSFGFMGHLLRLEFEILPSTPNF                               *LPSYQGEAAGSSLISHLQTFSPDLKGVYCTFP                               ASGLAPVPTHWTVSELSRSPVATATFC               633   1983   A   4696   1   1365   RTLGMEGERRASQAPSSGLPAGGANGESPGG                               GAPFPGSSGSSALLQAEVLDLDEDEDDLEVFS                               KDASLINSFSPIVMPTSPLSMINQIKFEDEP                               DLKDLFITVDEPESHVTTIETFTTYRIITKTSRG                               EFDSSEFEVRRRYQDFLWLKGKLEEAHPTLII                               PPLPEKFIVKGMVERFNDDFIETRRKALHKFL                               NRIADHPTLTFNEDFKIFLTAQAWELSSHKKQ                               GPGLLSRMGQTVRAVASSMRGVKNRPEEFM                               EMNFIELFSQKINLIDKISQRIYKEEREYFDE                               MKEYGPIHILLWSASEEDLVDTLKDVASCIDRC                               CKATEKRMSGLSEALLPVVHEYVLYSEEFM                               GVMKRRDQIQAELDSKVEVLTYKKADTDLL                               PEEIGKLEDKVECANNALKADWERWKQNM                               QNDIKLAFTDMAEENIHYYEQCLATWESFLT                               SQTNLHLEEASEDKP               634   1984   A   4708   421   158   SYWVGEDYTYKFFEVILIDPFHKAIRRNPDTQ                               WISKAVYKHREMCGLTSTGRKSHGLEKDRM                               FPHAIGGSCRAA*RRRKTLQFPCYH               635   1985   A   4709   42   341   YIKQPDAKERRRTVHWKKETESEASEITIPPST                               PGVPQAPGHWEDYGRGDNFYLPH*DPGGIVL                               WNIFNRMPIYIARKNITDGEHHEYLIEVPRLFHT                               SED               636   1986   A   4721   2   351   EKPDHFFPEGTSFIHEPRRPN*GDLVHCLGGIS                               RSTTVTVA*LMQKLNLSMNDAYYIVIMKMSS                               ISPNFNSMDQPLDFQRTLGLRSPCYNRVPAQK                               MYFITPSNHNAYQVDSVQST               637   1987   A   4726   664   253   NTGLTCSIQRKCGETQLYRREENRLILLLQDH                               LKSESFQVLTLSPRLEFSGLISAHCNLRLPGSS                               DSSASSSRAAGITGVHHHAWLIFFFLVETGFL                               HAG*AGLELLTSGDPPASASRSAGITGVSHHA                               RPRETRFL               638   1988   A   4734   24   592   GGMDSRVSGTTSNGETKPVYPVMEKKEEDG                               TLERGHWNNKMEFVLSVAGEIIGLGNVWRFP                               YLCYKNGGGAFFIPYLVFLTCGIPVFLLETAL                               GQYTSQGGVTAWRKICPLFEGIGYASQMIVIL                               LNVYYIIVLAWALFYLFSSFTIDLPWGGCYHE                               WNTEHCMEFQKTNGSLNGTSENATSPVIEFW               639   1989   A   4743   1040   699   QGLTLLPRMECSATITAHCSLELPGSIDLPTSA                               S*VARTTGTHHHPWLILVLLL*TWGSYYVAQ                               AGLELLGSSNLPAAMYSQSAQIIGHDHCAWA                               TSNHVLYTQEGLRRGKEG               640   1990   A   4771   527   2   GRIDCPHPATVLAQPIFIDACSVLGAYQGAQN                               WIRRRPCLPSGCLKMNREIGPLQHSLCCPGWS                               QTPGLKAILLRQPPK*LGLQMESHSCPPAWSA                               MARSRLTATSASQVQAILLPQPPGTTDSCSPS                               PDHEQQPLSWVLPPPQKDMNPREQQVALGP                               QAAALPWAVWRNDCFPR               641   1991   A   4780   16   473   RPSSQCGGIPTGWKKGLAPELSSELSSPPLPAR                               LQLAASPYFSPSWAECPQPVPAGTHATWCLA                               RVWARMTPPGPAGIPSHPLPPPPPERSVPIPSP                               FPARDSGSRQGHSTDRYKHTDAFRDAHRRVP                               QRDTDTQVHTGSGTHTHAHTPPEK               642   1992   A   4798   1   487   GYSFRCDIVDYSRSPTALRMARTCWLYYFSK                               FIELLDTIFFVLRKKNSQVTFLHVFHHTIMPW                               TWWFGVKFAAGGLGTFHALLNTAVHVVMY                               SYYGLSALGPAYQKYLWWKKYLTSLQLVQF                               VTVALHISQFFFMEDCKYQFPVFACIIMSYSFM                               FLLLFLH               643   1993   A   4799   2   391   LMAFIEMHISGSLVYLKIKIYSYFSMLNFLL                               QEIPLSEILRISSPRDFTNISQGSNPHGFEIITDT                               MVYFVGENNGDSSHNPVLAATGVGLDVAQS                               WEKAIRQALMPVTPQASVCTSPGQGKDHSK                               Q*ASVCTSPGQGKDHSKQ               644   1994   A   4800   488   101   AYPLFAVLIPVHTECVAGVVGRAYLLCALFFL                               LSFLGYCKAFRESNKEGAIISSTFWVLLSWLG                               AVAMLCKEQGITVLVRAATWLGPAFSVCPPP                               SYKDIWGWPCLCGVLHAYIPLLV               645   1995   A   4805   458   126   LLWTTVLCQTPARPQSTMIHLGHILFLLLLPV                               AAAQFFPGERSSLPAFYPGTSGSCSGCGSLSL                               PLLAGLVAADAVASLLIVGAVFLCARPRRSP                               AQEDGKVYINMPGRG               646   1996   A   4817   47   1033   LQQDTWHLSFLSHFSRLHGGVPGRGLLEGNL                               LQPQAPGHDMTSIPFPGDRLLQVDGVILCGLT                               HKQAVQCLKGPGQVARLVLERRVPRSTQQC                               PSANDSMGDERTAVSLVTALPGRPSSCVSVT                               DGPKF*SSN*KRIANGLGFSFVQMEKESCSHL                               KSDLVRIKRLFPGHPAEENGAIAAGDIILGRE                               WEGPRKASSSRCRGSWAMQLSVQAGPSFAS                               YYPAAVEVLHLLRGAFQEVTLLLCRPPPGAL                               PELEQEWQTPELSADKEFTRATCTDSCTSPIL                               GSRGQLGGTVPPQMQGKAWGLRPESSQKAIR                               EGTMGAKTERDLGPVP               647   1997   A   4854   1044   335   PRVRGDWPLEKKKSNSNIHPIFSWCGSTDSKD                               IVMPTYDLTDSVLETMGRVSLDMMSVQANT                               GPPWESKNSTAVWRGRDSRKERLELVKLSRK                               HPELIDAAFTNFFFFKIIDENLYGPIVKHISFFD                               FFKIIKYQINIDGTVAAYRLPYLLVGDSVVLK                               QDSIYYEHFYNELQPWKHYEPVKSNLSDLLEK                               LKWAKDHDEEAKKIAKAGQEFARNNLMGD                               DIFCYYFQTFPRNMPIYK               648   1998   A   4867   2030   837   AGMLPAVGSADEEEDPAEEDCPELVPMETTQ                               SEEEEKSGLGAKIPVTIITGYLGAGKITLLNYI                               LTEQHSKRVAVILNEFGEGSALEKSLAVSQG                               GELYEEWLELRNGCLCCSVKDNGLRAIENLM                               QKKGKFDYILLETTGLADPGAVASMFWVDA                               ELGSDIYLDGIITIVDSKYGLKHLAEEKPDGLI                               NEATRQVALADALLINKTDLVPEEDVKKLRT                               TIRSINGLGQILETQRSRVDLSNVLDLHAFDSL                               SGISLQKKLQHVPGTQPHLDQSIVTITFDVPG                               NAKEEHLNMFIQNLLWEKNVRNKDNHCMEV                               IRLKGLVSIKDKSQQVIVQGVHELYDLEETPV                               SWKDDTERTNRLVLLGRNLDKDILKQLFIAT                               VTETEKQWTTHPKEDQVCT               649   1999   A   4873   226   189   DGVSLLLPKLGVQWAQYWAHWQPPLPGFKR                               FSCLSLRSSWD*KCAPPHPAFVFLVEMGFHRV                               GQAGLELRTSGDPPASASQSAGITGVSHLA*P                               TSMPLLPFQRLCVYI               650   2000   A   4874   2   437   FPFLRRSFAFVAQAGVQWGDLGSPQPLPPGF                               K*FSCLSLPSSWDYRHAPPPCPS*FLYF**RQG                               FTMLARLVLNS*PHDLPTSPSQSAETKGVSHR                               CPASFYLFLKYYLEAKFCA*GECAPSAGVGA                               GYKRGIIKSCLLINCVVQI               651   2001   A   4898   1701   771   DAWGPETRLARILNPDSFIEPRPGRLPELEATR                               PHMEPKASCPAAAIPLMERKFHVLVGVTGSV                               AALKLPLLVSKLLDIPGLEVAVVTTERAKHFY                               SPQDIPVTLYSDADEWEMWKSRSDPVLHIDL                               RRWADLLLVAPLDANTLGKVASGICDNLLTC                               VMRAWDRSKPLLFCPAMNTAMWEHPITAQQ                               VDQLKAFGYVELPCVAKKLVCGDEGLGAMA                               EVGTIVDKVKEVLFQHSGFQQS*PGISVMGVP                               LYSEWVQAKSVKMDVGKIGGYPHLLNGGPA                               LSLPRGQACSRLNWTEGPGLSFFQPGEAAA               652   2002   A   4927   1   611   FRGRQTSRPARGFSPWRPPGTMQEPSSGECPA                               SP*LPCASNRLAFGGLIFPCAPLVPYPAPFSPLL                               PAFSGAPRPRAIITHSRTHPSAPLVPKPSSRAR                               GQSPLPSRASSPSCSWAQVPGVALARCAGVC                               KPGDSWRVAACISGRCCSRGRRRGSGPRNPE                               QSFRGAWGPSFWGSWKSQRELSAGGAQAWP                               LLGSAGSGLRGEA               653   2003   A   4965   2   283   FFFFI*DGVSLCHPGWNAVARSWLTATSASR                               VQAVSCFRLPSSWDYRHATMPG*FF*YF**R                               WGFTHLAILVLNS*PQVICPPWPPKVLTLQA               654   2004   A   4968   3   437   RPGIPGRRFRRSWFCQLP*EPEPGLESLATPGD                               IPAVGLGALGVIPPVRVPQRPPTQRSQGRGW                               DPERDPGCRVQVSRGPRFGEQKTPGLQGCLP                               PPCLTHLAAASCVVVWCGRWKRDSAECQCD                               HSCSAVSQQEDRCRSSSCS               655   2005   A   4983   201   397   MNNNTTCIQPSMISSMALPIIYILLCIVGVFGN                               TLSQWIFLTKIGKKTSTHIYLSHLVTANLLVC               656   2006   A   4988   332   159   LVHKDMYREFFEEEAQASNKHVTRCLTSLVI                               REVHIKTMR*HFLPIRLEKNKNNIKD               657   2007   A   5008   129   465   MAGMKTASGDYIDSSWELRVFVGEEDPEAES                               VTLRVTGESHIGGVLLKIVEQINRKQDWSDH                               AIWWEQKRQWLLQTIIWTLDKYGILADARLF                               FGPQHRPVILRLPNRRALRLX*               658   2008   A   5017   1   292   FFFFKETESHSVTQAGVQWHDLGSLQPPPPGF                               KRFSCLSLLSSWDYRCAPPHPAISIFVFLVETGF                               HHVAQAGLKLLTL*SANLGLSTSLPIPLFILLS               659   2009   A   5018   17   338   RGHGGKSLTGGTPGNWGDGLLVSEDWSHLIF                               T*NSLVSPVLGKWSPCLQGPGLSAVHTWPWL                               MAACWAVHVKTHMRPGLAVLPRLVLNSWS                               *AIILLWPPKALGLQA               660   2010   A   5028   2   310   SRVDDFVGERRGGCDECLCGIIRGLRAVPLG                               HPGHLCLQPPGGPA*FLDYCRGCCPHPVPGST                               AGSCPRQKKTFPGPTVLCVCSFWIYQRGEPH                               HRTGARWNH               661   2011   A   5050   752   431   RQSCSSTQAKVQWFHYGPLQSQPPGLKQSSQ                               LSLPNSRDHRHVPPRLAIFSFAETGSPYFAQAS                               LELLGSSLIPPTSASQSARITGVSHRAWPLK*F                               NLNQYQTLTMN               662   2012   A   5054   48   103   ELNNGPFQMPLCNGGNLAVTGSWADRSPLH                               EAASQGRLLALRTLLSQGYNVNAVTLDHVTP                               LHEACLGDHVACARTLLEAGANVNAITIDGV                               TPLFNACSQGSPSCAELLLEYGAQAQLESCLP                               SPTIIEGASKGHHECLDTLISWGIDVDQEIPHSG                               TPLYVACMAQQFHCIWNLIYAGAGVRKGKY                               WDTPLPGAGHQSTQKLE*LFAMVEIWQ               663   2013   A   5066   951   580   VRNS*SFAHCASVYKHHYIVIDGQTPCLFVSSK                               ADLPEGVAVSGPSPAEFCRKHRLPAPVPFSCA                               GPAEPSITIFTQLATMAAFPHLVHAELHPSSF                               WLRGLLGVVGAAVAAVLSFSLYRVLVKSQ               664   2014   A   5071   550   1   LSFIEVLSMEQVNKTVVREFVVLGFSSLARLQ                               QLLFVIFLLLYLFTLGTNAIIISTIVLDRALHTP                               MYFFLAILSCSEICYTFVIVPKMLVDLLSQKK                               TISFLGCAIQMFSFLFFGSSHSFLLAAMGYDR                               YMAICNPLRYSVLMGHGVCMGLMAAAWAC                               GETVSLVITSLVFHLPFHSSNQHE               665   2015   A   5074   496   692   QQYHNTGSAGHHAHCQVGHSPHVHYPSGCG                               PL*IQRGLPSFNSLEGHSLKDSGHEESVQLDSE                               HDVQRSLYCDTAVNDVLNTSVTSMGSQMPD                               HDQNEGFHCREECRILGHSDRCWMPRNPMPI                               RSKSPEHVRNUALSIEATAADVEAYDDCGPT                               KRTFATFGKDVSDHPAEERPTLKGKRTVDVT                               ICSPKVNSVIREAGNGCEAISPVTSPLHLKSSL                               PTKPSVSYEIVDPGITARRC               666   2016   A   5080   408   248   IMLLSTSS*VYFQSSTKDSHFFLFDFQKTGPPL                               VGPKAQLSGLQLQPCLYKRR               667   2017   A   5081   129   247   DLTNSHFFLFDFQKTGPPLGGPKAQFSSLQLQ                               PCVY*RR               668   2018   A   5086   852   233   NIKSNDRWVQIKTAYKYFF*KNGDNYNWVF                               RALPFADIENLKYLLFTRDASQPFYLGIHTV                               IFGDLEYVTVEGGIVLSRELMKRLNRLLDNSE                               TCADQSVIWKLSEDKQLAICLKYAGVHAENA                               EDYEGRDVFNTKPIAQLIEEALSNNPQQVVEG                               CGSDMAITFNGLTPQKMEVMMYGLYRLRAF                               GHYFNDTLVFLPPVGSEND               669   2019   A   5101   1   329   PGRPTRPPLLTLLAHVSPEPAGPSCDSLAQPG                               ASGV*VQHDSHPPLLCGSQCLSEPVPGSHGPP                               RGCQHEAAPCPRGPGSDGLHHASAACASLPP                               SPILPVLLPELGPL               670   2020   A   5102   3   547   DAWGNRCAVGAAPRLIHLHLCCTPADPSRKP                               DEL*NMNGRVDYLVTEEEINLTRGPSGLGFMT                               VGGTDQQYVSNDSG1YVSRIKENGAAALDGR                               LQEGDKILSVNGQDLKNLLHQDAVDLFRNA                               GYAVSLRVQHRLQVQNGPIGHRGEGDPSGIPI                               FMVLVPVFALTMVAAWAFMRYRQQL               671   2021   A   5105   672   400   RDGREELCLQQEPTLPSRICSSAPLLYFLFICPF                               VLLLLLLISLLCLYWKARKLSTLRSNTRKEKA                               LWVDLKEAGGVTTNEMED*EEDECN               672   2022   A   5148   72   314   IIYFSYNIFLKITELLNDVERLKQALNGLSQLT                               YTSGNPTKRQSQLIDTLQHQVKSLEQQLAVS                               NQAHGALQEYVLAPCS               673   2023   A   5152   210   335   REILCSRIGRLNIV*MSLFPNLTCRLNAIPLKIPA                               NHFVEVT               674   2024   A   5153   3   2953   LTEDQPFDILQKSLQEANTTEQTLAEEAYLDA                               SIGSSQQFAQAQLHPSSSASFTQASNVSNYSG                               QTLQPIGVTHVPVGASFASNTVGVQHGFMQH                               VGISVPSQHLSNSSQISGSGQIQLIGSFGNIIPS                               MMTINNLDGSQIILKGSGQQAPSNVSGGLLV                               HRQTPNGNSLFGNSSSSPVAQPVTVPFNSTNF                               QTSLPVHNIIIQRGLAPNSNKVPINIQPKPIQM                               GQQNTYNVNNLGIQQHHVQQGISFASASSPQ                               GSVYGPHMSVNIVNQQNTRKPVTSQAVSSTG                               GSIVIHSPMGQPHAPQSQFLIPTSLSVSSNSVH                               HVQTINGQLLQTQPSQLISGQVASEHVMLNR                               NSSNMLRTNQPYTGPMLNNQNTAVHLVSGQ                               TFAASGSPVIANHASPQLVGGQMPLQQASPT                               VLHLSPGQSSVSQGRPGFATMPSVTSMSGPSR                               FPAVSSASTAHPSLGSAVQSGSSGSNFTGDQL                               TQPNRTPVPVSVSHRLPVSSSKSTSTFSNTPGT                               GTQQQFFCQAQKKCLNQTSPISAPKTTDGLR                               QAQIPGLLSTTLPGQDSGSKVISASLGTAQPQ                               QEKVVGSSPGHPAVQVESHSGGQKRPAAKQ                               LTKGAFILQQLQRDQAIHTVTPDKSHFRSLSD                               AVQRLLSYHVCQGSMPTEEDLRKVDNEFETV                               ATQLLKRTQAMLNKYRCLLLEDAMRINPPAE                               MVMLDRMFNQEERASLSRDKRLALVDPEGFQ                               ADFCCSFKLDKAAHETQFGRSDQHGSKASSS                               LQPPAKAQGRDRAKTGVTEPMNHDQFHLVP                               NHIVVSAEGNISKKTECLGRALKFDKVGLVQ                               YQSTSEEKASRREPLKASQCSPGPEGHRKTSS                               RSDHGTESKLSSILADSHLEMTCNNSFQDKSL                               RNSPKNEVLHTDIMKGSGEPQPDLQLTKSLET                               TFKNILELKKAGRQPQSDPTVSGSVELDFPNF                               SPMASQENCLEKFIPDHSEGVVETDSILEAAV                               NSILEC               675   2025   A   5154   599   1880   LKKMEPFSCDTFVALPPATVDNRIIFGKNSDR                               LYDEVQEVVYFPAVVHDNLGERLKCTYIEID                               QVPETYAVVLSRPAWLWGAEMGANEHGVCI                               GNEAVWGREEVCDEEALLGMDLVRLGLERA                               DTAEKALNVIVDLLEKYGQGGNCTEGRMVF                               SYHNSFLIADRNEAWILETAGKYWAAEKVQE                               GVRNISNQLSTTTKIAREHPDMRNYAKRKGW                               WDGKKEFDFAAAYSYLDTAKMMTSSGRYCE                               GYKLLNKHKGNITFETMMEILRDKPSGINME                               GEFLTTASMVFILPQDSSLPCIHFFTGTPDPER                               SVFKPFIFVPHISQLLDTSSPTFELEDLVKKKS                               HFKPDRRHPLYQKHQQALEVVNNNEEKAKI                               MLDNMEKLEKELFREMESILQNKHLDVEKIV                               NLFPQCTKDEIQIYQSNLSVKVSS               676   2026   A   5155   2   306   FFFLRRSLALSPRPDCGLQWRNLGSLQAPPPG                               FTPFSCLSLPSSWDYRRPPPRPANFLYF**RRG                               FTLLARMVSIS*PHDPPASASQSAGITGVSHRA                               RPT               677   2027   A   5167   97   740   FFHSVDLLALEQSKTFYKPDWFDIVESEYKCC                               KEAVCVIDMSSFTEFEITSTGDQALEVLQYLF                               SNDLDVPVGHIVHTGMLNEGGGYENDCSIAR                               LNKRSFFMISPTDQQVHCWAWLKKIIMPKDS                               NLLLEDVTWKYTALNLIGPRAVDVLSELSYA                               PMTPDHFPSLFCKEMSVGYANGIRVMSMTHT                               GEPGFMLYIPIEYRWGFTMLSTLVSNS               678   2028   A   5183   1919   2018   PALCRLRDDMTVCVADFGLSKKIYSGDYYRQ                               GRIAKMPVKWIAIESLADRVYTSKSDVWAFG                               VTMWEIATRGMTPYPGVQNHEMYDYLLHG                               HRLKQPEDCLDELCKI**SPQSP               679   2029   A   5190   39   499   RESQVKHFKMRKIDLCLSSEGSEVIILATSSDE                               KHPPENIIDGNPETFWTITGMFPQEFIICFHKH                               VRIERLVIQSYFVQTLKIEKSTSKEPVDFEQWI                               EKDLVHTEGQLQNEEIVAHDGSATYLRFIIVS                               AFDHFASVHSVSAEGTVVSNLSS               680   2030   A   5204   541   92   EILAVLKLACGDISLNALALMVATAVLTLAPL                               LLICLSYLFILSAILRVPSAAGRCKAFSTCSAH                               RTVVVVFYGTISFMYFKPKAKDPNVDKTVAL                               FYGVVTPSLNPIIYSLRNAEVKAAVLTLLRGG                               LLSRKASHCYCCPLPLSAGIG               681   2031   A   5207   10   247   VPDNGDVTKLPVCSTLVEETSLTVSEAMEQSI                               KNESPLPGTLAHTCNTSTLGGRGRWIT*GREF                               DTSMANMVKPCLYRK               682   2032   A   5210   2   231   FFFETESYSITQAGVQWPNLSSLKTLPPGFK*F                               SCLSLPSSWDYRCLPPCPANFCTPSRNGVLPC                               WPGWSRTPDLS               683   2033   A   5218   85   402   CPSVSGLRRHNNINIGTNVDVKAVSNIF                               MIILLRSMYRINVKPYFFI*LFFSRVNC*SVIIG                               YARCYTFLIF*LFL*IPADSPTDQEPKTVMLSK                               QSESAI               684   2034   A   5220   1   194   NLMKEMQNLNSENHKTWEEYKDTK*IMSYF                               YG*ALNVLKMAVLPKLMYRFSATLVKIPQHL                               TDS               685   2035   A   5228   260   440   LHSQDGNSDPRKPQGEMSAHAFPVQTCGEED                               QKKTQVPTINFTELSKCS*S*KIMSGERE               686   2036   A   5239   79   508   GGEAAARAAKLSSPRPHRVGRRERGVGGMS                               AFSEAALEKKLSELSNSQQSVQTLSLWLIHHR                               KHSRPIVTVWERELRKAKPNRKLTFLYLAND                               VIQNSKRKGPEFTKDFAPVIVEAFKHVSSETD                               ESCKKHLGRVLSIWEERS               687   2037   A   5244   1   428   MAAVVAATALKGRGARNARVLRGILAGATA                               NKASHNRTRALQSHSSPEGKEEPEPLSPELEYI                               PRKIRGKNPMKAVGLAWAIQPPCGILLFILTKR                               EVDKDRVKQMKARQNMRLSNTGEYESQRFR                               ASSQSAPSPDVGSGVQT               688   2038   A   5249   1   1407   LQQTEDKSLLNQGSSSEEVAGSSQKMGQPGP                               SGDSDLATALHRLSLRRQNYLSEKQFFAEEW                               QRKIQVLADQKEGVSGCVTPTESLASLCTTQS                               EITDLSSASCLRGFMPEKLQIVKPLEGSQTLY                               HWQQLAQPNLGTILDPRPGVITKGFTQLPGD                               AIYHISDLEEDEEEGITFQVQQPLEVEEKLSTS                               KPVTGIFLPPITSAGGPVTVATANPGKCLSCT                               NSTFTFTTCRILHPSDITQVTPSSGFPSLSCGSS                               GSSSSNTAVNSPALAYRLSIGESTTNRRDSTIT                               FSSTMSLAKLLQERGISAKVYHSPISENPLQPL                               PKSLAIPSTPPNSPSHSPCPSPLPFEPRVHLSEN                               FLASRPAETFLQEMYGLRPSRNPPDVGQLKM                               NLVDRLKRLGIARVVKNPGAQENGRCQEAEI                               GPQKPDSAVYLNSGSSLLGGLRRNQSLPVIM                               GSFAAPVCTSSPKMGVLKED               689   2039   A   5254   2   2621   LSLFGSRALGRSGARAMAKAKKVGARRKAS                               GAPAGARGGPAKANSNPFEVKVNRQKFQILG                               RKTRHDVGLPGVSRARALRKRTQTLLKEYKE                               RDKSNVFRDKRFGEYNSNMSPEEKMMKRFA                               LEQQRHHEKKSIYNLNEDEELTHYGQSLADIE                               KHNDIVDSDSDAEDRGTLSGELTAAHFGGGG                               GLLHKKTQQEGEEREKPKSRKELIEELIAKSK                               QEKRERQAQREDALELTEKLDQDWKEIQTLL                               SHKTPKSENRDKKEKPKPDAYDMMVRELGF                               EMKAQPSNRMKTEAELAKEEQEHLRKLEAE                               RLRRMLGKDEDENVKKPKHMSADDLNDGFV                               LDKDDRRLLSYKDGKMNVEEDVQEEQSKEA                               SDPESNEEEGDSSGGEDTEESDSPDSHLDLES                               NVESEEENEKPAKEQRQTPGKGLISGKERAG                               KATRDELPYTFAAPESYEELRSLLLGRSMEEQ                               LLVVERIQKCNHPSLAEGNKAKLEKLFGFLLE                               YVGDLATDDPPDLTVIDKLVVHLYHLCQMFP                               ESASDAIKFVLRDAMHEMEEMIETKGRAALP                               GLDVLIYLKITGLLFPTSDFWHPVVTPALVCL                               SQLLTKCPILSLQDVVKGLFVCCLFLEYVALS                               QRFIPELINFLLGILYIATPNKASQGSTLVHPFR                               ALGKNSELLVVSAREDVATWQQSSLSLRWA                               SRLRAPTSTEANHIRLSCLAVGLALLKRCVLM                               YGSLPSFHAIMGPLRALLTDHLADCSHPQELQ                               ELCQSTLTEMESQKQLCRPLTCEKSKPVPLKL                               FTPRLVKVLEFGRKQGSSKEEQERKRLIHKHK                               REFKGAVREIRKDNQFLARMQLSEIMERDAE                               RKRKVKQLFNSLATQEGEWKALKRKKFKK               690   2040   A   5261   1   304   FPFFVFLVETGFHHVGQAGLELLTSGDPPTW                               ASQSAGITGVSHCSWPVIYVLSTLLHAVRNVL                               FKRTFPLKSSSFLSYDKEIFFILIIVLKFYLVTLT                               SFVK               691   2041   A   5270   3   158   NCHTTHCTANWVHLPGTPPGWKLDGPAAAL                               EVLSSFFFFFLKFSYKPQNW               692   2042   A   5282   56   1268   GMEPVGCCGECRGSSVDPRSTFVLSNLAEVV                               ERVLTFLPAKALLRVACVCRLWEECVRRVLR                               THRSVTWISAGLAEAGHLEGHCLVRVVAEEL                               ENVRILPHTVLYMADSETFISLEECRGHKRAR                               KRTSMETALALEKLFPKQCQVLGIVTPGIVVT                               PMQSGSNRPQEIEIGESGFALLFPQIEGIKIQPF                               HFIKDPKNLTLERHQLTEVGLLDNPELRVVLV                               FGYNCCKVGASNYLQQVVSTFSDMNIILAGG                               QVDNLSSLTSEKNPLDIDASGVVGLSFSGHRI                               QSATVLLNEDVSDEKTAEAAMQRLKAANIPE                               HNTIGFMFACVGRGFQYYRAKGNVEADAFR                               KFFPSVPLFGFFGNGEIGCDRIVTGNFILRKCN                               EVKDDDLFHSYTTIMALIHLGSSK               693   2043   A   5301   362   507   EEIKERFGPGLVIYWYGFIQELDCNRERGILLK                               ACFPTNIVTLCHSIA               694   2044   A   5310   1   204   RVLTAINHTLKENLRKFYKGKKDKPLDLRPK                               KTRAMRRRLNMHEENLKTKLKQHRKERLYPL                               RKYAAKA               695   2045   A   5315   125   1596   ETRSTAVKSEVQVCISLLLCLEDRTMIPKKAKP                               TGSGKEEGPAPCKQMKLEAAGGPSALNFDSP                               SSLFESLISPIKTETFWEFWEQKPLLIQRDDPA                               LATYYGSLFKLTDLKSLCSRGMYYGRDVNV                               CRCVNGKKKVLNKDGKAHFLQLRKDFDQKR                               ATIQFHQPQRFKDELWRIQEKLECYFGSLVGS                               NVYLTPAGSQGLPPHYDDVEVFILQLEGEKH                               WRLYHPTVPLAREYSVEAEERIGRPVHEFML                               KPGDLLYFPRGTIHQADTPAGLAIISTHVTIST                               YQNNSWGDFLLDTISGLVFDTAKEDVELRTG                               TPRQLLLQVESITVATRRLSGFLRTLADRLEG                               TKELLSSDMKKDFIMHRLPPYSAGDGAELSTP                               GGKLPRLDSVVRLQFKDHIVLTVLPDQDQSD                               ETQEKMVYIYHSLKNSRETHMMGNEEETEFH                               GLRFPLSHLDALKQIWNSPAISVKDLKLTTDE                               EKESLVLSLWTECLIQVV               696   2046   A   5318   1476   742   LMKXYLEAAELGELSDIHTKLLRLSSSQGTIET                               SLQDIDSRLSPGGSLADAWAHQEGTHPKDRN                               VEKLQVLLNCMTEIYYQFKKDKAERRLAYN                               EEQIHKFDKQKLYYHATKAMTHFTDECVKK                               YEAFLNKSEEWIRKMLHLRKQLLSLTNQCFDI                               EEEVSKYQEYTELQEILPQKMFTASSGIKHT                               MTPIYPSSNTLVEMTLGMKKLKEEMEGVVKE                               LAENNHILESCIGSLTMDGGLRNVDCL               697   2047   A   5320   244   478   LDYNFFLFEMTFGLVSQAGVQWHDLGSLQPP                               PPGFKQFSCLSLPSSWDYRHLPPIILANFSREG                               VSPSWPGWSRTPDFR               698   2048   A   5324   266   714   LPIRKSLRSVRSGFPTSQSPITRNLDGTASGSC                               LAKTVTGSLFRINVGLRGLVAGGIIGALLGTP                               VGGLLMAFQKYSGETVQERKQKDRKALHEL                               KLEEWKGRLQVTEHLPEKIESSLQEDEPENDA                               KKIEALLNLPRNPSVIDKQDKD               699   2049   A   5334   699   277   RPHGHLVCISSSAGLSGVNGLADYCASKFAA                               FGFAESVFVETFVQKQKGIKUIVCPFPIKTGM                               FEGCTTGCPSLLPILEPKYAVEKIVEAILQEKM                               YLYMPKLLYFMMFLKSFLPLKTGLLLADYLGI                               LHAMDGFADQKK               700   2050   A   5344   3   614   PTAEEMSSLTPESSPELAKRSWFGNFISLDKEE                               QIELVLKDKPLSSIKADIVHAFLSIPSLSHSVLS                               QTSFRAEYKASGGPSVFQKFVRFQVDISSSEG                               PEPSPRRDQSGGGGIYSVTFTLISGPSRRFKRV                               VETIQAQLLSTHDQPSVQALADEKNGAQTRP                               AGAPPRSLQPPPGRPDPELSSSPRRGPPKDKK                               LLATNGTPL               701   2051   A   5346   3   1383   HASVLFCRVMAASKTQGAVARMQEDRDGSC                               STVGGVGYGDSKDCILEPLSLPESPGGTITLE                               GSPSVPCIFCEEHFPVAEQDKLLKHMIIEHKIY                               IADVKLVADFQRYILYWRKRFTEQPITDFCSV                               IRINSTAPFEEQENYFLLCDVLPEDRILREELQ                               KQRLREILEQQQQERNDTNFHGVCMFCNEEF                               LGNRSVILNHMAEEHAFNIGLPDNIVNGNEFL                               CTLQKKLDNLQCLYCEKTFRDKNTLKDLIMR                               KKQHRKINPKNREYDRFYVINYLELGKSWEE                               VQLEDDRELLDHQEDDWSDWEEHPASAVCL                               FCEKQAETIEKLYVHMEDAHEFDLLKIKSELG                               LNFYQQVKLVNFIRRQVHQCRCYGCHVKFKS                               KADLRTHMEETKHTSLLPDRKTWDQLEYYFP                               TYENDTLLWTLSDSESDLTAQEQNENVPUSE                               DTSKLYALKQSSILNQLLL               702   2052   A   5356   2502   1540   MAAATRGCRPWGSLLGLLGLVSAAAAAWD                               LASLRCTLGAFCECDFRPDLPGLECDLAQHL                               AGQHLAKALVVKALKAFVRDPAPTKPLVLSL                               HGWTGTGKSYVSSLLAHYLFQGGLRSPRVH                               HFSPVLHFPHPSHIERYKKDLKSWVQGNLTA                               CGRSLFLFDEMDKMPPGLMEVLRPFLGSSWV                               VYGTNYRKAIFLFISNTGGEQINQVALEAWRS                               RRDREEILLQELEPVISRAVLDNPHHGFSNSGI                               MEERLLDAVVPFLPLQRHHVRHCVLNELAQL                               GLEPRDEVVQAVLDSTTFFPEDEQLFSSNGCK                               TVASRIAFFL               703   2053   A   5380   278   657   LFLQKLRMKTEEEARTHTELEMFLRKEQQKL                               EERLEFWMEKYDKDTEMKQNELNALKATKA                               SDLAIILQDLAKMIREYEQVIIEDRIEKERSKK                               KVKQDLLELKSVIKLQAWWRGTMIRREIGGF                               KM               704   2054   A   5381   1   1003   FRGRAVKMAAVVEVEVGGGAAGERELDEV                               DMSDLSPEEQWRVEHARMHAKHRGHEAMH                               AEMVLILIATLVVAQLLLVQWKQRHPRSYN                               MVTLFQMWVVPLYFTVKLHWWRFLVIWILF                               SAVTAFVTFRATRKPLVQITPRLVYKWFLLIY                               KISYATGIVGYMAVMFTLPGLNLLFKIKPEDA                               MDFGISLLFYGLYYGVLERDFAEMCADYMA                               STLGFYSESGMPTKIILSDSVCAVCGQQIFVDV                               SEEGIIENTYRLSCNHVFHEFCIRGWCIVGKK                               QTCPYCKEKVDLKRMFSNPWERPHVMYGQL                               LDWLRYLVAWQPVIIGVVQGINYILGLE               705   2055   A   5396   3   675   IYDRDPLQLATRAGQPLDINMAGEPKPYRPKP                               GNKRPLSALYRLESKEPFLSVGGYVFDYDYY                               RDDFYNRLFDYHGRVPPPPPAVIPLKRPRVA                               VTTTRRGKGVFSMKGGSRSTASGSTGSKLKS                               DELQTIKKELTQIKTKIDSVLGRLDKIEKQQK                               AEAEAQKKLLEESLVLIQEECVSEIADHSTEEP                               AEGGPDADGEEMTDGTEEAFDEDGGHELFLQ                               IK               706   2056   A   5410   2   98   GRVGLNLEGRGCSEPKWRHICTPTWATEQDSI                               S               707   2057   A   5415   6   287   PFKLTPSFLSHAFSSGQERKVFIELNHIKKCNT                               VRGVFVLEEFGNYTILLLGLDSHGSNSNLGAP                               EEGLGAGRKRTSVEKSGGAGVTRKKRDP               708   2058   A   5423   3   291   SSSNPLGSPSTLWKLCSFVLHNKSCCCSFFGS                               TPTLRAITLTVRVCGFIPEVSKTTNPLGRTLNS                               GCTIFKTVTLTARSTASLLKSVRPRTHQKE               709   2059   A   5424   679   347   R1RHEEKRGSRGRGRRTSEEDTPKKKKHKGG                               SEFTDTILSVHPSDVLDMPVDPNEPTYCLCHQ                               VSYGEMIGCDNPDCPIEWFHFACVDLTTKPK                               GKWFCPRCVQEKRKKK               710   2060   A   5442   1073   559   QESLKKKIQPKLSLTLSSSVSRGNVSTPPRHSS                               GSLTPPVTPPITPSSSFRSSTPTGSEYDEEEVDY                               EESDSDESWTTESAISSEAILSSMCMNGGEEK                               PFACPVPGCKKRYKNVNGIKYHAKNGHRTQI                               RVRKPFKCRCGKSYKTAQGLRHHTINFHPPV                               SAEIIRKMQQ               711   2061   A   5449   1   319   GDSLCVPQYNKYREERVILFLKMASGHAFQP                               DLVKRIRDAIRMGLSARHVPSLILETKGIPYTL                               NGKKVEVAVKQIIAGKAVEQGGAFSNPETLD                               LYRDIPELQGF               712   2062   A   5499   91   749   RPTPGHGDFWMQPLTKDAGMSLSSVTLASAL                               QVRGEALSEEEIWSLLFLAAEQLLEDLRNDSS                               DYVVCPWSALLSAAGSLSFQGRVSHIEAAPF                               KAPELLQGQSEDEQPDASQMHVYSLGMTLY                               WSAGFHVPPHQPLQLCEPLHSILLTMCEDQPH                               RRCTLQSVLEACRVHEKEVSVYPAPAGLHIR                               RLVGLVLGTISEVSREPGFSSSSCWSCVAIKI               713   2063   A   5506   22   478   VEELILNSRLDPHLHTPMYFFLAHLSFLDLSFT                               TSSIPQLLYNLNGCDKTISYMGCAIQLFLFLGL                               GGVECLLLAVMAYDRCVAICKPLHYMVIMN                               PRLCRGLVSVTWGCGVANSLAMSPVTLRLPR                               CGHHEVDHFLCEMPALIRMACISTV               714   2064   A   5514   25   220   AIRPYWCENNIIGIGKLSTADGKAFAIIPEVLR                               RLTSSVSCALDEAAAALTRMRAESTANAGQS                               DK               715   2065   A   5526   3   810   KVTAPRRPQRYSSGHGSDNSSVLSGELPPAM                               GRTALFHHSGGSSGYESLRRDSEATGSASSAP                               DSMSESGAASPGARTRSLKSPKKRATGLQRR                               RLIPAPLPDITALGRKPSLPGQWVDLPPPLAG                               SLKEPFEIKVYEIDDVERLQRPRPTPREAPTQG                               LACVSTRLRLAERRQQRLREVQAKHKHLCEE                               LAETQGRLMLEPGRWLEQFEVDPELEPESAE                               YLAALERATAALEQCVNLCKAHVMMVTCFD                               ISVAASAAIPGPQEVDV               716   2066   A   5529   458   790   SPGYGENKFTVTSXNIAVPLCEMNKIYSYYSD                               SSSSERTMDLVLEMCNTNSIHWCGISGRQLG                               KLHPSSSLCLALTLLSSVQGLQSISGLRLTDTF                               LKRTYEYDDIAQYCV               717   2067   A   5531   3   460   NSEDLLKYFNPESWQEDLDNMYLDTPRYRG                               RSYHDRKSKVDLDRLNDDAKRYSCTPRNYS                               VNIREELKLANVVFFPRCLLVQRCGGNCGCG                               TVNWRSCTCNSGKTVKKYHEVLQFEPGHIKR                               RGRAKTMALVDIQLDHHERCDCICSSRPPR               718   2068   A   5586   311   88   AVLKNMAPMTALGLLDLHILNLILFLSAGEDF                               TSVVSEIMMYILLVFLTLWLLIEMIYCYRKVS                               KAEEAAQENA               719   2069   A   5598   1   330   KNCANEAVVQKILDRVLSRYDVRLRPNFGSM                               LATNSTRGLNEDELMAHQQEKDSSSESEDSC                               PPSPGCSFTEGFSFDLLNPDYVPKVDKWSRFL                               FPLAFGLFNIVAAERC               720   2070   A   5628   798   148   LPPAQIPEAWLLLANVVVVLILVPLKDRLIDP                               LLLRCKLLPSALQKMALGMFFGFTSVIVAGV                               LEMERLHYIHHNIETVSQQIGEVLYNAAPLSIW                               WQIPQYLLIGISEIFASIPGLEFAYSEAPRSMQG                               AIMGIFFGLSGVGSLLGSSLVALLSLPGGWLH                               CPKDFGNINNCRMDLYFFLLAGIQAVTALLF                               VWIAGRYERASQGPASHSRFSRDRG               721   2071   A   5632   146   536   MSALIVRKLRSAELTLFSELPTVLGANVNAA                               KLHETALHHAAKVKNVDLIEMLIEFGGNIYA                               RDNRGKKPSDYTWSSSAPAKCFEYYEKTPLT                               LSQLCRVNLRKATGVRGLEKIAKLNIPPRLID                               YLSYN               722   2072   A   5638   3   3806   CPSLDIRSEVAELRQLENCSVVEGHLQILLMF                               TATGEDFRGLSFPRLTQVTDYLLLFRVYGLES                               LRDLFPNLAVTRGTRLFLGYALVIFEMPHLRD                               VALPALGAVLRGAVRVEKNQELCHLSTIDW                               GLLQPAPGANHIVGNKLGEECADVCPGVLGA                               AGEPCAKTTFSGHTDYRCWTSSHCQRVCPCP                               HGMACTARGECCHTECLGGCSQPEDPRACV                               ACRHLYFQGACLWACPPGTYQYESWRCVTA                               ERCASLHSVPGRASTFGIHQGSGLAQCPSGFT                               RNSSSIFCHKCEGLCPKECKVGTKTIDSIQAA                               QDLVGCTHVEGSLILNLRQGYNLEPQLQHSL                               GLVETITGFLKIKHSFALVSLGFFKNLKLLRGD                               AMVDGNYTLYVLDNQNLQQLGSWVAAGLTI                               PVGKIYFAFNPRLCLEHIYRLEEVTGTRGRQN                               KAEINPRTNGDRAACQTRTLRFVSNVTEADRI                               LLRWERYEPLEARDLLSFIVYYKESPFQNATE                               HVGPDAGGTQSWNLLDVELPLSRTQEPGVTL                               ASLKPWTQYAVFVRAITLTTEEDSPHQGAQS                               PIVYLRTLPAAPTVPQDVISTSNSSSHLLVRW                               KPPTQRNGNLTYYLVLWQRLAEDGDLYLND                               YCHRGLRLPTSNNDPRFDGEDGDPEAEMESD                               CCPCQHPPPGQVLPPLEAQEASFQKKFENFLH                               NAITIPISPWKVTSINKSPQRDSGRHRRAAGPL                               RLGGNSSDFEIQEDKVPREPAVLSGLRHFTEY                               RIDIHACNHAAHTVGGSAATFVFARTMPHRE                               ADGIPGKVAWEASSKNSVLLRWLEPPDPNGL                               ILKYEIKYRRLGEEATVLCVSRLRYAKFGGV                               HLALLPPGNYSARVRATSLAGNGSWTDSVAF                               YILGPEEEDAGGLHVLLTATPVGLTLLWLAA                               LGFFYGKKRNRTLYASVNPEYFSASDMYVPD                               EWEVPREQISIIRELGQGSFGMVYEGLARGLE                               AGEESTPVALKTVNELASPRECIEFLKEASVM                               KAFKCHHVVRLLGVVSQGQPTLVIMELMTR                               GDLKSHLRSLRPEAENNPGLPQPALGEMIQM                               AGEIADGMAYLAANKFVHRDLAARNCMVSQ                               DFTVKIGDFGMTRDVYETDYYRKGGKGLLP                               VRWMAPESLKDGIFTTHSDVWSFGVVLWEIV                               TLAEQPYQGLSNEQVLKFVMDGGVLEELEGC                               PLQLQELMSRCWQPNPRLRPSFTILDSIQEEL                               RPSFRLLSFYYSPECRGARGSLPTTDAEPDSSP                               TPRDCSPQNGGPGH               723   2073   A   5672   1   216   LAWIDNILPEKEKKETDKKRKRKKGAHEDCD                               EEPQFPPPSVIKIPMESVQSDPQNGIHCIARKR                               SSSWSYSL               724   2074   A   5704   4235   940   ARGRRSRPVWAASWGGRGRPAARRRPRGLA                               ATMGFELDRFDGDVDPDLKCALCHKVLEDP                               LTTPCGHVFCAGCVLPWVVQEGSGPARCRGR                               LSAKELNHVLPLKRLILKLDIKCAYATRGCGR                               VVKLQQLPEHLERCDFAPARCRHAGCGQVLL                               RRDVEAHMRDACDARPVGRCQEGCGLPLTH                               GEQRAGGHCCARALRAHNGALQARLGALHK                               ALKKEALRAGKREKSLVAQLAAAQLELQMT                               ALRYQKKFTEYSARLDSLSRCVAAPPGGKGE                               ETKSLTLVLHRDSGSLGFNIIGGRPSVDNHDG                               SSSEGIFVSKIVDSGPAAKEGGLQIHDRIIEVN                               GRDLSRATHDQAVEAFKTAKEPTVVQVLRRT                               PRTKMFTPPSESQLVDTGTQTDITFEHIMALT                               KMSSPSPPVLDPYLLPEEHPSAHEYYDPNDYI                               GDIHQEMDREELELEEVDLYRMNSQDKLGLT                               VCYRTDDEDDIGIYISEIDPNSIAAKDGRIREG                               DRIIQINGIEVQNREEAVALLTSEENKNFSLLI                               ARAELQLDEGWMDDDRNDFLDDLHMDMLE                               EQHHQAMQFTASVLQQKKHDEDGGTTDTAT                               ILSNQIIEKDSGVGRTDESTRNDESSEQENNG                               DDATASSNPLAGQRKLTCSQDTLGSGDLPFS                               NESFISADCTDADYLGIPVDECERFRELLELK                               CQVKSATPYGLYYPSGPLDAGKSDPESVDKE                               LELLNEELRSIELECLSIVRAHKMQQLKEQYR                               ESWMLHNSGFRNYNTSIDVRRHELSDITELPE                               KSDKDSSSAYNTGESCRSTPLTLEISPDNSLRR                               AAEGISCPSSEGAVGTTEAYGPASKNLLSITE                               DPEVGTPTYSPSLKELDPNQPLESKERRASDG                               SRSPTPSQKLGSAYLPSYHHSPYKHAHIPAHA                               QHYQSYMQLIQQKSAVEYAQSQMSLVSMCK                               DLSSPTPSEPRMEWKVKIRSDGTRYITKRPVR                               DRLLRERALKIREERSGMTTDDDAVSEMKM                               GRYWSKEERKQHLVKAKEQRRRREFMMQSR                               LDCLKEQQAADDRKEMNILELSHKKMMKKR                               NKKIFDNWMTIQELLTHGTKSPDGTRVYNSF                               LSVITV               725   2075   A   5707   3   1770   QISTEVSEAPVANDKPKTLVVKVQKKAADLP                               DRDTWKGRFDFLMSCVGYAIGLGNVWRFPY                               LCGKNGGGAFLIPYFLTLIFAGVPLFLLECSLG                               QYTSIGGLGVWKLAPMFKGVGLAAAVLSFW                               LNIYYIVIISWAIYYLYNSFTTTLPWKQCDNP                               WNTDRCFSNYSMVNTTNMTSAVVEFWERN                               MHQMTDGLDKPGQIRWPLAITLAIAWILVYF                               CIWKGVGWTGKVVYFSATYPYIMLIILFFRGV                               TLPGAKEGILFYITPNFRKLSDSEVWLDAATQ                               IFFSYGLGLGSLIALGSYNSFHNNVYRDSIIVC                               CINSCTSMFAGFVIFSIVGFMAHVTKRSIADV                               AASGPGLAFLAYPEAVTQLPISPLWAILFFSM                               LLMLGIDSQFCTVEGFITALVDEYPRLLRNRR                               ELFIAAVCIISYLIGLSNITQGGIYVFKLFDYYS                               ASGMSLLFLVFFECVSISWFYGVNRFYDNIQE                               MVGSRPCIWWKLCWSFFTPIIVAGVFIPSAVQ                               MTPLTMGNYVFPKWGQGVGWLMALSSMVL                               IPGYMAYMFLTLKGSLKQRIQVMVQPSEDIV                               RPENGPEQPQAGSSTSKEAYI               726   2076   A   5711   156   423   PRRDPGRTFELRGSAPRKTGANMPVRRGHVA                               PQNTFLGTIIRKFEGQNKKFIIANARVQNCAII                               YCNDGFCEMTGFSRPDVMQKPCTCD               727   2077   A   5716   3   274   HASEYFFKLCSFQVFLSFPLATTVIDVGLVVIP                               LVKSPNVHYVYVLLLVLSGLLFYIPLIHFKIRL                               AWFEKMTCYLQLLFNICLPDVSEE               728   2078   A   5737   1899   649   IQASRASPYPRVKVDFALSCHEDLLAPISEPIE                               WKYHSPEEEISLGPACWLWDFLRRSQQAGFL                               LPLSGGVDSAATACLIYSMGCQVCEAVRSGN                               EEVLADVRTIVNQISYTPQDPRDLCGRTLLC                               YMASKNSSQETCTRARELAQQIGSLLHISLNID                               PAVKAVMGIFSLVTGKSPLFAAHGGSSRENL                               ALQNVQARIRMVLAYLFAQLSLWSRGVHGG                               LLVLGSANVDESLLGYLTKYDCSSADINPIGG                               ISKTDLRAFVQFCIQRFQLPALQSILLAPATAE                               LEPLADGQVSQTDEEDMGMTYAELSVYGKL                               RKVAKMGPYSMFCKLLGMWRHICTPRQVAD                               KVKRFFSKYSMNRHKMTRTPAYHAENYSPE                               DNRFDLRPFLYNTSWPWQFRCIENQVLQLER                               AEPQSLDGVD               729   2079   A   5741   1   5976   PGCAARLSRARAPGPGAAGAGRKRLADPGPP                               PASRRLRAPGSRPRLAPCTRRAAQPAHAPIVIA                               PRAAGGAPLSARAAAASPPPFQTPPRCPVPLL                               LLLLLGAARAGALEIQRRFPSPTPTNNFALDG                               AAGTVYLAAVNRLYQLSGANLSLEAEAAVG                               PVPDSPLCHAPQLPQASCEHPRRLTDNYNKIL                               QLDPGQGLVVVCGSIYQGFCQLRRRGNISAV                               AVRFPPAAPPAEPVTVFPSMLNVAANHPNAS                               TVGLVLPPAAGAGGSRLLVGATYTGYGSSFF                               PRNRSLEDHRFENTPEIAIRSLDTRGDLAKLFT                               FDLNPSDDNILKIKQGAKEQHKLGFVSAFLHP                               SDPPPGAQSYAYLALNSEARAGDKESQARSL                               LARICLPHGAGGDAKKLTESYIQLGLQCAGG                               AGRGDLYSRLVSVFPARERLFAVFERPQGSPA                               ARAAPAALCAFRFADVRAAIRAARTACFVEP                               APDVVAVLDSVVQGTGPACERKLNIQLQPEQ                               LDCGAAHLQHPLSILQPLKATPVFRAPGLTSV                               AVASVNNYTAVFLGTVNGRLLKINLNESMQ                               VVSRRVVTVAYGEPVHHVMQFDPADSGYLY                               LMTSHQMARVKVAACNVHSTCGDCVGAAD                               AYCGWCALETRCTLQQDCTNSSQQHFVISA                               SEGPSRCPAMTVLPSEIDVRQEYPGMILQISGS                               LPSLSGMEMACDYGNNLRTVARVPGPAFGHQ                               LAYCNLLPRDQFPPFPPNQDHVTVEMSVRVN                               GRNIVKANFTTYDCSRTAQVYPHTACTSCLSA                               QWPCFWCSQQHSCVSNQSRCEASPNPTSPQD                               CPRTLLSPLAPVPTGGSQNILVPLANTAFFQG                               AALECSFGLEEIFEAVWVNESVVRCDQVVLH                               TTRKSQVFPLSLQLKGRPARFLDSPEPMTVM                               VYNCAMGSPDCSQCLGREDLGHLCMWSDGC                               RLRGPLQPMAGTCPAPEIRAIEPLSGPLDGGT                               LLTIRGRNLGRRLSDVAHGVWIGGVACEPLP                               DRYTVSEEIVCVTGPAPGPLSGVVTVNASKE                               GKSRDRFSYVLPLVHSLEPTMGPKAGGTRITI                               HGNDLHVGSELQVLVNDTDPCTELMRTDTSI                               ACTMPEGALPAPVPVCVRFERRGCVHGNLTF                               WYMQNPVITAISPRRSPVSGGRTITVAGERFLI                               MVQNVSMAVHHIGREPTLKCKVLNSTLITCPSP                               GALSINASAPVDFFINGRAYADEVAVAEELLD                               PEEAQRGSRFRLDYLPNPQFSTAKREKWIKH                               HPGEPLTLVIHVSTKGAGKEQDSLGLQSHEY                               RVKIGQVSCDIQIVSDRIIHCSVNESLGAAVGQ                               LPITIQVGNFNQTIATLQLGGSETAIIVSIVICSV                               LLLLSVVALFVFCTKSRRAERYWQKTLLQME                               EMESQIREEIRKGFAELQTDMTDLTKELNRSQ                               GIPPLEYKHFVTRTFFPKCSSLYEERYVLPSQT                               LNSQGSSQAQETHPLLGEWKIPESCRPNMEE                               GLSLFSSLLDNKIIFLIVFVHALEQQKDFAVRD                               RCSLASLLTIALHGKLEYYTSIMKELLVDLID                               ASAAKNPKLMLRRTESVVEKMLTNWMSICM                               YSCLRETVGEPFFLLLCAIKQQINKGSIDAITG                               KARYTLNEEWLLRENIEAKPRNLNVSFQGCG                               MDSLSVRAMDTDTLTQVKEKILEAFCKNVPY                               SQWPRAEDVDLEWFASSTQSYILRDLDDTSV                               VEDGRKKLNTLAIIYKIPEGASLAMSLIDKKD                               NTLGRVKDLDTEKYFHLVLPTDELAEPKKSH                               RQSHRKKVLPEIYLTRLLSTKGTLQKFLDDLF                               KAILSIREDKPPLAVKYFFDFLEEQAEKRGISD                               PDTLHIWKTNSLPLRFWVNILKNPQFVFDIDK                               TDHIDACLSVIAQAFIDACSISDLQLGKDSPTN                               KLLYAKEIPEYRKIVQRYYKQIQDMTPLSEQE                               MNAHLAEESRKYQNEFNTNVAMAEIYKYAK                               RYRPQIMAALEANPTARRTQLQHKFEQVVAL                               MEDNIYECYSEA               730   2080   A   5744   3   292   QPSPLFHSHLETLQLLRTAQLPEQVSWPWGQ                               VANGKGNQRNMGSPQPSLLAFERNLELQIMG                               LGYSLLMGKLRPRVAKDTLRVHRDSTPSPLT               731   2081   A   5747   1   382   FLKCMRKAFRSSKLLQVGYTPDGICDDYRWC                               FRVDEVNWITWNTNVGINEDPGNCEGVKRT                               LSFSLRSSRVSGRHWKNFALVPLLREASARD                               RQSAQPEEVYLRQFSGSLKPEDAEVFKSPAAS                               GEK                732   2082   A   5753   198   3   AQAESSTVASPEATAGPLCTRIPNVPPPTPIRP                               PGKLQAQLPCPSPVRFTSARIFPASRPQTKS               733   2083   A   5754   2   2223   AAGPPGLEAEGRAPESAGPGPGGDAAETPGL                               PPAHSGTLMMAFRDVTVQIANQNISVSSSTAL                               SVANCLGAQTVQAPAEPAAGKAEQGETSGR                               EAPEAPAVGREDASAEDSCAEAGASGAADG                               ATAPKTEEEEEEEETAEVGRGAEAEAGDLEQ                               LNRTSTSTKSAKSGSEASASASKDALQAMILS                               LPRYHCENPASCKSPTLSTDTLRKRLYRIGLN                               LFNINPDKGIQFLISRGFIPDTPIGVAHFLLQRK                               GLSRQMIGEFLGNSKKQFNRDVLDCVVDEM                               DFSSMELDEALRKFQAHIRVQGEAQKVERLIE                               AFSQRYCMCNPEVVQQFHNPDTIFILAFAIILL                               NTDMYSPNIKPDRKMMLEDFIRNLRGVDDG                               ADIPRELVVGIYERIQQKELKSNEDIIVTYVTK                               VEKSIVGMKTVLSVPHRRLVCCSRLFEVTDV                               NKLQKQAAHQREVFLFNDLLVILKLCPKKKS                               SSTYTFCKSVGLLGMQFQLFENEYYSHGITLV                               TPLSGSEKKQVLHFCALGSDEMQKFVEDLKE                               SIAEVTELEQIRIEWELEKQQGTKTLSFKPCGA                               QGDPQSKQGSPTAKREAALRERPAESTVEVSI                               HNRLQTSQHNSGLGAERGAPVPPPDLQPSPPR                               QQTPPLPPPPPTPPGTLVQCQQIVKVIVLDKPC                               LARMEPLLSQALSCYTSSSSDSCGSTPLGGPG                               SPVKVTHQPPLPPPPPPYNHPHQFCPPGSLLH                               GHRYSSGSRSLV               734   2084   A   5788   8   362   SSVMGDLVGQGLEEQWARDENSWLIDGGTP                               LDDVMRVLDIDEFPQSGNYETIGGFMMFMLR                               KIPKRTDSVKFAGYKFEVVDIDNYRIDQLLVT                               RIDSKATALSPKLPDAKDKEESVA               735   2085   A   5827   1   1257   MVFSAVLTAFHTGTSNTTFVVYENTYMNITL                               PPPFQHPDLSPLLRYSFETMAPTGLSSLTVNST                               AVPTTPAAFKSLNLPLQITLSAIMIFILFVSFLG                               NLVVCLMVYQKAAMRSAINILLASLAFADM                               LLAVLNMPFALVTILTIRWIFGKFFCRVSAMF                               FWLFVLEGVAILLIISIDRFLIIVQRQDKLNPYR                               AKVLIAVSWATSFCVAFPLAVGNPDLQIPSRA                               PQCVFGYTTNPGYQAYVILISLISFFIPFLVILY                               SFMGILNTLRHNALRIHSYPEGICLSQASKLGL                               MGLQRPFQMSIDMGFKTRAFTTLILFAVFIVC                               WAPFTTYSLVATFSKHFYYQHNFFEISTWLL                               WLCYLKSALNPLIYYWRIKKFHDACLDMMP                               KSFKFLPQLPGHTKRRIRPSAVYVCGEHRTVV               736   2086   A   5870   3   268   FTRSDELARHYRTHTGEKRFSCPLCPKQFSRS                               DHLTKHARRHPTYHPDMIEYRGRRRTPRIDPP                               LTSEVESSASGSGPGPAPSFTTCL               737   2087   A   5871   2   521   LTWPQLFLETLPELLHMSRFAEDGPSPGALVRS                               RSSSLGYISKAEEYFLLKSRSDLIVWEKQSERH                               GLARRLTTARRPPASSEQAQQELFNELKPAV                               DGANFIVNHMRDQNNYNEEKDSWNRVART                               VDRLCLFVVTPVMVVGTAWIFLQGVYNQPPP                               QPFPGDPYSYNVQDKRFI               738   2088   A   5881   1   1160   LVVTAITAILAFPNEYTRMSTSELISELFNDCG                               LLDSSKLCDYENRFNTSKGGELPDRPAGVGV                               YSAMWQLALTLILKIVTTTFTFGMKIPSGLFWS                               MAVGAIAGRLLGVGMEQLAYYHQEWTVFNS                               WCSQGADCTTPGLYAMVGAAACLGGVTRMT                               VSLVVIMFELTGGLEYIVPLMAAAMTSKWVA                               DALGRLEGIYDAHIRLNGYPFLEAKEEFAIIKTL                               AMDVMKPRLRNDPLLTVLTQDSMTVEDVETII                               SETTYSGFPVVVSRESQRLVGFVLRRDLHSLE                               NARKKQDGVVSTSIIYFTEHSPPLPPYTPPTLK                               LRNILDLSPTVTDLTPMEIVYDIFRKLGLRQC                               LVTHNGRLLGIITKKDVLKHIAQMANQDPDSI                               LFN               739   2089   A   5892   2   916   TLQLAASVPFFAISLISWWLPESARWLIINGKP                               DQALQELRKVARINGHKEAKNLTIEVLMSSV                               KEEVASAKEPRSVLDLFCVPVLRWRSCAMLV                               VNFSLLISYYGLVFDLQSLGRDIFLLQALFGA                               VDFLGRATTALLLSFLGRRTIQAGSQAMAGL                               AILANMLVPQDLQTLRVVFAVLGKGCFGISL                               TCLTIYKAELFPTPVRMTADGILHTVGRLGA                               MMGPLILMSRQALPLLPPLLYGVISIASSLVVL                               FFLPETQGLPLPDTIQDLESQKSTAAQGNRQE                               AFTVESTSLLEIVALHGAL               740   2090   A   5900   2   426   RPIKTLGIGFHFSVDGVHFLTQREVQNLWKE                               NLLILDTAKKHGYEVVDTFTITMGRYKEFLQG                               KCGCHFHEVYKSKLSKEYNFIKMKRSRNHIM                               GRYPSNQSKLQQGTVTNFRSPYHVRGPINQV                               CSEILLSRMCANKRTM               741   2091   A   5910   3   412   RMPESTLLIICENGY1LEAPLPTIKQEEDDHDV                               VSYEIKDMCIKCFHFSSVKSKILRLIEIEKRER                               QRELKEKIREERRNKLAAEMGEDGEKEFQEE                               EEEKEEEEEEEEPLPEIFIIPSTPSPILCGFYSEPG                               KFWV               742   2092   A   5936   1   482   MGCRLLCCVVPCLLQAGPLDTAVSQTPKYLV                               TQMGNDKSIKCEQNLGHDTMYWYKQDSKK                               FLKIMFSYNNKELIINETVPNRFSPKSPDKAHL                               NLHINSLELGDSAVYFCASSQDTALQSHCTPV                               HKPPGSARKLQGSVCTCTQGSSLHSLMASDG                               VPVC               743   2093   A   5938   1   1566   MNSFFGTPAASWCLLESDVSSALPDKEAGRER                               RALSVQQRGGPAWSGSLEWSRQSAGDRRRL                               GLSRQTAKSSWSRSRDRTCCCRRAWWILVPA                               ADRARRERFIMNEKWDTNSSENWHPIWNVN                               DTKHHLYSDINITYVNYYLHQPQVAAIFIISYF                               LIFFLGMMGNTVVCFIVMITLHCHMHTVTNLFI                               LNLAISDLLVGIFCNIPITLLDNILAGWPFGNTM                               CKISGLVQGISVAASVFTLVAIAVDRFQCVVY                               PFKPKLTIKTAFVIIMIIWVLAITIMSPSAVMLH                               VQEEKYYRVRLNSQNKTSPVYWCREDWPNQ                               EMRKIYTTVLFANIYLAPLSLIVIMYGRIGISLF                               RAAVPHTGRKNQEQWHVVSRKKQKIIKMLLI                               VALLFILSWLPLWTLMMLSDYADLSPNELQII                               NIYIYPFAHWLAFGNSSVNPIIYGFFNENFRRG                               FQEAFQLQLCQKRAKPMEAYALKAKSHVLIN                               TSNQLVQESTFQNPHGETLLYRKSAEKPQQE                               LVMEELKETTNSSEI               744   2094   A   5966   149   327   SHVCVSHYAGSSGCPAGAGAGAVALGISAVA                               LYDYQGGRLGVARGAWYMEAPDIRQGDM               745   2095   A   5970   413   856   GAPHTDWAWAPTPMSGLGSGRGRQGTLASS                               PLSLPLLLAGVTGILATELFDQMARPAACMV                               CGALMWIMLILVGLGFPFIMEALSHFLYVPFL                               GVCVCGAIYTGLFLPETKGKTFQEISKELHIRL                               NFPRRAQGPTWRSLEVIQSTEL               746   2096   A   5971   3   1343   AQTARRIIGLELDTEGHRLFVAFSGCIVYLPLS                               RCARHGACQRSCLASQDPYCGWHSSRGCVDI                               RGSGGTDVDQAGNQESMEHGDCQDGATGSQ                               SGPGDSAYGVRRDLPPASASRSVPIPLLLASV                               AAAFALGASVSGLLVSCACRRAHRRRGKDIE                               TPGLPRPLSLRSLARLHGGGPEPPPPSKDGDA                               VQTPQLYTTFLPPPEGVPPPELACLPTPESTPE                               LPVKHLRAAGDPWEWNQNRNNAKEGPGRSR                               GGHAAGGPAPRVLVRPPPPGCPGQAVEVTTL                               EELLRYLHGPQPPRKGAEPPAPLTSRALPPEP                               APALLGGPSPRPHECASPLRLDVPPEGRCASA                               PARPALSAPAPRLGVGGGRRLPFSGHRAPPAL                               LTRVPSGGPSRYSGGPGKHLLYLGRPEGYRG                               RALKRVDVEICPQLSLKPPLVGPSSRQAVPNG                               GRFNF               747   2097   A   5998   2   754   DHASLPCSWNHRFDVETRHVFIGDHSGQVTI                               LKLEQENCTLVTTFRGHTGGVTALCWDPVQ                               RVLFSGSSDHSVIMWDTGGRKGTAIELQGHN                               DRVQALSYAQHTRQLISCGGDGGIVVWNMD                               VERQETPEWLDSDSCQKCDQPFFWNFKQMW                               DSKKIGLRQHHCRKCGKAVCGKCSSKRSSIPL                               MGFEFEVRVCDSCHEAITDEERAPTATFHDSK                               INIVHVHFDATRGWLLTSGTDKVIKLWDMT                               PVVS               748   2098   A   6001   2   747   AMVFGGVVPYVPQYRDIRRTQNADGFSTYV                               CLVLLVANILRTLFWFGRRFESPLLWQSAIMIL                               TMLLMLKLCTEVRVANELNARRRSFTAADS                               KDEEVKVAPRRSFLDFDPHHFWQWSSFSDYV                               QCVLAFTGVAGYITYLSIDSALFVETLGFLAV                               LTEAMLGVPQLYRNHRHQSTEGMSIKMVLM                               WTSGDAFKTAYFLLKGAPLQFSVCGLLQVLV                               DLAILGQAYAFARIHPQKPAPHAVHPTGTKAL               749   2099   A   6002   2   447   GRPDRSELVRMHILEETFAEPSLQATQMKLK                               RARLADDLNEKIAQRPGPMELVEKNILPVDSS                               VKEAIIGVGKEDYPHTQGDFSFDEDSSDALSP                               DQPASQESQGSAASPSEPKVSESPSPVTTNTP                               AQFASVSPTVPEFLKTPPTAD               750   2100   A   6004   2   427   LLTQAMLVLPHRPQWFTPGPRLQAQGPCQEG                               WRWELRLRNYVPEDEDLNKRRVPQAKPDAV                               QEKVKEQLEAAKFEPVIEEVDLAKLAPRKPD                               WDLKRDVAKKLEKLLKRTQRAIAELIRERLK                               GQEDSLDSAVDAATEHKTC               751   2101   A   6007   33   1280   TDQAKVDNQPEKLVRSAEDVSTVPTQPDNPF                               SHPDKLKRMSKSVPAFLQDESDDRETDTASE                               SSYQLSRHKKSPSSLTNLSSSSGMTSLSSVSGS                               VMSVYSGDFGNLEVKGNIQFAIEYVESLKEL                               HVFVAQCKDLAAADVKKQRSDPYVKAYLLP                               DKGKMGKKKTLVVKKTLNPVYNEILRYKIEK                               QILKTQKLNLSIWHRDTFKRNSFLGEVELDLE                               TWDWDNKQNKQLRWYPLKRKTAPVALEAE                               NRGEMKLALQYVPEPVPGKKLPTTGEVHIWV                               KECLDLPLLRGSHLNSFVKCTILPDTSRKSRQ                               KTRAVGKITNPIFNHTMVYDGFRPEDLMEAC                               VELTVWDHYKLTNQFLGGLPIGFGTGKSYGT                               EVDWMDSTSEEVALWEKMVNSPNTWIEATL                               PLRMLLIAKISK               752   2102   A   6028   108   1283   KEIPSPFELISVKPLCLLLGVTCSQSMAFEELL                               SQVGGLGRFQMLHLVFILPSLMLLIPHILLENF                               AAAIPGHRCWVHMLDNNTGSGNETGILSEDA                               LLRISIPLDSNLRPEKCRRFVHPQWQLLIILNG                               TIHSTSEADTEPCVDGWVYDQSYFPSTIVTKW                               DLVCDYQSLKSWQFLLLTGMLVGGIIGGHV                               SDRFGRRFILRWGLLQLAITDTCAAFAPTFPV                               YCVLRFLAGFSSMHISNNSLPITEWIRPNSKAL                               VVILSSGALNIGQIILGGLAYVFRDWQTLHVV                               ASVPFFVFFLLSRWLVESARWLTITNKLDEGL                               KALRKVARTNGIKNAEETLNIEVVRSTMQEE                               LDAAQTKTTVWDLFRNPSMRKRICILVFLRK                               KNLKEKA               753   2103   A   6043   1   1470   DSFESILRLIFEIHHSGEKGDIVVFLACEQDIEK                               VCETVYQGSNLNPDLGELVVVPLYPKEKCSL                               FKPLDETEKRGQVYQRRVVLTTSSGEFLIWSN                               SVRFVLDVGVERRKVYNPRIRANSLVMQPISQ                               SQAEIRKQILGSSSSGKFFCLYTEEFASKDMTP                               LKPAEMQEANLTSMVLFMKR1DIAGLGHCDF                               MNRPAPESLMQALEDLDYLAALDNDGNLSE                               FGIIMSEFPLDPQLSKSILASCEFDCVDEVLTIA                               AMVTAPNCFSHVPHGAEEAALTCWKTFLHPE                               GDHFTLISIYKAYQDTTLNSSSEYCVEKWCRD                               YFLNCSALRMADVIRAELLEIIKRIELPYAEPA                               FGSKENTLNIKKALLSGYFMQIARDVDGSGN                               YLMLTHKQVAQLHPLSGYSITKKMPEWVLF                               HKFSISENNYIRITSELSPELFMQLVPQYYFSNL                               PPSESKDILQQVVDHLSPVSTMNKEQQMCET                               CPETEQRCTLQ               754   2104   A   6055   2   394   YYALHHWPFPDLLCQTTGAIFQMNMYGSCIF                               LMLINVDRYAAIVHPLRLRHLRRPRVARLLC                               LGVWALILVFAVPAARVHRPSRCRYRDLEVR                               LCFESFSDELWKGRLLPLVLLAEALGFLLPLA                               AVVYSS               755   2105   A   6059   3   1795   LGLGSGTLLSVSEYKKKYREHVLQLHARVKE                               RNARSVKITKRFTKLLIAPESAAPEEALGPAEE                               PEPGRARRSDTHTFNRLFRRDEEGRRPLTVVL                               QGPAGIGKTMAAKKILYDWAAGKLYQGQVD                               FAFFMPCGELLERPGTRSLADLILDQCPDRGA                               PVPQMLAQPQRLLFILDGADELPALGGPEAAP                               CTDPFEAASGARVLGGLLSKALLPTALLLVTT                               RAAAPGRLQGRLCSPQCAEVRGPSDKDKKK                               YFYKFFRDERRAERAYRFVKENETLFALCFV                               PFVCWIVCTVLRQQLELGRDLSRTSKTITSVY                               LLFITSVLSSAPVADGPRLQGDLRNLCRLARE                               GVLGRRAQFAEKELEQLELRGSKVQTLFLSK                               KELPGVLETEVTYQFIDQSFQEFLAALSYLLE                               DGGVPRTAAGGVGTLLRGDAQPHSHLVLTT                               RFLFGLLSAERMRDIERHFGCMVSERVKQEA                               LRWVQGQGQGCPGVAPEVTEGAKGLEDTEE                               PEEEEEGEEPNYPLELLYCLYETQEDAFVRQA                               LCRFPELALQRVRFCRMDVAVLSYCVRCCPA                               GQALRLISCRLVAAQEKKKKSLGKRLQASLQ                               GG               756   2106   A   6060   12   436   SGRPTRPAKPTGQGMGRFMLTLVCQGSIIVIMS                               ARDLIMNNLTELQPGLFHHLRFLEELRLSGNH                               LSHIPGQAFSGLYSLKILMLHNNQLGGLPAQA                               LWELPSLQSLRLDANLISLVPERSFEGLSSLRH                               LWLDDNALTETPS               757   2107   A   6063   54   419   ITPLGLGAADMCAFPWLLLLLLLQEGSQRRL                               WRWCGSEEVVAVLQESISLPLELPPDEEVENII                               WSSHKSLATVVPGKEGHPATIMVTNPHYQG                               QILTMLLRSLQQPSASWPRDCSSSCSW               758   2108   A   6066   125   438   IGISCPATIFVPMFSHSLIGIGEEYQLPYYNMV                               PSDPSYEDMREVVCVKRLRPIYSNRWNSDEC                               LRAVLKLMSECWAHNPASRLTALRIKKTLAK                               MVESQDVKI               759   2109   A   6072   3   650   PGRRFRPAALEERAMEKLREKVPFQNRGKGT                               LSSIIPNNSDTRKATETTSLSSKPEYVNPDFRW                               SKDPSSKSGNLLETSEVGWTSNPEELDPIRIA                               LLGKSGLSCQVGSATSHPVSCQEPTDEDQRISP                               KDKSTAGREFSGQVSHQTTSENQCTPIPSSTV                               HSSVADMQNMPAAVHALLTQPSLSAAPFAQ                               RYLGTLPSTGSITLPQCHAGNATVW               760   2110   A   6077   3   730   PLRLTLMEEVLLLGLKDREGYTSFWNDCISSG                               LRGCMLIELPLRGRLQLEACGMRRKSLLTRK                               VICKSDAPTGDVLLDEALKHVKETQPPETVQ                               NWIELLSGETWNPLKLHYQLRNVRERLAKNL                               VEKGVLTTEKQNFLLFDMTTHPLTNNNTKQR                               LIKKVQEAVLDKWVNDPHRMDRRLLALIYL                               AHASDVLENAFAPLLDEQYDLATKRVRQLLD                               LDPEVECLKANTNEVLWAVVAAFTK               761   2111   A   6078   833   390   IVSFHLSGFKKFVRPFSFLSVHGLQVDEYHSV                               HQKLSADMADHSNL1RSLLVGAEDARLMRD                               MKTMKSRYMELYDLNRDLLNGYKIRWNNH                               TELLGNLKAVNQAIQRAGRLRVGKPKNQVIT                               ACRDAIIRSNNTNTLFKIMRVGTASS               762   2112   A   6079   2   2686   KKAITCGEKEKQDLIKSLAMLKDGFRTDRGS                               HSDLWSSSSSLESSSFPLPKQYLDVSSQTDISG                               SFQINSNNQLAEKVRLRLRYEEAKRRIANLKI                               QLAKLDSEAWPGVLDSERDRLILINEKEELLK                               EMRPISPRKWTQGEVEQLEMARKRLEKDLQ                               AAIWTQSKALTERLKLNSKRNQLVRELEEAT                               RQVATLHSQLKSLSSSMQSLSSGSSPGSLTSSR                               GSLVASSLDSSTSASFTDLYYDPFEQLDSELQ                               SKVEFLLLEGATGFRPSGCITIIHEDEVAKTQ                               KAEGGGRLQALRSLSGTPKSMTSLSPRSSLSS                               PSPPCSPLMADPLLAGDAPLNSLEFEDPELSA                               TLCELSLGNSAQERYRLEEPGTEGKQLGQAV                               NTAQGCGLKVACVSAAVSDESVAGDSGVYE                               ASVQRLGASEAAAFDSDESEAVGATRIQIALK                               YDEKNKQFAILIIQLSNLSALLQQQDQKVNIR                               VAVLPCSESTTCLFRTRPLDASDTLVFNEVPW                               VSMSYPALHQKTLRVDVCTTDRSHLEECLGG                               AQISLAEVCRSGERSTRWYNLLSYKYLKKQS                               RELKPVGVMAPASGPASTDAVSALLEQTAVE                               LEKRQEGRSSTQTLEDSWRYEETSENEAVAE                               EEEEEVEEEEGEEDVFTEKASPDMDGYPALK                               VDKETNTETPAPSPTVVRPKDRRVGTPSQGPF                               LRGSTILRSKTFSPGPQSQYVCRLNRSDSDSST                               LSKKPPFVRNSLERRSVRMKRPSPPPQPSSVK                               SLRSERLTRTSLDLELDLQATRTWHSQLTQEIS                               VLKELKEQLEQAKSHGEKELPQWLREDERFR                               LLLRMLEKRMDRAEIIMGELQTDKMMRAAA                               KDVHRLRGQSCKEPPEVQSFREKMAFFTRPR                               MNIPALSADDV               763   2113   A   6082   3   1558   PHPIRFSKLCVSFNNQEYNQFCVIEEASKANE                               VLENLTQGKMCLVPGKTRKLLFKFVAKTED                               VGKKIEITSVDLALGNETGRCVVTINWQGGGG                               DAASSQEALQAARSFKRRPKLPDNEVHWGSII                               IQASTMIISRVPNISVHLLHEPPALTNEMYCLV                               VTVQSHEKTQIRDVKLTAGLKPGQDANLTQK                               THVTLHGTELCDESYPALLTDIPVGDLHPGEQ                               LEKMLYVRCGTVGSRMFLVYVSYLINTTVEE                               KEIVCKCHKDETVTIETVFPFDVAVKFVSTKF                               EHLERVYADIPFLLMTDLLSASPWALTWSSE                               LHLAPSMTTVDQLESQVDNVILQTGESASECF                               CLQCPSLGNLEGGVATGHYIISWKRTSAMENI                               PIITTVITLPHVIVENIPLHVNADLPSFGRVRES                               LPVKYHLQNKTDLVQDVEISVEPSDAFMFSG                               LKQIRLRILPGTEQEMLYNFYPLMAGYQQLPS                               LN1NLLRFPNFTNQLLRRFIPTSIFVKPQGRLM                               DDTSIAAA               764   2114   A   6093   1   1422   AAADLANSNAGAAVGRKAGPRSPPSAPAPAP                               PPPAPAPPTLGNNHQESPGWRCCRPTLRERN                               AIMFNNELMADVHFVVGPPGATRTVPALKY                               VLAVGSSVFYAMFYGDLAEVKSEIHIPDVEPA                               AFLLLLKYMYSDEIDLEADTVLATLYAAKkYI                               VPALAKACVNFLETSLEAKNACVLLSQSRLF                               EEPELTQRCWEVIDAQAEMALRSEGFCEIDR                               QTLEIIVTREALNTKEAVVFEAVLNWAEAEC                               KRQGLPITPRNKRHVLGRALYLVRIPTMTLEE                               FANGAAQSDILTLEETHSIFLWYTATNKPRLD                               FPLTKRKGLAPQRCHRFQSSAYRSNQWRYRG                               RCDSIQFAVDRRVFIAGLGLYGSSSGKAEYSV                               KIELKRLGVVLAQNLTKFMSDGSSNTFPVWF                               EHPVQVEQDTFYTASAVLDGSELSYPGQEGM                               TEVQCGKVAFQFQCSSDSTNGTGVQGGQLPE               765   2115   A   6099   1   1150   SGFTHYAIYDFIVKGSCFCNVHADQCIPVHGF                               RPVKAPGTFHMVHGKCMCKHNTAGSHCQH                               CAPLYNDRPWEAADGKTGAPNECRTCKCNG                               HADTCHFDVNVWEASGNRSGGVCDDCQHN                               TEGQYCQRCKPGFYRDLRRPFSAPDACKPCS                               CHPVGSAVLPANSVTFCDPSNGDCPCKPGVA                               GRRCDRCMVGYWGFGDYGCRPCDCAGSCD                               PITGDCISSHTDIDWYHEVPDFRPVHNKSEPP                               WEWEDAQGFSALLHSGKCECKEQTLGNAKA                               FCGMKYSYVLKIICILSAHDKGTHVEVNYKIK                               KVLKSTLKIFRGKRTLYPESWTDRGCTCPIL                               NPGLEYLVAGHEDIRTGKLIVNMKSFVQHWK                               PSLGRKVMDILKRECK               766   2116   A   6103   2   384   MTAAATATVLKEGVLEKRSGGLLQLWKRKR                               CVLTERGLQLFEAKGTGGRPKELSFARIKAVE                               CVESTGRHIYFTLVTEGGGEIDFRCPLEDPGW                               NAQITLGLVKFKNQQAIQTVRARQSLGTGTL                               VS               767   2117   A   6106   1   542   SGSSHASDGSGFQELRICSEDQTPLIAGMCSLP                               MARYYIIKYADQKALYTRDGQLLVGDPVAD                               NCCAEKICTLPNRGLDRTKVPIFLGIQGGSRC                               LACVETEEGPSLQLEDVNIEELYKGGEEATRF                               TFFQSSSGSAFRLEAAAWPGWFLCGPAEPQQ                               PVQLTKESEPSARTKFYFEQSW               768   2118   A   6109   3   292   FILQAVLQLSSQEARYKAFGTCVSHIGAILAF                               YTPSVISSVMHRVARCAAPHVHILLANFYLLF                               PPMVNPIIYGVKTKQIRDSLGSIPEKGCVNRE               769   2119   A   6110   1   711   RIAEPSCSNGVASTKSKQNHSKYPAPSSSSSSS                               SSSSSSSPSSVNYSESNSTDSTKSQHHSSTSNQ                               ETSDSEMEMEAEHYPNGVLGSMSTRIVNGAY                               KHEDLQTDESSMDDRHPRRQLCGGNQAATE                               RIILFGRELQALSEQLGREYGKNLAHTEMLQD                               AFSLLAYSDPWSCPVGQQLDPIQREPVCAAL                               NSAILESQNLPKQPPLMLALGQASECLRLMA                               RAGLGSCSFARVDDYLH               770   2120   A   6125   2   570   YFGLNLHVQHLGNNVFLLQTLFGAVILLANC                               VAPWALKYMNRRASQMLLMFLLAICLLAHF                               VPQEMQMLREVLATLGLGASALANTLAFAH                               GNEVIPTLIIRARAMGINATFANIAGALAPLMM                               ILSVYSPPLPWILYGVFPFISGFAFLLLPETRNK                               PLFDTIQDEKNERKDPREPKQEDPRVEVTQF               771   2121   A   6126   909   353   RSFVLDTASAICNYNAHYKNHPKYWCRGYF                               RDYCNILAFSPNSTNHVALRDTGNQLIVTMSC                               LTKEDTGWYWCGIQRDFARDDMDFTELIVT                               DDKGTLANDFWSGKDLSGNKTRSCKAPKVV                               RKADRSRTSILIICILITGLGIISVISHLTKRRRS                               QRNRRVGNTLKPFSRVLTPKEMAPTEQM               772   2122   A   6148   7   810   FVLGILALSHTISPFMNKFFPASFPNRQYQLLF                               TQGSGENKEEIINYEFDTKDLVCLGLSSIVGV                               WYLLRKHWIANNLFGLAFSLNGVELLHLNN                               VSTGCILLGGLFIYDVFWVFGTNVMVTVAKS                               FEAPIKLVFPQDLLEKGLEANNFAMLGLGDV                               VIPGIFIALLLRFDISLKKNTHTYFYTSFAAYIF                               GLGLTIFIMHIFKHAQPALLYLVPACIGFPVLV                               ALAKGEVTEMFSYEESNPKDPAAVTESKEGT                               EASASKGLEKKEK               773   2123   A   6161   3   1088   CQPMLVTRKNHPKLLLRRTESVAEKMLTNW                               FTFLLYKFLKESAGEPLFMLYCAIKHQMEKG                               PIDAITGEARYSLSEDKLIRHLIDYKTLTLNCV                               NPENENALPEVPVKGLDCDTGTQAKEKLLDA                               AYKGVPYSQRPKAADMDLEWRQQRMAPIIL                               QDEDVTTKIDNDWKRLNTLAHYQVTDGSSV                               ALVPKQTSAYNISNSSTFTKSLSRYESMLRTA                               SSPDSLRSRTPMITPDLESGTKLWHLVKNHDH                               LDQREGDRGSKMVSEIYLTRLLATKGTLQKF                               VDDLFETIFSTAHRGSALPLAIKYMFDFLDEQ                               ADKHQTHDADVRHTWKSNCLPLRFWVNVIK                               NPQFVFDIHKNSITDACLSW               774   2124   A   6163   860   125   KTAVKKRNLNPVPNETLRYSVPQAELQGRVL                               SLSVWHRESLGRNIFLGEVEVPLDTWDWQSE                               PTWLPLQPRVPPSPDDLPSRGLLALSLKYVPA                               GSEGAGLPPSGELHFWVKEARDLLPLRAGSL                               DTYVQCFVLPDDSRASRQRTRVVRRSLSPVF                               NHTMVYDGFGPADLRQACAELSLWDHGALA                               NRQLGGTRISLGTGSSYGLQVPWMDSTPEEK                               QLWQALLEQPCEWVDGLLPLRTNLAPRT               775   2125   A   6191   2   392   ARGIGSLGRDHSGSGGGTGMAGAWVRKAAD                               YVRSKDFEDYLMSTHFWGPVANWGLPIAAIT                               DMK\KSPEIISRRMTFAL*CYSLTFVRFAHYVQ                               \PWNWLMLGCHTAVDFDQLISSMIPCISHQMT                               ASASAL               776   2126   A   6217   1   827   FRGYWGVREAFTDASWSGGLGPGKPGMKIT                               RQKHAKKIILGFPRNNFGVREPYQILLDGTFC                               QAALRGRIQLREQLPRYLMGETQLCTTRCVL                               KELETLGKDLYGAKLIAQKCQVRNCPHFKNA                               VSGSECLLSMVEEGNPHHYFVATQDQNLSVK                               VKKKPGVPLMFIIQNTMVLDKPSPKTIAFVKA                               VESG\RLSQCMRKKVSNISKRNRV**KTLNRG                               RRKKRKKISGPNPLSCLKKKKKAPDTQSSASE                               KKRKRKRIRNRSNPKVLSEKQNAEGE               777   2127   A   6236   1038   1402   YYQISSLPSIVGNGLFLWLLICIFLAKQGGSRL*                               FQPFGRPRGGGHLRSGVLGQPGQHGETP/SFF                               YNSKISPALWGPPVIPSALGGEAGKSL*PRRQ                               RFQRGGIAPLPSRVRGRAKLFLKKK               778   2128   A   6237   422   913   ASFFHHHRGAFLLLLAIPGS*GQDQSLIHWSN                               AVSNAD\LLDLK\N*LDH\LEEKMPL\EVKVVP                               PQVL\SEPN*RSGGCFSAPSFEVPPWTGEVKP/                               SPQRDGGALG\QGPLGIPSDSILALLKKQT*RA                               LLNWPLGSLRRSSCFGGQDGQDLKPRSGLGC                               NSFRYRR               779   2129   A   6249   420   36   ARAPSPSFSVRDVELSDPARERGEMPVAVGP                               YGQSQPSCFDRVKMGFVMGCAVGMAAGAL                               FGTFSCLSSILVSSSG/SGMRGRELMGGIGKTM                               MQSGGTFGTFMAIGMGIRC*PWLPITSVPSH                               QSQPMY               780   2130   A   6263   415   1380   RIMRMCDRGIQMLITTVGAFAAPSLMTIAVG                               TDYWLYSRGVCRTKSTSDNETSRKNEEVMT                               HSGLWRTCCLEGAFRGVCKKIDHFPEDADYE                               QDTAEYLLRAVRASSVFPILSVTLLFFGGLCV                               AASEFHRSRHNVILSAGIFFVSAGLSNIIGIIVYI                               S\ANAGRTPGQR\DSKKSYSYGWSF/YFSGAFS                               FIIGRIHC*GVGLPWHIYIEKHQQLRAKSHSEF                               LKKSTFARLPPYRYRFRRRSSSRSTEPRSRDLS                               PISKGPHTIPSTDISMFTLSRDPSKITMGTLLNS                               DRDIIAFLQFHNSTPKEFKESLHNNPANRRTT                               PV               781   2131   A   6274   832   318   RIIKVKDLKQTLAIKTAYPRCKGLVEMDQIFH                               LQVKQKQLACLCTWQARDPDCPPSTKVVL/L                               VGPGMGCMVALFQDSIAWSNKSMPSSLSAIS                               QSPCQVQAPEGPSSFHLPTLS1TICLSWQGGD                               LEFLGDLKGCSELKNFQELITQSALVHPKADV                               WWYGGRPLLGTLPSN               782   2132   A   6281   1324   393   WISLPSSLLCRKNGSSAEDDRR\GEPSAEEAEG                               EREDWGIQSA*SVGAVSKVPSARF*RTYPS\E                               DEEEVTHQKSSSSDSNSEEHRKKKTSRSRNK                               KKRKNKSSKRKHRKYSDSDSNSESDTNSDSD                               DDKKRVKAKKKKKKKKHKTKKKKNKKTKK                               ESSDSSCKDSEEDLSEATWMEQPNVADTMDL                               IGPEAPIIHTSQDEKPLKYGHALLPGEGAAMA                               EYVKAGKRIPRRGEIGLTSEEIGSFECSGYVM                               SGSRHRRMEAVRLRKENQIYSADEKRALASF                               NQEERRKRESKILASFREMVHKKTKGKDDK               783   2133   A   6305   201   1032   WDDYPQGALRREEAAEGLHFLGPPGRVRGQ                               LRGITGPAWYCHSPSHSLLSAFCHLPTPSRCP                               AMARPPVPGSVVVPNWHES/RRGQGVPGLHS                               AQEPPAGVWAA*AASAAAA\LSIDTASYKIFV                               SGKSGVGKTALVAKLAGLEVPVVHHETTGIQ                               TTVVFWPAKLQASSRVVMFRFEFWDCGESA                               LKKFDHMLLACMENTDAFLFLFSFTDRASFE                               DLPGQLARIAGEAPGVVRMVIGSICFDQYMHT                               DVPERDLTAFRQAWELPLLRVKSVPGRRLG               784   2134   A   6308   86   96   GSSPDPASLITMKNQDKKNGAAKQSNPKSSP                               GQPEAGPEGAQERIPSQAAPAVEAEGPGSSQA                               PRKPEGAQARTAQSGALRDVSEELSRQLEDIL                               STYCVDNNQGGPGEDGAQGEPAEPEDAEKSR                               TYVARNGEPEPTPVVNGEKEPSKGDPNTEEIR                               QSDEVGDRDHRRPQEKKKAKGLGKEITLLM                               QTLNTLSTPEEKLAALCKKYAELLEEHRNSQ                               KQMKLLQKKQSQLVQEKDHLLRGEHSKAVLA                               RSKLESLCRELQRHNRSLKEEGVQRAREEEE                               KRKEVTSHFQVTLNDIQLQMEQHNERNSKLR                               QENMELAERLKKUEQYELREEHIDKVFKHK                               DLQQQLVDAKLQQAQEMLKEAEERHQREKD                               FLLKEAVESQRMCELMKQQETHLKQQLALY                               TEKFEEFQNTLSKSSEVFITFKQEMEKMTKKI                               KKLEKETTMYRSRWESSNKALLEMAEEKTV                               RDKELEGLQVKIQRLEKLCRALQT/GAQ*PVR                               GQRWGSHRTSAVRIFS               785   2135   A   6319   1493   889   SPQGPLLRSVSPVSAGASSVTPGGAQPGVTIT                               PPSLVAVAPAPGSAAGPAAGWQ*HAGCRIWIT                               KLPWSWGMRPMKIFFSEEYRSISTRISHDAL*                               EKCTQPAKPLSMIR\TGSSVSPG/PLVKWNWT                               RREFRNSGTRVVSSCCGMSCMYSFLGHCSV/S                               QDLPLVHVDVGWQPPLGPTVGLRPGLLPLHD                               TTPCQKLVVDDLDWA               786   2136   A   6320   551   135   RWLPVAECDSSCVGCTGEGPGNCKECISGYA                               REHGQCADVDECSLAEKTCVRKNENCYNTP                               GSYVCVCPDGFEETIRRCLCAAGRG*SHRRRK                               PDTAALPRRPVMCRTYPLNYSEGCPVENVAL                               RMPSPAVDSGGERLPAL               787   2137   A   6330   1693   227   DYVLTAELHRQRSPGVSFGLSVFNLMNALMG                               SGILGLAYVMANTGVFGFSFLLLTVALLASYS                               VHLLLSMCIQTAYLGP*TNYFMVLPAH*LTCL                               PLIEFLQSL*NSL\*AVTSYEDLGLFAFGLPGKL                               VVAGTLIIQNIGAMSSYLLIIKTELPAAIAEFLT                               GDYSRYWYLDGQTLLIHCVGIVFPLALLPKIG                               FLGYTSSLSFFFMMFFALVVIIKKWSIPCPLTL                               NYVEKGFQISNVTDDCKPKLFHFSKESAYALP                               TMAFSFLCHTSILPIYCELQSPSKKRMQNVTN                               TAIALSFLIYFISALPGYLTFYD/GTTKAQRGE                               VTCHRIKDKVESELLKC***IP*SHDVVVM1W                               KLCILFAVLL\TVPLIHFPARKAVTMMFFSNFP                               FSWIRHFLITLALNIIIVLLAIYVPDIRNVFGVV                               GASTSTCLIFIFPGLFYLKLSREDFLSWKKLGV                               GCFC/LLSFKTSILRNSLSVYLILPASRKSIYFKI               788   2138   77   6351   1   6622   PRSLCFSLWAEAAVLADGGLRRRRRLLRGTM                               SASFVPNGASLEDCHCNLFCLADLTGIKWKK                               YVWQGPTSAPILFPVTEEDPILSSFSRCLKADV                               LG/VWRRDQRFERRE\L*IFWGGEDP\VLLTLF                               TMTYQKKKMECGRMDFPMNAVLCFSKAVH                               NLLERCLMNRNFVRIGKWFVKPYEKDEKPIN                               KSEHLSCSFTFFLHGDSNVCTSVEINQHQPVY                               LLSEEHITLAQQSNSPFQVILCPFGLNGTLTGQ                               AFKMSDSATKKLIGEWKQFYPISCCLKEMSE                               EKQEDMDWEDDSLAAVEVLVAGVRMIYPAC                               FVLVPQSDIPTPSPVGSTHLCSSSCLGVHQVPAS                               TRDPAMSSVTLTPPTSPEEVQTVDPQSVQKW                               VKFSSVSDGFNSDSTSHHGGKIPRKLANHVV                               DRVWQECNMNRAQNKRKYSASSGGLCEEAT                               AAKVASWDFVEATQRTNCSCLRLHKNLKSRN                               AGQQGQAPSLGQQQQILPKHKTNEKQEKSEK                               PQKRPLTPFHHRVSVSDDVGMD\ADS\ASQRL                               V\ISAP\DSQWRFSNIR\TNDVAK\TPQMHGTE                               MANSPQPPPLSP\HPCDVVDEGVTKTPSTPQS                               QHFYQMPTPDPLVPSKPMEDRIDSLSQSFPPQ                               YQEAVEPTVYVGTAVNLEEDEANIAWKYYK                               FPKKKDVEFLPPQLPSDKFICDDPVGPFGQESV                               TSVTELMVQCKKPLKVSDELVQQYQIKNQCL                               SAIASDAEQEPKIDPYAFVEGDEEFLFPDKKD                               RQNSEEEAGKKHKVEDGTSSVTVLSHEEDA                               MSLFSPSIKQDAPRPTSHARPPSTSLIYDSDLA                               VSYTDLDNLFNSDEDELTPGSKRSANGSDDK                               ASCKESKTGNLDPLSCISTADLHKMYPTPPSL                               EQHIMGFSPMNMNNKEYGSMDTFPGGTVLE                               GNSSSIGAQFKIEVDEGFCSPKPSEIKDFSYVY                               KPENCQILVGCSMFAPLKTLPSQYLPLIKLPEE                               CIYRQSWTVGKLELLSSGPSMPFIKEGDGSNM                               DQEYGTAYTPQTHTSCGMPPSSAPPSNSGAGI                               LPSPSTPRFPTPRTPRTPRTPRGAGGPASAQGS                               VKYENSDLYSPASTPSTCRPLNSVEPATVPSIP                               EAHSLYVNLILSESVMNLFKDCNSDSCCICVC                               NMNIKGADVGVYIPDPTQEAQYRCTCGFSAV                               MNRKFGNNSGLPFEDELDIIGRNTDCGKEAE                               KRFEALRATSAEHVNGGLKESEKLSDDLILLL                               QDQCTNLFSPFGAADQDPFPKSGVISNWVRV                               EERDCCNDCYLALEHGRQFMDNMSGGKVDE                               ALVKSSCLHPWSKRNDVSMQCSQDILRMLLS                               LQPVLQDAIQKKRTVRPWGVQGPLTWQQFLI                               KMAGRGSYGTDESPEPLPIPTPLLGYDYDYLV                               LSPFALPYWERLMLEPYGSQRDIAYVVLCPE                               NEALLNGAKSFFRDLTAIYESCRLGQHRPVSR                               LLTDGIMRVGSTASKKLSEKLVAEWFSQAAD                               GNNEAFSKLKLYAQVCRYDLGPYLASLPLDS                               SLLSQPNLVAPTSQSLITPPQMTNTGNANTPS                               ATLASAASSTMTVTSGVAISTSVATANSTLTT                               ASTSSSSSSNLNSGVSSNKLPSFPPFGSMNSNA                               AGSMSTQANTVQSGQLGGQQTSALQTAGISG                               ESSSLPTQPHPDVSESTMDRDKVGIPTDGDSH                               AVTYPPAIVVYIIDPFTYENTDESTNSSSVWTL                               GLLRCFLEMVQTLPPHIKSTVSVQIIPCQYLLQ                               PVKHEDREIYPQIILKSLAFSAFTQCRRPLPTS                               TNVKTLTGFGPGLAMETALRSPDRPECIRLYA                               PPFILAPVKDKQTELGETFGEAGQKYNVLFV                               GYCLSHDQRWILASCTDLYGELLETCIINIDVP                               NRARRKKSSARKFGLQKLWEWCLGLVQMSS                               LPWRVVIGRLGRIQHGELKDWSCLLSRRNLQ                               SLSKRLKDMCRMCGISAADSPSILSACLVAM                               EPQGSFVIMPDSVSTGSVFGRSTTLNMQTSQL                               NTPQDTSCTHILVFPTSASVQVASATYTTENL                               DLAFNPNNDGADGMGIFDLLDTGDDLDPDII                               NTLPASPTGSPVHSPGSHYPHGGDAGKGQSTD                               RLISTEPHEEVPNILQQPLALGYFVSTAKAGP                               LPDWFWSACPQAQYQCPLFLKASLHLHVPSV                               QSDELLHSICHSHPLDSNQTSDVLRFVLEQYN                               ALSWLTCDPATQDRRSCLPIHFVVLNQLYNFI                               MNML               789   2139   A   6359   1   2002   TGTLTEDQLDVMGVVPLKGQAFLPLVPEPRR                               LPVGPLLRALATCHALSRLQDTPVGDPMDLK                               MVESTGWVLEEEPAADSAFGTQVLAVMRPP                               LWEPQLQAMEEPPVPVSVLHRFPFSSALQRM                               SVVVAWPGATQPEAYVKGSPELVAGLCNPET                               VPTDFAQMLQSYTAAGYRVVALASKPLPSVP                               SLEAAQQLTRDTVEGDLSLLGLLVMRNLLKP                               QTTPVIQALRRTRIRAVMVTGDNLQTAVTVA                               RGCGMVAPQEHLIIVHATHPERGQPASLEFLP                               MESPTAVNGVKDPDQAASYTVEPDPRSRHLA                               LSGPTFGIIVKHFPKLLPKVLVQGTVFARMAP                               EQKTELVCELQKLQYCVGMCGDGANDCGAL                               KAADVGISLSQAEASVVSPFTSSMASIECVPM                               VLREGRCSLDTSFSVFKYMALYSLTQFISVLIL                               YTINTNLGDLQFLAIDLVITTTVAVLMSRTGP                               ALVLGRVRPPGALLSVPVLSSLLLQMVLVTG                               VQLGGYFLTLAQPWFVPLNRTVAAPDNLPNY                               ENTVVFSLSSFQYLILAAAVSKGAPFR\RPLTN                               NVPFLLASAL*SSVLVVLVLSPGLLHGPLALR                               NITDTGFKLLLVGLVTLNFVGGLHAGERARP                               VPPRLPAPPPAQAG\SKKRFKQLERELAEQPW                               PPLPAGPLR               790   2140   A   6380   76   1059   SSAGSARKLQVMALAARLWRLLPFRIRGAAP                               GSRLPAGTSGSRGHCGPCRFRGFEVMGNPGT                               FKRGLLLSALSYLGFETYQVISQAAVVHATA                               KVEEILEQADYLYESGETEKLYQLLTQYKESE                               DAELLWRLARASRDVAQLSRTSEEEKKLLVY                               EALEYAKRA/L/EKNESSFASHKWYAICLSDV                               GDYEGIKAKIANAYLTKEHFEKAIELNPKDATS                               IHLMGIWCYTFAEMPWYQRRIA*NACLQLPP                               *FPPYEKALG\YFHRAEQVDPNFYSKNLLLLG                               KTYLKLHNKKLAAFWLMKAKDYPAHTEED                               KQIQTEAAQLLTSFSEKN               791   2141   A   6434   3   1460   IALLLVDGLAWDDQGGLALLHISPSKLIL*QDS                               SGMSIYVMVRCTITRAFFKSLLCHICQYSIGPQ                               *VT\CPGQDACKE*KSTAN*GG*RE**PQVLFF                               AFLSNPAVKPGRMSKKQRDSLYAEVQKHQQ                               RLQEQRQQQSGEAEALARVYSSSISNGLSNLN                               NETSGTYANGSVIDLPKSEGYYNVVSGQPSP                               DQSGLDMT\GIKQTKQEPIYDLTSVPNLFTY\SS                               FNN\GQLAPGIT\MTEIDRIAQNIIKSHLETCQY                               TMEELHQLAWQTHTYEEIKAYQSKSREALW                               QQCAIQITHAIQYVVEFAKRITGPMELCQNDQ                               ILLLKSGCLEVVLVRMCRAFNPLNNTVLFEG                               KYGGMQMFKALGSDDLVNEAFDFAKNLCSL                               QLTEEEIALFSSAVLISPDRAWLIEPRKVQKLQ                               EKIYFALQHVIQKNHLDDETLAKLIAKIPTITA                               VCNLHGEKLQVFKQSHPEIVNTLFPPLYKELF                               NPDCATACK               792   2142   A   6440   92   781   SRGTFRCFCRDFFPCFSNMRLFLWNAVLTLFV                               TSLIGALIPEPEVKIEVLQKPFICHRKTKQGDL                               MLVHYEGYLEKDGSLPHSTHKHNNGQPIWFT                               LGILEALKGWGPGA*KIDMCVGEKRKLILPPA                               LGYGKEGKGKIPPESTLIFNIDLLEIRNGPRSH                               ESFQEMDLNDDWKLSKDEVKAYLKKEFEKE                               GAVVNESHHDALVEDTFDKEDEDKDGFISAR                               EFTYKHDEL               793   2143   A   6446   3201   152   PRLKRLVVTEEDGQARPEALGKIAPRTPAELG                               ARADQELVTALMCDLRRPAAGGMMDLAYV                               CEWEKWSKSTHCPSVPLACAWSCRNLIAFTM                               DLRSDDQDLTRMIHILDTEHPWDLHSIPSEHH                               EAITC\LEWDQSGFPGFLFSRWPTGQIK\CWS                               MGVSTLA\NSWE\SSVGSL\VEGGPHLWALS\                               WLH\NGVKLALHVEKSGASSFGEKFSRWKFS                               P\SLTLF\GGNAMEGWIAVTVSGLVTVSLLQ\P                               SGQVL\TST\ESLCRLRARVALADIAFTGGGNI                               VVATADGSSA\SPVQFYKVCVSVVSEKCRIDT                               DLPSLFRCTTDLNRKDFPAITHLKFLARD                               MSEQVLLCASSQTSSIVECWSLRKEGLPVNNI                               FQQISPVVGDKQPTILKWRILSATNDLDRVSA                               V\ALPKLPISLTNTDLKVASDTQFYPGLGLAL                               AFHDGSVHIVIIRLSLQTMAVFYSSAAPRPVD                               EPAMKRPRTAGPAVHLKAMQLSWTSLALVG                               IDSHGKLSV\LRLSPSMGHPLEVGLALRHLLFL                               LEYCMVTQYDWWDLLHVQPSMVQSLVEKL                               HEEYTRQTAALQQVLSTRILAMKASLCKLSP                               CTVTRVCDYHTKLFLIAISSTLKSLLRPHFLNT                               PDKSPGDRLTEICTKITDVDIDKVMINLKTEEF                               VLDMNTLQALQQLLQWVGDFVLYLLASLPN                               QPCPTSEPCPTSEPSPTSEPSPTSEPSSP*SLC\G                               SLLRPGHSFLRDGTSLGMLRELMVVIRIWGLL                               KPSCLPVYTATSDTQDSMSLLFRLLTKLWICC                               RDEGPASEPDEALVDECCLLPSQLLIPSLDWL                               PASDGLVSRLQPKQPLRLQFGRAPTLPGSAAT                               LQLDGLARAPGQPKIDHLRRLHLGACPTEEC                               KACTRCGCVTMLKSPNRITAVKQWEQRWIK                               NC/LVRWALVAGAPQLPLSPAAPQLLLSYPSA                               APEPGCCKSHRSPWTLLGAVNLSPPCRAVEG                               RGPDACVTSRASEEAPAFVQLGPQSTHHSPRT                               PRSLDHLHPEDRP               794   2144   A   6490   418   585   NGDKADLENESCRAQVLMPVVPALWEAEGG                               GSIEPRDLRLQ*AVITPL\TPAWVTQ               795   2145   A   6499   395   1027   KLLWLPPHSEQKRSPLYHPQGPSGTTPSAP\FS                               SHSPPPSLLQA\PSIAAFLRTHGHISASGPLRMP                               FPH/H*NAFLLVFPGQRSQLTSIPSHYLCREVFP                               DHHHHLCRLSLESSPLFHHRVLFCVPKQNVN                               STRAQIFCLFVHIYGCRCINTFPLHLFRLHLWL                               HFLQIPLCKKNKSVKLGKTVVGRGCQSAAGS                               DTRVRAAVGAPGLPVEPLV               796   2146   A   6503   68   936   HSALLTHSSFCVFTLCQDFFTYSSMSEEVTYA                               DLQFQNSSEMEKIIPEIGKFGEKAPPAPSHVWR                               PAALFLTLLCLLLLIGLGVLASMFHVTLKIEM                               KKMNKLQNISEELQRNISLQLMSNMNISNKIR                               NLSTTLQTIATKLCRELYSKEQEHKCKPCPRR                               WIWHKDSCYFLSDDVQTWQESKMACAAQN                               ASLLKINNKNALEFIKSQSRSYDYWLGLSPEE                               DS/YSWYESG*YNQ\PSAWVIRNAPDLNNMY                               CGYINRLYVQYYHCTYKQRMICEKMANPVQ                               LGSTYFREA               797   2147   A   6507   1   881   PGSTHASARSQVPRSAGEAAPHSRRPPGLLPH                               APRAASAQLEERMRDPHPGMTLQEGDCRGS                               QTVSLTMGTADSDEMAPEAPQHTHIDVHIHQ                               ESALAKLLLTCGSALRPRATQARGSSRLLVAS                               WVMQIVLGILSAVLGGFFYIEDYTLLVTSGA                               AIWTGAVAVLAGAAAFIYEKRGGTYWALLR                               TLLALAAFSTAIAALKLWNEDFRYGYSYYNS                               ACRISSSSDWNTPAPTQSPEEVRRLHLCTSFM                               DMLKALFRTLQAMLLGVWILLLLASLTPLWL                               /SL/RGECSQPKG*VPKKRDQKEMLEVSGI*PG                               STHASARSQVPRSAGEAAPHSRAPPGLLPHAP                               RAASAQLEERMRDPHPGMTLQEGDCRGSQT                               VSLTMGTADSDEMAPEAPQHTHIDVHIHQES                               ALAKLLLTCCSALRPRATQARGSSRLLVASW                               VMQIYLGILSAVLGGFFYIRDYTLLVTSGAAI                               WTGAVAVLAGAAAFIYEKRGGTYWALLRTL                               LALAAFSTAIAALKLWNEDFRYGYSYYNSAC                               RISSSSDWNTPAPTQSPEEVRRLHLCTSFMDM                               LKALFRTLQAMLLGVWILLLLASLTPLWLYC                               WRMFPTKGVSP               798   2148   A   6528   912   2287   VPNYLPSVSSAIGGEVPQRYVWRFCIGLHSAP                               RFLVAFAYWNHYLSCTSPCSCYRPLCRLNFG                               LNVVENLALLVLTYVSSSEDFITWVPG*GRSG                               EVFPEGTGLPLPHSDLPTSWCGHSLQCGSQSS                               FPPAIHENAF1VFIASSLGHMLLTCILWRLTKK                               HTVSQE\DGLSLAGAPRQPRRKSRTSVLRIRV                               MVRWELSSNGNPGRGVLGLGLGLGNKLRVV                               GQNLGL*HCVWVVWETGE*KRWRLQMGW*                               GVASRQ*VRNSVRGLVCHNSSAPPMYMGFF                               SPTVFGGGVGG*LIIVTFILHPPEVEAAGIPLLL                               GPSLPQRQGREHIVVILAAPACAPFHDR*WEP                               REIRPSP*ELGLRQEPTLSYPASCRVIRQPIP*D                               RKSYSWKQRLFHNFISFFSALAVYFRHNMYC                               EAGVYTIFAILEYTVVLTNMAFHIVITAWWDF                               GNKELLITSQPEEKRF               799   2149   A   6529   1   874   FFFFQRTNFIEHSGSVSLLALACDLGWCEDWS                               CCLVQGGGDLVDVVQTNHGEDEAGGDTDSV                               DEARCKESQQEAQENLREDLCLESFAKDKIL                               QIIEGSEREHEETRTKQAALDGEPLGGGQLTA                               VHLHPSKEQQGQEGGERQRGARTHHWRGW                               EKGRRVRLRPPSGKLRADQPVRKLGGPTPS/T                               ELPGLQPHAPTPHTAIPATPIYSPAPDTPNPPV                               RWKCPLPVEPRTRQLCRERTRKACPPKPRLPPL                               GLPGDPTGPVTHHAPPVSPTGASGQERRAEP                               GAVSYAHASATK               800   2150   A   6544   2   662   SAQRWAAVAGRWGCRLLALLLLVPGPGGAS                               EITFELPDNAKQCFYEDIAQGTKCTLEFQVITG                               GHYDVDCRLEDPDGKVLYKEMKKQYDSFTF                               TASKNGTYKFCFSNE\FSTFTHKTVYFDFQVG                               E\THLCFLVRIDRVSALTQMESACVSIHEALKS                               VIDYQTHFRLREAQGRSRAEDLNTRVAYWSV                               GEALILLVVSIGQVFLLKSFFSDKRTYLTRVGS               801   2151   A   6556   1   1319   TPCMECIKGEGLREPQNLSGSQREPQTEGSM                               DGWRRPRWGLLLLLWGSCTFGLPTDTTTTF                               KRIFLKRMPSIRESLKERGVDMARLGPEWSQP                               MKRLTLGNTTSSVILTNYMDTQYYGEIGIGTP                               PQTFKVVFDTGSSNVWVPSSKCSRLYTACVY                               HKLFDASDSSSYKHNGTELTLRYSTGTVSGFL                               SQDIITVGGITVTQMFGEVTEMPALPFMLAEF                               DGVVGMGFIEQAIGRVTPIFDNIISQGVLKED                               VFSFYYNRDSENSQSLGGQIVLGGSDPQHYE                               GNFHYINLIKTGVWQIQMKGVSVGSSTLLCE                               DGCLALVDTGASYISGSTSSIEKLMEALGAKE                               KRLFDYVVKCNEGPTLPPTFLFLLGGKDTPLT                               SADYLFQESYSSKKLSTLAIHAMYIPPPTGPTL                               \ALGATF\IRKFYTEFDRGNNPHGFALAR               802   2152   A   6567   13   6147   MCLGRMGASSPRSPEPVGPPAPGLPFCCGGSL                               LAVVVLLALPVAWGQCNAPEW\LPFARPTNL                               TDEFEFPIGTYLNYECRPGYSGRPFSIICLKNS                               VWTGAKDRCRRKSCRNPPDPVNGMVHVIKG                               IQFGSQIKYSCTKGYRLIGSSSATCIISGDTVIW                               DNETPICDRIPCGLPPTITNGDFISTNRENFHY                               GSVTYRCNPGSGGRKWELVGEPSIYCTSND                               DQVGIWSGPAPQCIIPNKCTPPNVENGILVSD                               NRSLFSLNEVVEFRCQPGFVMKGPRRVKCQA                               LNKWEPELPSCSRVCQPPPDVLHAERTQRDK                               DNFSPGQEVFYSCEPGYDLRGAASMRCTPQG                               DWSPAAPTCEVKSCDDFMGQLLNGRVLFPV                               NLQLGAKVDFVCDEGFQLKGSSASYCVLAG                               MESLWNSSVPVCEQIFCPSPPVIPNGRHTGKP                               LEVFPFGKAVNYTCDPHPDRGTSFDLIGESTIR                               CTSDPQGNGVWSSPAPRCGILGHCQAPDHFL                               FAKLKTQTNASDFPIGTSLKYECRFEYYGRPF                               SITCLDNLVWSSPKDVCKRKSCKTPPDPVNG                               MVHVITDIQVGSRINYSCITGHRLIGHSSAECI                               LSGNAAHWSTKPPICQRTPCGLPPTIANGDFIS                               TNRENFHYGSVVTYRCNPGSGGRKVFELVGE                               PSIYCTSNDDQVGTWSGPAPQGIIPNKCTPPNV                               ENGILVSDNRSLFSLNEVVEFRCQPGFVMKGP                               RRVKCQALNKWEPELPSCSRVCQPPPDVLHA                               ERTQRDKDNFSPGQEVFYSCEPGYDLRGAAS                               MRCTPQGDWSPAAPTCEVKSCDDFMGQLLN                               GRVLFPVNLQLGAKVDFVCDEGFQLKGSSAS                               YCVLAGMESLWNSSVPVCEQIFCPSPPVIPNG                               RHTTGKPLEVFPFGKAVNYTCDPHPDRGTSFD                               LIGESTIRCTSDPQGNGVWSSPAPRCGILGHC                               QAPDHFLFAKLKTQTNASDFPIGTSLKYECRP                               EYYGRPFSITCLDNLVWSSPKDVCKRKSCKTP                               PDPVNGMVHVITDIQYGSRINYSCTTGHRLIG                               HSSAECILSGNTAHWSTKPPICQRIPCGLPPTI                               ANGDFISTNRENFHYGSVVTYRCNLGSRGRK                               VFELVGEPSIYCTSNDDQVGIWSGPAPQCIIPN                               KCTPPNVENGILVSDNRSLFSLNEVVEFRCQP                               GFVMKGPRRVKCQALNKWEPELPSCSRVCQ                               PPPEILHGEHTPSHQDNFSPGQEVFYSCEPGY                               DLRGAASLHGTPQGDWSPEAPRCAVKSCDDF                               LGQLPHGRVLFPLNLQLGAKVSFVCDEGFRL                               KGSSVSHCVLVGMRSLWNNSVPVCEHIFCPN                               PPAILNGRHTGTPSGDIPYGKEISYTCDPHPDR                               GMTFNLIGESTIRCTSDPHGNGVWSSPAPRCE                               LSVRAGHCKTPEQFPFASPTIPINDFEFPVGTS                               LNYECRPGYFGKMFSISCLENLVWSSVEDNC                               REKSCGPPPEPFNGMVHINTDTQFGSTVNYSC                               NEGFRLIGSPS1TCLVSGNNVTWDKKAPICEII                               SGEPPPTISNGDFYSNNRTSFHNGTVVTYQCH                               TGPDGEQLFELVGERSIYCTSKDDQVGVWSS                               PPPRCISTNKCTAPEVENAIRVPGNRSFFSLTEI                               IRFRCQPGFVMVGSHTVQCQTNGRWGPKLPH                               CSRVCQPPPETLHGEHTLSHQDNFSPGQEVFY                               SCEPSYDLRGAASLHCTPQGDWSPEAFRCTV                               KSCDDPLGQLPHGRVLLPLNLQLGAKVSFVC                               DEGFRLKGRSASHCVLAGMKALWNSSVPVC                               EQIFCPNPPAILNGRHTGTPLGDIPYGKEVSYT                               CDPHIPDRGMTFNLIGESTIRRTSEPHGNGVWS                               SPAPRCELPVGAACPHPPKIQNGHYIGGHVSL                               YLPGMTISYTCDPGYLLVGKGFIFCTDQGIWS                               QLDHYCKEVNCSFPLFMNGISKELEMKKVYH                               YGDYVTLKCEDGYTLEGSPWSQCQADDRWD                               PPLAKGTSRTHDALLTVGTLSGTIFFILLIIELSWI                               ILKHRKGNNAHENPKEVAIHLHSQGGSSVHP                               RTLQTNEENSRVLP               803   2153   A   6574   2   3233   HGRSARLAAVPAEAMPGPRRPAGSRLRLLLL                               LLLPPLLLLLRG\SHAGNLTVAVVLPLANTSY                               PWSWA\RVGPAVELALAQVKARPDLLPGWT                               VRTVLGSSENALGVCSDTAAPLAAVDLKWE                               HNPAVFLGPGCVYAAAPVGRFTAHWRVPLL                               TAGAPALGFGVKDEYALTTRAGPSYAKLGDF                               VAALHRRLGWERQALMLYAYRPGDEEHCFF                               LVEGLFMRVRDRLNITVDHLEFAEDDLSHYT                               RLLRTMPRKGRVIYICSSPDAFRTLMLLALEA                               GLCGEDYVFFHLDIPGQSLQGGQGPAPRRPW                               ERGDGQDVSARQAFQAAICIITYKDPDNPEYL                               EFLKQLKRLAYEQFNFIMEDGLVNTIPASFH                               DGLLLYIQAVTETLAHCIGTVTDGENITQRMW                               NRSFQGVTGYLKIDSSGDRETDFSLWDMDPE                               NGAFRVVLNYNGTSQELVAVSGRKLNWPLG                               YPPPDIPKCGFDNEDPACNQDHLSTLEVLALV                               QSLSLLGILIVSFFIYRKMQLEKELASELWRVR                               WEDVEPSSLERHLRSAGSRLTLSGRGSNYGSL                               LTPEGQFQVFAKTAYYKGNLVAVKRVNRKR                               IELTRKVLFELKHMRDVQNEHLTRFVGACTD                               PPNICILTEYCPRGSLQDILENESITLDWMFRY                               SLTNDIVKGMLFLHNGAICSHGNLKSSNCVV                               DGRFVLKITDYGLESFRDLDPEQGHTVYAKK                               LWTAPELLRMASPPVRGSQAGDVYSFGIILQE                               LALRSGVFHVEGLDLSPKEHERVTRGEQPPFR                               PSLALQSHLEELGLLMQRCWAEDPQERPPFQ                               QIRLTLRKFNRENSSNILDNLLSRMEQYANNL                               EELVEERTQAYLEEKRKAEALLYQILPHSVAE                               QLKRGETVQAEAFDSVTIYFSDIVGFTALSAE                               STPMQVVTLLNDLYITCFDAVIDNFDVYKVET                               IGDAYMVVSGLPVRNGRLHACEVARMALAL                               LDAVRSFRIRHRPQEQLRLRIGIHTGPVCAGV                               VGLKMPRYCLFGDTVNTASRMESNGEAL\KI                               HLSS\ETKAVL\EEFGGFELELRGDVEMKGKQ                               KVRTYWLLGERGSSTRG               804   2154   A   6585   2   3837   DAPGRPPVRLPTMELEDGVVYQEEPGGSGAV                               MSERVSGLAGSIYREFERLIVRYDEEVVKELIP                               LVVAVLENLDSVFAQDQEHQVELELLRDDNE                               QLITQYEREKALRKHIAEEKFIEPEDSQEQEKK                               DLQTRVESLESQTRQLELKAKNYADQISILEE                               REAELKKEYNALHQRIHTEMIHNYMEHLERT                               KLHQLSGSDQLESTAHSRIRKERPISLGIFPLP                               AGDGLLTPDAQKGGETPGSEQWKFQELSQPR                               SHTSLKDELSDVSQGGSKATTPASTANSDVA                               TIPTDTPLKEENEGFVKVWDAPNKSEISKH1EV                               QVAQETRNVSTGSAENEEKSEVQAIIESTPEL                               DMDKDLSGYKGSSTPTKGIENKAFDRNTESL                               FEELSSAGSGLIGDVDEGADLLGMGREVENLI                               LENTQLLETKNALNIVKNDLIAKVDELTCEK                               DVLQGELEAVKQAKLKLEEKNRELEEELRKA                               RAEAEDARQKAKDDDDSDIPTAQRKRFTRVE                               MARVLMERNQYKERLMELQEAVRWTEMIR                               ASRENPAMQEKKRSSIWQFFSRLFSSSSNTTK                               KPEPPVNLKYNAPTSHVTPSVKKRSSTLSQLP                               GDKSKAFDFLSEETEASLASRREQKREQYRQ                               VKAHVQKEDGRVQAFGWSLPQKYKQVTNG                               QGENKMKNLPVPVYLRPLDEKDTSMKLWCA                               VGVNLSGGKTRDGGSVVGASVFYKDVAGLD                               TEGSKQRSASQSSLDKLDQELKEQQKELKNQ                               EELSSLVWICTSTHSATKVLIIDAVQPGNILDS                               FTVCNSHVLCIASVPGAEETDYPAGEDLSESG                               QVDICASLCGSMTSNSSAETDSLLGGITVVGC                               SAEGVTGAATSPSTNGASPVMDKPPEMEAEN                               SEVDENVPTAEE\ATEATEGNAGSAEDTV\DIS                               QTGVYTEHVFTDPLGWQIPEDLSPVYQSSND                               SDAYKDQISVLPNEQDLVREEAQKMSSLLPT                               MWLGAQNGCLYVHSSVAQWRKCLHSIKLKD                               SILSIVHVKGIVLVALADGTLAIFHRGVDGQW                               DLSNYHLLDLGRPHILSIRCMTVVHDKVWCG                               YRNKIYVVQPKAMKIEKSFDAHPRKESQVRQ                               LAWVGDGVWVSIRLDSTLRLYHAHTYQHLQ                               DVDLEPYVSKMLGTGKLGFSFVRITALMVSC                               NRLWVGTGNGVIISIPLTETVILHQGRLLGLR                               ANKTSGVPGNRPGSVIRVYGDENSDKVTPGT                               FIPYCSMAHAQLCFHGIIRDAVKFFVAVPGQV                               ISPQSSSSGTDLTGDKGRGHLHRSLVVRRP               805   2155   A   6605   469   2602   FGRLLWGTAFKSWKMKAPIPHLILLYATFTQ                               SLKVVTKRGSADGCTDWSIDIKKYQVLVGEP                               VRIKCALFYGYIRTNYSLAQSAGLSLMWYKS                               SGPGDFEEPIAFDGSRMSKEEDSIWFRPTLLQ                               DSGLYACVIRNSTYCMKVSISLTVGENDTGL                               CYNSKMKYFEKAELSKSKEISCRDIEDFLLPT                               REPEILWYKECRTKTWRPSIVFKRDTLLIREV                               REDDIGNYTCELKYGGFVVRRTTELTVTAPL                               TDKPPKLLYPMESKLTIQETQLGDSANLTCRA                               FFGYSGDVSPLKGEKFIEDLDENRVWE                               SDI\KILKEHLGEQEVSISLIVDSVEEGDLQNYS                               CYVENGNGERHASVLLHKRELMYTVELAGG                               LGAILLLLVCLVTIYKCYKIEIMLFYRNHFGA                               EELDGDNKDYDAYLSYTKVDPDQWNQETGE                               EERFALEILPDMLEKIIYGYKLFIPDRDLIPTGT                               YIEDVARCVDQSKRLIIVMTPNYVVRRGWSW                               ELETRLRNMLVTGEIKVILIECSELRGIMNYQE                               VEALKHTIKLLTVIKWHGPKCNKLNSKFWKR                               LQYEMPFKRIEPITHEQALDVSEQGPFGELQT                               VSAISMAAATSTALATAHPDLRSTFHNTYHS                               QMRQKIIYYRSYEYDVPPTGTLPLTSIGNQHT                               YCNIPMTLINGQRPQTKSSREQNPDEAHTNSA                               ILPLLPRETSISSVIW               806   2156   A   6614   3   1584   NSARGGVGVRGARAMATVQEKAAALNLSAL                               HSPAHRRPPGFSVAQKPFGATYVWSSINTLQT                               QVEVKKRRMRLKRHNDCFVGSEAVDVIFSHL                               IQNKYFGDVDIPRAKVVRVCQALMDYKVFE                               AVPTKVFGKDKKPTFEDSSCSLYRFTTIPNQD                               SQLGKENKLYSPARYADALFKSSDIRSASLED                               LWENLSLKPANSPHVNISTTLSPQVINEVWQE                               ETIGRLLQLVDLPLLDSLLKQQEAVPKIPQPK                               RQSTMVNSSNYLDRGILKAYSDSQEDEWLSA                               AIDCLEYLPDQMVVEISRSFPEQPDRTDLVKE                               LLFDAIGRYYSSREPLLNHLLSDVHNGIAELLV                               NGKTEIALEATQLLLKLLDFQNREEFRRLLYF                               MAVAANPSEFKLQKESDNRMVVKRIFSKAW                               DNKNLSKGKTDLLVLFL\MDHQKDVFKWGT                               L\HKIVSWK\LMAIQNGRDPNRDAGYIYCQRI                               DQRDYSMTEKTTIDELLYLLKTLDEDSKLSA                               KEKKK\LLGQFYKCHPDIFGD               807   2157   A   6615   4198   2094   FGIVGTFALETDELDSDRDPAIFSLCDFGAMR                               PQILLLLALLTLGLAAQHQDKVPCKM/VKML                               CPDRVDKKVSCQVLGLLQVPSVLPPDTETLD                               LSGNQLRSILASPLGFYTALRHLDLSTNEISFL                               QPGAFQALTHLEHLSLAHNRLAMATALSAG                               GLGPLPRVTSLDLSGNSLYSGLLERLLGEAPS                               LHTLSLAENSLTRLTRHTFRDMPALEQLDLHS                               NVLMDIEDGAFEGLPRLTHLNILSRNSLTCLSD                               FSLQQLRVLDLSCNSIEAFQTAS\QPQAEFQLT                               WLDLRENKLLHPPDLAALPRIAYLNLSNNLIR                               LPTGPPQDSKGIHAPSEGWSALPLS\APSGNAS                               GRPLSQLLNLDLSYNEIELWDSFLEHLTSLCFL                               NLSRNCLRTFEAERLGSLPCLMLLDLSHNALE                               TLELGARALG\SLRTLLLQGNALRDLPPYTFA                               NLASLQRLNLQGNRVSPCGGPDEPGP\SGCV\                               AFSGITSLRSLSLVDNEIELLRAGAFLHTPLTE                               LDLSSNPGLEVATGALGGLEASLEVLALQGN                               GLMVLQVDLPCFICLKRLNLAENRLSHLPAW                               TQAVSLEVLDLRNNSFSLLPGSAMGGLETSLR                               RLYLQGNPLSCCGNGWLAAQLHQGRVDVDA                               TQDLLCRFSSQEEVSLSHVRPEDCEKGGLKNI                               NLIIILTFILVSAILUITLAACCCVRRQKFNQQ                               YKA               808   2158   A   6619   153   1852   FKALSQYIYTNTHLEREAAFEVAILLRRMEEG                               ARHRNNTEKKHPGGGESDASPEAGSGGGGV                               ALKKEIGLVSACGIIVGNIIGSGIFVSPKGVLEN                               AGSVGLALIVWIVTGFITVVGALCYAELGVNI                               PKSGGDYFYVKDIFGGLAGFLRLWIAVLVLYP                               TNQAVIALTFSNYVLQPLFPTCFPPESGLRLLA                               AICLLLLTWVNCSSVRWATRVQDIFTAGKLL                               ALALIIIMGIVQICKGEYFWLEPKNAFENFQEP                               DIGLVALAFLQGSFAYGGWNFLNY\VTEELV                               DP\YKNL\PRAIFISIP\LVTFVYVFANV/ALYVT                               AMSPQEL\LAS\NAVAVTFGEKLLGVMAWIM                               PISVALSTFGGVNGSLFTSSRLFFAGAREGHLP                               SVLAMIHVKRCTPIPALLFTCISTLLMLVTSD                               MYTLINYVGFINYLFYGVTVAGQIVLRWKKP                               DLPRPLKTNLLFPUYLLFWAFLLVFSLWSEPVV                               CGIGLAIMLTGVPVYFLGVYWQHKPKCFSDFI                               ELLTLVSQKMCVVVYPEVERGSGTEEANED                               MEEQQQPMYQPTPTKDKDVAGQPQP               809   2159   A   6621   1041   223   QDSRKMLPSTSVNSLVQGNGVLNSRDAARH                               TAGAKRYKYLRRLFRFRQMDFEFAAWQMLY                               LFTSPQRVYRNFHYRKQTKDQWARDDPAFL                               VLLSIWLCVSTIGFGFVLDMGFFETIKLLLWV                               VLIDCVGVGLLIATLMWFISNKYLVKRQSRD                               YDVEWGYAFDVHLNAFYPLLVILHFIQLFFN                               HVILTDTFIGYLVGNTLWLVAVGYYIYVTFL                               GYSVGLLFFS\ALPFLKNTVILLYPFAPLILLYG                               LSLALGWNFTHTLCSFYKYRVK               810   2160   A   6623   160   822   SPASGHCRLNGAAVAMFGCLVAGRLVQTAA                               QQVAEDKFVFDLPDYESINHVVVFMLGTIPFP                               EGMGGSVYFSYPDSNGMPVWQLLGFVTNGK                               PSAIFKISGLKSGEGSQHPFGAMNIVRTPSVAQ                               IGISVELLDSMAQQTPVGNAAVSSVDSFTQFT                               QKMLDNFYNFASSFAVSQIVPDDTQIRPSEMF                               IPANVVLKWYENFQRRTSTEPSLLENIIWIKIN                               F               811   2161   A   6627   18   3367   LEGSLNTERAKYYLTITMPHFTVTKVEDPEEG                               AAASISQEPSLADIKARIQDSDEPDLSQNSITG                               EHSQLLDDGHKICARNAYLNNSNYEEGDEYF                               DKNLALFEEEMDTRPKVSSLLNRMANYTNLT                               QGAKEHEEAENITEGKKKPTKTPQMGTFMG                               VYLPCLQNIFGVILFLRLTWVVGTAGVLQAF                               AIVLICCCCTMLTAISMSAIATNGVVPAGGSY                               FMISRALGPEFGGAVGLCFYLGTTFAAAMYIL                               GAIEIFLVYIVPRAAIFHSDDALKESAAMLNN                               MRVYGTAFLVLMVLVVFIGVRYVNKFASLFL                               ACVTVSILAIYAGAIKSSFAPPHFPVCMLGNRT                               LSSRHIDVCSKTKEINNMTVPSKLWGFFCNSS                               QFFNATCDEYFVHNNVTSIQGIPGLASGIITEN                               LWSNYLPKGEITEKPSAKSSDVLGSLNHEYVL                               VDITTSFTLLVGIFFPSVTGIMAGSNRSGDLKD                               AQKSIPIGTILAILITSFVYLSNVVLFGACTEGV                               VLRDKFGDAVKGNLVVGTLSWPSPWVIVIGS                               FFSTCGAGLQSLTGAPRLLQAIAKDNIIPFLRV                               FGHSKANGEPTWALLLTAAIAELGILIASLDL                               VAPILSMFFLMCYLFVNLACALQTLLRTPNW                               RPRFRYYHWALSFMGMSICLALMFISSWYYA                               IVAMVIAGMIYKYIEYQGAEKEWGDGIRGLS                               LSAARFALLRLEEGPPHTKNWRPQLLVLLKL                               DEDLHVKHPRLLTFASQLKAGKGLTIVGSVIV                               GNFLENYGEALAAEQTIKHLMEAEKVKGFCQ                               LVVAAKLREGISHLIQSCGLGGMKHNTVVM                               GWPNGWRQSEDARAWKTFIGTVRVTTAAHL                               ALLVAKNISFFPSNVEQFSEGNIDVWWWHDG                               GMLMLLPFLLK\QHKVWRKCSIRFF\TVAQLE                               DNSIQMKKDLATFLYHLRIEAEVEVVEMHDS                               DISAYTYERTLMMEQRSQMLRHMRLSKTER                               DREAQLVKDRNSMLRLTSIGSDEDEETETYQ                               EKVHMTWTKDKYMASRGQKAKSMEGFQDL                               LNMRPDQSNVRRMHTAVKLNEVIVNKSHEA                               KLVLLNMPGPPRNPEGDENYMEFLEVLTEGL                               ERVLLVRGGGSEVITIYS               812   2162   A   6628   66   640   AVCTMSEMAELSELYEESSDLQMDVMPGEG                               DLPQMEVGSGSRELSLRPSRSGAQQLEEEGP                               MEEEEAQPMAAPEGKRSLANGPNAGEQPGQ                               VAGADFESEDEGEEFDDWEDDYDYPEEEQLS                               GAGYRVSAALEEADKMFLRTREPALDGGFQ                               MHYEKTPFDQLAFIEELF\SLMVVNRLTEELG                               CDEIIDRE               813   2163   A   6630   708   1355   AKMGAYKYIQELWRKKQSDVMRFLLRVRC                               WQYRQLSALHRAPRPTRPDKARRLGYKAKQ                               GY/VYIYIGFVFAVIYRIRVRRGGRKRPVPKG                               ATYGKPVHHGVNQLKFARSLQSVAEERAGR                               HCGALRVLNSYWVGEDSTYKFFEVILIDPFHK                               AIRRNPDTQWITKPVHKHREMRGLTSAGRKS                               RGLGKGHKFHHTIGGSRPAAWRRRNTLQLH                               RYR               814   2164   A   6635   201   1705   KGTEMNKSRWQSRRRHGRRSHQQNPWFRLR                               DSEDRSDSRAAQPAHDSGHGDDESPSTSSGT                               AGTSSVPELPGFYFDPEKKRYFRLLPGHNNCN                               PLTKESIRQKEMESKRLRLLQEEDRRKKIARM                               GFNASSMLRKSQLGFLNVTNYCHLAHELRLS                               CMERKKVQIRSMDPSALASDRFNULADTNS                               DRLFIVNDVTVGGSKYGIINLQSLKTPTLKVF                               MHENLYFTNRKV\NSVCWASLNHLDSHILLC                               LMGLAETPGCATLLPASLFVNSHPAGIDRPG\                               MLCSFRIPGAWSCAWSLNIQANNCFSTGLSR                               RVLLTNVVTGHRQSFGTNSDVLAQQFALMA                               PLLFNGCRSGEIFAIDLRCGNQGKGWKATRLF                               HDSAVTSVRILQDEQYLMASDMAGKIKLWD                               LRTTKCVRQYEGHVNEYAYLPLHVHEEEGIL                               VAVGQDCYTRIWSLHDAELLRTIPSPYPASKA                               DIPSVAFSSRLGGSRGAPGLLMAVGDLYCY                               SYS               815   2165   A   6643   659   3282   NKNILEVPSARTTRIMGDHLDLLLGVVLMAG                               PVFGIPSCSFDGRIAFYRFCNLTQVPQVLNITE                               RLLLSFNYIRTVTASSFPFLEQLQLLELGSQYT                               PLTIDKEAFRNLPNLRLLDLGSSKIYFLHPDAF                               QGLFIILFELRLYFCGLSDAVLKDGYFRNLKA                               LTRLDLSKNQIRSLYLHPSFGKLNSLKSIDFSS                               NQIFLVCEHELEPLQGKTLSFFSLAANSLYSR                               VSVDWGKCMNPFRNMVLEILDVSGNGVITV                               DITGNFSNAISKSQAFSLILAHHIMGAGFGFHN                               IKDPDQNTFAGLARSSVRHLDLSHGFVFSLNS                               RVFETLKDLKVLNLAYNKINKIADEAFYGLD                               NLQVLNLSYNLLGELYSSNFYGLPKVAYIDL                               QKNHIAIIQDQTFKFLEKLQTLDLRDNALTTIH                               FIPSIPDIFLSGNKLVTLPKINLTANLIHLSENR                               LENLDILYFLLRVPHLQTLILNQNRFSSCSGDQ                               TPSENPSLEQLFLGENMLQLAWETELCWDVF                               EGLSHLQVLYLNHNYLNSLPPGVFSHLTALR                               GLSLNSNRLTVLSIINDLPANLEILDISRNQLL                               APNPDVFVSLSVLDITHNKFICECELSTFINWL                               NHTNVTIAGPPADIYCVYPDSLSGVSLFSLSTE                               GCDEEEVLKSLKFSLFIVCTVTLTLFLMTILTV                               TKFRGFCFICYKTAQRLVFKDHPQGTEPDMY                               KYDAYLCFSSKDFTWVQNALLKHLDTQYSD                               QNRPNLCFEERDFVPGENRP\ANIQDAIWNSR                               KIVCLVSRIIFLRDGWCLEAFSYAQGRCLSDL                               NSALIMVVVGSLSQYQLMKHQSIRGPVQKQQ                               YLRWPEDLQDVGWFLHKLSQQILKKEKEKK                               KDNNIPLQTVATIS               816   2166   A   6646   1   3811   RDRAGVRPAGKQHIAAAAFYDVGGDRPWDS                               GNTQLPPRNPVKANAIVIFGAGDEDDTDFLSPS                               GGARLASLFGLDQAAAGHGNEFFQYTAPKQP                               KKGQGTAATGNQATPKTAPATMSTPTILVAT                               AVHAYRYTNGQYVKQGKFGAAVLGNHTTR                               EYRILLYISQQQPVTVARIHVNFELMVRPNNY                               STFYDDQRQNWSIMFESEKAAVEFNKQVCIA                               KCNSTSSLDAVLSQDLIVADGPAVEVGDSLE                               VAYTGWLFQNHYLGQVFDSTANKDKLLRLK                               LGSGKVIKGWEDGMLGMKKQGKRLLIVPPA                               CAVGSEGVIGWTQATDSTLVFEVEVRRVKIA                               KDSGSDGHSVSSRDSAAPSPIPGADNLSADPV                               VSPPTSIPFKSGEPALRTKSNSLSEQLAINTSPD                               AVKAKLISRMAKMGQPMLPILPPQLDSNDSEI                               EDVNTLQGGGQPVVTPSVQPSLQPAHPALPQ                               MTSQAPQPSVTGLQAPSAALMQVSSLDSHSA                               VSGNAQSFQPYAGMQAYAYPQASAVTSQLQ                               PVRPLYPAPLSQPPHFQGSGDMASFLMTEAR                               QHNTEIRMAVSKVADKMDHLMTKVEELQKH                               SAGNSMLIPSMSVTMETSMIMSNIQRIIQENER                               LKQEILEKSNRIEEQNDKISELIERNQRYVEQS                               NLMMEKRNNSLQTATENTQARVLHAEQEKA                               KVTEELAAATAQVSHLQLKMTAHQKKETEL                               QMQLTESLKETDLLRGQLTKVQAKLSELQET                               SEQAQSKFKSEKQNRKQLELKVTSLEEELTDL                               RVEKESLEKNLSERKKKSAQERSQAEEEIDEI                               RKSYQEELDKLRQLLKKTRVSTDQAAAEQLS                               LVQAELQTQWEAKCEHLLASAKDEHLQQYQ                               EVCAQRDAYQQKLVQLQEKSVCFA\CLALQA                               QITALTKQNEQHIKELEKNKSQMSGVEAAAS                               DPSEKVKKIMNQVFQSLREEFELEESYNGRTI                               LGTIMNTIKMVTLQLLNQQEQEKEESSSEEEE                               EKAEERPRRPSQEQSASASSGQPQAPLNRERP                               ESPMVPSEQVVEEAVPLPPQALITSQDGHRR                               KGDSEAEALSEIKDGSLPPELSCIPSHRVLGPP                               TSIPPEPLGPVSMDSECEESLAASPMAAK\PDN                               PSGK\VCVREVAPDGPLQESSTRLSLTS\DPEE                               GDPLALGPESPGEPQPPQLKICDDVTSSTGPHK                               ELSSTEAGSTVAGAALRPSHHSQRSSLSGDEE                               DELFKGATLKALRPKAQPEEEDEDEVSMKGR                               PPPTPLFGDDDDDDDIDWLG               817   2167   A   6649   63   1073   FFRSSSDNGSPIRQYE/HSTPAHQGPVMGLEG                               KS/ARNSQLRIVLVGKTGAGKSATGNSILGRK                               VFHSGTAAKSITKKCEKRSSSWKETELVVVD                               TPGIFDTEVPNAETSKETIRCILLTSPGPHALLL                               VVPLGRYTEEEHKATEKILKMFGERARSFMIL                               TFTRKDDLGDTNLHDYLREAPEDIQDLMDIFG                               DRYCALNNKATGAEQEAQRAQLLGLIQRVV                               RENKEGCYTNRMYQRAEEEIQKQTQAMQEL                               HRVELEREKARIREEYEEKIRKLEDKVEQEKR                               KKQMEKKLAEQEAHYAVRQQRARTEVESKD                               GILELIMTALQIASFILLRLFAED               818   2168   A   6660   357   1890   APSGSWTRVVLTLDPCSLRSRSPRSLLDPGMP                               GISARGLSHEGRKQLAVNLTRVLALYRSILDA                               YIIEFF\TDNLWDTLPCSWQEALDGLKPPQLA                               TMLLGMPGEGEVVRYRSVWPLTLLALKSTA                               CALAFTRMPGFQTPSEFLEIWSQSSRLTAPFR                               KHVRPKKQHEIRRLGELVKKLSDFT/GLHPGC                               RRGLRPG\HLSRFMALGLGLMVKSIEGDQRL                               VERAQRLDQELLQALEKEEKRNPQVVQTSPR                               HSPHHVVRWVDPTALCEELLLPLENPCQGRA                               RLLLTGLHACG\DLSVALLPIIFSCCPEVVALA                               SVGCGYMKLSDPGGYPLSQWVAGLPGYELP                               YRLREGACHALEEYAERLQKAGPGLRTHCY                               RAALETVIRRARPELRRPGVQGIPRVHELKIEE                               YVQRGLQRVGLDPQLPLNLAALQAHLAQEN                               RVVAFFSLALLLAPLVETLILLDRLLYLQEQA                               LSP\GFHAELLPIPSPELSPPNLVLVATKMPLG                               QALSVLETEDS               819   2169   A   6661   65   2686   SGSGHCLAEAASMGPWGWKLRWIWALLLA                               AAGTAVGDRCERNEFQCQDGKCISYKWVCD                               GSAECQDGSDESQETCLSVTCKSGDFSCGGR                               VNRCIPQFWRCDGQVDCDNGSDEQGCPPKTC                               SQDEFRCHDGKCISRQFVCDSDRDCLDGSDE                               ASCPVLTCGPASFQCNSSTCIPQLWACDNDPD                               CEDGSDEWPQRCRGLYVFQGDSSPCSAFEFH                               CLSGECIHSSWRCDGGPDCKDKSDEENCAVA                               TCRPDEFQCSDGNCIHGSRQCDREYDCKDMS                               DEVGCVNVTLCEGPNKFKCHSGECITLDKVC                               NMARDCRDWSDEPLKECGTNECLDNNGGCS                               HVGNDLKIGYECLCPDGFQLVAQRRCEDIDE                               CQDPDTCSQLCVNLEGGYKCQCEEGFQLDPH                               TKACKAVGSIAYLFFINRHEVRKMTLDRSEY                               TSLIPNLRNVVALDTEVASNRIYWSDLSQRMI                               CSTQLDRAHGVSSYDTVLSRDIQAPDGLAVD                               WIHSNIYWTDSVLGTVSVADTKGVKRKTLFR                               ENGSKPRAIVVDPVHGFMYWTDWGTPAIKIK                               KGGLNGVDIYSLVTENIQWPNGITLDLLSGRL                               YWVDSKLHSISSIDVNGGNRKTTLEDEKRLAH                               PFSLAVFEDKVFWTDIINEAIFSANRLTGSDV                               NLLAENLLSPEDMVLFIINLTQPRGVNWCERT                               TLSNGGQYLCLPAPQINPHSPKFTCACPDGM                               LLAR\DMRSCLTEG\EAAVATQETSTVRLKVS                               STAVRTQHTTTRPVPDTSRLPGATPGLTTVEI                               VTMSHQALGDVAG\RGN\EKKPSSVRALSIVL                               PIV\LLVFLCLGVFLLWKNWRLKNINSINFDNP                               VYQKTTEDEVHICHNQDGYSYPSRQMVSLED                               DVA               820   2170   A   6666   17   4146   ERGISSQIKGMKSGSGGGSPTSLWGLLFLSAA                               LSLWPTSQEICGPGIDIRNDYQQLKELENCTVI                               EGYLHTLLISKAEDYRSYRFPKLTVITEYLLLF                               RVAGLESLGDLFPNLTVTRGWKLFYNYALVIP                               EMTNLKDIGLYNLRNITRG\AIRIEKNADLCYL                               STVDWSLILDAVSNNYIVGNKPPKECGDLCP                               GTMEEKPMCEKTTINNEYNYRCWTTNRCQK                               MCPSTCGKRACTENNECCHPECLGSCSAPDN                               DTACVACRHYYYAGVCVPACPPNTYRFEGW                               RCVDRDFCANILSAESSDSEGFVIHDGECMQE                               CPSGFIRNGSQSMYCIPCEGPCPKVCEEEKKT                               KTIDSVTSAQMLQGCTIFKGNLLINIRRGNNIA                               SELENFMGLIEVVTGYVKIRLHSHALVSLSFLK                               NLRLILGEEQLEGNYSFYVLDNQNLQQLWD                               WDHRNLTIKAGKMYFAFNPKLCVSEIYRMEE                               VTGTKGRQSKGDINTRNNGERASCESDVLHF                               TSTTTSKNRIIITWHRYRPPDYRDLISFTVYYK                               EAPFKNVTEYDGQDACGSNSWNMVDVDLPP                               NKDVEPGILLHGLKPWTQYAVYVKAVTLTM                               VENDHIRGAKSEILYIRTNASVPSIPLDVLSAS                               NSSSQLIVKWNPPSLPNGNLSYYIYRWQRQP                               QDGYLYRHNYCSKDKIPIRKYADGTIDIEEVT                               ENPKTEVCGGEKGPCCACPKTEAEKQAEKEE                               AEYRKVFENFLHNSIFVPRPERKRRDVMQVA                               NTTMSSRSRNTTAADTYNITDPEELETEYPPF                               ESRVDNKERTVISNLRPFTLYRIDIHSCNHEAE                               KLGCSASNFVFARTMPAEGADDIPGPVTWEP                               RPENSIFLKWPEPENPNGLILMYEIKYGSQVE                               DQRECVSRQEYRKYGGAKLNRLNPGNYTARI                               QATSLSGNGSWTDPVFFYVQAKRYENFIHLII                               ALPVAVLLIVGGLVIMLYVFILRKRNNSRLGN                               GVLYASVNPEYPSAADVYVPDEWEVAREKIT                               MSRELGQGSFGMVYEGVAKGVVKDEPETRV                               AIKTVNEAASMRERIEFLNEASVIVIKEFNCHH                               VVRLLGVVSQGQPTLVIMELMTRGDLKSYLR                               SLRPEMENNPVLAPPSLSKMIQMAGEIADGM                               AYLNANKFVHRDLAARNCMVAEDFTVKIGD                               FGMTRDWETDYYRKGGKGLLPVRWMSPESL                               KDGVFTTYSDVWSFGVVLWEIATLAEQPYQ                               GLSNEQVLRFV\MEGGLLDKPDNCPDMLFEL                               MRMCWQYNPKMRPSFLEIISSIKEEMEPGFRE                               VSFYYSEENKLPEPEELDLEPENMESVPLDPS                               ASSSSLPLPDRHSGHKAENGPGPGVLVLRASF                               DERQPYAHMNGGRKNERALPLPQSSTC               821   2171   A   6691   106   825   GRVLFRGCGVGHKGQVLMGTFILAQDWLSE                               SNHVFCVSSMLRLQKRLASSVLRCGKKKVW                               LDPNETNEIANANSRQQIRKLIKDGLIIRKPVT                               VHSRARCRKNTLARRKGRHMGIGKRKGTAN                               ARMPEKVTWMRRMRILRRLLRRYRES/KRYR                               ESKKIDRHMYHSLYLKVKGNVFKNKRILMEH                               IHKLKADKARKKLLADQAEARRSKTKEAPK                               RREERLQAKKEEIIKTLSKEEETKK               822   2172   A   6715   772   21   DFRPGLLLPRKKKMFGFHKPKMYRSIEGC\CI                               SGAKSSSS\RYIDSKRYEK\DFQ\SCFGLHETR\                               SGDI\CNA\CVLL\LKRWKKLPAGSKIQNWNH                               VVDARAGPS\LKTTLKPKKVKTL\SGNRIK\ST                               QISKLQKEFKR\HNSDAHSTTS\SASP\AQSPLF                               TVNQFRWTGSDTGVGFPGSNENHPVFSFLDL\                               TYWKRQKICCGIMYKGRFGEVLTDTHLFKPCC                               SNKKA\AAEKPEEQGPEPLPISTQEWVTEVFM               823   2173   A   6727   3   4063   PYLATLQLDSSLLIPPKYQTPPAAAQGQATPG                               NAGPLAPNGSAAPPAGSAFNPTSNSSSTNPAA                               SSSASGSSVPPVSSSASAPGISQISTTSSSGFSGS                               VGGQNPSTGGISADRTQGMGCGGDTDPGQS                               SSQPSQDGQESNYPSVGSLADPDYLNTPQMN                               TPVTLNSAAPASNSGAGVLPSPATPRFSVPTP                               RTPRTPRTPRGGGTASGQGSVKYDSTDQGSP                               ASTPSITRPLNSVEPATMQPIPEAHSLYVTLIL                               SDSVMNIFKDRNFDSCGICACNMNIKGADVG                               LYIPDSSNEDQYRCTCGFSAIMNRKLGYNSGL                               FLEDELDIFGKNSDIGQAAERRLM\MCQSTFL                               PQVEGTKKPQEPPISLLLLLQNQHTQPFASLN                               FLDYISSNNRQTLPCVSWSYDRVQADNNDY                               WTECFNALEQGRQYVDNPTGGKVDEALVRS                               ATVHSWPHSNVLDISMLSSQDVVRMLLSLQP                               FLQDAIQKKRTGRTWENIQHVQGPLTWQQFH                               KMAGRGTYGSEESPEPLPIPTLLVGYDKDFLT                               ISPFSLPFWERLLLDPYGGHRDVAYIVVCPEN                               EALLEGAKTFFRDLSAVYEMCRLGQHKPICK                               VLRDGIMRVGKTVAQKLTDELVSEWFNQPW                               SGEENDNHSRLKLYAQVCRHHLAPYLATLQL                               DSSLLLPPKYQTPPAAAQGQATPGNAGPLAIPN                               GSAAPPAGSAFNPTSNSSSTNPAASSSASGSSV                               PPVSSSASAPGISQISTTSSSGPSGSVGGQNPST                               GGISADRTQGNGCGGDTLPGQSSSQPSQDG                               QESVTERERIGIPTEPDSADSHAHPPAVVIYM                               VDPFTYAAEEDSTSGNFWLLSLMRCYTEMLD                               NLPEHMRNSFILQIVPCQYMLQTMKDEQVFY                               IQYLKSMAFSVYCQCRRPLPTQIIIIKSLTGFGP                               AASIEMTLKNPERPSPIQLYSPPFILAPIKDKQT                               ELGETFGEASQKYNVLFVGYGLSHDQRWLL                               ASCTDLHGELLETCVVNIALPNRSRRSKVSAR                               KIGLQKLWEWCIGIVQMTSLPWRVVIGRLGR                               LGHGELKDWSILLGECSLQTISKKLKDVCRM                               CGISAADSPSILSACLVAMEPQGSFVVMPDAV                               TMGSVFGRSTALNMQSSQLNTPQDASCTHIL                               VFPTSSTIQVAPANYPNEDGFSPNNDDMFVDL                               PFPDDMDNDIGILMTGNLHSSPNSSPVPSPGSP                               SGIGVGSHFQHSRSQGERLLSREAPEELKQQP                               LALGYFVSTAKAENLPQWFWSSCPQAQN\QC                               PLFLKASLHHHISVAQTDELLPARNSQRVPHP                               LDSKTTSDVLRFVLEQYNALSWLTCNPATQD                               RTSCLPVHFVVLTQLYNAIMNIL               824   2174   A   6732   2440   365   VEEGLGRRRTPPCIGRRGPVTPARPGPDSVRR                               RLLPPSSAAAFSSHRHNLLCSRRRGGGGGGG                               GGGGGTIKRPGLTGPTAATSPSGEPGNAASAP                               LSLLSPFPGQTTYQHPGVAEPSAYGGRDVAC                               ASLVFGRLQHRGGDRKRGLLGRSSGDAASD                               QPFRCRSGSTAGRLVKQMDFTEAYADTCSTV                               GLAAREGNVKVLRKLLKKGRSVDVADNRG                               WMPIHEAAYHNSVECLQMLTNADSSENYIKM                               KTFEGFCALHLAASQGHWKIVQILLEAGADP                               NATILEETITPLFLAVENGQIDVLRLLLQHGAN                               VNGSHSMCGWNSLHQASFQENAEIIKLLLRK                               GANKECQDDFGITPLFVAAQYG\KLESL\SILIS                               SG\ANVNCQALDKATPLFIAAQEGHTKCVELL                               LSSGADPDLYCNEDSWQLPTHAAAQMGHTKI                               LDLLIPLTNRACDTGLNKVSPVYSAVFGGHE                               DCLEILLRNGYSPDAQACLVFGFSSPVCMAFQ                               KDCEFPGIVNILLKYGAQINELHLAYCLKYEK                               FSIFRYFLRKGCSLGPWNHIYEFVNHAIKAQA                               KYKEWLPHLLVAGFDPLTLLCNSWIDSVSIDT                               LIFTLEFTNWKTLAFAVERMLSARASNAWIL                               QQHIATVPSLTHLCRLEIRSSLKSERLRSDSYIS                               QLPLPRSLHNYLLYEDVLRMYEVPELAMQD               825   2175   A   6735   277   1252   RIMGLFDRGVQMLLTTVGAFAAFSLMTIAVG                               TDYWLYSRGVCKTKSVSENETSKKNEEVMT                               HSGLWRTCCLEGNFKGLCKQIDHFPEDADYE                               DTAEYFLRAVASSIFPILSVILLFMGGLCIA                               ASEFYKTRHNLILSAGIFFVSAGLSNIIGIWYIS                               ANAGDPSKSDSKKNSYSYGWSFYFGALSFIIA                               EMVGVLAVHMFIDRHKQLRATAIRA\TDYLQ                               ASAITRIPSYRYRYQRRSRSSSRSTEPSHSRDA                               SPVGIKGFNTLPSTEISMYTLSRDPLKAATTPT                               ATYNSDRDNSPLQVHNCIQKENKDSLHSNTA                               NRRTTPV               826   2176   A   6744   3   5177   SDDLRTGLFQDVQDAESLKLPGVYEVLFYNE                               TEDCPGMMLWRYPEPRGLTLVRITPVPFNTT                               EDPDISTADLGDVLQDPCSLEYWDELQKVFV                               AFREFNLSESKVCELQLPDINLVNDQKKLVSS                               DLWRIVLNSSQNGADDQSSASESGSQSTCDPL                               VTPTALAACTRVDSCFTPWFVPSLCVSFQFAH                               LEFLCLDQLGTAAPQYLQPFVSDRNMPS                               ELEYMLVSFREPHMYLRQWNNGSVCQEIQFL                               AQADCKLLECENVTMQSVVKPFSIFGQMAVS                               SDVVEKLLDCTVIYDSVFVNLGQHVVHSLNT                               AIQAWQQNKCPEVEELVFSHPVICNDTQETL                               RFGQVDTDENTLLASLHSHQYSWRSHKSPQL                               LHICIEGWGNWRWSEPFSVDHAGTFIRTIQYR                               GRTASLIIKVQQLNGVQKQIIICGRQIICSYLSQ                               SIELKVVQHYIGQDGQAVVREIIFDCLTAKQK                               LPSYILENNELTELCVKAKGDEDWSRDVCLE                               SKAPEYSIVIQVPSSNSSIIYVWCTVLTLEPNS                               QVQQRMIVFSPLFIMRSHLPDPIIIHLEKRSLGL                               SETQILPGKGQEKPLQNIEPDLVHHLTFQAREE                               YDPSDCAVPISTSLTKQIATKVHPGGTVNQILD                               EFYGPEKSLQPIWPYNKKDSDRNEQLSQWDS                               PMRVKLSIWKPYVRTLLIELLPWALLINESKW                               DLWLFEGEKIVLQVPAGKIIIPPNFQEAFQIGW                               WANTNTVHKSVAIKLVHNLTSPKWKDGGNG                               EVVTLDEEAFVDTEIRLGAFPGHQKLCQFCIS                               SMVQQGIQIIQIEDK1TIINNTPYQIPYKPQLSV                               CNPHSGKEYFRVPDSATFSICPGGEQPAMKSS                               SLPCWDLMPDISQSVLDASLLQKQIMLGFSPA                               PGADSSQCWSLPAIYRPEFPRQSVAVPLGNFR                               ENGFCTRAIVLTYQEHLGVTYLTLSEDPSPRV                               IIHNRCPVKMLIKENIKDLPKFEVYCKKIPSECS                               IHHELYHQISSYPDCKTKDLLPSLLLRVEPLDE                               VTTEWSDAIDINSQGTQVVFLTGFGYVYVDV                               VHQCGTVFITVAPEGKAGPILTNTNRAPEKIV                               TF/KMFITQLSLAVFDDLTHHKASAELLRLTL                               DNIFLCVAPGAGPLPGEEPVAALFELYCVEIC                               CGDLQLDNQLYNKSNFHFAVLVCQGEKAEPI                               QGSKMQSLLISNKELEEYKEKCPIKLCITLNEG                               KSELCDINEFSFELKPARLYVEDTFVYYIKTLF                               DTYLPNSRLAGHSTHLSGGKQVLPMQVTQH                               ARALVNPVKLRKLVIQPVNLLVSIHASLKLYI                               ASDHTPLSFSVFERGPIFTTARQLVHALAMHY                               AAGALFRAGWVVGSLDILGSPASLVRSIGNG                               VADFFRLPYEGLTRGPGAFVSGVSRGITSFVK                               HISKGTLTSITNLATSLARNMDRLSLDEEHYN                               RQEEWRRQLPESLGEGLRQGLSRLGISLLGAI                               AGIVDQPMQNFQKTSEAQASAGHKAKGVISG                               VGKGIMGVFTKPIGGAAELVSQTGYGILHGA                               GLSQLPKQRHQPSD\VHADQAPNSHVKYVW                               KMLQSLGRPEVHMALDVVLVRGSGQEHEGC                               LLLTSEVLFVVSVSEDTQQQAFPVTEIDCAQD                               SKQNNLLTVQLKQPRVACDVEVDGVRERLSE                               QQYNRLVDYITKTSCHLAPSCSSMQIPCPVVA                               AEPPPSTVKTYHYLVDPHFAQVFLSKFTMVK                               NKALRKGFP               827   2177   A   6748   2   1662   FVGAPRRGNPFGSPGNPGRHQGPCHRPRGTK                               ASGVSPTLWRPQAAATGLEMPSSGRALLDSP                               LDSGSLTSLDSSVFCSEGEGEPLALGDCFTVN                               VGGSRFVLSQQALSCFPHTRLGKLAVVVASY                               RRPGALAAVPSPLELCDDANPVDNEYFFDRS                               SQAFRYVLHYYRTGRLHYMEQLCALSFLQEI                               QYWGIDELSIDSCCRDRYFRRKELSETLDFKK                               DTEDQESQHESEQDFSQGPCPTVRQKLWNIL                               EKPGSSTAARIFGVISIIFVGVSIINMALMSAEL                               SWLDLQLLEILEYVCISWFTGEFVLRFLCVRD                               RCRFLRKVPNIIDLLAILPFYITLLVESLSG\SQT                               TQEL\ENVGAHCPGCLRLLRAL\RMLKAWGR                               HSTGLRSLGMTITQCYEEVGLLLLFLSVGISIF                               STVEYFAEQSIPDTTFTSVPCAWWWATTSMT                               TVGYGDIEPDTTTGKIVAFMCILSGIINLALPI                               AIINDRFSACYFTLKLKEAAVRQREALKKLTK                               NIATDSYISVNLRDVYARSIMEMLRLKGRER                               ASTRSSGGDDFWF               828   2178   A   6786   5672   1360   GTHPASSGPVPLPPAAVSAATREELGEPVPFV                               TASSGFQSMLHSSNPKVRSSPSGNTQSSPKSKQ                               EVMVRPPTVMSPSGNPQLDSKFSNQGKQQGS                               ASQSQPSPCDSKSGGHTPKALPGPGGSMGLK                               NGAGNGAKGKGKRERSISADSFDQRDPGTPN                               DDSDIKECNSADHIKSQDSQHTPHSMTPSNAT                               APRSSTPPHGQTTATEPTPAQKTPAKVVYVFS                               TEMANKAAEAVLKGQVETIVSFHIQNISNNK                               TERSTAPLNTQISALRNDPKPLPQQPPAPANQ                               DQNSSQNTRLQPTPPIPAPAPKPAAPPRPLDRE                               SPGVENKLIPSVGSPASSTPLPPDGTGPNSTPN                               NRAVTPVSQGSNSSSADPKAPPPPPVSSGEPPT                               LGENPDGLSQEQLEIIRERSLQTLRDIQRMLFP                               DEKEFTGAQSGGPQQNPGVLDGPQKKPEGPI                               QAMMAQSQSLGKGPGPRTDVGAFFGPQGHR                               DVPFSPDEMVPPSMNSQSGTIGPDHLDHMTP                               EQIAWLKLQQEFYEEKRRKPEQVVVQQCSLQ                               DMMVHQHGPRGVVRGPPPPYQMTPSEGWAP                               GGTEPFSDGINMPHSLPPRGMAPHPNMPQSQ                               MRLPQFAGMINSEMEGPNVPNPASRLPGLSGV                               SWPDDVPKIPDGRNPPPGQGIFSGPGRGERFP                               NPQGLSEEMFQQQLAEKQLGLPPGMAMEGIR                               PSMEMNRMIPGSQRIIMEPGNNPIFPRIPVEGP                               LSPSRGDFPKGIPPQMGPGRELEFGMVPSGM                               KGDVNLNVNMGSNSQMIPQKMREAGAGPEE                               MLKLRPGGSDMLPAQQKMVPLPFGEHPQQE                               YQMGPRPFLPMSQGPGSNSGLRNLRRPIGPDQ                               RTNSRLSHMPPLPLNPSSNPTSLNTAPPVQRG                               LGRKPLDISVAGSQVHSPGINFLKSPTMHQVQ                               SPMLGSPSGNLKSPQTPSQLAGMLAGPAAAA                               SIKSPPVLGSAAASPVHLKSPSLPAPSPGWTSS                               PEPPLQSPGIPPNHKAPLTMASPAMLGNVESG                               GPPPPTASQPASVNIPG\SLPSSTPYTMPPEPTL                               SQNFLSIM\MSR\MSKFAM\PS\SNPGYNHDAI                               KTVASSDDDSPPARSPNLPSMNNMPGMGINT                               QNPRLISGPNPVVPMPTLSPMGMTQPLSHSNQ                               MPSPNAVGPNIPPHGVPMGPGLMSHNPIMGH                               GSQEPPMVPQGRMGFPQGFPPVQSPPQQVPFP                               HNGPSGGQGSFPGGMGFPGEGPLGRPSNLPQ                               SSADAALCKPGQPGGPDSFTVLGNSMPSVFT                               DPDLQEVIRPGATGIPEFDLSRIIPSEKPSQTLQ                               YFPRGEVPGRKQPQGPGPGFSHMQGMMGEQ                               APRMGLALPGMGGPGPVGTPDIPLGTAPSMP                               GHNPMRPPAFLQQGMMGPHHRMMSPAQST                               MPGQPTLMSNPAAAVGMIPGKDRGPAGLYT                               HPGPVGSPGMMMSMQGMMGP\NRTS               829   2179   A   6797   433   3   ASFFSICICKIILEVGPPVGHPAHDDVGGRH                               GPGGRIGSRSPRSLQCAPGGGRRSGCPAGSSP                               ASTCPPSPGGSGADRFGPSPPPPSREAAPTAG                               AAASSTSSGASCPPVPASSRWGVRSRTRSGSG                               GEREPRDRPSERPRLV               830   2180   A   6800   3   1911   LPERAFGPRTPRAPRRRRRRLLLSPPPRPPPPL                               DREPRAPGPWLCPSRAGTAQDPARIRERRGR                               VAGGAAGPAMELRARGWWLLCAAAALVAC                               ARGDPASKSRSCGEVRQIYGAKGFSSS\DVPQ                               AEISGEHLPICPQGYTCCTSEMEENLANRSHA                               ELETALRDSSRVLQAMLATQLRSFDDHFQHL                               LNDSERTLQATFPGAFGELYTQNARAFRDLY                               SELRLYYRGANLHLEETLAEFWARLLERLFK                               QLHPQLLLPDDYLDCLGKQAEALRPF\GEAP\                               RELRLRAT\RA\FVAAR\SFVQGLGVAS\DVVR                               KVAQVPLG\PEC\SRAVIEAGSYC/ALHCVGVP                               GARPCPDYCRNVLKGCLANQADLDAEWRNL                               LDSMVLITDKFWGTSGVESVIGSVHTWLAEA                               INALQDNRDTLTAKVLQGCGNPKVNPQGPGP                               EEKRRRGKLAPRERPPSGTLEKLVSEAIKAQL                               RDVQDFWISLPGTLCSEKMALSTASDDRCWN                               GMARGRYLPEVMGDGLANQINNPEVEVDIT                               KPDMTIRQQIMQLKIMTNRLRSAYNGNDVDF                               QDASDDGSGSGSGDGCLDDLCGRKVSRKSSS                               SRTPLTHALPGLSEQEGQKTSAASCPQPPTFL                               LPLLLFLALTVARPRWR               831   2181   A   6808   2   1522   ASRHGMTPGALLMLLGALGPPLAFGVRGSEA                               EGRLREKLFSGYDSSVRPAEEVGDRVRVSVG                               LILAQLISLNEKDEEMSTKVYLDLEWTDYRLS                               WDPAEHDGIDSLRITAESVWLPDVVLLNNND                               GNFDVALDISVVVSSDGSVRWQPPGIYRSSCS                               IQVTYFPFDWQNCTMVFSSYSYDSSEVSLQT                               GLGPDGQGHQEIHTHEGTFIENGQWENTHKPS                               RLIQPPGDPRGGREGQRQEVIFYLIIRRKPLFY                               LVNVIAPCILITLLAIFVFYLPPDAGEKMGLSIF                               ALLTLTVFLLLLADKVPFTSLSVPIIIKYLMFT                               MVLVTFSVILSVVVLNLHHRSPHTHQMPLWV                               RQIFIHKLPLYLRLKRPKPERDLMPEPPHCSSP                               GSGWGRGTDEYFIRKPPSDFLFPKPNRFQPEL                               SAPDLRRFIDGPNRAVALLPELREVVSSISYIA                               RQLQEQEDHDALKEDWQFVAMVVDRLFLW                               TFIIFTSVGTL\VIFLDATYHLPPPDPFP               832   2182   A   6824   71   1079   ETMAKNPPENCEDCHILNAEAFKSKKICKSLK                               ICGLVFGILALTLIVLFWGSKHFWPEVPKKAY                               DMEHTFYSNGEKKKIYMEIDPVTRTEIFRSGN                               GTDETLEVHDPKNGYTGIYFVGLQKCFIKTQI                               KVIPEFSEPEEEIDENEE1TITFFEQSVIWVPAE                               KPIENRDFLKNSKILEICDNVTMYW\TNPTL\IS                               GTFAKQLHHNFAFIILVSELQDFEEEGEDLHFP                               ANEKKGTEQNEQWVVPQVKVEKTRHARQAS                               EEELPINDYTLNGIEFDPIVELDERGYCCIYCRR                               GNRYCRRVCEPLLGYYPYPYCYQGGRVICRV                               IMPCNWWVARMLGRV               833   2183   A   6846   116   602   EAEGEQVCCGDAKCCGDAPHVENREEETARIGP                               GVMESKEERALNNLIVENVNQENDEKDEKE                               QVANKGEPLALPLNVSEYCVPRGNRRRFRVR                               QPILQYRWDIMHRLGEPQARMREENMERIGE                               EVRQLMEKLREKQLSHSLRAVSTDPPHHDHH                               DEFC\LMP               834   2184   A   6851   3   2024   PNGVALLHLPGAAVIPNTNYMFQDALGGRSR                               GSREESPAPSRAPASASLWRRLVVVEAKMAA                               HAAAAAQAAAAQAAHAEAADSWYLALLGF                               AEHFRTSSPPKIRLCVHCLQAVFPFKPPQRIEA                               RTHLQLGSVLYHHTKNSEQARSHLEKAWLIS                               QQIPQFEDVKFEAASLLSELYCQENSVDAAKP                               LLRKAIQISQQTPYWHCRLLFQLAQLHTLEKD                               LVSACDLLGVGAEYARVVGSEYTRALFLLSK                               GMLLLMERKLQEVHPLLTLCGQIVENWQGN                               PIQKESLRVFFLVLQVTHYLDAGQVKSVKPC                               LKQLQQCIQTISTLHDDEILPSNPADLFHWLP                               KEHMCVLVYLVTVMHSMQAGYLEKAQKYT                               DKALMQLEKLKMLDCSPILSSFQVILLEHIIM                               CRLVTGHKATALQEISQVCQLCQQSPRLFSN                               HAAQLHTLLGLYCVSVNCMDNAEAQFITAL                               RLTNHQELWAFIVTNLASVYIREGNRHQEVV\                               LYSLLERINPDHSFPVSSHCLRAAAFYVRGLF                               SFFQGRYNEAKRFLRETLKMSNAEDLNRLTA                               CSLVLLGHIFYVLGNHRESNNAVVPAMQLAS                               KIPDMSVQLWSSALLRDLNKACGNAMDAHE                               AAQMHQNFSQQLLQDHIEACSLPEIINLITWT                               DGPPPVQFQAQNGPNTSLASLL               835   2185   A   6855   334   1268   PTRRPILPLTSPKAISVPSPLQGKQHTLVKSCL                               SVSGIGGPLVSLSSRMKLQTLAVSVTALKFWS                               AYVPCQTQDRDALRLTLEQLDLIRRMCASYSE                               LELVTSAKALNDTQKLACLIGVEGGHSLDNS                               LSILRTFYMLGVRYLTLTHTCNTPWAESSAK                               GVHSFYNNISGLTDFGEKVVAEMNRLGMMV                               DLSHVSDAVARRALEVSQAPVIFSHSAARGV                               CNSARNVPDDILQLLEEERWAFVMVSLFHGE                               LIQWQPIRPMCSTVADHFDHIKAV\IGSKFIGI                               GGDYDGAGKYEKKTTCKAPWRTSSRMSS               836   2186   A   6862   315   11   PPRSRPSCWRKKVGPGRPWWWGGTGPPGQG                               RPEIRLLPLPMTGACGAVAASRTGSSGPG/SSL                               PNGHGGKGSGLANGLAGNP\GHLGLGSSFGT                               GPGSGRPPP               837   2187   A   6863   2   1615   VLRGQRGPAGGLAEERRRGRNEWRIHDVIT                               APFPGLVQRRSRLLIVSQVRYFLKNKVSPDLC                               NEDGLTALHQCCIDNFEEIVKLLLSHGANVN                               AKDNELWTPLHAAATCGHINLVKILVQYGA                               DLLAVNSDGNMPYDLCEDEPTLDVIETCMAY                               QGITQEKINEMRVAPEQQMIADIHCMIAAGQ                               DLDWIDAQGATLLHIAGANGYLRAAELLLDH                               GVRVDVKDWDGWEPLHAAAFWGQMQMAE                               LLVSHGAN\LNARTSMDEMPIDLCEEEEFKVL                               LLELK\HKHDVIMKSQLRHKSSLSRRTSHRQA                               SISVGKVVRRTQPVGTGPNL\YRKEYEIGEEAI                               LWQRSA\AEDQRTSTYNGDIRET\RTDQENKD                               PNPRLEK\PVLLSEFPTKIPRGELDMPVENGLR                               APVSAYQYALANGDVWKVHEVPDYSMAYG                               NPGVADATPPWSSYKEQSPQTLLELKRQRAA                               AKLLSHFFLSTHLGSSMARTGESSSEGKAPLI                               GGRTSPYSSNGTSVYYTVTSGDPPLLKFKAPI                               EEMEEKVHGCCRIS               838   2188   A   6865   6291   739   AGPLEPRVQGAMALQLWALTLLGLLGAGAS                               LRPRKLDFFRSEKELNHLAVDEASGVVYLGA                               VNALYQLDAKLQLEQQVATGPVLDNKKCTP                               PIEASQCHEAEMTDNVNQLLLVDPPRKRLVE                               CGQLLKGI\CALRALSNISLRLFYEDGSGEKSF                               VASNDEGVATVGLVSSTGPGGDRVLFVGKG                               NGPHDNGLIVSTRLLDRTDSREAFEAYTDHAT                               YKAGYLSTNTQQFVAAFEDGPYVFFVFNQQD                               KHPARNRTLLARMCREDPNYYSYLEMDLQC                               RDPDIHAAAFGTCLAASVAAPGSGRVLYAVF                               SRDSRSSGGFGAGLCLFPLDEVHAKMEANRN                               ACYTGTREARDIFYKPFHGDIQCGGHAPGSSK                               SFPCGSEHLPYPLGSRDGLRGTAVLQRGGLN                               LTAVTVAAENNHTVAFLGTSDGRILKVYLTP                               DGTSSEYDSILVEINKRVKRDLVLSGDLGSLY                               AMTQDKVFRLPVQECLSYPTCTQCRDSQDPY                               CGWCVVEGRCTRKAECPRAEEASHWLWSRS                               KSCVAVTSAQPQNMSRRAQGEVQLTVSPLPA                               LSEEDELLCLFGESPPHPARVEGEAVICNSPSS                               IPVTPPGQDHVAVTIQLLLRRGNIFLTSYQYPF                               YDCRQAMSLEENLPCISCVSNRWTCQWDLR                               YHECREASPNPEDGIVRAHMEDSCPQFLGPSP                               LVIPMNHETDVNFQGKNLDTVKGSSLHVGSD                               LLKFMEPVTMQESGTFAFRTPKLSHDANETL                               PLHLYVKSYGKNIDSKLHVTLYDCSFGRSDC                               SLCRAANPDYRCAWCGGQSRCVYEALCNTT                               SECPPPVITRIQPETGPLGGGIRITILGSNLGVQ                               AGDIQRISVAGRNGSFQPERYSVSTRIVCVIEA                               AETPFTGGVEVDVFGKLGRSPPNVQFTFQQP                               KPLSVEPQQGPQAGGTTLTLHGTHLDTGSQED                               VRVTLNGVPCKVTKFGAQLQCVTGPQATRG                               QMLLEVSYGGSPVPNPGIFFTYRENPVLRAFE                               PLRSFASGGRSINVTGQGFSLIQRFAMVVIAEP                               LQSWQPPREAESLQPMTVVGTDYVFHNDTK                               VVFLSPAVPEEPEAYNLTVLIEMDGHRALLRT                               EAGAFEYVPDPTFENFTGGVKKQVNKLIRAR                               GTNLNKAMTLQEAEAFVGAERCTMKTLTET                               DLYCEPPEVQPPPKRRQKEIYTTHNLPEFIVKF                               GSREWVLGRVEYDTRVSDVPLSLILPLVIVPM                               VVVIAVSVYCYWRKSQQAEREYEKIKSQLEG                               LEESVRDRCKKEFTDLMIEMEDQTLDVHEAG                               IPVLDYKTYTDRVFFLPSKDGDKDVMITGKL                               DIPEPRRPVVEQALYQFSNLLNSKSFLINFIHT                               L\ENQPEFSARAKVYFASLLTVALHGKLEYYT                               DIMHTLPLELLEQYVVAKNPKLMLRRSETVV                               ERMLSNWMSICLYQYLKDSAGEPLYKLFKAI                               KHQVEKGPVDAVQKKAICYTLNDTGLLGDD                               VEYAPLTVSVIVQDEGVDAIPVKVLNCDTISQ                               VKEKIIDQVYRGQPGSCWPRPDSVVLEWRPG                               STAQILSDLDLTSQREGRWKRVNTLMHYNVR                               DGATLILSKVGVSQQPEDSQQDLPGERHALL                               EEENRVWHLVRPTDEVDEGKSKRGSVKEKE                               RTKAITEIYLTRLLSVKGTLQQFVDNFFQSVL                               APGIIAVPPAVKYPFDFLDEQAEKIINLQDEDTI                               HIWKTNSLPLRFWVNILKNFHFIFDVHVHEYV                               DASLSVIAQTFMDACTRTEHKLSRDSPSNKLL                               YAKEISTYKKMVEDYYKGIRQMVQVSDQDM                               NTHLAEISRAHTDSLNTLVALHQLYQYTQKY                               YDEIINALEEDPAAQKMQLAFRLQQIAAALE                               NKVTDL               839   2189   A   6872   1   1485   RAERLALQCHVGVCALTPGEQSGRELPGQT                               WLMFSCFCFSLQDNSFSSTTVTECDEDPVSLH                               EDQTDCSSLRDENNKENYPDAGALVEEHAPP                               SWEPQQQNVEATVLVDSVLRPSMGNFKSRKP                               KSIFKAESGRSHGESQETEHVVSSQSECQVRA                               GTPAHESPQNNAFKCQETWRL\QPRIDQRTAT                               SPKDAFETR\QDLNEEEAAQVHGVKDPAPAS                               TQSVLA\DGTDSADPSPVHKDGQNEADSAIPE                               DLHSVGTSRLLLIYHITDGDNPTAVRHGCSL/F                               SGQSQRFNLDPESAPSPPSTQQFMIVIPRSSSRC                               SCGDGKEPQTITQLTKHIQSLKRKIRKFEEKFE                               QEKKYRPSHGDKTSNPEVLKWMNDLAKGRK                               QLKELKLKISEEQGSAPKGFPRNLLCEQPTVP                               RENGKPEAAGPEPSSSGEETPDAALTCLKERR                               EQLPPQEDSKVTKQDKNLIKPLYDRYRIIKQIL                               STPSLIPTIVSQDTCMLLLCTDV               840   2190   A   6873   2   2054   FFRFYFSFIRLFAMSLADLTKTNIDEHFPGVAL                               ENNRRSAACKRSPGTGDFSRNSNASNKSVDY                               SRSQCSCGSLSSQYDYSEDFLCDCSEKAINRN                               YLKQPVVKEKEKKKYNVSKISQSKGQKEISV                               EKKHTWNASLPNSQIHMIAQRRDAMAHIULS                               ARLHKIKGLKNELADMHHKLEAILTENQFLK                               QLQLRHLKAIGKYENSQNNLPQIMAKHQNEV                               KNLRQLLRKSQEKERTLSRKLRETDSQLLKT                               KDILQALQKLSEDKNLAEREELTHKLSIITTK                               MDANDKKIQSLEKQLRLNCRAFSRQLAIETR                               KTLAAQTATKTLQVEVKHLQQKLKEKDREL                               EIKNLYSHRILKNLHDTEDYPKVSSTKSVQAD                               RKILPFTSMRHQGTQKSDVPPL/TITKGKKATG                               NIDHKEKSTETINHEIPHCVNKLPKQEDSKRKY                               EDLSGEEKHLEVQILLENTGRQKDKKEDQEK                               KNIFVKEEQELPPKUEVIHPERESNQEDVLVR                               EKFKRSMQRNGVDDT\LGKGTAPYTKGPLRQ                               RRHYSFTEATENLHHGLPASGGPANAGNMR                               YSHSTGKHLSNREEMELEHS\DSGYEPSFGKS                               SRIKVKDTTFRDKKSSLMEELFGSGYVLKTD                               QSSPGVAKGSEEPLQSKESHPLPPSQASTSHA                               FGDSKVTVVNSIKPSSPTEGKRKIII               841   2191   A   6874   3   2867   SSRTREMEEKEILRRQIRLLQGLIDDYKTLHG                               NAPAPGTPAASGWQPPTYHSGRAFSARYPRP                               SRRGYSSHHGPSWRKKYSLVNRPPGPSDPPA                               DHAVRFLHGARGGQPPVPQQHYLERQVQLS                               QGQNVVIKVKPPSKSGSASASGAQRGSLEEFE                               DTPWSDQRPREGEGEPPRGQLQPSRPTRARG                               TCSVEDPLLVCQKEPGKPRMVKSVGSVGDSP                               REPRRTVSESVIAVKASFPSSALPPRTGVALG                               RKLGSHSVASCAPQLLGDRRVDAGHTDQPVP                               SGSVGGPARPASGPRQAREASLVVTCRTNKF                               RICNNYKWVAASSKSPRVARRALSPRVAAEN                               VCKASAGMANKVEKPQLIADPEPKPRKPATS                               SKPGSAPSKYKWKASSPSASSSSSFRWQSEAG                               SKDHASQLSPVLSRSPSGD\RPALAHSGLKPLS                               GETPLSAYKVKTRTKIIRERGSTSLPGDKKSG                               TSPAATAKSHSLRERQALRGKSSPVLKKTPN                               KGLVQVTKHRLCRLPPSRAHLPTKEASSLHA                               VRTAPTSKVIKTRYRIVKKTPASPLSAPPFPLS                               LPSWRARRLSLSRSLVLNRLRPVASGGGKAQ                               PGSPWWRSKGYRCTGGVLYKVSANKLSKTSG                               QPSDAGSRPLLRTGRLDPAGSCSRSLASRAVQ                               RSLAIIRQARQRREKRKEYCMYYNRFGRCNR                               GERCPYIHDPEKVAVCTRFVRGTCKKTDGTC                               PFSHHVSKEKMPVCSYFLKGICSNSNCPYSHV                               YVSRKAEVCSDFLKGYCPLGAKCKKKHTLLC                               PDFARRGACPRGAQCQLLHRTQKRHSRRAAT                               SPAPGPSDATARSRVSASHGPRKPSASQRPTR                               QTPSSAALTAAAVAAPPHCPGGSASPSSSKAS                               SSSSSSSSPPASLDHE\APSLQEAALAAACSNR                               LCKLPSFISLQSSPSPGAQPRVRAPRAPLTKDS                               GKPLHIKPRL               842   2192   A   6898   506   2071   WPDLVHTWSSEEAMGSCCSCPDKDTVPDNH                               RNKFKVINVDDDGNELGSGIIVIELTDTELILYT                               RKRDSVKWHYLCLRRYGYDSNLFSFESGRRC                               QTGQGIFAFKCARAEELFNMLQEIMQNNSIN                               VVEEPVVERNHQTELEVPRTPRTPTTPGFAA                               QNLPNGYPRYPSFGDASSHFSSRHPSVGSARL                               PSVGEESTHPLLVAEEQVHTYVNTTGVQEER                               KNRTSVHVPLEARVSNAESSTPKEEPSSIEDR                               DPQILLEPEGVKFVLGPTPVQKQLMEKEKLE                               QLGRDQVSGSGANNTEWDTGYDSDERRDAP                               SVNKLVYENINGLSIPSASGVRRGRLTSTSTSD                               TQNINNSAQRRTALLNYENLPSLPPVWEARK                               LSRDEDDNLGPKTPSLNGYHNNLDPMHNYV                               NTENVTVPASAHKIEYSRRRDCTPTVFNFDIR                               RPSLEHRQLNYIQVDLEGGSDSDNPQTPKTPT                               TPLPQTPTRRTELYAVIDIERTAAMSNLQKAL                               PRDDGTSR\KTRHNST\DLPL               843   2193   A   6919   2   663   AGRPGTITHASGKMAYQSLRLEYLQLPPVSRA                               YTTACVLTTAAVQLELITPFQLYFNPELIFKHF                               QIWRUTNFLFFGPVGFNFLFNMIFLYRYCRM                               LEEGSFRGRTADFVPMFLFGGFLMTLFGLFVS                               L/VFLGPGLYNN/GSSMCGAE\EPLCPHELLRP                               SQLPGPLSALGAHGIFLVVGELNHCGPFGYCS                               WTHIFFLGRCISQSTWWNKNSENTIYFESYF               844   2194   A   6928   902   366   HRLCMPIQGACGERMEIFSLLLPGLECNGVIL                               AHCNLRLPGSSNSPASASQVAGITGVCHHAR                               LIFVFSVETGFLHAGQAGLELLTSGDPPASAS                               QSAGITGKSQHTRPGYEFIIPYSAAQEDALKA                               LM               845   2195   A   6939   1660   317   LYPENLGESLFPILLLPPPWPDGGRPCCVEMS                               TRAKKLRRIWRILEEKESVAGAVQTLLLRSQE                               GGV\TSAAASTLSEPPRRTQESRTRTRALGLPT                               LPMEKLAASTEPQGPRPVLGRESVQVPDDQD                               FRSFRSECEAEVCIWNLTYSRAGVSVWVQAV                               EMDRTLHKIKCRMECCDVPAETLYDVLHDIE                               YRKKWDSNVIETFDIARLTVNADVGYYSWR                               CPKPLKNRDVITLRSWLPMGADYIIMNYSVK                               HPKYPPRKDLVRAVSIQTGYLIQSTGPKSCVIT                               YLAQVDPKGSLPKWVVNKSSQFLAPKAMKK                               MKACLKYPEWKQKHL\PHFKPWL\HPEQSP                               LPSLALS\ELSVQHADS\LENIDESAV\AESREE                               R\MGGAGGEG\SDDDTSLYAEAPHRFRETETG                               PGAGRALGAAAAPALSPLIIPPGTWWHRARP                               RRVLQPGWTEPQ               846   2196   A   6944   42   2672   RRKMAGCRGSLCCCCRWCCCCGERETRTPE                               ELTILGETQEEEDEILPRKDYESLDYDRCINDP                               YLEVLETMDNKKGRRYEAVKWMVVFAIGV                               CTGLVGLFSIDFFVRLFTQLKFGVVQTSVEECS                               QKGCLALSLLELLGFNLTFVFLESLLGLIEPVE                               AGSGITEGKCYLYARQVPGLVRLPTLLWKAL                               GVLLTVAAMLLI\GLGSPMIHSGSVVGAGLPQ                               PQSISLRKIQFNFPYFRSDRYGK\DKRDPVSAG                               AAAGVAAAFGAPIGGTLFSLEEGSSFWNQGL                               TWKVLFCSMSATFTLNFFRSGIQFGSWGSFQL                               PGLLNFGEFKCSDSDEKCHLWTAMDLGFFV                               VMGVIGGLLGATFNCLNKRLAKYRMRNVHP                               KPKLVRVLESLLVSLVTUVVVFVASMVLGEC                               RQMSSSSQIGNDSFQLQVTEDVNSSIKTFFCP                               NDTYNDMATLFFNPQESAILQLFIIQDGTFSPV                               TLALFFVLYFLLACWTYGISVPSGLFVPSLLC                               GAAFGRLVANVLKSYIGLGHTYSGTFALIGAA                               AFLGGVVRMTISLTVILIEST\NEITYGLPIMVT                               LMVGKWTGDFFNKGI\YDIHVGLRGVPLLEW                               ETEVEMDFCLRASDIMEPNLTYVYPHTRIQSLV                               SILRTTVHHAFPVVTENRGNEKEFMKGNQLIS                               NNIKFKKSSILTRAGEQRKRSQSMKSYPSSEL                               RNMCDEHIASEEPAEKEDLLQQMLERRYTPY                               PNLYPDQSPSEDWTMEERFRPLTFHGLILRSQ                               LVTLLVRGVCYSESQSSASQPRLSYAEMAED                               YPRYPDIHDLDLTLLNPRMIVDVTPYMNPSPF                               TVSPNTHVSQVFNLFRTMGLRHLPVVNAVGE                               IVGIITRIINLTYEFLQARLRQHYQTI               847   2197   A   6951   3   1994   NTNSSSVTNSAAGVEDLNIVQVTVPDNEKER                               LSSIEKIKQLREQVNDLFSRKFGEAIGVDFPVK                               VPYRKITFNPGCVVIDGMPPGVVFKAPGYLEI                               SSMRRILEAAEFIKFTVIRPLPGLELSNGEYST                               VGKRKIDQEGRVFQEKWERAYFFVEVQNIST                               CLICKRSMSVSKEYNLRRHYQTNHSKHYDQY                               MERMRDEKLHELKKGLRKYLLGLSDTECPE                               QKQVFANPSPTQKSPVQPVEDLAGNLWEKLR                               EKIRSFVAYSIAIDEITDINNTTQLAIFIRGVDE                               NFDVSEELLDTVPMTGTKSGNEIFSRVEKSLK                               NFCINWSKLVSVASTGTPPMVDANNGLVTKL                               KSRVATFCKGAELKSICCIIHPESLCAQ\KLKM                               DHYMDVVVKSVNWICSRGLNHSEFLTLLYEL                               DSQYGSLLYYTEIKWLSRGLVLKRFFESLEEI                               DSFMSSRGKPLPQLSSIDWIRDLAFLVDMTM                               HLNALNISLQGHSQIVTQMYDLIRAFLAKLCL                               WETILTRNNLAHFPTLKLVSRNESDGLNYIP                               KIAELKTEFQKRLSDFKLYESELTLFSSPFSTKI                               DSVHEELQMEVIDLQCNTVLKTKYDKVGIPE                               FYKYLWGSYPKYKHIICAKILSMFGSTYICEQ                               LFSIMKLSKTKYCSQLKDSQWDSVLHIAT               848   2198   A   6985   3   289   SVQYLPGRPTRTHASTDAPLMLKFTPLPSKTK                               ASAPVQCLLLMAATFSPQGLAKPHSGTTPIT\C                               CFNAINTKIPIQRLESYTRITNIQCPKEAVM               849   2199   A   6999   963   5   LDFLCHRDMGDNITSITEFLLLGFPVGPRIQM                               LLFGLFSLFYVFTLLGNGTILGLISLDSRLHIAP                               MYFFLSHL\AVVDIAYACNTVPRMLVNLLHP                               AKPISFAGRMMQTFLESTFAVTECLLLVVMS                               YDLYV\AICHPLRYLAIMTWRVCITLAVTSWT                               TGVLLSLIHLVLLLPLPFCRPQKIYHFFCEILA                               VLKLACADTHINENMVLAGAISGLVGPLSTIV                               VSYMCILCAILQIQSREVQRKAFCTCFSHLCVI                               GLFYGTAIIMYVGPRYGNPKEQKKYLLLFHS                               LFNPMLNPLICSLRNSEVKNTLKRVLGVERAL               850   2200   A   7001   1   1011   MGNDSVSYEYGDYSDLSDRPVDCLDGACLAI                               DPLRVAPLPLYAAIFLVGVPGNAMVAWVAG                               KVARRRVGATWLLHLAVADLLCCLSLPILAV                               PIARGGHWPYGAVGCRALPSIILLTMYASVLL                               LAALSADLCFLALGPAW\CLRFS/GACGVQVA                               CGAAWTLALLLTVPSAIYRELHQEHPPARLQ                               CVVDYGGSSSTENAVTAIRFLFGFLGPLVAVA                               SCHSALLCWAARRCRPLGTAIVVGFFVCWAP                               YHLLGLVLTVAAPNSATTARATRAFFLWGL                               ALAHSCLNPMLFLYFGRAQLRRSLPAACHW                               ALRESQGQDESVDSKKSTSHDLVSEMEV               851   2201   A   7011   1   2310   AAASPLRMSRKGPRAEVCADCSAPDPGWASI                               SRGVLVCDECCSVHRSLGRHISIVKHLRHSA                               WPPTLLQMVHTLASNGANSIWEHSLLDPAQV                               QSGPALKQTPKDKV\HPIKSEFIRAKYQMLAF                               VHKLPCRDDDGVTAKDLSKQLHSSVRTGNLE                               TCLRLLSLGAQANFFHPEKGTTPLHVAAKAG                               QTLQAELLVVYGADPGSPDVNGRTPIDYARQ                               AGHHELAERLVECQYELTDRLAFYLCGRKPD                               HKNGHYIIPQMADSLDLSELAKAAKKKLQAL                               SNRLFEELAMDVYDEVDRRENDAVWLATQN                               HSTLVTERSAVPFLPVNPEYSATRNQGRQKL                               ARFNAREFATLIIDILSEAKRRQQGKSLSSPTD                               NLELSLRSQSDLDDQHDYDSVASDEDTDQEP                               LRSTGATRSNRARSMDSSDLSDGAVTLQEYL                               ELKKALATSEAKVQQLMKVNSSLSDELRRLQ                               REIHKLQAENLQLRQPPGPVPTPPLPSERAEH                               TPMAPGGSTHRRDRQAFSMYEPGSALKPFGG                               PPGDELTTRLQPFHSTELEDDALYSVHVPAGL                               YRIRKGVSASAVPFTPSSPLLSCSQEGSRHTSK                               LSRHGSGADSDYENTQSGDPLLGLEGKRFLE                               LGKEEDFHPELESLDGDLDPGLPSTEDVILKT                               EQVTKNIQELLRAAQEFKHDSFVPCSEKIHLA                               VTEMASLFPKRPALEPVRSSLRLLNASAYRLQ                               SECRKTVPPEPGAPVDFQLLTQQVIQCAYDIA                               KAAKQLVTTTTREKKQ               852   2202   A   7016   484   1777   RISKIQVYYSTGYSSRKMNPTLGLAIFLAVLL                               TVKGLLKPSFSPRNYKALSEVQGWKQRMAA                               KELARQNMDLGFKLLKKLAFYNPGRNIFLSP                               LSISTAFSMLCLGAQDSTLDEIKQGFNFRKMP                               EKDLHEGFHYIIHELTQKTQDLKLSIGNTLFID                               QRLQPQRKFLEDAKNFYSAETILTNFQNLEM                               AQKQINDFIIESKTHGKINNLIENIDPGTVMLL                               ANYIFFRARWKHEFDPNVTKEEDFFLEKNSS                               VKVPMMFRSGIYQVGYDDKLSCTILEIPYQK                               NITAIFILPDEGKLKHLEKGLQVDTFSRWKTL                               LSRRVVDVSVPRLHMTGTFDLKKTLSYIGVS                               KIFEEHGDLTKIAPHRSLKVGEAVNKAELKM                               DERGTEGAAGTGAQTLPMETPLVVKIDKPYL                               LLIYSEKIPSVLFLGKIYNPIGK               853   2203   A   7017   1   3293   MTHACNFSTLGGQGRRITRSHGRRRSSRGPV                               ARHVAAGAGHENKHGGSRRFPAGVAPRRAM                               ANVSKKVSWSGRDRDDEEAAPLLRRTARPG                               GGTPLLNGAGPGAARQSPRSALFRVGHMSSV                               ELDDELLEP\DMDPPHPFPKEIPHNEKLLSLKY                               ESLDYDNSENQLFLEEERRINHTAFRTVEIKR                               WVICALIGILTGLVACFIDIVVENLAGLKYRVI                               KGSILPNIDKFTEKGGLSFSLLLWATLNAAFV                               LVGSVIVAFIEPVAAGSGIPQIKCFLNGVKIPH                               VVRLKTLVIKVSGVILSVVGGLAVGKEGPMI                               HSGSVLAAGISQGRSTSLKRDFKIFEYFRRDTE                               KRDFVSAGAAAGVSAAFGAPVGGVLFSLEEG                               ASFWNQFLTWRIFFASMISTFTLNFVLSIYHG                               NMWDLSSPGLINFGRFDSEKMAYTIHEIPVFI                               AMGVVGGVLGAVFNALNYWLTMFRIRYIHR                               PCLQVIEAVLVAAVTATVAFVLIYSSRDCQPL                               QGGSMSYPLQLFCADGEYNSMAAAFFNTPEK                               SVVSLFHDPPGSYNPLTLGLFTLVYFFLACWT                               YGLTVSAGVFIPSLLIGAAWGRLFGISLSYLTG                               AAIWADPGKYALMGAAAQLGGIVRMTLSLT                               VIMMEATSNVTYGFPIMLVLMTAKIVGDVFIE                               GLYDMHIQLQSVPFLHWEAFVTSHSLTAREV                               MSTPVTCLRREEKVGVIVDVLSDTASNHNGF                               PVVEHADDTQPARLQGLILRSQLIVLLKHKVF                               VERSNLGLVQRRLRLKDFRDAYPRFPPIQSIH                               VSQDERECTMDLSEFMNPSPYTVPQEASLPR                               VFKLFRALGLRHLVVVDNRNQVVGLVTRKD                               LARYRLGKRGLEELSLAQTGPKAQATAEGRV                               AGAAQQPCQLRAVTLEDLGLLLAGGLASPEP                               LSLEELSERYESSHPTSTASVPEQDTAKHWNQ                               LEQWVVELQAEVACLREHKQRCERATRSLL                               RELLQVRARVQLQGSELRQLQQEARPAAQAP                               EKEAPEFSGLQNQMQALDKRLVEVREALTRL                               RRRQVQQEAERRGAEQEAGLRLAKLTDLLQ                               QEEQGREVACGALQKNQEDSSRRVDLEVAR                               M               854   2204   A   7037   139   2604   AGTWEPRPYDQAKETGAPGSQPPVPPMELRP                               WLLWVVAATGTLVLLAADAQGQKVFTNTW                               AVRIPGGPAVANSVARKHGFLNLGQIFGDYY                               HFWHRGVTKRSLSPHRPRHSRLQREPQVQWL                               EQQVAKRRTKRDVYQEPTDPKFPQQWYL\SG                               VTQ\RDLMVKAAWAQGYTGHGIVVSILDDGI                               EKNHPDLAGNYDPGASPDVNDQDPDPQPRY                               TQMNDNRHGTRCAGEVAAVANNGVCGVGV                               AYNARIGGVRMLDGEVTDAVEARSLGLNPN                               HIHIYSASWGPEDDGKTVDGPARLAEEAFFR                               GVSQGRGGLGSIFVWASGNGGREHDSCNCD                               GYTNSIYTLSISSATQFGNVPWYSEACSSTLA                               TTYSSGNQNEKQIVTTDLRQKCTESHTGTSAS                               APLAAGIIALTLEANKNLTWRDMQHLVVQTS                               KPAHLNANDWATNGVGRKVSHSYGYGLLD                               AGAMVALAQNWTIVAPQRKCIIDILTEPKDI                               GKRLEVRKTVTACLGEPNHITRLEHAQARLT                               LSYNRRGDLAIIILVSPMGTRSTLLAARPHDY                               SADGFNDWAFMTTHSWDEDPSQEWVLEIEN                               TSEANNYGTLTKFTLVLYGTAPEGLPVPPESS                               GCKTLTSSQACVVCEEGFSLHQKSCVQHCPP                               GFAPQVLDTHYSTENDVETIRASVCALPCHAS                               CATCQGPALTDCLSCPSHASLDPVEQTCSRQS                               QSSRESPPQQQPPRLPPEYEAGQRLRAGLLPS                               HLPEVVAGLSCAFIVLVFVTVFLVLQLRSGFS                               FRGVKVYTMDRGLISYKGLPPEAWQEECPSD                               SEEDEGRGERTAFIKDQSAL               855   2205   A   7058   3   1441   QRPASQLLAPFAAEALPGAFRAAMAQHFSLA                               ACDVVGFDLDMTLCRYNLPESAPLIYNSFAQF                               LVKEKGYDKELLNVTPEDWDFCCKGLALDL                               EDGNPLKLANNGTVLRASHGTKMMTPEYLA                               EAYGKKEWKHFLSDTGMACRSGKYYFYDN                               YFDLPGALLCARVVDYLTKLNNGQKTFDFW                               KDIVAAIQHNYKMSAFKENCGIYFPEIKRDPG                               RYLHSRPESVKKWLRQLKNAGKILLLTTSSHS                               DYCRLLGA\YILGNDFTDLFDIVITNALKPGFF                               SHLPSQRPFRTLENDEEQEALPSLDKPGWYSQ                               GNAVHLYELLKKMTGKPEPKVVYFGDSMHS                               DIFPARHYSNWETVLILEELRGDEGTRSQRPE                               ESEPLEKKGKYEGPKAKPLNTSSKKWGSFF\I                               DSVLGLENTEDSLVYTWSCKRISTYSTIAIPSI                               EAIAELPLDYKFTRFSSSNSKTAGYYPNPPLV                               LSSDETLISK               856   2206   A   7082   396   1635   SSPSVFEFEHAVQPVFTMEFLKTCVLRRNACT                               AVCFWRSKVVQKPSVRRISTTSPRSTVMPAW                               VIDKYGKNEVLRFTQNMMMPIIHYPNEVIVK                               VHAASVNPIDVNMRSGYGATALNMKEDPLH                               VKIKGEEFPLTLGRDVSGVVMECGLDVKYFK                               PGDEVWAAVPPWKQGTLSEFVVVSGNEVSH                               KPKSLTHTQAASLPYVALTAWSAINKVGGLN                               DKNCTGKRVLILGASGGVGTFAIQVMKAWD                               AHVTAVCSQDASELVRKLGADDVIDYKSGSV                               EEQLKSLKPFDFILDNVGGSTETWAPDFLKK                               WSGATYVTLVTPFLLNMDRLGIADGMLQTG                               VTVGSKALKHFWKQVHYRWAFFMASQPCL                               DDIAELVDAGKIRPV\IEQTFPFSKVPEAFLKV                               ERGHARGKTVINVV               857   2207   A   7088   320   2417   LRRRKMTPQSLLQTTLFLLSLLFLVQGAHGR                               GHEEDFRFCSQRNQTHRSSLHYKPTPDLRISIE                               NSEEALTVHAPFPAAHPASRSEPDPRGLYHFC                               LYWNRHAGRLHLLYGKRDFLLSDKASSLLCF                               QHQEESLAQGPPLLATSVTSWWSPQNISLPSA                               ASFTFSFHSPPHTGAIINASVDMCELKRDLQL                               LSQFLKHPQKASRRPSAAPASQQLQSLESKLT                               SVEFMGDMGSFEEDRLINATVWKLQPTAGLQ                               DLHIHSRQEEEQSEIMEYSVLLPRTLFQRTKG                               RSGEAEKRLLLVDPSSQALFQDKNSSQVLGE                               KVLGTVVQNTKVANLTEPVVLTFQHQLQPKN                               VTLQCVFWVEDPTLSSPGHWSSAGCETVRRE                               TQTSCFCHHLTYFAVLMVSSVEVDAVHKHY                               LSLLSYVGCVVSALACLVTIAAYLCSRVPLPC                               RRKPRDYTIKVHMNLLLAVFLLDTSFLLSEPV                               ALTGSEAGCRASAIFLHFSLLTCLSWMGLEG                               YNLYRLVVEVFGTYVPGYLLKLSAMGWGFPI                               FLVTLVALVDVDNYGPIILAVHRTPEGVIYPS                               MCWIRDSLVSYITNLGLFSLVFLFNMAMLAT                               MVVQILRLRPHTQKWSHVLTLLCLSLVLG\LP                               WALIFFSFASGTFQLVVLYLFSIITSFQGFLIFI                               WYWSMRLQARGGPSPLKSNSDSARLPISSGS                               TSSSRI               858   2208   A   7091   185   415   DAGAVKSSDTNIWPRGMCDDKKGHRCPS*G                               QPQHFHVAFHTEAEGAMFYPRLHVIHRVMQS                               QQQLFPSTLFSWLLE               859   2209   A   7136   3   302   FFFWRQSLALLPRLECSGATGAHCNLHFPGSS                               DCPTSAS*IAGITGACYHAWLLFVFLAETGFH                               HVGQGGLELLTSSDPSGSASQSAGITGVSHCT                               WPI               860   2210   A   7156   23   591   ALSTETRTPDMRRLLLVTSLVVVLIWEAGAV                               PAPKVPIKMQVKHWPSEQDPEKAWGARVVE                               PPEKDDQLVVLFPVQKPKLLTIEEKPRGQGR                               GPIILPGTKAWMETEDTLGRVLSPEPDHDSLY               861   2211   A   7161   1220   1003   NYVCTIAF*EKKMGF*LSLSCLVLLFVLFLDCI                               LTTTTRIMFHCTYLFASVCLSLLNTLLSPNCL                               KSAMILQ               862   2212   A   7211   665   847   LKYYHITMGIYKTGKKVIIL*KSSMSNRFS VIP                               YKNIQKLSFSNYVYHQNYVFSSDWSYDF               863   2213   A   7212   924   1273   HGSSCALGDLAPG*LPSGPVLSSPAVRL*RKP                               LVWDSPSCLPATGPT*GLVLVLGGPDCT*WA                               RGQHEHKRMRAP*SCRVTVNLAKKKKKTDQ                               CIKPNYQSPPKECDYNILANSVA               864   2214   A   7214   845   1619   SDKGGKKADRKNHLRHAFPLLPHRVRERLH                               DPKVPVDADHVQGQDPGRAAHDIHGEDVTE                               KVSKDPLAPDEVGDTDEGHDRHGHREVGQR                               HGHDQEEVAYEERACEGGKFATVEVTDKPV                               DEALREAMPKVAKYAGGTNDKGIGMGMTV                               PISFAVFPNEDGSLQKKLKVWFRIPNQFQSDP                               PAPSDKSVKIEEREGITVYSMQFGGYAKEAD                               YVAQATRLRAALEGTATYRGDIYFCTGYDPP                               MKPYGRRNEIWLLKT               865   2215   A   7246   559   682   RRLGAVAHAYTSSTLGGRGGWIT*GQELQTS                               LANMAKPRLY               866   2216   A   7257   641   1310   TCTYKYLMGWLRGRRSRHSWEMSEFHNYNL                               DLKKSDFSTRWQKQRCPVVKSKCRENASPFF                               FCCFIAVAMGIRFIIMVAIWSAVFLNSLFNQEV                               QIPLTESYCGPCPKNWICYKNNCYQFFDESKN                               WYESQASCMSQNASLLKVYSKEDQDLLKLV                               KSYHWMGLVHIPTNGSWQWEDGSILSPNLLT                               IIEMQKGDCALYASSFKGYIENGSTPNTYICM                               QRTV               867   2217   A   7288   151   396   SIKIIEAFGSNGPDFWFFRYWSP*LFRQQVVFI                               MPFFQTLWLMNANRFCSIFTTTNVANNCWW                               TPYHCWLSVVVCRCESHGI               868   2218   A   7298   3   272   PDTVIGGRGSGGKEFGRWVLW*VFE*RLGTP                               KGSCPAGGSRMVSESD*EGRGC*ASYPCAC*                               AGS*WR*GSRPAGRGTPPRSLSHARPP               869   2219   A   7332   1223   332   PRRDAEDRDESCLNPAFPIGLLHPNSVNSMAR                               FLTLCTWLLLLGPGLLATVRAECSQDCATCS                               YRLVRPADINFLACVMECEGKLPSLKIWETC                               KELLQLSKPELPQDGTSTLRENSKPEESHLLA                               KRYGGFMKRYGGFMKKMDELYPMEPEEEA                               NGSEILAKRYGGFMKKDAEEDDSLANSSDLL                               KELLETGDNRERSHHQDGSDNEEEVSKRYGG                               FMRGLKRSPQLKEKAKELQKRYGGFMIRRVG                               PQKW*MTSPQNRYGGFLKRFAEALPSDEEGE                               SYSKEVPEMEKRYGGFMRF               870   2220   A   7382   216   1018   EIHQRLTERTQFLDESRKNPNSQANLLRGGG                               AGQGRGREGAESGGSRGEGPGSDGRLPATGD                               FWSPRSQRRGCCGRRAPRPEAMENGAVYSPT                               TEEDPGPARGPRSGLAAYFFMGRLPLLRRVL                               KGLQLLLSLLAPICEEVVSQCTLCGGLYFFEF                               VSCSAFLLSLLILIVYCTPFYERVDTTKVKSSD                               FYITLGTGCVPLLASIIFVSTHDRTSAEIAAIVF                               GFLASFMFLLDFITMLYEKRQESQLRKPENTT                               RAEALTEPLNA               871   2221   A   7403   3   393   SCAMCSGLL*LLLPIWLSWTLGTRGSEPRSVN                               DPGNMSFVKETVDKLLTGFRCFREREAAPRR                               ALRGAALPGESEAGDPESLRSSVNADWIQYS                               DLWEAEVSTPRCEAGFGQEGFRTPGNQEKDG                               PFIC               872   2222   A   7413   1061   359   FVD1VSVVEFPHCPEARFPAQHGQDSKRLTLC                               PGGS*PQATLHLDRMRVSASPTKEIQVKKYK                               CGLIKPCPANYFAFKICSGAANVVGPTMCFED                               RMIMSPVKNNVGRGLNIALVNGTTGAVLGQ                               KAFDMYSGDVMHLVKFLKEIPGGALVLVAS                               YDDPGTKMNDESRKLFSDLGSSYAKQLGFRD                               SWVFIGAKDLRGKSPFEQFLKEQPQTQNKYE                               GWPELLEMEGCMPPKPF               873   2223   A   7429   2242   2394   ILKCAGHGGSCL*SQHFGRLRWEDRLRLGVQ                               DHPGQHCETPSLLKIERKLF               874   2224   A   7468   146   894   PCTSCVLWATLHLFASTRKAPQAECGMISITE                               WQKIGVGITGFGIFFILFGTLLYFDSVLLAFGN                               LLFLTGLSLIIGLRKTFWFFFQRHKLKGTSFLL                               GGVVIVLLRWPLLGMFLETYGFFSLFKGFFPV                               AFGFLGNVCNIPFLGALFRRLQGTSSMV*KTE                               MSSLNLDHWLKGAKREEWEPPPQSPALTHSP                               TYPGPPQVQKERNGAEQLTSNPQVDSRGCQE                               AEMQTPRRLGWGWYHTLTLYLWEEK               875   2225   A   7498   91   251   GEKPVPTWLQDEAGQWLLGFVAQPWGWPG                               SERHEP*HGGVLFRLGPSAPPGKL               876   2226   A   7544   403   587   YSCLCFLFKHITSFKNSVHIWLGTVVHAYNPN                               ILGGQGGWIA*GQEFKTSLGNTVRPCLYK               877   2227   A   7566   2   940   GCAPDTRFFVPEPGGRGAAPWVALVARGGC                               TFKDKVLVAARRNASAVVLYNEERYGNITLP                               MSHAGTGNIVVIMISYPKGREILELVQKGIPV                               TMTIGVGTRHVQEFISGQSVVFVAIAFITMMII                               SLAWLIFYYIQRFLYTGSQIGSQSHRKETKKVI                               GQLLLHTVKHGEKGIDVDAENCAVCIENFKV                               KDIIRILPCKHIFHRICIDPWLLDHIRTCPMCKL                               DVIKALGYWGEPGDVQEMPAPESPPGRDPAA                               NLSLALPDDDGSDESSPPSASPAESEPQCDPSF                               KGDAGENTALLEAGRSDSRHGGPIS               878   2228   A   7586   315   1232   ERSLLCKVDVRWIYVSEGTKTQRRHRQGSLR                               RGRMQAACWYVLFLLQPTVYLVTCANLTNG                               GKSELLKSGSSKSTLKHIWTESSKDLSLSRLLS                               QTFRGKENDTDLDLRYDTPEPYSEQDLWDW                               LRNSTDLQEPRPRAKRRPIVKTGKFKKIVIFGW                               GDFHSNTKTVKLNLLTTGKIVDHGNGTFSVYF                               RHNSTGQGNVSVSLVPPTKIVEFDLAQQTVID                               AKDSKSFNCRIEYEKVDKATKNTLCNYDPSK                               TCYQEQTQSHVSWLCSKPFKVICIYISFYSTD                               YKLVQKVCPDYNYHSDTPYFPSG               879   2229   A   7605   479   391   TESWKLKWWSPTCLDQLNGSAPGNVFIHG               880   2230   A   7612   93   659   DAAVAMTAQGGLVANRGRRFKWAIELSGPG                               GGSRGRSDRGSGQGDSLYPVGYLDKQVPDTS                               VQETDRILVEKRCWDIALGPLKQIPMNLFIMY                               MAGNTISIFPTMMVCMMAWRPIQALMAISAT                               FKMLESSSQKPLQGLVYLIGNLMGLALAVYK                               CQSMGLLPTHASDWLAFIEPPERMEFSGGGL                           LL               881   2231   A   7615   291   1452   SPQKTMRSHTTTMTTTSVSSWPYSSHRIVIRFIT                               NHSDQPPQNFSATPNVTTCPMDEKLLSTVLTT                               SYSVIFIVGLVGNIIALYVFLGIHRKRNSIQIYL                               LNVAIADLLLIFCLPPRIMYHNQNKWTLGVIL                               CKVVGTLFYMNMYISIILLGFISLDRYIKINRSI                               QQRKAITTKQSIYVCCIVWMLALGGFLTMIIL                               TLKKGGHNSTMCFHYRDKHNAKGEAIFNFIL                               VVMFWLLFLLIILSYIIKIGKNLLRISKRRSKFPN                               SGKYATTARNSFIVLIIFTICFVPYHAFRFIYISS                               QLNVSSCYWKEIVHKTNEIMLVLSSFNSCLDP                               VMYFLMSSNIRKIMCQLLFRRFQGEPSRSEST                               SEFKPGYSLHDTSVAVKIQSSSKST               882   2232   A   7617   67   379   RQMALLKANKDLISAGLKEFSVLLNQQVFND                               PLVSEEDMVTVVEDWMNFYINYYRQQVTGE                               PQERDKALQELRQELNTLANPFLAKYRDFLK                               SHELPSHPPPSSS               883   2233   A   7622   400   215   KVKTCRYNPKYSAANDTGFVDIPSREKDLAK                               AVATVGPISVAVGASHVFFQFYKKGKHLSS               884   2234   A   7638   2640   2861   APVLILQMVKLSIVLTPQFLSHDQGQLTKELQ                               QHVKSVTCPCEYLRKVSECRQMGPGALEQFP                               GLSC8HTSHSG               885   2235   A   7642   201   455   PSRGKMELEAMSRYTSPVNPAVFPHLTVVLL                               AIGMFFTAWFFVYEVTSTKYTRDIYKELLISL                               VASLFMGFGVLFLLLWVGIYV               886   2236   A   7692   61   569   APENPFSRQHFNSETKVKLSLKTGTWLGNHA                               HLGEHFSTHHELGLSGKVVGFLVKNILEVIRN                               GGMETRHPGKVSSWFHRWDSRAEQHNHAE                               HHEDVPQGDEDSKVSEAQQEFPDVVTCAGLP                               GLLPKALRVLLFQLKVQHRPGIHQQRFEQQD                               VSDHRYGRSVRQNRK               887   2237   A   7693   85   315   NPGCCLPVAMRTSYLLLFTLCLLLSEMASGG                               NFLTGLGHRSDHYNCVSSGGQCLYSACPIFTK                               IQGTCYRGKAKCCK               888   2238   A   7702   242   1298   APSHRRRYLSPSRSAGQLGNMALERLCSVLK                               VLLITVLVVEGIAVAQKTQDGQNIGIKHIPAT                               QCGIWVRTSNGGHFASPNYPDSYPPNKECIYI                               LEAAPRQRIELTFDEHYYIEPSFECRFDHLEVR                               DCIPFGFSPLIDRYCGVKSFPLIRSTGRFMWIKF                               SSDEELEGLGFRAKYSFIPDPDFTYLGGILNPIP                               DCQFELSGADGIVRSSQVEQEEKTKPGQAVD                               CIWTIKATPKAKIYLRFLDYQMEHSNECKRNF                               VAVYDGSSSIENLKAKFCSTVANDVMLKTQI                               GVIRMWADEGSRLNRFRMLFTSFGGASPAQA                               ALSFCHSNMCINNSLVCNGVQNCAYPWDEN                               HC               889   2239   A   7707   185   2911   CHYIMNPSTHHPASAGGSILGLFDFFGLGLGE                               MTMDALLARLKLLNPDDLREEIVKAGLKCGP                               ITSTFRFIFEKKLAQALLEQGGRLSSFYHHEA                               GVTALSQDPQRILKPAEGNPTDQAGFSEDRDF                               GYSVGLNPPEEEAVTSKTCSVPPSDTDTYRAG                               ATASICEPPLYYGVCPVYEDVPARNERIYVYE                               NKKEALQAVKMIKGSRFKAFSTREDAEKFAR                               GICDYFPSPSKTSLPLSPYKTAPLFSNDRLKDG                               LCLSESETVNKERANSYKNPRTQDLTAKLRK                               AVEKGEEDTFSDLIWSNPRYLIGSGDNPTIVQ                               EGCRYNVMHVAAKENQASICQLTLDVLENP                               DFMRLMYPDDDEAMLQKRIRYVVDLYLNTP                               DKMGYDTPLHFACKFGNADVVNVLSSHHLI                               VKNSRNKYDKTPEDVICERSKNKSVELKERIR                               EYLKGHYYVPLLRAEETSSPVIGELWSPDQTA                               EASHYSRYGGSPRDPVLTLRAFAGPLSPAKAE                               DFRKLWKTPPREKAGFLHHYKKSDPERGFER                               VGRELAHELGYPWVEYWEFLGCFVDLSSQE                               GLQREEYLTQQEIGKKAQQETGEREASCRD                               KATTSGSNSISVRAFLDEDDMSLEEIKNRQNA                               ARNNSPPTVGAFGHTRCSAFPLEQEADLIEAA                               EPGGPHSSRNGLCHPLNHSRTLAGKRIPKAPR                               GEEAHLPPVSDLTVEFDKLNLQNIGRSVSKTP                               DESTKTKDQILTSRINAVERDLLEPSPADQLG                               NGHERTESEMSARIAKMSLSPSSPRHEDQLEV                               TREPARRLFLFGEEPSKLDQDVLAALECADV                               DPHQFPAVHRWKSAVLCYSPSDRQSWPSPAV                               KGRFKSQLPDLSGPHSYSPGRNSVAGSNPAKP                               GLGSPGRYSPVHGSQLRRMARLAELAAL               890   2240   A   7711   360   269   RHMPVIPALWEAEVGGLLEPRSSRSAWATE               891   2241   A   7721   61   1175   KLPWEPSFLIKMQIIRHSEQTLKTALISKNPVL                               VSQYEKLDAGEQRLMNEAFQPASDLFGPITL                               HSPSDWITSHPEAPQDFEQFFSDPYRKTPSPN                               KRSTYIQSIGSLGNTRIISEEYIKWLTGYCKAYF                               YGLRVKLLEPVPVSVTRCSFRVNENTHNLQIH                               AGDILKFLKKKKPEDAFCVVGITMIDLYPRDS                               WNFVFGQASLTDGVGIFSFARYGSDFYSMHY                               KGKVKKLKKTSSSDYSIFDNYYIPEITSVLLLR                               SCKTLTHEIGHIFGLRHCQWLACLMQGSNHL                               EEADRRPLNLCPICLHKLQCAVGFSIVERYKA                               LVRWIDDESSDTPGATPEIISHEDNGNLPKPV                               EAFKEWKEWIIKCLAVLQK               892   2242   A   7723   2   1650   SAPTAFARPCRAERGSGGGMLALLAASVALA                               VAAGAQDSPAPGSRFVCTAIYPEAVHAGCPL                               PAMPMQGGAQSPEEELRAAVLQLRETVVQQ                               KETLASARAIRELTGKLARCEGLAGGKARGA                               GATGKDTMGDLPRDPGHVVEQLSRSLQTLK                               DRLESLEPLPAMPMQGGAQSPEEELRAAVLQ                               LRETVVQQKETLASARAIRELTGKLARCEGL                               AGGKARGAQATGKDTMGDLPRDPGHVVEQ                               LSRSLQTLKDRLESLEHQLRANVSNAGLPGD                               FREVLQQRLGELERQLLRKGAELEDEKSLLH                               NETSAHRQKTESTLNALLQRVIELERGNSAF                               KSPNAFKVSLPLRTNYLYGKIKKTLPELYAFT                               ICLWLRSSASPGMGTPFSYAVPGQANEIVLIE                               WGNNPIELLINDKVAQLPLFVSDGKWHHICV                               TWTTRDGMWEAFQDGKKLGTGENLAPWHPI                               KPGGVLILGQEQDTVGGRFDATQAFVGELSQ                               PNIWDRVLRAQEWNIANCSTNMPGNIIPWVD                               NNVDVFGGASKWPVETCEERLLDL               893   2243   A   7729   3554   2419   LTAGTAMNYPLTLEMDLENLEDLFWELDRL                               DNYNDTSLVENHLCFATEGPLMASFKAVFVP                               VAYSLIFLLGVIGNVLVLVILERHRQTRSSTET                               FLFHLAVADLLLVFILPFAVAEGSVGWVLGTF                               LCKTVIALHKVNFYCSSLLLACIAVDRYLAIV                               HAVHAYRHRRLLSIHITCGTIWLVGFLLALPEI                               LFAKVSQGHHNNSLPRGTFSQENQAETHAWF                               TSRFLYHVAGPLLPMLVMGWCYVGVVHRLR                               QAQRRPQRQKAVRVAILVTSIFFLCWSPYHIV                               IFLDTLARLKAVDNTCKLNGSLPVAITMCEFL                               GLAHCCLNPMLYTFAGVICFRSDLSRLLTKLG                               CTGPASLCQLFPSWRRSSLSESENATSLTTF               894   2244   A   7738   670   287   FVTRAGRWGAGARVRGGAGGMASGAARWL                               VLAPVRSC3ALRSGPSLRKDGDVSAAWSGSGR                               SLVPSRSVIVTRSGAILPKPVKMSFGLLRVFSI                               VIPFLYVGTLISKNFAALLEEHDIFVPEDDDDD                               D               895   2245   A   7753   119   278   APYAHSQVHCLDKVCGLLPFLNPEVPDQFYR                               LWLSLFLHAGKEAPHCPRTRPL               896   2246   A   7754   1   372   SPAWWNSQQRVVSPFLALLTLEPTFHHLLPIM                               QVSTAALAVLLCTMALCNQVLSAPLAADTPT                               ACCFSYTSRQIPQNFIADYFETSSQCSKPSVIFL                               TKRGRQVCADPSEEWVQKYVSDLELSA               897   2247   A   7761   1725   445   RPRRRGTHHFSCVLGSFRVSAMFPRVSTFLPL                               RPLSRHPLSSGSPETSAAAIMLLTVRHGTVRY                               RSSALLARTKNNIQRYFGTNSVICSKKDKQSV                               RTEETSKETSESQDSEKENTKKDLLGILKGMK                               VELSTVNVRTTKPPKRRPLKSLEATLGRLRRA                               TEYAPKKRIEPLSPELVAAASAVADSLPFDKQ                               TTKSELLSQLQQHEEESRAQRDAKRPKISFSNI                               ISDMKVARSATARVRSRPELRIQFDEGYDNYP                               GQEKTDDLKKRKNIFTGKRLNIFDMMAVTKE                               APETDTSPSLWDVEFAKQLATVNEQPLQNGF                               EELIQWTKEGKLWEFPINNEAGFDDDGSEFH                               EHIFLEKHLESFPKQGPIRHFMELVTCGLSKNP                               YLSVKQKVEHIEWPRNYFNEKKDILKESNIQF                               KLRPWKFLFRNN               898   2248   A   7775   85   496   SCQITQPPAQSCSTGTMRIMLLFTAILAFSLA                               QSFGAVCKEPQEEVVPGGGRSKRDPDLYQLL                               QRLFKSHSSLEGLLKALSQASTDPKESTSPEK                               RDMIHDFFVGLMGKRSVQPDSPTDVNQENVP                               SFGILKYPPRAE               899   2249   A   7785   179   703   PFHLGASSNTFRLQVQTQESKAQKEVKMGFI                               FSKSMNESMKNQKEFMLMNARLQLERQLIM                               QSEMRERQMAMQIAWSREPLKYFGTFFGLA                               AISLTAGAIICIKKKPAFLVPIVPLSFILTYQYDL                               GYGTLLERMKGEAEDILETEKSKLQLPRGMIT                               FESIEKARKEQSRFFIDK               900   2250   A   7789   1465   300   VWLPLKSYKIRSPSLHCQCEIFREEFLFSSLQE                               GRDKDTFSKMAMVSEFLKQAWFIENEEQEY                               VQTVKSSKGGPGSAVSPYPTFNPSSDVAALH                               KAIMVKGVDEATIIDILTKRNNAQRQQIKAAY                               LQETGKPLDETLKKALTGHLEEVVLALLKTP                               AQFDADELRAAMKGLGTDEDTLIEILASRTN                               KEIRDLNRVYREELKRDLAKDITSDTSGDFRN                               ALLSLAKGDRSEDFGVNEDLADSDARALYEA                               GERRKGTDVNVFNTILTTRSYPQLRRVFQKY                               TKYSKHDMNKVLDLELKGDIEKCLTAIVKCA                               TSKPAFFAEKLHQAMKGVGTRHKALIRIMVS                               RSEIDMNDIKAFYQKMYGISLCQAILDETKGD                               YEKILVALCGGN               901   2251   A   7796   2   807   VEFHPQRARAGARAPSMGVLLTQRTLLSLVL                               ALLFPSMASMAAIGSCSKEYRVLLGQLQKQT                               DLMQDTSRLLDPYIRIQGLDVPKLREHCRERP                               GAFPSEETLRGLGRRCFLQTLNATLGCVLHRL                               ADLEQRLPKAQDLERSGLNIEDLEKLQMARP                               NILGLRNNIYCMAQLLDNSDTAEPTKAGRGA                               SQPPTPTPASDAFQRKLEGCRFLHGYHRFMH                               SVGRVPSKWGESPNRSRRHSPHQALRKGVRR                               TRPSRKGKRLMTRGQLPR               902   2252   A   7802   2   721   TAARRRQKGTAARRLQKGTAARRRQKGTAA                               RRRQKGTAARRPQKGTAARRRQKCITAARRR                               QKGTAARRRQKGTAARRPQKGTAARRRQKG                               TAARRRQKGTAARRRQKGLAIASRGCPCASR                               AGGVRGAGSRLRAMAPKVFRQYWDIPDGTD                               CHRKAYSTTSIASVAGLTAAAYRVTLNPPGTF                               LEGVAKVGQYTFTAAAVGAVFGLTTCISAHV                               REKPDDPLNYFLGGCAGGLTLGARTHNYGIG                               AAACVYFGLAASLVKMGRLEGWEVFAKPKV               903   2253   A   7807   1   584   PWLPWSDGRAARSSRKCPRSRFPVQVGKMA                               VSTVFSTSSLIVWALSR1SLLSPLLSVTSFRRFY                               RGDSPTDSQKDMIEWLPPWQERTDESIETKR                               ARLLYESPKRGMLENCILLSLFAKEHLQHMT                               EKQLNLYDRLINEPSNDWDIYYWATEAKPAP                               EIFENEVMALLRDFAKNKEQRLRAPDLEY                               LFEKPR               904   2254   A   7813   40   821   GAGRLGHLETGAGDVAAALPARKSLLG                               AGARLTGWTMNVFRILGDLSHLLAMILLLGK                               IWRSKCCKGLSGKSQILFALVFTTRYLDLFTNF                               ISIYNTVMKVVFLLCAYVTVYMIYGKFRKTF                               DSENDTFRLEFLLVPVIGLSFLENTSFTLLEIL                               WTFSIYLESVAILPQLFMISKTGEAETTTTHYL                               FFLGLYRALYLANWIRRYQTENFYDQIAVVS                               GVVQTIFYCDFFYLYVTKGRSWDDSNADTGL                               RSYSSI               905   2255   A   7817   1399   881   LSNKDVLSPQLKDENSKLRRKLNEYQSFSEA                               QTEMVRTLERKLEAKMIKEESDYHDLESVVQ                               QVEQNLELMTKRAVKAENHVVKLKQEISLL                               QAQVSNFQRENEALRCGQGASLTVVKQNAD                               VALQNLRVVMNSAQASIEQLVSGAETLVA                               EILKSIDRISEVKDEEEDS               906   2256   A   7822   3   1462   DSPRRFELGRPRTPTRPGPRPAMEDLDAL                               LSDLETTTSHWRSGAPKERPAEPLTPPPSYG                               HQPQTGSGESSGASGDKDHLYSTVCKPRSPK                               PAAPAAPPFSSSSGVLGTGLCELDRLLQELNA                               TQFNITDEIMSQFPSSKVASGEQKEDQSEDKK                               RPSLPSSPSPGLPKASATSATLELDRLMASLSD                               FRVQNHLPASGPTQPPVVSSTNEGSPSPPEPTG                               KGSLDTMLGLLQSDLSRRGVPTQIAKGLCGSC                               NKPIAGQVVTALGRAWHPEHFVCGGCSTAL                               GGSSFFEKDGAPFCPECYFERFSPRCGFCNQPI                               RHKMVTALGTHWHPEHFCCVSCGEPFGDEG                               FHEREGRPYCREDFLQLFAPRCQGCQGPILDN                               YISALSALWHPDCFVCRECFAPFSGGSFFEHE                               GRPLCENHPHARRGSLCATCGLPVTGRCVSA                               LGRFHPDHFTCTFCLRPLTKGSFQERAGKPY                               CQPCFLKLFG               907   2257   A   7828   1792   1671   FIYVNQSFAPSPDQEVGTLYECFGSDGKLVLH                               YCKSQAWG               908   2258   A   7842   110   1172   KLSCPCSHGTRVTAVRGPRLKAGVQWHDLQ                               SLQPPPSGLKQSSHLSLSSSWDFRHAPTHPET                               YTCPKMIEMEQAEAQLAELDLLASMFPGENE                               LPNDQLAVAELKDCEKKTMEGRSSSKVYFTII                               NMNLDVSDEKMAMFSLACILPFKYPAVLPEI                               TVRSVLLSRSQQTQLNTDLTAFLQKHCHGDV                               CLNATEWREHASGYVSRDTSSSPTTGSTVQ                               SVDLIFTRLWIYSHYNKCKRKNILEWAKEL                               SLSGFSMGKPGVVCVEGPQSACEEFWARLR                               KLNWKRILIRHREDIPFDGTNDETERQRKSIF                               EEKFSVNGARGNHMDFGQLYQFLNTKGCG                               DVFQMFLWV               909   2259   A   7870   3067   2923   EGLCVYTFTYVHMYTRTCMRTYPYMYMNSV                               LISSEILLIPSKYLFESK               910   2260   A   7884   212   4874   GALTWSHPLLAVCPQGVWLGSTPSGSPALLP                               PSHRVNAEPGCVVTNACASGPCPPHANCRDL                               WQTFSCTCQPGYYGPGCVDACLLNPCQNQG                               SCRHLPGAPHGYTCDCVGGYFGHHCEHRMD                               QQPRGWWGSPTCGPCNCDVHKGFDPNCNK                               TNGQCHCKEFHYRPRGSDSCLPCDCYPVGST                               SRSCAPHSGQCPCRPGALGRQCNSCDSPFAEV                               TASGCRVLYDACPKSLRSGVWWPQTKFGVL                               ATVPCPRGALGLRGAGAAVRLCDEAQGWLE                               PDLFNCTSPAFRELSLLLDGLELNKTALDTME                               AKICLAQRLREVTGHTDHYFSQDVRVTARLL                               AHLLAFESHQQGFGLTATQDAHFNENLLWA                               GSALLAPETGDLWAALGQRAPGGSPGSAGLV                               RHLEEYAATLARNMELTYLNPMGLVTPNIML                               SIDRMEHPSSPRGARRYPRYHSNLPRGQDAW                               DPHTHVLLPSQSPRPSPSEVLPTSSSIENSTTSS                               VVPPPAPPEPEPGISIIILLVYRTLGGLLPAQFQ                               AERRGARLPQNPVMNSPVVSVAVFHGRI*IFLR                               GILESPISLEFRLLQTANRSKAICVQWDPPGLA                               EQHGVWTARDCELVHRNGSHARCRCSRTGT                               FGVLMDASPRERLEGDLELLAVFTHVVVAVS                               VAALVLTAAILLSLRSLKSNVRGIHANVAAA                               LGVAELLFLLGIHRTHNQLVCTAVVILLHYPF                               LSTFAWLFVQGLHLYRMQVEPRNVDRGAMR                               FYHALGWGVPAVLLGLAVGLDPEGYGNPDF                               CWISVHEPLIWSFAGPVVLVIVMNGTMFLLA                               ARTSCSTGQREAKKTSALTLRSSFLLLLLVSA                               SWLFGLLAVNHSILAFHYLHAGLCGLQGLAV                               LLLFCVLNADARAAWMPACLGRKAAPEEAR                               PAPGLGPGAYNNTALFEESGLIRITLGASTVSS                               VSSARSGRTQDQDSQRGRSYLRDNVLVRHGS                               AADHTDHSLQAHAGPTDLDVAMFHRDAGA                               DSDSDSDLSLEEERSLSIPSSESEDNGRTRGRF                               QRPLCRAAQSERLLTHPKDVDGNDLLSYWPA                               LGECEAAPCALQTWGSELGLDTSKDAAN                               NNQPDPALTSQDETSLGRAQRQRKGILKNRL                               QYPLVPQTRGAPELSWCRAATLGHRAVPAAS                               YGRAGGGTGSLSQPASRYSSREQLDLLLRR                               QLSRERLEEAPAPVLRPLSRPGSQECMDAAPG                               RLEPKDRGSTLPRRQPPRDYGAMAGRFGSR                               DALDLGAPREWLSTLPPPRRTRDLDPQPPPLP                               LSPQRQLSRDPLLPSRPLDSLSRSNSEEQLDQ                               VPSRHPSREALGPLPQLLRAREDSVSGPSHGP                               STEQLDILSSILASFNSSALSSVQSSSTPLGPHT                               TATPSATASVLGPSTPRSATSHSISELSPDSEPR                               DTQALLSATQAMDLRRRDYHMERPLLNQEH                               LEELGRWGSAPRTHQWRTWLQCSRARAYAL                               LLQHLPVLVWLPRYPVRDWLLGDLLSGLSVA                               IMQLPQGLAYALLAGLPPVFGLYSSFYPVFLY                               FLFGTSRHISVESLCVPGPVDT               911   2261   A   7890   21   806   EFGTSRSSRSMAEDLGLSFGETASVEMLPEHG                               SCRPKARSSSARWALTCCLVLLFFLAGLTTYL                               LVSQLRAQGEACVQFQALKGQEFAPSHQQV                               YAPLRADGDKPRAHLTVVRQTPTQHFKNQFP                               ALHWEHELGLAFTKNRMNYTNKFLLIPESGD                               YFIYSQVTPRGMTSECSEIRQAGRPNKPDSITV                               VITKVTDSYPEPTQLLMGTKSVCEVGSNWFQ                               PIYLGAMFSLQEGDKLMVNVSDISLVDYTKE                               DKTFFGAFLL               912   2262   A   7891   1263   111   ACGIRHEGALPGLTATPEAMLRFLPDLAFSFL                               LILALGQAVQFQEYVFLQFLGLDKAPSPQKFQ                               PVPYILKIUFQDREAAATTGVSRDLCYVKELG                               VRGNVLRFLPDQGFFLYPKKISQASSCLQKLL                               YFNLSAIKEREQLTLAQLGLDLGPNSYYNLGP                               ELELALFLVQEPHVWGQTTPICPGKMFVLRSV                               PWPQGAVHFNLLDVAKDWNDNPRKNFGLFL                               EILVKEDRDSGVNFQPEDTCARLRCSLHASLL                               VVTLNPDQCHPSRKRRAAIPVPKLSCKNLCH                               RHQLFINFRDLGWHKWIIAPKGFMANYCHGE                               CPFSLTISLNSSNYAFMQALMIIAVDPEIPQAV                               CIPTKLSPISMLYQDNNDNVILRHYEDMVVD                               ECGCG               913   2263   A   7892   15   849   ASRLPRGPGCGADMRPLLGLLLVFAGCTFAL                               YLLSTRLPRGRRLGSTEEAGGRSLWFPSDLAE                               LRELSEVLREYRKEHQAYVFLLFCGAYLYKQ                               GFAIPGSSFLNVLAGALFGPWLGLLLCCVLTS                               VGATCCYLLSSIFGKQLVVSYFPDKVALLQR                               KVEENRNSLFFFLLFLRLFPMTPIIWFLNLSAPI                               LNIPIVQFFFSVLIGLIPYNFICVQTGSLLSTLTS                               LDALFSWDTVFKLLAIAMVALIPGTLIKKFSQ                               KHLQLNETSTANHIHSRKDT               914   2264   A   7893   815   959   KSGWVWWLTPLIPALWEAQTEGSLRPEVKN                               RLSNITRPFFSKKKKILV               915   2265   A   7909   3   641   HASGPGGLLRRRRGSGANMPVARSWVCRKT                               YVTPRRPFEKSRLDQELKLIGEYGLRNKREV                               WRVKFTLAKIRKAARELLTLDEKDPRRIFEG                               NALLRRLVRIGVLDEGKMKLDYILGLKIEDFL                               ERRLQTQVFKLGLAKSIHHAHVLIQQCHIRVR                               EQVVNTLFFTVRLDSQKHIDFSLCFPIGVANPS                               HVKRKNASKGQGGAGARDDEEEE               916   2266   A   7914   3   967   VAHTQWHTCQRLSQLTHRSILKYLLIDTHAC                               QVLILKHTHASLSLPSCQECFPSSIPSASHMVS                               HPHPPPSPRWGQTPEGLPAASPCGPGPRSCFS                               SILPTGDSWGMLACLCTVLWHLPAVPALNRT                               GDPGPGPSIQKTYDLTRYLEHQLRSLAGTYLN                               YLGPPFNEPDFNPPRLGAETLPRATVDLEVW                               RSLNDKLRLTQNYEAYSHLLCYLRGLNRQAA                               TAELRRSLAIIFGTSLQGLLGSIAGVMAALGY                               PLPQPLPGTEPTWTPGPAHSDFLQKMDDFWL                               LKELQTWLWRSAKDFNRLKKKMQPPAAAVT                               LHLGAHGF               917   2267   A   7921   2   1166   RPRRGQGLVQEVQTENVTVAEGGVAEITCRL                               HQYDGSIVVIQNPARQTLFFNGTRALKDERFQ                               LEEFSPRRVRIRLSDARLEDEGGYFCQLYTED                               THHQIATLTVLVAPENPVVEVREQAVEGGEV                               ELSCLVPRSRPAATLRWYRDRKELKGVSSSQ                               ENGKVWSVASTVRFRVDRKDDGGIIICEAQN                               QALPSGHSKQTQYVLDVQYSPTARIHASQAV                               VREGDTLVLTCAVTGNPRPNQIRWNRGNESL                               PERAEAVGETLTLPGLVSADNGTYTCEASNK                               HGHARALYVLVVYGESRLRPTEGGGGAPDP                               GAVVEAQTSVPYAIVGGILALLVFLIICVLVG                               MVWCSVRQKGSYLTIIEASGLDEQGEAREAF                               LNGSDGHKRKEEPFI               918   2268   A   7938   3   2653   RRRLPPASPPSSSVSSSLSPSAVVMACRWSTK                               ESPRWRSALLLLFLAGVYGNGALAEHSENVH                               ISGVSTACGETPEQIRAPSGIITSPGWPSEYPAK                               INCSWFIRANPGEIITISFQDFDIQGSRRCNLD                               WLTIETYKNIESYRACGSTIPPPYISSQDHIWIR                               FHSDDNISRKGPRLAVFSGKSEEPNCACDQFR                               CGNGKCIPEAWKCNNMDECGDRSDEEICAKE                               ANPPTAAAFQPCAYNQFQCLSRFTKVYTCLP                               ESLKCDGNIDGLDLGDEIDCDVPTCGQWLKY                               FYGTFNSPNYPDFYPPGSNCTWLIDTGDHEK                               VILRFTDFKLDGTGYGDYVKIYDGLEENPHK                               LLRVLTAFDSHAPLTVVSSSGQIRVHFCADKV                               NAARGFNATYQVDGFCLPWEIPCGGNWGCY                               TEQQRCDGYWHCPNGRDETNCTMCQKEEFP                               CSRNGVCYPRSDRCNYQNHCPNGSDEKNCFF                               CQPGNFHCKNNRCVFESWVCDSQDDCGDGS                               DEENCPVIVPTRVITAAVIGSLICGLLLVIALG                               CTCKLYSLRMFERRSFETQLSRVEAELLRREA                               PPSYGQLIAQGLIPPVEDFPVCSPNQASVLENL                               RLAVRSQLGFTSVRLPMAGRSSNIWNRIFNFA                               RSRHSGSLALVSADGDEVVPSQSTSREPERNH                               THRSLFSVESDDTDTENERRDMAGASGGVAA                               PLPQKVPPTTAVEATVGACASSSTQSTRGGH                               ADNGRDVTSVEPPSVSPARHQLTSALSRMTQ                               GLRWVRFTLGRSSSLSQNQSPLRQLDNGVSG                               REDDDDVEMLIPISDGSSDFDVNDCSRPLLDL                               ASDQGQGLRQPYNATNPGVRPSNRDGPCERC                               GIVHTAQIPDTCLEVTLKNETSDDEALLLC               919   2269   A   7951   1674   1839   VVRVTCCPPARSTTERTNAYDEEDCVEMVAS                               GGWNDVACHTTMYFMCEFDKKNM               920   2270   A   7953   47   572   GGRASWPEQAKEPRREGHTDKQQTEDVLAA                               GLRCLPHLPAICARRMSPAFRAMDVEPRAKG                               VLLEPFVHQVGGHSCVLRFNETTLCKPLVPRE                               HQFYETLPAEMRKIFTPQYKGKSQLLEGLPHW                               RGDVRDRGHGRPWQPSLEPSLPPTLCFPSLSS                               FSSSWPSAQHLTPSVFNPW               921   2271   A   7957   612   812   RSGRTVVTGIGYSKALQSSNRNTKSLLQNEF                               MMVYSFRALSFKESTWATFQHGGEATKSRSL                               SSTQ               922   2272   A   7967   1443   1660   ENITEKWKEIWMCRGNKKSCCWTFIKDRHLT                               VSCCKSKSGETLLICIFCSNLVGFFFFGIRGFSN                               WELVKPN               923   2273   A   7981   1   3023   GSAPRAATAMARARPPPPPSPPPGLLPLLPPLL                               LLPLLLLPAGCRALEETLMDTKWVTSELAWT                               SHPESGWEEVSGYDEAMNPIRTYQVCNVRES                               SQNNWLRTGFIWRRDVQRVYVELKFTVRDC                               NSIPNTPGSCKETFNLFYYEADSDVASASSPFW                               MENPYVKVDTIAFDESFSRLDAGRVNTKVRS                               FGPLSKAGPYLAFQDQGACMSLISVRAFYKK                               CASTTAGFALFPETLTGAEPTSLVIAPGTCIPN                               AVEVSVPLKLYCNGDGEWMVPVGACTCATG                               HEPAAKESQCRPCPPGSYKAKQGEGPCLPCPP                               NSRTTSPAASICTCHNNPYRADSDSADSACTT                               VPSPPRGVISNVNETSLILEWSEPRDLGVRDD                               LLYNYICKKCHGAGGASACSRCDDNVEFVPR                               QLGLSEPRVHTSHLLAHTRYTFEVQAVNGVS                               GKSPLPPRYAAVNITTNQAAPSEVPTLRLHSS                               SGSSLTLSWAPPERPNGVILDYEMKYFEKSEG                               IASTVTSQMNSVQLDGLRPDARYVVQVRART                               VAGYGQYSRPAEFETTSERGSGAQQLQEQLP                               LIVGSATAGLVFVVAVVVIAIVGLRKQRLHGS                               DSEYTEKLQQYIAPGMKVYIDPFTYEDPNEA                               VREFAKEIDVSCVKIEEVIGAGEFGEVCRGRL                               KQPGRREVFVAIKTLKVGYTERQRRDFLSEA                               SNGQFDHPNIIRLEGVVTKSRPVMILTEFME                               NCALDSFLRLNDGQFTVIQLVGMLRGIAAGM                               KYLSEMNYVHRDLAARNILVNSNLVCKVSDF                               GLSRFLEDDPSDPTYTSSLGGKIPIRWTAPEAI                               AYRKFTSASDVWSYGIVMWEVMSYGERPY                               WDMSNQDVINAVEQDYLPPPMDCPTALHQ                               LMLDCWVDRNLRPKFSQIVNTLDKLIRNAA                               SLKVIASAQSGMSQPLLDRTVPDYTTFTTVGD                               WLDAIKMGRYKESFVSAGFASFDLVAQMTA                               EDLLRIGVTLAGHQKLSSIQDMRLQMNQT                               LPVQV               924   2274   A   7985   1   503   FRPRTKKATAMYLEIIYLDSIENLPGELQRNF                               QLMRELDQRTEDKKAEIDTLAAEYISTVKTLS                               PDQRVERLQKIQNAYSKCKEYSDDKVQLAM                               QTYEMVDKHIRRLDADLARFEADLKDKMEG                               SDFESSGGRGLKKGRGQKEKRGSRGRGRRTS                               EEDTPKKKKHKGG               925   2275   A   7994   447   589   LPCSFCAQCMSSFER\LQQSHFNPRWNSR                               SPIRCYCQHWPHCVHC               926   2276   A   7996   925   582   GPCKVCCITLALQCHSFYRKDVQVEHPKS                               LNPKYSQIENFLSADMALKRKCLLSISDLDFW                               IWDAQPVGIMQTLQNLKKIPNPGCFWSQAFQI                               RDTQPILPLGGRYYITIRQ               927   2277   A   7998   2   353   RIQRPLNSRSPNHSLFVKAELTAKQATMKLSV                               CLLLVTLALCCYQANAEFGPALVSELLDFFFI                               SEPLFKLSLAKFDAPPEAVAAGVKRCTDQ                               MSLQKRSLIAEVLYKILKKCSV               928   2278   A   8004   130   588   LAPLRCQPGTRTQPRSHPAANDPSAAMSAAG                               ARGLRATYHRLLDKVELMLPEKLRPLYNHPA                               GPRTVFFWAPIMKWGLVCAGLADMARPAEK                               LSTAQSAVLMATGFIWSRYSLVIIPKNWSLFA                               VNFFVGAAGASQLFRIWRYNQELKAKAHK               929   2279   A   8007   2   1016   EFARRRVFIAAREMSLLRSLRVFLVARTGSYP                               AGSLLRQSPQPRHTFYAGPRLSASASSKELLM                               KLRRKTGYSFVNCKKALETCGGDLKQAEIWL                               HKEAQKEGWSKAAKLQGRKTKEGLIGLLQE                               GNTTVLVEVNCETDFVSRNLKFQLLVQQVAL                               GTMMHCQTLKDQPSAYSKGFLNSSELSGLPA                               GPDREGSLKDQLALAIGKLGENMILKRAAWV                               KVPSGFYVGSYVHGAMQSPSLHKLVLGKYG                               ALVICETSEQKTNLEDVGRRLGQHVVGMAPL                               SVGSLDDEPGGEAETKMLSQPYLLDPSITLGQ                               YVQPQGVSVVDFVRFECGEGEEAAETE               930   2280   A   8008   3   1679   NSRVWGPWTEPSAGSLRPMAKQNRNSKEL                               GLVPLTDDTSHAGPPGPGRALLECDHLRSGV                               PGGRRRKDWSCSLLVASLAGAFGSSFLYGYN                               LSVVNAPTPYIKAFNESWERRHGRPIDPDTL                               TLLWSVTVSIFAIGGLVGTLIVKMIGKVLGRK                               HTLLANNGFAISAALLMACSLQAGAFEMLW                               GRFTMGIDGGVALSVLPMYLSEISPKEIRGSLG                               QVTAIFICIGVFTGQLLGLPELLGKESTWPYLF                               GVIVVPAVVQLLSLPFLPDSPRYLLLEKHNEA                               RAVKAFQTFLGKADVSQEVEEVLAESRVQRS                               IRIVSVLELLRAPYVRWQVVTVIVTMACYQL                               CGLNAFYTNSIFGKAGIPPAKIPYVTLSTGG                               IETLAAVFSGLVIEHLGRRPLLIGGFGLMGLFF                               GTLTTTLTLQDHAPWVPYLSIVGILAIIASFCSG                               PGGIPFLTGEFFQQSQRPAAFIIAGTVNWLSN                               FAVGLLFPFIQKSLDTYCFLVFATICITTGAIYL                               YFVLPETKNRTYAEISQAFSKRNKAYPPEEKI                               DSAVTDGKINGRP               931   2281   A   8009   861   300   AAGAVVSAPKAKGKTRRQKFGYSVNRKRL                               NRNARRKAAPRIECSHIRHAWDHAKSVRQNL                               AEMGLAVDPNRAVPLRKRKVKAMEVDIEER                               PKELVRKPYVLNDLEAEASLPEKKGNTLSRD                               LIDYVRYMVENHGEDYKAMARDEKNYYQD                               TPKQIRSKINVYKRFYPAEWQDFLDSLQKRK                               MEVE               932   2282   A   8011   412   1   SNLCLGNSWRWRWAKSRHHCIPTVTLSKRSG                               DIRGSHFSSPQRQRSQRVPGKETARVLRAGK                               QGRGQIPIPCPWPPPPPPPPPGSPGPGCRQFHQ                               SLEAKARIIPASVREMRGKVKMRRALRRAPA                               STRASSRQPNPK               933   2283   A   8012   147   1077   PPVPPASRSDMAQNLKDLAGRLPAGPRGMGT                               ALKLLLGAGAVAYGVRESVFTVEGGHRAIFF                               NRIGGVQQDTILAEGLHFRIPWFQYPIIYDIRA                               RPRKISSPTGSKDLQMVNISLRVLSRPNAQEL                               PSMYQRLGLDYEERVLPSIVNEVLKSVVAKF                               NASQLITQRAQVSLLIRRELTERAKDFSLILDD                               VAITELSFSREYTAAVEAKQVAQQEAQRAQF                               LVEKAKQEQRQKIVQAEGEAEAAKMLGEAL                               SKNPGYIKLRKIRAAQNISKTIATSQNRIYLTA                               DNLVLNLQDESFTRGSDSLIKGICK               934   2284   A   8023   255   982   SQFSLSQVLVDSAEEGSLAAAAELAAQKREQ                               RLRKFRELHLMRNEARKLNHQEVVEEDKRL                               KLPANWEAKKARLEWELKEEEKKKECAARG                               EDYEKVKLLEISAEDAERWERKKKRKNPDLG                               FSDYAAAQLRQYHRLTKQLKPDMETYERLRIE                               KHGEEFFPTSNSLLHGTHVPSTEEIDRMVIDLE                               KQIEKRDKYSRRRPYNDDADIDYNERNAKF                               NKKAERFYGKYTAEIKQNLERGTAV               935   2285   A   8027   59   310   LVSSTVNLLTEKAPWNSLAWTVTSYVFLKFL                               QGGGTGSTGMRDSALTLLGIGPSHRHSLSLRL                               SQHSSPAPMYSQTFHIINLG               936   2286   A   8032   1   639   SGRECNMAKTYDYLFKLLLIGDSGVGKTCVL                               FRFSEDAFNSTPISTIGIDFKIRTIELDGKPIKLQ                               IWDTAGQERFRTITTAYYRGAMGIMLVYDIT                               NEKSFDNIRNWIRNLEEHASADVEKMILGNKC                               DVNDKRQVSKERGEKLALDYGIKFMETSAK                               ANINWENAFFTLARDIKAKMDKKLEGNSPQG                               SNQGVKITPDQQKRSSFFRCVLL               937   2287   A   8039   393   311   EETIHSENSYILEKYIPISANLTLTIA               938   2288   A   8052   675   1334   LHPAATSTAWLHVPPQLSMALSWVLTVLSLL                               PLLEAQIPLCANLVPVPITNATLDRITGKWFYI                               ASAFRNEEYNKSVQEIQATFFYFTPNKTEDTIF                               LREYQTRQDQCIYNTTYLNVQRENGTLSRYV                               GGQEHFAHLLILRDTKTYMLAFDVNDEKNW                               GLSVYADKPET1TKEQLGEFYEALDCLRIPKSD                               VVYTDWKKDKCEPLEKQHEKERKQEEGES               939   2289   A   8055   12   1039   SSVAEFPERVQLSQPQNWNFSGAGGAWSLDF                               AEQLKWSAELARLGESTMDGKQGGMDGSKP                               AGPRDFPGIRLLSNPLMGDAVSDWSPMHEAA                               IHGHQLSLRNLISQGWAVNIITADHVSPLHEA                               CLGGHLSCVKILLKHGAQVNGVTADWHTPL                               FNACVSGSWDCVNLLLQHGASVQPESDLASP                               IHEAARRGHVECVNSLIAYGGNIDHKISIILGT                               PLYLACENQQRACVKKLLESGADVNQGKGQ                               DSPLHAVARTASEELACLLMDFGADTQAKN                               AEGKRPVELVPPESPLAQLFLEREQPPSLMQL                               CRLRIRKCFGIQQHHKITKLVLPEDLKQFLLH                               L               940   2290   A   8058   2   1203   KVLSIREPAHSTARKASEPSQPSQPSQPGGHLI                               ARLRTMDLHLFDYSEPGNFSDISWPCNSSDCI                               VVDTVMCPNMPNKSVLLYTLSFIYIFIFVIGMI                               ANSVVVWVNIQAKTTGYDTHCYILNLAIADL                               WVVLTIPVWVVSLVQIINQWPMGELTCKVTH                               LIPSINLFGSIFFLTCMSVDRYLSITYFTNTPSS                               RKKMVRRVVCILVWLLAFCVSLPDTYYLKT                               VTSASNNETYCRSFYPEHSIKEWLIGMELVSV                               VLGFAVPFSIIAVFYFLLARAISASSDQEKHSS                               RKIIFSYVVVFLVCWLPYHVAVLLDIFSILHYI                               PFTCRLEHALFTALHVTQCLSLVHCCVNPVL                               YSFINRNYRYELMKAFIFKYSAKTGLTKLTDA                               SRVSETEYSALEQSTK               941   2291   A   8059   73   432   DMAGLMTIVTSLLFLGVCAHHIIPTGSVVLPS                               PCCMFFVSKRIPENRVVSYQLSSRSTCLKAGV                               IFITKKGQQFGGDPKQEWVQRYMKNLDAKQ                               KKASPRARAVAVKGPVQRYPGNQTTC               942   2292   A   8067   278   1262   GGIGEIKQRPSCLGRCLDPSLSVLMNISLGLGS                               VFSAVISQKPSRDICQRGTSLTIQCQVDSQVT                               MMFWYRQQPGQSLTLIATANQGSEATYESGF                               VIDKFPISRPNLTFSTLTVSNMSPEDSSIYLCSA                               GRQGTYEQYFGPGTRLTVTEDLKNVFPPEVA                               VPEPSEAEISHTQKATLVCLATGFYPDHVELS                               WWVNGKEVHSGVSTDPQPLKEQPALNDSRY                               CLSSRLRVSATFWQNPRNHFRCQVQFYGLSE                               NDEWTQDRAKPVTQIVSAEAWGRADCGFTS                               ESYQQGVLSATILYEILLGKATLYAVLVSALV                               LMAMVKRKDSRG               943   2293   A   8070   1   879   MVKVVPATRGNLPRSQLTGTHQHCQPREPKI                               TASERLRRRPRATARLRAHAAPPEPPLAVFAP                               PSDRKELLALPVACDPVIASVMSWVQAASLI                               QGPGDKGDVFDEEADESLLAQREWQSNMQR                               RVKEGYRDGIDAGKAVTLQQGFNQGYKKGA                               EVILNYGRLRGTLSALLSWCHLHNNNSTLINK                               INNLLDAVGQCEEYVLKHLKSITPPSHYVDLL                               DSIEDMDLCHVVPAEKKIDEAKDERLCENNA                               EFNKNCSKSHSGIDCSYVECCRTQEHAHSGK                               PKPHMDFGTDSQF               944   2294   A   8073   1   797   ESARWSRQLRRTLIRLSFPISCGRSHAFGGCK                               MAATSGTDEPVSGELVSVAHALSLPAESYGN                               DPDIEMAWAMRAMQHAEVYYKLISSVDPQF                               LKLTKVDDQIYSEFRKNFETLIUDVLDPEELK                               SESAKEKWRPFCLKFNGIVEDFNYGTLLRLD                               CSQGYTEENTIFAPRIQFFAIEIARNREGYNKA                               VYISVQDKEGEKGVNNGGEKRADSGEEENT                               KNGGEKGADSGEEKEEGINREDKTDKGGEK                               GKEADKEINKSGEKAM               945   2295   A   8074   2   505   GAATLLRSASSAARKAAEAEQVWLHLHRYL                               SADRRVLGLREWGRPASERECSLCQRLKREL                               NMGDVEKGKKIFIMKCSQCHTVEKGGKHKT                               GPNLHGLFGRKTGQAPGYSYTAANKNKGUW                               GEDTLMEYLENPKKYIPGTKIVIIFVGIKKKEER                               ADLIAYLKKATNE               946   2296   A   8081   42   590   EGRRGKFGGKLCNFLFYFHSNSAESRMDVLF                               VAIFAVPLILGQEYEDEERLGEDEYYQVVYY                               YTVTPSYDDFSADFTIDYSIFESEDRLNRLDK                               DITEAIETTISLETARADHPKPVTVKPVTTEPQ                               SPRSEAMIPCPVLRSPIPLPPVRVPLFRWGCISC                               KKVGRRLLMTLWMGVWQEEIGR               947   2297   A   8084   322   549   GGGSSPRELAGAAGLTVTSQAVAARRQQPSF                               SRARAPAHSLRAALSLASSARSWGAVSIWRG                               PCPPAIMYQSSNKG               948   2298   E   8093   3905   846   MEPGEVKDRILENISLSVKKLQSYFAACEDEI                               PAIRNHDKVLQRLCEHLDHALLYGLQDLSSG                               YWVLVVHFTRREAIKQIEVLQHVATNLGRSR                               AWLYLALNENSLESYLRLFQENLGLLHKYYV                               KNALVCSHDHLTLFLTLVSGLEFIRFELDLDA                               PYLDLAFYMPDYYKPQYLLDFEDRLPSSVHG                               SDSLSLNSFNSVTSTNLEWDDSAIAPSSEDYD                               FGDVFPAVPSVPSTDWEDGDLTDTVSGPRST                               ASDLTSSKASTRSPTQRQNPFNEEPAETVSSS                               DTTPVHTTSQEKEEAQALDPPDACTELEVIRV                               TKKKKIGKKKKSRSDEEASPLHPACSQKKCA                               KQGDGDSRNGSPSLGRDSPDTMLASPQEEGE                               GPSSTPESSERSEPGLLIPEMKDTSMERLGQPL                               SKVIDQLNGQLDPSTWCSRAEPPDQSFRTGSP                               GDAPERPPLCDFSEGLSAPMDFYRFTVESPST                               VTSGGGHHDPAGLGQPLHVPSSPEAAGQEEE                               GGGGEGQTPRPLEDTTREAQELEAQLSLVRE                               GPVSEPEPGTQEVLCQLKRDQPSPCLSSAEDS                               GVDEGQGSPSEMVIISSEFRVDNNHLLLLMIH                               VFRENEEQLFKMIRMSTGHMEGNLQLLYVLL                               TDCYVYLLRKGATEKPYLVEEAVSYNELDY                               VSVGLDQQTVKLVCTNRRKQFLLDTADVAL                               AEFFLASLKSAMIKGCREPPYPSILTDATMEK                               LALAKFVAQESKCEASAVTVRFYGLVHWED                               PTDESLGPTPCHCSPPEGTITKEGMLHYKAGT                               SYLGKEHWKTCFVVLSNGILYQYPDRTDVIP                               LLSVNMGGEQCGGCRRANTTDRPHAFQVILS                               DPPCLELSAESEAEMAEWMQHLCQAVSKGVI                               PQGVAPSPCIPCCLVLTDDRLFTCHEDCQTSF                               FRSLGTAKLGDISAVSTEPGKEYCVLEFSQDS                               QQLLPPWVLYLSCTSELDRLLSALNSGWKTIY                               QVDLPHTAIQEASNKKKFEDALSLIHSAWQR                               SDSLCRCIRASRDPWC*               949   2299   A   8095   9   2374   ARRADTVLLESPSMLQGLLPVSLLLSVAVSAI                               KELPGVKKYEVVYPIELHPLHKREAKEPEQQ                               EQFETELKYKMTINGKIAVLYLKKNKNLLAP                               GYTETYYNSTGKEITTSPQIMDDCYYQGLIILN                               EKVSDASISTCRGLRGYFSQGDQRYFIEPLSPI                               HRDGQEHALFICYNPDEKNYDSTCGMDGVL                               WAHDLQQNIALPATKLVKLKDRKVQEHEKY                               IEYYLVLDNGEFKRYNENQDEIRKRVFEMAN                               YVNMLYKKLNTHVALVGMEIWTDKDKIKIT                               PNASFTLENFSKWRGSVLSRRKRHDIAQLITA                               TELAGTTVGLAFMSTMCSPYSVGVVQDHSD                               NLLRVAGTMAHEMGHNFGMFHDDYSCKCPS                               TICVMDKALSFYIPTDFSSCSRLSYDKFFEDKL                               SNCLFNAPLPTDIISTPICGNQLVEMGEDCDC                               GTSEECTNICCDAKTCKIKATFQCALGECCEK                               CQFKKAGMVCRPAKDECDLPEMGNGKSGNC                               PDDRFQVNGFPCHHGKGHCLMGTCPTLQEQ                               CTELWGPGTEVADKSCYNRNEGGSKYGYCR                               RVDDTLIPCKANDTMCGKLFCQGGSDNLPW                               KGRIVTFLTCKTFDPEDTSQEIGMVANGTKCG                               DNKVCINAECVDIEKAYKSTNCSSKCKGHAV                               CDHELQCQCEEGWIPPDCDDSSVVFHFSIVVG                               VLFVIAVIFVVVAMVIRHQSSREKQKKDQRP                               LSTTGTRPHKQKRKPQMVKAVQPQEMSQK                               PHVYDLPVEGNEPPASFHKDTNALPPTVFKD                               NPMSTPKDSNPKA               950   2300   A   8100   1   1251   MGLLLMILASAYLGSFLTLLAQFFLLYRRQPE                               PPADEAARAGEGFRYIKPVPGLLLREYLYGG                               GRDEEPSGAAPEGGATPTAAPETPAPPTRETC                               YFLNATILFLFRELRDTALTRRWVTKKIKVEF                               EELLQTKTAGRLLEGLSLRDVFLGETVPFIKTI                               RLVRPVVPSATGEPDGPEGEALPAACPEELAF                               EAEVEYNGGFHLAIDVDLVFGKSAYLFVKLS                               RVVGRLRLVFTRVPFTHWFFSFVEDPLIDFEV                               RSQFEGRPMPQLTSIIVNQLKKIIKRKHTLPNY                               KIRFKPFFPYQTLQGFEEDEEHIHIQQWALTE                               GRLKVTLLECSRLLIFGSYDREANVHCTLELS                               SSVWEEKQRSSIKTGTISLTAVFMGWHRVSE                               AFPGLWYKLLVDLPFWGLEDGGPLLTVPLRQ                               CPG               951   2301   A   8108   1612   839   EVALFCFEMAAGMYLEHYLDSIENLPFELQR                               NFQLMRDLDQRTEDLKAEIDKLATEYMSSAR                               SLSSEEKLALLKQIQEAYGKCKEFGDDKVQL                               AMQTYEMVDKHIRRLDTDLARFEADLKEKQI                               ESSDYDSSSSKGKKKGRTQKEKKAARARSKG                               KNSDEEAPKTAQKKLKLVRTSPEYGMPSVTF                               GSVHPSDVLDMPVDPNEPTYCLCHQVSYGE                               MIGCDNPDCSIEWFHFACVGLITKPRGKWFC                               PRCSQERKKK               952   2302   A   8112   595   291   PSVASLARRFSGRALWPPSHSVPGNRALCPRL                               LHGTTLPGGNQRELARQKNMKKQSDSVKGK                               RRDDGLSAAAIRKQRDSTPRPSELMQQKQKK                               ANEKKEEPK               953   2303   A   8118   1   669   VCAGIRDPCSTPLAKPAAGGAENLSFGKQPG                               LETNILKMTTPNKTPPGADPKQLERTGTVREI                               GSQAVWSLSSCKPGFGVDQLRDDNLETYWQ                               SDGSQPHLVNIQFRRKTTVKTLCLYADYKSDE                               SYTPSKISVRVGNNFHNLQEIRQLELVEPSGW                               IHVPLTDNIIKKPTRTFMIQIAVLANHQNGRD                               THMRQIKIYTPVEESSIGKFPRCTTIDFMMYRS                               IR               954   2304   A   8133   66   1015   PPLPPRSFPNLFSRPEPLPEPGRRGCNRSREPA                               ARAPSPPPPFEGAPGRAMVKVTFNSALAQKE                               AKKDEPKSGEEALIIPPDAVAVDCKDPDDVV                               PVGQRRAWCWCMCFGLAFMLAGVILGGAY                               LYKYFALQPDDVYYCGIKYIKDDVILNEPSAD                               APAALYQTIEENIKIFEEEEVEFISVPVPEFADS                               DPMNIVHDFNKKLTAYLDLNLDKCYVIPLNT                               SIVMPPRNLLELLINIKAGTYLPQSYLIHEIIMV                               ITDRIENIDHLGFFIYRLCHDKETYKLQRRETI                               KGIQKREASNCFAIRHFENKFAVETLICS               955   2305   A   8143   35   1171   VESRSAWHEGEDQIDELDFIRNQMNLLTLDV                               KKKIKEVTEEVANKVSCAMTDEICRLSVLVD                               EFCSEFHPNPDVLKIYKSELNKHIEDGMGRNL                               ADRCTDEVNALVLQTQQEIIENLKPLLPAGIQ                               DKLHTLIPCKKFDLSYNLNYHKLCSDFQEDW                               FRFSLGWSSLVHRFLGPRNAQRVLLGLSEPIF                               QLPRSLASTPTAPITPATPDNASQEELMITLVT                               GLASVTSRTSMGUWGGVIWKTIGWKLLSVS                               LTMYGALYLYERLSWTTHAKERAFKQQFVN                               YATEKLRMIVSSTSANCSHQVKQQIATTFARL                               CQQVDITQKQLEEEIARLPKEIDQLEICIQNNS                               KLLRNKAVQLENELENFTKQFLPSSNEES               956   2306   A   8157   1854   798   ASGSPAPSSSSAMAAACGPGAAGYCLLLGLH                               LFLLTAGPALGWNDPDRMLLRDVKALTLHY                               DRYTTSRRLDPIPQLKCVGGTAGCDSYTPKVI                               QCQNKGWDGYDVQWECKTDLDIAYKFGKT                               VVSCEGYESSEDQYVLRGSCGLEYNLDYTEL                               GLQKLKESGKQHGFASFSDYYYKWSSADSC                               NMSGLITTVVLLGIAFVVYKLFLSDGQYSPPP                               YSEYPPFSHRYQRFTNSAGPPPPGFKSEFTGPQ                               NTGHGATSGFGSAFTGQQGYENSGPGFWTGL                               GTGGILGYLFGSNRAATPFSDSWYYPSYPPSY                               PGTWNRAYSPLHGGSGSYSVCSNSDTKTRTA                               SGYGGTRRR               957   2307   A   8159   1492   528   THVVMTGMCYAPHQVLSYINGWITSKPGVSL                               VYSMPSRIMLSLRLEGLQEKDSGPYSCSVNVQ                               DKQGKSRGHSIKTLELNVLVPPAPPSCRLQGV                               PHVGANVTLSCQSPRSKPAVQYQWDRQLPSP                               QTFFAPALDVIRGSLSLTNLSSSMAGVYVCKA                               HNEVGTAQCNVTLEVSTGPGAAVVAGAVVG                               TLVGLGLLAGLVLLYHRRGKALEEPANDIKE                               DAIAPRTLPWPKSSDTISKNGTLSSVTSARAL                               RPPHGPPRPGALTPTPSLSSQALPSPRLPTDG                               AHPQPISPIPGGVSSSGLSRMGAVPVMVPAQS                               QAGSLV               958   2308   A   8161   2340   1192   ELARRPKQQSSEKSRNMIRNWLTIFILFPLKLV                               EKCESSVSLTVPPVVKLENGSSTNVSLTLRPP                               LNATLVITFEITFRSKNITILELPDEVVVPPGVT                               NSSFQVTSQNVGQLTVYLHGNIISNQTGPRIR                               FLVIRSSAISIINQVIGWIYFVAWSISFYPQVIM                               NWRRKSVIGLSFDFVALNLTGFVAYSVFNIGL                               LWVPYIKEQFLLKYPNGVNPVNSNDVFFSLH                               AVYLTLIIVQCCLYERGGQRVSWPAIGFLVL                               AWLFAFVTMIVAAVGVITWLQFLFCFSYIKL                               AVTLVKYFPQAYMNFYYKSTEGWSLGNVLL                               DFTGGSFSLLQMFLQSYNNDQWTLIFGDPTK                               FGLGVFSIVFDVVFFIQHFCLYRKEPGYDQLN               959   2309   A   8163   521   1345   GERAGRRRGRLGVWAQPQPLLPRFVGSRRE                               MQPPGPPPAYAPTNGDFTFVSSADAEDLSGSI                               ASPDVKLNLGGDFIKESTATTFLRQRGYGWL                               LEVEDDDPEDNKPLLEELDIDLKDIYYKIRCV                               LMPMPSLGFNRQVVRDNPDFWGPLAVVLFFS                               MISLYGQFRVVSWIITIWIFGSLTIFLLARVLG                               GEVAYGQVLGVIGYSLLPIIVIAPVLLVVGSF                               EVVSTLIKLFGVFWAAYSAASLLVGEEFKTK                               KPLLIYPIFLLYIYFLSLYTGV               960   2310   A   8167   1   2921   MTCFKGQKGEQRSHAFEANKDHKAKVPSPN                               LYSQLNALQFTVDERSILWLNQFLLDLKQSL                               NQFMAVYKLNDNSKSDEHVDVRVDGLMLK                               FVIPSEVKSECHQDQPRAISIQSSEMIATNTRR                               CPNCRHSDLEALFQDPKDCDFFSKTYTSFPKS                               CDNFNLLHPIFQRHAHEQDTKMHEIYKGNITP                               QLNKNTLKTSAATDVWAVYFSQFWIDYEGM                               SGKGRPISFVDSPPLSIWICQPTRYAESQKEP                               QTCNQVSLNTSQSESSDLAGRLKRKKLLKEY                               YSTESEPLTNGGQKPSSSDTFFRFSPSSSEADI                               HLLVHVHKHVSMQINHYQYLLLLFLHESLLLL                               SENLREDVEAVTGSPASQTSICIGILLRSAELA                               LLLITPVDQANTLKSPVSESVSPVVPDYLPTEN                               GDFLSSKRKQISRDINRIRSVTVNHMSDNRSM                               SVDLSHIPLKDPLLFKSASDTNLQKGISFMDY                               LSDKHLGKISEDESSGLVYKSGSGEIGSETSD                               KKDSFYTDSSSVLNYREDSNILSFDSDGNQNI                               LSSTLTSKGNETIESIFKAEDLLPEAASLSENL                               DISKEETPPVRTLKSQSSLSGPKERCPPNLAP                               LCVSYKNMKRSSSQMSLDTISLDSMILEEQLL                               ESDGSDSHMFLEKGNKKNSTTNYRGTAESVN                               AGANLQNYGETSPDAISTNSEGAQENHDDLM                               SVVVFKITGVNGEIDIRGEDTEICLQVNQVTP                               DQLGNISLRHYLCNRPVGSDQKAVIHSKSSPE                               ISLRFESGPGAVIHSLLAEKNGFLQCHIENFST                               EFLTSSLMNIQHFLEDETVATVPMKIQVSNT                               KINLKDDSPRSSTVSLEPAPVTVHIDHLVVER                               SDDGSFHLRDSHMLNTGNDLKENVKSDSVLL                               TSGKYDLKKQRSVTQATQTSPGVPWPSQSAN                               FPEFSFDFTREQLMEENESLKQELAKAKMAL                               AEAHLEKDALLHIHIKKMTVE               961   2311   A   8172   1442   682   TAAMSIFTPTNQIRLTNVAVVRMKRAGKRFEI                               ACYKNKVVGWRSGVEKDLDEVLQTHSVFN                               VSKGQVAKKEDLISAFGTDDQTEICKQILTKG                               EVQVSDKERHTQLEQMFRDIATIVADKCVNP                               ETKRPYTVILTERCDHYSVKTNKSTKQQA                               LEVIKQLKEKMKIERAHMRLRFILPVNEGKKL                               KEKLKPLIKVIESEDYGQQLEIVCLIDPGCFREI                               DELIKKETKGKGSLEVLNLKDVEEGDEKFE               962   2312   A   8175   286   587   NISNKAEVSSHPSVISHSMDSFGQPRPEDNQS                               VLRRMQKKYWKTKQVFIKATGKKEDEHLVA                               SDAELDAKLEVFHSVQETCTELLKIIEKYQLR                               LNGMKS               963   2313   A   8181   13   2215   AEGCAERRGTEPVVELSMSWESGAGPGLGSQ                               GMDLVWSAWYGKCVKGKGSLPLSAHGIVV                               AWLSRAEWDQVTVYLFCDDHKLQRYALNRI                               TVWRSRSGNELPLAVASTADLLRCKLLDVTG                               GLGTDELRLLYGMALVRFVNLIKTKFAK                               VPLKCLAQEVNIPDWIVDLRHELTHICKMPHI                               NDCRRGCYFVLDWLQKTYWGRQLENSLRET                               WELEEFREGIEEEDQEEDKNIVVDDITEQKPE                               PQDDGKSTESDVKADGDSKGSEEVDSHCKK                               ALSHKELYERARELLVSYEEEQFTVLEKFRYL                               PKAIKAWNNFSPRVECVLAELKGVTCENREA                               VLDAFLDDGFLVPTFEQLAALQIEYEENVDL                               NDVLVPKPFSQFWQPLLRGLHSQNFTQALLE                               RMLSELPALGISGIRPTYILRWTVELIVANTKT                               GRNARRFSAGQWEARRGWRLFNCSASLDWP                               RMVESCLGSPCWASPQLLRIIFKAMGQGLPD                               EEQEKLLRICSIYTQSGENSLVQEGSEASPIGK                               SPYTLDSLYWSVKPASSSFGSEAKAQQQEEQ                               GSVNDVKEEEKEEKEVLPDQVEEEEENDDQE                               EEEEDEDDEDDEEEDRMEVGPFSTGQESPTA                               ENARLLAQKRGALQGSAWQVSSEDVRWDTF                               PLGRMPGQTEDPAELMLENYDTMYLLDQPV                               LEQRLEPSTCKTDTLGLSCGVGSGNCSNSSSS                               NFEGLLWSQGQLHGLKTGLQLF               964   2314   A   8184   6   1393   EPRRNFRDDSTRPRTRGRTRGRRRRACRSAE                               GTGLRSLLLPPRLQLPAGPFSRCRWDPVSSPR                               PSTMPPKKGGDGIKPPPTIGRFGTSLKIGWGLP                               NVGKSTFFNVLTNSQASAENFPFCTIDPNESR                               VPVPDERFDFLCQYHKPASKIPAFLNVVDIAG                               LVKGANGQGLGNAFLSHISACDGIFHLTRA                               FEDDDITHVEGSVDPIDIEIIHEELQLKDEEMI                               GPIIDKLEKVAVRGGDKKLKPEYDIMCKVKS                               WVIDKLEKVAVRGGDKKLKPEYDIMCKVKS                               KPMVYLVNLSEKDYIRKKNKWLIKIKEWVD                               KYDPGAFSGALELKLQELSAEERQKYLE                               ANMTQSALPKIIKAGFAALQLEYFFTAGPDEV                               RAWTIRKGTKAPQAAGKIHTDFEKGFIMAEV                               MKYEDFKEEGSENAVKAAGKYRQQGRNYN                               EDGDIIFFKFNTPQQPKKK               965   2315   A   8195   1437   594   RSFSLSFSLLSPSEMMALGAAGATRVFVAMV                               AAALGGHPLLGVSATLNSVLNSNAIKNLPPPL                               GGAAGHPGSAVSAAPGILYPGGNKYQTIDNY                               QPYPCAEDEECGTDEYCASPTRGGDAGVQIC                               LACRKRRKRCMRHAMCCPGNYCKNGICVSS                               DQNHFRGEIEETFESFGNDHSTLDGYSRRTT                               LSSKMYHTKGQEGSVCLRSSDCASGLCCARH                               FWSKICKFVLKEGQVCTKHRRKGSHGLEIFQ                               RCYCGEGLSCRIQKDHHQASNSSRLHTCQRH               966   2316   A   8207   416   4082   KFKLIKIMLLTLIILLPVVSKFSFVSLSAPQHW                               SPEGTLAGNGNSTCVGPAPFLIFSHGNSIFRI                               DTEGTNYEQLVVDAGVSVFHYNEKRIY                               WVDLERQLLQRVFLNGSRQERVCNIEKNVSG                               MAINWINEEVIWSNQQEGIITVTDMKGNNSHI                               LLSALKYPANVAVDPVERFIFWSSEVAGSLY                               RADLDGVGVKALLETSEKITAVSLDVLDKRL                               FWIQYNREGSNSL1CSCDYDGGSVHISKHPTQ                               HNLFAMSLFGDRIPYSTWKMKTIWIANKHTG                               KDMVRINLHSSFVPLGELKVVHPLAQPKAED                               DTWEPEQKLCKLRKGNCSSTVCGQDLQSHLC                               MCAEGYALSRDRKYGEGNDWKYCEDVNEC                               AFWNHGCTLGCKNTPGSYYCTCPVGFVLLPD                               GKRCHQLVSCPRNVSECSHDCVLTSEGPLCF                               CPEGSVLERDGKTCSGCSSPDNGGCSQLCVPL                               SPVSWECDCFPGYDLQLDEKSCAASGPQPFL                               LFANSQDIRHMHFDGTDYGTLLSQQMGMVY                               ALDHDDPVENKIYFAHTALKWIERANMDGSQ                               RERLIEEGVDVPEGLAVDWIGRRFYWTDRGK                               SLIGRSDLNGKRSKITTIENISQPRGIAVHPMAK                               RLFWTDTYGINPRIESSSLQGLGRLLVIASSDLIW                               PSGITIDFLTDKLYWCDAKQSVIEMANLDGSK                               RERLTQNDVGHPFAVAVFEDYVWFSDWAMP                               SVIRVNKRTGKDRVRLQGSMLKPSSLVVVIIP                               LAKPGADPCLYQNGGCEHICKKRLGTAWCS                               CREGFMKASDGKTCLALDGHQLLAGGEVDL                               KNQVTPLDILSKTRVSEDNITESQHMLVAEIM                               VSDQDDCAPVGCSMYARCISEGEDATCQGLK                               GFAGDGICLCSDIDECEMGVPVCPPASSKCINT                               EGGYVCRCSEGYQGDGIHCLDIDECQLGVHS                               CGENASCTNTEGGYTCMCAGRLSEPGLICPD                               STPPPHLREDDHHYSVRNSDSECPLSHDGYCL                               HDGVCMYIEALDKYACNCVVGYIGERCQYR                               DLKWWELRHAGHGQQQICVVVAVCVVVLV                               MLLLLSLWGAHYYRTQKLLSKNPKNPYEESS                               RDVRSRRPADTEDGMSSCPQPWFVVIKEHQD                               LKNGGQPVAGEDGQAADGSMQPTSWRQEPQ                               LCGMGTEQGCWIPVSSDKGSCPQVMERSFH                               MPSYGTQTLEGGVEKPHSLLSANPLWQQRAL                               DPPHQMELTQ               967   2317   A   8210   3   601   SSAMGSRSSHAAVIPDGDSIRRETGFSQASLL                               RLHHRFRALDRNKKGYLSRMDLQQIGALAV                               NPLGDRIIESFFPDQSQRVDFPGFVRVLAHFRP                               VEDEDTETQDPKKPEPLNSRRNKLHYAFQLY                               DLDRDGKISRHEMLQVLRLMVGVQTEEQL                               ENIADRTVQEADEDGDGAVSFVEFTKSLEKM                               DVEHKMSIRILK               968   2318   A   8211   2   409   ISSCPHTAYEGSMSTLSNFTQTLEDVFRRTFIT                               YMDNWRQNTTAEQEALQAKVDAENFYYVIL                               YLMYMIGMFSFIIVAILVSTVKSKRREHSNDP                               YHQYIVEDWQEKYKSQILNLEESKATIHENIG                               AAGFKMSP               969   2319   A   8215   1   1938   GMPRSRGGRAAFGPPPPPPPPGQAPRWSRWR                               VPGRLLLLLLPALCCLPGAARAAAAAAGAGN                               RAAVAVAVARADEAEAPFAGQNWLKSYGY                               LLPYDSRASALHSAKALQSAVSTMQQFYGIP                               VTGVLDQTTIEWMKKPRCGVPDHPHLSRRRR                               NKRYALTGQKWRQKHITYSIHNYTPKVGELD                               TRKAIRQAFDVWQKVTPLTFEEVPYHEIKSDR                               KEADLMIFFASGFHGDSSPFDGEGGFLAHAYF                               PGPGIGGDTIIFDSDEPWTLGNANHDGNDLFL                               VAVHELGHALGLEHSSDPSAIMAPFYQYMET                               HNFKLPQDDLQGIQKIYGPPAEPLEPTRPLPTL                               PVRRIHSPSERKHERQPRPPRPPLGDRPSTPGT                               KPNICDGNFNTVALFRGEMFVFKDRWFWRL                               RNNRVQEGYPMQIEQFWKGLPAEIDAAYER                               ADGRFVFFKGDKYWVFKEVTVEPGYPHSLG                               ELGSCLPREGIDTALRWEPVGKTYFFKGERY                               WRYSEERRATDPGYPKPITVWKGIPQAPQGA                               FISKEGYYTYFYKGRDYWKFDNQKLSVEPGY                               PRNILRDWMGCNQKEVERRKERRLPQDDVDI                               MVTINDVPGSVNAVAVVIPCILSLCILVLVYTI                               FQFKNKTGPQPVTYYKRPVQEWV               970   2320   A   8216   1235   2223   SRLSLQFYVSFRRTGLFTCKLIYEIPFRNYMN                               DSLRTNVFVRFQPETIACACIYLAARALQIPLP                               TRPHWFLLFGTTEEEIQEICIETLRLYTRKKPN                               YELLEKEVEKRKVALQEAKLKAKGLNPDGTP                               ALSTLGGFSPASKPSSPREVKAEEKSPISINVK                               TVKKEPEDRQQASKSPYNGVRKDSKRSRNSR                               SASRSRSRTRSRSRSHTPRRHYNNRRSRSGTY                               SSRSRSRSRSHSESPRRHHNHGSPHLKAKHTR                               DDLKSSNRHGHKRKKSRSRSQSKSRDHSDAA                               KKHRHERGHHRDRRERSRSFERSHKSKHHGG                               SRSGHGRHRR               971   2321   A   8217   3   3274   DCRLQAAMPTNFTVVPVEAHADGGGDETAE                               RTEAPGTPEGPEPERPSPGDGNPRENSPFLNN                               VEVEQESFFEGKNMALFEEEMDSNPMVSSLL                               NKIANYTNLSQGVVEHEEDEESRRREAKAPR                               MGTFIGVYLPCLQNILGVILFLRLTWTVGVAG                               VLESFLIVAMCCTCTMLTAISMSAIATNGVVP                               AGGSYYMISRSLGPEFGGAVGLCFYLGTTFA                               GAMYLLGTIEIFLTYISPGAAIFQAEAAGGEAA                               AMLHNMRVYGTCTLVLMALVVFVGVKYVN                               KLALVFLACVYLSILAIYAGVIKSAFDPPDIPV                               CLLGNRTLSRRSFDACVKAYGIHNNSATSAL                               WGLFCNGSQPSAACDEYFIQNNVTEIQGIPGA                               ASGVFLENLWSTYAHAGAFVEKKGVPSVPV                               AEESRASTLPYVLTDIAASFTLLVGIYFPSVTG                               IMAGSNRSGDLKDAQKSIPTGTILAIVTTSFIY                               LSCIVLFGACTEGVVLRDKFGEALQGNLVIGM                               LAWPSPWVIVIGSFFSTCGAGLQTLTGAPRLL                               QAIARDGIVPFLQVFGHGKANGEPTWALLLT                               VLICETGILIASLDSVAPILSMFFLMCYLFVNL                               ACAVQTLLRTPNWRPRFKFYHWTLSFLGMSL                               CLALMFICSWYYALSAMLIAGCIYKYIEYRG                               AEKEWGDGIRGLSLNAARYALLRVEHGPPHT                               KNWRPQVLVMLNLDAEQAMKHPRLLSFTSQ                               LKAGKGLTIVGSVLEGTYLDKHMEAQRAEE                               NIRSLMSTEKTKGFCQLVVSSSLRDGMSHLIQ                               SAGLGGLKHNTVLMAWPASWKQEDNPFSW                               KNFVDTVRDTTAAHQALLVAKNVDSFPQNQ                               ERFGGGHIDVWWIVHDGGMLMLLPFLLRQH                               KVWRKCRMIUFTVAQVDDNSIQMKKDLQMF                               LYHLRISAEVEVVEMVENDISAFTYERTLMM                               EQRSQMLKQMQLSKNEQEREAQLIHDRNTAS                               HTAAAARTQAPPTPDKVQMTWTREKLIAEK                               YRSRDTSLSGFKDLFSMKPDQSNVRRMHTAV                               KLNGVVLNKSQDAQLVLLNMPGPPKNRQGD                               ENYMEFLEVLTEGLNRVLLVRGGGREVTTTYS               972   2322   A   8224   701   246   TSRRVTMKFNPFVTSDRSKNKKRHFNAPSHV                               RRKIMSSPLSKELRQKYNVRSMPIRKDDEVQ                               VVRGHYKGQQIGKVVQVYRKKYVIYIERVQ                               REKANGTTVHVGIHPSKVVLTRLKLDKDRKKI                               LERKAKSRQVGKEKGKYKEELIEKMQE               973   2323   A   8237   873   4610   GCPHAGGKGRVPTGGLTGGRTWSPSAAPRSC                               PRPGPTPAPGAMDKLPPSMRKRLYSLPQQVG                               AKAWIMDEEEDAEEEGAGGRQDPSRRSIRLR                               PLPSPSPSAAAGGTESRSSALGAADSEGPARG                               AGKSSTNGDCRRFRGSLASLGSRGGGSGGTG                               SGSSHGHLHDSAEERRLIAEGDASPGEDRTPP                               GLAAEPERPGASAQPAASPPPPQQPPQPASAS                               CEQPSVDTAIKVEGGAAAGDQILPEAEVRLG                               QAGFMQRQFGAMLQPGVNKFSLRMFGSQKA                               VEREQERVKSAGFWIIHPYSDFRFYWDLTML                               LLMVGNLIIIPVGITFFKDENITPWWFNVVSD                               TFFLIDLVLNFRTGTVVEDNEIILDPQRIKMK                               YLKSWFMVDFISSIPVDYIFLIVETRIDSEVYK                               TARALRIVRFTKILSLLRLLRLSRLIRYIHQWE                               EIFHMTYDLASAVVRIVNLIGMMLLLCHWDG                               CLQFLVPMLQDFPDDCWVSINNMVNNSWGK                               QYSYALFKAMSHMLCIGYGRQAPVGMSDV                               WLTMLSMIVGATCYAIVIFIGHATALIQSLDSS                               RRQYQEKYKQVEQYMSFHKLPPDTRQRIHD                               YYEHRYQGKMFDEESILGELSEPLREEIINFNC                               RKLVASMPLFANADPNFVTSMLTKLRFEVFQ                               PGDYIIREGTIGKKMYFIQHGVVSVLTKGNKE                               TKLADGSYFGEICLLTRGRRTASVRADTYCR                               LYSLSVDNFNEVLEEYPMMRRAFETVALDRL                               DRIGKKNSILLHKVQHDLNSGVFNYQENEIIQ                               QIVQHDREMAHCAHRVQAAASATPTPTPVIW                               TPLIQAPLQAAAATTSVAIALTHHPRLPAAIFR                               PPPGSGLGNLGAGQTPPHLKRLQSLIPSALGS                               ASPASSPSQVDTPSSSSFHIQQLAGFSAPAGLS                               PLLPSSSSSPPPGACGSPSAPTPSAGVAAITIA                               GFGHFHKALGGSLSSSDSPLLTPLQPGARSPQ                               AAQPSPAPPGARGGLGLPEHFLPPPPSSRSPSS                               SPGQLGQPPGELSLGLATGPLSTPETPPRQPEP                               PSLVAGASGGASPVGFTPRGGLSPPGHSPGPP                               RTFPSAPPRASGSHGSLLLPPASSPPPPQVPQR                               RGTPPLTPGRLTQDLKLISASQPALPQDQAQT                               LRRASPHSSGESMAAFPLFPRAGGGSGGSGSS                               GGLGPPGRPYGAIPGQHVTLPRKTSSGSLPPP                               LSLFGARATSSGGPPLTAGPQREPGARPEPVR                               SKLPSNL               974   2324   A   8247   279   468   EYKQWERRFLSCQNRNDLGYGKPRKGGGLL                               LVPVKDASRICSLTYLLGSHWNNLVVRSPVL                               G               975   2325   A   8249   62   1571   LVALKNWKPKGTNIPAPQSPVPGEAVSGVYM                               MTKVLGMAPVLGPRPPQEQVGPLMVKVEEK                               EEKGKYLPSLEMFRQRFRQFGYHDTPGPREA                               LSQLRVLCCEWLRPEIHTKEQILELLVLEQFLT                               ILPQELQAWVQEHCPESAEEAVTLLEDLEREL                               DEPGHQVSTPPNEQKPVWEKISSSGTAKESPS                               SMQPQPLETSHKYESWGPLYIQESGEEQEFAQ                               DPRKVRDCRLSTQHEESADEQKGSEAEGLKG                               DIISVIIANKPEASLERQCVNLENEKGTKPPLQ                               EAGSKKGRESVPTKPTPGERRYICAECGKAFS                               NSSNLTKHRRTHTGEKPYVCTKCGKAFSHSS                               NLTLHYRTHLVDRPYDCKCGKAFQQSSDLLK                               HQRMHTEEAPYQCKDCGKAFSGKGSLIRHYR                               IHTGEKPYQCNECGKSFSQHAGLSSHQRLHT                               GEKPYKCKECGKAFNHSSNFNKHHRIHTGEK                               PYWCHHCGKTFCSKSNLSKHQRVHTGEGEA                               P               976   2326   A   8257   298   7086   GNMACWPQLRLLLWKNLTFRRRQTCQLLLE                               VAWPLFIFLILISVRLSYPPYEQHECHFPNKAM                               PSAGTLPWVQGIICNANNPCFRYPTPGEAPGV                               VGNFNKSIVARLFSDARRLLLYSQKDTSMKD                               MRKVLRTLQQTKKSSSNLKLQDFLVDNETFS                               QFLYHNLSLPKSTVDKMLRADVILHKVFLQG                               YQLHLTSLCNGSKSEEMIQLGDQEVSELCGLP                               REKLAAAERVLRSNMDLLKPILRTLNSTSPFPS                               KELAEATKTLLHSLGTLAQELFSMRSWSDMR                               QEVMFLTNVNSSSSSTQIYQAVSRIVCGHPEG                               GGLKIKSLNWYEDNNYKALFGGNGTEEDAE                               TFYDNSTTPYCNDLMKNLESSPLSRITWKALK                               PLLVGKILYTPDTPATRQVMAEVNKTFQELA                               VFHDLEGMWEELSPKIWTFMENSQEMDLVR                               MLLDSRDNDHFWEQQLDGLDWTAQDIVAPL                               AKHPEDVQSSNGSVYTWREAFNETNQAIRTIS                               RFMECVNLNKLEPIATEVWLINKSMELLDER                               KFWAGIVFTGITPGSIELPHHVKYKIRMGIDN                               VERTNKIKDGYWDPGPRADPFEDMRYVWGG                               FAYLQDVVEQAIIRVLTGTEKKTGVYMQQMP                               YPCYVDDIPLRVMSRSMPLFMTLAWIYSVAV                               IIKGIVYEKEARLKETMRIMGLDNSILWFSWFI                               SSLIPLLVSAGLLVVILKLGNLLPYSDPSVVFV                               FLSVFAVVTILQCFLISTLFSRANLAAACGGII                               YFTLYLPYVLCVAWQDYVGFTLKIFASLLSP                               VAFGFGCEYFALFEEQGIGVQWDNLFESPVE                               EDCIFNLTTSVSMMLFDTPLYGVMTWYIEAVF                               PGQYGIPRPWYFPCTKSYWFGEESDEKSHPGS                               NQKRISEICMEEEPTHLKLGVSIQNLVKVYRD                               GMKVAVDGLALNFYEGQITSFLGHNGAGKT                               TTMSILTGLFPPTSGTAYILGKDLRSEMSTIRQ                               NLGVCPQHNVLFDMLTVEEHIWFYARLKGLS                               EKHVKAEMEQMALDVGLPSSKLKSKTSQLS                               GGMQRKLSVALAFVGGSICVVILDEPTAGVDP                               YSRRGIWELLLKYRQGRTIILSTHHMDEADVL                               GDRIAIISHGKLCCVGSSLFLKNQLGTGYYLT                               LVKKDVESSLSSGRNSSSTVSYLKKEDSVSQS                               SSDAGLGSDHESDTLTIDVSAISNLIRKHVSEA                               RLVEDIGHELTYVLPYEAAKEGAFVELFHEID                               DRLSDLGISSYGISETTLEEIFLKVAEESGVDA                               ETSDGTLPARRNRRAFGDKQSCLRPFTEDDA                               ADPNDSDIDPESRETDLLSGMDGKGSYQVKG                               WKLTQQQFVALLWKRLLIARRSRKGFFAQIV                               LPAVFVCIALVFSLIVPPFGKYPSLELQPWMY                               NEQYTFVSNDAPEDTGTLELLNALTKDPGFG                               TRCMEGNPIPDTPCQAGEEEWTTAPVPQTIM                               DLFQNGNWTMQNPSPACQCSSDKIKKMLPV                               CPPGAGGLPPPQRKQNTADILQDLTGRNISDY                               LVKTYVQIIAKSLKNKIWVNEFRYGGFSLQVS                               NTQALPPSQEVNDATKQMKKHLKLAKDSSA                               DRFLNSLGRFMTGLDTRNNVKVWFNNKGW                               HAISSFLNVINNAILRANLQKGENPSHYGITAF                               NHPLNLTKQQLSEVAPMTTSVDVLVSICVIFA                               MSFVPASFVVFLIQERVSKAKHLQFISGVKPVI                               YWLSNFVWDMCNYVVPATLVIIIFICFQQKSY                               VSSTNLPVLALLLLLYGWSITPLMYPASFVFK                               IPSTAYVVLTSVNLFIGINGSVATFVLELFTDN                               KLNNINDILKSVFLIFPHFCLGRGLIDMVKNQ                               AMADALERFGENEFVSPLSWDLVGRNLFAM                               AVEGVVFFLITVLIQYRFFIRPRPVNAKLSPLN                               DEDEDVRRERQRILDGGGQNDILEIKELTKIY                               RRKRKPAVDRICVGIPPGECFGLLGVNGAGK                               SSTFKMLTGDTTVTRGDAFLNRNSILSNIHEV                               HQNMGYCPQFDAITELLTGREHVEFFALLRG                               VPEKEVGKVGEWAIRKLGLVKYGEKYAGNY                               SGGNKRKLSTAMALIGGPPVVFLDEPTTGMD                               PKARRFLWNCALSVVKEGRSVVLTSHSMEEC                               EALCTRMAIMVNGRFRCLGSVQHLKNRFGD                               GYTIVVRIAGSNPDLKPVQDFFGLAFPGSVPK                               EKHRNMLQYQLPSSLSSLARIFSILSQSKKRLH                               IEDYSVSQTTLDQVFVNFAKDQSDDDHLKDL                               SLHKNQTVVDVAVLTSFLQDEKVKESYV               977   2327   A   8260   3   1567   IPGSTISFSLCFIPPPCVPTMVRKPVVSTISKGG                               YLQGNVNGRLPSLGNKEPPGQEKVQLKRKV                               TLLRGVSIIIGTIIGAGIFISPKGVLQNTGSVGM                               SLTIWTVCGVLSLFGALSYAELGTTIKICSGGH                               YTYILEVFGPLPAFVRVWVELLIIRPAATAVIS                               LAFGRYILEPFFIQCEIPELAIKLITAVGITVVM                               VLNSMSVSWSARIQIFLTFCKLTAILIIIVPGV                               MQLIKGQTQNFKDAFSGRDSSITRLPLAFYYG                               MYAYAGWFYLNFVTEEVENPEKTIPLAICISM                               AIVTIGYVLTNVAYFTTINAEELLLSNAVAVT                               FSERLLGNFSLAVPIFVALSCFGSMNGGVFAV                               SRLFYVASREGHLPEILSMIHVRKHTPLPAVIV                               LHPLTMIMLFSGDLDSLLNFLSFARWLFIGLA                               VAGLIYLRYKCPDMHRPFKVPLFIPALFSFTC                               LFMVALSLYSDPFSTGIGFVITLTGVPAYYLFII                               WDKKPRWPRIMSEKITRTLQIILEVVPEEDKL               978   2328   A   8261   2   2165   RGGSLRCVLGKLLGQLLCFQSERCVRFPEGLL                               RHRGCGLLSSRLSAGKPPLRTSFFGSWGVLPP                               LADAASMSGVRAVRISIESACEKQVHEVGLD                               GTETYLPPLSMSQNLARLAQRIDFSQGSGSEE                               EEAAGTEGDAQEWPGAGSSADQDDEEGVVK                               FQPSLWPWDSVRNNLRSALTEMCVLYDVLSI                               VRDKKFMTLDPVSQDALPPKQNPQTLQLISK                               KKSLAGAAQILLKGAERLTKSVTENQENKLQ                               RDFNSELLRLRQHWKLRKVGDKILGDLSYRS                               AGSLFPHHGTFEVIKNTDLDLDKKIPEDYCPL                               DVQTPSDLEGSAYIKVSIQKQAPDIGDLGTVN                               LFKRPLPKSKPGSPHWQTKLEAAQNVLLCKEI                               FAQLSREAVQIKSQVPHIVVKNQIISQPFPSLQ                               LSISLCHSSNDKKSQKFATEKQCPEDHLYVLE                               HNLHLLIREFHKQTLSSIMMPHPASAPFGHKR                               MRLSGPQAFDKNEINSLQSSEGLLEKIIKQAK                               HIFLRSRAAATIDSLASRLEDPQIQAHWSNIND                               VYESSVKVLITSQGYEQICKSIQLQLNIGVEQI                               RVVHRDGRVITLSYQEQELQDFLLSQMSQHQ                               VHAVQQLAKVMGWQVLSFSNHVGLGPIESIG                               NASAITVASPSGDYAISVRNQPESGSKIMVQF                               PRNQCKDLPKSDVLQIYNKWSHLRGPFKEVQ                               WNKMEGRNFVYKIVIELLMSALSPCLL               979   2329   A   8289   2   1053   FVWNPRGGRKRRRQAAVTQAATRASGTPSP                               RDGTMTQGKLSVANKAPGTEGQQQVHGEKK                               EAPAVPSAPPSYEEATSGEGMKAGAFPPAPTA                               VPLHPSWAYVDPSSSSSYDNGFPTGDHELFTT                               FSWDDQKVRRVFVRKVYTILLIQLLVTLAVV                               ALFTFCDPVKDYVQANPGWYWASYAVFFAT                               YLTLACCSGPRRHFPWNLILLTVFTLSMAYLT                               GMLSSYYNTTSVLLCLGITALVCLSVTVFSPQ                               TKDFTSCQGVLFVLLMTLFFSGLILAILLPFQ                               YVPWLHAVYAALGAGVFFTLFLALDTQLLMG                               NRRHSLSPEEYIFGALNIYLDIIYIFTFFLQLFG                               TNRE               980   2330   A   8305   59   857   ASQLPDYSISPPSLPPRISFHPSPTLARVAMAEP                               SEATQSHSISSSSFGAEPSAPGGGGSPGACPAL                               GTKSCSSSCAVHDLIFWRDVKKTGFVFGTTLI                               MLLSLAAFSVISVVSYLILALLSVTISFRIYKSV                               TQAVQKSEEGHPFKAYLDVDITLSSEAFHNY                               MNAAMVHIINRALKLIIRLFLVEDLVDSLKLA                               VFMWLMTYVGAVFNGITLLILAELLIFSVP1V                               YEKYKTQIDHYVGIARDQTKSIVEKIQAKLPG                               IAKKKAE               981   2331   A   8308   186   1337   TRMSRHEGVSCDACLKGNFRGRRYKCLICYD                               YDLCASCYESGATTTRHTTDHPMQCILTRVD                               FDLYYGGEAFSVEQPQSFTCPYCGKMGYTET                               SLQEHVTSEHAETSTEVICPICAALPGGDPNH                               VTDDFAAHLTLEHRAPRDLDESSGVRHVRR                               MFHPGRGLGGPRARRSNMHFTSSSTGGLSSS                               QSSYSPSNREAMDPIAELLSQLSGVRRSAGGQ                               LNSSGPSASQLQQLQMQLQLERQHAQAARQ                               QLETARNATRRTNTSSVYITITQSTMTNIAN                               TESSQQTLQNSQFLLTRLNDPKMSETERQSM                               ESERADRSLFVQELLLSTLVREESSSSDEDDR                               GEMADFGAMGCVDIMPLDVALENLNLKESN                               KGNEPPPPPL               982   2332   A   8315   1   1004   GSTHASADAWAQWFCTEALVMGAPVWYLV                               AAALLVGFILFLTRSRGRAASAGQEPLHNEEL                               AGAGRVAQPGPLEPEEPRAGGRPRRRRDLGS                               RLQAQRRAQRVAWAEADENEEEAVILAQEE                               EGVEKPAETHLSGKIGAKKLRKLEEKQARKA                               QREAEEAEREERKRLESQREAEWKKEEERLR                               LEEEQKEEEERKAREEQAQREHEEYLKLKEA                               FVVEEEGVGETMTEEQSQSFLTEFINYIKQSK                               VVLLEDLASQVGLRTQDTINRIQDLLAEGTIT                               GVIDDRGKFIYITPEELAAVANFIRQRGRVSIA                               ELAQASNSLIAWGRESPAQAPA               983   2333   A   8320   244   1420   RRRWRARGGLVPTLAWAEATGAYVPGRDKP                               DLPTWKRNFRSALNRKEGLRLAEDRSKDPHD                               PHKIYEFVNSGVGDFSQPDTSPDTNGGGSTSD                               TQEDILDELLGNMVLAPLPDPGPPSLAVAPEP                               CPQPLRSPSLDNPTPFPNLGPSENPLKRLLVPG                               EEWEFEVTAFYRGRQVFQQTISCPEGLRLVGS                               EVGDRTLPGWPVTLPDPGMSLTDRGVMSYV                               RHVLSCLGGGLALWRAGQWLWAQRLGHCH                               TYWAVSEELLPNSGHGPDGEVPKDKEGGVF                               DLGPFIVGSLGPPDLITFTEGSGRSPRYALWFC                               VGESWPQDQFWTKRLVMVKVVPTCLRALVE                               MARVGGASSLENTVDLHISNSHPLSLTSDQY                               KAYLQDLVEGMDFQGPGES               984   2334   A   8321   1   1243   ANMAPVEHVVADAGAFLRHAALQDIGKNIY                               TIREVVTEIRDKATRRRLAVLPYELRFKEPLPE                               YVRLVTEFSKKTGDYPSLSATDIQVLALTYQL                               EAEFVGVSHLKQEPQKVKVSSSIQHIPETPLHIS                               GFHLPYKPKPPQETEKGHSACEPENLEFSSFM                               FWRNPLPNIDHELQELLIDRGEDVPSEEEEEEE                               NGFEDRKDDSDDDGGGWITPSNIKQIQQELE                               QCDVPEDVRVGCLTTDFAMQNVLLQMGLHV                               LAVNGMLIREARSYILRCHGCFKTTSDMSRV                               FCSHCGNKTLKKVSVTVSDDGTLHMHFSRNP                               KVLNPRGLRYSLPTPKGGKYAINPHLTEDQRF                               PQLRLSQKARQKTNVFAPDYIAGVSPFVENDI                               SSRSATLQVRDSTLGAGRRRLNPNAERKKFV               985   2335   A   8322   352   529   RRNNIRQFIMKVCISGQARWLTPVVPVLWET                               EAGRSLELKSLRPAWATWGNPISTKINK               986   2336   A   8325   89   1172   KMNPTDIADTTLDESIYSNYYLYESIPKPCTKE                               GIKAFGELFLPPLYSLVFVFGLLGNSVVVLVL                               FKYKRLRSMTDVYLLNLAISDLLFVFSLPFWG                               YYAADQWVFGLGLCKMISWMYLVGFYSGIF                               FVMLMSEDRYLAIVHAVFSLRARTLTYGVITS                               LATWSVAVFASLPGFLFSTCYTERNHTYCKT                               KYSLNSTTWKVLSSLEINILGLVIPLGIMLFCY                               SMIIRTLQHCKNEKKNKAVKMIFAVVVLFLG                               FWTPYNIYLFLETLVELEVLQDCTFERYLDYA                               IQATETLAFVHCCLNPIIYFFLGEKFRKYILQL                               FKTCRGLFVLCQYCGLLQIYSADTPSSSYTQS                               TMDHDLHDAL               987   2337   A   8326   3   470   SLSAMRFLAATFLLLALSTAAQAEPVQFKDC                               GSVDGVIKEVNVSPCPTQPCQLSKGQSYSVN                               VTFTSNIQSKSSKAVVHGILMGVPVPFPIPEPD                               GCKSGINCPIQKDKTYSYLNKLPVKSEYPSIK                               LVVEWQLQDDKNQSLFCWEIPVQIVSHL               988   2338   A   8335   1205   323   VIKMALAARLLPQFLHSRSLPCGAVRLRTPA                               VAEVRLPSATLCYFCRCRLGLGAALFPRSAR                               ALAASALPAQGSRWPVLSSPGLPAAFASFPAC                               PQRSYSTEEKPQQHQKTKMIVLGFSNPINWV                               RTRIKAFLIWAYFDKEFSITEFSEGAKQAFAH                               VSKLLSQCKFDLLEELVAKEVLHALKEKVTS                               LPDNHKNALAANIDEIVFTSTGDISTYYDEKG                               RKFVNILMCFWYLTSANIPSETLRGASYFQVK                               LGNQNVKQLLSASYEFQREFTQGVKPDWT                               IARIEHSKLLE               989   2339   A   8349   67   185   MSGFHQLLIQNLFCVYIITRLKTSQGLCLLSL                               KSLHPMS               990   2340   A   8361   210   1115   ASPFLRPQGHDSCIEREPFSQTPGLMQPFSIFVQ                               ITLQGSRRRQGRTAFPASCIKKRETDYSDGDPL                               DVLPSSTGEDRAVLGFAMMGFSVLMF                               FLLGITILKPFMLSIQREESTCTAIHTDIMDDW                               LDCAFTCGVHCHGQGKYPCLQVFVNLSHPG                               QKALLHYNEEAVQINTPKCFYTPKCHQDRNDL                               LNSALDIKEFFDHKNGTPFSCFYSPASQSEDVI                               LIKKYDQMAIFHCLFWPSLTLLGGALIVGMV                               RLTQHLSLLCEKYSTVVRDEVGGKVPYIEQH                               QFKLCIMRRSKGRAEKS               991   2341   A   8369   9   921   SSVVEFSALSVSMACLSPSQLQKFQQDGFLVL                               EGFLSAEECVAMQQRIGEIVAEMDVPLHCRT                               EFSTQEEEQLRAQGSTDYFLSSGDKIRFFFEK                               GVFDEKGNFLVPPEKSINKIGHALHAHDPVFK                               SITHSPKVQTLARSLGLQMPVVVQSMYIFKQP                               IIFGGEVSPHQDASFLYTEPLGRVLGVWIAVE                               DATLENGCLWFIPGSHTSGVSRRMVRAPVGS                               APGTSFLGSEPARDNSLFVPTPVQRGALVLIH                               GEVVHKSKQNLSDRSRQAYTITHLMEASGIT                               WSPENWLQPTAELPFPQLYT               992   2342   A   8370   906   4   MALSGNCSRYYPREQGSAVPNSFPEVVELNV                               GGQVYFTRHSTLISIPHSLLWKMFSPKRDTAN                               DLAKDSKGRFFIDRDGFLFRYILDYLRDRQVV                               LPDHFPEKGRLKREAEYFQLPDLVKLLTPDEI                               KQSPDEFCHSDFEDASQGSDTRICPPSSLLPAD                               RKWGFITVGYRGSCTLGREGQADAKFRRVPR                               ILVCGRISLAKEVFGETLNESRDPDRAPERYTS                               RFYLKFKHLMGAPASNFILGFWGLGQNQDK                               HPVNIYLQQRSVIRPDLTSKKAGDLKGKGDA                               QEVSRRRRWLGDPEHL               993   2343   A   8379   1   2794   MRMQRHKNDTMDFGDSGKRIGGGVLCLLHQ                               SNTSFIKLNNNGFEDIVIVIDPSVPEDEKIIEQIE                               DMVTTASTYLPEATEKRFFFKNVSILIPENWK                               ENPQYKRPKHENHKHADVIVAPPTLPGRDEP                               YTKQPTECGEKGEYIHFTPDLLLGKKQNEYG                               PPGKLFVHEWAHLRWGVFDEYNEDQPFYRA                               KSKKIEATRCSAGISGRNRVYKCQGGSCLSRA                               CRIDSTTKLYGKDCQFFPDKVQTEKASTMFM                               QSIDSVYEFCNEKTHNQEAPSLQNIKCNFRST                               WEVISNSEDFKNTIPMVTPPPPPVFSLLKIRQRI                               VCLVLDKSGSMGGKDRLNRIVINQAAKHFLLQ                               TVENGSWVGMVHFDSTATWNKLIQIKSSDER                               NTLMAGLPTYPLGGTSICSGIKYAFQVIGELH                               SQLDGSEVLLLTDGEDNTASSCIDEVKQSGAI                               VHFIALGRAADEAVIEMSKITGGSHFYVSDEA                               QNNGLIDAFGALTSGNTDLSQKSLQLESKGLT                               LNSNAWMNDTVIIDSTVGKDTFFLITWNSLPP                               SISLWDPSGTIMENFTVDATSKMAYLSIPGTA                               KVGTWAYNLQAKANPETLTITVTSRAANSSV                               PPITVNAKMNKDVNSFPSPMIVYAEILQGYVP                               VLGANVTAFIESQNGHTEVLELLDNGAGADS                               FKNDGVYSRYFTAYTENGRYSLKVRAHGGA                               NTARLKLRPPLNRAAYIPGWVVNGEIEANPP                               RPEIDEDTQTTLEDFSRTASGGAFVVSQVPSL                               PLPDQYPPSQITDLDATVHEDKIILTWTAPGD                               NFDVGKVQRYIIRISASILDLRDSFDDALQVN                               TTDLSPKEANSKESPAFKPENISEENATHIFIAI                               KSIDKSNLTSKVSNIAQVTLFIPQANPDDIDPT                               PTPTPTPTPDKSHNSGVNISTLVLSVIGSVYIV                               NFILSTTI               994   2344   A   8385   231   644   INSSPRTGRDHQELNLHTERDSRSQRAVLKIP                               RQNPGIPYWTFLPSRSHSASHGSRQRQVSCQG                               TQDEILKMRNTFAELKNSLEALSSRMDQAEE                               RIGTQAGVQWRDHGSLQPQPPEPKQCFHLSL                               PSSWDYRACLS               995   2345   A   8390   194   3421   AWRKSSVVPPRGTRRGEKSDQDKSGQKNKR                               DFLSMKQSPALAPEERCRRAGSPKPVLRADD                               NNMGNGCSQKLATANLLRFLLLVLIPCICALV                               LLLEILLSYVGTLQKVYFKSNGSEPLVTDGEI                               QGSDVILTNTIYNQSTVVSTAHPDQHVPAWT                               TDASLPGDQSHRNTSACMNITHSQCQMLPYH                               ATLTPLLSVVRNMEMEKFLKFFTYLHRLSCY                               QHIMLFGCTLAFPECIIDGDDSHGLLPCRSFCE                               AAKEGGESVLGMVNYSWPDFLRCSQFRNQT                               ESSNVSRICFSPQQENGKQLLCGRGENFLCAS                               GICIPGKLQCNGYNDCDDWSDEAHCNCSENL                               FHCHTGKCLNYSLVCDGYDDCGDLSDEQNC                               DCNPTTEHRCGDGRCIAMEWVCDGDHDCVD                               KSDEVNCSCHSQGLVECRNGQCIPSTFQCDG                               DEDCKDGSDEENCSVIQTSCQEGDQRCLYNP                               CLDSCGGSSLCDPNNSLNNCSQCEPITLELCM                               NLPYNSTSYPNYFGHRTQKEASISWESSLFPA                               LVQTNCYKYLMFFSCTILVPKCDVNTGEHIPP                               CRALCEHSKERCESVLGIVGLQWPEDTDCSQ                               FPEENSDNQTCLMPDEYVEECSPSHPKCRSGQ                               CVLASRRCDGQADCDDDSDEENCGCKERDL                               WECPSNKQCLKHTVICDGFPDCPDYMDEKN                               CSFCQDDELECANHACVSRDLWCDGEADCS                               DSSDEWDCVTLSINVNSSSFLMYHRAATEHH                               VCADGWQEILSQLACKQMGLGEPSVTKLLQE                               QEKEPRWLTLHSNWESLNGTTLHELLVNGQS                               CESRSKISLLCTKQDCGRRPAARMNKRILGGR                               TSRPGRWPWQCSLQSEPSGHIGGCVLIAKKW                               VLTVAHCFEGRENAAVWKVVLGINNLDHPS                               VFMQTRFVKTIILHPRYSRAVVDYDISIVELSE                               DISETGYVRPVCLPNPEQWLEPDTYCYITGW                               GHMGNKMPFKLQEGEVRIISLEHCQSYFDMK                               TFITRMICAGYESGTVDSCMGDSGGPLVCEK                               PGGRWTLFGLTSWGSVCPSKVLGPGVYSNVS                               YFVEWIKRQIYIQTFLLN               996   2346   A   8392   199   3085   KVILSSEMSKTNKSKSGSRSSRSRSASRSRSRS                               FSKSRSRSRSLSRSRKRRLSSRSRSRSYSPAHN                               RERNHPRVYQNRDFRGHNRGYRRPYYFRGR                               NRGFYPWGQYNRGGYGNYRSNWQNYRQAY                               SPRRGRSRSRSPKRRSPSPRSRSHSRNSDKSSS                               DRSRRSSSSRSSSNHSRVESSKRKSAKEKKSSS                               KDSRPSQAAGDNQGDEVKEQTFSGGTSQDTK                               ASESSKPWPDATYGTGSASRASAVSELSPRER                               SPALKSPLQSVVVRRRSPRPSPVPKPSPPLSST                               SQMGSTLPSGAGYQSGTHQGQFDHGSGSLSP                               SKKSPVGKSPPSTGSTYGSSQKEESAASGGAA                               YTKRYLEEQKTENGKDKEQKQTNTDKEKIKE                               KGSFSDTGLGDGKMKSDSFAPKTDSEKPFRG                               SQSPKRYKLRDDFEKKMADFHKEEMDDQDK                               DKAKGRKESEFDDEPKFMSKVIGANKNQEEE                               KSGKWEGLVYAPPGKEKQRKTEELEEESFPE                               RSKKEDRGKRSEGGHRGFVPEKNFRVTAYK                               AVQEKSSSPPPRKTSESRDKLGAKGDFPTQKS                               SFSITREAQVNVRMDSFDEDLAEPSGLLAQER                               KLCRDLVHSNKKEQEFRSIFQHIQSAQSQRSP                               SELFAQHIVTTVHHVKEHHFGSSGMTLHERFT                               KYLKRGTEQEAAKNKKSPEIHRRIDISPSTFRK                               HGLAHDEMKSPREPGYKAEGKYKDDPVDLR                               LDLERRKKHKERDLKRGKSRESVDSRDSSHSR                               ERSAEKTEKTHKGSKKQKKHRRARDRSRSSS                               SSSQSSHSYKAEEYTEETEEEEESTTGFDKSRL                               GTKDFVGPSERGGGRARGTFQFRARGRGWG                               RGNYSGNNNNNSNNDFQKRNREEEWDPEYT                               PKSKKYYLHDDREGEGSDKWVSRGRGRGAF                               PRGRGRFMFEKSSTSPKWAHDKFSGEEGEIE                               DDESGTENREEKDNIQPTTE               997   2347   A   8398   202   552   CPALGGRQDLQGTRLLWAHDSGVGGQKAKS                               KQENLESLEATGREEEGGQGPPVTKGVLLA                               LLMAGLALQPGTALLCYSCKAQVSNEDCLQ                               VENCTQLGEQCWTARIREWGDDSRQA               998   2348   A   8400   697   301   NPPSACTPGSCDSCSGRGRDLAFDSVWSTNN                               MSDPRRPNKVLRYKPPPSECNPALDDPTPDY                               MNLLGMIFSMCGLMLKLKWCAWVAVYCSFI                               SFANSRSSEDTKQMMSSFMLSISAVVMSYLQ                               NPQPMTPPW               999   2349   A   8401   93   1126   ASASHITSGHLRCFPGSEGVGTMARCFSLVLL                               LTSIWTTRLLVQGSLRAEELSIQVSCRIMGITL                               VSKKAISIQQLNFTEAKEACRLLGLSLAGKDQ                               VETALKASFETCSYGWVGDGFVVISRISPNPK                               CGKNGVGVLIWKVPVSRQFAAYCYNSSDTW                               TNSCIPEIITTKDPIFNTQTATQTTEFTVSDSTYS                               VASPYSTLPAPTTTPPAPASTSIPRRKKLICVTE                               VFMETSTMSTETEPFVENKAAFKNEAAGFGG                               VPTALLVLALLFFGAAAGLGFCYVKRYVKAF                               PFTNKNQQKEMIETKVVKEEKANDSNPNEES                               KKTDKNPEESKSPSKTTMRCLEAEV               1000   2350   A   8406   2   777   KERCQFVVKPMLSTVGSFLQDLQNEDKGIKT                               AAIFTADGNMISASTLMDILLMNDFKLVINKI                               AYDVQCPKREKPSNEHTAEMEHMKSLVHRL                               FTILHLEESQKKREHHLLEKIDHLKEQLQPLE                               QVKAGIEAHSEAKTSGLLWAGLALLSIQGGA                               LAWLTWWVYSWDIMEPVTYFWFANSMVFF                               AYFIVTRQDYTYSAVKSRQFLQFFHKKSKQQ                               HFDVQQYNKLKEDLAKAKESLKQARHSLCL                               QMQVEELNEKN               1001   2351   A   8410   1400   264   VGFWERPLRSSRWFRRSLRRWEMLARAARG                               TGALLLRGSLLASGRAPRRASSGLPRNTVVLF                               VPQQEAWVVERMGRFHRILEPGLNILIPVLDR                               IRYVQSLKEIVINVPEQSAVTLDNVTLQIDGV                               LYLRIMDPYKASYGVEDPEYAVTQLAQTTM                               RSELGKLSLDKVFRERESLNASIVDAINQAAD                               CWGIRCLRYEIKDIHVPPRVKESMQMQVEAE                               RRKRATVLESEGTRESAINVAEGKKQAQILAS                               EAEKAEQINQAAGEASAVLAKAKAKAEAIRI                               LAAALTQHNGDAAASLTVAEQYVSAFSKLA                               KDSNTILLPSNPGDVTSMVAQAMGVYGALT                               KAPVPGTPDSLSSGSSRDVQGTDASLDEELDR                               VKMS               1002   2352   A   8421   134   941   NRENLLESRMIVIDPCSVGVQLRTTNECHKTY                               YTRHTGFKTLQELSSNDMLLLQLRTGMTLSG                               NNTICFHHVKIYIDRFEDLQKSCCDPFNIHKKL                               AKKNLHVIDLDDATFLSAKFGRQLVPQWKLC                               PKCTQIINGSVDVDTEDRQKRKLPESDGRTAK                               ALRSLQFTNPGRQTEFAPETGKREKRRLTKN                               ATAGSDRQVIPAKSKVYDSQGLLIPSGMDLC                               DCLDEDCLGCFYACPACGSTKCGAECRCDRK                               WLYEQIEIEGGEIIHNKHAG               1003   2353   77   8427   3   1416   TEWGLSGSCPGCSPLEPGSRGRGAAAWRILR                               CRRLPEPSPFLTQPNLAQSQPPAPVPVTDPSVT                               MHPAVPLSLPDLRCSLLLLVTWVFTPVTTEIT                               SLDTENIDEILNNADVAILVNFYADWCRFSQM                               LHPIFEEASDVIKEEFPNENQVVFARVDCDQH                               SDIAQRYRISKYPTLKLFRNGMMMKREYRGQ                               RSVKALADYIRQQKSDPIQEIRDLAEITTLDRS                               KRNIIGYFEQKDSDNYRVFERVAMLHDDCAF                               LSAFGDVSKPERYSGDNIIYKPPGHSAPDMVY                               LGAMTNFDVTYNWIQDKCVPLVREITFENGE                               ELTEEGLPFLILFHMKEDTESLEIFQNEVARQL                               ISEKGTINFLHADCDKFRHPLLHIQKTPADCP                               VIAIDSFRHMYVFGDFKDVLIPGKLKQFVFDL                               HSGKLHREFHHGPDPTDTAPGEQAQDVASSP                               PESSFQKLAPSEYRYTLLRDRDEL               1004   2354   A   8432   910   387   GLSRKLRAGFLPGFCRVSPCGSWVVETLVKM                               ACAAARSPADQDRFICIYPAYLNNKKTIAEGR                               RIPLSKAVENPTATEIQDVCSAVGLNVFLEKN                               KMYSREWNRDVQYRGRVRVQLKQEDGSLC                               LVQFPSRKSVMLYAAEMHPKLKTRTQKTGGA                               DQSLQQGEGSKKGKGKKKK               1005   2355   A   8453   90   530   QSHETKMQSGTHWRVLGLCLLSVGVWGQD                               GNEEMGGITQTPYKVSISGTIYILTCPQYPGSE                               ILWQHNDKNIGGDEDDKNIGSDEDHLSLKEF                               SELEQSGYYVCYPRGSKPEDANFYLYLRARG                               NPGLQNRYHRLFREDHSKGHSQ               1006   2356   A   8458   3   307   AVQRIRHEMNIFRLTGDLSHLAAIVILLLKIW                               KTRSCAGISGKSQLLFALVFTTRYLDLFTSF1S                               LYNTSMKVWYAIHRNVPHLQCTGLWTLNLC                               QLCIFN               1007   2357   A   8459   43   553   GAGAGGDWAAMDKLKKVLSGQDTEDRSGL                               SEVVEASSLSWSTRIKGFIACFAIGILCSLLGT                               VLLWVPRKGLHLFAVFYTFGNIASIGSTIFLM                               GPVKQLKRMFEPTRLIATIMVLLCFALTLCSA                               FWWHNKGLALIFCILQSLALTWYSLSFIPFAR                               DAVKKCFAVCLA               1008   2358   A   8462   487   150   AQDIRSVHSLGQKSTFVKHFRTLSHLHGLPDP                               PPHPPQERSPPSHPCMPSHRPQIPQLSNSGPS                               DPRWGCVGPSMPTSTCLPGAVEASTTKASLP                               KCPVDSSLPTPEACFL               1009   2359   A   8465   134   954   ETRVKTSLELLRTQLEPTGTVGNTIMTSQPVP                               NETIIVLPSNVINFSQAEKPEPTNQGQDSLKKH                               LHAEIKVIGTIQILCGMMVLSLGIILASASFSPN                               FTQVTSTLLNSAYPFIGPFFFIISGSLSIATEKRL                               TKLLVHSSLVGSILSALSALVGFIILSVKQATL                               NPASLQCELDKNNIPTRSYVSYFYHDSLYTTD                               CYTAKASLAGTLSLMLICTLLEFCLAVLTAVL                               RWKQAYSDFPGSVLFLPHSYIGNSGMSSKMT                               HDCGYEELLTS               1010   2360   A   8468   2   473   KYRYRRPYPVMEKICQVGPAGLAFILNISPVA                               HRVALCHLAGCQEQAAWYHTLQILFFLVSAY                               FFSCPVPEKYFPGSCDIVGHGHQIFHAFLSICT                               LSQLEAILLDYQGRQEIFLQRHGPLSVHMACL                               SFPFLAACSAATAALLRHKVKARLTKKDS               1011   2361   A   8478   5   409   TELSQLEKAHPPADMGRRKSKRKPPPKKKMT                               GTLETQFTCPFCNHEKSCDVKMDRARNTGVI                               SCTVCLEEFQTPITCILGNLGFFQRVGRGLESG                               PCSSGPLCALVQGQSRPEEQVPPSDFCGVRRC                               RAGFQGQ               1012   2362   A   8481   2810   1652   RTSTQKWQSVFNDSQEHLERFYCNPENDRM                               RMKYGGQEFWADLNAMNVYETTEFDQLRR                               LSTPPSSNVNSIYHTVWKFFCRDHFGWREYPE                               SVIRLIEEANSRGLKEVRFMMWNNHYTLHNS                               FFRREIKRRPLFRSCFILLPYLQTLGGVPTQAP                               PPLEATSSSQIICPDGVTSANFYPETWVYMHP                               SQDFIQVPVSAEDKSYRITYNLPHKTVPEFKYR                               TLQILRVQNQFLWEKYKRKKEYMNRKMFGR                               DRIINERHLFHGTSQDVVDGICKHNFDPRVCG                               KHATMFGQGSYFAKKASYSHNFSKKSSKGV                               HFMFLAKVLTGRYTMGSHGMRRPPPVNPGS                               VTSDLYDSCVDNFFEPQIFVIFNDDQSYPYFVI                               QYEEVSNTVSI               1013   2363   A   8488   2   517   IENCRTRLRQAWHEVCGNKMAAPIPQGFSCL                               SRFLGWWFRQPVLVTQSAAIVPVRTKKRFTP                               PIYQPKFKTEKEFMQHARKAGLVIPPEKSDRS                               IHLACTAGIFDAYVPPEGDARISSLSKEGLIER                               TERMKKTMASQVSTRRIKDYDANFKIKDFPE                               KAKDIFIEGSPLY               1014   2364   A   8501   363   11   YIRTGYVYICIIYAQLMYTYYIRTAYVYICILY                               AQLMYTYVLYTHSLCIHMYSIRTAYVYICIIY                               AQIMYTYVFYTHRLCIHMYSIRTDYVYICILY                               AQLMYTYVFYTHSYMSDE               1015   2365   A   8504   3   2190   NSSEHFSQAPQRLSFYSWYGSARLFRFRVPPD                               AVLLRWLLQVSRESGAACTDAEITVHFRSGA                               PPVINPLGTSFPDDTAVQPSFQVGVPLSTTPRS                               NASVNVSHPAPGDWFVAAHLPPSSQKIELKG                               LAPTCAYVFQPELLVTRVVEISIMEPDVPLPQ                               TLLSHPSYLKVFVPDYTRELLLELRDCVSNGS                               LGCPVRLTVGPVTLPSNFQKVLTCTGAPWPC                               RLLLPSPPWDRWLQVTAESLVGPLGTVAFSA                               VAALTACRPRSVTIQPLLQSSQNQSFNASSGL                               LSPSPDHQDLGRSGRVDRSPFCLTNYPVTRED                               MDVVSVFIFQPLDRVSVRVCSDTPSVMRLRL                               NTGMDSGGSLTISLRANKTEMRNETVVVACV                               NAASPFLGFNTSLNCTTAFFQGYPLSLSAWSR                               RANLIIPYPETDNWYLSLQLMCPENAEDCEQ                               AVVHVETTLYLVPCLNIICGPYGQCLLLRRHS                               YLYASCSCKAGWRGWSCTDNSTAQTVAQQR                               AATLLLTLSNLMFLAPIAVSVRRFFLVEASVY                               AYTMFFSTPYHACDQPGEAVLCILSYDTLQY                               CDFLGSQAAIWVTIILCMARLKTVLKYVLFLL                               GTLVIAMSLQLDRRGMWNMLGPCLFAFVIM                               ASMWAYRCGHRRQCYPTSWQRWAFYLLPG                               VSMASVGIAIYTSMMTSDNYYYTHSIWHILL                               AGSAALLLPPPDQPAEPWACSQKFPCHYQIC                               KNDREELYAVT               1016   2366   A   8511   1   453   KWYPSGPVRIPCIRFYYKLPAGHRRCRMAPAK                               KGGEKKKGRSAINEVVTREYTINTHKRIHGVG                               FKKRAPRALKEIRKFAMKEMGTPDVRIDTRL                               NKAVWAKGIRNVPYRIRVRLSRKRNEDEDSP                               NKLYTLVTYVPVTTFKNLQTVNVDEN               1017   2367   A   8513   54   1196   LERTPASADMAWTKYQLFLAGLMLVTGSINT                               LSAKWADNFMAEGCGGSKEHSFQHPFLQAV                               GMFLGEFSCLAAFYLLRCRAAGQSDSSVDPQ                               QPFNPLLFLPPALCDMTGTSLMYVALNMTSA                               SSFQMLRGAVIIFTGLFSVAFLGRRLVLSQWL                               GILATIAGLVVVGLADLLSKHDSQHKLSEVIT                               GDLLIIMAQIIVAIQMVLEEKFVYKHNVHPLR                               AVGTEGLFGFVILSLLLVPMYYIPAGSFSGNP                               RGTLEDALDAFCQVGQQPLIAVALLGNISSIA                               FFNFAGISVTKELSATTRIAVLDSLRTVVIWAL                               SLALGWEAFHALQILGFLILLIGTALYNGLHR                               PLLGRLSRGRPLAEESEQERLLGGTRTPINDA                               S               1018   2368   A   8518   324   694   SPFWTEKRRMEKPLFPLVPLHWFGFGYTALV                               VSGGIVGYVKTGSVPSLAAGLLFGSLAGLGA                               YQLYQDPRNVWGFLAATSVTFVGVMGMRS                               YYYGKFMPVGLIAGASLLMAAKVGVRMLM                               TSD               1019   2369   A   8526   2   1787   VSAAAVNMEPPDAPAQARGAPRLLLLAVLL                               AAHPDAQAEVRLSVPPLVEVMRGKSVILDCT                               PTGTHDHYMLEWFLTDRLSGARPRLASAEMQ                               GSELQVTMHDTRGRSPPYQLDSQGRLVLAEA                               QVGDERDYVCVVRAGAAGTAEAAARLNVF                               AKPEATEVSPNKGTLSVMEDSAQEIATSNSRN                               GNPAPKITWYRNGQRLEVPVEMNPEGYMTS                               RTVREASGLLSLTSTLYLRLRKDDRDASFHC                               AAHYSLPEGRHGRLDSPTFHLTLHYPTEHVQ                               FWVGSPSTPAGWVREGDTVQLLCRGDGSPSP                               EYTLFRLQDEQEEVLNVNLEGNLTLEGVTRG                               QSGTYGCRVEDYDAADDVQLSKTLELRVAY                               LDPLELSEGKVLSLPLNSRAVVNCSVHGLPTP                               ALRWTKDSTPLGDGPMLSLSSITFDSNGTYVC                               EASLPTVPVLSRTQNFTLLVQGSPELKTAEIEP                               KADGSWREGDEVTLICSARGHPDPKLSWSQL                               GGSPAEPIPGRQGWVSSSLTLKVTSALSRDGI                               SCEASNPHGNKRHVFHFGTVSPQTSQAGVAV                               MAVAVSVGLLLLVVAVFYCVRRKGGPCCRQ                               RREKGAP               1020   2370   A   8530   2   1200   PRVRLLRPSRSRSCRGLLSTRAPGPSPFRSLHS                               SPLLPHAMKSPFYRCQNTTSVEKGNSAVMGG                               VLFSTGLLGNLLAILGLLARSGLGWCSRRPLR                               PLPSVFYMLVCGLTVTDLLGKCLLSPVVLAA                               YAQNRSLRVLAPALDNSLCQAFAFFMSFPGL                               SSTLQLLAMALECWLSLGHPFFYRRHITRLG                               ALVAPVVSAFSLAFCALPFMGFGKFVQYCPG                               TWCFIQMVHEEGSLSVLGYSVLYSSLMALLV                               LATVLCNLGAMRNLYAMHRRLQRHPRSCTR                               DCAEPRADGREASPQPLEELDHLLLLALMTV                               LFTMCSLPVIYRAYYGAFKDVKEKNRTSEEA                               EDLRALRFLSVISIVDPWTFIIFRSPVFRWFHKI                               FIRPLRYRSRCSNSTNMESSL               1021   2371   A   8536   1   237   RRGEIDMATEGDVELELETETSGPERPPEKPR                               KHDSGAADLERVTDYAEEKEIQSSNLETAMS                               VIGDRRSREQKAKQER               1022   2372   A   8537   94   541   RKERRRRRRRMEAVVFVFSLLDCCALIFLSV                               YFIITLSDLECDYINARSCCSKLNKWYIFELIG                               HTIVTVLLLMSLHWFIFLLNLPVATWNIYRYI                               MVPSGNMGVFDPTEIHNRGQLKSHMKEAMI                               KLGFHLLCFFMYLYSMILALIND               1023   2373   A   8540   26   431   RMIVIKCPQALLAIFWLLLSWVSSEDKVVQSPL                               SLVVHEGDTVTLNCSYEVTNFRSLLWYKQEK                               KAPTFLFMLTSSGIEKKSGRLSSILDKKELSSIL                               NITATQTGDSAIYLCAVEAQCSLVTCSLYSNS                               TAEALQL               1024   2374   A   8544   1731   743   GVRLRYSPIAVVMVGEAGRDLRRRRAVAVT                               AEKMAVLAFLIALVYSVPRLSRWLAQPYYLL                               SALLSAAFLLVRKLPPLCHGLPTQREDGNPCD                               FDWREVEILMFLSAIVMMKNRRSITVEQHIGN                               IFMFSKVANTILFFRLDIRMGLLYITLCIVFLM                               TCKPPLYMGPEYIKYFNDKTIDEELERDKRVT                               WIVEFFANWSNDCQSFAPIYADLSLKYNCTG                               LNFGKVDVGRYTDVSTRYKVSTSPLTKQLPT                               LILFQGGKEAMRRPQIDKKGRAVSWTFSEEN                               VIREFNLNELYQRAKKLSKAGDNWEEQPVAS                               TPTTVSDGENKKDK               1025   2375   A   8546   2194   1707   TVSFHKTMASLKCSTVVCVICLEKPKYRCPA                               CRVPYCSVVCFRKITKEQCNPETRPVEKKIRS                               AIPTKTVKPVENKDDDDSIADFLNSDEEEDR                               VSLQNLKNLGESATLRSLLLNPHLRQLMVNL                               DQGEDKAKLMRAYMQEPLFVEFADCCLGIV                               EPSQNEES               1026   2376   A   8547   1078   594   VGMELPAVNLKV1LLGHWLLTTWGCIVFSGS                               YAWANFTILALGVWAVAQRDSIDAISMFLGG                               LLATFLDIVH1SWYPRVSLTDTGRFGVGMIL                               SLLLKPLSCCFVYHMYRERGGELLVHTGFLG                               SSQDRSAYQTIDSAEAPADPFAVPEGRSQDAR                               GY               1027   2377   A   8557   1   340   DFLGPASPQEEGGSESSTMTELETAMGMIIDV                               FSRYSGSEGSTQTLTKGELKVLMEKELPGFLQ                               SGKDKDAVDKLLKDLDANGDAQVDFSEFTVF                               VAAITSACHKYFEKAGLK               1028   2378   A   8569   20   963   KMAATLGPLGSWQQWRRCLSARDGSRRLLL                               LLLLGSGQGPQQVGAGQTFEYLKREHSLSKP                               YQGEAPRPCFLRDWELQVHFKIHGQGKKNL                               HGDGLAIWYTKDRMQPGPVFGNMDKFVGLG                               VFVDIYPNEEKQQERVFPYISAMYNNGSLSY                               DHERDGRPTELGGGTAIVRNLHYDTFLVIRY                               VKRHLTIMMDIDGKHEWRDCIEVPGVRLPRG                               YYFGTSSITGDLSDNHDVISLKLFELTVERTPE                               EEKLHRDVFLPSVDNMKLPEMTAPLPPLSGL                               ALFLIVFFSLVFSVFAIWGLLYNKWQEQSRK                               REY               1029   2379   A   8572   1   578   AAAASHRSRARSRPRRVSSGPAPRRAQSSAG                               RVASGLDSAPLCTMARALCRLPRRGLWLLLA                               HHLFMTTACQEANYGALLRELCLTQFQVDM                               EAVGERWCDWGRT1RSYRELADCTWHMAE                               KLGCFWPNAEVDRFPLAVHGRYFRSCPISGR                               AVRDPPGSILYPFWVPITVTLLVTALVVWQS                               KRTEGIV               1030   2380   A   8574   1352   372   DSSTVKGGSESRHLCLLPDLKGKARTREASSG                               SRTCGRRTSLCTSAKSSWTYRSGRLSWQSIKG                               THLTITQALRQPLHRAPLLPGQLCWSPRPLEK                               NKAMGRPLLLPLLLLLQPPAFLQPQGSTGSGP                               SYLYGVTQPKHLSASMGGSVEIPFSFYYPWEL                               AIVPNVRISWRRGHFHGQSFYSTRPPSIHKDY                               VNRLFLNWTEGQESGFLPISNLRKEDQSVYF                               CRVELDTRRSGRQQLQSIKGTKLTITQAVTTT                               TTWRPSSTTTIAGLRVTESKGHSESWHLSLDT                               AIRVALAVAVLKTVILGLLCLLLLWWRRRKG                               SRAPSSDF               1031   2381   A   8580   905   340   RRTAGIYPCFPKPGRTRIIALCSVVLLLLTGQL                               AFDDFQESCAMMWQKYAGSRRSMPLGARIL                               FHGVFYAGGFAIVYYLIQKFHSRALYYKLAV                               EQLQSHPEAQEALGPPLNIHYLKLIDRENFVDI                               VDAKLKIPVSGSKSEGLLYVHSSRGGPFQRW                               HLDEVFLELKDGQQIPVFKLSGENGDEVKKE               1032   2382   A   8593   2558   961   RRRPLLPGAEPCEPRVGPRRADMGCSAKAR                               WAAGALGVAGLLCAVLGAVMIVMVPSLIKQ                               QVLKNVRIDPSSLSFNMWKEWIPFYLSVYFFD                               VMNPSEILKGEKPQVRERGPYVYREFRHKSNI                               TFNNNDTVSFLEYRTFQFQPSKSHGSESDYIV                               MPNILVLGAAVMMENKPMTLKLIMTLAFTTL                               GERAFMNRTVGEIMWGYKDPLVNLINKYFP                               GMFPFKDKFGLFAELNNSDSGLFTGFTGVQNI                               SRIHLVDKWNGLSKVDFWHSDQCNMINGTS                               GQMWPPFMTPESSLEFYSPEACRSMKLMYKE                               SGVFEGIPTYRFVAPKTLFANGSIYPPNEGFCP                               CLESGIQNVSTCRFSAPLFLSHPHFLNADPVL                               AEAVTGLHPNQEAHSLFLDIHPVTGIPMNCSV                               KLQLSLYMKSVAGIGQTGKIEPVVLPLLWFA                               ESGAMEGETLHTPYTQLVLMPKVMHYAQYV                               LLALGCVLLLVPVICQIRSQEKCYLFWSSSKK                               GSKDKEAIQAYSESLMTSAPKGSVLQEAKL               1033   2383   A   8595   595   767   AHLPDTLLLPPHSPTVPTPKSFQCSQKACFSRS                               FCLLLSLVSSSLVSLSLCPPLTQA               1034   2384   A   8597   640   164   VTTSCIIPFAFGLGVRASERLAEIDMPYLLKYQ                               PMMQTIGQKYCMDPAVIAGVLSRKSPGDKTL                               VNMGDRTSMVQDPGSQAPTSWISESQVFQTT                               EVLTTRITELQRRFPTWTPDQYLRGGLCAYSG                               GAGYVRSSQDLSCDFCNDVLARAKYLKRHG                               F               1035   2385   A   8603   936   204   AMASTLEYSPSPLRRLVGPAAGFSRAARADL                               SWDPMAFFTGLWGPFTCVSRVLSHHCFSTTG                               SLSAIQKMTRVRVVDNSALGNSPYHRAPRCI                               HVYKKNGVGKVGDQILLAIKGQKKKALIVG                               HCMPGPRMTPRFDSNNVVLIEDNGNPVGTRI                               KTPIPTSLRKREGEYSKVLAIAQNFV               1036   2386   A   8606   1   562   PTRAHSFDLCCSPCRRRLLGREEAGEEPTSPV                               TQYLQPRSPEECKMFACAKLACTPSLIRAGSR                               VAYRPISASVLSRPEASRTGEGSTVFNGAQNG                               VSQLIQREFQTSAISRDIDTAAKFIGAGAATVG                               VAGSGAGIGTVFGSLIIGYARNPSLKQQLFSY                               AILGFALSEAMGLFCLMVAFLILFAM               1037   2387   A   8615   2   2364   SPGPSLPESAESLDGSQEDKPRGSCAEPTFTDT                               GMVAHINNSRLKAKGVGQHDNAQNFGNQSF                               EELRAACLRKGELFEDPLFPAEPSSLGFKDLG                               PNSKNVQNISWQRPKDIINNPLFIMDGISPTDI                               CQGILGDCWLLAAIGSLLCPKLLYRVVPRG                               QSFKKNYAGIFHFQIWQFGQWVNVVVDDRL                               PTKNDKLVFVHSTERSEFWSALLEKAYAKLS                               GSYEALSGGSTMEGLEDFTGGVAQSFQLQRP                               PQNLLRLLRKAVERSSLMGCSIEVTSDSELES                               MTDKMLVRGHAYSVTGLQDVHYRGKMETLI                               RVRNPWGRIEWNGAWSDSAREWEEVASDIQ                               MQLLHKTEDGEFWMSYQDFLNNFTLLEICNL                               TPDTTLSGDYKSYWHTTFYEGSWRTGSSAGGC                               RNHPGTFWTNPQFKISLPEGDDPEDDAEGNV                               VVCTCLVALMQKNWRHARQQGAQLQTIGFV                               LYAVPKEFQNIQDVHLKKEFFTKYQDHGFSEI                               FTNSREVSSQLRLPPGEYIIIPSTFEPHRDADFL                               LRVFTEKHSESWELDEVNYAEQLQEEKVSED                               DMDQDFLHLFKWAGEGKEIGVYELQRLLNR                               MAIKFKSFKTKGFGLDACRCMINLMDKDGSG                               KLGLLEFKILWKKLKKWMDIFRECDQDHSGT                               LNSYEMRLVIEKAGIKLNNKVMQVLVARYA                               DDDLIIDFDSFISCFLRLKTMFTFFLTMDPKNT                               GHICLSLEQVLGEGWEGICRIAPACPSTPPPPS                               SDVPGPASCPRLFPPWDLLPVSTVAADDHVGI               1038   2388   A   8621   3   1494   RSRMARAPLGVLLLLGLLGRGVGKNEELRLY                               HHLFNNYDPGSRPVREPEDTVTISLKVTLTNL                               ISLNEKEETLTTSVWIGIDWQDYRLNYSKDDF                               GGIETLRVPSELVWLPEIVLENNIDGQFGVAY                               DANVLVYEGGSVTWLPPAIYRSVCAVEVTYF                               PFDWQNCSLIFRSQTYNAEEVEFTFAVDNDG                               KTINKIDIDTEAYTENGEWAIDFCPGVIRRHH                               GGATDGPGETDVIYSLIIRRKPLFYVINIIVPCV                               LISGLVLLAYFLPAQAGGQKCTVSINVLLAQT                               VFLFLIAQKIPETSLSVPLLGRFLIFVMVVATLI                               VMNCVIVLNVSQRTPTTHAMSPRLRHVLLEL                               LPRLLGSPPPPEAPRAASPPRRASSVGLLLRAE                               ELILKKPRSELVFEGQRHRQGTWTAAFCQSL                               GAAAPEVRCCVDAVNFVAESTRDQEATGEE                               VSDWVRMGNALDNICFWAALVLFSVGSSLIF                               LGAYFNRVPDLPYAPCIQP               1039   2389   A   8636   1   900   PGRERPGGGGARRRPQHLPALLPSERPDCATL                               QAMENELPVPHTSSSACATSSTSGASSSSGCN                               NSSSGGSGRPTGPQISVYSGIPDRQTVQVIQQ                               ALHRQPSTAAQYLQQMYAAQQQHLMLQTA                               ALQQQHLSSAQLQSLAAVQQASLVSNRQGST                               SGSNVSAQAPAQSSSINLAASPAAAQLLNRA                               QSVNSAAASGIAQQAVLLGNTSSPALTASQA                               QMYLRAQMLIFTPTATVATVQPELGTGSPAR                               PPTPAQVQNLTLRTQQTPAAAASGPTPTQPVL                               PSLALKPTPGGSQPLPTPA               1040   2390   A   8645   98   1388   ASQLAFGGKLTSTPSRDFQGCGRGAVTCCSF                               HEHRLQSGRCLSTGMAPNLKQRPRKKKPCPQ                               RRDSFSGVKDSNNNSDGKAVAKVKCEARSA                               LTKPKNNHNCKKVSNEEKPKVAIGEECRADE                               QAFLVALYKYMKERKTPIERIPYLGFKQINLW                               TMFQAAQKLGGYETITARRQWKIUYDELGG                               NPGSTSAATCTRRHYERLILPYERFIKGEEDKP                               LPPIKPRKQENSSQENENKTKVSGTKRIKHEIP                               KSKKEKENAPKPQDAAEVSSEQEKEQETLISQ                               KSIPEPLPAADMKKKIEGYQEFSAKPLASRVD                               PEKDNETDQGSNSEKVAEEAGEKGPTPPLPSA                               PLAPEKDSALVPGASKQPLTSPSALVDSKQES                               KLCCFTESPESEPQEASPPRLPHHTGHRWQTR                               MRRRMTNCPPWQITLPTAP               1041   2391   A   8646   113   1492   LLQEMCTKTIPVLWGCFLLWNLYVSSSQTIYP                               GIKARITQRALDYGVQAGMKMIEQMLKEKK                               LPDLSGSESLEFLKVDYVNYNFSNIKISAFSFP                               NTSLAFVPGVGIKALTNHGTANISTDWGFESP                               LFVLYMSFAEPMEKPILKNLNEMLCPIIASEVK                               ALNANLSTLEVLTKIDNYTLLDYSLISSPEITE                               NYLDLNLKGVFYPLENLTDPPFSPVPFVLPER                               SNSMLYIGIAEYFFKSASFAHFTAGVFNVTLS                               TEEISNHFVQNSQGLGNVLSRIAEIYIILSQPFM                               VRIMATEPPIINLQPGNFTLDIPASIMMLTQPK                               NSTVETIVSMDFVASTSVGLVILGQRLVCSLS                               LNRFRLALPESNRSNIEVLRPENILSSILHFGVL                               PLANAKLQQGFPLPNPHKPLFVNSDIEVLEGF                               LLISTDLKYETSSKQQPSFHVWEGLNLISRQW                               RGKSAP               1042   2392   A   8672   538   170   ARRIARTRESKAAVSQDNVPALQPGKKKKLR                               LGGKKKKFKFFRLPKEFKKQLMYSPSNFKKM                               TSLAGNTVQCLNKLKYVIYSAQYPAYGNYIT                               LDMITSTDHVLEQDFWICFTFYSVKERQI               1043   2393   A   8688   359   17   GLKTRAIPATPTFQREVLGPAKQDMQRRCPRI                               GLMTSLLKPIKRRWRDYKRWKSGGFTGESC                               HHADTLGDRGGLQGDHSELLQWQKRILRTE                               GEPSPKYISKNIFPICSYITGFL               1044   2394   A   8718   292   1490   GTVKTSVATPITAGHSCSSGGVLQVKSPATQS                               GFKFTSKMEDFNMESDSFEDFWKGEDLSNYS                               YSSTLPPFLLDAAPCEPESLEINKYFVVIIYAL                               VFLLSLLGNSLVMLVILYSRVGRSVTDVYLL                               NLALADLLFALTLPIWAASKVNGWIFGTFLC                               KVVSLLKEVNFYSGILLLACISVDRYLAIVHA                               TRTLTQKRYLVKFICLSIWGLSLLLALPVLLFR                               RTVYSSNVSPACYEDMGNNTANWRMLLRIL                               PQSFGFIVPLLIMLFCYGFTLRTLFKAHMGQK                               HRAMRVIFAVVLIFLLCWLPYNLVLLADTLM                               RTQVIQETCERRNHIDRALDATEILGILHSCLN                               PLIYAFIGQKFRHGLLKILAIHGLISKDSLPKDS                               RPSFVGSSSGHTSTTL               1045   2395   A   8724   254   3184   FRANLAITVANRRGAQGGKMHTCCPPVTLEQ                               DLHRKMHSWMLQTLAFAVTSLVLSCAETIDY                               YGEICDNACPCEEKDGILTVSCENRGIISLSEIS                               PPRFPIYHLLLSGNLLNRLYPNEFVNYTGASIL                               HLGSNVIQDIETGAFHGLRGLRRLHLNNNIKL                               ELLRDDTFLGLENLEYLQVDYNYISVIEPNAF                               GKLHLLQVLILNDNLLSSLPNNLFRFVPLTHL                               DLRGNRLKLLPYVGLLQHMDKVVELQLEEN                               PWNCSCELTSLKDWLDSISYSALVGDVVCETP                               FRLHGRDLDEYSKQELCPRRLISDYEMRPQTP                               LSTTGYLHTTPASVNSVATSSSAVYKPPLKPP                               KGTRQPNKPRVRPTSRQPSKDLGYSNYGPSIA                               YQTKSPVPLECPTACSCNLQISDLGLNVNCQE                               RKIESIAELQPKPYNPKKMYLTENYIAVVRRT                               DLLEATGLDLLHLGNNRISMIQDRAFGDLTN                               LRRLYLNGNRIERLSPELFYGLQSLQYLFLQY                               NLIREIQSGTFDPVPNLQLLFLNNNLLQAMPS                               GVFSGLTLLRLNLRSNHFTSLPVSGVLDQLKS                               LIQIDLHDNPWDCTCDIVGMKLWVEQLKVG                               VLVDEVICKAPKKFAETDMRSIKSELLCPDYS                               DVVVSTPTPSSIQVPARTSAVTPAVRLNSTGA                               PASLGAGGGASSVPLSVLILSLLLVFIMSVFVA                               AGLFVLVMKRRKKNQSDHTSTNNSDVSSFN                               MQYSVYGGGGGTGGHPHAHVHHRGPALPK                               VKTPAGHVYEYIPHPLGHMCKNPIYRSREGN                               SVEDYKDLHELKWFYSSNHIILQQQQQPPPPP                               QQPQQQPPPQLQLQPGEEERRESHHLRSPAYS                               VSTIEPREDLLSPVQDADRFYRGILEPDKHCST                               TPAGNSLPEYPKFPCSPAAYTFSPNYDLRRPH                               QYLHPGAGDSRLREPVLYSPPSAVFVEPNRNE                               YLELKAKLNVEPDYLEVLEKQTTFSQF               1046   2396   A   8736   28   452   SPSAAGCILAWVSLALGSGSRCIRDHSGSGVGT                               AMAGALVRKAADYVRSKDFRDYLMSTHFW                               GPVANWGLPIAANDMKKSPEIISGRMTFALC                               CYSLTFMRFAYKVQPRNWLLFACHATNEVA                               QLIQGGRLIKHEMTKTASA               1047   2397   A   8741   673   924   ALPGTPQQTVTLNTDGKVKSFTSPHSNPNLPP                               AKFFTSLQSLNWSSHLPPSPATESVGKRGNAK                               PPTTKLLHSSPLWNFFAQQL               1048   2398   A   8747   3   5054   PEVTKPSLSQPTAASPIGSSPSPPVNGGNNAKR                               VAVPNGQPPSAARYMPREVPPRFRCQQDHIK                               VLLKRGQPPPPSCMLLGGGAGPPPCTAPGAN                               PNNAQVTGALLQSESGTAPDSTLGGAAASNY                               ANSTWGSGASSNNGTSPNPIHIWDKVIVDGS                               DMEEWPCIASKDTESSSENTIDNNSASNPGSE                               KSTLPGSTTSNKGKGSQCQSASSGNECNLGV                               WKSDPKAKSVQSSNSITENNNGLGNWRNVS                               GQDRIGPGSGFSNFNPNSNPSAWPALVQEGTS                               RKGALETDNSNSSAQVSTVGQTSREQQSKME                               NAGVNFVVSGREQAQIHNTDGPKNGNTNSL                               NLSSPNPMENKGMPFGMGLGNTSRSTDAPSQ                               STGDRKTGSVGSWGAARGPSGTDTVSGQSNS                               GNNGNNGKEREDSWKQASVQKSTGSKNDS                               WDNNNRSTGGSWNFGPQDSNDNKWGEGNK                               MTSGVSQGEWKQPTGSDELKIGEWSGPNQPN                               SSTGAWDNQKGHPLLENQGNAQAPCWGRSS                               SSTGSEVEGQSTGSNHKAGSSDSHNSGRRSY                               RPTHPDCQAVLQTLLSRTDLDPRVLSNTGWG                               QTQIKQDTVWDIEEVPRPEGKSDKGTEGWES                               AATQTKNSGGWGDAPSQSNQMKSGWGELS                               ASTEWKDPKNTGGWNDYKNNNSSNWGGGR                               PDEKTPSSWNENPSKDQGWGGGRQPNQGWS                               SGKNGWGEEVDQTKNSNWESSASKPVSGWG                               EGGQNEIGTWGNGGNASLASKGGWEDCKRS                               PAWNETGRQPNSWNKQHQQQQPPQQPPPPQ                               PEASGSWGGPPPPPPGNVRPSNSSWSSGPQPA                               TPKDEEPSGWEEPSPQSISRKMDIDDGTSAWG                               DPNSYNYKNVNLWDKNSQGGPAPREPNLPTP                               MTSKSASDSKSMQDGWGESDGPVTGARHPS                               WEEEEDGGVWNTTGSQGSASSHNSASWGQG                               GKKQMKCSLKGGNNDSWMNPLAKQFSNMG                               LLSQTEDNPSSKMDLSVGSLSDKKFDVDKRA                               MNLGDFNDIMRKDRSGFRPPNSKDMGTTDS                               GPYFEKGGSHGLFGNSTAQSRGLHTPVQPLN                               SSPSLRAQVPPQFISPQVSASMLKQFPNSGLSP                               GLFNVGPQLSPQQIAMLSQLPQIFQFQLACQL                               LLQQQQQQQLLQNQRKISQAVRQQQEQQLA                               RMVSALQQQQQQQQRQPGMKHSPSHPVGPK                               PHLDNMVPNALNVGLPDLQTKGPIPGYGSGF                               SSGGMDYGMVGGKEAGTESRFKQWTSMME                               GLPSVATQEANMHKNGAIVAPGKTRGGSPY                               NQFDIIPGDTLGGHTGPAGDSWLPAKSPPTNK                               IGSKSSNASWPPEPQPGVPWKGIQNIDPESDP                               YVTPGSVLGGTATSPIVDTDHQLLRDNTTGS                               NSSLNTSLPSPGAWPYSASDNSFTNVHSTSAK                               FPDYKSTWSPDPIGHNPTHLSNKMWKNHISS                               RNTTPLPRPPPGLTNPKPSSPWSSTAPRSVRG                               WGTQDSRLASASTWSDGGSVRPSYWLVLHN                               LTPQIDGSTLRTICMQHGPLLTFHLNLTQGTA                               LIRYSTKQEAAKAQTALHMCVLGNTTLLAEF                               ATDDEVSRFLAQAQPPTPAATPSAPAAGWQS                               LETGQNQSDPVGPALNLFGGSTGLGQWSSSA                               GGSSGADLAGASLWGPPNYSSSLWGVPTVED                               PHRMGSPAPLLPGDLLGGGSDSI               1049   2399   A   8748   200   1387   VPWKRQDEQLSLQYETLYLDSPAVIHLLSPTF                               LPPSSLPPFLQIVDSSSSACTLDSFFPFLAPWDS                               PQDCGFKDHQPLTLQALTVELARWTLMLLLS                               TAMYGAHAPLLALCHVDGRVPFRPSSAVLLT                               ELTKLLLCAFSLLVGWQAWPQGPPPWRQAA                               PFALSALLYGANNNLVIYLQRYMDPSTYQVL                               SNLKIGSTAVLYCLCLRHRLSVRQGLALLLL                               MAAGACYAAQGLQVPGNTLPSPPPAAAASP                               MPLHITPLGLLLLILYCLISGLSSVYTELLMKR                               QRLPLALQNLFLYTFGVLLNLGLHAGGGSGP                               GLLECIFSGWAALVVLSQALNGLLMSAVMKH                               GSSITRLFVVSCSLVVNAVLSAVLLRLQLTAA                               FFLATLLIGLAMRLYYGSR               1050   2400   A   8758   3   1660   WVSSMGFEELLEQVGGFGPFQLRNVALLALP                               RVLLPLIIFLLPIFLAAVPAHRCALPGAPANFS                               HQDVWLEAHLPREPDGTLSSCLRFAYPQALP                               NTTLGEERQSRGELEDEPATVPCSQGWEYDH                               SEFSSTIATESQWDLVCEQKGLNRAASTFFFA                               GVLVGAVAFGYLSDRFGRRRLLLVAYVSTLV                               LGLASAASVSYVMFAIITRTLTGSALAGFTILV                               MPLELEWLDVEHRTVAGVLSSTFWTGGVML                               LAIVGYLIRDWRWLLLAVTLPCAPGILSLWW                               VPESARWLLTQGHVKEAHRYLLHCARLNGR                               PVCEDSFSQEAVSKVAAGERVVRRPSYLDLF                               RTPRLRHISLCCVVVWFGVNFSYYGLSLDVS                               GLGLNVYQTQLLFGAVELPSKLLVYLSVRYA                               GRRLTQAGTLLGTALAFGTRLLVSSDMKSWS                               TVLAVMGKAFSEAAFTTAYLFTSELYPTVLR                               QTGMGLTALVGRILGGSLAPLAALLDGVWLS                               LPKLTYGGIALLAAGTALLLPETRQAQLPETI                               QDVERKSAPTSLQEEEMPMKQVQN               1051   2401   A   8759   515   1625   EIRTPVAVSSAPSGDSEGDEEETTQDEVSSHTS                               EEDGGVVKVEKELENTEQPVGGNEVVEHEV                               TGNLNSDPLLELCQCPLCQLDCGSREQLIAHV                               YQHTAAVVSAKSYMCPVCGRALSSPGSLGR                               HLLIHSEDQRSNCAVGGARFTSHATFNSEKLP                               EVLNMESLPTVHNEGPSSAEGKDIAFSPPVYP                               AGILLVCNNCAAYRICLLEAQTPSVRKWALRR                               QNEPLEVRLQRLERERTAKKSRRDNETPEERE                               VRRMRDREAKRLQRMQETDEQRARRLQRDR                               EAMRLKRANETPEKRQARLIREREAKRLKRR                               LEKMDMMLRAQFGQDPSAMAALAAEMNPF                               QLPVSGVELDSQLLGKMAFEEQNSSSLH               1052   2402   A   8763   1106   70   RHGHGGRDRRGGGRVARPGGLGRYPGRGAA                               ASLVFVPTRRRSGPSGTASVAAMAYHSGYGA                               HGSKHRARAAPDPPPLFDDTSGGYSSQPGGY                               PATGADVAFSVNHLLGDPMANVAMAYGSSI                               ASHGKDMVHKELHRFVSVSKLKYFFAVDTA                               YVAKKLGLLVFPYTHQNWEVQYSRDAPLPP                               RQDLNAPDLYWTMAFITYVLLAGMALGIQK                               RFSPEVLGLCASTALVWVVMEVLALLLGLYL                               ATVRSDLSTFHLLAYSGYKYVGMILSVLTGL                               LFGSDGYYVALAWTSSALMYFIVRSLRTAAL                               GPDSMGGPVPRQRLQLYLTLGAAAFQPLIIY                               WLTFHLVR               1053   2403   A   8768   2   712   RPPRVWYPELRELSAAAPRWSHRTAPGIMVF                               YFTSSSVNSSAYTIYMGKDKYENEDLIKHGW                               PEDIWFHVDKLSSAHVYLRLHKGENIEDIPKE                               VLMDCAHLVKANSIQGCKMNNVNVVYTPW                               SNLKKTADMDVGQIGFHRQKDVKIVTVEKK                               VNEILNRLEKTKVERFPDLAAEKECRDREER                               NEKKAQIQEMKKREKEEMKKKEEMDELRSY                               SSLMKVENMSSNQDGNDSDEFM               1054   2404   A   8769   344   527   REAITLACRNSCWVFSRCSLGACKPTVCSMP                               SLSRQGSQTLCLRLAEYCMESVDSQRLLLS               1055   2405   A   8770   430   1104   QQESPAAGAARNCKEGTDSSCGCRGNDEK                               KMLKCVVVGDGAVGKTCLLMSYANDAFPEE                               YVPTVFDHYAVTVTVGGKQHLLGLYDTAGQ                               EDYNQLRPLSYPNTDVFLICFSVVNPASYHNV                               QEEWVPELKDCMPHVPYVLIGTQIDLRDDPK                               TLARLLYMKEKPLTYEHGVKLAKAIGAQCYL                               ECSALTQKGLKAVFDEAILTIFHPKKKKKRCS                               EGHSCCSII               1056   2406   A   8773   261   332   NPRIQLSGNSCCAGSCRVWLSEQ               1057   2407   A   8778   3   477   PAGIRHEQARGADRMGKCRGLRTARKLRSH                               RRDQKWHDKQYKKAHLGTALKANPFGGAS                               HAKGIVLEKVGVEAKQPNSAIRKCVRVQLIK                               NGKKITAFVPNDGCLNFIEENDEVLVAGFGR                               KGHAVGDIPGVRFKVVKVANVSLLALYKGK                               KERPRS               1058   2408   A   8808   171   881   PGLSQEPSGSMETVVIVAIGVLATIFLASFAAL                               LVCRQRYCRPRDLLQRYDSKPWDLIGAME                               TQSEPSELELDDVVITNPHIEAILENEDWEDA                               SGLMSHCIAILKICHTLTEKLVAMTMGSGAK                               MKTSASVSDIIVVAKRISPRVDDWKSMYPPL                               DPKLLDARTTALLLSVSHLVLVTRNACHLTG                               GLDWIDQSLSAAEEHLEVLREAALASEPDKG                               LPGPEGFLQEQSAI               1059   2409   A   8809   246   757   MRLQGAIFVLLPHLGPILVWLFTRDHMSGWC                               EGPRMLSWCPFYKVLLLVQTAIYSVVGYASY                               LVWKDLGGGLGWPLALPLGLYAVQLTISWT                               VLVLFFTVHNPGLALLHLLLLYGLVVSTALI                               WHPITNKLAALLLLPYLAWLTVTSALTYHLWR                               DSLCPVHQPQPTEKSD               1060   2410   A   8810   304   381   PKLSVYPLQSHHCLSEPFQSLVCCLA               1061   2411   A   8820   1673   848   SCKTENLLEMFQQGLSFLPSALVIWTSAA                               FIFSYITAVTLHHTDPALPYISDTGTVAPEKCLF                               GAMLNIAAVLCIATWVRYKQSPEENVI                               IKLNAGLVLGILSCLGLSIVANFQKTTLFAA                               HVSGAVLTFGMGSLYMFVQTILSYQMQPKIH                               GKQVFWIRLLLVIWCGVSALSMLTCSSVLHS                               GNPGTDLEQKLHWNPEDDKGYVLHMITTAAE                               WSMSFSFFGFFLTYIRDFQKISLRVEANLHGL                               TLYDTAFCPINNERTRLLSRDI               1062   2412   A   8824   1   763   GGAPPASVPARESPVSGAQGSSRTRGHKRAA                               GARAPQLCSSWQRRSAPAMSRGLQLLLLSCA                               YSLPATPEVKVACSEDVDLPCTAPWDPQVP                               YTVSWVKLLEGGEERMETPQEDHLRGQHYH                               QKGQNGSFDAPNERPYSLKIRNTTSCNSGTYR                               CTLQDPDGQRNLSGKVILRVTGCPAQRKEET                               FKKYRAEIVLLLALVIFYLTLIIFTCKFARLQSI                               FPDPSKAGMERFLPVTSPNKHLGLVTPHKT                               ELV               1063   2413   A   8826   147   627   CETSTSSAGHAPCRHAAQGPPAEPTGLRLCSE                               HQRLHAWPPGPRRPSLWPPKNGKWHSGKRT                               AGGRPQRRPSRRQSQRPSAWSGSPRMHSPGQ                               KCSLMCPHRSQDSLSTAIFQRSPGANTGRALH                               CVLSKEMKSVQRSLGLSRIILQSKRKIIHFVL                               TR               1064   2414   A   8835   2982   1869   LKDTLKSQMTQEASDEAEDMKEAMNRMIDE                               LNKQVSELSQLYKEAQAELEDYRKRKSLEDV                               TAEYIHKAEHEKLMQLTNVSRAKAEDALSE                               MKSQYSKVLNELTQLKQLVDAQKENSVSITE                               HLQVITTLRTAAKEMEEK1SNLKLASKEVE                               VAKLEKQLLEEKAAMTDAMVPRSSYEKLQS                               SLESEVSVLASKLKESVKEKEKVHSEVVQIRS                               EVSQVKREKENIQTLLKSKEQEVNELLQKFQ                               QAQEELAEMKRYSESSSKLEEDKDKKINEMS                               KEVTKLKEALNSLSQLSYSTSSSKRQSQQLEA                               LQQQVKQLQNQLAECKKQHQEVISVYRMHL                               LYAVQGQMDEDVQKVLKQILTMCKNQSQK                               K               1065   2415   A   8841   3   663   AAATAASLSPRGCRLRTPSSDVGPSRAPPPSA                               APLPTGRAQMSPSGRLCLLTTVGLILPTRGQTL                               KDTTSSSSADATIMDLQVPTRAPDAVYTELQP                               TSPTPTWPADETPQPQTQTQQLEGTDGPLVT                               DPETHKSTKAAHPTDDTTTLSERPSPSTDVQT                               DPQTLKPSGFHEDDPFFYDEHTLRKRGLLVA                               AVLFITGIIILTSGKCRQLSRLCRNHCR               1066   2416   A   8853   3806   2204   FVGEQEGGCEAGAGRGAQTYPGEAGERWFG                               RRRRRGRVVSRKKMSLKSERRGIHVDQSDLL                               CKKGCGYYGNPAWQGFCSKCWREEYHKAR                               QKQIQEDWELAERLQREEEEAFASSQSSQGA                               QSLTFSKFEEKKTNEKTRKVTTVKKFFSASSR                               VGSKKEIQEAKAPSPSINRQTSIETDRVSKEFIE                               FLKTFHKTGQEIYKQTKLFLEGMHYKRDLSIE                               EQSECAQDFYHNVAERMQTRGKVPPERVEKI                               MDQIEKYIMTRLYKYVFCPETTDDEKKDLAI                               QKRIRALRWVTPQMLCVPVNEDIPEVSDMVV                               KAITDIIEMDSKRVPRDKLACITKCSKHIFNAI                               KITKNEPASADDFLPTLIYIVLKGNPPRLQSNI                               QYITRFCNPSRLMTGEDGYYFTNLCCAVAFIE                               KLDAQSLNLSQEDFDRYMSGQTSPRKQEAES                               WSPDACLGVKQMYKNLDLLSQLNERQERIM                               NEAKKLEKDLIDWTDGIAREVQDIVEKYPLEI                               KPPNQPLAAIDSENVENDKLPPPLQPQVYAG               1067   2417   A   8855   1372   1513   SNMREVGCGWLVPVIPAFWEAEVGGSLEARS                               LRQAWATKQDPISKKK               1068   2418   A   8856   1530   1583   PCRPGMECNSMISVHCNL               1069   2419   A   8857   1530   1583   PCRPGMECNSMISVHCNL               1070   2420   A   8866   293   1675   PYPQGGYPQGPYPQEGYPQGPYPQGGYPQGP                               YPQSPFPPNPYGQPQVFPGQDPDSPQHGNYQ                               EEGPPSYYDNQDFPATNWDDKSLRQAFIRKVF                               LVLTLQLSVTLSTVSVFTFVAEVKGFVRENV                               WTYYVSYAVFFISLIVLSCCGDFRRKHPWNL                               VALSVLTASLSYMVGMIASFYNTEAVIMAVG                               ITTAVCFTVVIFSMQTRYDFTSCMGVLLVSM                               VVLFIFAILCIFIRNRILEIVYASLGALLFTCFLA                               VDTQLLLGNKQLSLSPEEYVFAALNLYTDIINI                               FLYILTIIGRAKE*PSSSSLCPLRWHGWPGPCP                               WHGSASCTSPLSCPQAQPREKDASLQPSCMY                               TADTSIWTRCGHSMAPLVLPPPPRGTKATFPC                               HLLSTHCCMSPVCQPTPGTGGSTRSRGEGLSQ                               EVRVHVFPPVPAPQPGVEHPSPPPHPPGVLPS                               GDMRSGGLIPVLSPE               1071   2421   A   8868   2   358   ARGNTLYHLPRLCRKLNLRWFSASTLYDVQH                               DDKMGSNTFFKRNDCRYVMISCKADMAYDN                               VRHPFMI*SI\KLIMEETYLNITKAVYDRPTASII                               LNGEKLKVPPVRSGT*QGGSVWP               1072   2422   A   8870   33   658   MESVLSKYEDQITIFTDYLEEYPDTDELVWIL                               GKQHLLKTEKSKLLSDISARLWFTYRRKFSPI                               GGTGPSSDAGWGCMLRCGQMMLAQALICRH                               LGRDWSWEKQKEQPKEYQRILQCFLDRKDC                               CYSIHQMAQMGVGEGKSIGEWVLGPNTV\AQ                               GV*KNLA\LFDEW\NSLGLVYVSM\DNPSGSIA                               RFPKKLCRVLPL\SADTAGLTGP               1073   2423   A   8879   146   412   DFSV*GDVDIEVTCPICLQLLTEPLSLNCGLRL                               *QVCITA*IKESVIISGG*SSSPVCHTTPQPANL                               RTSRYLPT*SIKSLGPDEPQEG               1074   2424   A   8884   67   435   HLQGRSIRTLQLTGENEKNCEVSERIRRSGPW                               KEISFGDYICHTFQGDCWADRSPLHEAAAHG                               RLLALKTLIAQGVNVNLWTLIDRVSSLHEACL                               *QPVACAKPYWKMVPRHGGTVTGPPLLMV               1075   2425   A   8896   1294   248   RSGDRNGLTHQLGGLSQGSRNQSYRSRSRSR                               SRERIPSAPRGIPFASASSSVYYGSYSRPYGSDK                               PWPSLLDKEREESLRQKRLSERERIGELGAPE                               VWGLSPKNPEPDSDEHTPVEDEEPKKSTTSAS                               TSEEEKKKKSSRSKERSKKREKKKSSKRKHK                               KYSEDSDSDSDSETDSSDEDNKRRAKKAKKK                               EKKKKHRSKKYKKKRSKKSRKESSDSSSKES                               QEEFLENPWKDRTKAEEPSDLIGPEAPKTLTS                               QDDKPLNYGHALLPGEGAAMAEYVKAGKRI                               PRRGEIGLTR*RNCHHLNAQVM**VVSRHRR                               MEAVRTAKREPESTVLMRREPLHPFNPRRET                               KERE               1076   2426   A   8899   146   789   GRSTEAEKEPAFDERTGKGRRLPRAGEFHG*E                               *APGPGPRSFQVSRKMPEE\PPGARKHPFSGKS                               FYLDLPAGKNLQFLTGAIQQLGGVIEGFLSKE                               VSYIVSSRREVKAESSGKSHRGCPSPSPSEVR                               VETSAMVDPKGSHPRPSRKPVDSVPLSRGKE                               LLQKAIRNQK**CTVQQLSHCRLY\GEKTTAK                               RSQREHVQQQSQEHGKWPDLKGPR               1077   2427   A   8901   352   3   AKIGAYKYIQELWRKKQSDVMHFLLRVRCW                               QYPALHRAGTEWQLSALHRAPRSTQPDKAC                               RLGYKAKQGYIIYRICVRRGGWKCPVPKAVT                               \YGKPVHHGVN*LKFAQSLQSVAEEQ               1078   2428   A   8905   536   781   ACPAENREVPEMAAGQAPHAGPGAGPGQPA                               PALPFAATPGSRGQALCRGGRRRQHLHGPLH                               RP*QAAPALHAGCQLAPHPPT               1079   2429   A   8912   121   376   NLIWKLCVTERRLVILDNYDLASE/YEANKYI                               CNRIIQFKPGQDKYFTLGLPTGSTPL*CYPKLI                               EYNKNGHLSFKYVKTFSMDEY               1080   2430   A   8920   381   1788   SSESPSDPGRMAIVITWIVFSLWPLTVFMGHIG                               GHSLFSCEPITLRMCQDLPYNFIFMPNLLNHY                               DQQTAALAMEPFHPMVNLDCSRDFRPFLCAL                               YAPICMEYGRVTLPCRRLCQRAYSECSKLME                               MFGVPWPEDMECSRFPDCDEPYPRLVDLNLA                               GEPTEGAPVAVQRDYGFWCPRELKIDPDLGY                               SFLHVRDCSPPCPNMYFRREELSFARYFIGLIS                               IICLSATLFTFVTFLITDVTRFRYPERPIKCYAV                               WHMMVSLIFF\IGFLLEDRVACNA\STPAQYKA                               STVTQGSHNKACTMLFMILYFFTMAGSVWW                               VILTITWFLAAVPKWGSEAIEKKALLFHASA                               WGIPGTLTTILLAMNKIEGDNISGVCFVGLYD                               VDALRYFVLAPLCLYVVVGVSLLLAGIISLNR                               VRIEIPL*KENQDKLVKFMIRIGVFSILYLVPLL                               VVIGCYFYEQAYRGIWTTWIQERC               1081   2431   A   8922   56   420   EERTKMSTGPDVKATVGDISSDGNLNVAQEE                               CSRKGIVDEFFPLLSN*CIWTQPQGYPQSSYG                               TLANFVF\CSVRHGLALILQLCNFSIYTQQMN                               LSIAIPAMVNNTAPPSQPNASTERPST               1082   2432   A   8923   355   1079   PFQWSSTMAVVKNKCLMKGGKKGVKKKVV                               GPFSKKDQYDVKAPAMNIRNTGK/TLVART                               QGTQIASDGLKGLLFEVSLADLQNDEVAFRK                               FKLITEDVQDKNCLTNFYGMDLTCDKICSMV                               EKWSTMIEAHVDVKTTDGYFFHLFCVGFTKK                               HNNQILKTSYA*HQQS/RQIQKKMMEIMT*EV                               QTNDLKEVVNKLIPDNIGKDTEKV/CPWPLH                               DVFIRKVKMLENPGFER\MELRGGGSSS               1083   2433   A   8948   28   385   LTWPQPHIPSCPAMSEETLQSKLAAAKKKLP                               WGAVQGSRAMSDLLLLLLDLTLLLLLMLLGF                               AGYSGQLAGVAVSAGSPPI/RYKFHVEPYGET                               GWLLT/ESCSISPKLCSIAVH*DNPAWF               1084   2434   A   8950   156   318   HYTPINTDTIENSENNKCW*GY*E\VGLIHHW                               WGGKRVQPFWKRVWQKRTLNLRV               1085   2435   A   8956   16   413   HMGQLGYFIQCWWECKRLISF\WKTI*QSPAK                               *TTTSYDTAIPIS/GI/YPKRMSSKCHQETCAR                               MFILAPFTATIKGKQLTCPLVEERIDY\MWYS                               HKYYIKVKRNL*VTTTH\TWVNLNILMFEILLW                               YSHKYY               1086   2436   A   8962   868   1026   H*KILQVGRAQRAHKSRL*SQLLRRLRHESHL                               NPGARGCSEARLHRCTPAVPIT               1087   2437   A   8985   58   330   LHVKHLGHFQLVFSEVICHCILMPVS*ELQRL                               *ERSVCAFHVCIQTWCLQVYACMCVYYICM                               FVYSVYGCGLCTCVCMDVYICVCVQEFL               1088   2438   A   8989   394   404   N*KWILHVNVRIQSIFF/IKRNQK/INSHELKLD                               KKFLDMMSNA*STKKIIDKLD/LIKFKT/LCSA                               KYTVKRIKIHPTDLEKMLPNHLSDKD*YS/GV                               YKDLSKLNRRKTE/S*/VKKWVKDLSRYFIKE                               VISMENKHKKIPSTS               1089   2439   A   8991   60   329   MALTPESPSSFPGLAATGSSVPEPPGGPNATL                               NSSWDSPTEPSSLEDLEATGTIGTLLSDMGVV                               GVEDNAYTLEVNSRYMRAVGIM*IHL               1090   2440   A   8996   2   351   SNTTITLT*MKKYDNTFCW*GCGQIG/T/LIYC                               WQESKFIQAFWSKIQQYLA*ISIHILFDPAFLFL                               GGYPGGTQSVFLTGVLVSSVFYNMKMLHTR                               LLIAALFUVQYWKQSKDHYI               1091   2441   A   8997   97   456   YPLPVCSYLSGPRGEHWNSLGGKSSCPLPLPT                               LVSSRFKISKVIVVGDLSVGKTCLNR*GGAG                               AELGRVGPSLARWAGSRSQHLVPSQ\VCKDS                               FDKNYKAPIGADFEMERFEVLGIPF               1092   2442   W   8999   548   811   SSFIKRHILIFEDDWHQTTCCHHPHHP\F*RCQ                               FHIFYVSVQNSISPSLSVSSSHPDRPDHEVHQH                               RAAHHHQHGQGPLGHGLVARVG               1093   2443   A   9002   3   2745   ALLGLQQPAQSLILSRSSVMGVRGLQGFVGS                               TCPHICTVVNFKELAEHHRSKYPGCTPTWVD                               AMCCLRYWYTPESWICGGQWREYFSALRDF                               VKTFTAAGIKLIFFFDGMVEQDKRDEWVKRR                               LKNNREISRIFHYIKSHKEQPGRNMFFIPSGLA                               VFTRFALKTLGQETLCSLQEADYEVASYGLQ                               HNCLGILGEDTDYLIYDTCPYFSISELCLESLD                               TVMLCREKLCESLGLCVADLPLLACLLGNDH                               PEGMFESFRYKCLSSYTSVICENFDKKGNIILA                               VSDHISKVLYLYQGEKKLEEILPL/VTKQSSFL                               *RNGIISFTRT/INLHGFSKNPKV**LWTNK*YP                               RVQTPNPGKKFPCVQMLNPGKKFPCVQALNP                               GEKFPCIHI/PEPRQEVPTCSDPEPRQEVPTCTG                               PESRREVPMCSDPEPRQEVPMCTGPEFRQEVP                               MCTGPEARQEVPMCTDSEPRQEVPMCTDSEP                               RQEVPMYTGSEPRQEVPMYTGPESRQEVPMY                               TGPESRQEVLIRTDPESRQEIMCTGHESKQEV                               PICTDPISKQEDSMCTHAEINQKLPVATDFEFK                               LEALMCTNPEIKQEDPTNVGPEVKQQVTMVS                               DTEILKVARTHHVQAESYLVYNIMSSGEIECS                               NTLEDELDQALPSQAFIYRPIRQRVYSLLLED                               CQDVTSTCLAVKEWFVYPGNPLRHPDLVRPL                               QMTIPGGTPSLKILWLNQEPEIQVRRLDTLLA                               CFNLSSSREELQAVESPFQALCCLLIYLFVQV                               DTLCLEDLHAFIAQALCLQGKSTSQLVNLQP                               DYINPRAVQLGSLLVRGLTTLVLVNSACGFP                               WKTSDFMPWNVFDGKLFHQKYLQSEKGYA                               VEVL/CRTK*ISAHQIPQPEGSRLQGLHEGEQT                               HHWPSPLGLTPRREVGKTGLQLPQDGLWV               1094   2444   A   9021   97   834   AREAGRAKTDFPGRRFRLWPSGCCRVIVGAE                               T*H\MAEPVSPLKHFVLAKKAITAIFDQLLEFV                               TEGSHFVEATYKNPELDRIATEDDLVEMQGY                               ICDKLSHGEVLSRRHMKVAFFGRTSSGKSSVI                               NAMLWDKVLPSGIGHITNCFLSVEGTDGDKA                               YLMTEGSDEKKSVKTVNQLAHALHMDKDLK                               AGCLVRVFWPKAKCALLRDDLVLVDGPGTD                               VTTELDSWLDKFCTKSSTREITNSGSDT               1095   2445   A   9022   1   537   LVLNSRVEDFVPPEGAGRTLPFALRPLAACW                               LLHRRARRSSALCPRPRSWGVSGGEGAGARE                               P*ITSSSCCLSAAISHISIQSPNMAGARRRIRPQ                               LAKEKIEGCHICTSVTPGEPQVFLGKDKAFTF                               DYVFDIDSQQEQIYIQCIEKLIEGCFEGYNATV                               FAYGQT\GAGKTYTMGTGFD               1096   2446   A   9029   1   285   FFFFNVCKSPKVPKPGCKEESTGTLFKNTLISL                               GQHSETPSLKKK\LAGYSGMCL*SQVLRRLRQ                               EDCLSPGGGNCRES*SCPYTPAWITERDPV               1097   2447   A   9032   716   357   ARSTGFWGEILWCGFLKRSLALSPRVKGSGAI                               LAHCNFRHAGFPPLSCLSLPNRWEYRRPPARP                               GKFFLVFLVETGFQC/G*DGLDLLTSRSACLG                               LPKCWDYRREPAASIIFQTTFFINSK               1098   2448   A   9038   230   652   KVVVMSCEDTNISGSFYRNKLKYLAFLCKRTS                               TNPSQGPYHLWVPSHIFWQTTCGRLPHKTKQ                               G*AALDHLKVFDRIPLPYDKKKQMAVSATLE                               VVRPKP*RKFAYLGHWAQKVDWKYQAMTA                               TMGEKRKVYYQKICYQKK               1099   2449   A   9043   185   372   IIFYSHQQCMRV/WQGCGDIETLIHCW*E*KII                               HSL/WK/TV*QFLKRLYLHLPHNSVIAFLGISP                               RKIKTCPQNSCTSMLTNAIHNDQKWKKINI               1100   2450   A   9045   763   584   RQSLALSPRLECSCITISAHCRLCPLVFTPLSCL                               SLTSSWDYRRPPPHPANFLYFK*RRGF               1101   2451   A   9050   275   2   LFFLRKVSNQFLSPSLLPVNFQGPVFAFLLLLL                               FLL/FEMESLPVA/RVECSGTISAHCNLCLPGSS                               DSPASAS*VAQITDMCRYTQLILFHAS               1102   2452   A   9053   449   1224   KTSMFWKFDLHSSSHIDTLLEREDVTLKELM                               DEEDVLQECKAQNRKLIEPLLKAECLEDLVSF                               I\*EEPPQDMDEKIRYKYPNISCELLTSDVSQM                               NDRLGEDESLLMKLYSFLLNDSPLNPLLASFF                               SKVLSILISRKPEQIVDFLKKKHDFVDLIIKHIG                               TSAIMDLLLRLLTCIEPPQPRQDVLN/WFKVQ                               RNL*HST*NVMDISKYVNLHWGLNKSHSLL*                               LLLQCVLQWLNEEKIIQRLVEIVLIPSQEEDVS                               SLV               1103   2453   T   9058   403   3   GLHVYDFQVYREHILTLNVKKCSVSFWGLRE                               WLYLQMYEKSPRFPIIKMTDITKCW*GC\GA                               AGMQI/H/CW\WCVNVGKFWEMS*YYLLKLSI                               ST/PYDPAIPLLGIYL*ETRVYIHPKTCMRMLIA                               APFVLAVNG               1104   2454   A   9064   75   393   KWLFSSLNITGRGDIIGHLKWLDCR\NCSSFPI                               KRNRQTHSTESNKLKAGHSFGYN*LIH*NS\V                               KTDCGCGANSKGVVVVMKV\KTAQQKQTTS                               YMQIGTTKNSRAT               1105   2455   A   9065   366   778   DLLILRNLAFPELKRRNCISRFYLAYHLHKIYS                               RSILLCNNCSGFYILSL*QYDVFFFNYFFFRDR                               AWPCCPGWSAAWLTIYILAHYRRPGLERSCC                               LSLSSSWDITRRVPPCPANF*IYFSMGFTAFPRL                               VLNS*TQGI               1106   2456   A   9083   673   816   ESGSLLH*WWENKPAQPLWWEI*QHVQKLPT                               HFPCDPAIPLLGICPED               1107   2457   A   9086   580   18   KPSSGSFIRAIYIFLSTAHVPALFSVLVRTKLT*                               AFSQSSVLWAHKQQKTSLSLVIRIERLQIKTA                               VRENFLPIRLAKILKLDNVKCWQG/SGSNMSL                               UHCWWEYNVIHIIWNSVTFPRKVEHVYITYA                               PEISVR*IHGGLPTLVHQETHTSVFRGAPSVIP                               ETR\CRPTKESINKLLHIYTMEHYGDENK               1108   2458   A   9093   540   1   GGNDCSVTPTTEPGRKEIT*KRKF*EKTDRLP                               GAIPPSRTPPTPYPCPHGDRLLPPSRPLPAGPA                               SAFPPAERSRGHRRASL*RARWSAAVPRRSA                               GSASEPVQSRWLRLPVGSDSPPAVPVRVCPAP                               DSRPAAPGSRLPDPGLDSPAPSRTPSSSVD*GG                               QRPPPPSGDSLSPPGCCRY               1109   2459   A   9099   1255   1425   HESYHVNPNLCNPVAPTSGAHSIG*KWFSWL                               GAVAHSCNPSTLVGRGGRITRGQELR               1110   2460   A   9103   242   70   EEQFFFFAVGMFP*VDFLAPASGELWDRLRLT                               CSRPFTRHQSFGLAFLRVCSSLDSLDDSVVGP                               SALLSSVUNQGGRNVLEAREAAKHFTI*RQS                               LLRKQRNKRMAIP               1111   2461   A   9110   189   121   SFLSVRLECNGAIMAHCALPLPG               1112   2462   A   9113   100   910   RRRGGGSRPRRTPVPAPGPGPSFGMDVRFYP                               AAAGDPASLDFAQCLGYYGYSKFGNNNNYM                               NMAEANNAFFAASEQTFHTPSLGDEEFEIPPIT                               PPPESDPALGMPDVLLPFQALSDPLPSQGSEFT                               PQFPPQSLDLPSITISRNLVEQDGVLHSSGLHM                               DQSHTQVSQYRQDPSLIMR\PSST*PDAARSG                               VMPPAQLTTINQSQLSAQLGLNLGGASMPHT                               SPSPPASKSATPSPSSSINEEDADEANRAIGEK                               RAAPDSGKKPKTPKK               1113   2463   A   9120   3452   3051   FLRFSFALVPQAGVQWCALSWLQPPSPRFK*F                               SCLSLPSSWDYRRVPPRPANFFVLLVETGFLH                               VGQAGHEPLTSGDPPASASQSAGITGVSHQA                               WPSFFIFSRDTVLLCCSGWSRTSGLKQSACLS                               LLKCWDY               1114   2464   A   9122   152   377   NQLPLQQWTFFIYETGFCSVAQAGVQCRDHS                               SLHF*PPG\SSDPPAPPS*VLGITGQRYIIACLII                               YLYVQTVPQRV               1115   2465   A   9124   553   981   QRPLLRQQLGSWPTCRSLEGDLASPW**RLPG                               SPRMRRSGT/ATLNLPLSPQGTVRTAVEFQVM                               TQTQSLSFLLGSSASLDCGFSMAPGLDLISVE                               WRLQHKGRGRGDLHLPDHHLSVPSSADTIFA                               QQPSQFNGRNLYFLPLFR               1116   2466   A   9135   48   410   SASHEPAEHDGGADSLSASQPPRPAGRPAGA                               QHVHVPPWTDVLAGQDRRAPTAGDGAPWP                               APGGHVPSTRPHDPAEFHADEAAGRGGRGLQ                               PAAPHALPAGLFHGPPAPAIPAEGGGTP*GSA                               GAGGP*GSPAGRACGAAGCRPRPPRPAASSA                               *NSAGS*GLVEGT*PPGAGHGAPSPAVGARLS                               CPARTSVQGGTWTC*APAGRPAGLGGWEAE                               RESAPPSCSAGS*DAD*GAEPWGAGSRSWGS               1117   2467   A   9141   380   939   KSGHWAKECLQPRIPPRPCPICVGPHWKSDCP                               TCPGAVPRAPGTLPQGSLTDSFPDLLSLVAED                               *CCLMASEASWTTT\ELWVTLTVEGKSKTP/CL                               NTEATHSTLPSFQGPVSLASITVVGIDGQASKP                               LKTPQLWCQLGQYSPMHYFLVIPTCPVPLLG*                               GILTKLSAFLTIPRLQPHLIAALSPSS               1118   2468   A   9154   471   2   AAGQVVVEVTSHLYLCITSDAAGLRLLPPAES                               ERGEGGHCPAEAPLPPRPQYCLAKHPLLRKLP                               EEKIKLDPYLTQHTKINSKQIKYLS/VRAKTTQ                               LVEGNIGVNLQNTELKQH*INGFLDTTPEAQE                               TKEKTNKLNFIKKVKRQLAEWEKIFQIA               1119   2469   A   9155   2   3187   ACPRLARRRRRVRSLRRRRGWLRARWSRGQ                               NNMAARRITQETFDAVLQEKAKRYHMDASG                               EAVSETLQFKAQDLLRAVPRSRAEMYDDVHS                               DGRYSLSGSVAHSRDAGRESLRSDVFSGPSFR                               SSNPSISDDSYFRKECGRDLEFSHSNSRDQVIG                               HRKLGHFRSQDWKFALRGSWEQDFGHPVSQ                               ESSWSQEYSFGPSAVLGDFGSSRLIEKECLEK                               ESRDYDVDHPGEADSV/LRGGSQVQARGRAL                               NIVDQEGSLLGKGETQGLLTAKGGVGKLVTL                               RNVSTKKIPTVNRITPKTQGTNQ1QKNTPSPD                               VTLGTNPGTEDIQFPIQKIPLGLDLKNLRLPRR                               KMSFDIIDKSDVFSRPGLEHKWAGFHTIKDDIK                               FSQLFQTLFELETETCAKMLASFKCSLKPEHR                               DFCFFTIKFLKHSALKTPRVDNEFLNMLLDKG                               AVKTKNCFFEIIKPFDKYIMRLQDRLLKSVTP                               LLMACNAYELSVKMKTLSNPLDLALALETTN                               SLCRKSLALLGQTPSLASSFRQEKIL*AVGLQ                               DIAPSPAAFPNFEDSTLFGREYDHLKAWLVS                               SGCPLQVKKAEPEPMREEEKMIPPTKPEIQAK                               APSSLSDAVPQRDHRVVGTIDQLVKRVIEGS                               LSPKERTLLKEDPAYWFLSDENSLEYKYYKL                               KLAEMQRMSENLRGADQKPTSADCAVRAML                               YSRAVNLKKKLLP\WQRRGLLRAQG\LRG\                               WKARRAVITQTQTLLFLRAFGLKHHGRQAPG                               LSQAKPSLPDRNDAAKDCPPDPVGPSPQDPSL                               EASGPSPKPAGVDISEAPQTSSPCPSADIDMKT                               METAEKLAEFVAQVGPEIEQFSIENSTDNPDL                               WFLHDQNSSAFKFYRKKVFELCPSICFTSSPH                               NLHTGGGDTTGSQESPVDLMEGEAEFEDEPP                               PREAELESPEVMPEEEDEDDEDGGEEAPAPG                               GAGKSEGSTPADGLPGEAAEDDLAGAPALSQ                               ASSGTCFPRKRISSKSLKVGMIPAPKRVCLIQE                               PKGECPPVGTVASSTVLGWWAVRVRRDRWR                               HFNPKEFCAPLQNVSRHSCFPVV               1120   2470   A   9163   124   207   PPRACRPCPRACPCPPT*KCSQPVSWPC               1121   2471   A   9166   272   523   PMSSLQGCFYTFKCLIFKGLFLLLISNLIAF**EK                               V/CSHITDSLKFIGKGWVGMVTHACNPGTLG                               G*GGWIA*VREFETSLGNM               1122   2472   C   9170   442   236   MNRRRFLRPADCHSGMRGTENGACSEGESQI                               HCGAGGEGVQLVHVVNQPENGCLQFDSTHIT                               FSKRQN*               1123   2473   A   9171   10   423   MVDRSPLLTSVIIFYLAIGAAIFEVLEEPHWKE                               AKKNYYTQKLHLLKEFPCLGQEGLDKILEVV                               SDAAGQGVAITGNQTFNNWNWPNAMIFAAT                               VITTIGYGNVASKTPGGRLFCGFYGLFGVPFC                               LTWINALGKPFG               1124   2474   A   9173   3   374   GPSPSLLVLLPQEPGGTGTPVRAGAGAGMWL                               WEDQGGLLGPFSFLMLMLLLETRNPVNACLL                               TGSLFVLLGVFSFEPVPSCRALQELKPRDRISA                               IAHRGGRHDPPENTLGAIRIQGS**WSNRR               1125   2475   A   9179   704   188   ESSSGLLFQCFQCIHVQKLTLQARPTLFSWWL                               CSKPPKETGELENAESGGDGGRRGGKQDNV                               AWWRRM\QKG\DFPWDDEDFPQSGPFGGQA                               LPMGFFYLYFRDPGRETTWKKFVQYYLARGL                               VDRLEVVNKQSVRVIPAPGTSSEVRGEFKAE                               YCRRKFISCKNVVFYFFQ               1126   2476   A   9183   153   233   MEYMAESTDRSPGHILCCECGVPISPN               1127   2477   A   9185   1   321   LTGQLGSILLRVFSKSRAGLGARKLKAYRTM                               EYMAESTDRSPGHILCCECGVPISPNPAQY\CV                               ACLRSSFHIYHCIPKLFIHPFSKTSSSAFITPSHY                               LTFFSTIS               1128   2478   A   9186   183   847   VLKFLLLQTMDEQSQGMQGPPVPQFQPQKAL                               RPDMGYNTLANFRIEKKIGRGQ\FSEVYRAAC                               L\LDGVPVALKKVQIFDLMDAKARADCIKEID                               LLKQLNHPNVIKYYASFIEDNELNIVLELADA                               GDLSRMIKHFKKQKRLLPERTVWKYFVQLCS                               ALEHMHSRRVMHRDIKPANVFITATGVVKLG                               DLGLGRFFSSKLAAHSLVGTPYYMSPERIHD                               NG               1129   2479   A   9190   1   370   GTSWKIPSAAVSESSPNGAAYASGLPCGVRG                               PPWAGLALLPSPTLMALLRRPTVSSDLDNIDT                               RATT\KIRVVATITRARIEDMRLHSATALTRPD                               ATTAQIPKLPVTTVCNRRANPGIPPSVL               1130   2480   A   9194   131   487   AYLKRLPVPESLTGFAIRLTVSEWLRLLPFLGV                               LALLGYLAVRPFLPKKKQQKDSLINLKIQKEN                               PKVVNEINIEDLCLTKAAYCRCWRSKTFPAC               1131   2481   A   9201   184   605   KELVDEKSERGRAMDPVSQLASAGTFRVLKE               1132   2482   A   9206   1   852   GGGRAGAGSRDMGSTDSKLNFRKAVIQLTTK                               TQPVEATDDAFWDQFWADTATSVQDVFALV                               PAAEIRAVREESPSNLATLCYKAVEKLVQGA                               ESGCHSEKEKQIVLNCSRLLTRVLPYIFEDPD                               WRGFFWSTVPGAGRGGQGEEDDEHARPLAE                               SLLLAIADLLFCPDFTVQSHRRSTVDSAEDVH                               SLDSCEYIWEAGVGFAHSPQPNYIHDMNRME                               LLKLLLTCFSEAMYLPPAPESWQHIRTHWFSS                               FVSSENRHALPLFTSLLNTVCAYDPVEYGIPY                               NELY               1133   2483   A   9208   1165   1463   GPRARVQGFSGADIVKFMALGSMYLVLTLIV                               AKVLRGAEPCCGPLKNRVLRPCPLPIVPLPPP                               HPQPSRGNPVGCLPTYKVVYKLLSWPLHSNS                               NVYFIV               1134   2484   A   9210   66   1586   MAGAGPKRRALSAPVAEEKEEAREKIMAAK                               RADGAAPAGEGEGVTLQGNITLLKGVAVIVV                               AIMGSGIFVTPTGVLKEAGSPGLALVVWAAC                               GVFSIVGALCYAELGTTISICSGGDYAYMLDV                               YGSLPAFLKLWIELLIIRPSSQYIVALVFATYL                               LKPLFPTCPVPEEAAKLVACLCVLLLTAVNC                               YSVKAATRVQDAFAAAKLLALALIILLGFVQI                               GKGDVSNLDPNFSFEGTKLDVGNIVLALYSG                               LFAYGGWNYLNFVTEEMINFYRNLPAIIISLP                               IVTLVYVLTNLAYFTTLSTEQMLSSEAVAVDF                               GNYHLGVMSWIIPVFVGLSCFGSVNGSLFTSS                               RLFFVGSREGHLPSILSMIHPQLLTPVPSLVFT                               CVMTLFYAFSKDIFSVINFFSFFNWLCVALAII                               GMIWLRHRKPELERPIKVNLALPVFFILACLF                               LIAVSFWKTTPWSVASDFTIILSGLPVYFFGV                               WWKNKPKWAPPGHLSPRIPSCVRSSCMVVPQ               1135   2485   A   9216   40   410   RDRLPPAYFCRPVVCVVTALDVG\SPESQEM                               DLVAFEDVAVNFTQEEWSLLDPSQKNLYREV                               MQETLRNLASIGEKWKDQNIEDQYKNPRNNL                               RSLLGERVDENTEENHCGETSSQIPDDTLNK               1136   2486   A   9223   3   983   RRRRRSRYRRCSRFPRPGPLAVSMPHAFKPG                               DLVFAKMKGYPHWPARIDDIADGAVKPPPN                               KYPIFFFGTHETAFLGPKDLFPYDKCKDKYGK                               PNKRKGFNEGLWEIQNNPHASYSAPPPVSSSD                               SEAPEANPADGSDADEDDEG\RGVMAVTAVT                               ATAASDRMESDSDSDKSSDNSGLKRKTPALK                               MSVSKRARKASSDLDQASVSPSEEENSESSSE                               SEKTSDQDFTPEKKAAVRAPRRGPLGGRKKK                               APSASDSDSKADSDGAKPEPVAMARSASSSSS                               SSSSSDSDVSVKKPPRGRKPAEKIPLPKPRGRK                               PKPERPPSSSSSD               1137   2487   A   9229   21   239   LFPRLECRDPVTVNCTLNLPGSKNAPTTASQV                               GSTWNYRGGLPHPTNFFVKTGFRCSQAGLKL                               RGSRLEPPAWA               1138   2488   A   9231   1664   2   TRSVGVNTCEVGVVTEPECLGPCEPGTSVNL                               EGIVWHETEEGVLVVNVTWRNKTYVGTLLD                               CTKHDWAPPRECESPTSDLEMRGGRGRGKR                               ARSAAAAPGSEASFTESRGLQNKNRGGANGK                               GRRGSLNASGRRTPPNCAAEDIKASPSSTNKR                               KNKPPMELDLNSSSEDNKPGKRVRTNSRSTP                               TTPQGKPETTFLDQGCSSPVLIDCPHPNCNKK                               YKHINGLRYHQAHAHLDPENKLEPEPDSEDK                               ISDCEEGLSNVALECSEPSTSVSAYDQLKAPA                               SPGAGNPPGTPKGKRELMSNGPGSIIGAKAGK                               NSGKKKGLNNELNNLPVISNMTAALDSCSAA                               DGSLAAEMPKLEAEGLIDKKNLGDKEKGKK                               ANNCKTDKN\PSKLKSARPIAPAPAPTPPQLIA                               IPTATFTTTTTTGTIPGLPSLTTTVVQATPKSPPL                               KPIQPKPTIMGEPITVNPALVSLKDKKKKEKR                               KLKDKEGKETGSPKMDAKLGKLEDSKGASK                               DLPGHFLKDHLNKNEGLANGLSESQESRMAS                               IKAEADKVYTFTDNAPSPSIGS               1139   2489   A   9234   207   443   TRRGQPWRRRAAAAGILPGREAAACLPSC/AS                               VTAAVSGLLVGYELGIISGALLQIKTLLALSC                               HEQEMGVSSLVIGALL               1140   2490   A   9238   248   328   MAQGNNYGQTSNGVADESPNMLVYRKV               114   12491   A   9242   2   535   FVEAAVKMLGSLVLRRKALAPRLLLRLLRSP                               TLRGHGGASGRNVTTGSLGEPQWLRVATGG                               RPGTSPALFSGRGAATGGRQGGRFDTKCLAA                               ATWGRLPGPEETLPGQDSWNQVPSRAGLGM\                               WPWAAALVVHCYSKSPSNKDAALLEAARAQ                               \NMQEVSRNRCALLHSAAVQEYGYGN               1142   2492   A   9245   157   466   HLCFWFFVGLFLPEQQIMLFATLLRMAQGCD                               PALGNDFLNITTKAQA/TKEKLDKLDFIKIKTC                               CTSMDAIEKTEPLTKWTKAFVSHVSYKRLLF                               GICKEYSRQ               1143   2493   A   9247   264   115   GLPQQTSTIQPPGTPDGARDFTSTIQPPGAPDG                               ARDSTSIIRMGPEIPPP       1144   2494   A   9260   1   401   KKVPGRLSEMSFSLNFTLPANTTSSPVT\DCGP                               SLGLAAGIPLLVATALLVALLFTLIHRRRSSIE                               AMEESDRPCEISEIDDNPKISENPRRSPTHEKN                               TMGAQEAHIYVKTVAGSEEPVHDRYRPTIEM                               ERRR               1145   2495   A   9264   175   411   WIYQFRLIEIGDSTVGKSCLLHRFTQGRF                               PGLRSPACDPTVGVDFFSRLLEIEPGKRIKLLL                               WDTAGQERFISIT               1146   2496   A   9277   592   814   MFTYLEGREGIKSQPKMEPHSVT\RLECSGMI                               SAHCSLNLPGTSDSPASASRNAGTTGMRHHA                               WLIFAFLVETGF               1147   2497   A   9279   1255   2   FRRGRRGEEEKEEEEEEEEGWVNGMENSHPP                               HHEHQQPPPQPGPSGERRNHHWRSYKLMIDP                               ALKKGHHKLYRYDGQHFSLAMSSNRPVEIVE                               DPRVVGIWTKNKE\LELSVPKFKIDEFYVDQV                               PPKQVTFAKLNDNIRENFLRDMCKKYGEVEE                               VEILYNPKTKKHLGIAKVVFATVRGAKDAVQ                               HLHSTSVMGNIIHVELDTKGETRMRFYEL\LV                               TGRYTPQTLPVGELDAVSPIVNETLQLSDALK                               RLKDGGLSAGCGSGSSSVTPNSGGTPFSQDTA                               YSSCRLDTPNSYGIQGTPLTPRLGTPFSQDSSY                               SSRQPTPSYLFSQDPAVTFKARRHESKFTDAY                               NRRHEHHYVHNSPAVTAVAGATAAFRGSSD                               LPFGTVGGTGGSSGPPFKAQPQDSATFAHTPP                               PAQATPAPGFR               1148   2498   A   9302   1026   6   IASIQNADTMPGVGLLVSHFSTLVSRQRCPNY                               ADPQNLTDVSIFLLLEVSGDPELQPVLAGLFL                               SMCLVTVLGNLLIILAISPDSHLHTPMYFFFSN                               LSLPDV\GFTSTTVPK\MIVDI\QSRSRVISYAG                               CLTQKSLFAIFGGTEE\NMLLSVMAYDRFVAI                               CHPLYHSAIMNPCFCAFLVLLSFFFLSLLDSQL                               HSWIVLQFTIIKNVEISNFVCDPSQLLKFACSD                               SIINSTFIYFHKDPERQLVLAGLFLSMCLVTVL                               GNLIIILDVSPDSHLPTPMYFFLSNLSLPDIGFT                               STTVPKMIVDIQSHGRVIFYAGCLTQMSLFAIF                               GGMEERHAPECDGL               1149   2499   A   9303   1   699   MASQEKDIFIGWGTIHLFRKPQRSFFGKLLRE                               FRIVAADRSMGRYMLFGVINLICTGFLLMWC                               SSTNSIALT\SYTYLTIFDLFSLMTCLISYWVTL                               RKPSPVYSFGPERLEVLAVFASTVLAQLGALF                               ILKESAERFLEQPELHTGRLLVGTFVALCFNLF                               TMLSIENKPFAYVSEAASTSWLQEHVADLSR                               SLCGIIPGLSSIFLPRMNPFVLIDLAGAFALCIT                               YMLIEI               1150   2500   A   9308   797   693   DRSTSVTRAGVQWCSLGSLQPRTPGLLRSSCL                               SLP               1151   2501   A   9309   205   406   VAIKELPVLWKWSKPTR\TAKEPPQTQQRAG                               SKTAAFPCQWSRMASEGPNIPCPGARIISDKQ                               FLICTI               1152   2502   A   9314   913   504   KPSPLITPPAVVLPPSAVLNLVNTFSSFPQVEV                               QGPLCGPRKGRLAVTIPFFGLSILPKYMDHRR                               PPPHR\EIFFVFLAETGFHRASQAGPDLPTS/S/I                               PPTSAIFPKCWEYRSEPQCLPGCLSFSGILLDL                               GTNVSLRAA               1153   2503   A   9315   392   1   HPHRPRPGFRSPARSSRPCPVLTSLLPPFPSPSP                               PADDLVKAGRDRKDPQVR/ERELRPNPGRLG                               GPR\PRPARARS/CHQPRLTRVCPRSPPPEARA                               PAPAAPARGRGAPKRNRPRTDTRAPRGSSAR                               PGNS               1154   2504   A   9321   331   433   MPCIIQAQYGTPAPSPGPRDHSASDPLTPEFIK                               PT               1155   2505   A   9324   180   275   MEEPQSDPSVEPPLSQETFSDLWKLLSENNYL               1156   2506   A   9326   383   619   MISPSRTEGDPLPLPP/EGEGQEVRGFGGGPAK                               EAAQRHCRASVSILRMRRPGQGSSRPARVPL                               RGPDSHRLREPPPSPP               1157   2507   A   9327   152   292   YERRGRSQGGGSHPAGAQPGGRAIGAGWQS                               KEPLWEGLQRSGSPLPG               1158   2508   A   9328   1   430   QELKQGPNPLAPSPSAPSTSAGLGDCNHRVD                               LSKTFSVSSALAMLQERRCLYVVLTDSRCFL                               VCMCFLTFIQALMVSGYLSSVITTIERRYSLKS                               SESGLLVSCFDIGNLVVVVFVSYFRGRRRRP/                               RVAAVGGLLDLEGGEMI               1159   2509   A   9334   108   383   KGNQVNGNGNQLKIRKHESMCPVSLTQNTVR                               LMEAGLPQKQAIERADELFEAGLVIYVKLDER                               VLNAL\YSSVGLQWFKESDLSHLRLLEISFR               1160   2510   A   9338   2   430   FVGRPRGLSDRLEDLFLAGFRVGERLRTAAM                               KRYVRILLLGEGAEHVADPVPGGRGVPRGEA                               DHTDQELREELHKANVERVVHDVSQEATIEKI                               RTKWIPLV/RWGDHA/EGPVGIKSYLPSGRSM                               EAELPIMSQLTEIETCVEC               1161   2511   A   9341   1   390   NSRVDDFVAPGLSEAGKLLGLEFPERQRLAA                               AVG/CSPMSGVISMSAIPFFLGKIIDAIYTNPTV                               DYSDNLTRLCLGLSGVFLCGAAANAIRVYLM                               QTSRQRVVKRLRTSLFSSILGQEVAFSDKAGT                               GELI               1162   2512   A   9343   84   837   QGRFRAFCWQRDFLQPPGMRLSALLALASKV                               TLPPHYRYGMSPPGSVADKRKNPPWIRRRPV                               VVEPISDEDWYLFCGDTVEILEGKDAGKQGK                               VVQVIRQRNWVWGGLNTHYRYIGKTMDYR                               GTMIPSEAFLLHRQVKLVDPMDRKPTEIEWR                               FTEAGERVRVSTRSGRIIPKPEFPRADGIVPET                               WIDGPKDTSVEDALERTYVPCLKTLQEEVME                               AMGIKETR\NTRRSIGIEPGAEQLLPNFCPSLE                               G               1163   2513   A   9346   967   616   DSLALSPRLECSGAISAHCNLTPPCIFTPFSCLS                               LPSSWAYRCASPHPDNFFVFLVESGFHKVGQ                               AGLKLLISSDPPTSA/FPKCWDYRRD\SSAPAT                               FSSYQRNNPDLILNDTIMFNIK               1164   2514   A   9347   3   1099   SSFPTCMRTVFHSNTSVSSLLHRPGHVTPQLTT                               HGGWRHHRDHTAIDEWDFNPSKFLIYTCLLL                               FSVLLPLRLDGIIQWSYWAVFAPIWLWKLLV                               VAGASVGAGVWARNPRYRTEGEACVEFKA                               MLIAVGIHLLLLMFEVLVCDRVERGTHFWLL                               VFMPLFFVSPVSVAACVWGFRHDRSLELEILC                               SVNILQFIFIALKLDRIIHWPWLVVFVPLWILM                               SFLCLVVLYYIVWSLLFLRSLDVVAEQRRTH                               VTMAISWITIVVPLLTFEVLLVHRLDGHNTFS                               YVSIFVPLWLSLLTLMATTFRRKGGNHWWF                               AIRRDF/CQDQLPQPTGICPPPPPLTDHHGEKA                               LPLQNKDRGSWPASRGSPRLL               1165   2515   A   9362   547   991   DVSIGPPLLRRPCSGREQTRSLSFPSDPESSFSP                               VPEGVRLADGPGHCKGRVEVIUIQNQWYTV                               CQTGWSLRAAKVVCRQLRCGRAVLT\QKRC                               TKHAYGRKPIWLSQMACSGPEFTLHDCPFRP                               LGEDTLFHVEYTSVHGRERLSAKD               1166   2516   A   9363   201   387   PPILRWTPPSGKNFFFFFFFESEFY/SSPRVECS                               GAISAHLAHCNLCLPGSSDSPASAFQVAS               1167   2517   77   9368   707   1087   AVLTPCLSPCSPSRIPRP\SRPYPGRRSLSHTPP                               PRPLILYAPAP\RPAGTAFIPHSHPPPPDLLRFT                               ATPAITPCPSLPPPPRPLHPTQPSTALLPDPPPW                               PLPFPPPSS/RPPRPDGSTSYSPTFPPFT               1168   2518   A   9375   511   15   MMLSEETSAVRPQKQTRFNGAKLVWMLKGS                               PITVTSAVIIVLMLLMMIIFSPWLATHDPNAID                               LTARLLPPSAAHWFGTDEVGRDLFSRVLVGS                               QQSILAGLVVVATTGMIGSPLECLFGELGGRA                               DAIFMRVMDIMRS/IPSLVLTMEKTAALGPSL                               FNAMQASSEH               1169   2519   A   9377   42   410   GNGRVAPRDPGAVASAEPGLTTHDSGVNPN                               NSARRMEAMASGSNWLSGVNVVLVMAYWS                               LVFVLLFIFAKRQIMRFAMKSLRGPHGPVGH                               NAPKDLKEEIDILLSRVHNIKYEP\HLLADDDA               1170   2520   A   9378   302   1303   GVSGFSASVLRQRRMEDELEPSLRPRTQIQGR                               ILLLTICAAGIGGTFQFGYNLSIINAPTLHIQEF                               TNETWQARTGEPLPDHLVLLMWSLLVSLYPL                               GGLFGALLAGPLAITLGRKKSLL\VNNIFVVS                               AAILFGFSRKAGSFEMIMLGRLASWGVNAGV                               SMNIQP\MLPGGESAPKELRGAVAMSSAIFTA                               LGIVMGQVVGLSITAATGLRGL\AGELEELEE                               ERAACQGCRARRPWELFQHRALRRQVTSLV                               VLGSAMELCGNDSVYAYASSVFRKAGVPEA                               KIQYAIIGTGSCELLTAVVSVSLEGALPPPAL                               WGGTPRSFALNQFTLQKKKK               1171   2521   A   9381   2   412   RGPASAQEDERARTAPLERVRARGRMTTSSA                               LFPSLLPCSWSTSNKYLAEFRAGKMSLKGITE                               TPDKRKGLAY/TQQTDDSLIHFCWKDRTSGNV                               EDDLIIFPDDCEFKRLPQCPNGRVYVLKFKAG                               SKRLFFWMQEP               1172   2522   A   9384   20   355   GWNGRSTEASPAAEAPHYPHKET\KAAMGTQ                               CTHGGKVRPDPHDMLITVVHKIKLFVLCHSL                               LQLCAIMISDYLKSSIYTVEKRLGLFRPTSGLL                               ASFNEVGNTALIVLESY               1173   2523   A   9393   430   87   LCQCIVPGQQKETFSLNPSSATVRFYL*LSLQ                               QRKEDQ*IIL*YHLNKDCLHIFMSAITLYMKI*                               KIFVLFDFNTMFETPFYII*FIFLFSQNLKRIRQV                               IRPPISFSKINNGP               1174   2524   A   9397   77   374   ERLEIGRLGGERGSGPASCLRVIDVSGMWDQ                               RLVKLALLQLLRAFYGIKVKGVRVHRDCGTF                               ESSSTLIRVS*FGVPCNALAHFGVTHF*YILDF                               LGML               1175   2525   A   9399   66   397   HESSRADRDKMDTRGSTYTDADPVNKSGGT                               AKMNKWSKGKVRDKLNNLVLFDTATYDKL                               CKEVPNYKLITLAVVSERLKIPGSLARAALHE                               LLSRGLI*LVIQHIAQVIY               1176   2526   A   9408   2   299   LDLTHVLSLSISLTVTLLGTTFGMVTPLLDVVY                               GERGYAQNGDF*DAQLDDYSFSCYSHAQVN                               GAPNSLTRAYDDP*VKISGLECQKVGALVEV                               KCLNL               1177   2527   A   9416   2   402   CNFLRSSRIRVHSTPAASTMPPKVDPNEIKVV                               YLRCTGGEVRATSALAPKTGPLGLSSIKVGVD                               FV*ATGDWNVLIISVILTIRILLSHIFVVPPFFCF                               DHLIAFWDLQSLIFLHVIFSLFITLLLFCFFSIF               1178   2528   A   9419   142   426   TPLFDLWPRVVLSWLETVLTSLRTRRAASGPP                               ACRIMPITVDDVLEHGGEVHFLQKQMLYLL                               ALI*DTFAPIYVGIVFLGFTPDHRCRSPGVAEL               1179   2529   A   9420   1450   1655   LSSAGTKMNLN*KNYWPGASAHACNPSTLG                               GQSRCRSGDRDHPG*HGETPSVLKIQKISRA                               WWRAP               1180   2530   A   9422   176   375   HRPQTTRPDWKPRT*PQGK*GRLSSEISPASPP                               SRFSRSTKPVPPKADPPARQKLTGVLHAPLLK                               L               1181   2531   A   9436   2   274   PIAASLRMYNLQPYTEENLICTAFATMVETVP                               IARTILDRLTGIPHGYCFVE*ADWATADKCVH                               IYNGKPLPGATPLLSLQLHQLAHLGS               1182   2532   A   9442   3   240   VDKCSSKSIVLSEYCPHCMCSLSTDPKPFGQL                               SMILK*MGAGDEKISAMGKARVDHRELYLGL                               LYPTEDYKLTFRARH               1183   2533   A   9444   384   3   LKDFQPWALHDWPLFCCCTFLLFLVLECFTR                               KGCSGWAPWLSLQGQHFGRPRWADHLRSGV                               RDQPGQYSKTTFLPKIQKLAGHSGAHL*S*LL                               ERMRWKNRLNPGGRSCSEPRWHHCTPGWAT                               ERG               1184   2534   A   9462   391   655   LSGFKSLMPKIPLQYIYYRVRTIWSFCLPLDG                               RKLMLS*YSK*LT*KYNILPEYSRMTLPPGMV                               IHTCNPSTLGGRAGWIV*AQEFET               1185   2535   A   9467   215   566   RCPMWQGQASRMDPAKAKDREASTCCSLA                               WWWGWECWVRALKLSSGPAGPLACWVAK                               KKSLSLSGPVYPSEKGAGLYVF*DRVSLCHPG                               WSAVVQFWLTAASNSCFSLLSSWDYRCA               1186   2536   A   9468   275   452   HIIPQLHTKTHYVPTRMYNKI*QIDNSKPWQR                               GG*TGILTHCW*ESKLVQPLWKIVWHYQ               1187   2537   A   9469   388   3   EVAPGPSQILPRRVTDGGDRPQFSLPGPRLPQ                               SSRGAEPCLSNCIHSPAPRKQRMGDSDQ*STP                               NPASPHPEAPQEPWDSASGSVGSFSLGRGAK                               ASS*VPGKGRGPRQGSELLAETILELFLALAN                               S               1188   2538   A   9471   124   397   TMDKKNRHGNSLDMASEIHMTGPMCLIENTT                               GRLMANPEALKILSAITQPMVEEAIAGLYRAC                               *FYLTNNLAGMKKGLCLGSTEQAMTIGI               1189   2539   A   9480   584   769   GHVQSQHPGRPRRADHLRSGDRDHPG*HDET                               PSLLKIQKISWAWWRAPVVPATWEAEAEEW                               R               1190   2540   A   9483   463   86   VTVGLTLLLRGAPRFTAG*PPSGGGPPLAPLL                               PRQHCTLQTHRHLHPEAPVKV*KT*RLFPGLR                               GASSCRRRRCNPVLAARKAGSPRSHSTRENC                               RRSRCPDTAHRRRRRGRRRNPSCVRSPRWR               1191   2541   A   9489   1   411   LADALCLSAAATGAVRPGARAQPSTRRRLSP               1192   2542   A   9497   389   161   VSFLSMSSGHCIRSTRGSKMVSWSVIAKIQEI*                               KDTYSDHEEINTS               1193   2543   A   9509   186   1   IAKSQ*KRWQRSGAMETLKHGWWECKLVQF                               FGKTFVNVN*S*TYVYPCDKIILLLGLYPTEM               1194   2544   A   9512   58   433   PLQRSKCLTLRCLRAKPWAWSQSPRACSSAL                               LKSSRSRASSLNVQCILQSNPQGHQRI*KQKA                               SSKGQQFRR*KEHPFMLKTLNKLRIEGT*LKI                               RRAIYDNPTANIIVEGQKLEAFPLRTGTRQ               1195   2545   A   9515   595   1223   GHGALPSFQTQVPRTP*ASWPVVPAASESAPAF                               AGGGASLPVAAGSCAAAPHTEPGAPQHLLDC                               PCPLCLARPPRRPLPDTCYGPGSGRSASLAEPP                               LPRCSCAPLRSASAPQVS*CV*AVNLLPHNL*                               PLHLLLHD*EKAWGFLFSSASHCFQGQICLLP                               APGSGPCGATARPSRGGRAGGSRARRPIPPGP                               GTRRTPSGCQNPAASGG               1196   2546   A   9518   229   468   RSPTATPAPHAMGPGAPFARGGRPLPLLGAM                               AERVAPGWDLHTPYLPRTNSRRTPHL**EPHA                               GYIGALFPMSGGWPGGQ               1197   2547   A   9521   289   448   IAWLSGLFFPSNQANLCFLCYKLTADSRYRG                               HAMRHLTGNTSMAIEFL*ADSRPQVQRARYE                               APNWKYKYGY*IPVDMLC               1198   2548   A   9524   204   1   KNKKTTKGLSIVTLNISGPNQ*NKRIHRVAEWI                               VKQEPNICHL*ETHFPFRDTYRLKEREQKKRK                               SSYS               1199   2549   A   9546   1785   1943   GGRFKESKLTNAGWQRNSFFIGPPKS1PWAA                               V*QRGDGKNPGVTHLNRPVGTX               1200   2550   A   9548   186   1   VNAEKEF*KIQHYFMTKSQNKLHIEHTYLKPI                               KAIYDKWTSDIMLNLQKL*AFFLRVIVRQI               1201   2551   A   9549   591   2   SSVVEFPRGPRSSLPPLDSTFPCGSSPNWTGGC                               GSCPSGE*LVSPGSEQRKKYSNSNVIMHETSQ                               YHVQHLATFIMDKSEAITSVDDAIRKLVQLSS                               KEKIWTQEMLLQVNDQSLRLLDIESQEELEDF                               PLPTVQRSQTVLNQLRYPSVLLLVCQDSEQSK                               PDVHFFHCDEVEAELVHEYMESALTDCRLGK                               AMRP               1202   2552   A   9552   428   1   KYGNEGHWSRQCPNPGKPIRPCPLCRGPHWK                               LDCERPPQGPLPSLPELAKTSYSDLTGLATED                               *WGPGMDAPATTIASSKTRVTLMVAGRPVFF                               LI*YRATYSALPNFSGPTQSSQVSVVGIDGQV                               SKPRATPPLFCSLHTF               1203   2553   A   9568   517   738   RRKFERKQKQ*RYREGKQYRQRDKMKEWG                               EKEKREREKGEREERKMRHRERKGESGQRD                               TMENWRVERLTEKER               1204   2554   A   9573   83   415   EDKRLRLVDGDSRCAGRV*IYHDGFWGTICD                               DGWDLSDAHVVCQKLGCGVAFNATVSAHFG                               EGSGPIWLDDLNCTGTESHLWQCPSRGWGQ                               HDCRHKEDAGVICSEFIALR               1205   2555   A   9577   64   424   ARGSGPTRPRTANGRMGETKDAPQMLVTFK                               DVAVTFFREEWRQLVLVHRTLYR*GMLETC                               GLLDTLRHNVPQPDVVHLLYHGTQLLIVKRE                               VSHSPCAGDMRELFTREATLTPHPYNNGA               1206   2556   A   9584   38   476   TLGAVLFSEVSKESSTSHSGGQLGRQNRHPKL                               SNFTTSSPRLKPTASSQRNLGQILNMFLTAV                               NPQPLSTPSWQIETKYSTKVLTGNWMEERRK                               GLPYKHLITHHQEPPHRYLLSTYDDHYNRHG                               YNPGLPPLRTWNGQKLLWL               1207   2557   A   9586   2   412   LRSSPAALLRALCITTVTGTALALRSRVATTN                               PDGCRNVLRPKYYRLCDKAESWQIALETVPT                               GVAVTSWAIMLTVLTLVCKGQDYNRRQKLP                               THILCLL*EKGIFGLTFAFIIGLDGSTGPTRFFL                               FGILFSICFS               1208   2558   A   9597   122   3   IKNYWPGMVAHACNPSPLGGRGRWIA*AQK                               FADAWADAW               1209   2559   A   9611   148   558   KSLRNVWDLLNNTWKADRFFCHSSRTSTIRK                               GDPGPTFSKMSIWTSGRTSSSYRHDEKRNIYQ                               RIRDHDLLDKRKTVTALKAGEDRAILLGLAM                               MVCSIMM*FLLGITLLRSYMQSVWTRESQCT                               LLNASITETFNC               1210   2560   A   9618   384   2   SLHDMLMLAEQQQKQKWAVNTQNTAWSNA                               DSKFGQRILEKMEWSKGRGLGVQEQGGPDDI                               KVQVKNNDLGLQATINNEANWIAIIQDDFNW                               LLAELNTCQRQETADS***WSPKNSHVGKDS                               GELSAK               1211   2561   A   9620   316   610   QKHPGGGQLGRSPQEDSRFHNKASSGVSRVR                               LGRAWWLTPVIPTLWEAKAGGSPE*D*AGRG                               GSRL*SQHFGRPERVDHLRSAVQDQPGQHGE                               TPSLLKIQKIN*VWGRRL*SSYSEAEAGESL               1212   2562   A   9623   297   344   QFPVDGDYQKIEKITQLFQAQNLSLCLAMTR                               TREL*KGGGKGRHE*AVVPFLKKGGYGVKAP                               AILNTSNCT*CF*ETKMLSDDPKACVFEVSSA                               DL*NTSFGVIR               1213   2563   A   9624   2   356   AELSLASTACGRNTSGDSLPDYDRAPISSPLA                               TSGTILSAISCLWDLPTPVLRVGLSCQPSMSSQ                               LPRMYSTDVEAAVNSLEDLYLQAYYAYLCVG                               LYFHRDDMALEGVSRFL*ELAE               1214   2564   A   9634   776   912   SLSRWVRAKL*VPYNQENCLNPRGGGCSEPR                               SHYCTPAWATEKDS               1213   2565   A   9636   220   426   KPGNFAVSSEY*DITSGQLKTAVRG*IEMTST                               EENFGEKLHDIGFGNGFLDKT*KAQATKAKI                               DK               1216   2566   A   9637   391   76   CFLEDGCTQAS*AEEAAVSPSMAEEEQGSTSC                               RERRSIRFKMKNHSPDDTIKENVTISNTRTRKI                               NHLPETERNLLEHGLMYIRLNAAFCSLVAHS                               LFGFILKAT               1217   2567   A   9655   2008   2432   LHCKMGALETQTHPCSQNMLRSLQKCCCKV                               EEHHLQPVQVLQTLLHSATAGTGCRRPARPP                               PAPPTPTPWRSRQSGKQSERAS*LKGRGRYGL                               GALGGRGGRALGGSRWPPPLPGETLFSGCKH                               RRRRRGSDAAPGEEAGT               1218   2568   A   9658   3   405   HASARALLSPNLSPNNKMAISGGPVLGFFIIA                               VLMSAQEPWAIKEEHVIIQAEFYLNPDQSGEF                               MLDFEGEDTFHGDMAKKETVWRLE*LARLD                               NFEAQRALANIAADQAALEIMDMGSDYTLIP                               NVPPKVTVL               1219   2569   A   9662   3   284   PDWTEKRKMQDTGSILPLHWFGFCIYAALVA                               YGGIIGYVKAGSVPSLAAGLLFGSLSGLGAYQ                               LSQDPRNVWVFLATSGTLAGIMGMRFYHSG                               KL               1220   2570   A   9669   200   699   LLLTGYIQTLQNQQLSGNQQEMQAVDNLTSA                               PGNTSLCTRDYKITQVLFPLLYTVLFFVGLITN                               GLAMRIFFQIRSKSNFIIFLKNTVISDLLMILTF                               PFKILSDAKLGTGPLRTPVCQVTSVIFYFTMYI                               SISFLGLITIDRYQKTTRPFKTSNPKNLLGAKIL                               K               1221   2571   A   9676   164   562   KERDSSTFSAAMTTMQGMEQAMFGACIPGVP                               QLGNMAVIHSHLWKGLQEKFLKGEPKVLGV                               VQILTALMSLSMGITMMCMASNTYGSNPISV                               YIGYTIWGSVMFIISGSLSIAAGIRTTKGLVRG                               SLGMNITSS               1222   2572   A   9688   43   412   VAKMVKCCSAIGCASRCLPNSKLKGLTFHVF                               PTDENIKRKWVLAMICRLDVNAAGIWEPKKG                               DVLCSRHFKKTDFDRSAPNIKLKPGVWSIFDS                               PYHLQGKREKLHCRKNFTLKTVPATNYNH               1223   2573   A   9696   308   564   RTSMGILYSEPICQAAYQNDFGQVWRWVKE                               DSSYANVQDGFNGDTPLICACRRGHVRIVSFL                               LKKECLCQPQKPERENLLALCCE               1224   2574   A   9700   3   632   DAWASGGELGSLFDHHVQRAVCDTRAKYRE                               GRRPRAVKVYTINLESQYLLIQGVPAVGVMK                               ELVERFALYGAIEQYNALDEYPAEDFTEVYLI                               KFMNLQSARTAKRKMDEQSFFGGLLHVCYA                               PEFETVEETRKKLQMPKAYVVKTTENKDHY                               VTKKKLVTEHKDTEDFRQDFHSEMSGFCKA                               ALNTSAGNSNPYLPYSCELPLCYFSSK               1225   2575   A   9710   1   163   RSGCVLRMTEWETGAPAVAETPDIKLFGKWS                               TDDVHINDISLQDYIAGVRLILL               1226   2576   A   9713   82   492   QGLPSFLPAFGPSGSWLGPAFTLGSSCNTVDT                               ICHGYSEIRPLFYLSFCDLLLGLCWLTETLLYG                               ASVANKDIICYNLQAVGQIFYLSSFLYTVNYI                               WYLYTELRMKHTQSGQSTSPLVIDYTCRVCQ                               MAFVFSSLI               1227   2577   A   9720   3   416   GKWKRTQVPLLGEECADMDLARKEFLRGNG                               LAAGKMNISIDLDTNYAELVLNVGRVTLGEN                               NRKKMKDCQLRKQQNENVSRAVCALLNSGG                               GVIKAEVENKGYSYKKDGIGLDLENSFSNML                               PFVPNFLDFMQNGNYF               1228   2578   A   9723   278   411   EASSSNTVASNVADKTDPHSMNSRVFIGNLN                               TLVLQKSDVEAVF               1229   2579   A   9725   121   902   LFAMSGFENLNTDFYQTSYSIDDQSQQSYDY                               GGSGGPYSKQYAGYDYSQQGRFVPPDMMQP                               QQPYTGQIYQPTQAYTPASPQPFYGNNFEDEP                               PLLEELGINFDHIWQKTLTVLHPLKVADGSIM                               NETDLAGPMVFCLAFGATLLLAGKIQFGYVY                               GISAIGCLGMFCLLNLMSMTGVSFGCVASVL                               GYCLLPMILLSSFAVIFSLQGMVGIILTAGIIG                               WCSFSASKIFISALAMEGQQLLVAYPCALLYG                               VFALISVF               1230   2580   A   9739   11   247   TFVLNMNTPKEEFQDWPIVRIAAHLPDLIVYG                               HFSPERPFMDYFDGVLMFVDISGKCKRDVCL                               MWMSNRLAWEFTCRA               1231   2581   A   9744   37   1100   TPLFDFWPGFVLSWLQPLSASLRARRAASGPP                               ACRIMPTTVDDVLEHGGEFHFPQKQMFFLLA                               LLSATFAPIYVGIVFLGFTPDHRCRSPGVAELS                               LRCGWSPAEELNYTVPQPGPAGEASPRQCRR                               YEVDWNQSTFDCVDPLASLDTNRSRLPLGPC                               RDGWVYETPGSSWLEFNLVCANSWMLDLFQ                               SSVNVGFFIGSMSIGYIADRPGRKLCLLTTVLI                               NAAAGVLMAISPTYTWMLIFRLIQGLVSKAG                               WLIGYILITEFVGRRYRRTVGIFYQVAYTVGL                               LVLAGVAYALPHWRWLQFTVALPNFFFLLY                               YWCIPESPRWLISQNKNAEAMRIIKHIAKKNG                               KSLPASL               1232   2582   A   9753   164   517   PGPGMQGPPPITPTSWSLPPWRAYVAAAVLC                               YINLLNYMNWFIIAGVLLDIQEVFQISDNHAG                               LLQTVFVSCLLLSAPVFGYLGDRHSRKATMS                               FGILLWSGAGLSSSFISPRYSWLF               1233   2583   A   9757   25   419   LPAPWTERVRKSEGLVGTCLGDPMASPRTVT                               IVALSVALGLFFVFMGTIKLTPRLSKDAYSEM                               KRAYKSYVRALPLLKKMGINSILLRKSIGALE                               VACGIVMTLVPGRPKDVANFFLLLLVLAVLF                               FHQLV               1234   2584   A   9765   71   456   RLELDWGFSLHFLPVAYLCPLSSGFEMNVQP                               CSRCGYGVYPAEKISCIDQIWHKACFHCEVC                               KMMLSVNNFVSHQKKPYCHAHNPKNNTFTS                               VYHTPLNLNVRTFPEAISGIHDQEDGEQCKSV                               FHWD       1235   2585   A   9765   71   456   IRSGAMSVDKAELCGSLLTWLQTFHVPSPCA                               SPQDLSSGLAVAYVLNQIDPSWFNEAWLQGI                               SEDPGPNWKLKVTSGLLLRGQTGEEMTRDGP                               ARHMSWVMGRKRDRCLVINHLFIHSSMEYSP                               CARPGHSARNNTDKNLPHTAIILVTSNTYTTI                               KINFQAGRSGSGL               1236   2586   A   9770   352   608   FRGEALTVRFLTKRFIGEYASNFESIYKKHLC                               LERKQLNLEIYDPCSQTQKAKFSLTSELHWA                               DGFVIVYDISDRSSFAFAKALI               1237   2587   A   9793   266   515   NILAIIYFPFPRLFLLRDSQSNPKAFALTLCHH                               QKIKNFQILPVSIDALTPPLVVCFLVSFLTHFS                               RYKPTRPVCITQFQGCS               1238   2588   A   9802   537   967   ELGAGRSDREAMEAAVKEEISVEDEAVDKNI                               FRDCNKIAFYRRQKQWLSKKSTYRALLDSVT                               TDEDSTRFQIINEASKVPLLAEIYGIEGNIFRLK                               INEETPLKPRFEVPDVLTSKPSTVRLISCSGDT                               GSLILADGKGDLKC               1239   2589   A   9805   105   540   VPGDPAMVRAGAVGAHLPASGLDIFGDLKK                               MNKRQLYYQVLNFAMIVSSALMIWKGLIVLT                               GSESPIVVVLSGSMEPAFHRGDLLFLTNFRED                               PIRAGEIVVFKVEGRDIPIVHRVIKVHEKDNG                               DIKFLTKGDNNEGDDRGSYK               1240   2590   A   9819   3   305   TDGRDPLPCAARRRGGGGECCGAGWVAEWS                               PQPLDPAMLLWMQGFVLEAVACQDNDDYLR                               YGILFEDLDCNGDGVVDIIELQEGLRNWSSAF                               DPNSEEHG               1241   2591   A   9834   841   1209   SPARGKSNRTDVMITAPKNKKMTENLAAPEA                               LDSSTHSSSTATQSRAKMNTPAPTPSTVPAIPR                               GGSGGPPPCAPHDRVSSVLQCDTQAMDHKTE                               SSHSVVEFLFKRTKTPSPFHPAVRENRN               1242   2592   A   9843   3   589   TLSCQPATEPPASLLSSASSDDFCKEKTEDRYS                               LGSSLDSGMRTPLCRICFQGPEQGELLSPCRC                               DGSVKCTHQPCLIKWISERGCWSCELCYYKY                               HVIAISTKNPLQWQAISLTVIEKVQVAAAILGS                               LFLIASISWLLWSTFSPSARWQRQDLLFQICYG                               MYCIFMDVMIVAVDSEDMVQAAKEVGKRWS                               DIPP               1243   2593   A   9846   198   411   WRISHHAGKMPVMKGLLAPQNTFLDTIATRF                               DGTHSNFILANAQVAKGFPIVYCSDGFCELAG                               FARTEVMQ               1244   2594   A   9848   116   650   PICGFLYLCSAMASESSPLLAYRLLGEEGVAL                               PANGAGGPGGASARKLSTFLGVVVPTVLSMF                               SIYVFLRIGFVVGHAGLLQALAMLLVAYFILA                               LTVLSVCAIATNGAVQGGGAYCILQHRWTG                               VWPVLPAREVMISRTLGPEVGGSIGLMFYLA                               NVCGCAVSLLGLVESVLDVFGA               1245   2595   A   9849   573   1620   KSKCRFPEGLSEGFGPMRKEALSSGSVQEAE                               AMLDEPQEQAEGSLTVYVISEHSSLLPQDMM                               SYIGPKRTAVVRGIMHREAFNIIGRRIVQVAQ                               AMSLTEDVLAAALADHLPEDKWSAEKRRPL                               KSSLGYEITFSLLNPDPKSHDVYWDIEGAVRR                               YVQPFLNALGAAGNFSVDSQILYYAMLGVNP                               RFDSASSSYYLDMHSLPHVINPVESRLGSSAA                               SLYPVLNFLLYVPELAHSPLYIQDKDGAPVAT                               NAFHSPRWGGIMVYNVDSKTYMASVLPVRV                               EVDMVRVMEVFLAQLRLLFGIAQPQLPPKCL                               LSGPTSEGLMTWELDRLLWARSVENLATATT                               TLTSLA               1246   2596   A   9850   114   464   PPQLGAQRVREPRHPDVRAPLRVTSPGLRSRS                               ARSLGRRPRIAMVTVGNYCEAEGPVGPAWM                               QDGLSPCFFFTLVPSTRMALGTLALVLALPCK                               RRERPAGADSLSWGAGPRISSYV               1247   2597   A   9851   2   327   FVRNKKMTRSCSAVGCSTRDTVLSRERGLSF                               HQFPTDTIQRSKWIRAVNRVDPRSKKIWIPGP                               GAILCSKHFQESDFESYGIRRKLKKGAVPSVS                               LYKVFKYSSRCTS               1248   2598   A   9853   58   444   RVDDFVYSKGGKDAGGADVSLACRRQSIIPEE                               FRGITVVELIKKEGSTLGLTISGGTDKDGKPR                               VSNLRPGGLAARSDLLNIGDYIRSVNGIHLTR                               LRHDEIITLLKNVGERVVLEVEYELPPPGGCP                               WT               1249   2599   A   9856   2   1265   LPPPRPSRHRRGRAGTRASAAAAAGPTVSAV                               RAPVRGQDSGAGTPQGRLAGRGAHLSRVGA                               SGSGVAAGPAARHAPRRRCADAGEAVGASC                               GRCAVALLSGVCTLVSTHYCVGSGCPGAAGT                               PMGAGDAGASAESAVTTAPQEPPARPLQAGS                               GAGPAPGRAMRSTTLLALLALVLLYLVSGAL                               VFRALEQPHEQQAQRECGEVREKFLRAHPCV                               SDQELGLLIKEVADALGGGADPETNSTSNSSH                               SAWDLGSAFFFSGTTTTTGGGGDWHVGGGK                               ELPHGGRCRETEGSQVAPRLPASPLCPGYGN                               VALRTDAGRLFGIFYALVGIPLFGILLAGVGD                               RLGSSLRHGIGHIEAIFLKWHVPPELVRVLSA                               MLFLLIGCLLFVLTPTFVFCYMEDWSKLEAIY                               FVIVTLTTVGFGDYVA               1250   2600   A   9873   2   652   FVVPSPCGGLPGRAPNGASRPTMGNSASRNDF                               EWVYTDQPHTQRRKEILAKYPAIKALMRPDP                               RLKWAVLVLVLVQMLACWLVRQLAWRWLL                               FWAYAEGGCVNHSLTLAIHDISHNAAFGTGR                               AARNRWLAVFANLPEGVPYAASFKKYHVDH                               HRYLGGDGLDVDVPTRLEGWPFCTPARKLL                               WLVLQPFFYSLRPLCVHPKAVTRMEVLNTLV                               QLA               1251   2601   A   9875   150   1209   PVIMPLHFSPGDIVRPSCCVSSSPKLRRNAHSR                               LESYRPDTDLSREDTGCNLQHISDRENIDDLN                               MEPNPSDSTIFLSKSQTDVREKRKSLFTN                               HHPPGQLARKYSSCSTIFLDDSTVSQPNLKYTI                               KCYALAIIYYHIKNRDPDGRMLLDIFDENLHPL                               SKSEVPPDYDKHNPEQKQTYRFVRTLFSAAQL                               TAECAIVTLVYLERLLTYAEIDICPANWKRIV                               LGAILLASKVWDDQAVWNVDYCQILKDITVE                               DMNELERQFLELLQFNINVPSSVYAKYYFDL                               RSLAEANNLSFPLEPLSRERAHKLEAISRLCED                               KYKDLRRSARKRSASADNLTLPRWSPAIIS               1252   2602   A   9879   6   376   KRPDSRPPAQYRAGPTRPRTRGCELLYWKAT                               KAVGIKMGSLSTANVEFCLDVFKELNSNNIG                               DNIFFSSLSLLYALSMVLLGARGETEEQLEKV                               WNSSEVCSEPRSLSGSRSGSAKLILSLYQ               1253   2603   A   9880   180   388   KEQAELLYGLYCQCDLTLSSHPSSVPAMSSC                               NFTHATPVLIGIPGLEKAHFWVGFPLLSMYVA                               AMFGNC               1254   2604   A   9881   19   494   VISFQITTDTIMDSSTAHSPVFLVFPPEITASEYE                               STELSATTFSTQSPLQKLFARKMKILGTIQTLF                               GIMTFSFGVIFLFTLLKFYPRFPFIFLSGYPFWG                               SVLFINSGAFLIAVKRKETTETLIILSRIMNFLSA                               LGAIAGEILLTPEFHPRSKLHL               1255   2605   A   9896   72   386   RPGREQRDCFQAPPLGLGGRQTDMMHHPLT                               GATCVGLPNVGMCPQLSGALTFMYLQQGNQ                               EATVAFDTMAQPYASAQFAPPQNGIPGEYTA                               PHPHPAPEYTGQTT               1256   2606   A   9902   95   399   SGGPACILLHRPVLPKMGLSGLLPILVFFILLG                               DIQEPGHAEGILGKPCPKIKVECEVEEIDQCTK                               PRDCPENMKCCPFSRGKKCLDFRKVSLTLYH                               KEELE               1257   2607   A   9905   374   459   EHLKSTPNRLGVVARTCNPSTLGGRGGW               1258   2608   A   9911   364   1974   AGPGVPAVGGRWASGPGLGGRTLCSGPPDH                               QRRGPSCGASGDPQCVGSPHIPQRARPLLARP                               GARLLPGHLPSPRPPRLPTGQPPAAAFRGPVR                               PQGGGHIHPLPTPGGRPCFAVSEGSGSALLLS                               YLGECGSSSYVTGAACISPVLRCREWFEAGLP                               WPYERGFLLHQKIALSRYATALEDTVDTSRL                               FRSRSLREFEEALFCHTKSFPISWDAYWDRND                               PLRDVDEAAVPVLCICSADDPVCGPPDHTLTT                               ELFHSNPYFFLLLSRRGGHCGFLRQEPLPAWS                               HEVILESFRALTEFFRTEERIKGLSRHRASFLG                               GRRRGGALQRREVSSSSNLEEIFNWKRSYTRL                               MAAAAGAAAAPGSREPQDRPECGAGHPGPR                               YYRHPERWLLRPEAFLGPLRTRAPSAEDSQR                               ERPAARSGPEMRVRYPVVAAVLAPYLALSQD                               PMYKSSASGQGASGSYNHVREEMLIKAGGA                               MSRRVVRQSKFRHVFGQAAKADQAYEDIRV                               SKVTWDSSFCAVNPKFLAIIVEAGGGGAFIVL                               PLAK               1259   2609   A   9919   693   935   GCFKFIGESTCCWIFPSSVTTQCVVAKAPRAA                               TLSKAERLRSQPGPEQGGSSYRPRTPTAAAIL                               PPRPGRSHRKRKLVSTK               1260   2610   A   9921   455   1082   QRSCLCSAIEKDGGDVKALYRRSQALEKLGR                               LDQAVLDLQRCVSLEPKNKVFQEALRMGGQ                               IQEKVRYMSSTDAKVEQMFQILLDPEEKGTE                               KKQKASQNLVVLAREDAGAEKIFRSNGVQLL                               QRLLDMGETDLMLAALRTLVGICSEHQSRTV                               ATLSILGTRRVVSILGVESQAVSLAACHLLQV                               MFDALKEGVKKGFRGKEGAIIV               1261   2611   A   9928   1   438   GPRGAEAPGAAQAPKKKKPRPTEGGPGAGSG                               RGKDPYRGPTLLHQPKPPKDEFLSSLESYEIAF                               PTRVDHNGALLAFSPPPPQRQRRGTGATAES                               RLFYKEASPSTHFLLNLTRSSRLLAGHVSVEY                               WTREGLAWQRADRPHCLYA               1262   2612   A   9931   168   435   AAEMGRAGAAAVIPGLALLWAVGLGGPPPA                               PPRLPFCLQELQGRHALHTFSLERTCSYQDFL                               WADEGRLLHVGAQDLATWHTLSPLGLW               1263   2613   A   9938   247   488   RMSATSVDQRPKGQGNKVSVQNGSIHQKDG                               CNDDDFEPYLRSPDNQSNSYPPMSDPYMPGY                               YAPSIGFPYSLGEAAWSQL               1264   2614   A   9941   61   277   ESIGLTALGPRRRPWEHRWSDPITLKMKGWG                               WLALLLGALLGTAWARRSQDLHCGACKAVR                               RRVRQPNIYDY               1265   2615   A   9956   2   522   FVASEVSKMPVPASWPHPPGPFLLLTLLLGLT                               EVAGEEELQMIQPEKLLLVTVGKTATLHCTV                               TSLLPVGPVLWFRGVGPGRELIYNQKEGHFP                               RVTTVSDLTKRNNMDFSIRISSITPADVGTYY                               CVKFRKGSPDHVEFKSGAGTELSVRGEYSVG                               FLSQVWWWLSSHPFMN               1266   2616   A   10002   243   387   PKNNACHLLFTAVCQPRCKHGECIGPNKCKC                               HPGYAGKTCNQGRKTV               1267   2617   A   10004   36   707   LPAPASTWSVARETMASSSVPPATVSAATAG                               PGPGFGFASKTKKKHFVQQKVKVFRAADPLV                               GVFLWGVAHSINELSQVPPPVMLLPDDFKAS                               SKIKVNNHLFHRENLPSHFKFKEYCPQVFRNL                               PDRFGIDDQDYLVSLTRNPPSESEGSDGRFLIS                               YDRTLVTKEVSSEDIADMHSNLSNYHQVRPLS                               SPILSLSSLLTYSSAIVSNRCQLGRKLIGRENF               1268   2618   A   10005   2   209   GEGYELFVPSNGVPAVCHMVGRRPHRAVLSP                               SQDELEHSLGESAAQGAAGVVLWVSWENTR                               TKVSLGLA               1269   2619   A   10010   245   688   FGMLKNKGHSSKKDNLAVNAVALQDHILHD                               LQLRNLSVADHSKTQVQKKENKSLKRDTKAI                               IDTGLKKTQCPKLEDSEKEYVLDPKPPPLTL                               AQKLGLIGPPPPPLSSDEWEKVKQRSLLQGDS                               VQPCPICKEEFELRPQVFSIRG               1270   2620   A   10011   2   588   RVDDFVRPLPPQLMSRSRASIHRGSIPAMSYA                               PFRDVRGPSTHRTQYVHSPYDRPGWNPRFCII                               SGNQLLMLDEDEIHPLLIRDRRSESSRNKLLR                               RTVSVPVEGRPHGEHEYHLGRSRRKSVPGGK                               QYSMEGAPAAPFRPSQGFLSRELKSSIKRTKS                               QPKLDRTSSFRQILPRFRSADHDRYRGWSMW                               DEIDV               1271   2621   A   10013   209   363   LPAPPNLSPRLSFGFQFPGGNDNYLTITGPSHP                               FLSGAEVSQSCRRRGGRA               1272   2622   A   10014   7   388   SAVTISWKWRSVMGIQTSPALLASLGAGLVT                               LLGLAVGSYLVRRSRRPQVTLLDPNEKDLLR                               LIDKTLSARSPCKIIIYLSTRIDGSLSIRPYTPVT                               SDEDQGYVDIDIKVYLKGVHPTFPEGGKMSH               1273   2623   A   10016   1   1339   MAARTLGRGVGRLLGSLRGLSGQPARPPCGV                               SAPRRAASGPSGSAPAVAAAAAQPGSYPALS                               AQAAREPAAFWGPLARDTLVWDTPYHWW                               DCDFSTGKIGWFLGGQLNVSVNCLDQHVRKS                               PESVALIWERDEPGTEVRITYRELLETTCRLA                               NTLKRHGVHRGDRVAIYMPVSPLAVAAMLA                               CARIGAVHTVIFAGFSAESLAGRINDAKCKVV                               ITFNQGLRGGRVVELKKIVDEAVKHCPTVQH                               VLVAHRTDNKVHMGDLDVPLEQEMAKEDP                               VCAPESMGSEDMIFMLYTSGSTGMPKGIVHT                               QAGYLLYAALTHKLVFDHQPGDIFGCVADIG                               WITGHSYVVYGPLGNGATSVLPESTPVYPNA                               GRYWETVERLKINQFYGAFTAVRLLLKYGD                               AWVKKYDRSSLRTLGSVGEPINGEAWEWLH                               RVVGDSRCTLVDTWWQT               1274   2624   A   10017   1   3750   FRPQGTPRSPASHVLTMSAPDEGRRDPPKPKG                               KTLGSFFGSLPGFSSARNLVANAHSSARARPA                               ADPTGAPAAEAAQPQAQVAAHPEQTAPWTE                               KELQPSEKMVSGAKDLVCSKMSRAKDAVSS                               GVASVVDVAKGWQGGLDTFRSALTGTKEV                               VSSGVTGAMDMAKGAVQGGLDTSKAVLTG                               TKDTVSTGLTGAVNVAKGTVQAGVDVTTKTV                               LTGTKDTVTTGVMGAVNLAKGTVQTGVETS                               KAVLTGTKDAVSTGLTGAVNVARGSIQTGV                               DTSKTVLTGTKDTVCSGVTGAMNVAKGTIQT                               GVDTSKTVLTGTKDTVCSGVTGAMNVAKGT                               IQTGVDTSKTVLTGTKDTVCSGVTQAMNVA                               KGTIQTGVDITKTVLTGTKNTVCSGVTGAVN                               LAKEAIQGGLDTTKSMYMGTKDTMSTGLTG                               AANVAKGAMQTGLNTTQNIATGTKDTVCSG                               VTGAMNLARGTIQTGVDTTKIVLTGTICDTVC                               SGVTQAANVAKGAVQGGLDTTKSVLTGTKD                               AVSTGLTGAVNVAKGTVQTGVDTTKTVLTG                               TKDTVCSGVTSAVNVAKGAVQGGLDTTKSV                               VIGTKDTMSTGLTGAANVAKGAVQTGVDTA                               KTVLTGTKDTVTTGLVGAVNVAKGTVQTGM                               DTTKTVLTGTKDTIYSGVTSAVNVAKGAVQT                               GLKTTQNIATGTKNTFGSGVTSAVNVAKGAA                               QTGVDTAKTVLTGTKDTVTTGLMGAVNVAK                               GTVQTSVDTTKTVLTGTKDTVCSGVTGAAN                               VAKGAIQGGLDTTKSVLTGTKDAVSTGLTGA                               VKLAKGTVQTGMDITKTVLTGTKDAVCSGV                               TGAANVAKGAVQMGVDTAKTVLTGTKDTV                               CSGVTGAANYAKGAVQTGLKTTQNIATGTK                               NTLGSGVTGAAKVAKGAVQGGLDTTKSVLT                               GTKDAVSTGLTGAVNLAKGTVQTGVDTSKT                               VLTGTKDTVCSGVTGAVNVAKGTVQTGVDT                               AKTVLSGAKDAVITGVTGAVNVAKGTVQTG                               VDASKAVLMGTKDTVFSGVTGAMSMAKGA                               VQGGLDTTKTVLTGTKDAVSAGLMGSGNVA                               TGATHTGLSTFQNWLPSTPATSWGGLTSSRT                               IDNGGEQTALSPQEAPFSGISTPPDVLSVGPEP                               AWEAAATTKGLATDVATFTQGAAPGREDTG                               LLATTHGPEEAPRLAMLQNELEGLGDIFHPM                               NAEEQAQLAASQPGPKVLSAEQGSYFVRLGD                               LGPSFRQRAFEFIAVSHLQHGQFQARDTLAQL                               QDCFRL               1275   2625   A   10025   124   415   TILARKKEKTCPCKKEIGRNSRSGMYSRKAM                               YKRKYSAANTKVEKKKKEKVLAPVTKPVGG                               DKNGGTRVVKLPTMPRYYPTEDVPRKLLSHG                               KKPFS               1276   2626   A   10030   3   507   GGSLRFSPPRVPSCSRVFCPVPPGGCGLPSPMS                               ASRPQSPITPWCLPRRYMKHKRDDGPEKQED                               EAVDVTPVMTCVFVVMCCSMLVLLYYFYDL                               LVYVVIGIFCLASATGLYSCLAPCVRRLPFGK                               CRIPNNSLPYFHKRPQARMLLLALFCVAVSV                               VWGVFRNEDQ               1277   2627   A   10035   51   869   YSRFTVPLPATMASSEVARHLLFQSHMATKT                               TCMSSQGSDDEQIKRENIRSLTMSGHVGFESL                               PDQLVNRSIQQGFCFNILCVGETGIGKSTLIDT                               LFNTNFEDYESSHFCPNVKLKAQTYELQESN                               VQLKLTIVNTVGFGDQINKEERQLGRSQSTEN                               PQKYRSEQHPVEPKKCTSFWKGALGKWAGIE                               SSGQSAQQPYLPINSPPHRLADVADVHLFSSV                               LSGAFGCYHLDVTVNEFKKQQNRDEQEGYS                               KGDQEQGSWICHGADPLRGGEM               1278   2628   A   10036   3   457   RAFDVRRKKSLRPCCPRDFHAGCLTVSGPST                               VMGAVGESLSVQCRYEEKYKTFNKYWCRQP                               CLPIWHEMVETGGSEGVVRSDQVIITDHPGDL                               TTFTVTLENLTADDAGKYRCGIATILQEDGLSG                               FLPDPFFQVQVLVSSASSTENSVKTP               1279   2629   A   10039   214   435   NDSLVPMSSWRSCARAPSSESAWRRSAATRR                               SRKCLRTKRKRWSSGKGTQMQSTLSETPRDA                               QMPCMWWYPFWG               1280   2630   A   10043   2   344   RATWHNAGKEREAVQLMAGAEKRVKASHS                               FLRGLFGGNTRIEEACEMYTRAANMFKMAK                               NWSAAGNAFCQAAKLHMQLQSKHDSATSFV                               DAGNAYKKADPQGKTARHVACYLCV               1281   2631   A   10080   620   818   VIYKLDSSLFSYFIYFFIFETESHFLPLMKWTG                               PIMAHCSLKILASRNSADSAFLSAGDTSLSHST               1282   2632   A   10084   3   1640   SASIIIRGDKRASGEVGIAPSSRHILIGEPSAKY                               NGTAIISLVRGPGILGEVTVFWRIFPPSVGEFA                               ETSGKLTMRDEQSAVIVVTQALNDDIPEEKSF                               YEFQLTAVSEGGVLSESSSTANITVVASDSPY                               GRFAFSHEQLRVSEAQRVNITIIRSSGDFGHVR                               LWYKTMSGTAEAGLDFVPAAGELLFEAGEM                               RKSLHVEILDDDYPEGPEEFSLTITKVELQGR                               GYDFTIQENGLQIDQPPEIGNISIVRIIIMKNDN                               AEGIIEFDPKYTAFEVEEDVGLIMIPVVRLHGT                               YGYVTADFISQSSSASPGGVDYILHGSTVTFQ                               HGQNLSFINISIIDDNESEFEEPIEILLTGATGG                               AVLGRHLVSRIIIAKSDSPFGVIRFLNQSKISIA                               NPNSTMILSLVLERTGGLLGEIQVNWETVGPN                               SQEALLPQNRDIADPVSGLFYFGEGEGGVRTII                               LTIYPHEEIEVEETFIIKLHLVKGEAKLDSRAK                               DVTLTIQEFGDPNGVVQFAPETLSKKTYSEPL                               ALEGPLLITFFVRRVKGTFGEIM               1283   2633   A   10088   316   516   MGSKTLPAPVPIHPSLQLTNYSFLQAVNGLPT                               VPSDHLPNLYGFSALHAVHLHQWTLGYPAM                               HLXRS               1284   2634   A   10091   2   569   FVSPSRAMASALIYVSKFKSFVILVVTPLLLLP                               LVILMPAKFVRCAYVIILMAIYWCTEVIPLAV                               TSLMPVLLFPLFQILDSRQVCVQYMKDTNML                               FLGGLIVAVAVERWNLHKRIALRTLLWVGA                               KPARLMLGFMGVTALLSMWISNTAITAMMV                               PIVEAILQQMEATSAATEAGLELVDKGKAKE                               LP               1285   2635   A   10092   290   728   KQSTRPDVMTLYPLHWQEEMSGESVVSSAVP                               AAATRTTSFKGTSPSSKYVKLNVGGALYYTT                               MQTLTKQDTMLKAMFSGRMEVLTDSEGWIL                               IDRCGKHFGTILNYLRDGAVPLPESRREIEELL                               AEAKYYLVQGLVEECQAALQV               1286   2636   A   10100   1   574   RPRGRGAWAGPGQDYSGVRRQQRRRTPISGS                               QRGSDAAGTMGCCTGRCSLICLCALQLVSAL                               ERQIFDFLGFQWAPILGNFLHHVVILGLFGTIQ                               YRPRYIMVYTVWTALWVTWNVFIICFYLEVG                               GLSKDTDLMTFNISVHRSWWREHGPGCVRR                               VLPPSAHGMMDDYTYVSVTGCIVDFQYLEVI                               NSA               1287   2637   A   10103   252   376   RSRMGDKPIWEQIGSSFIQHYYQLFDNDRTQL                               GAIYVSFQL               1288   2638   A   10107   1   478   MEEEDESRGKTEESGEDRGDGPPDRDPTLSPS                               AFILRAIQQAVGSSLQGDLPNDKDGSRCHGL                               RWRRCRSPRSEPRSQESGGTDTATVLDMATD                               SFLAGLVSVLDPPDTWVPSRLDLRPGESEDM                               LELVAEVRIGDRDPIPLPVFSLLPRLRAWRTG                               KT               1289   2639   A   10113   237   438   LLSRMPSTNRAGSLKDPEIAELFFKEDPEKLFT                               DLREIGHGSFGAAYFARDVRTNEVVAIKKMS                               YSG               1290   2640   A   10114   367   856   RGAKAKSAVLPPGPPCSSLLILSPPAPLTPRSPG                               TEATRPTAMSKSLKKKSHWTSKVHESVIGRN                               PEGQLGFELKGGAENGQFPYLGEVKPGKVAY                               ESGSKLVSEELLLEVNETPVAGLTIRDVLAVI                               KHCKDPLRLKCVKQGESSGLLSVLPGGGTAR                               GAGQ               1291   2641   A   10116   128   591   RTIRETERRSALSCSVLKSEPLPGLQPQASQQR                               RRRLPGRRQVQVQEGGGSGLRAWVLAMASV                               LGSGRGSGGLSSQLKCKSKRRRRRRSKRKDK                               VSILSTFLAPFKHLSPGITNTEDDDTLSTSSAE                               VKENRNVGNLAARPPPSGDRARGGATR               1292   2642   A   10121   1   749   QRRRFRAGLWGGHGLTDGLRRNGGCGCSAR                               VPRVGERLRGERCPDPLCLLLDMLFLSFHAG                               SWESWCCCCLIPADRPWDRGQHWQLEMADT                               RSVHETRFEAAVKVIQSLPKNGSFQPTNEMM                               LKFYSFYKQATEGPCKLSRPGFWDPIGRYKW                               DAWSSLGDMTKEEAMIAYVEEMKKIIETMP                               MTEKVEELLRVIGPFYEIVEDKKSGRSSDITSD                               LGNVLTSTPNAKTVNGKAESSDSGAESEEEE                               AC               1293   2643   A   10124   2   989   PLMSLVRVVEFVAASSAQKTPSRLENYYMVC                               KDEKFNQLVHFLRNHKQEKHLVFFRYSSGL                               CGRGIRDSARMCSTCACVEYYGKALEVLVK                               GVKIMCIHGKMKYKRNKIFMEFRKLQSGILV                               CTDVMARGIDIPEVNWVLQYDPPSNASAFVH                               RCGRTARIGHGGSALVFLLPMEESYINFLAIN                               QKCPLQEMKPQRNTADLLPKLKSMALADRA                               VFEKGMKAFVSYVQAYAKHECNLIFRLKDL                               DFASLARGFALLRMPKMPELRGKQFPDFVPV                               DVNTDTWFKDKIREKQRQKLLEQQRRRKTEN                               EGRRKFIKNKAWSKQKAKKK               1294   2644   A   10129   91   1042   VTMYKDCIESTGDYFLLGDAEGPWGIILESLA                               ILGIVVTILLLLAFLFLMRKIQDCSQWNVLPTQ                               LLFLLSVLGLFGLAFAFIIELNQQTAPVRYFLP                               GVLFALCPSCLLAHASNLVKLVRGCVSFSWT                               TILCIAIGCSLLQIIIATEYVTLIMTRGMMFVN                               MTPCQLNVDFVVLLVYVLFLMALTFFVSKAT                               FCGPCENWKQHGRLIFITVLFSIIIWVVWISML                               LRGNPQFQRQPQWDDPVVCIALVTNAWVFL                               LLYLVPELCILYRSCRQECPLQGNACPVTAYQ                               HSFQVENQELSPDKWKVLLNSDFLSHSGA               1295   2645   A   10133   376   518   RPRVVTHNSQWCFLPQDHPGWLPGQSGAPG                               GRGAPRQEGPGSSWRQV               1296   2646   A   10135   3   551   EWSLDPFMGIMSGQVGDLSPSQEKSLAQFRE                               NIQDVLSALPNPDDYFLLRWLQARSFDLQKS                               EDMLRKHMEFRKQQDLANILAWQPPEVVRL                               YNANGICGHDGEGSPVWYHIVGSQDPKGLLL                               SASKQELLRDSFRSCELLLRECELQSQKLGKR                               VEKIIAIFGLEGLGLRDLWKPGIELLQE               1297   2647   A   10138   48   407   MVSSCCGSVCSDQGCGQDLCQETCCRPSCCE                               TPCCRIITCCRPSCCVSSCCRPQCCQSVCCQPT                               CSRPSCCQTTCCRTTCYRPSCCVSSCCRPQCC                               QPVCCQPTCCRPSCCEITCCHPQCC               1298   2648   A   10156   94   453   GGNRKSAEMFSQVPRTPASGCYYLNSMTPEG                               QEMYLRFDQTTRRSPYRMSRILARHQLVTKI                               QQEIEAKEACDWLRAAGFPQYAQLYEDSQFP                               INIVAVKNDHDFLEKDLGEPLCRRLNT               1299   2649   A   10161   1   393   PRFSELVDGRGRVSARFGGSPSKAATVRSQPT                               ASAQLENMEEAPKRVSLALQLPEHGSKDIGN                               VPGNCSENPCQNGGTCVPGADAHSCDCGPGF                               KGRRCELACIKVSRPCTRLFSETKAFPVWEGG                               VCHHV               1300   2650   A   10162   98   391   AKIASLERIMPANYTCTRPDGDNTDFRYFIYA                               VTYTGILGPGLIGNILALWVFYGYMKETKRA                               VIFMINLAIADLLQVLSLPLRIFYYLKHDWPF                               VPV               1301   2651   A   10165   1   7545   PGIRVGITSQTGLSSNLQENCSKLAFISSHGTE                               KQLQCMPMEGRGRASSSISDLQGKGFEKGTG                               EKHVPGVGSARHSPQASAGGSPWQRGKAQT                               RWLGKPDPGRKRRRGSPQEEGGLRVSAAAR                               LLCSGANRCKVLVRQNSTPNTQQPAVHPSTP                               PSRPLPQAGRCLVAPLRPHPDWVAAKTLAKA                               LRAPGKPWRLAAPSPLGDLGAPGLPGPSTAP                               RTLSVEEPGVECNQLCLYADVTDPVLCLGQK                               DPGVEGKHCEKEKISSSKELKHVHAKSEPSKP                               ARRLSESLHVVDENKNESKIEREHKRRTSTPV                               IMEGVQEETDTRDVKRQVERSEICTEEPQKQ                               KSTLKNEKHLKKDDSETPHLKSLLKKEVKSS                               KEKPEREKTPSEDKLSVKHKYKGDCMHKTG                               DETELHSSEKGLKVEENIQKQSQQTKLSSDDK                               TERKSKHRNERKLSVLGKDGKPVSEYIIKTDE                               NVRKENNKKERRLSAEKTKAEHKSRRSSDSK                               IQKDSLGSKQHGITLQRRSESYSEDKCDMDST                               NMDSNLKPEEVVIIKEKRRTKSLLEEKLVLKS                               KSKTQGKQVKVVETELQEGATKQATTPKPD                               KEKNTEENDSEKQRKSKVEDKPFEETGVEPV                               LETASSSAHSTQKDSSHRAKLPLAKEKYKSD                               KDSTSTRLERKLSDGHKSRSLKHSSKDIKKKD                               ENKSDDKDGKEVDSSHEKARGNSSLMEKKL                               SRRLCENRRGSLSQEMAKGEEKLAANTLSTP                               SGSSLQRPKKSGDMTLIPEQEPMEIDSEPGVE                               NVFEVSKTQDNRNNNSHQDIDSENMKQKTS                               ATVQKDELRTCTADSKATAPAYKPGRGTGV                               NSNSEKHADHRSTLTKKMHIQSAVSKMNPGE                               KEPIHRGTTEVNIDSETVHRMLLSAPSENDRV                               QKNLKNTAAEEHVAQGDATLEHSTNLDSSPS                               LSSVTVVPLRESYDPDVIPLFDKRTVLEGSTA                               STSPADHSALPNQSLTVRESEVLKTSDSKEGG                               EGFTVDTPAKASITSKRHIPEAHQATLLDGKQ                               GKVIMPLGSKLTGVIVENENITTKEGGLVDMA                               KKENDLNAEPNLKQTIKATVENGKKDGIAVD                               HVVGLNTEKYAETVKLKRKRSPGKVKDISID                               VERRNENSEVDTSAGSGSAPSVLHQRNGQTE                               DVATGPRRAEKTSVATSTEGKDKDVTLSPVK                               AGPATTTSSETRQSEVALPCTSIEADEGLIIGT                               HSRISINPLITIVGAEASECTVFAAAEEGGAVVTE                               GFAESETFLTSTKEGESGECAVAESEDRAADL                               LAVHAVKIEANVNSVVTTEKDDAVTSAGSEE                               KCDGSLSRISEIVEGTTTFISEVESDGAVTSAG                               TEIRAGSISSEEVDGSQGNMMRMGPKKETEG                               TVTCTGAEGRSDNFVICSVTGAGPREERMVT                               GAGVVLGDNDAPPGTSASQEGDGSVNDGTE                               GESAVTSTGITEDGEGPASCTGSEDSSEGFAIS                               SESEENGESAMDSTVAKEGTNVPLVAAGPCD                               DEGIVTSTGAKEEDEEGEDVVTSTGRGNEIGH                               ASTCTGLGEESEQVLICESAEGDSQIGTVVEH                               VEAEAGAAIMNANENNVDSMSGTEKGSKDT                               DICSSAKGIVESSVTSAVSGKDEVTPVPGGCE                               GPMTSAASDQSDSQLEKVEDITISTGLVGGS                               YDVLVSGEVPECEVAHTSPSEKEDEDIITSVE                               NEECDGLMATTASGDITNQNSLAGGKNQGK                               VLIISTSTTNDYTPQVSAITDVEGGLSDALRTE                               ENMEGTRVTTEEFEAFMPSAVSGDDSQLTAS                               RSEEKDECAMISTSIGEEFELPISSATTIKCAES                               LQPVAAAVEERATGPVLISTADFEGPMPSAPP                               EAESPLASTSKEEKDECALISTSIAEECEASVS                               GVVVESENERAGTVMEEKDGSGIISTSSVEDC                               EGPVSSAVPQEEGDPSVTPAEEMGDTAMISTS                               TSEGCEAVMIGAVLQDEDRLTITRVEDLSDA                               AIISTSTAECMPLSASIDRHEENQLTADNPEGN                               GDLSATEVSKHKVPMPSLIAENNCRCPGPVR                               GGKEPGPVLAVSTEEGHNGPSVHKPSAGQGH                               PSAVCAEKEEKHGKECPEIGPFAGRGQKESTL                               HLINAEEKNVLLNSLQKEDKSPETGTAGGSST                               ASYSAGRGLEGNANSPAHLRGPEQTSGQTAK                               DSSVSSIRYLAAVNTGAIKADDMPVQGTVA                               EHSFLPAEQQGSEDNLKTSTTKCITGQESKIAP                               SHTMIPPATYSVALLAPKCEQDLTIKNDYSGK                               WTDQASAEKTGDDNSTRKSFPEEGDIMVTVS                               SEENVCDIGNEESPLNVLGGLKLKANLKMEA                               YVPSEEEKNGELLAPPESLCGGKPSGIAELQRE                               PLLVNESLNVENSGFRTNEEIHSESYNKGEISS                               GRKDNAEAISGHSVEADPKEVEEEERHMPKR                               KRKQHYLSSEDEPDDNPDVLDSRIETAQRQC                               PETEPHATKEENSRDLEELPKTSSETNSTTSRV                               MEEKDEYSSSETPGEKPEQNDDDTIKSQE               1302   2652   A   10167   321   842   EPSLFPFLRPSPARPPPRPPAPFPSPELAGPEPH                               FVFYFFLSYVHPPKELAKYEYMEEQVILTEKG                               NSTVAGRGTSVRCLSPSPRPLPPLLPLLADLLE                               DGFGEHPFYHCLVAEVPKEHWTPEGNPSPFP                               EARETKCYVRSSVGCVEPLTTQAEVTENLDR                               KNSQQVFKLLKKK               1303   2653   A   10171   206   429   NMILLKKRRLLINSLGEGTINGLLDELLETNV                               LSQEDTEIVKCENVTVIDKARDLLDSVIRKGA                               RACEICITYI               1304   2654   A   10184   970   1524   LGTLSPGISGTAGSCLTTEPGTELGTSFAQNGF                               YHEAVVLFTQALKLNPQDHRLFGNRSFCHER                               LGQPAWALADAQVALTTRPGWPRGLFRLGK                               ALMGLQRPREAAAVFQETTRGGSQPDAAREL                               RSCLLHLTLQGQRGGICAPPLSPGALQPLPHA                               ELAPSGLPSLRCPRSTALRSPGLSPLLH               1305   2655   A   10194   2   394   TDLLGRRFRVDGAAMAACEGRRSGALGSSQ                               SDFLTPPVGGAFWAVATTIVMYPPPPPPPHIR                               DFISVTLSFGESYDNSKSWRRRSCWRKWKQL                               SRLQRNMILFLLAFLLFCGLLFYINLADHWKG                               TRNTCT               1306   2656   A   10195   1   410   IPGSTISLEGPLSKWTNVMKGWQYRWFVLDY                               NAGLLSYYTSKDKMMRGSRRGCVRLRGAVI                               GIDDEDDSTFTITVDQKTFHFQARDADEREK                               WIHALEETTLRHTLQLQVRVFTWFPDSSLVGA                               FFFWLVSGFFFK               1307   2657   A   10205   85   308   QGLPSTMVKLGCSFSQKPGKDPGDQDGAAM                               DSVPLISPLDISQLQPPLPDQVVIKTQTEYQLS                               SPDQQNYTKSR               1308   2658   A   10214   2   453   ECGGIRQPGPGPPPALASAPAATMNRVGGSPS                               AAANYLLCTNCRKVLRKDKRIRVSQPLTRRGP                               SAFIPEKEVVQANTVDERTNFLVEEYSTSGRL                               DNITQVMSLHTQYLESFLRSQFYMLRMDGPL                               PLPYRHYIAIMAAARHQCSYLINM               1309   2659   A   10233   45   421   RGWPEQQSTGRPRDVARQPRCQKEEGRELRP                               RALESRTFQGSERSRWGPPLESTKENVQCGH                               RPAFPNSSWLPFHERIQVQNGECPWQVSIQM                               SRKHLCGGSILHWWWVLTAAHCPRRTLLDM                               AV               1310   2660   A   10241   243   442   AFQLFNAKCESAFLSKRNPLQRNWTVLYRRK                               HKKGQSAEIQKKRTRRAFKFQRAITGASLADI                               MAK               1311   2661   A   10261   751   176   LPGADYGGGHLSLRLFHLLLTSAAWVPDESQ                               VTLNSAICVLSTVLIMEFPDLGKHCSEKTCKQ                               LDFLPVKCDACKQDFCKDHFPYAAHKCPFAF                               QKDVHVPVCPLCNTPIPVKKGQIPDVVVGDHI                               DRDCDSHPGKKKEKIFTYRCSKEGCKKKEML                               QMVCAQCHGNFCIQHRHPLDHSCRHGSRPTI                               KAG               1312   2662   A   10270   3   669   STSSDEGSPSASTPMINKTGFKFSAEKPVIEVP                               SMTILDKKDGEQAKALFEKVRKPRAHVEDSD                               LIYKLYVVQTVIKTAKFIFILCYTANFVNAISF                               EHVCKPKVEHLIGYEVFECTHNMAYMLKKL                               LISYISIICVYGFICLYTLFWLFRIPLKEYSFEKV                               REESSFSDIPDVICNDFAFLLHMVDQYDQLYS                               KRFGVFLSEVSENKLREISLNHEWTFEKL               1313   2663   A   10287   1221   266   GAIIRVLSPAQGAQPRLRSAASVEVSMVGQR                               VLLLVAFLLSGVLLSEAAKILTISTLGGSHYLL                               LDRVSQILQEHGHNVTMLHQSGKFLIPDIKEE                               EKSYQVIRWFSPEDHQICRIKKHFDSYIETALD                               GRKESEALVKLMEIFGTQCSYLLSRKDIMDSL                               KNENYDLVFVEAFDFCSFLIAEKLVKPFVAIL                               PTTFGSLDFGLPSPLSYVPVFPSLLTDHMDFW                               GRVKNFLMFFSFSRSQWDMQSTFDNTIKEHF                               PEGSRPVLSHLLLKAELWFVNSDCAFDFARPL                               LPNTVYIGGLMEKPIKPVPQVSEPSAFSLGFT               1314   2664   A   10288   536   1890   NVQLAICFSSTLVFFFSCDADPSALAKYVLAL                               VKKDKSEKELKALCIDQLDVFLQKETQIPVEK                               LFDAVNTKSYLPPPEQPSSGSLKVEFFPPQEK                               DIKKEEITKEEEREKKFSRRLNHSPPQSSSRYR                               ENRSRDERKKDDRSRKRDYDRNPPREDSYRD                               RYNRRRGRSRSYSRSRSRSWSKERLRERDRD                               RSRTRSRSRTRSRERDLVKPKYDLDRTDPLEN                               NYTPVSSVPSISSGHYPVPTLSSTITVIAPTHHG                               NNTTESWSEFHEDQVDHNSYVRPPMPKKRC                               RDYDEKGFCMRGDMCPFDHGSDPVVVEDVN                               LPGMQPFPAQPPVVEGPPPPGLPPPPPILTPPPV                               NLRPPVPPPGPLPPSLPPVTGPPPPLPPLQPSG                               MDAPPNSATSSVPTVVTTGIHHQPPPAPPSLFT                               ADTYDTDGYNPEAPSITNTSRPMYRHRVHPR                               AKLG               1315   2665   A   10293   447   1331   SHPLLSCPEKVSAKLRAAAEAAAEERRTRGA                               GSRGICAGLRSVAPGPEPLKQEEGRREWGSSI                               GTPSPCGSAQAAAAAAAEEATEKIPALRPALL                               WALLALWLCCATPAHALQCRDGYEPCVNEG                               MCVTYHNGTGYCKGPEGFLGEYCQHRDPCE                               KNRCQNGGTCVAQAMLGKATCRCASGFTGE                               DCQYSTSHPCFVSRPCLNGGTCHMLSRDTYE                               CTCQVGFTGRNPKCPGGNLNYQFNGIIVVYS                               GGSVPPSGTKTSKPAEHNAMGTGSKNFASGT                               LWVMVSGATSTSTSTL               1316   2666   A   10294   118   572   SLSMESNHKSGDGLSGTQKEAALRALVQRTG                               YSLVQENGQRKYGGPPPGWDAAPPERGCEIFI                               GKLPRDLFEDELIPLCEKIGKIYEMRMMMDF                               NGNNRGYAFVTFSNKVEAKNATKQLNNYEIR                               NGRLLGVCASVDNCRLFVGGIPKTKK               1317   2667   A   10301   158   1956   LLKSCGVLLSGVCIPCEGKGPTVLVIQTAVPQ                               DRPTKSSMRSAAKPWNPAIRAGGHGPDRVRP                               LPAASSGMKSSKSSTSLAFESRLSRLKRASSE                               DTLNKPGSTAASGVVRLKKTATAGAISELTES                               RLRSGTGAFITTKRTGIPAPREFSVTVSRERSV                               PRGPSNPRKSVSSPTSSNTPTPTKHLRTPSTKP                               KQENEGGEKAALESQVRELLAEAKAKDSEIN                               RLRSELKKYKEKRTLNAEGTDALGPNVDGTS                               VSPGDTEPMIRALEEKNKNFQKELSDLEEENR                               VLKEKLIYLEUSPNSEGAASHTGDSSCPTSITQ                               ESSFGSPTGNQLSSDIDEYKKNLHGNALRTSG                               SSSSDVTKASLSPDASDFEHITAETPSRPLSSTS                               NPFKSSKCSTAGSSPNSVSELSLASLTEKIQKM                               EENHHSTAEELQATLQELSDQQQMVQELTAE                               NEKLVDEKTILETSFHQHRERAEQLSQENEKL                               MNLLQERVKNEEPITQEGKLIELEQKCTGILE                               QGRFEREKLLNIQQQLTCSLRKVEEENQGAL                               EMIKRLKEENEKLNEFLELERIINNNMMAKTL                               EECRVTLEGLKMENGSLKSHLQG               1318   2668   A   10303   333   879   GECFIMAAVVQQNDLVFEFASNVMEDERQL                               GDPAIFPAVIVEHVPGADILNSYAGLAGVEEP                               NDMITESSLDVAEEEIIDDDDDDITLTVEASCH                               DGDETETIEAAEALLNMDSPGPMLDEKRINN                               NIFSSPEDDMVVAPVTHVSVTLDGIPEVMETQ                               QVQEKYADSPGASSPEQPKRKKK               1319   2669   A   10322   169   654   MEVRMSGSVAVTRAIAVPGLLLLLIIATALSL                               LIGAKSLPASVVLEAFSGTCQSADCTIVLDAR                               LPRTLAGLLAGGALGLAGALMQTLTRNPLAD                               PGLLGVNAGASFAIVLGAALFGYSSAQEQLA                               MAFAGALVASLIVAFTGSQGGGQLSPVRLTL                               AGVXL               1320   2670   A   10323   441   2   KMNQYAVVIGGGQTLGAFLCHGLAAEGYRV                               AVVDIQSDKAANVAQEINAEYGESMAYGFG                               DATSEQSVLALSRGVDEIFGRVDLLVYSAGI                               AKAAFISDFQLGDFDRSLQVNLVGYFLCARE                               FSRLMIRDGIQGRIIQINSKSDE               1321   2671   A   10332   1   453   RHRTAGPGSTISSRTDSASAPAARAMPCEYTY                               AKLTSDCSRPSLQWYTKAQSKMREPRLLLKD                               ILKCTLLVFGVRIIYILKLNYTTEECDMKNMH                               YVDPDHVKRAQKYAQQVLQKESPPKFAKTS                               MALLFEHRYSVDLLPFVQKAPTDSEA               1322   2672   A   10333   25   423   EPSNGPVVYSALGNEDDEILLLGKDIIGTFAAS                               ERKMRAHQVLTFLLLFVITSGASENASTSRGC                               GLDLLPQNVYLCDLDAIWGIVVEAVAGAGA                               LITLLLMLILLGRLPFIKEKEKKSPAVLHFLFL                               LGTLG               1323   2673   A   10334   52   426   SSLGNEDDE1LSLAKDITGMFVASHRKMRAH                               QVLTFLLLFVITSVASENASTSRGCGLDLLPQ                               YVSLCDLDAIWGWVEAAAQAGALITLLLMLI                               LLVRLPFFKEKEKKSPVGLHFLFLLGTLGP               1324   2674   A   10336   1   932   ERLCFPCMQSKIYSYMSPNKCSGMRFPLQEE                               NSVTIIHEVKCQGKPLAGIYRKREEKRNAGN                               AVRSAMKSEEQKIKDARKGPLVPFPNQKSEA                               AEPPKTPPSSCDSTNAAIAKQALKKPIKGKQA                               PRKKAQGKTQQNRKLTDFYPVRRSSRKSKAE                               LQSEERKRIDELIESGKEEGMKIDLIDGKGRG                               VIATKQFSRGDFVVEYHGDLIEITDAKKREAL                               YAQDPSTGCYMYYFQYLSKTYCVDATRETN                               RLGRLINHSKCGNCQTKLHDIDGVPHLILIAS                               EDIAAGEELLYDYGDRSKASIEAHPWLKH               1325   2675   A   10338   3   870   PGSTISCSELKGTQCRATAGSRGRRPPMTCWL                               RGVTATFGRPAEWPGYLSHLGGRSAAMDLG                               PMRKSYRGDREAFEETHLTSLDPVKQFAAWP                               EEAVQCPDIGEANAMCLATCTRDGKPSARML                               LLKGFGKDGFRFFTNFESRKGKELDSNPFASL                               VFYWEPLNRQVRVEGPVKKLPEEEAECYFHS                               RPKSSQIGAVVSHQSSVIPDREYLRKKNEELE                               QLYQDQEVPKPKSWGGYVLYPQVMEFWQG                               QTNRLHDRIVFRRGLPTGDSPLGPMTHRGEE                               DWLYERLAP               1326   2676   A   10344   2   984   ARAAAHCGICRLVRWWRKRRSVMGIQTSPV                               LLASLGVGLVTLLGLAVGSYLVRRSRRPQVT                               LLDPNEKYLLRLLDKTTVSHNTKRFEFALPTA                               HHTLGLPVGKHIYLSTRIDGSLVTRPYTPVTSD                               EDQGYVDLVIKVYLKGVHPKFPEGGKMSQY                               LDSLKVGDVVEFRGPSGLLTYTGKGHFNIQP                               NKKSPPEPRVAKKLGMIAGGTGITPMLQLIRA                               ILKVPEDPTQCFLLFANQTEKDIILREDLEELQ                               ARYPNRFKLWFTLDHPPKDWAYSKGFVTAD                               MIREHLPAPGDDVLVLLCGPPPMVQLACHPN                               LDKLGYSQKMRFTY               1327   2677   A   10345   1   968   LQSAGEGVTHVLILLESPARPVAAVTQVQRR                               RYHRLSDMSMLAERRRKQKWAVDPQNTAW                               SNDDSKFGQRMLEKMGWSKGKGLGAQEQG                               ATDHIKVQVKNNHLGLGATINNEDNWIAIIQ                               DDFNQLLAELNTCHGQETTDSSDKKEKKSFS                               LEEKSKISKNRVHYMKFTKGKDLSSRSKTDL                               DCIFGKRQSKKTPEGDASPSTPEENETTTTSAF                               TIQEYFAKRMAALKNKPQVPVPGSDISETQVE                               RKRGKKRNKEATGKDVESYLQPKAKRHTEG                               KPERAEAQERVAKKKSAPAEEQLRGPCWDQ                               SSKASAQDAGDHVQPA               1328   2678   A   10346   173   439   GSAAMKVKIKCWNGVATWLWVANDENCGI                               CRMAFNGCGPDCKVPGDDCPLVWGQCSHCF                               HMHCILKWLHAQQVQQHCPMCRQRQEWKFKE               1329   2679   A   10351   3   964   QMEPGNDTQISEFLLLGFSQEPGLQPFLFGLFL                               SMYLVTVLGNLLHLATISDSHLHTPMYFFLSN                               LSFADICVTSTTIPKMLMNIQTQNKVITYIACL                               MQMYFFILFAGFENFLLSVMAYDRFVAICHP                               LHYMVIMNPHLCGLLVLASWTMSALYSLLQI                               LMVVRLSFCTALETPHFFCELNQVIQLACSDSF                               LNHMVIYPTVALLGGGPLTGILYSYSKIISSIH                               AISSAQGKYKAFSTCASHLSVVSLFYGAILGV                               YLSSAATRNSHSSATASVMYTV\TPMLNPFI                               YSLRNKDIKRALGIHLLWGTMKGQPFKKCP               1330   2680   A   10352   34   2573   IPFLKSCCCCCLFDFPPPPLDQVQEEECEVERV                               TEHGTPKPFRKPDSVAPGESQSEDEQFENDLE                               TDPPNWQQLVSREVLLGLKPCEIKRQEVINEL                               FYTERAHVRTLKVLDQVFYQRVSREGILSPSE                               LRKIFSNLEDILQLHIGLNEQMKAVRKRNETS                               VIDQIGEDLLTWFSGPGEEKLKHAAATFCSNQ                               PFALEMIKSRQKKDSRFQTPVQDAESNPLCRR                               LQLKDIIPTQMQRLTKYPLLLDNIATYTEWPT                               EREKVKKAADHCRQILNYVNQAVKEAENKQ                               RLEDYQRRLDTSSLKLSEYPNVEELRNLDLTK                               RKMLHEGPLVWKVNRDKTIDLYTLLLEDILV                               LLQKQDDRLVLRCHSKILASTADSKHTFSPVI                               KLSTVLVRQVATDNKALFVISMSDNGAQIYE                               LVAQTVSEKTVWQDLICRMAASVKEQSTKPI                               PLPQSTPGEGDNDEEDPSKLKEEQHGISVTGL                               QSPDRDLGLESTLISSKPQSHSLSTSGKSEVRD                               LFVAERQFAKEQHTDGTLKEVGEDYQIAIPDS                               HLPVSEERWALDALRNLGLLKQLLVQQLGLT                               EKSVQEDWQHFPRYRTASQGPQTDSVIQNSE                               NIKAYHSGEGHMPFRTGTGDIATCYSPRTSTE                               SFAPRDSVGLAPQDSQASNILVMDHMIMTPE                               MPTMEPEGCILDDSGEHFFDAREAHSDENPSE                               GDGAVNKEEKDVNLRISGNYLILDGYDPVQE                               SSTDEEVASSLTLQPMTGIPAVESTHQQQHSP                               QNTHSDGAISPFTPEFLVQQRWGAMEYSCFEI                               QSPSSCADSQSQIMEYIHKIEADLEHLKKVEE                               SYTLLGQRLAGSALTDKHSDKS               1331   2681   A   10353   1   2100   AVEFAEGALTMAPWPELGDAQPNPDKYLEG                               AAGQQPTAPDKSKETNKTDNTEAPVTKIELLP                               SYSTATLIDEPTEVDDPWNLPTLQDSGIKWSE                               RDTKGKILCFFQGIGRLILLLGFLYFFVCSLDIL                               SSAFQLVGGKMAGQFFSNSSIMSNPLLGLVIG                               VLVTVLVQSSSTSTSIVVSMVSSSLLTVRAAIP                               IIMGANIGTSITNTIVALMQVGDRSEFRRAFA                               GATVHDFFNWLSVLVLLPVEVATHYLEIITQL                               IVESFHFKNGEDAPDLLKVITKPFTKLIVQLDK                               KVISQIAMNDEKAKNKSLVKIWCKTFTNKTQ                               INVTVPSTANCTSPSLCWTDGIQNWTMKNVT                               YKENIAKCQHIFVNFHLPDLAVGTILLILSLLV                               LCGCLIMIVKILGSVLKGQVATVIKKTINTDFP                               FPFAWLTGYLAILVGAGMTFIVQSSSVFTSAL                               TPLIGIGVITIERAYPLTLGSNIGTTTTAILAAL                               ASPGNALRSSLQIALCHFFFNISGILLWYPIPFT                               RLPIRMAKGLGNISAKYRWFAVFYLLIFFFLIP                               LTVFGLSLAGWRVLVGVGVPVVFIIILVLCLR                               LLQSRCPRVLPKKLQNWNFLPLWMRSLKPW                               DAVVSKFTGCFQMRCCCCCRVCCRACCLLC                               GCPKCCRCSKCCEDLEEAQEGQDVPVKAPET                               FDNITISREAQGEVPASDSKTECTAL               1332   2682   A   10354   30   1377   SQQGSQPHRQGPPSLLTAPHSLDLPALPPGPR                               GSQGKLRRVLVPMSVKPSWGPGPSEGVTAVP                               TSDLGEIHNWTELLDLFNHTLSECHVELSQST                               KRVVLFALYLAMFVVGLVENLLVICVNWRG                               SGRAGLMNLYILNMAIADLGIVLSLPVWMLE                               VTLDYTWLWGSFSCRFTHYFYFVNMYSSIFF                               LVCLSVDRYVTLTSASPSWQRYQHRVRRAM                               CAGIWVLSAIIPLPEVVHIQLVEGPEPMCLFM                               APFETYSTWALAVALSTTILGFLLPFPLITVFN                               VLTACRLRQPGQPKSRRHCLLLCAYVAVFV                               MCWLPYHVTLLLLTTHGTHISLHCHLVHLLY                               FFYDVIDCFSMLHCVINPILYNFLSPHFRGRLL                               NAVVHYLPKDQTKAGTCASSSSCSTQHSIIIT                               KGDSQPAAAAPHPEPSLSFQAHHLLPNTSPISP                               TQPLTPS               1333   2683   A   10358   2   884   AAGAGADGREPASERASRAEPPAVAMGQND                               LMGTAEDFADQFLRVTKQYLPHVARLCLIST                               FLEDGIRMWFQWSEQRDYIDTTWNCGYLLA                               SSPVFLNLLGQLTGCVLVLSRNFVQYACFGLF                               GIIALQTIAYSILWDLKFLMRNLALGGGLLLL                               LAESRSEGKSMFAGVPTMRESSPKQYMQLGG                               RVLLVLMFMTLLHFDASFFSIVQNTVGTALMI                               LVAIGFKTKLAALTLVVWLFAINVYFNAFWT                               IPVYKPMHDFLKYDFFQTMSVIGGLLLVVAL                               GPGGVSMDEKKKEW               1334   2684   A   10367   59   1562   QAWSLQVALSPFFFPASPSNSFAAAVPQLLPP                               ELPLPHVPGQESAKRRSARRFLIMSELTKELM                               ELVWGTKSSPGLSDTIFCRWTQGFVFSESEGS                               ALEQFEGGPCAVIAPVQAFLLKKLLFSSEKSS                               WRDCSQEEQKELLCHTLCDILESACCDHSGS                               YCLVSWLRGKTTEETASISGSPAESSCQVEHS                               SALAVEELGFERFHALIQKRSPRSLPELKDAV                               LDQYSMWGNKFGVLLFLYSVLLTKGTENTKN                               EIEDASEPLIDPVYGHGSQSLINLLLTGHAVSN                               VWDGDRECSGMKLLGIHEQAAVGFLTLMEA                               LRYCKVGSYLKISKIPYLDCLASETHLTVFFA                               KDMALVAPEAPSEQARRVFQTYDPEDNQFIP                               DSLLEDVMKALDLVSDPEYINLMKNKLDPEG                               LGIILLGPFLQEFFPDQGSSGPESFTVYHYNGL                               KQSNYNEKVMYVEGTAVVMGFEDPMLQTD                               DTPIKRCLQTKWPYIELLWITDRSPSLN               1335   2685   A   10375   82   2929   TRTKRRLGREKAMASPPRGWGCGELLLPFML                               LGTLCEPGSGQIRYSMPEELDKGSFVGNIAKD                               LGLEPQELAERGVRIVSRGRTQLFALNPRSGS                               LVTAGRIDREELCAQSPLCVVNFNILVENKM                               KIYGVEVEIIDINDNFPRFRDEELKVKVNENA                               AAGTRLVLPFARDADVGVNSLRSYQLSSNLH                               FSLDVVSGTDGQKYPELVLEQPLDREKETVH                               DLLLTALDGGDPVLSGTFHIRVTVLDANDNA                               PLFTPSEYSVSVPENIPVGTRLLMLTATDPDE                               GINGKLTYSFRNEEEKISETFQLDSNLGEISTL                               QSLDYEESRFYLMEVVAQDGGALVASAKVV                               VTVQDVNDNAPEVILTSLTSSISEDCLPGTVIA                               LFSVHDGDSGENGEIACSIPRNLPFKLEKSVD                               NYYHLLTTRDLDREETSDYNITLTVMDHGTP                               PLSTESHIPLKVADVNDNPPNFPQASYSTSVT                               ENNPRGVSIFSVTAHDPDSGDNARVTYSLAE                               DTFQGAPLSSYVSINSDTGVLYALRSFDYEQL                               RDLQLWVTASDSGNPPLSSNVSLSLFVLDQN                               DNTPEILYPAILPTDGSTGVELAPRSAEPGYLV                               TKVVAVDKDSGQNAWLSYRLLKASEPGLFA                               VGLHTGEVRTARALLDRDALKQSLVVAVED                               HGQPPLSATFTVTVAVADRIPDILADLGSIKTP                               IDPEDLDLTLYLVVAVAAVSCVPLAFVIVLLV                               LRLRRWHKSRLLQAEGSRLAGVPASHFVGV                               DGVRAFLQTYSHEVSLTADSRKSHLIFPQPNY                               ADTLLSEESCEKSEPLLMSDKVDANKEERRV                               QQAPPNTDWRFSQAQRPGTSGSQNGDDTGT                               WPNNQFDTEMLQAMILASASEAADGSSTLGG                               GAGTMGLSARYGPQFTLQHVLQGELGSDYR                               QNVYIPGSNATLTNAAGKRDGKAPAGGNGN                               KKKSGKKEKK               1336   2686   A   10379   1   557   RPRRRQPSFSCRVLVLEDPPCFRFTNSMNQEK                               LAKLQAQVRIGGKGTARRKKKVVHRTATAD                               DKKLQSSLKKLAVNNIAGIEEVNMIKDDGTVL                               HFNNPKVQASLSANTPAITGHAEAKPITEMLP                               GILSQLGADSLTSLRKLAEQFPRQVLDSKAPK                               PEDIDEEDDDVPDLVENFDEASKNEAN               1337   2687   A   10380   1   1263   IPGSTISWSPAAARGLSVCRCCRLHPASAMDL                               FGDLPEPERSPRPAAGKEAQKGPLLFDDLPPA                               SSTDSGSGGPLLFDDLPPASSQDSGSLATSISQ                               MVKTEGKGAKRKTSEEEKNGSEELVEKKVC                               KASSVIFGLKGYVAERKGEREEMQDAHVILN                               DITEECRPPSSLITRVSYFAVFDGHGGIRASKF                               AAQNLHQNLTRKFPKGDVISVEKTVKRCLLD                               TFKHTDEEFLKQASSQKPAWKDGSTATCVLA                               VDNILYIANLGDSRAILCRYNEESQKHAALSL                               SKEHNPTQYEERMRTQKAGGNVRDGRVLGV                               LEVSRSIGDQQYKRCGVTSVPDIERCQLTPND                               RFILLACDGLFKVFTPEEAVNFILSCLEDEKIQ                               TREGKSAADARYEAACNRLANKAVQRGSAD                               NVTVMVVRIGH               1338   2688   A   10385   3   589   GPSQSMAAGELEGGKPLSGLLNALAQDTPHG                               YPGITEELLRSQLYPEVPPEEFRPFLAKMRGIL                               KSIASADMDFNQLEAFLTAQTKKQGGITSDQ                               AAVISKFWKSHKTKIRESLMNQSRWNSGLRG                               LSWRVDGKSQSRHSAQIHTPVAIIELELGKYG                               QESEFLCLEPDEVKVNQILKTLSEVEESISTLIS                               QPN               1339   2689   A   10386   50   390   LGAMAKHHPDLIFCRKQAGVAIGRLCEKCDG                               KCVICDSYVRPCTLVRICDECNYGSYQGRCVI                               CGGPGVSDAYYCKECTIQEKDRDGCPKIVNL                               GSSKTDLFYERKKYGFKKR               1340   2690   A   10388   113   3472   SQLRKGASATHSSPSRTDCIAQMMDIYVCLK                               RPSWMVDNKRMRTASNFQWLLSTFILLYLM                               NQVNSQKKGAPHDLKCVTNNLQVWNCSWK                               APSGTGRGTDYEVCIENRSRSCYQLEKTSIKIP                               ALSHGDYEITINSLHDFGSSTSKFTLNEQNVSL                               IPDTPEILNLSADFSTSTLYLKWNDRGSVFPHR                               SNVIWEIKVLRKESMELVKLVTHNTTLNGKD                               TLHHWSWASDMPLECAIHFVEIRCYIDNLHFS                               GLEEWSDWSPVKNISWIPDSQTKVFPQDKVIL                               VGSDITFCCVSQEKVLSALIGHTNCPLIHLDGE                               NVAIKIRNISVSASSGTNVVFITEDNIFGTVIF                               AGYPPDTPQQLNCETHDLKEIICSWNPGRVTA                               LVGPRATSYTLVESFSGKYVRLKRAEAPTNES                               YQLLFQMLPNQEIYNFTLNAHNPLGRSQSTIL                               VNITEKVYPHTPTSFKVKDINSTAVKLSWHLP                               GNFAKINFLCEIEIKKSNSVQEQRNVTIKGVE                               NSSYLVALDKLNPYTLYTFRIRCSTETFWKW                               SKWSNKKQHLTTEASPSKGPDTWREWSSDG                               KNLIIYWKPLPINEANGKILSYNVSCSSDEETQ                               SLSEIPDPQHKAEIRLDKNDYIISVVAKNSVGS                               SPPSKIASMELPNDDLKIEQVVGMGKQILLTW                               HYDPNMTCDYVIKWCNSSRSEPCLMDWRKV                               PSNSTETVIESDEFRPGIRYNFFLYGCRNQGY                               QLLRSMIGYIEELALPIVAFNFTVEDTSADSILV                               KWEDIPVEELRGFLRGYLFYFGKGERDTSKM                               RVLESGRSDIKVKNITDISQKTLRIADLQGKTS                               YHLVLRAYTDGGVGPEKSMYVVTKENSVGL                               IIAILIPVAVAVIVGVVTSILCYRKREWIKETFY                               PDIPNPENCKALQFQKSVCEGSSALKTLEMNP                               CTPNNVEVLETRSAFPKIEDTEIVSPVAERPEN                               RSDAKPENHVVESYCPPIIEEEIPNPAADETGG                               TAQVIYIDVQSMYQPQAKPEEEQENDPVGGA                               GYKPQMHLPINSTVEDIAAEEDLDKTAGYRP                               QANYNTWNLVSPDSPRSIDSNSEIVSPGSPCSI                               NSRQFLIPPKDEDSPKSNGGGWSFTNFFQNKP                               ND               1341   2691   A   10392   1   5057   MLPPKHLSATKFKKSWAPNLYELDSDLTKEP                               DVIIGEGPTDSEFFHQRFNRNLIYVEFVGPRKTL                               IKLRNLCLDWLQPETRTKEEIIELLVLEQYLTII                               PEKLKPWVRAICKPENCEKLVTLLENYKEMY                               QPEGESLHGVLVVSAGLRCPLGLSASTLLTW                               SGLDNSLSWAAVGMSCVLWDIELHHDFLGV                               ATKSVSTHAQGDAAQGLGGTTVRMWARDSN                               LATGVLLDDNNSDVTSDDDMTRNRRESSPPH                               SVHSFSGDRDWDRRGRSRDTEPRDRWSHTR                               NPRSRMPPRDLSLPVVAKTSFEMDREDDRDS                               RAYESRSQDAESYQNVVDLAEDRKPHNTIQD                               NMENYRKLLSLGVQLAEDDGHSHMTQGHSS                               RSKRSAYPSTSRGLKTMPEAKKSTHRRGICED                               ESSHGVIMEKFIKDVSRSSKSGRARESSDRSQ                               RFPRMSDDNWKDISLNKRESVIQQRVYEGNA                               FRGGFRFNSTLVSRKRVLERIKRRYHFDTDGK                               GSIHDQKGCPRKKPFECGSEMRKAMSVSSLS                               SLSSPSFTESQPIDFGAMPYVGDECGRSFSVIS                               EFVEHQIMHTRENLYEYGESFIHSVAVSEVQK                               SQVGGKRFECKDCGETFNKSAALAEHRKIHA                               RGYLVECKNQECEEAFMPSPTFSELQKIYGK                               DKFYECRVCKETFLHSSALIEHQKIHFGDDKD                               NEREHERERERERGETFRPSPALNEFQICMYG                               KEKMYECKVCGETFLHSSSLKEHQKIHTRGN                               PFENKGKVCEETFIPGQSLKRRQKTYNKEKLC                               DFTDGRDAFMQSSELSEHQKIHSRKNLFEGR                               GYEKSVIHSGPFTESQKSHTITRPLESDEDEKA                               FTISSNPYENQKIPTKENVYEAKSYERSVIHSL                               ASVEAQKSHSVAGPSKPKVMAESTIQSFDAIN                               HQRVRAGGNTSEGREYSRSVIHSLVASKPPRS                               HNGNELVESNEKGESSIYISDLNDKRQKIPAR                               ENPGEGGSKNRNYEDSVIQSVFRAKPQKSVP                               GEGSGEFKKDGEFSVPSSNVREYQKARAKKK                               YEHRSNETSVIHSLPFGEQTFRPRGMLYECQ                               ECGECFAHSSDLTEHQKIHDREKPSGSRNYE                               WSVIRSLALPTDPQTSYAQEQYAKEQARNKCK                               DFRQFFATSEDLNTNQKIYDQEKSHGEESQGE                               NTDGEETHSEETIIGQETIEDPVIQGSDMEDPQ                               KDDPDDKIYECEDCGLGFVDLTDLTDHQKVH                               SRKGLVDSREYTHSVIHTHSISEYQRDYTGEQ                               LYECPKCGESFIHSSFLFEHQRIHEQDQLYSM                               KGCDDGFIALLPMKPRRAAERNPALAGSA                               IRCLLCGQGFIHSSALNEHMRLHREDDLLEQS                               QMAEEAIIPGLALTEFQRSQTEERLFECAVCG                               ESFVNPAELADHVTVHKNEPYEYGSSYTHTS                               FLTEPLKGAIPFYECKDCGKSFIHSTVLTKHKE                               LHLEEEEEDEAAAAAAAAAQEVEANVHVPQ                               VVLRIQGLMVEAAEPEVEAAEPEVEAAEPEV                               EAAEPNGEAEGPDGEAAEPIGEAGQPNGEAE                               QPNGDADEPDGAGIEDPEERAEEPEGKAEEPE                               GDADEPDGVGIEDPEEGEDQEIQVEEPYYDC                               HECTETFTSSTAFSEHLKTHASMIIFEPANAFG                               ECSGYIERASTSTGGANQADEKYFKCDVCGQ                               LFNDHLSLARHQNTHTG               1342   2692   A   10393   2   1350   GRPRSSSDNRNPLRERAGLSSAAVQTRIGNSA                               ASRRSPAARPPVPAPPAIPRGRPGTEGSTSLS                               APAVLVVAVAVVVVYVSAVAWAMANYIHV                               PPGSPEVPKLNVTVQDQEEHRCREGALSLLQ                               HLRPHWDPQEVTLQLFTDGITMKLIGCYVGN                               TMEDVVLVRIYGNKTELLVDRDEEVKSFRVL                               QAHGCAPQLYCTFNNGLCYEFIQGEALDPKH                               VCNPAIFRLIARQLAKIHATHAHNGWIPKSNL                               WLKMGKYFSLIPTGFADEDINKRFLSDIPSSQI                               LQEEMTWMKEILSNLGSPVVLCHNDLLCKNII                               YNEKQGDVQFIDYEYSGYNYLAYDIGNHFNE                               FAGVSDVDYSLYPDRELQSQWLRAYLEAYK                               EPKGFGTEVTEKEVEILFIQVNQFALASIIFFW                               GLWALIQAKYSTIEFDFLGYAIVRFNQYFKM                               KPEVTALKVPE               1343   2693   A   10394   102   839   PEAQTSAVLAREKGHLPTMRHEAPMQMASA                               QDARYGQKDSSDQNFDYMFKLLIIGNSSVGK                               TSFLFRYADDSFTSAFVSTVGIDFKVKTVFKN                               EKRIKLQIWDTAGQERYRTFITAYYRGAMGFI                               LMYDITLNESFNAVQDWSTQIKTYSWDNAQ                               VILVGNKCDMEDERVISTERGQHLGEQLGFE                               FFETSAKDNINVKQTFERLVDIICDKMSESLET                               DPAITAAKQNTRLKETPPPPQPNCAC               1344   2694   A   10395   2   4136   DRPPWNSRVDDFVTNLIHLSSKGHISPAKDTS                               LQQRTPAEMSPVLHFYVRPSGHEGAASGHTR                               RKLQGKLPELQGVETELCYNVNWTAEALPSA                               EETKKLMWLFGCPLLLDDVARESWLLPGSN                               DLLLEVGPRLNFSTPTSTNIVSVCRATGLGPV                               DRVETTRRYRLSFAHPPSAEVEAIALATLHDR                               MTEQHFPHPIQSFSPESMFEPLNGPINILGEGR                               LALEKANQELGLALDSWDLDFYTKRFQELQR                               NPSTVEAFDLAQSNSEHSRHWFFKGQLHVDG                               QKLVHSLFESIMSTQESSNFNNVLKFCDNSSA                               IQGKEVRFLRPEDPTRPSRFQQQQGLRHVVFT                               AETHNFPTGVCPFSGATTGTGGRIRDVQCTG                               RGAHVVAGTAGYCFGNLHIPGYNLPWEDLSF                               QYPGNFARPLEVAIEASNGASDYGNKFGEPV                               LAGFARSLGLQLPDGQREEWIKPIMFSGGIGS                               MEADHISKEAPEPGMEVVKVGGPVYRIGVGG                               GAASSVQVQGDNTSDLDFGAVQRGDPEMEQ                               KMNRVIRACVEAPKGNPICSLHDQGAGGNG                               NVLKELSDPAGAIIYTSRFQLGDPTLNALEIW                               GAEYQESNALLLRSPNRDFLTHVSARERCPA                               CFVGTTTGDRRIVLVDDRECPVRRNGQGDAP                               PTPPPTPVDLELEWVLGKMPRKEFFLQRKPP                               MLQPLALPPGLSVHQALERVLRLPAVASKRY                               LTNKVDRSVGGLVAQQQCVGPLQTPLADVA                               VVALSHEELIGAATALGEQPVKSLLDPKVAA                               RILAVAEALTNLVFALVTDLRDVKCSGNWM                               WAAKLPGEGAALADACEAMVAVMAALGVA                               VDGGKDSLSMAARVGTETVRAPGSLVISAYA                               VCPDITATVTPDLKHPEGRGHLLYVALSPGQ                               HRLGGTALAQCFSQLGEHPPDLDLPENLVRA                               FSITQGLLKDRLLCSGHDVSDGGLVTCLLEM                               AFAGNCGLQVDVPVPRVDVLSVLPAEEPGLV                               LEVQEPDLAQVLKRYRDAGLHCLELGHTGE                               AGPHAMVRVSVNGAVVLEEPVGELRALWEE                               TSFQLDRLQAEPRCVAEEERGLRERMGPSYC                               LPPTFPKASVPREPGGPSPRVAILREEGSNGDR                               EMADAPHLAGFEVWDVTMQDLCSGAIGLDT                               FRGVAFVGGFSYADVLGSAKGWAAAVTFHP                               RAGAELRRFRKRPDTFSLGVCNGCQLLALLG                               WVGGDPNEDAAEMGPDSQPARPGLLLRHNL                               SGRYESRWASVRVGPGPALMLRGMEGAVLP                               VWSAHGEGYVAFSSPELQAQIEARGLAPLHW                               ADDDGNPTEQYPLNPNGSPGGVAGICSCDGR                               HLAVMIPHPERAVRPWQWAWRPPPFDTLTTS                               PWLQLPINARNWTLEGSC               1345   2695   A   10396   65   642   GVRGFWAGTMASRAGPRAAGTDGSDFQHRE                               RVAMHYQMSVTLKYEIKKLIYVHLVIWLLLV                               AKMSVGHLRLLSHDQVAMPYQWEYPYLLSI                               LPSLLGLLSFPRNNISYLVLSMISMGLFSIAPLI                               YGSMEMFPAAQQLYRHGKAYRFLFGFSAVSI                               MYLVLVLAVQVHAWQLYYSKKLLDSWFTST                               QEKKHK               1346   2696   A   10398   1   718   DDFVRCGPQSAAMGASARLLRAVIMGAPGS                               GKGTVSSRITTHFELKHLSSGDLLRDNMLRGT                               EIGVLAKAFIDQGKLIPDDVMTRLALHELKNL                               TQYSWLLDGFPRTLPQAEALDRAYQIDTVINL                               NVPFEVIKQRLTARWIHPASGRVYNIEFNPPK                               TVGIDDLTGEPLIQREDDKPETVIKRLKAYED                               QTKPVLEYYQKKGVLETFSGTETNKIWPYVY                               AFLQTKVPQRSQKASVTP               1347   2697   A   10402   153   1969   KHRQENNALDMAPEHMTGPMCLIENTNGEL                               VANPEALKILSAITQPVVVVAIVGLYRTGKSY                               LMNKLAGKNKGFSLGSTVKSHTKGIWMWCV                               PHPKKPEHTLVLLDTEGLGDVKKGDNQNDS                               WIFTLAVLLSSTLVYNSMGTINQQAMDQLYY                               VTELTHRIRSKSSPDENENEDSADFVSFFPDFV                               WTLRDPSLDLEADGQPLTPDEYLEYSLKLTQ                               GTSQKDKNFNLPRLCIRKFFPKKKCFVFDLPI                               HRRKLAQLEKLQDEELDPEFVQQVADFCSYI                               FSNSKTKTLSGGIKVNGPRLESLVLTYINAISR                               GDLPCMENAVLALAQIENSAAVQKAIAHYD                               QQMGQKVQLPAETLQELLDLHRVSEREATEV                               YMKNSFKDVDHLFQKKLAAQLDKKRDDFCK                               QNQEASSDRCSALLQVIFSPLEEEVKAGIYSK                               PGGYCLFIQKLQDLEKKYYEEPRKGIQAEEIL                               QTYLKSKESVTDAILQTDQILTEKEKEIEVEC                               VKAESAQASAKMVEEMQIKYQQMMEEKEKS                               YQEHVKQLTEKMERERAQLLEEQEKTLTSKL                               QEQARVLKERCQGESTQLQNEIQKLQKTLKK                               KTKRYMSHKLKL               1348   2698   A   10404   5   892   TQLPAPLSGVLSRLQLGSGAPLLTWVQETAG                               VAGGAPRRRTPVTMWRLLARASAPLLRVPLS                               DSWALLPASAGVKTLLPVPSFEDVSIPEKPKL                               RFIERAPLVPKVRREPKNLSDIRGPSTEATEFT                               EGNFAILALGGGYLHWGHFEMMRITINRSM                               DPKNMFAIWRVPAPFKPITRKSVGHRMGGGK                               GAIDHYVTPVKAGRLVVEMGGRCEFEEVQG                               FLDQVAHKLPFAAKAVSRGTLEKMRKDQEE                               RERNNQNPWTFERIATANMLGIRKVLSPYDL                               THKGKYWGKFYMPKRV               1349   2699   A   10409   59   1184   LRRNCSALGGLFQTIISDMKGSYPVWEDFINK                               AGKLQSQLRTTVVAAAAFLDAFQKVADMAT                               NTRGGTREIGSALTRMCMRHRSIEAKLRQFSS                               ALIDCLINPLQEQMEEWKKVANQLDKDHAK                               EYKKARQEIKKKSSDTLKLQKKAKKGRGDIQ                               PQLDSALQDVNDKYLLLEETEKQAVRKALIE                               ERGRFCTFISMLRPVIEEEISMLGEITHLQTISE                               DLKSLTMDPHKLPSSSEQVILDLKGSDYSWS                               YQTPPSSPSTTMSRKSSVCSSLNSVNSSDSRSS                               GSHSHSPSSHYRYRSSNLAQQAPVRLSSVSSH                               DSGFISQDAFQSKSPSPMPPEAPNQRRKEKRE                               PDPNGGGPTTASGPPAAAEEAQRPRSM               1350   2700   A   10410   511   958   AGRGGPGKPVSWSSGPGSPGQTQRRSWVKST                               RGHSSLLPPSQDFVAGLSVILRGTVDDRLNW                               AFNLYDLNKDGCITKEEMLDIMKSIYDMMG                               KYTYPALREEAPREHVESFFQKMDRNKDGV                               VTTEEFIESCQKDENIMRSMQLFDNVI                    
     [0420] 
    
     
       
         0 
         
           
               
            
               
                   
               
               
                   
               
               
                 SEQUENCE LISTING 
               
            
           
           
               
            
               
                 The patent application contains a lengthy “Sequence Listing” section. A copy of the “Sequence Listing” is available in electronic form from the USPTO 
               
               
                 web site (http://seqdata.uspto.gov/sequence.html?DocID=20040053245). An electronic copy of the “Sequence Listing” will also be available from the 
               
               
                 USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3).